IL71455A - A method for the preparation of an immunoglobulin chain of chimeras and compounds containing them - Google Patents

A method for the preparation of an immunoglobulin chain of chimeras and compounds containing them

Info

Publication number
IL71455A
IL71455A IL7145584A IL7145584A IL71455A IL 71455 A IL71455 A IL 71455A IL 7145584 A IL7145584 A IL 7145584A IL 7145584 A IL7145584 A IL 7145584A IL 71455 A IL71455 A IL 71455A
Authority
IL
Israel
Prior art keywords
chain
antibody
fragment
species
constant region
Prior art date
Application number
IL7145584A
Other languages
English (en)
Hebrew (he)
Other versions
IL71455A0 (en
Original Assignee
Genetechm Inc
Hope City
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=23920101&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=IL71455(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Genetechm Inc, Hope City filed Critical Genetechm Inc
Priority to IL9950784A priority Critical patent/IL99507A/en
Publication of IL71455A0 publication Critical patent/IL71455A0/xx
Priority to IL99507A priority patent/IL99507A0/xx
Publication of IL71455A publication Critical patent/IL71455A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01N—PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
    • A01N65/00—Biocides, pest repellants or attractants, or plant growth regulators containing material from algae, lichens, bryophyta, multi-cellular fungi or plants, or extracts thereof
    • A01N65/40—Liliopsida [monocotyledons]
    • A01N65/44—Poaceae or Gramineae [Grass family], e.g. bamboo, lemon grass or citronella grass
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01N—PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
    • A01N25/00—Biocides, pest repellants or attractants, or plant growth regulators, characterised by their forms, or by their non-active ingredients or by their methods of application, e.g. seed treatment or sequential application; Substances for reducing the noxious effect of the active ingredients to organisms other than pests
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3007—Carcino-embryonic Antigens
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C07K16/461—Igs containing Ig-regions, -domains or -residues form different species
    • C07K16/462—Igs containing a variable region (Fv) from one specie and a constant region (Fc) from another
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/80—Vectors or expression systems specially adapted for eukaryotic hosts for fungi
    • C12N15/81—Vectors or expression systems specially adapted for eukaryotic hosts for fungi for yeasts
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
    • Y10S530/866—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof involving immunoglobulin or antibody fragment, e.g. fab', fab, fv, fc, heavy chain or light chain
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
    • Y10S530/867—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof involving immunoglobulin or antibody produced via recombinant dna technology
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S930/00—Peptide or protein sequence
    • Y10S930/01—Peptide or protein sequence
    • Y10S930/30—Signal or leader sequence

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Plant Pathology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicinal Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Cell Biology (AREA)
  • Oncology (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Agronomy & Crop Science (AREA)
  • Dentistry (AREA)
  • Environmental Sciences (AREA)
  • Toxicology (AREA)
  • Pest Control & Pesticides (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
IL7145584A 1983-04-08 1984-04-06 A method for the preparation of an immunoglobulin chain of chimeras and compounds containing them IL71455A (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
IL9950784A IL99507A (en) 1983-04-08 1984-04-06 Preparation of antigen-specific immunoglobulins known in a transformed host cell, vectors and transformed cells using it
IL99507A IL99507A0 (en) 1983-04-08 1991-09-16 Recombinant immunoglobin preparations

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US06/483,457 US4816567A (en) 1983-04-08 1983-04-08 Recombinant immunoglobin preparations

Publications (2)

Publication Number Publication Date
IL71455A0 IL71455A0 (en) 1984-07-31
IL71455A true IL71455A (en) 1994-08-26

Family

ID=23920101

Family Applications (1)

Application Number Title Priority Date Filing Date
IL7145584A IL71455A (en) 1983-04-08 1984-04-06 A method for the preparation of an immunoglobulin chain of chimeras and compounds containing them

Country Status (16)

Country Link
US (3) US4816567A (de)
EP (1) EP0125023B2 (de)
JP (5) JP3162055B2 (de)
KR (2) KR840008264A (de)
AT (1) ATE64151T1 (de)
AU (2) AU598441B2 (de)
CA (1) CA1218613A (de)
CY (1) CY1793A (de)
DE (1) DE3484664D1 (de)
DK (2) DK174048B1 (de)
ES (1) ES8602119A1 (de)
HK (1) HK129394A (de)
IE (1) IE57198B1 (de)
IL (1) IL71455A (de)
NZ (3) NZ222543A (de)
ZA (1) ZA842583B (de)

Families Citing this family (9009)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6630328B2 (en) 1909-07-15 2003-10-07 Genencor International, Inc. Increasing production of proteins in gram-positive microorganisms
GB8308235D0 (en) * 1983-03-25 1983-05-05 Celltech Ltd Polypeptides
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US5639639A (en) * 1983-11-02 1997-06-17 Genzyme Corporation Recombinant heterodimeric human fertility hormones, and methods, cells, vectors and DNA for the production thereof
DE10199028I2 (de) * 1983-11-02 2004-07-01 Applied Research Systems Produkte und Methoden für die Herstellung einer heterodimerer menschlicher LH mit einem Met42 Val55 alpha Untereinheit.
US5229272A (en) * 1989-04-25 1993-07-20 Igen, Inc. Catalytic antibody components
JPS6147500A (ja) * 1984-08-15 1986-03-07 Res Dev Corp Of Japan キメラモノクロ−ナル抗体及びその製造法
US5807715A (en) * 1984-08-27 1998-09-15 The Board Of Trustees Of The Leland Stanford Junior University Methods and transformed mammalian lymphocyte cells for producing functional antigen-binding protein including chimeric immunoglobulin
EP0173494A3 (de) * 1984-08-27 1987-11-25 The Board Of Trustees Of The Leland Stanford Junior University Chimäre Rezeptoren durch Verbindung und Expression von DNS
GB8422238D0 (en) * 1984-09-03 1984-10-10 Neuberger M S Chimeric proteins
US6808901B1 (en) * 1984-09-03 2004-10-26 Celltech R&D Limited Production of chimeric antibodies
JPS61134325A (ja) * 1984-12-04 1986-06-21 Teijin Ltd ハイブリツド抗体遺伝子の発現方法
US5169939A (en) * 1985-05-21 1992-12-08 Massachusetts Institute Of Technology & Pres. & Fellows Of Harvard College Chimeric antibodies
US5672502A (en) * 1985-06-28 1997-09-30 Celltech Therapeutics Limited Animal cell culture
US5369010A (en) * 1985-08-16 1994-11-29 Genetic Systems Corporation Monoclonal antibody to polymorphic HLA determinant -B27
DE3689123T2 (de) * 1985-11-01 1994-03-03 Xoma Corp Modulare einheit von antikörpergenen, daraus hergestellte antikörper und verwendung.
US5618920A (en) * 1985-11-01 1997-04-08 Xoma Corporation Modular assembly of antibody genes, antibodies prepared thereby and use
EP0536566A1 (de) * 1985-11-01 1993-04-14 Xoma Corporation Modulare Einheit von Antikörpergenen, daraus hergestellte Antikörper und Verwendung
US5576195A (en) * 1985-11-01 1996-11-19 Xoma Corporation Vectors with pectate lyase signal sequence
US4935233A (en) * 1985-12-02 1990-06-19 G. D. Searle And Company Covalently linked polypeptide cell modulators
JPS62153300A (ja) * 1985-12-26 1987-07-08 Teijin Ltd ヒト免疫グロブリンＧＦｃ領域蛋白質およびその製造方法
EP0234592A1 (de) * 1986-02-28 1987-09-02 Teijin Limited Plasmid, das ein DNA-Fragment enthält, welches für die Fc-Region von menschlichem Immunoglobulin G Protein codiert, und Verwendung desselben zur Herstellung des genannten Proteins
US6548640B1 (en) 1986-03-27 2003-04-15 Btg International Limited Altered antibodies
US5225539A (en) * 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
GB8607679D0 (en) * 1986-03-27 1986-04-30 Winter G P Recombinant dna product
US5955584A (en) * 1986-03-31 1999-09-21 Charter Ventures Atherosclerotic plaque specific antigens, antibodies thereto, and uses thereof
US6025477A (en) * 1986-03-31 2000-02-15 Calenoff; Emanuel Atherosclerotic plaque specific antigens, antibodies thereto, and uses thereof
US5811248A (en) * 1986-03-31 1998-09-22 Charter Ventures Atherosclerotic plaque specific antigens, antibodies thereto, and uses thereof
US4859609A (en) * 1986-04-30 1989-08-22 Genentech, Inc. Novel receptors for efficient determination of ligands and their antagonists or agonists
JPS63112995A (ja) * 1986-07-07 1988-05-18 セントコ−・インコ−ポレ−テッド 腫瘍関連抗原に特異的なキメラ齧歯類／ヒト免疫グロブリン
JPH0698021B2 (ja) * 1986-08-01 1994-12-07 帝人株式会社 マウス−ヒトキメラ抗体、それをコ−ドする発現型キメラｄｎａ配列、プラスミド及び細胞
JPS6336786A (ja) * 1986-07-31 1988-02-17 Teijin Ltd 抗体ｌ鎖発現型核酸塩基配列，プラスミド，細胞及びキメラ抗体ｌ鎖
US5126433A (en) * 1986-08-21 1992-06-30 The Trustees Of Columbia University In The City Of New York Soluble forms of the t cell surface protein cd4
US6673896B1 (en) * 1986-08-21 2004-01-06 The Trustees Of Columbia University In The City Of New York Derivatives of soluble T-4
US5958678A (en) * 1986-08-21 1999-09-28 The Trustees Of Columbia University In The City Of New York DNA encoding the T cell surface protein T4 and use of fragments of T4 in the treatment of AIDS
WO1988001304A1 (en) 1986-08-21 1988-02-25 The Trustees Of Columbia University In The City Of Dna encoding the t cell surface protein t4 and use of fragments of t4 in the treatment of aids
US5260203A (en) * 1986-09-02 1993-11-09 Enzon, Inc. Single polypeptide chain binding molecules
US5869620A (en) * 1986-09-02 1999-02-09 Enzon, Inc. Multivalent antigen-binding proteins
EP0281604B1 (de) * 1986-09-02 1993-03-31 Enzon Labs Inc. Bindungsmoleküle mit einzelpolypeptidkette
US4946778A (en) * 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
IL84285A (en) * 1986-10-27 1993-03-15 Int Genetic Engineering Chimeric antibody with specificity to human tumor antigen
US6893625B1 (en) 1986-10-27 2005-05-17 Royalty Pharma Finance Trust Chimeric antibody with specificity to human B cell surface antigen
CA1339445C (en) * 1986-11-12 1997-09-09 The General Hospital Corporation Recombinant hybrid immunoglobulin molecules and method of use
IL85035A0 (en) * 1987-01-08 1988-06-30 Int Genetic Eng Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same
US5180660A (en) * 1987-02-19 1993-01-19 Nissin Shokuhin Kabushiki Kaisha Methods and materials for HIV detection
US5140105A (en) * 1987-02-19 1992-08-18 Nissin Shokuhin Kabushiki Kaisha Methods and materials for HIV detection
US5217895A (en) * 1987-02-19 1993-06-08 Nissin Shokuhin Kabushiki Kaisha Monoclonal anti-idiotypic antibodies specific for anti-T4 antibodies and cross-reactive with HIV
US5169752A (en) * 1987-02-19 1992-12-08 Nissin Shokuhin Kabushiki Kaisha Methods and materials for HIV detection
ES2102347T3 (es) 1987-02-20 1997-08-01 Genentech Inc Metodos y composiciones para la utilizacion de polipeptidos env y anticuerpos anti-env de hiv.
JP3101690B2 (ja) * 1987-03-18 2000-10-23 エス・ビィ・２・インコーポレイテッド 変性抗体の、または変性抗体に関する改良
US5610034A (en) * 1987-04-29 1997-03-11 Alko Group Ltd. Immunoglobulin production by trichoderma
JPH02500329A (ja) * 1987-05-21 1990-02-08 クリエイテイブ・バイオマリキユールズ・インコーポレーテツド ターゲット化多機能蛋白質
US5258498A (en) * 1987-05-21 1993-11-02 Creative Biomolecules, Inc. Polypeptide linkers for production of biosynthetic proteins
US5091513A (en) * 1987-05-21 1992-02-25 Creative Biomolecules, Inc. Biosynthetic antibody binding sites
US5132405A (en) * 1987-05-21 1992-07-21 Creative Biomolecules, Inc. Biosynthetic antibody binding sites
US5834599A (en) * 1987-05-29 1998-11-10 Tanox Biosystems, Inc. Immunoconjugates which neutralize HIV-1 infection
US6657050B1 (en) 1987-05-29 2003-12-02 Tanox, Inc. Chimeric viral-neutralizing immunoglobulins
US5981278A (en) * 1987-05-29 1999-11-09 Tanox, Inc. Chimeric monoclonal antibodies which neutralize HIV-1 infection and their applications in therapy and prevention for AIDS
CA1341235C (en) * 1987-07-24 2001-05-22 Randy R. Robinson Modular assembly of antibody genes, antibodies prepared thereby and use
US5677425A (en) * 1987-09-04 1997-10-14 Celltech Therapeutics Limited Recombinant antibody
ATE120492T1 (de) * 1987-09-09 1995-04-15 Celltech Ltd Fv antikörperfragment-herstellung.
US5336603A (en) * 1987-10-02 1994-08-09 Genentech, Inc. CD4 adheson variants
US6710169B2 (en) * 1987-10-02 2004-03-23 Genentech, Inc. Adheson variants
FI884924A7 (fi) * 1987-10-28 1989-04-29 Oncogen Yhdistelmä-DNA-tekniikalla tuotettuja ihmisimmunoglobuliineja
US4978745A (en) * 1987-11-23 1990-12-18 Centocor, Inc. Immunoreactive heterochain antibodies
AU625613B2 (en) * 1988-01-05 1992-07-16 Novartis Ag Novel chimeric antibodies
US5843708A (en) * 1988-01-05 1998-12-01 Ciba-Geigy Corporation Chimeric antibodies
GB8800077D0 (en) * 1988-01-05 1988-02-10 Ciba Geigy Ag Novel chimeric antibodies
US5750375A (en) * 1988-01-22 1998-05-12 Zymogenetics, Inc. Methods of producing secreted receptor analogs and biologically active dimerized polypeptide fusions
US6018026A (en) * 1988-01-22 2000-01-25 Zymogenetics, Inc. Biologically active dimerized and multimerized polypeptide fusions
ZA89430B (en) * 1988-01-22 1989-10-25 Gen Hospital Corp Cloned genes encoding ig-cd4 fusion proteins and the use thereof
US6004781A (en) * 1988-01-22 1999-12-21 The General Hospital Corporation Nucleic acid encoding Ig-CD4 fusion proteins
US5567584A (en) * 1988-01-22 1996-10-22 Zymogenetics, Inc. Methods of using biologically active dimerized polypeptide fusions to detect PDGF
JP2646007B2 (ja) 1988-01-30 1997-08-25 財団法人 化学及血清療法研究所 抗ｈｉｖ抗体可変領域をコードする遺伝子断片およびこれらを用いて発現された抗ｈｉｖキメラ抗体ならびにその製法
JP3095168B2 (ja) * 1988-02-05 2000-10-03 エル． モリソン，シェリー ドメイン‐変性不変部を有する抗体
US5846534A (en) * 1988-02-12 1998-12-08 British Technology Group Limited Antibodies to the antigen campath-1
IL89489A0 (en) * 1988-03-09 1989-09-10 Hybritech Inc Chimeric antibodies directed against human carcinoembryonic antigen
AU3342689A (en) * 1988-03-24 1989-10-16 Igen Incorporated Luminescent chimeric proteins
US5372812A (en) * 1988-04-04 1994-12-13 The General Hospital Corporation Composition and method for acceleration of clot lysis
US5582862A (en) * 1988-04-04 1996-12-10 General Hospital Corporation Antibodies that bind to α2-antiplasmin crosslinked to fibrin which do not inhibit plasma α2-antiplasmin
KR900700134A (ko) * 1988-04-15 1990-08-11 원본미기재 Il-2 수용체-특이적 키메릭 항체
US4975369A (en) * 1988-04-21 1990-12-04 Eli Lilly And Company Recombinant and chimeric KS1/4 antibodies directed against a human adenocarcinoma antigen
US5171666A (en) * 1988-04-22 1992-12-15 Eli Lilly And Company Monoclonal antibodies reactive with a cell-surface gylcoprotein expressed on human carcinomas
US5770198A (en) * 1988-05-18 1998-06-23 The Research Foundation Of The State Of New York Platelet-specific chimeric 7E3 immunoglobulin
JP2749167B2 (ja) 1988-06-21 1998-05-13 ジェネンテク，インコーポレイテッド 心筋梗塞の処置のための方法および治療用組成物
US5811265A (en) * 1988-08-19 1998-09-22 The General Hospital Corporation Hybrid immunoglobulin-thrombolytic enzyme molecules which specifically bind a thrombus, and methods of their production and use
US5609869A (en) * 1988-08-19 1997-03-11 The General Hospital Corporation Hybrid immunoglobulin-thrombolytic enzyme molecules which specifically bind a thrombus, and methods of their production and use
DE68928124T2 (de) 1988-09-02 1997-10-16 Chiron Corp., Emeryville, Calif. Makrophagenabgeleiteter entzündungsmediator(mip-2)
ES2146572T3 (es) * 1988-09-06 2000-08-16 Xoma Technology Ltd Elementos de expresion genica y la produccion de anticuerpos quimericos de raton-ser humano.
US5576184A (en) * 1988-09-06 1996-11-19 Xoma Corporation Production of chimeric mouse-human antibodies with specificity to human tumor antigens
DE3835350A1 (de) * 1988-10-17 1990-04-19 Boehringer Mannheim Gmbh Aktivierung von gentechnologisch hergestellten, in prokaryonten exprimierten antikoerpern
US6051225A (en) 1988-10-19 2000-04-18 The Dow Chemical Company Family of high affinity, modified antibodies for cancer treatment
FI903489A7 (fi) 1988-11-11 1990-07-10 Medical Res Council Yhden osan sisältävät ligandit, näitä ligandeja sisältävät reseptorit, menetelmiä niiden valmistamiseksi sekä ligandien ja reseptorien käytt ö
US20040049014A1 (en) * 1988-12-28 2004-03-11 Protein Design Labs, Inc. Humanized immunoglobulins
US5530101A (en) * 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
IL162181A (en) * 1988-12-28 2006-04-10 Pdl Biopharma Inc A method of producing humanized immunoglubulin, and polynucleotides encoding the same
EP0376851A3 (de) * 1988-12-29 1991-06-26 Cytogen Corporation Molekular-Erkennungseinheiten
US5116964A (en) * 1989-02-23 1992-05-26 Genentech, Inc. Hybrid immunoglobulins
US5225538A (en) * 1989-02-23 1993-07-06 Genentech, Inc. Lymphocyte homing receptor/immunoglobulin fusion proteins
US6406697B1 (en) 1989-02-23 2002-06-18 Genentech, Inc. Hybrid immunoglobulins
DE69023900D1 (de) * 1989-02-24 1996-01-11 Univ California Gentechnologisch veränderte immunglobuline.
US5602015A (en) * 1989-04-25 1997-02-11 Igen, Inc. Autoantibodies which enhance the rate of a chemical reaction
US5318897A (en) * 1989-04-25 1994-06-07 Igen, Inc. Monoclonal antibody and antibody components elicited to a polypeptide antigen ground state
US5599538A (en) * 1989-04-25 1997-02-04 Igen, Inc. Autoantibodies which enhance the rate of a chemical reaction
US6048717A (en) * 1989-04-25 2000-04-11 Igen International, Inc. Inhibitors of catalytic antibodies
US5236836A (en) * 1989-04-25 1993-08-17 Igen, Inc. Autoantibodies which enhance the rate of a chemical reaction
US5658753A (en) * 1989-04-25 1997-08-19 Paul; Sudhir Catalytic antibody components
US6291160B1 (en) * 1989-05-16 2001-09-18 Scripps Research Institute Method for producing polymers having a preselected activity
US6291159B1 (en) 1989-05-16 2001-09-18 Scripps Research Institute Method for producing polymers having a preselected activity
US6291161B1 (en) * 1989-05-16 2001-09-18 Scripps Research Institute Method for tapping the immunological repertiore
US6969586B1 (en) 1989-05-16 2005-11-29 Scripps Research Institute Method for tapping the immunological repertoire
US6291158B1 (en) 1989-05-16 2001-09-18 Scripps Research Institute Method for tapping the immunological repertoire
US6680192B1 (en) 1989-05-16 2004-01-20 Scripps Research Institute Method for producing polymers having a preselected activity
US5897861A (en) * 1989-06-29 1999-04-27 Medarex, Inc. Bispecific reagents for AIDS therapy
US6020145A (en) * 1989-06-30 2000-02-01 Bristol-Myers Squibb Company Methods for determining the presence of carcinoma using the antigen binding region of monoclonal antibody BR96
US5081235A (en) * 1989-07-26 1992-01-14 City Of Hope Chimeric anti-cea antibody
US7247475B2 (en) * 1989-07-28 2007-07-24 Wyeth Method for producing monoclonal antibodies
US6475787B1 (en) * 1989-07-28 2002-11-05 Wyeth Method for producing monoclonal antibodies
US5580774A (en) * 1989-07-31 1996-12-03 Eli Lilly And Company Chimeric antibodies directed against a human glycoprotein antigen
US5959087A (en) * 1989-08-07 1999-09-28 Peptide Technology, Ltd. Tumour necrosis factor binding ligands
EP0486526B2 (de) 1989-08-07 2001-03-07 Peptech Limited Bindeligande für tumornekrosisfaktor
US20030225254A1 (en) * 1989-08-07 2003-12-04 Rathjen Deborah Ann Tumour necrosis factor binding ligands
CA2022959C (en) * 1989-08-10 2001-03-20 Hiroaki Maeda Cat-mouse heterohybridoma and gene fragment coding for constant region of feline immunoglobulin
US6586222B1 (en) 1989-08-16 2003-07-01 Chiron Corporation Recombinant PR-3 and compositions thereof
ATE148992T1 (de) 1989-08-16 1997-03-15 Chiron Corp Zusammensetzungen zur hemmung der bildung von proteinhormon und deren verwendungen
US5843693A (en) * 1989-08-16 1998-12-01 Chiron Corporation Assay method for screening for inhibitors of proTNF conversion
US5998378A (en) * 1989-08-16 1999-12-07 Chiron Corporation Compositions for the inhibition of TNF hormone formation and uses thereof
JPH05500611A (ja) * 1989-08-23 1993-02-12 ザ・ジェネラル・ホスピタル・コーポレーション 非ヒト霊長類ｃｄ４ポリペプチド、グリコシル化可能なヒトｃｄ４分子、その断片、その融合タンパク質、その遺伝子配列および使用
US5672683A (en) * 1989-09-07 1997-09-30 Alkermes, Inc. Transferrin neuropharmaceutical agent fusion protein
US6329508B1 (en) 1989-09-07 2001-12-11 Alkermes, Inc. Transferrin receptor reactive chimeric antibodies
US5977307A (en) * 1989-09-07 1999-11-02 Alkermes, Inc. Transferrin receptor specific ligand-neuropharmaceutical agent fusion proteins
DE59010908D1 (de) 1989-09-12 2000-08-10 Hoffmann La Roche TNF-bindende Proteine
WO1991004055A1 (en) * 1989-09-15 1991-04-04 Tanox Biosystems, Inc. Treatment of autoimmune disease
CA2066720A1 (en) * 1989-09-19 1991-03-20 David M. Knight Method for improving human monoclonal antibody production
US5196320A (en) * 1989-09-20 1993-03-23 Abbott Biotech, Inc. Method of producing engineered binding proteins
US6018031A (en) * 1989-10-20 2000-01-25 Trustees Of Dartmouth College Binding agents specific for IgA receptor
US7037722B1 (en) 1989-10-27 2006-05-02 The Scripps Research Institute Transgenic plants expressing assembled secretory antibodies
US7005560B1 (en) 1989-10-27 2006-02-28 The Scripps Research Institute Transgenic plants expressing assembled secretory antibodies
US5202422A (en) * 1989-10-27 1993-04-13 The Scripps Research Institute Compositions containing plant-produced glycopolypeptide multimers, multimeric proteins and method of their use
US5959177A (en) * 1989-10-27 1999-09-28 The Scripps Research Institute Transgenic plants expressing assembled secretory antibodies
US6995014B1 (en) 1989-10-27 2006-02-07 The Scripps Research Institute Transgenic plants expressing assembled secretory antibodies
WO1991006305A1 (en) * 1989-11-07 1991-05-16 Bristol-Myers Squibb Company Oligomeric immunoglobulins
EP0457875A4 (en) * 1989-11-13 1993-03-03 Xoma Corporation Chimeric mouse-human a10 antibody with specificity to a human tumor cell antigen
US6750325B1 (en) 1989-12-21 2004-06-15 Celltech R&D Limited CD3 specific recombinant antibody
GB8928874D0 (en) * 1989-12-21 1990-02-28 Celltech Ltd Humanised antibodies
US7037496B2 (en) 1989-12-27 2006-05-02 Centocor, Inc. Chimeric immunoglobulin for CD4 receptors
US6232444B1 (en) * 1990-01-29 2001-05-15 The Regents Of The University Of California Conserved anti-DNA antibody idiotype associated with nephritis in murine and human lupus
DE69127749T2 (de) * 1990-03-20 1998-04-16 The Trustees Of Columbia University In The City Of New York, New York, N.Y. Chimäre antikörper mit rezeptor-bindenden liganden anstelle ihrer konstanten region
GB9009548D0 (en) * 1990-04-27 1990-06-20 Celltech Ltd Chimeric antibody and method
GB9009549D0 (en) * 1990-04-27 1990-06-20 Celltech Ltd Recombinant antibody and method
WO1991017177A1 (en) * 1990-05-04 1991-11-14 Baxter Diagnostics Inc. High affinity antibodies to small peptides
US6395888B1 (en) * 1996-02-01 2002-05-28 Gilead Sciences, Inc. High affinity nucleic acid ligands of complement system proteins
US7253264B1 (en) 1990-06-28 2007-08-07 Sanofi-Arentideutschland GmbH Immunoglobulin fusion proteins, their production and use
US20030064480A1 (en) * 1990-06-28 2003-04-03 Leander Lauffer Fusion proteins with immunoglobulin portions, the preparation and use thereof
US7063943B1 (en) 1990-07-10 2006-06-20 Cambridge Antibody Technology Methods for producing members of specific binding pairs
US6916605B1 (en) * 1990-07-10 2005-07-12 Medical Research Council Methods for producing members of specific binding pairs
GB9015198D0 (en) * 1990-07-10 1990-08-29 Brien Caroline J O Binding substance
JP3283041B2 (ja) * 1990-07-13 2002-05-20 学校法人藤田学園 人工抗体
AU657911B2 (en) * 1990-07-16 1995-03-30 Roal Oy Immunoglobulin production by (Trichoderma)
DE4107154A1 (de) * 1990-10-11 1992-04-16 Boehringer Mannheim Gmbh Monoklonale antikoerper gegen melanom
GB9022543D0 (en) * 1990-10-17 1990-11-28 Wellcome Found Antibody production
WO1992008801A1 (en) * 1990-11-09 1992-05-29 Abbott Laboratories Bridging antibody fusion constructs
AU656934B2 (en) 1990-11-23 1995-02-23 General Hospital Corporation, The Inhibition of cell adhesion protein-carbohydrate interactions
US5709859A (en) * 1991-01-24 1998-01-20 Bristol-Myers Squibb Company Mixed specificity fusion proteins
US5571894A (en) * 1991-02-05 1996-11-05 Ciba-Geigy Corporation Recombinant antibodies specific for a growth factor receptor
MX9203138A (es) * 1991-03-12 1992-09-01 Biogen Inc Dominio de enlace cd2-de antigeno 3 (lfa-3) asociado con funcion linfositos.
EP0503648B1 (de) * 1991-03-12 2000-06-07 Biogen, Inc. CD2 bindender Bereich für das Lymphocyten-Funktion assoziierte Antigen-3
US20040120952A1 (en) * 2000-08-07 2004-06-24 Centocor, Inc Anti-TNF antibodies and peptides of human tumor necrosis factor
US6277969B1 (en) * 1991-03-18 2001-08-21 New York University Anti-TNF antibodies and peptides of human tumor necrosis factor
US7192584B2 (en) * 1991-03-18 2007-03-20 Centocor, Inc. Methods of treating psoriasis with anti-TNF antibodies
US6284471B1 (en) 1991-03-18 2001-09-04 New York University Medical Center Anti-TNFa antibodies and assays employing anti-TNFa antibodies
US6582959B2 (en) * 1991-03-29 2003-06-24 Genentech, Inc. Antibodies to vascular endothelial cell growth factor
US20030206899A1 (en) * 1991-03-29 2003-11-06 Genentech, Inc. Vascular endothelial cell growth factor antagonists
US20020032313A1 (en) * 1991-03-29 2002-03-14 Genentech, Inc. Vascular endothelial cell growth factor antagonists
US5223396A (en) * 1991-05-03 1993-06-29 Boehringer Ingelheim Pharmaceuticals, Inc. Method for detecting organ transplant rejection
US20050196400A1 (en) * 1991-05-06 2005-09-08 Xoma Technology Ltd. Production of chimeric mouse-human antibodies with specificity to human tumor antigens
US6797492B2 (en) 1991-05-17 2004-09-28 Merck & Co., Inc. Method for reducing the immunogenicity of antibody variable domains
US5834229A (en) * 1991-05-24 1998-11-10 Genentech, Inc. Nucleic acids vectors and host cells encoding and expressing heregulin 2-α
US6800738B1 (en) 1991-06-14 2004-10-05 Genentech, Inc. Method for making humanized antibodies
EP0590058B1 (de) 1991-06-14 2003-11-26 Genentech, Inc. Humanisierter Heregulin Antikörper
WO1994004679A1 (en) * 1991-06-14 1994-03-03 Genentech, Inc. Method for making humanized antibodies
US5939531A (en) * 1991-07-15 1999-08-17 Novartis Corp. Recombinant antibodies specific for a growth factor receptor
IE922437A1 (en) * 1991-07-25 1993-01-27 Idec Pharma Corp Recombinant antibodies for human therapy
US5756096A (en) * 1991-07-25 1998-05-26 Idec Pharmaceuticals Corporation Recombinant antibodies for human therapy
US6136310A (en) * 1991-07-25 2000-10-24 Idec Pharmaceuticals Corporation Recombinant anti-CD4 antibodies for human therapy
PT528767E (pt) * 1991-08-21 2000-06-30 Novartis Ag Derivados de anticorpos
EP0604580A1 (de) * 1991-09-19 1994-07-06 Genentech, Inc. Expression in E.Coli von Antikörperfragmenten mit mindestens einem cystein in freier -SH Form. Anwendung in der Herstellung bifunktioneller Antikörper.
US20070031409A1 (en) * 1991-09-26 2007-02-08 Stichting Rega Vzw Recombinant DNA-molecule complex for the expression of anti-human-interferon-gamma chimeric antibodies or antibody fragments
US6764681B2 (en) * 1991-10-07 2004-07-20 Biogen, Inc. Method of prophylaxis or treatment of antigen presenting cell driven skin conditions using inhibitors of the CD2/LFA-3 interaction
US6027725A (en) * 1991-11-25 2000-02-22 Enzon, Inc. Multivalent antigen-binding proteins
PT1024191E (pt) * 1991-12-02 2008-12-22 Medical Res Council Produção de auto-anticorpos a partir de reportórios de segmentos de anticorpo e exibidos em fagos
WO1993011794A1 (en) * 1991-12-13 1993-06-24 Xoma Corporation Methods and materials for preparation of modified antibody variable domains and therapeutic uses thereof
US5869619A (en) * 1991-12-13 1999-02-09 Xoma Corporation Modified antibody variable domains
CA2127462C (en) † 1992-01-13 1999-03-23 Roy R. Lobb Treatment for asthma
US5635177A (en) 1992-01-22 1997-06-03 Genentech, Inc. Protein tyrosine kinase agonist antibodies
WO1993017694A1 (en) * 1992-03-09 1993-09-16 San Diego Regional Cancer Center An anti-idiotypic antibody and its use in diagnosis and in therapy in hiv-related disease
US5518887A (en) * 1992-03-30 1996-05-21 Abbott Laboratories Immunoassays empolying generic anti-hapten antibodies and materials for use therein
US7754211B2 (en) * 1992-04-10 2010-07-13 Research Development Foundation Immunotoxins directed against c-erbB-2(HER-2/neu) related surface antigens
US6599505B1 (en) * 1992-04-10 2003-07-29 Research Development Foundation Immunotoxins directed against CD33 related surface antigens
AU4283793A (en) * 1992-04-16 1993-11-18 Albert Einstein College Of Medicine Of Yeshiva University Monocyte adhesion protein and monoclonal antibody thereto
US5851787A (en) * 1992-04-20 1998-12-22 The General Hospital Corporation Nucleic acid encoding amyloid precursor-like protein and uses thereof
WO1993023434A2 (en) * 1992-05-19 1993-11-25 Xoma Corporation Bpi-immunoglobulin fusion proteins
US6274348B1 (en) 1992-05-19 2001-08-14 Xoma Corporation Methods for the preparation of positively charged proteins
US5397703A (en) * 1992-07-09 1995-03-14 Cetus Oncology Corporation Method for generation of antibodies to cell surface molecules
US6765087B1 (en) * 1992-08-21 2004-07-20 Vrije Universiteit Brussel Immunoglobulins devoid of light chains
US5437951A (en) * 1992-09-03 1995-08-01 The United States Of America As Represented By The Department Of Health And Human Services Self-assembling recombinant papillomavirus capsid proteins
US5573924A (en) * 1992-09-08 1996-11-12 Immunex Corporation CD27 ligand
US5639641A (en) * 1992-09-09 1997-06-17 Immunogen Inc. Resurfacing of rodent antibodies
KR100335584B1 (ko) 1992-10-28 2002-11-29 제넨테크, 인코포레이티드 혈관내피세포성장인자에대한길항제
US7744877B2 (en) 1992-11-13 2010-06-29 Biogen Idec Inc. Expression and use of anti-CD20 Antibodies
ATE139900T1 (de) 1992-11-13 1996-07-15 Idec Pharma Corp Therapeutische verwendung von chimerischen und markierten antikörper gegen menschlichen b lymphozyt beschränkter differenzierung antigen für die behandlung von b-zell-lymphoma
US5736137A (en) * 1992-11-13 1998-04-07 Idec Pharmaceuticals Corporation Therapeutic application of chimeric and radiolabeled antibodies to human B lymphocyte restricted differentiation antigen for treatment of B cell lymphoma
DE69334156T2 (de) 1992-11-16 2008-04-10 Centocor, Inc. Verfahren zur Reduzierung der Immunogenizität der variablen Regionen von Antikörpern
WO1994012520A1 (en) * 1992-11-20 1994-06-09 Enzon, Inc. Linker for linked fusion polypeptides
SG44845A1 (en) 1993-01-12 1997-12-19 Biogen Inc Recombitant anti-vla4 antibody molecules
DE69333627T2 (de) * 1993-01-14 2005-09-22 Juridical Foundation The Chemo-Sero-Therapeutic Research Institute Rekombinanter anti-hiv antikörper und seine herstellung
US20050255104A1 (en) * 1993-01-29 2005-11-17 Centocor, Inc. Methods of treating psoriasis using anti-TNF receptor fusion proteins
EP0621338A3 (de) * 1993-04-21 1997-10-29 Ajinomoto Kk Die Interleukin-2 Antwort blockierende Immunsuppressor.
WO1994025591A1 (en) 1993-04-29 1994-11-10 Unilever N.V. PRODUCTION OF ANTIBODIES OR (FUNCTIONALIZED) FRAGMENTS THEREOF DERIVED FROM HEAVY CHAIN IMMUNOGLOBULINS OF $i(CAMELIDAE)
EP0697888B1 (de) 1993-05-12 2003-09-17 Chiron Corporation Konserviertes Motiv der Hepatitis C Virus E2/NS1 Region
US6562333B1 (en) 1993-06-14 2003-05-13 Schering Corporation Purified mammalian CTLA-8 antigens and related reagents
US20040067157A1 (en) * 1993-07-22 2004-04-08 Clearant, Inc. Methods for sterilizing biological materials
US5684144A (en) * 1993-07-28 1997-11-04 University Of North Texas Escherichia coli csrA gene, protein encoded thereby, and methods of use thereof
US5491071A (en) * 1993-08-03 1996-02-13 Abbott Laboratories Reagents and methods for the detection and quantification of testosterone in fluid samples
US5780028A (en) * 1993-09-20 1998-07-14 Anadis Ltd. Method of obtaining immunoglobulins from colostrum and their use in pharmaceutical composition
AU7732894A (en) * 1993-09-22 1995-04-10 Nichols Institute Diagnostics Graves' ophthalmopathy associated antibodies, graves' ophthalmopathy orbital antigen, and methods of use thereof
US5827690A (en) * 1993-12-20 1998-10-27 Genzyme Transgenics Corporatiion Transgenic production of antibodies in milk
DK145493D0 (da) * 1993-12-23 1993-12-23 Dako As Antistof
US5476939A (en) * 1993-12-30 1995-12-19 Abbott Laboratories Certain pyridyl and isoquinolyl carbinolamine derivatives
US6660256B1 (en) 1994-01-03 2003-12-09 Genetech, Inc. Porcine mpl ligand
US5605793A (en) * 1994-02-17 1997-02-25 Affymax Technologies N.V. Methods for in vitro recombination
US6995017B1 (en) 1994-02-17 2006-02-07 Maxygen, Inc. Methods for generating polynucleotides having desired characteristics by iterative selection and recombination
US6117679A (en) 1994-02-17 2000-09-12 Maxygen, Inc. Methods for generating polynucleotides having desired characteristics by iterative selection and recombination
US6395547B1 (en) 1994-02-17 2002-05-28 Maxygen, Inc. Methods for generating polynucleotides having desired characteristics by iterative selection and recombination
US6335160B1 (en) 1995-02-17 2002-01-01 Maxygen, Inc. Methods and compositions for polypeptide engineering
US6406855B1 (en) 1994-02-17 2002-06-18 Maxygen, Inc. Methods and compositions for polypeptide engineering
US6165793A (en) * 1996-03-25 2000-12-26 Maxygen, Inc. Methods for generating polynucleotides having desired characteristics by iterative selection and recombination
US5874080A (en) * 1994-03-03 1999-02-23 Genentech, Inc. Anti-IL-8 monoclonal antibodies for treatment of asthma
US5707622A (en) * 1994-03-03 1998-01-13 Genentech, Inc. Methods for treating ulcerative colitis
WO1995024501A1 (en) 1994-03-07 1995-09-14 Cetus Oncology Corporation Compositions for the inhibition of tnf formation and uses thereof
EP0746613B1 (de) * 1994-03-08 2006-05-24 Memorial Sloan-Kettering Cancer Center Rekombinante humanisierte antikörper gegen fb5
US5877016A (en) 1994-03-18 1999-03-02 Genentech, Inc. Human trk receptors and neurotrophic factor inhibitors
US6992175B1 (en) * 1994-04-15 2006-01-31 Amgen Inc. Nucleic acids encoding Eph-like receptor tyrosine kinases
US6074642A (en) 1994-05-02 2000-06-13 Alexion Pharmaceuticals, Inc. Use of antibodies specific to human complement component C5 for the treatment of glomerulonephritis
US5708142A (en) 1994-05-27 1998-01-13 Genentech, Inc. Tumor necrosis factor receptor-associated factors
USRE39548E1 (en) 1994-06-17 2007-04-03 Celltech R&D Limited Interleukin-5 specific recombinant antibodies
GB9412230D0 (en) 1994-06-17 1994-08-10 Celltech Ltd Interleukin-5 specific recombiant antibodies
US5686600A (en) * 1994-06-28 1997-11-11 Novartis Finance Corporation Antibodies which bind to insect gut proteins and their use
CU22615A1 (es) 1994-06-30 2000-02-10 Centro Inmunologia Molecular Procedimiento de obtención de anticuerpos monoclonales murinos menos inmunogénicos. anticuerpos monoclonales obtenidos
US6576236B1 (en) 1994-07-01 2003-06-10 Dana Farber Cancer Institute Methods for stimulating T cell responses by manipulating a common cytokine receptor γ chain
US6140075A (en) * 1994-07-25 2000-10-31 Monsanto Company Method for producing antibodies and protein toxins in plant cells
US6080560A (en) * 1994-07-25 2000-06-27 Monsanto Company Method for producing antibodies in plant cells
US5885574A (en) 1994-07-26 1999-03-23 Amgen Inc. Antibodies which activate an erythropoietin receptor
US8771694B2 (en) * 1994-08-12 2014-07-08 Immunomedics, Inc. Immunoconjugates and humanized antibodies specific for B-cell lymphoma and leukemia cells
EP0699754B2 (de) 1994-08-12 2009-08-12 The University of Utah Research Foundation Verfahren zum Nachweis von Prädisposition von Ovarial- und Brustkrebs
DE69521002T3 (de) 1994-08-12 2010-02-25 The University Of Utah Research Foundation, Salt Lake City Mutationen des mit 17q verbundenen Ovarial- und Brustkrebs Empfindlichkeitsgens
AU3272695A (en) * 1994-08-12 1996-03-07 Immunomedics Inc. Immunoconjugates and humanized antibodies specific for b-cell lymphoma and leukemia cells
US6350730B1 (en) 1994-08-17 2002-02-26 The Rockefeller University OB polypeptides and modified forms as modulators of body weight
US6124439A (en) * 1994-08-17 2000-09-26 The Rockefeller University OB polypeptide antibodies and method of making
US6124448A (en) * 1994-08-17 2000-09-26 The Rockfeller University Nucleic acid primers and probes for the mammalian OB gene
US6001968A (en) 1994-08-17 1999-12-14 The Rockefeller University OB polypeptides, modified forms and compositions
US6048837A (en) * 1994-08-17 2000-04-11 The Rockefeller University OB polypeptides as modulators of body weight
US6471956B1 (en) 1994-08-17 2002-10-29 The Rockefeller University Ob polypeptides, modified forms and compositions thereto
US6309853B1 (en) 1994-08-17 2001-10-30 The Rockfeller University Modulators of body weight, corresponding nucleic acids and proteins, and diagnostic and therapeutic uses thereof
CA2204355C (en) 1994-11-02 2001-01-16 Gail Mandel Peripheral nervous system specific sodium channels, dna encoding therefor, crystallization, x-ray diffraction, computer molecular modeling, rational drug design, drug screening, and methods of making and using thereof
US7820798B2 (en) * 1994-11-07 2010-10-26 Human Genome Sciences, Inc. Tumor necrosis factor-gamma
US7597886B2 (en) * 1994-11-07 2009-10-06 Human Genome Sciences, Inc. Tumor necrosis factor-gamma
US6017697A (en) 1994-11-14 2000-01-25 Eli Lilly And Company Excitatory amino acid receptor protein and related nucleic acid compounds
US20030086922A1 (en) * 1994-12-02 2003-05-08 David B. Ring Method of promoting an immune response with a bispecific antibody
US6692920B1 (en) * 1994-12-07 2004-02-17 Incyte Corporation Antibodies to a chemokine expressed in inflamed adenoid
US5633149A (en) * 1994-12-07 1997-05-27 Incyte Pharmaceuticals, Inc. Polynucleotide encoding novel chemokine expressed in inflamed adenoid
IL114615A0 (en) 1995-07-16 1995-11-27 Yeda Res & Dev Modulators of the function of fas receptors and other proteins
US5876950A (en) * 1995-01-26 1999-03-02 Bristol-Myers Squibb Company Monoclonal antibodies specific for different epitopes of human GP39 and methods for their use in diagnosis and therapy
US7803904B2 (en) * 1995-09-01 2010-09-28 Millennium Pharmaceuticals, Inc. Mucosal vascular addressing and uses thereof
US6551593B1 (en) 1995-02-10 2003-04-22 Millennium Pharmaceuticals, Inc. Treatment of Inflammatory bowel disease by inhibiting binding and/or signalling through α 4 β 7 and its ligands and madcam
US7005509B1 (en) 1995-02-17 2006-02-28 Incyte Corporation Chemokine PANEC-1 polynucleotides and compositions and methods related thereto
US5795966A (en) 1995-02-22 1998-08-18 Immunex Corp Antagonists of interleukin-15
US6130364A (en) * 1995-03-29 2000-10-10 Abgenix, Inc. Production of antibodies using Cre-mediated site-specific recombination
US6091001A (en) * 1995-03-29 2000-07-18 Abgenix, Inc. Production of antibodies using Cre-mediated site-specific recombination
IL117645A (en) * 1995-03-30 2005-08-31 Genentech Inc Vascular endothelial cell growth factor antagonists for use as medicaments in the treatment of age-related macular degeneration
US20060193862A1 (en) * 1995-03-30 2006-08-31 Genentech, Inc. Vascular endothelial cell growth factor antagonists
US6015555A (en) * 1995-05-19 2000-01-18 Alkermes, Inc. Transferrin receptor specific antibody-neuropharmaceutical or diagnostic agent conjugates
US5686292A (en) 1995-06-02 1997-11-11 Genentech, Inc. Hepatocyte growth factor receptor antagonist antibodies and uses thereof
US6214344B1 (en) 1995-06-02 2001-04-10 Genetech, Inc. Hepatocyte growth factor receptor antagonists and uses thereof
US5646036A (en) * 1995-06-02 1997-07-08 Genentech, Inc. Nucleic acids encoding hepatocyte growth factor receptor antagonist antibodies
GB0112226D0 (en) * 2001-05-18 2001-07-11 Danisco Method of improving dough and bread quality
CA2222231A1 (en) 1995-06-07 1996-12-19 Imclone Systems Incorporated Antibody and antibody fragments for inhibiting the growth of tumors
US7060808B1 (en) * 1995-06-07 2006-06-13 Imclone Systems Incorporated Humanized anti-EGF receptor monoclonal antibody
US7175847B1 (en) * 1995-06-07 2007-02-13 Biogen Idec Inc. Treating intestinal inflammation with anti-CD80 antibodies that do not inhibit CD80 binding to CTLA-4
US7153508B2 (en) * 1995-06-07 2006-12-26 Biogen Idec Inc. Treatment of B cell lymphoma using anti-CD80 antibodies that do not inhibit the binding of CD80 to CTLA-4
CA2223088A1 (en) 1995-06-07 1996-12-19 Bob Dale Brown Novel carbamate-based cationic lipids
EP0833911B1 (de) * 1995-06-07 2004-05-12 Ortho Pharmaceutical Corporation Cdr-transplantierte antikörper gegen "tissue factor" und verfahren zur deren verwendung
US6113898A (en) * 1995-06-07 2000-09-05 Idec Pharmaceuticals Corporation Human B7.1-specific primatized antibodies and transfectomas expressing said antibodies
WO1997000271A1 (en) 1995-06-14 1997-01-03 The Regents Of The University Of California Novel high affinity human antibodies to tumor antigens
US5925351A (en) * 1995-07-21 1999-07-20 Biogen, Inc. Soluble lymphotoxin-β receptors and anti-lymphotoxin receptor and ligand antibodies as therapeutic agents for the treatment of immunological disease
US6685940B2 (en) * 1995-07-27 2004-02-03 Genentech, Inc. Protein formulation
CA2226575C (en) 1995-07-27 2011-10-18 Genentech, Inc. Stabile isotonic lyophilized protein formulation
US20040197326A1 (en) * 1995-07-27 2004-10-07 Genentech, Inc. Method for treatment of allergic asthma
US6267958B1 (en) 1995-07-27 2001-07-31 Genentech, Inc. Protein formulation
US6248555B1 (en) 1995-08-31 2001-06-19 The General Hospital Corporation Genetic alterations related to familial alzheimer's disease
EP1416280A3 (de) * 1995-09-14 2005-08-10 The Regents of the University of California Antikörper spezifisch für natives PrPsc
WO1997012972A2 (en) 1995-09-29 1997-04-10 Universita'degli Studi Di Siena Regulated genes and uses thereof
US7368111B2 (en) 1995-10-06 2008-05-06 Cambridge Antibody Technology Limited Human antibodies specific for TGFβ2
JPH09124509A (ja) * 1995-10-27 1997-05-13 Sumitomo Electric Ind Ltd 肝炎治療剤
US6440418B1 (en) * 1995-11-07 2002-08-27 Idec Pharmaceuticals Corporation Methods of treating autoimmune diseases with gp39-specific antibodies
US6001358A (en) * 1995-11-07 1999-12-14 Idec Pharmaceuticals Corporation Humanized antibodies to human gp39, compositions containing thereof
US5783186A (en) 1995-12-05 1998-07-21 Amgen Inc. Antibody-induced apoptosis
US5837492A (en) 1995-12-18 1998-11-17 Myriad Genetics, Inc. Chromosome 13-linked breast cancer susceptibility gene
CA2239733C (en) 1995-12-18 2001-04-03 Myriad Genetics, Inc. Chromosome 13-linked breast cancer susceptibility gene
US6998116B1 (en) * 1996-01-09 2006-02-14 Genentech, Inc. Apo-2 ligand
US6046048A (en) * 1996-01-09 2000-04-04 Genetech, Inc. Apo-2 ligand
US20050089958A1 (en) * 1996-01-09 2005-04-28 Genentech, Inc. Apo-2 ligand
US6030945A (en) 1996-01-09 2000-02-29 Genentech, Inc. Apo-2 ligand
US7888466B2 (en) 1996-01-11 2011-02-15 Human Genome Sciences, Inc. Human G-protein chemokine receptor HSATU68
AU730816B2 (en) * 1996-02-12 2001-03-15 Cedars-Sinai Medical Center Vitamin D response element binding protein
US20040006018A1 (en) * 1996-02-14 2004-01-08 Genentech, Inc. Cardiotrophin and uses therefor
WO1997034636A1 (en) * 1996-03-20 1997-09-25 Immunomedics, Inc. Humanization of an anti-carcinoembryonic antigen anti-idiotype antibody and use as a tumor vaccine and for targeting applications
US5714352A (en) * 1996-03-20 1998-02-03 Xenotech Incorporated Directed switch-mediated DNA recombination
US6635743B1 (en) 1996-03-22 2003-10-21 Human Genome Sciences, Inc. Apoptosis inducing molecule II and methods of use
JP2000507245A (ja) * 1996-03-22 2000-06-13 ユニバーシティー オブ ジョージア リサーチ ファウンデーション，インコーポレイテッド Ｐｏｒｐｈｙｒｏｍｏｎａｓ ｇｉｎｇｉｖａｌｉｓペプチドを含む免疫原性組成物および方法
US7964190B2 (en) * 1996-03-22 2011-06-21 Human Genome Sciences, Inc. Methods and compositions for decreasing T-cell activity
US6506602B1 (en) 1996-03-25 2003-01-14 Maxygen, Inc. Methods for generating polynucleotides having desired characteristics by iterative selection and recombination
US5968511A (en) * 1996-03-27 1999-10-19 Genentech, Inc. ErbB3 antibodies
CA2249206A1 (en) 1996-04-01 1997-10-09 Genentech, Inc. Apo-2li and apo-3 apoptosis polypeptides
US20020165157A1 (en) * 1996-04-01 2002-11-07 Genentech, Inc. Apo-2LI and Apo-3 polypeptides
US7241568B2 (en) * 1996-04-03 2007-07-10 Kyowa Hakko Kogyo Co., Ltd. Anti-fibroblast growth factor-8 monoclonal antibody
US6497878B1 (en) 1996-04-23 2002-12-24 Chugai Seiyaku Kabushiki Kaisha Treatment of cerebral disorders by inhibition of IL-8 binding to receptor
US6107090A (en) 1996-05-06 2000-08-22 Cornell Research Foundation, Inc. Treatment and diagnosis of prostate cancer with antibodies to extracellur PSMA domains
US6136311A (en) 1996-05-06 2000-10-24 Cornell Research Foundation, Inc. Treatment and diagnosis of cancer
US6100071A (en) 1996-05-07 2000-08-08 Genentech, Inc. Receptors as novel inhibitors of vascular endothelial growth factor activity and processes for their production
AU2937597A (en) * 1996-05-10 1997-12-05 Biogen, Inc. Common gamma chain blocking agents
GB9610967D0 (en) 1996-05-24 1996-07-31 Cambridge Antibody Tech Specific binding members,materials and methods
CA2256481A1 (en) 1996-05-31 1997-12-04 The National American Red Cross Therapeutic and diagnostic methods and compositions based on jagged/notch proteins and nucleic acids
US6716974B1 (en) 1996-05-31 2004-04-06 Maine Medical Center Research Institute Therapeutic and diagnostic methods and compositions based on jagged/notch proteins and nucleic acids
EP0909277B2 (de) 1996-06-07 2008-12-24 Poniard Pharmaceuticals, Inc. Humanisierte antikörper die an das gleiche antigen wie antikörper nr-lu-13 binden und deren verwendung in "pretargeting" verfahren
ATE465257T1 (de) 1996-07-03 2010-05-15 Genentech Inc Agonisten für den rezeptor des hepatozyten- wachstumsfaktors und deren anwendungen
GB9712818D0 (en) * 1996-07-08 1997-08-20 Cambridge Antibody Tech Labelling and selection of specific binding molecules
ES2354379T3 (es) 1996-07-12 2011-03-14 Institut National De La Sante Et De La Recherche Medicale (Inserm) Factor intermediario transcripcional 2.
CA2262756C (en) 1996-08-07 2012-06-12 Biogen, Inc. A tumor necrosis factor related ligand
US7147851B1 (en) 1996-08-15 2006-12-12 Millennium Pharmaceuticals, Inc. Humanized immunoglobulin reactive with α4β7 integrin
US5851984A (en) * 1996-08-16 1998-12-22 Genentech, Inc. Method of enhancing proliferation or differentiation of hematopoietic stem cells using Wnt polypeptides
US6159462A (en) * 1996-08-16 2000-12-12 Genentech, Inc. Uses of Wnt polypeptides
DK0920505T3 (da) 1996-08-16 2008-09-08 Schering Corp Pattedyrcelleoverfladeantigener og tilhörende reagenser
WO1998007880A1 (en) 1996-08-16 1998-02-26 Human Genome Sciences, Inc. Human endokine alpha
US20030044859A1 (en) * 1996-08-19 2003-03-06 Henslee Jerry G. Reagents and methods useful for detecting diseases of the breast
US20030017147A1 (en) * 1996-09-20 2003-01-23 Guy L Reed Composition and method for enhancing fibrinolysis
US6462176B1 (en) 1996-09-23 2002-10-08 Genentech, Inc. Apo-3 polypeptide
CZ106299A3 (cs) * 1996-09-26 1999-08-11 Chugai Seiyaku Kabushiki Kaisha Protilátky proti proteinu příbuznému s lidským parathyroidálním hormonem
US6136958A (en) * 1996-09-30 2000-10-24 Genentech, Inc. Antibodies to vertebrate smoothened proteins
US5990281A (en) * 1996-09-30 1999-11-23 Genentech, Inc. Vertebrate smoothened proteins
US6261836B1 (en) * 1996-10-01 2001-07-17 Geron Corporation Telomerase
US6808880B2 (en) * 1996-10-01 2004-10-26 Geron Corporation Method for detecting polynucleotides encoding telomerase
US6475789B1 (en) 1996-10-01 2002-11-05 University Technology Corporation Human telomerase catalytic subunit: diagnostic and therapeutic methods
US7585622B1 (en) 1996-10-01 2009-09-08 Geron Corporation Increasing the proliferative capacity of cells using telomerase reverse transcriptase
US6093809A (en) * 1996-10-01 2000-07-25 University Technology Corporation Telomerase
EA199900355A1 (ru) 1996-10-01 2000-08-28 Джерон Корпорейшн Теломераза обратная тринскриптаза
US6610839B1 (en) * 1997-08-14 2003-08-26 Geron Corporation Promoter for telomerase reverse transcriptase
US6420140B1 (en) * 1996-10-11 2002-07-16 Abgenix, Inc. Production of multimeric protein by cell fusion method
US5916771A (en) * 1996-10-11 1999-06-29 Abgenix, Inc. Production of a multimeric protein by cell fusion method
US6653104B2 (en) 1996-10-17 2003-11-25 Immunomedics, Inc. Immunotoxins, comprising an internalizing antibody, directed against malignant and normal cells
US5977319A (en) * 1996-10-21 1999-11-02 Cambridge Antibody Technology Limited Specific binding members for estradiol; materials and methods
US7255854B1 (en) 1996-10-25 2007-08-14 Biogen, Inc. Use of lymphotoxin-β receptor blocking agents for the treatment of antibody mediated immunological diseases
NZ334309A (en) 1996-10-25 2000-08-25 Human Genome Sciences Inc Neutrokine alpha protein, a member of the TNF family, and its use in treating and/or detecting immune disorders
US6348581B1 (en) 1996-10-31 2002-02-19 The Dow Chemical Company High affinity humanized anti-TAG-72 monoclonalantibodies
US20040146507A1 (en) * 1996-11-27 2004-07-29 Genentech, Inc. Antibody mutants
US6037454A (en) * 1996-11-27 2000-03-14 Genentech, Inc. Humanized anti-CD11a antibodies
PT1114864E (pt) 1996-12-13 2008-10-08 Schering Corp Antigénios de superfície de células de mamífero, reagentes relacionados
US20070009930A1 (en) * 1996-12-18 2007-01-11 Maxygen, Inc. Methods and compositions for polypeptide engineering
EP1780277A1 (de) 1997-01-15 2007-05-02 Yeda Research And Development Company, Ltd. IFN Rezeptor 1 bindende Proteine, dafür kodierende DNA und Verfahren zur Regulierung der zellulären Antwort auf Interferone
US6100076A (en) 1997-01-31 2000-08-08 Genentech, Inc. O-fucosyltransferase
DK0942992T3 (da) 1997-01-31 2007-07-02 Genentech Inc O-fucosyltransferase
US20040241645A1 (en) * 1997-01-31 2004-12-02 Genentech, Inc. O-fucosyltransferase
EP2172478A3 (de) 1997-02-07 2010-07-28 THE GOVERNMENT OF THE UNITED STATES OF AMERICA as represented by the SECRETARY OF THE DEPARTMENT OF HEALTH AND HUMAN SERVICES Aktivitätsabhängiger neurotrophischer Faktor III (ADNF III)
US7528239B1 (en) * 1997-02-13 2009-05-05 Immunex Corporation Receptor that binds trail
US6893636B2 (en) * 1997-02-20 2005-05-17 Biogen Idec Ma Inc. Gamma-1 and gamma-3 anti-human CD23 monoclonal antibodies and use thereof as therapeutics
US7033589B1 (en) * 1997-02-20 2006-04-25 Biogen Idec Ma Inc. γ-1 anti-human CD23 monoclonal antibodies and use thereof as therapeutics
US20030109680A1 (en) * 2001-11-21 2003-06-12 Sunol Molecular Corporation Antibodies for inhibiting blood coagulation and methods of use thereof
US5986065A (en) * 1997-03-10 1999-11-16 Sunol Molecular Corporation Antibodies for inhibiting blood coagulation and methods of use thereof
US7749498B2 (en) * 1997-03-10 2010-07-06 Genentech, Inc. Antibodies for inhibiting blood coagulation and methods of use thereof
US20060235209A9 (en) * 1997-03-10 2006-10-19 Jin-An Jiao Use of anti-tissue factor antibodies for treating thromboses
WO1998041641A1 (en) * 1997-03-20 1998-09-24 The Government Of The United States As Represented By The Secretary Of The Department Of Health And Human Services Recombinant antibodies and immunoconjugates targeted to cd-22 bearing cells and tumors
AU736282B2 (en) 1997-03-21 2001-07-26 Chugai Seiyaku Kabushiki Kaisha A preventive or therapeutic agent for sensitized T cell- mediated diseases comprising IL-6 antagonist as an active ingredient
US5914394A (en) * 1997-03-27 1999-06-22 Millenium Pharmaceuticals, Inc. Methods and compositions for the diagnosis and treatment of neuropsychiatric disorders
US5866412A (en) * 1997-03-27 1999-02-02 Millennium Pharmaceuticals, Inc. Chromosome 18 marker
US5939316A (en) * 1997-03-27 1999-08-17 Millennium Pharmaceuticals, Inc. Chromosome 18 marker
US5955355A (en) * 1997-03-27 1999-09-21 Millennium Pharmaceuticals, Inc. Chromosome 18 marker
US20020102706A1 (en) * 1997-06-18 2002-08-01 Genentech, Inc. Apo-2DcR
US20020137890A1 (en) * 1997-03-31 2002-09-26 Genentech, Inc. Secreted and transmembrane polypeptides and nucleic acids encoding the same
US6969601B2 (en) 1997-04-03 2005-11-29 Jensenius Jens Chr MASP-2, a complement-fixing enzyme, and uses for it
US6884879B1 (en) 1997-04-07 2005-04-26 Genentech, Inc. Anti-VEGF antibodies
CN104231078A (zh) 1997-04-07 2014-12-24 基因技术股份有限公司 抗-血管内皮生长因子的抗体
DE69829891T2 (de) 1997-04-07 2005-10-06 Genentech, Inc., South San Francisco Anti-VEGF Antikörper
US20070059302A1 (en) * 1997-04-07 2007-03-15 Genentech, Inc. Anti-vegf antibodies
US20020032315A1 (en) * 1997-08-06 2002-03-14 Manuel Baca Anti-vegf antibodies
SI0994728T1 (sl) 1997-04-09 2009-02-28 Intellect Neurosciences Inc Rekombinantna protitelesa, specifična za beta-amiloidne konce, kodirana z DNA ter postopki za njihovo uporabo
AU7019498A (en) 1997-04-10 1998-10-30 Diagnocure Inc. Pca3, pca3 genes, and methods of use
CA2284726A1 (en) 1997-04-11 1998-10-22 G.D. Searle & Co. Antagonistic anti-avb3 integrin antibodies
US6193968B1 (en) 1997-04-11 2001-02-27 The Burnham Institute Methods for using anti-αvβ3 integrin antibody
DE69842225D1 (de) 1997-04-16 2011-05-26 Millennium Pharm Inc Zusammensetzung, umfassend einen Antikörper, der selektiv an ein cysteinreiches sekretiertes Protein (CRSP) bindet
US6316408B1 (en) * 1997-04-16 2001-11-13 Amgen Inc. Methods of use for osetoprotegerin binding protein receptors
EA003636B1 (ru) 1997-04-16 2003-08-28 Амген Инк. Остеопротегеринсвязующие белки и рецепторы
US7413864B2 (en) * 1997-04-18 2008-08-19 Geron Corporation Treating cancer using a telomerase vaccine
US7622549B2 (en) * 1997-04-18 2009-11-24 Geron Corporation Human telomerase reverse transcriptase polypeptides
US20050013825A1 (en) * 1997-04-18 2005-01-20 Geron Corporation Vaccine containing the catalytic subunit of telomerase for treating cancer
EP2311957A1 (de) 1997-04-25 2011-04-20 Antigenics Inc. Antigene aus granulozytischer Ehrlichia
US6593132B1 (en) 1997-04-30 2003-07-15 Twinstrand Therapeutics Inc. Ricin-like toxin variants for treatment of cancer, viral or parasitic infections
US20020062010A1 (en) * 1997-05-02 2002-05-23 Genentech, Inc. Method for making multispecific antibodies having heteromultimeric and common components
ATE302217T1 (de) * 1997-05-02 2005-09-15 Us Gov Health & Human Serv Immuntoxine, die ein onc protein enthalten, gegen bösartige zellen
US20030207346A1 (en) * 1997-05-02 2003-11-06 William R. Arathoon Method for making multispecific antibodies having heteromultimeric and common components
EP0979281B1 (de) * 1997-05-02 2005-07-20 Genentech, Inc. ein verfahren zur herstellung multispezifischer antikörper die heteromultimere und gemeinsame komponenten besitzen
US7951917B1 (en) 1997-05-02 2011-05-31 Genentech, Inc. Method for making multispecific antibodies having heteromultimeric and common components
WO2001090151A2 (en) 2000-05-25 2001-11-29 Schering Corporation Human receptor proteins; related reagents and methods
EP1988166A1 (de) 1997-05-07 2008-11-05 Schering Corporation Menschliche Toll-Like-Rezeptorproteine, zugehörige Reagenzien und Verfahren
US6342369B1 (en) * 1997-05-15 2002-01-29 Genentech, Inc. Apo-2-receptor
PT981618E (pt) 1997-05-15 2007-11-23 Genentech Inc ''anticorpo anti-apo-2''
US20100152426A1 (en) * 1997-05-15 2010-06-17 Ashkenazi Avi J Apo-2 receptor fusion proteins
PT1015477E (pt) 1997-05-30 2010-12-28 Human Genome Sciences Inc 32 proteínas humanas segregadas
US7541151B2 (en) 1997-06-05 2009-06-02 Duke University Single-cell biosensor for the measurement of GPCR ligands in a test sample
EP1003856A1 (de) 1997-06-05 2000-05-31 Board of Regents, The University of Texas System Apaf-1, menschluches ced-4 homolog, ein aktivator von caspase-3
US5891646A (en) * 1997-06-05 1999-04-06 Duke University Methods of assaying receptor activity and constructs useful in such methods
US6528271B1 (en) * 1997-06-05 2003-03-04 Duke University Inhibition of βarrestin mediated effects prolongs and potentiates opioid receptor-mediated analgesia
US6121428A (en) 1997-06-13 2000-09-19 Genentech, Inc. Protein recovery
CA2206774A1 (en) 1997-06-16 1998-12-16 Rick E. Preddie "prionins", highly specific markers for noninvasive presymptomatic defection of tse diseases, and targets for therapeutic reagents to prevent and control tse diseases in animals and humans
AU740227B2 (en) 1997-06-18 2001-11-01 Genentech Inc. Apo-2DcR
EP1754490A3 (de) 1997-06-20 2010-01-20 Biogen Idec MA Inc. CD154-Blockadetherapie der Pankreasinselzellentransplantation bei Primaten
US7147854B2 (en) * 1997-06-23 2006-12-12 Yes Biotech Laboratories Ltd. Topical treatment of psoriasis using neutralizing antibodies to interleukin-8
US5994511A (en) 1997-07-02 1999-11-30 Genentech, Inc. Anti-IgE antibodies and methods of improving polypeptides
US6172213B1 (en) 1997-07-02 2001-01-09 Genentech, Inc. Anti-IgE antibodies and method of improving polypeptides
AR014891A1 (es) 1997-07-09 2001-04-11 Schering Corp Genes aislados de proteinas de membranas de mamiferos; reactivos relacionados
US6165476A (en) * 1997-07-10 2000-12-26 Beth Israel Deaconess Medical Center Fusion proteins with an immunoglobulin hinge region linker
US6187564B1 (en) 1997-07-10 2001-02-13 Beth Israel Deaconess Medical Center DNA encoding erythropoietin multimers having modified 5′ and 3′ sequences and its use to prepare EPO therapeutics
US6242570B1 (en) 1997-07-10 2001-06-05 Beth Israel Deaconess Medical Center Production and use of recombinant protein multimers with increased biological activity
US6228638B1 (en) 1997-07-11 2001-05-08 University Of North Texas, Health Science Center At Fort Worth Escherichia coli CSRB gene and RNA encoded thereby
US6103466A (en) * 1997-07-14 2000-08-15 University Of Liege Double-muscling in mammals
WO1999002667A1 (en) * 1997-07-14 1999-01-21 University Of Liege Mutations in the myostation gene cause double-muscling in mammals
US20070067859A1 (en) * 1997-07-14 2007-03-22 Michel Georges Double-muscling in mammals
US6506579B1 (en) 1997-07-15 2003-01-14 Genencor International, Inc. Increasing production of proteins in gram-positive microorganisms using SecG
US6723550B1 (en) * 1997-07-15 2004-04-20 Genencor International, Inc. Proteases from gram-positive organisms
US6762039B2 (en) * 1997-07-15 2004-07-13 Genencor International, Inc. Bacillus subtillis with an inactivated cysteine protease-1
US20030157642A1 (en) 1997-07-15 2003-08-21 Caldwell Robert M. Increasing production of proteins in gram-positive microorganisms
US6521421B1 (en) 1997-07-16 2003-02-18 Genencor International, Inc. Expression vectors encoding Bacillus subtilis disulfide bond isomerase and methods of secreting proteins in gram-positive microorganisms using the same
ZA986596B (en) 1997-07-25 1999-02-08 Schering Corp Mammalian cytokine related reagents
EP1798286B1 (de) 1997-08-01 2011-09-07 Schering Corporation Membranproteine aus Säugetierzellen und verwandte Reagentien
KR20040024561A (ko) 1997-08-15 2004-03-20 츄가이 세이야꾸 가부시키가이샤 항 인터루킨-6 수용체 항체를 유효성분으로서 함유하는전신성 홍반성 낭창의 예방 및/또는 치료제
US6342220B1 (en) 1997-08-25 2002-01-29 Genentech, Inc. Agonist antibodies
US20030175856A1 (en) * 1997-08-26 2003-09-18 Genetech, Inc. Rtd receptor
AU8485098A (en) * 1997-08-26 1999-03-16 Genentech Inc. Rtd receptor
PL339463A1 (en) * 1997-09-12 2000-12-18 Biogen April - novel protein of growth promoting action
US6300117B1 (en) * 1997-09-15 2001-10-09 Genencor International, Inc. Proteases from gram-positive organisms
US6521440B1 (en) 1997-09-15 2003-02-18 Genencor International, Inc. Proteases from gram-positive organisms
EP1015488B1 (de) 1997-09-17 2009-09-09 Human Genome Sciences, Inc. Interleukin-17 rezeptor-ähnliches protein
US20020192209A1 (en) * 1997-09-17 2002-12-19 Genentech, Inc. Methods and compositions for inhibiting neoplastic cell growth
US20040231011A1 (en) * 2001-06-28 2004-11-18 Genentech, Inc. DcR3 polypeptide, a TNFR homolog
WO1999014330A1 (en) * 1997-09-18 1999-03-25 Genentech, Inc. DcR3 POLYPEPTIDE, A TNFR HOMOLOG
US20030082767A1 (en) * 1997-09-18 2003-05-01 Genentech, Inc. Secreted and transmembrane polypeptides and nucleic acids encoding the same
US7378244B2 (en) * 1997-10-01 2008-05-27 Geron Corporation Telomerase promoters sequences for screening telomerase modulators
AU749948B2 (en) 1997-10-10 2002-07-04 Genentech Inc. APO-3 ligand
WO1999018997A1 (en) 1997-10-14 1999-04-22 Chugai Seiyaku Kabushiki Kaisha Potentiator for antibody against lymphoid tumor
AU1070399A (en) 1997-10-17 1999-05-10 Genentech Inc. Human toll homologues
US6639051B2 (en) * 1997-10-20 2003-10-28 Curis, Inc. Regulation of epithelial tissue by hedgehog-like polypeptides, and formulations and uses related thereto
DE69836823D1 (de) 1997-10-21 2007-02-15 Univ Glasgow Jmy, mit-aktivator für p300/cbp, dafür kodierendenucleinsäure und deren verwendungen
EP2033970A3 (de) 1997-10-29 2009-06-17 Genentech, Inc. WNT-1-induzierbare Gene
ATE406441T1 (de) 1997-10-29 2008-09-15 Genentech Inc Verwendung des wnt-1 induzierten sekretierten polypeptids wisp-1
EP1992633A1 (de) 1997-11-03 2008-11-19 Human Genome Sciences, Inc. VEGI, ein Hemmstoff der Angiogenese und Tumorwachstum
EP1029049A2 (de) * 1997-11-07 2000-08-23 Biogen, Inc. Bmog, ein mitglied der myelin-oligodendrocyte glycoprotein familie and seine verwendung
GB9724627D0 (en) 1997-11-20 1998-01-21 Genencor Int Bv Gram positive microorganism formate pathway
GB9724629D0 (en) * 1997-11-20 1998-01-21 Genencor Int Bv Alpha/beta hydrolase-fold enzymes
DK1481990T3 (da) 1997-11-21 2007-10-01 Genentech Inc A33-beslægtede antigener og deres farmakologiske anvendelser
WO1999027078A1 (en) 1997-11-21 1999-06-03 Human Genome Sciences, Inc. Chemokine alpha-5
US7192589B2 (en) 1998-09-16 2007-03-20 Genentech, Inc. Treatment of inflammatory disorders with STIgMA immunoadhesins
US7964192B1 (en) 1997-12-02 2011-06-21 Janssen Alzheimer Immunotherapy Prevention and treatment of amyloidgenic disease
US7790856B2 (en) * 1998-04-07 2010-09-07 Janssen Alzheimer Immunotherapy Humanized antibodies that recognize beta amyloid peptide
TWI239847B (en) * 1997-12-02 2005-09-21 Elan Pharm Inc N-terminal fragment of Abeta peptide and an adjuvant for preventing and treating amyloidogenic disease
US7179892B2 (en) * 2000-12-06 2007-02-20 Neuralab Limited Humanized antibodies that recognize beta amyloid peptide
US6761888B1 (en) * 2000-05-26 2004-07-13 Neuralab Limited Passive immunization treatment of Alzheimer's disease
US7588766B1 (en) 2000-05-26 2009-09-15 Elan Pharma International Limited Treatment of amyloidogenic disease
US20080050367A1 (en) * 1998-04-07 2008-02-28 Guriq Basi Humanized antibodies that recognize beta amyloid peptide
ES2221717T3 (es) 1997-12-08 2005-01-01 Emd Lexigen Research Center Corp. Proteinas de fusion heterodimeras utiles para inmunoterapia dirigida e inmunoestimulacion general.
IL136574A0 (en) 1997-12-08 2001-06-14 California Inst Of Techn A method for forming a polynucleotide of desired properties
US6248542B1 (en) * 1997-12-09 2001-06-19 Massachusetts Institute Of Technology Optoelectronic sensor
EP1947119A3 (de) 1997-12-12 2012-12-19 Genentech, Inc. Krebsbehandlung mit Antikörpern gegen ERBB2 und einem chemotherapeutischen Mittel
US6528255B1 (en) * 1997-12-30 2003-03-04 Genencor International, Inc. Proteases from gram positive organisms
GB9727470D0 (en) * 1997-12-30 1998-02-25 Genencor Int Bv Proteases from gram positive organisms
US6599731B1 (en) * 1997-12-30 2003-07-29 Genencor International, Inc. Proteases from gram positive organisms
US6465186B1 (en) * 1997-12-30 2002-10-15 Genecor International, Inc. Proteases from gram positive organisms
EP1044211A4 (de) * 1998-01-07 2005-03-23 Human Genome Sciences Inc 36 menschliche sekretierte proteine
CA2318029C (en) 1998-01-15 2009-05-19 Genentech, Inc. Apo-2 ligand
US6673914B1 (en) 1998-01-22 2004-01-06 John Wayne Cancer Institute Human tumor-associated gene
US6764830B1 (en) 1998-01-23 2004-07-20 The Regents Of The University Of California Thermomyces lanuginosus kinesin motor protein and methods of screening for modulators of kinesin proteins
US7060667B1 (en) 1998-01-30 2006-06-13 Biogen Idec Ma, Inc. Treatment of follicular lymphomas using inhibitors of the LT pathway
ATE393912T1 (de) 1998-02-04 2008-05-15 Invitrogen Corp Microarrays und ihre verwendungen
US20020136721A1 (en) * 1998-02-17 2002-09-26 Schwall Ralph H. Hepatocyte growth factor receptor antagonists and uses thereof
US6051228A (en) * 1998-02-19 2000-04-18 Bristol-Myers Squibb Co. Antibodies against human CD40
US20030105294A1 (en) * 1998-02-25 2003-06-05 Stephen Gillies Enhancing the circulating half life of antibody-based fusion proteins
US6727079B1 (en) * 1998-02-25 2004-04-27 The United States Of America As Represented By The Department Of Health And Human Services cDNA encoding a gene BOG (B5T Over-expressed Gene) and its protein product
US6617171B2 (en) * 1998-02-27 2003-09-09 The General Hospital Corporation Methods for diagnosing and treating autoimmune disease
AU2980199A (en) 1998-03-04 1999-09-20 Genencor International, Inc. Modified forms of pullulanase
NZ525914A (en) 1998-03-10 2004-03-26 Genentech Inc Novel polypeptides and nucleic acids encoding the same
US20040176572A1 (en) * 1998-03-16 2004-09-09 Freimer Nelson B. Methods of compositions for diagnosing and treating chromosome-18p related disorders
WO1999047535A1 (en) 1998-03-16 1999-09-23 Millennium Pharmaceuticals, Inc. METHODS AND COMPOSITIONS FOR DIAGNOSING AND TREATING CHROMOSOME-18p RELATED DISORDERS
EP1064382B1 (de) 1998-03-17 2008-08-20 Genentech, Inc. Zu vegf und bmp1 homologe polypeptide
ATE490980T1 (de) 1998-03-19 2010-12-15 Human Genome Sciences Der gemeinsamen gamma-kette ähnlicher zytokinrezeptor
US20030224001A1 (en) * 1998-03-19 2003-12-04 Goldstein Neil I. Antibody and antibody fragments for inhibiting the growth of tumors
DE69932510T2 (de) 1998-03-24 2007-02-15 Chugai Seiyaku K.K. Vaskularisierungsinhibitoren
EP1941905A1 (de) 1998-03-27 2008-07-09 Genentech, Inc. APO-2 Liganden-Anti-HER-2-Antikörper-Synergismus
US6337200B1 (en) * 1998-03-31 2002-01-08 Geron Corporation Human telomerase catalytic subunit variants
WO1999051620A1 (en) * 1998-04-03 1999-10-14 Invitrogen Corporation Libraries of expressible gene sequences
US20050059802A1 (en) * 1998-04-07 2005-03-17 Neuralab Ltd Prevention and treatment of amyloidogenic disease
US6348575B1 (en) * 1998-04-15 2002-02-19 Genentech, Inc. Patched-2
CN1318092C (zh) * 1998-04-15 2007-05-30 利思进药品公司 含有抗体－细胞因子融合蛋白和血管生成抑制剂的免疫治疗用组合物
US20020029391A1 (en) * 1998-04-15 2002-03-07 Claude Geoffrey Davis Epitope-driven human antibody production and gene expression profiling
US6709838B1 (en) 1998-04-15 2004-03-23 Genentech, Inc. Nucleic acid encoding patched-2
US7157083B2 (en) * 1998-04-17 2007-01-02 Surrogate Pharmaceutical Pathways, Llc Compositions and methods for treating retroviral infections
GB9809951D0 (en) 1998-05-08 1998-07-08 Univ Cambridge Tech Binding molecules
ZA200007412B (en) * 1998-05-15 2002-03-12 Imclone Systems Inc Treatment of human tumors with radiation and inhibitors of growth factor receptor tyrosine kinases.
EP1865061A3 (de) 1998-05-15 2007-12-19 Genentech, Inc. IL-17-homologe Polypeptide und ihre therapeutische Verwendung
EP3112468A1 (de) 1998-05-15 2017-01-04 Genentech, Inc. Il-17-homologe polypeptide und therapeutische verwendung davon
ES2292242T5 (es) 1998-05-15 2011-05-04 Genentech, Inc. Utilizaciones terapéuticas de polipéptidos homólogos de il-17.
US6197947B1 (en) 1998-06-01 2001-03-06 The Rockefeller University Translation initiation factor 4AIII and methods of use thereof
WO2001060397A1 (en) 2000-02-16 2001-08-23 Genentech, Inc. Uses of agonists and antagonists to modulate activity of tnf-related molecules
PT1086138E (pt) * 1998-06-12 2010-01-04 Genentech Inc Anticorpos monoclonais, anticorpos de reacção cruzada e método para produzir os mesmos
US6252050B1 (en) * 1998-06-12 2001-06-26 Genentech, Inc. Method for making monoclonal antibodies and cross-reactive antibodies obtainable by the method
JP2000000097A (ja) 1998-06-15 2000-01-07 Nippon Zoki Pharmaceut Co Ltd Ｎｅｆ結合蛋白質、該蛋白質をコードするＤＮＡ並びに該蛋白質に対するモノクローナル抗体
US6365408B1 (en) 1998-06-19 2002-04-02 Maxygen, Inc. Methods of evolving a polynucleotides by mutagenesis and recombination
EP1096955B9 (de) 1998-07-13 2006-07-05 Board of Regents, The University of Texas System Verwendung von antikörper gegen aminophospholipide zur krebsbehandlung
US6780582B1 (en) * 1998-07-14 2004-08-24 Zyomyx, Inc. Arrays of protein-capture agents and methods of use thereof
US6406921B1 (en) * 1998-07-14 2002-06-18 Zyomyx, Incorporated Protein arrays for high-throughput screening
US20020119579A1 (en) * 1998-07-14 2002-08-29 Peter Wagner Arrays devices and methods of use thereof
ATE231186T1 (de) 1998-07-21 2003-02-15 Danisco Lebensmittel
US6727349B1 (en) 1998-07-23 2004-04-27 Millennium Pharmaceuticals, Inc. Recombinant anti-CCR2 antibodies and methods of use therefor
US6312689B1 (en) 1998-07-23 2001-11-06 Millennium Pharmaceuticals, Inc. Anti-CCR2 antibodies and methods of use therefor
US6696550B2 (en) * 1998-07-23 2004-02-24 Millennium Pharmaceuticals, Inc. Humanized anti-CCR2 antibodies and methods of use therefor
PT1974747E (pt) 1998-08-11 2012-09-05 Biogen Idec Inc Terapias de combinação para linfomas de células b compreendendo a administração de anticorpo anti-cd20
US20020172678A1 (en) 2000-06-23 2002-11-21 Napoleone Ferrara EG-VEGF nucleic acids and polypeptides and methods of use
JP2002523071A (ja) * 1998-08-31 2002-07-30 バイオジェン インコーポレイテッド 記憶エフェクターｔ細胞を調整する方法と組成物
DE69942063D1 (de) * 1998-09-11 2010-04-08 Curis Inc Antagonisten von 'hedgehog' und 'patched' zur inhibierung des wachstums und der differenzierung von zellen und geweben, als auch deren verwendungen
AU6394399A (en) 1998-09-18 2000-04-10 Rockefeller University, The Lynx, a novel family of receptor ligands in the central nervous system, corresponding nucleic acids and proteins and uses thereof
CA2343979C (en) 1998-09-21 2011-11-15 Schering Corporation Human interleukin-b50, therapeutic uses
EP0997476A3 (de) 1998-09-25 2000-07-19 Schering-Plough Antikörper gegen ein Antigen auf Langerhans Zellen in Säugetieren und deren Verwendungen
IL142094A0 (en) * 1998-09-29 2002-03-10 Gamida Cell Ltd Methods of controlling proliferation and differentiation of stem and progenitor cells
TR200100974T2 (tr) * 1998-10-09 2001-11-21 Biogen, Inc. Virütik kaynaklı sistematik şok ve solunum zorluğunun,lenfotoksin beta yolunu bloke etmek suretiyle geri çevrilmesi
US7488590B2 (en) 1998-10-23 2009-02-10 Amgen Inc. Modified peptides as therapeutic agents
US20030027998A1 (en) * 1998-10-30 2003-02-06 Holtzman Douglas A. Novel genes encoding proteins having prognostic, diagnostic, preventive, therapeutic, and other uses
US20060205034A1 (en) * 1998-10-30 2006-09-14 Millennium Pharmaceuticals, Inc. Novel genes encoding proteins having prognostic, diagnostic, preventive, therapeutic, and other uses
US6818749B1 (en) * 1998-10-31 2004-11-16 The United States Of America As Represented By The Department Of Health And Human Services Variants of humanized anti carcinoma monoclonal antibody cc49
ES2351149T3 (es) 1998-11-09 2011-02-01 Biogen Idec Inc. Anticuerpo quimérico dirigido contra cd20, el rituxan, para uso en el tratamiento de la leucemia linfocítica crónica.
MXPA01004649A (es) * 1998-11-09 2002-05-06 Idec Pharma Corp Tratamiento con anticuerpo quimerico anti-cd20 para pacientes que reciben transplantes de medula osea o celulas madre de sangre periferica.
AU1727500A (en) * 1998-11-17 2000-06-05 Tanox, Inc. Bispecific molecules cross-linking itim and itam for therapy
SI1135498T1 (sl) 1998-11-18 2008-06-30 Genentech Inc Variante protitelesa z višjo vezavno afiniteto vprimerjavi z izvirnimi protitelesi
US6773911B1 (en) 1998-11-23 2004-08-10 Amgen Canada Inc. Apoptosis-inducing factor
CA2450402A1 (en) 1998-12-22 2000-06-29 Genentech, Inc. Methods and compositions for inhibiting cancer cell growth comprising pro224
EP1579871A1 (de) 1998-12-22 2005-09-28 Genentech, Inc. Antagonisten von vaskular-endothelialen Zellwachstumsfaktoren und ihre Anwendung
CA2354027A1 (en) 1998-12-23 2000-07-06 Genentech, Inc. Il-1 related polypeptides
KR20010089764A (ko) 1999-01-11 2001-10-08 둘락 노먼 씨. 인터류킨-17과 관련된 포유류의 사이토카인, 이를코딩하는 폴리뉴클레오티드 및 이의 용도
HUP0104865A3 (en) 1999-01-15 2004-07-28 Genentech Inc Polypeptide variants with altered effector function
CZ299819B6 (cs) 1999-01-25 2008-12-03 Biogen Idec Ma Inc. Farmaceutické kompozice obsahující protilátky specifické pro rozpustný BAFF
US6303749B1 (en) 1999-01-29 2001-10-16 Amgen Inc. Agouti and agouti-related peptide analogs
US7708993B2 (en) * 1999-02-03 2010-05-04 Amgen Inc. Polypeptides involved in immune response
US8624010B1 (en) 1999-02-03 2014-01-07 Steven K. Yoshinaga Nucleic acids encoding B7RP1
US7435796B1 (en) 1999-02-03 2008-10-14 Amgen Inc. Antibodies which bind B7RP1
EP2332976B1 (de) 1999-02-03 2014-04-02 Amgen, Inc An der Immunreaktion beteiligte neuartige Polypeptiden
US6972125B2 (en) * 1999-02-12 2005-12-06 Genetics Institute, Llc Humanized immunoglobulin reactive with B7-2 and methods of treatment therewith
CN1360596A (zh) * 1999-02-12 2002-07-24 遗传研究所有限公司 与b7分子发生反应的人源化免疫球蛋白及应用该免疫球蛋白的治疗方法
AU3382800A (en) 1999-02-26 2000-09-14 Millennium Pharmaceuticals, Inc. Secreted proteins and uses thereof
WO2000050620A2 (en) 1999-02-26 2000-08-31 Human Genome Sciences, Inc. Human endokine alpha and methods of use
PT1157041E (pt) * 1999-03-01 2005-10-31 Genentech Inc Anticorpos para terapia e diagnostico de cancro
MY133346A (en) * 1999-03-01 2007-11-30 Biogen Inc Kit for radiolabeling ligands with yttrium-90
US20020102208A1 (en) 1999-03-01 2002-08-01 Paul Chinn Radiolabeling kit and binding assay
PT1159003E (pt) * 1999-03-02 2011-02-22 Centocor Inc Anti-tnf alfa na terapêutica da asma resistente a esteróides
US6531125B1 (en) 1999-03-02 2003-03-11 Twinstrand Therapeutics Inc. Antiviral ricin-like proteins
US6599710B1 (en) 1999-03-10 2003-07-29 The General Hospital Corporation Treatment of autoimmune disease
DE60041393D1 (de) 1999-03-11 2009-03-05 Schering Corp Cytokine aus säugetieren, verwandte reagenzien und verfahren
WO2000056363A1 (en) 1999-03-19 2000-09-28 Genentech, Inc. Treatment of lfa-1 associated disorders with increasing doses of lfa-1 antagonist
WO2000058479A1 (en) 1999-03-26 2000-10-05 Amgen Inc. Beta secretase genes and polypeptides
US6911429B2 (en) * 1999-04-01 2005-06-28 Transition Therapeutics Inc. Compositions and methods for treating cellular response to injury and other proliferating cell disorders regulated by hyaladherin and hyaluronans
DE19915057A1 (de) 1999-04-01 2000-10-19 Forschungszentrum Borstel Monoklonale Antikörper gegen das humane Mcm3 Protein, Verfahren zu ihrer Herstellung und ihre Verwendung
EP2275540B1 (de) * 1999-04-09 2016-03-23 Kyowa Hakko Kirin Co., Ltd. Verfahren zur Steuerung der Aktivität von immunologisch funktionellen Molekülen
GB9908533D0 (en) 1999-04-14 1999-06-09 Novartis Ag Organic compounds
US6492497B1 (en) 1999-04-30 2002-12-10 Cambridge Antibody Technology Limited Specific binding members for TGFbeta1
EP1645292A1 (de) 1999-05-07 2006-04-12 Genentech, Inc. Behandlung von Autoimmunkrankheiten mit Antagonisten die Oberflächenmarker von B Zellen binden
IL146005A0 (en) * 1999-05-07 2002-07-25 Genentech Inc Treatment of autoimmune diseases with antagonists which bind to b cell surface markers
US6831060B2 (en) 1999-05-07 2004-12-14 Genentech, Inc. Chimpanzee erythropoietin (CHEPO) polypeptides and nucleic acids encoding the same
US8383081B2 (en) * 1999-05-10 2013-02-26 Immunomedics, Inc. Anti-CD74 immunoconjugates and methods of use
US8119101B2 (en) * 1999-05-10 2012-02-21 The Ohio State University Anti-CD74 immunoconjugates and methods of use
US7829064B2 (en) * 1999-05-10 2010-11-09 Immunomedics, Inc. Anti-CD74 immunoconjugates and methods
EP2336321A1 (de) 1999-05-13 2011-06-22 Medical Research Council Ox2 Rezeptor Homolog
US6974684B2 (en) * 2001-08-08 2005-12-13 Curagen Corporation Therapeutic polypeptides, nucleic acids encoding same, and methods of use
US20040023874A1 (en) * 2002-03-15 2004-02-05 Burgess Catherine E. Therapeutic polypeptides, nucleic acids encoding same, and methods of use
EE200100603A (et) 1999-05-14 2003-02-17 Imclone Systems Incorporated Inimese refraktaarsete kasvajate ravi epidermaalse kasvufaktori retseptori antagonistidega
US20040229779A1 (en) * 1999-05-14 2004-11-18 Ramesh Kekuda Therapeutic polypeptides, nucleic acids encoding same, and methods of use
US6221597B1 (en) 1999-05-21 2001-04-24 Rosetta Inpharmatics, Inc. Essential genes of yeast as targets for antifungal agents, herbicides, insecticides and anti-proliferative drugs
US6197517B1 (en) 1999-05-21 2001-03-06 Rosetta Inpharmatics, Inc. Essential genes of yeast as targets for antifungal agents, herbicides, insecticides and anti-proliferative drugs
US6200803B1 (en) 1999-05-21 2001-03-13 Rosetta Inpharmatics, Inc. Essential genes of yeast as targets for antifungal agents, herbicides, insecticides and anti-proliferative drugs
US7166573B1 (en) * 1999-05-28 2007-01-23 Ludwig Institute For Cancer Research Breast, gastric and prostate cancer associated antigens and uses therefor
CA2305716A1 (en) 1999-05-28 2000-11-28 University Of Guelph Method for assay of wbpm
IL130225A0 (en) 1999-05-31 2000-06-01 Yissum Res Dev Co Novel uses of antibodies against ache and peptides thereof
EP1181366B2 (de) 1999-06-01 2013-08-21 Merck Sharp & Dohme Corp. Säugetier-rezeptorproteine; ähnliche reagentien und methoden
US20040067490A1 (en) * 2001-09-07 2004-04-08 Mei Zhong Therapeutic polypeptides, nucleic acids encoding same, and methods of use
US7534605B2 (en) * 1999-06-08 2009-05-19 Yissum Research Development Company Of The Hebrew University Of Jerusalem CD44 polypeptides, polynucleotides encoding same, antibodies directed thereagainst and method of using same for diagnosing and treating inflammatory diseases
DE60043367D1 (de) 1999-06-15 2009-12-31 Genentech Inc Sekretierte und Transmembran-Polypeptide sowie Nukleinsäuren zu deren Kodierung
GB9914210D0 (en) 1999-06-17 1999-08-18 Danisco Promoter
US20030166561A1 (en) * 1999-06-18 2003-09-04 Cooper Garth J. S. Peptide
AR024464A1 (es) 1999-06-25 2002-10-02 Genentech Inc Anticuerpos anti-erbb2 humanizados.
EP2977063A1 (de) 1999-06-25 2016-01-27 Genentech, Inc. Methoden zur Behandlung unter Verwendung von Anti-ErbB Antibody-Maytansinoid Konjugaten
US20040001826A1 (en) * 1999-06-30 2004-01-01 Millennium Pharmaceuticals, Inc. Glycoprotein VI and uses thereof
JP2003527826A (ja) 1999-06-30 2003-09-24 ルードヴィッヒ インスティテュート フォー キャンサー リサーチ 癌関連抗原およびその使用
US7291714B1 (en) * 1999-06-30 2007-11-06 Millennium Pharmaceuticals, Inc. Glycoprotein VI and uses thereof
FR2797402B1 (fr) 1999-07-15 2004-03-12 Biomerieux Stelhys Utilisation d'un polypeptide pour detecter, prevenir ou traiter un etat pathologique associe a une maladie degenerative, neurologique ou autoimmune
US7001766B2 (en) * 1999-07-20 2006-02-21 Curagen Corporation Nucleic acid sequences encoding human angiopoietin-like polypeptides
US7067110B1 (en) 1999-07-21 2006-06-27 Emd Lexigen Research Center Corp. Fc fusion proteins for enhancing the immunogenicity of protein and peptide antigens
SK782002A3 (en) * 1999-07-21 2003-08-05 Lexigen Pharm Corp FC fusion proteins for enhancing the immunogenicity of protein and peptide antigens
ES2330406T3 (es) 1999-07-30 2009-12-10 Schering Corporation Citocinas de mamifero; reactivos relacionados.
WO2001010912A1 (en) * 1999-08-09 2001-02-15 Lexigen Pharmaceuticals Corp. Multiple cytokine-antibody complexes
US8557244B1 (en) 1999-08-11 2013-10-15 Biogen Idec Inc. Treatment of aggressive non-Hodgkins lymphoma with anti-CD20 antibody
US6927203B1 (en) 1999-08-17 2005-08-09 Purdue Research Foundation Treatment of metastatic disease
HK1043608B (en) 1999-08-17 2007-12-07 Biogen Ma Inc. Baff receptor (bcma), an immunoregulatory agent
US7192698B1 (en) * 1999-08-17 2007-03-20 Purdue Research Foundation EphA2 as a diagnostic target for metastatic cancer
KR20020025990A (ko) 1999-08-23 2002-04-04 나가야마 오사무 에이치엠1.24 항원의 발현 증강제
ES2539411T3 (es) 1999-08-23 2015-06-30 Dana-Farber Cancer Institute, Inc. PD-1, receptor para la B7-4 y su utilización
NZ517202A (en) 1999-08-24 2004-05-28 Medarex Inc Human CTLA-4 antibodies and their uses
EP2110138A1 (de) 1999-08-27 2009-10-21 Genentech, Inc. Dosierungen zur Behandlung von Anti-erbB2-Antikörpern
KR20050004240A (ko) * 1999-08-31 2005-01-12 제넨테크, 인크. 종양 치료용 조성물 및 방법
US7408047B1 (en) * 1999-09-07 2008-08-05 Amgen Inc. Fibroblast growth factor-like polypeptides
US7459540B1 (en) * 1999-09-07 2008-12-02 Amgen Inc. Fibroblast growth factor-like polypeptides
EP1905832A3 (de) 1999-09-09 2009-09-09 Schering Corporation Säuger Interleukin-12 P40 und Interleukin B30, Antikörper, Verwendungen in pharmazeutischen Zusammenstellungen
US6900043B1 (en) * 1999-09-21 2005-05-31 Amgen Inc. Phosphatases which activate map kinase pathways
US7297478B1 (en) 2000-09-22 2007-11-20 Large Scale Biology Corporation Creation of variable length and sequence linker regions for dual-domain or multi-domain molecules
EP1903107A1 (de) 1999-09-24 2008-03-26 Cybios LLC Pluripotente embryonische Stammzellen sowie Zusammensetzungen daraus, Verfahren dafür und Verwendungen davon
DK1222266T3 (da) 1999-09-29 2006-07-10 Diagnocure Inc PCA3-messenger-RNA i benigne og maligne prostatavæv
US7892541B1 (en) 1999-09-30 2011-02-22 Tumor Biology Investment Group, Inc. Soluble epidermal growth factor receptor isoforms
IL148980A0 (en) 1999-10-01 2002-11-10 Chugai Pharmaceutical Co Ltd An antibody to human tissue factor and experimental animals having inserted cells with the gene encoding human tissue factor
UA74798C2 (uk) 1999-10-06 2006-02-15 Байоджен Айдек Ма Інк. Спосіб лікування раку у ссавця за допомогою поліпептиду, що протидіє взаємодії april з його рецепторами
US7947496B2 (en) 1999-10-08 2011-05-24 Hoffmann-La Roche Inc. Cytotoxicity mediation of cells evidencing surface expression of CD44
US6855806B1 (en) * 1999-10-15 2005-02-15 Curagen Corporation Thymosin beta 10-like proteins and nucleic acids encoding same
EP1222313A2 (de) * 1999-10-19 2002-07-17 Curagen Corporation Gene asoziert mit fettleibigkeit und benutzung derselben
WO2001029220A2 (en) 1999-10-19 2001-04-26 Ludwig Institute For Cancer Research Mage-a12 antigenic peptides and uses thereof
WO2001029070A2 (en) 1999-10-20 2001-04-26 Genentech, Inc. Modulation of t cell differentiation for the treatment of t helper cell mediated diseases
US6342587B1 (en) 1999-10-22 2002-01-29 Ludwig Institute For Cancer Research A33 antigen specific immunoglobulin products and uses thereof
US6346249B1 (en) 1999-10-22 2002-02-12 Ludwig Institute For Cancer Research Methods for reducing the effects of cancers that express A33 antigen using A33 antigen specific immunoglobulin products
US7078382B1 (en) 1999-11-02 2006-07-18 Genentech, Inc. Modulation of eNOS activity and therapeutic uses thereof
EP1228085A4 (de) 1999-11-05 2005-02-02 Gen Hospital Corp Ein 'gridlock'-nukleinsäuremolekül, polypeptide, und diagnostische und therapeutische verfahren
US20050202538A1 (en) * 1999-11-12 2005-09-15 Merck Patent Gmbh Fc-erythropoietin fusion protein with improved pharmacokinetics
CA2391080A1 (en) 1999-11-12 2001-05-25 Merck Patent Gesellschaft Mit Beschraenkter Haftung Erythropoietin forms with improved properties
CA2389979C (en) 1999-11-24 2011-08-16 Schering Corporation Methods of inhibiting metastasis
US7425437B2 (en) * 1999-11-26 2008-09-16 Crucell Holland B.V. Vaccines against West Nile Virus
CA3016482A1 (en) 1999-11-30 2001-06-07 Mayo Foundation For Medical Education And Research B7-h1, a novel immunoregulatory molecule
CA2391455A1 (en) 1999-12-01 2001-06-07 Genentech, Inc. Secreted and transmembrane polypeptides and nucleic acids encoding the same
US6544792B1 (en) 1999-12-21 2003-04-08 Genencor International, Inc. Production of secreted polypeptides
DK1897944T3 (da) 1999-12-23 2011-10-24 Genentech Inc IL-17 homologe polypeptider og terapeutisk anvendelse deraf
KR20020073491A (ko) 1999-12-30 2002-09-26 제넨코 인터내셔날 인코포레이티드 트리코데르마 레제이 자일란 분해효소
US6979537B2 (en) 2000-01-10 2005-12-27 Scios, Inc. Methods for identifying inhibitors of neuronal degeneration
CN1425066B (zh) * 2000-01-13 2010-05-26 杰南技术公司 新的stra6多肽
WO2003074738A1 (en) * 2000-01-18 2003-09-12 Quantom Dot Corporation Oligonucleotide-tagged semiconductor nanocrystals for microarray and fluorescence in situ hybridization
AU2002219944B2 (en) 2000-11-28 2008-02-21 Medimmune, Llc Methods of administering/dosing anti-RSV antibodies for prophylaxis and treatment
EP1259544B1 (de) 2000-02-11 2011-08-24 Biogen Idec MA Inc. Heterologes polypeptid der tnf familie
JP5179689B2 (ja) * 2000-02-11 2013-04-10 メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツング 抗体ベース融合タンパク質の循環系内半減期の増強
US20030176385A1 (en) * 2000-02-15 2003-09-18 Jingfang Ju Antisense modulation of protein expression
US6894021B2 (en) * 2000-02-17 2005-05-17 Cv Therapeutics, Inc. Method for identifying and using A2B adenosine receptor antagonists to mediate mammalian cell proliferation
JP3439195B2 (ja) * 2000-02-17 2003-08-25 浜松ホトニクス株式会社 抗原の定量的検出方法
US20030103978A1 (en) 2000-02-23 2003-06-05 Amgen Inc. Selective binding agents of osteoprotegerin binding protein
US8623373B2 (en) * 2000-02-24 2014-01-07 Philogen S.P.A. Compositions and methods for treatment of angiogenesis in pathological lesions
EP1259548A1 (de) 2000-02-24 2002-11-27 Eidgenössische Technische Hochschule Zürich Antikörper gegen die ed-b domäne von fibronektin, konjugate die diesen antikörper enthalten, und deren verwendung zum nachweis und zur behandlung von angiogenese
US20040002068A1 (en) 2000-03-01 2004-01-01 Corixa Corporation Compositions and methods for the detection, diagnosis and therapy of hematological malignancies
WO2001066747A2 (en) * 2000-03-03 2001-09-13 Curagen Corporation Proteins named fctrx and nucleic acids encoding same
GB2361704C (en) 2000-03-03 2006-08-02 Cambridge Antibody Tech Human antibodies against eotaxin and their use
US6630584B1 (en) * 2000-03-16 2003-10-07 Ramot At Tel-Aviv University Ltd. Single chain antibody against mutant p53
US6740520B2 (en) 2000-03-21 2004-05-25 Genentech, Inc. Cytokine receptor and nucleic acids encoding the same
US20040086970A1 (en) * 2000-03-22 2004-05-06 Genentech, Inc. Novel cytokine receptors and nucleic acids encoding the same
EP1276904B1 (de) 2000-03-22 2013-08-28 Life Technologies Corporation Verfahren zur verwendung von halbleiter-nanokristallen bei nukleinsäure-assays auf bead-basis
AU2001252958A1 (en) * 2000-03-23 2001-10-03 Elan Pharmaceuticals, Inc. Compounds and methods to treat alzheimer's disease
US6992081B2 (en) 2000-03-23 2006-01-31 Elan Pharmaceuticals, Inc. Compounds to treat Alzheimer's disease
US20030212022A1 (en) * 2001-03-23 2003-11-13 Jean-Marie Vogel Compositions and methods for gene therapy
WO2001072281A2 (en) 2000-03-24 2001-10-04 Biosphere Medical Inc. Microspheres for active embolization
US20030185796A1 (en) * 2000-03-24 2003-10-02 Chiron Corporation Methods of therapy for non-hodgkin's lymphoma
US7514239B2 (en) 2000-03-28 2009-04-07 Amgen Inc. Nucleic acid molecules encoding beta-like glycoprotein hormone polypeptides and heterodimers thereof
US20050043262A1 (en) * 2000-03-29 2005-02-24 Weiss Robert H. Novel specific inhibitor of the cyclin kinase inhibitor p21Waf1/Cip1 and methods of using the inhibitor
US20030144236A1 (en) * 2000-03-29 2003-07-31 Weiss Robert H Novel specific inhibitor of the cyclin kinase inhibitor p21 (wafl/cip1)
AU2001253140A1 (en) * 2000-04-03 2001-10-15 The Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services Tumor markers in ovarian cancer
US20030108927A1 (en) * 2000-04-03 2003-06-12 Kathryn Leishman Compositions and methods for the prevention, treatment and detection of tuberculosis and other diseases
PT2857516T (pt) * 2000-04-11 2017-08-28 Genentech Inc Anticorpos multivalentes e utilizações dos mesmos
US6926898B2 (en) 2000-04-12 2005-08-09 Human Genome Sciences, Inc. Albumin fusion proteins
AU5345901A (en) * 2000-04-13 2001-10-30 Univ Rockefeller Enhancement of antibody-mediated immune responses
US20010046496A1 (en) * 2000-04-14 2001-11-29 Brettman Lee R. Method of administering an antibody
ES2317898T3 (es) 2000-04-18 2009-05-01 Schering Corporation Usos medicinales de agonistas y antogonistas de il-174.
US7632929B2 (en) * 2000-04-20 2009-12-15 The Board Of Trustees Of The University Of Arkansas Methamphetamine-like hapten compounds, linkers, carriers and compositions and uses thereof
EP1278065A4 (de) * 2000-04-25 2004-09-15 Tokuyama Dental Corp Verfahren zum nachweis von streptococcus sobrinus und antikörper dafür
WO2001080884A1 (en) * 2000-04-25 2001-11-01 Idec Pharmaceuticals Corporation Intrathecal administration of rituximab for treatment of central nervous system lymphomas
US20040013674A1 (en) * 2001-04-27 2004-01-22 Christine Ambrose Taci as an anti-tumor agent
WO2001082968A1 (fr) 2000-04-28 2001-11-08 Chugai Seiyaku Kabushiki Kaisha Inhibiteurs de proliferation cellulaire
US7279160B2 (en) 2000-05-02 2007-10-09 The Uab Research Foundation Combinations of DR5 antibodies and other therapeutic agents
US6696620B2 (en) 2000-05-02 2004-02-24 Epicyte Pharmaceutical, Inc. Immunoglobulin binding protein arrays in eukaryotic cells
TWI318983B (en) 2000-05-02 2010-01-01 Uab Research Foundation An antibody selective for a tumor necrosis factor-related apoptosis-inducing ligand receptor and uses thereof
CA2408291C (en) * 2000-05-04 2014-07-15 Yale University High density protein arrays for screening of protein activity
US6835545B2 (en) 2000-05-08 2004-12-28 President And Fellows Of Harvard College Methods, products and treatments for diabetes
US7439330B2 (en) * 2000-05-08 2008-10-21 President And Fellows Of Harvard College Anti-glycated CD59 antibodies and uses thereof
US7560534B2 (en) 2000-05-08 2009-07-14 Celldex Research Corporation Molecular conjugates comprising human monoclonal antibodies to dendritic cells
US20030219786A1 (en) * 2000-08-11 2003-11-27 Applied Research Systems Ars Holding N.V. Novel glycoproteins and methods of use thereof
US20040005554A1 (en) * 2000-05-08 2004-01-08 Tayar Nabil El Novel glycoproteins and methods of use thereof
US6756481B2 (en) 2000-05-10 2004-06-29 Schering Corporation IL-23 receptor binding compositions
US7422743B2 (en) 2000-05-10 2008-09-09 Schering Corporation Mammalian receptor protein DCRS5;methods of treatment
EP2287190B1 (de) 2000-05-10 2014-12-17 Mayo Foundation For Medical Education And Research Menschliche IgM-Antikörper, welche die Fähigkeit besitzen, den Wiederaufbau der Myelinstruktur zu induzieren und deren diagnostische und therapeutische Anwendung im Zentralen Nervensystem
AU2001263114A1 (en) 2000-05-12 2001-11-26 Amgen Inc Methods and compositions of matter concerning april/g70, bcma, blys/agp-3, and taci
EP1935431A3 (de) 2000-05-15 2008-08-13 Health Research, Inc. Krebsbehandlungen unter Verwendung einer Kombination aus einem HER2-Antikörper und Interleukin-2
EP1714661A3 (de) 2000-05-19 2012-03-14 The Center for Blood Research, INC. Verfahren zur Diagnose und Behandlung von hämostatischen Störungen durch Modulation der P-Selectin Aktivität
US20030009016A1 (en) * 2000-05-25 2003-01-09 Shimkets Richard A. Nucleic acids containing single nucleotide polymorphisms and methods of use thereof
EP1950297A2 (de) 2000-05-31 2008-07-30 Novartis Vaccines and Diagnostics, Inc. Zusammensetzungen und Verfahren zur Behandlung neoplastischer Erkrankungen mithilfe von Chemotherapie und Strahlungssensibilisatoren
WO2001092338A1 (en) 2000-06-01 2001-12-06 The Brigham And Women's Hospital, Inc. Diagnosis of endometrial precancers
US20030031675A1 (en) 2000-06-06 2003-02-13 Mikesell Glen E. B7-related nucleic acids and polypeptides useful for immunomodulation
AU7522401A (en) * 2000-06-06 2001-12-17 Idec Pharma Corp Non-agonistic antibodies to human gp39, compositions containing, and therapeuticuse thereof
DE60141463D1 (de) 2000-06-08 2010-04-15 Immune Disease Inst Inc Methoden und verbindungen zur hemmung immunoglobulin-vermittelter reperfusions-verletzungen
EP1294949A4 (de) 2000-06-15 2004-08-25 Human Genome Sciences Inc Menschlicher tumornekrosefaktor delta und epsilon
AU2001268427B2 (en) 2000-06-16 2007-03-29 Glaxosmithkline Intellectual Property Limited Antibodies that immunospecifically bind to blys
AU6836301A (en) 2000-06-20 2002-01-02 Idec Pharma Corp Treatment of b-cell associated diseases such as malignancies and autoimmune diseases using a cold anti-cd20 antibody/radiolabeled anti-cd22 antibody combination
EP1176200A3 (de) 2000-06-20 2005-01-12 Switch Biotech Aktiengesellschaft Verwendung von Polypeptiden oder diese kodierende Nukleinsäuren zur Diagnose oder Behandlung von Hauterkrankung oder Wundheilung sowie ihre Verwendung zur Indentifizierung von pharmakologisch aktiven Substanzen
WO2001098543A2 (en) * 2000-06-21 2001-12-27 Diadexus, Inc. Method of diagnosing, monitoring, staging, imaging and treating breast cancer
EP2792747A1 (de) 2000-06-23 2014-10-22 Genentech, Inc. Zusammensetzungen und Verfahren zur Diagnose und Behandlung von Erkrankungen in Verbindung mit Angiogenese
EP2075253A1 (de) 2000-06-23 2009-07-01 Genentech, Inc. Methoden und Verbindungen zur Diagnose und Behandlung von Krankheiten, an denen Angiogenese beteiligt ist
AU2001271618B8 (en) * 2000-06-28 2006-04-27 Amgen, Inc. B7-Like molecules and uses thereof
US20060034828A1 (en) * 2000-06-28 2006-02-16 Gerngross Tillman U Immunoglobulins comprising predominantly a GlcNAcMAN5GLCNAC2 glycoform
US20060029604A1 (en) * 2000-06-28 2006-02-09 Gerngross Tillman U Immunoglobulins comprising predominantly a GlcNAc2Man3GlcNAc2 glycoform
US20060257399A1 (en) * 2000-06-28 2006-11-16 Glycofi, Inc. Immunoglobulins comprising predominantly a Man5GIcNAc2 glycoform
US20060024304A1 (en) * 2000-06-28 2006-02-02 Gerngross Tillman U Immunoglobulins comprising predominantly a Man5GlcNAc2 glycoform
US20060034830A1 (en) * 2000-06-28 2006-02-16 Gerngross Tillman U Immunoglobulins comprising predominantly a GalGlcNAcMan5GLcNAc2 glycoform
US7964713B2 (en) 2000-06-28 2011-06-21 Amgen Inc. Nucleic acid molecules encoding thymic stromal lympopoietin receptor proteins and a process for producing the encoded polypeptides thereof
CZ2003214A3 (cs) * 2000-06-29 2003-08-13 Merck Patent Gmbh Zesílení odpovědi mediovaných fúzním proteinem protilátka-cytokin kombinovanou léčbou pomocí činidel zvyšujících uptake imunocytokinu
CA2410680A1 (en) * 2000-06-30 2002-01-10 Elan Pharmaceuticals, Inc. Compounds to treat alzheimer's disease
US20030096864A1 (en) * 2000-06-30 2003-05-22 Fang Lawrence Y. Compounds to treat alzheimer's disease
US6846813B2 (en) * 2000-06-30 2005-01-25 Pharmacia & Upjohn Company Compounds to treat alzheimer's disease
PE20020276A1 (es) 2000-06-30 2002-04-06 Elan Pharm Inc COMPUESTOS DE AMINA SUSTITUIDA COMO INHIBIDORES DE ß-SECRETASA PARA EL TRATAMIENTO DE ALZHEIMER
US20040235173A1 (en) * 2000-07-03 2004-11-25 Gala Design, Inc. Production of host cells containing multiple integrating vectors by serial transduction
US20030224415A1 (en) * 2001-06-29 2003-12-04 Gala Design, Inc. Selection free growth of host cells containing multiple integrating vectors
US6852510B2 (en) 2000-07-03 2005-02-08 Gala Design Inc Host cells containing multiple integrating vectors
AU2001270252B2 (en) * 2000-07-03 2007-02-08 Catalent Pharma Solutions, Llc Expression vectors
FR2811323B1 (fr) * 2000-07-07 2006-10-06 Fuma Tech Gmbh Materiau hybride, utilisation dudit materiau hybride et procede de sa fabrication
US6951947B2 (en) * 2000-07-13 2005-10-04 The Scripps Research Institute Labeled peptides, proteins and antibodies and processes and intermediates useful for their preparation
US7176037B2 (en) 2000-07-13 2007-02-13 The Scripps Research Institute Labeled peptides, proteins and antibodies and processes and intermediates useful for their preparation
US20040023259A1 (en) * 2000-07-26 2004-02-05 Luca Rastelli Therapeutic polypeptides, nucleic acids encoding same, and methods of use
WO2002009755A2 (en) 2000-07-27 2002-02-07 Genentech, Inc. Apo-2l receptor agonist and cpt-11 synergism
WO2002010187A1 (en) 2000-07-27 2002-02-07 Mayo Foundation For Medical Education And Research B7-h3 and b7-h4, novel immunoregulatory molecules
US6984522B2 (en) * 2000-08-03 2006-01-10 Regents Of The University Of Michigan Isolation and use of solid tumor stem cells
US20060018907A1 (en) * 2000-08-07 2006-01-26 Centocor, Inc. Anti-TNF antibodies and peptides of human tumor necrosis factor
US20110195063A1 (en) * 2000-08-07 2011-08-11 Centocor, Inc. Methods of Treating Ankylosing Spondylitis Using Anti-TNF Antibodies and Peptides of Human Tumor Necrosis Factor
US6902734B2 (en) 2000-08-07 2005-06-07 Centocor, Inc. Anti-IL-12 antibodies and compositions thereof
US7288390B2 (en) 2000-08-07 2007-10-30 Centocor, Inc. Anti-dual integrin antibodies, compositions, methods and uses
US20050249735A1 (en) * 2000-08-07 2005-11-10 Centocor, Inc. Methods of treating ankylosing spondylitis using anti-TNF antibodies and peptides of human tumor necrosis factor
UA81743C2 (uk) 2000-08-07 2008-02-11 Центокор, Инк. МОНОКЛОНАЛЬНЕ АНТИТІЛО ЛЮДИНИ, ЩО СПЕЦИФІЧНО ЗВ'ЯЗУЄТЬСЯ З ФАКТОРОМ НЕКРОЗУ ПУХЛИН АЛЬФА (ФНПα), ФАРМАЦЕВТИЧНА КОМПОЗИЦІЯ, ЩО ЙОГО МІСТИТЬ, ТА СПОСІБ ЛІКУВАННЯ РЕВМАТОЇДНОГО АРТРИТУ
AU2001281168A1 (en) 2000-08-08 2002-02-18 St. Jude Children's Research Hospital Group b streptococcus polypeptides nucleic acids and therapeutic compositions and vaccines thereof
US20030114410A1 (en) 2000-08-08 2003-06-19 Technion Research And Development Foundation Ltd. Pharmaceutical compositions and methods useful for modulating angiogenesis and inhibiting metastasis and tumor fibrosis
AU2001295002B2 (en) * 2000-08-09 2007-05-31 Imclone Systems Incorporated Treatment of hyperproliferative diseases with epidermal growth factor receptor antagonists
US6911204B2 (en) 2000-08-11 2005-06-28 Favrille, Inc. Method and composition for altering a B cell mediated pathology
CN101275136A (zh) 2000-08-11 2008-10-01 麒麟医药株式会社 调节磷酸代谢,钙代谢,钙化和维生素d代谢的多肽及其编码dna
SG143058A1 (en) * 2000-08-11 2008-06-27 Favrille Inc Method and composition for altering a t cell mediated pathology
US8568766B2 (en) 2000-08-24 2013-10-29 Gattadahalli M. Anantharamaiah Peptides and peptide mimetics to treat pathologies associated with eye disease
DE60136281D1 (de) 2000-08-24 2008-12-04 Genentech Inc Methode zur inhibierung von il-22 induziertem pap1
EP1197550A3 (de) * 2000-08-25 2002-11-20 Pfizer Products Inc. Methoden und Zusammensetzungen zur Diagnose unde Behandlung von Krankheiten an denen Angiogenese beteiligt ist
DE60143959D1 (de) 2000-08-25 2011-03-10 Basf Plant Science Gmbh En kodieren
JP2003000268A (ja) 2000-08-25 2003-01-07 Pfizer Prod Inc 血管新生にかかわる疾患を診断および治療するための方法および組成物
EP1944317A3 (de) 2000-09-01 2008-09-17 Genentech, Inc. Sekretierte und Transmembran-Polypeptide sowie Nukleinsäure zu deren Kodierung
CA2417432C (en) 2000-09-01 2010-11-02 The Center For Blood Research, Inc. Modified polypeptides stabilized in a desired conformation and methods for producing same
AU8867501A (en) * 2000-09-01 2002-03-13 Biogen Inc Co-crystal structure of monoclonal antibody 5c8 and cd154, and use thereof in drug design
ATE549347T1 (de) 2000-09-08 2012-03-15 Schering Corp Gene von säugetiere, und damit verbundene reagentien, methoden
WO2002022683A1 (fr) * 2000-09-12 2002-03-21 Kirin Beer Kabushiki Kaisha Nouvelle membrane a paroi cellulaire dendritique et son utilisation
US6673623B1 (en) 2000-09-12 2004-01-06 Novocure, Inc. Methods and compositions that control lipid production
DE60130565D1 (de) * 2000-09-12 2007-10-31 Univ Bern Pde8a und seine verwendung
US7101976B1 (en) 2000-09-12 2006-09-05 Purdue Research Foundation EphA2 monoclonal antibodies and methods of making and using same
AU8901901A (en) 2000-09-14 2002-03-26 Biogen Inc Tweak receptor agonists as anti-angiogenic agents background
WO2002022212A2 (en) * 2000-09-18 2002-03-21 Idec Pharmaceuticals Corporation Combination therapy for treatment of autoimmune diseases using b cell depleting/immunoregulatory antibody combination
WO2002022667A2 (en) * 2000-09-18 2002-03-21 Genencor International, Inc. Twin-arginine translocation in bacillus
UA83458C2 (uk) 2000-09-18 2008-07-25 Байоджен Айдек Ма Інк. Виділений поліпептид baff-r (рецептор фактора активації в-клітин сімейства tnf)
GB0022978D0 (en) 2000-09-19 2000-11-01 Oxford Glycosciences Uk Ltd Detection of peptides
US20030044803A1 (en) * 2000-09-22 2003-03-06 Pedersen Finn Skou Methods for diagnosis and treatment of diseases associated with altered expression of JAK1
US20030077590A1 (en) * 2000-09-22 2003-04-24 Pedersen Finn Skou Methods for diagnosis and treatment of diseases associated with altered expression of neurogranin
US20020115058A1 (en) * 2000-09-22 2002-08-22 Pedersen Finn Skou Methods for diagnosis and treatment of diseases associated with altered expression of Pik3r1
AU2001293187A1 (en) * 2000-09-28 2002-04-08 Uab Research Foundation Chimeric retroviral gag genes and screening assays
WO2002028481A2 (en) 2000-10-02 2002-04-11 Chiron Corporation Methods of therapy for b-cell malignancies using antagonist anti-cd40 antibodies
US20030022247A1 (en) * 2000-10-03 2003-01-30 Masabumi Shibuya Substance which inhibits binding of information transfer molecule for 1175-tyrosine phosphorylated KDR/FLK-1 and usages of the same
US6946292B2 (en) * 2000-10-06 2005-09-20 Kyowa Hakko Kogyo Co., Ltd. Cells producing antibody compositions with increased antibody dependent cytotoxic activity
US20050059031A1 (en) 2000-10-06 2005-03-17 Quantum Dot Corporation Method for enhancing transport of semiconductor nanocrystals across biological membranes
DE60137953D1 (de) 2000-10-06 2009-04-23 Life Technologies Corp Zellen mit spektraler signatur sowie verfahren zu ihrer herstellung und nutzung
ATE449791T1 (de) 2000-10-10 2009-12-15 Genentech Inc Inhibierung von c5 komplement-aktivierung für die behandlung und vorbeugung von xeno-transplantat oder akute vaskuläre abstossung
WO2002031745A1 (en) * 2000-10-10 2002-04-18 Genencor International, Inc. Information rich libraries
DE60139944D1 (de) 2000-10-12 2009-10-29 Genentech Inc Niederviskose konzentrierte proteinformulierungen
JP5305553B2 (ja) 2000-10-12 2013-10-02 ユニバーシティー オブ ロチェスター 癌細胞の増殖を阻害する組成物
ES2338757T3 (es) 2000-10-18 2010-05-12 The Brigham And Women's Hospital, Inc. Polipeptidos ligandos para selectina-e/selectina-l de la celula hematopoyetica y metodos de utilizacion de los mismos.
US7393532B1 (en) 2000-10-18 2008-07-01 Genentech, Inc. Modulation of T cell differentiation for the treatment of T helper cell mediated diseases
AU2002213357A1 (en) * 2000-10-20 2002-05-06 Idec Pharmaceuticals Corporation Variant igg3 rituxan r and therapeutic use thereof
US7259232B1 (en) 2000-10-27 2007-08-21 Nymox Pharmaceutical Corporation Preferred segments of neural thread protein
US20050144655A1 (en) 2000-10-31 2005-06-30 Economides Aris N. Methods of modifying eukaryotic cells
US6596541B2 (en) 2000-10-31 2003-07-22 Regeneron Pharmaceuticals, Inc. Methods of modifying eukaryotic cells
WO2002046208A2 (en) * 2000-11-01 2002-06-13 Elusys Therapeutics, Inc. Method of producing biospecific molecules by protein trans-splicing
US7163800B2 (en) * 2000-11-03 2007-01-16 Molecular Devices Corporation Methods of screening compositions for G protein-coupled receptor desensitization inhibitory activity
US20050136431A1 (en) * 2000-11-03 2005-06-23 Oakley Robert H. Methods of screening compositions for G protein-coupled receptor desensitization inhibitory activity
US7018812B2 (en) * 2000-11-03 2006-03-28 Duke University Modified G-protein coupled receptors
WO2002043658A2 (en) * 2000-11-06 2002-06-06 The Jackson Laboratory Fcrn-based therapeutics for the treatment of auto-immune disorders
US6890734B2 (en) 2000-11-10 2005-05-10 Schering Corporation Nucleic acids encoding a cytokine receptor complex
AU2002230524A1 (en) * 2000-11-16 2002-05-27 California Institute Of Technology Apparatus and methods for conducting assays and high throughput screening
CN1306272C (zh) * 2000-11-17 2007-03-21 罗切斯特大学 筛选编码抗原特异性免疫球蛋白分子或其抗原特异性片段的方法
US20050196755A1 (en) * 2000-11-17 2005-09-08 Maurice Zauderer In vitro methods of producing and identifying immunoglobulin molecules in eukaryotic cells
NZ526617A (en) 2000-11-28 2004-09-24 Wyeth Corp Expression analysis of KIAA nucleic acids and polypeptides useful in the diagnosis and treatment of prostate cancer
EP2042596B1 (de) 2000-11-28 2015-02-11 Amgen Inc. Neue Polypeptide, die an der Immunabwehr beteiligt sind
JP2004526425A (ja) 2000-11-28 2004-09-02 ワイス 前立腺癌の診断および治療に有用なｆｋｂｐ核酸およびポリペプチドの発現分析
US6989247B2 (en) 2000-11-28 2006-01-24 Celltech R & D, Inc. Compositions and methods for diagnosing or treating psoriasis
US7534429B2 (en) * 2000-11-29 2009-05-19 Hoffmann-La Roche Inc. Cytotoxicity mediation of cells evidencing surface expression of CD63
WO2002044366A2 (en) * 2000-11-29 2002-06-06 Lynkeus Biotech Gmbh Retina-specific human proteins c70rf9, c120rf7, mpp4 and f379
US7700751B2 (en) 2000-12-06 2010-04-20 Janssen Alzheimer Immunotherapy Humanized antibodies that recognize β-amyloid peptide
PE20020574A1 (es) * 2000-12-06 2002-07-02 Wyeth Corp Anticuerpos humanizados que reconocen el peptido amiloideo beta
WO2002046477A2 (en) 2000-12-07 2002-06-13 Chiron Corporation Endogenous retroviruses up-regulated in prostate cancer
CA2431861A1 (en) 2000-12-08 2002-06-13 Curagen Corporation Method of detecting and treating tuberous sclerosis complex associated disorders
ES2269509T3 (es) * 2000-12-08 2007-04-01 Genentech, Inc. Gen expresado altamente en el tejido cartilaginoso.
EP1355919B1 (de) 2000-12-12 2010-11-24 MedImmune, LLC Moleküle mit längeren halbwertszeiten, zusammensetzungen und deren verwendung
US6979556B2 (en) * 2000-12-14 2005-12-27 Genentech, Inc. Separate-cistron contructs for secretion of aglycosylated antibodies from prokaryotes
BR0116680A (pt) * 2000-12-14 2005-04-05 Genentech Inc Linhagem de e. coli e método de produção de um polipeptìdeo
US20020187100A1 (en) * 2000-12-21 2002-12-12 David Rizzieri Anti-tenascin monoclonal antibody therapy for lymphoma
AU2002231736A1 (en) 2000-12-22 2002-07-08 Max-Planck-Gesellschaft Zur Forderung Der Wissenschaften E.V. Use of repulsive guidance molecule (rgm) and its modulators
US20030165878A1 (en) * 2000-12-22 2003-09-04 Morris David W. Novel compositions and methods in cancer associated with altered expression of MCM3AP
US7820447B2 (en) 2000-12-22 2010-10-26 Sagres Discovery Inc. Compositions and methods for cancer
US20030232334A1 (en) 2000-12-22 2003-12-18 Morris David W. Novel compositions and methods for cancer
US7700274B2 (en) * 2000-12-22 2010-04-20 Sagres Discovery, Inc. Compositions and methods in cancer associated with altered expression of KCNJ9
US7892730B2 (en) 2000-12-22 2011-02-22 Sagres Discovery, Inc. Compositions and methods for cancer
WO2002052005A1 (fr) 2000-12-22 2002-07-04 Kazusa Dna Research Institute Foundation Genes et proteines codees par ceux-ci
US20030099963A1 (en) * 2000-12-22 2003-05-29 Morris David W. Novel compositions and methods in cancer associated with altered expression of TBX21
US7645441B2 (en) 2000-12-22 2010-01-12 Sagres Discovery Inc. Compositions and methods in cancer associated with altered expression of PRLR
US20030087252A1 (en) * 2000-12-22 2003-05-08 Morris David W. Novel compositions and methods in cancer associated with altered expression of PRDM11
US7445802B2 (en) * 2000-12-26 2008-11-04 Yeda Research And Development Co. Ltd Site-specific in situ generation of allicin using a targeted alliinase delivery system for the treatment of cancers, tumors, infectious diseases and other allicin-sensitive diseases
US6964849B2 (en) 2001-01-11 2005-11-15 Curagen Corporation Proteins and nucleic acids encoding same
US20030133939A1 (en) * 2001-01-17 2003-07-17 Genecraft, Inc. Binding domain-immunoglobulin fusion proteins
US7829084B2 (en) * 2001-01-17 2010-11-09 Trubion Pharmaceuticals, Inc. Binding constructs and methods for use thereof
EP1361892A4 (de) 2001-01-17 2004-10-13 Trubion Pharmaceuticals Inc Bindungsdomäne-immunglobulin-fusionsproteine
US7754208B2 (en) 2001-01-17 2010-07-13 Trubion Pharmaceuticals, Inc. Binding domain-immunoglobulin fusion proteins
US20040043928A1 (en) * 2001-08-02 2004-03-04 Ramesh Kekuda Therapeutic polypeptides, nucleic acids encoding same, and methods of use
US7279324B2 (en) * 2001-01-23 2007-10-09 Duke University Nucleic acid encoding G-protein coupled receptor with modified DRY motif
WO2002059337A1 (en) * 2001-01-26 2002-08-01 Georgetown University School Of Medicine Anti-apoptopic gene scc-s2 and diagnostic and therapeutic uses thereof
US20020159996A1 (en) 2001-01-31 2002-10-31 Kandasamy Hariharan Use of CD23 antagonists for the treatment of neoplastic disorders
CA2436180C (en) 2001-01-31 2011-11-08 Idec Pharmaceutical Corporation Immunoregulatory antibodies and uses thereof
US20020147312A1 (en) * 2001-02-02 2002-10-10 O'keefe Theresa Hybrid antibodies and uses thereof
US8216797B2 (en) * 2001-02-07 2012-07-10 Massachusetts Institute Of Technology Pathogen detection biosensor
US20040077081A1 (en) * 2001-02-07 2004-04-22 Egbert Oosterwijk Hybridoma cell line g250 and its use for producing monoclonal antibodies
US7422860B2 (en) * 2001-02-07 2008-09-09 Massachusetts Institute Of Technology Optoelectronic detection system
DK1358318T3 (da) * 2001-02-07 2007-01-02 Wilex Ag Hybridomcellelinje G250 og dens anvendelse til frembringelse af monoklonale antistoffer
CN100507003C (zh) * 2001-02-07 2009-07-01 麻省理工学院 光电子探测系统
JP3986439B2 (ja) 2001-02-07 2007-10-03 中外製薬株式会社 造血器腫瘍の治療剤
WO2002064612A2 (en) 2001-02-09 2002-08-22 Human Genome Sciences, Inc. Human g-protein chemokine receptor (ccr5) hdgnr10
CA2438433A1 (en) * 2001-02-14 2002-08-22 Tularik Inc. Methods for the diagnosis and treatment of tumors employing the hepsin gene
DE60238308D1 (de) * 2001-02-20 2010-12-30 Univ Georgia Schnellproduktion monoklonaler antikörper
US7087726B2 (en) 2001-02-22 2006-08-08 Genentech, Inc. Anti-interferon-α antibodies
AU2002240466A1 (en) 2001-02-23 2002-09-12 Dana-Farber Cancer Institute, Inc. Hin-1, a tumor suppressor gene
US20030044406A1 (en) * 2001-03-02 2003-03-06 Christine Dingivan Methods of preventing or treating inflammatory or autoimmune disorders by administering CD2 antagonists in combination with other prophylactic or therapeutic agents
WO2002070668A2 (en) * 2001-03-06 2002-09-12 Sierra Sciences, Inc. Methods and compositions for modulating telomerase reverse transcriptase (tert) expression
DK1366067T3 (da) * 2001-03-07 2012-10-22 Merck Patent Gmbh Ekspressionsteknologi for proteiner indeholdende en hybrid isotype-antistof-enhed
WO2002079399A2 (en) * 2001-03-14 2002-10-10 Genencor International, Inc. Regulatable growth of filamentous fungi
AU2002257067A1 (en) 2001-03-14 2002-09-24 Myriad Genetics, Inc Tsg101-gag interaction and use thereof
JP2004537976A (ja) 2001-03-15 2004-12-24 インターナショナル バイオイムン システムズ，インコーポレーテッド 膵癌のモノクローナル抗体治療
US20020177239A1 (en) 2001-03-16 2002-11-28 Thomas Gregory Brian Anti-GPE antibodies, their uses, and analytical methods for GPE
US20080008704A1 (en) * 2001-03-16 2008-01-10 Mark Rubin Methods of treating colorectal cancer with anti-epidermal growth factor antibodies
US20090081199A1 (en) * 2001-03-20 2009-03-26 Bioxell S.P.A. Novel receptor trem (triggering receptor expressed on myeloid cells) and uses thereof
US8981061B2 (en) 2001-03-20 2015-03-17 Novo Nordisk A/S Receptor TREM (triggering receptor expressed on myeloid cells) and uses thereof
US8231878B2 (en) * 2001-03-20 2012-07-31 Cosmo Research & Development S.P.A. Receptor trem (triggering receptor expressed on myeloid cells) and uses thereof
WO2002076507A2 (en) * 2001-03-23 2002-10-03 Genentech, Inc. Uses of opg ligand to modulate immune responses
CA2441228A1 (en) * 2001-03-23 2002-10-03 Aphton Corporation Combination treatment of pancreatic cancer
US6992174B2 (en) 2001-03-30 2006-01-31 Emd Lexigen Research Center Corp. Reducing the immunogenicity of fusion proteins
UA80091C2 (en) 2001-04-02 2007-08-27 Chugai Pharmaceutical Co Ltd Remedies for infant chronic arthritis-relating diseases and still's disease which contain an interleukin-6 (il-6) antagonist
EP2388590A1 (de) 2001-04-02 2011-11-23 Dana Farber Cancer Institute PD-1, ein Rezeptor für B7-4, und Verwendungen dafür
US20030148298A1 (en) * 2001-04-03 2003-08-07 O''toole Margot Methods for diagnosing and treating systemic lupus erythematosus disease and compositions thereof
WO2002081642A2 (en) 2001-04-06 2002-10-17 Georgetown University Gene brcc-3 and diagnostic and therapeutic uses thereof
WO2002081640A2 (en) * 2001-04-06 2002-10-17 Georgetown University Gene shinc-1 and diagnostic and therapeutic uses thereof
WO2002081641A2 (en) * 2001-04-06 2002-10-17 Georgetown University Gene scc-112 and diagnostic and therapeutic uses thereof
AU2002303261A1 (en) * 2001-04-06 2002-10-21 Georgetown University Gene brcc2 and diagnostic and therapeutic uses thereof
JP2004536579A (ja) 2001-04-13 2004-12-09 ヒューマン　ジノーム　サイエンシーズ，　インコーポレイテッド 血管内皮増殖因子２
KR100886095B1 (ko) 2001-04-16 2009-02-27 와이어쓰 홀딩스 코포레이션 폴리펩티드 항원을 암호화하는 신규한 스트렙토코쿠스 뉴모니애 개방형 판독 프레임 및 이를 포함하는 조성물
CN1247258C (zh) 2001-04-24 2006-03-29 默克专利有限公司 使用抗血管生成剂和TNFα的联合疗法
US20040058445A1 (en) * 2001-04-26 2004-03-25 Ledbetter Jeffrey Alan Activation of tumor-reactive lymphocytes via antibodies or genes recognizing CD3 or 4-1BB
CZ20033208A3 (en) 2001-04-26 2004-03-17 Biogen, Inc. Cripto blocking antibodies and uses thereof
DE10121255A1 (de) * 2001-04-30 2002-11-07 Switch Biotech Ag Verwendung von alpha 1-Antichymotrypsin Polypeptiden oder diese kodierende Nukleinsäuren, oder einer ein ACT Polypeptid oder diese kodierende Nukleinsäure exprimierende Zelle, zur Behandlung und/oder Prävention von diabetes-assoziierten und/oder arteriellen schlecht heilenden Wunden und zur Identifizierung von pharmakologisch aktiven Substanzen
US7256257B2 (en) * 2001-04-30 2007-08-14 Seattle Genetics, Inc. Pentapeptide compounds and uses related thereto
US20030017159A1 (en) * 2001-05-02 2003-01-23 Jerome Ritz Immunogenic tumor antigens: nucleic acids and polypeptides encoding the same and methods of use thereof
BR0209177A (pt) 2001-05-03 2004-10-05 Merck Patent Gmbh Anticorpo especìfico a tumor recombinante e uso do mesmo
US7803382B2 (en) * 2001-05-04 2010-09-28 Ludwig Institute For Cancer Research Ltd. Method for inducing immune response to NY-CO-58
US20090191232A1 (en) * 2001-05-04 2009-07-30 Gevas Philip C Combination therapy for the treatment of tumors
US6794501B2 (en) * 2001-05-04 2004-09-21 Ludwig Institute For Cancer Research Colon cancer antigen panel
WO2002090510A2 (en) * 2001-05-08 2002-11-14 Emory University Regulating immine responses using dendritic cells
US20110313230A1 (en) 2001-05-11 2011-12-22 Terrance Grant Johns Specific binding proteins and uses thereof
GB0111628D0 (en) * 2001-05-11 2001-07-04 Scancell Ltd Binding member
US20100056762A1 (en) 2001-05-11 2010-03-04 Old Lloyd J Specific binding proteins and uses thereof
DK1392359T4 (da) * 2001-05-11 2013-06-10 Ludwig Inst For Cancer Res Ltd Specifikke bindingsproteiner og deres anvendelser.
HU229910B1 (hu) * 2001-05-11 2014-12-29 Amgen Inc Thousand Oaks A TALL-1-hez kötõdõ peptidek és rokon molekulák
WO2002094123A2 (en) 2001-05-18 2002-11-28 Danisco A/S Method of preparing a dought with an enzime
US6972324B2 (en) * 2001-05-18 2005-12-06 Boehringer Ingelheim Pharmaceuticals, Inc. Antibodies specific for CD44v6
EP1395274A2 (de) * 2001-05-22 2004-03-10 Duke University Zusammensetzungen und verfahren zur metastasenhemmung
US20020197253A1 (en) * 2001-05-22 2002-12-26 Cheek Dennis J. Compositions and methods for promoting or inhibiting NDPK
US7132401B2 (en) 2001-05-22 2006-11-07 Merck & Co., Inc. Beta-secretase substrates and uses thereof
GB0112844D0 (en) * 2001-05-25 2001-07-18 Psimei Pharmaceuticals Plc Neutron capture therapy
MXPA03010747A (es) 2001-05-25 2004-03-02 Human Genome Sciences Inc Anticuerpos que se unen inmunoespecificamente a receptores de ligando inductor de apoptosis relacionado con factor de necrosis tumoral.
US7279274B2 (en) * 2001-05-29 2007-10-09 Pride Proteomics A/S Method for diagnosing diabetes in a mammal
KR20100132559A (ko) 2001-05-30 2010-12-17 제넨테크, 인크. 다양한 질환의 치료에 유용한 항-엔지에프 항체
EP1390069A1 (de) * 2001-05-30 2004-02-25 Cornell Research Foundation, Inc. Endopeptidase/anti-psma-antikörper-fusionsproteine zur behandlung von krebs
KR20030033007A (ko) * 2001-05-31 2003-04-26 코울터 파머수티컬, 인코포레이티드 세포독소, 약물전구체, 링커 및 이에 유용한 안정화제
US7744882B2 (en) 2001-05-31 2010-06-29 Tumor Biology Investment Group, Inc. Soluble ErbB3 methods of detection and antibodies
US7745398B2 (en) 2001-05-31 2010-06-29 Tumor Biology Investment Group, Inc. Soluble ErbB3 and treatment of cancer
US7514078B2 (en) 2001-06-01 2009-04-07 Cornell Research Foundation, Inc. Methods of treating prostate cancer with anti-prostate specific membrane antigen antibodies
CA2447695C (en) 2001-06-01 2015-02-24 Cornell Research Foundation, Inc. Modified antibodies to prostate-specific membrane antigen and uses thereof
US7553484B2 (en) * 2001-06-05 2009-06-30 The Regents Of The University Of California Modulating neuronal outgrowth via the major histocompatibility complex class I (MHC I) molecule
ATE291925T1 (de) * 2001-06-05 2005-04-15 Curevac Gmbh Stabilisierte mrna mit erhöhtem g/c-gehalt und optimierter codon usage für die gentherapie
US20070160576A1 (en) 2001-06-05 2007-07-12 Genentech, Inc. IL-17A/F heterologous polypeptides and therapeutic uses thereof
US20090324612A1 (en) * 2001-06-05 2009-12-31 Kaufman Daniel L Modulating neuronal outgrowth via the major histocompatibility complex class i (mhc i) molecule
US7468253B2 (en) * 2001-06-07 2008-12-23 Chemocentryx, Inc. Method for multiple chemokine receptor screening for antagonists using RAM assay
ATE347695T1 (de) * 2001-06-07 2006-12-15 Chemocentryx Inc Zellwanderungsassay
BR0210283A (pt) * 2001-06-07 2004-09-14 Wyeth Corp Receptor acoplado à proteìna-g e usos para o mesmo
EP2339344A1 (de) 2001-06-15 2011-06-29 Inhibitex, Inc. Kreuzreaktive monoklonale und polyklonale Antikörper, die Oberflächenprotein aus koagulasenegativen Staphylococci und Staphylococcus Aureus erkennen
IL159177A0 (en) * 2001-06-20 2004-06-01 Prochon Biotech Ltd Antibodies that block receptor protein tyrosine kinase activation, methods of screening for and uses thereof
EP1409549A4 (de) 2001-06-20 2007-10-24 Genentech Inc Zusammensetzungen und verfahren für die diagnose und behandlung von tumoren
AU2002345743A1 (en) * 2001-06-21 2003-01-08 Sierra Sciences, Inc. Telomerase expression repressor proteins and methods of using the same
TR201809678T4 (tr) 2001-06-26 2018-07-23 Amgen Fremont Inc Opgl ye karşi antikorlar.
AU2002316384A1 (en) * 2001-06-26 2003-03-03 Photomed Technologies, Inc. Multiple wavelength illuminator
US20030013081A1 (en) 2001-06-26 2003-01-16 Olson William C. Uses of DC-SIGN and DC-SIGNR for inhibiting hepatitis C virus infection
CA2452039A1 (en) * 2001-06-27 2003-01-09 Elan Pharmaceuticals, Inc. Beta-hydroxyamine derivatives useful in treatment of alzheimer's disease
WO2003002608A1 (fr) 2001-06-28 2003-01-09 Kyowa Hakko Kogyo Co., Ltd. Anticorps humanise contre le facteur-8 de croissance des fibroblastes et fragment de cet anticorps
US20030129613A1 (en) * 2001-07-05 2003-07-10 Fernandes Elma R. Novel human proteins and polynucleotides encoding them
US20040029790A1 (en) * 2001-07-05 2004-02-12 Meera Patturajan Novel human proteins, polynucleotides encoding them and methods of using the same
US20030087274A1 (en) * 2001-07-05 2003-05-08 Anderson David W. Therapeutic polypeptides, nucleic acids encoding same, and methods of use
US20030148306A1 (en) * 2001-07-05 2003-08-07 Agostino Michael J. Aggrecanase molecules
JP2004536835A (ja) * 2001-07-09 2004-12-09 アフトン コーポレーション 肝臓、肺および食道の癌性ならびに前癌性状態の治療および防止
US7393656B2 (en) 2001-07-10 2008-07-01 The Board Of Trustees Of The Leland Stanford Junior University Methods and compositions for risk stratification
US20050069947A1 (en) * 2001-07-16 2005-03-31 Erlanger Bernard F. Antibodies specific for nanotubes and related methods and compositions
JP2005502330A (ja) 2001-07-17 2005-01-27 ザ ジェネラル ホスピタル コーポレーション 消化器系の疾患および病態ならびに癌の診断および治療の方法
EP1434862A4 (de) 2001-07-20 2005-04-06 Univ Georgia Res Found Attenuiertes tollwutvirus mit einer nukleoproteinmutation an der phosphorylierungsstelle zur impfung gegen tollwut und gentherapie im zns
AU2002320352A1 (en) * 2001-07-24 2003-02-17 Biogen Idec Ma Inc. Methods for treating or preventing sclerotic disorders using cd2-binding agents
WO2003012038A2 (en) * 2001-07-27 2003-02-13 Wyeth Aggrecanase molecules
AUPR673001A0 (en) * 2001-07-31 2001-08-23 Prince Henry's Institute Of Medical Research Pregnancy-related enzyme activity
US7413870B2 (en) 2001-08-01 2008-08-19 Rigel Pharmaceuticals, Incorporated SAK: modulation of cellular proliferation for treatment of cancer
TWI327597B (en) * 2001-08-01 2010-07-21 Centocor Inc Anti-tnf antibodies, compositions, methods and uses
US20040030096A1 (en) * 2001-08-02 2004-02-12 Linda Gorman Novel human proteins, polynucleotides encoding them and methods of using the same
KR20040019105A (ko) * 2001-08-03 2004-03-04 제넨테크, 인크. ＴＡＣＩｓ 및 ＢＲ3 폴리펩티드 및 이의 용도
EP1283053A1 (de) 2001-08-09 2003-02-12 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. Inhibitore der HER3 Aktivität
CA2451919A1 (en) * 2001-08-09 2003-02-20 Curagen Corporation Nucleic acids, polypeptides, single nucleotide polymorphisms and methods of use thereof
US20030035802A1 (en) * 2001-08-14 2003-02-20 Dewan Zeng Localization of A2B AdoR on human normal and diseased tissue: the use of anti-A2B antibody to diagnose and treat human tumors
US6861231B2 (en) * 2001-08-17 2005-03-01 Qiagen Gmbh Suppression of cross-reactivity and non-specific binding by antibodies using protein A
EP1878441B1 (de) 2001-08-17 2018-01-24 Genentech, Inc. Komplement-Inhibitoren, die an C5 und C5a binden, ohne die Bildung von C5b zu hemmen
EP2518142B1 (de) * 2001-08-24 2015-07-15 UVic Industry Partnerships Inc. Proaerolysin enthaltend Proteaseaktivierungssequenzen und Verfahren zur Anwendung bei der Behandlung von Prostatakrebs
US20030099985A1 (en) * 2001-08-27 2003-05-29 Jing Li Amplified gene involved in cancer
CA2459183A1 (en) * 2001-08-27 2003-03-06 Tularik Inc. Amplified oncogenes and their involvement in cancer
EP1427744B1 (de) 2001-08-27 2007-12-26 Genentech, Inc. System zur antikörperexpression und- synthese
KR100942880B1 (ko) 2001-08-29 2010-02-17 제넨테크, 인크. 유사분열촉진 활성을 가진 Ｂｖ８ 핵산 및 폴리펩티드
US7270960B2 (en) 2001-08-29 2007-09-18 Pacific Northwest Research Institute Diagnosis of ovarian carcinomas
US20040235068A1 (en) * 2001-09-05 2004-11-25 Levinson Arthur D. Methods for the identification of polypeptide antigens associated with disorders involving aberrant cell proliferation and compositions useful for the treatment of such disorders
US20040142325A1 (en) * 2001-09-14 2004-07-22 Liat Mintz Methods and systems for annotating biomolecular sequences
US20070082337A1 (en) * 2004-01-27 2007-04-12 Compugen Ltd. Methods of identifying putative gene products by interspecies sequence comparison and biomolecular sequences uncovered thereby
NZ573739A (en) 2001-09-18 2010-07-30 Genentech Inc Compositions and methods for the diagnosis and treatment of tumor, particularly colorectal tumor - TAT201
US7981863B2 (en) 2001-09-19 2011-07-19 Neuronova Ab Treatment of Parkinson's disease with PDGF
US7691605B2 (en) 2001-09-20 2010-04-06 Immunex Corporation Selection of cells expressing heteromeric polypeptides
US6982159B2 (en) 2001-09-21 2006-01-03 Genencor International, Inc. Trichoderma β-glucosidase
US20070098728A1 (en) * 2001-09-24 2007-05-03 Pedersen Finn S Novel compositions and methods in cancer
RU2305111C2 (ru) 2001-09-25 2007-08-27 Джуридикэл Фаундейшн Дзе Чемо-Серо-Терапьютик Рисерч Инститьют Рекомбинантное антитело против остеопонтина и его применение
US7320789B2 (en) 2001-09-26 2008-01-22 Wyeth Antibody inhibitors of GDF-8 and uses thereof
AU2002331897A1 (en) 2001-09-27 2003-04-07 Pioneer Hi-Bred International, Inc. Phytate polynucleotides and methods of use
US20050053935A1 (en) 2001-10-01 2005-03-10 Fishman Mark C. Methods for diagnosing and treating diseases and conditions of the heart or digestive system, and cancer
EP3254687A1 (de) 2001-10-04 2017-12-13 Genetics Institute LLC Verfahren und zusammensetzungen zur modulation der interleukin-21-rezeptoraktivität
US7084257B2 (en) 2001-10-05 2006-08-01 Amgen Inc. Fully human antibody Fab fragments with human interferon-gamma neutralizing activity
US20030199442A1 (en) * 2001-10-09 2003-10-23 Alsobrook John P. Therapeutic polypeptides, nucleic acids encoding same, and methods of use
MX339524B (es) 2001-10-11 2016-05-30 Wyeth Corp Composiciones inmunogenicas novedosas para la prevencion y tratamiento de enfermedad meningococica.
US7521053B2 (en) 2001-10-11 2009-04-21 Amgen Inc. Angiopoietin-2 specific binding agents
JP4381140B2 (ja) 2001-10-12 2009-12-09 シェーリング コーポレイション 免疫応答を調節するための二重特異性抗体の使用
IL161417A0 (en) * 2001-10-15 2004-09-27 Immunomedics Inc Affinity enhancement agents
CA2463927A1 (en) * 2001-10-16 2003-04-24 Raven Biotechnologies, Inc. Antibodies that bind to cancer-associated antigen cd46 and methods of use thereof
DE10151511A1 (de) 2001-10-18 2003-05-08 Basf Lynx Bioscience Ag ee3-Proteinfamilie und zugrundeliegende DNA-Sequenzen
US20050123925A1 (en) 2002-11-15 2005-06-09 Genentech, Inc. Compositions and methods for the diagnosis and treatment of tumor
US20030228319A1 (en) 2002-04-16 2003-12-11 Genentech, Inc. Compositions and methods for the diagnosis and treatment of tumor
US20110045005A1 (en) 2001-10-19 2011-02-24 Craig Crowley Compositions and methods for the treatment of tumor of hematopoietic origin
US20040151721A1 (en) 2001-10-19 2004-08-05 O'keefe Theresa Humanized anti-CCR2 antibodies and methods of use therefor
US20040166490A1 (en) * 2002-12-17 2004-08-26 Morris David W. Novel therapeutic targets in cancer
US20040126762A1 (en) * 2002-12-17 2004-07-01 Morris David W. Novel compositions and methods in cancer
US7445925B2 (en) * 2001-10-27 2008-11-04 Sanofi-Aventis Deutschland Gmbh Aequorin as a reporter gene in yeast
US20030190705A1 (en) * 2001-10-29 2003-10-09 Sunol Molecular Corporation Method of humanizing immune system molecules
US7282205B2 (en) 2001-11-07 2007-10-16 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Anti-hepatitis A virus antibodies
BRPI0214168B8 (pt) 2001-11-14 2021-05-25 Centocor Inc anticorpos anti-il-6, moléculas de ácido nucleico codificando os mesmos, vetores compreendendo as referidas moléculas, composições e formulações compreendendo os referidos anticorpos, bem como métodos de produção dos mesmos
AU2002334746B2 (en) * 2001-11-15 2007-10-11 Becton, Dickinson And Company Methods and devices for the integrated discovery of cell culture environments
AU2002356898A1 (en) * 2001-11-15 2003-06-10 Tularik Inc. Gene amplification and overexpression in cancer
US6952704B2 (en) * 2001-11-26 2005-10-04 Microsoft Corporation Extending a directory schema independent of schema modification
US7052860B2 (en) 2001-11-28 2006-05-30 University Of Florida Research Foundation Identification of Actinobacillus actinomycetemcomitans antigens for use in the diagnosis, treatment, and monitoring of periodontal diseases
TW200408407A (en) * 2001-11-30 2004-06-01 Dana Farber Cancer Inst Inc Methods and compositions for modulating the immune system and uses thereof
US20060040262A1 (en) * 2002-12-27 2006-02-23 Morris David W Novel compositions and methods in cancer
US7871619B2 (en) 2001-11-30 2011-01-18 Chemocentryx, Inc. Compositions and methods for detecting and treating diseases and conditions related to chemokine receptors
EP2990394A1 (de) 2001-11-30 2016-03-02 Biogen MA Inc. Antikörper gegen chemotaktische proteine
US20040197778A1 (en) * 2002-12-26 2004-10-07 Sagres Discovery, Inc. Novel compositions and methods in cancer
US20040180344A1 (en) * 2003-03-14 2004-09-16 Morris David W. Novel therapeutic targets in cancer
EP1454138B1 (de) * 2001-12-04 2012-01-18 Merck Patent GmbH Immunocytokine mit modulierter selektivität
GB0129105D0 (en) 2001-12-05 2002-01-23 Celltech R&D Ltd Expression control using variable intergenic sequences
EP2002827A2 (de) 2001-12-05 2008-12-17 The Baylor College Of Medicine Verfahren und Zusammensetzungen zur Regulierung der Knochenbildung mittels Modulation des sympathischen Tonus
US8178128B2 (en) * 2001-12-05 2012-05-15 Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd. Nanoparticles containing polymeric nucleic acid homologs
JP4822490B2 (ja) * 2001-12-07 2011-11-24 ノバルティス バクシンズ アンド ダイアグノスティックス，インコーポレーテッド 腫瘍形成形質転換に関連する内因性レトロウイルスポリペプチド
US20060275747A1 (en) * 2001-12-07 2006-12-07 Hardy Stephen F Endogenous retrovirus up-regulated in prostate cancer
JP2005516917A (ja) 2001-12-12 2005-06-09 アメリカ合衆国 細胞外アデノシン阻害剤およびアデノシン受容体阻害剤を用いて免疫応答および炎症を増強するための方法
US7049125B2 (en) 2001-12-18 2006-05-23 Genencor International, Inc. EGVIII endoglucanase and nucleic acids encoding the same
US7858297B2 (en) * 2001-12-18 2010-12-28 Centre National De La Recherche Scientifique Cnrs Chemokine-binding protein and methods of use
WO2003051917A2 (en) * 2001-12-18 2003-06-26 Endocube Sas Novel death associated proteins of the thap family and related par4 pathways involved in apoptosis control
US7005289B2 (en) * 2001-12-18 2006-02-28 Genencor International, Inc. BGL5 β-glucosidase and nucleic acids encoding the same
US7045332B2 (en) 2001-12-18 2006-05-16 Genencor International, Inc. BGL4 β-glucosidase and nucleic acids encoding the same
US7056721B2 (en) * 2001-12-18 2006-06-06 Genencor International, Inc. EGVI endoglucanase and nucleic acids encoding the same
US7045331B2 (en) * 2001-12-18 2006-05-16 Genencor International, Inc. EGVII endoglucanase and nucleic acids encoding the same
WO2003054155A2 (en) * 2001-12-19 2003-07-03 Bristol-Myers Squibb Company Pichia pastoris formate dehydrogenase and uses therefor
DE10162480A1 (de) 2001-12-19 2003-08-07 Ingmar Hoerr Die Applikation von mRNA für den Einsatz als Therapeutikum gegen Tumorerkrankungen
GB0130543D0 (en) 2001-12-20 2002-02-06 Univ Cambridge Tech Human antibodies and their use
AU2002359697A1 (en) * 2001-12-20 2003-07-09 Tularik Inc. Identification of an amplified gene and target for drug intervention
CA2841097A1 (en) 2001-12-21 2003-07-24 Human Genome Sciences, Inc. Albumin and g-csf fusion proteins
US20060034829A1 (en) * 2001-12-27 2006-02-16 Gerngross Tillman U Immunoglobulins comprising predominantly a MAN3GLCNAC2 glycoform
US20060024292A1 (en) * 2001-12-27 2006-02-02 Gerngross Tillman U Immunoglobulins comprising predominantly a Gal2GlcNAc2Man3GlcNAc2 glycoform
DE60329070D1 (de) 2001-12-28 2009-10-15 Kyowa Hakko Kirin Co Ltd Antikörper gegen den fibroblastenwachstumsfaktor 23
AU2002362197A1 (en) 2001-12-28 2003-07-24 Chugai Seiyaku Kabushiki Kaisha Method of stabilizing protein
US20030228676A1 (en) * 2001-12-31 2003-12-11 Agostino Michael J. Aggrecanase molecules
ES2338774T3 (es) 2001-12-31 2010-05-12 Dana-Farber Cancer Institute, Inc. Expresion de psoriasina por las celulas epiteliales mamarias.
EP1575571A4 (de) 2002-01-02 2008-06-25 Genentech Inc Zusammensetzungen und verfahren zur diagnose und behandlung eines tumors
AU2003207459A1 (en) * 2002-01-03 2003-07-24 The Scripps Research Institute Cancer-associated epitope
US20040009498A1 (en) * 2002-01-14 2004-01-15 Diversa Corporation Chimeric antigen binding molecules and methods for making and using them
AU2003209340A1 (en) * 2002-01-18 2003-09-02 Bristol-Myers Squibb Company Predictor sets for tyrosine kinase pathways
IL152904A0 (en) * 2002-01-24 2003-06-24 Gamida Cell Ltd Utilization of retinoid and vitamin d receptor antagonists for expansion of renewable stem cell populations
EP1465982A4 (de) * 2002-01-25 2006-06-07 Gamida Cell Ltd Verfahren zur expansion von stamm- und vorläuferzellen und damit erhaltene expandierte zellpopulationen
JP2005515779A (ja) * 2002-01-31 2005-06-02 ワイス アグレカナーゼ分子
US20040052928A1 (en) * 2002-09-06 2004-03-18 Ehud Gazit Peptides and methods using same for diagnosing and treating amyloid-associated diseases
US7781396B2 (en) * 2002-01-31 2010-08-24 Tel Aviv University Future Technology Development L.P. Peptides directed for diagnosis and treatment of amyloid-associated disease
MXPA04007426A (es) 2002-02-01 2004-10-11 Schering Corp Usos de citosina de mamifero; reactivos relacionados.
JP2005516614A (ja) 2002-02-05 2005-06-09 ワイス 切断アグレカナーゼ分子
EP1472275B1 (de) 2002-02-05 2008-12-17 Genentech, Inc. Proteinaufreinigung
EP1572168B1 (de) 2002-02-06 2010-05-26 Vicor Technologies, Inc. Anti-infarkt-moleküle
EP2360476B1 (de) 2002-02-13 2017-10-25 BioMedica Diagnostics Inc. Verfahren zur auswahl von behandlungsschemata und vorhersage von behandlungsresultaten bei krebspatienten
US6992176B2 (en) 2002-02-13 2006-01-31 Technion Research & Development Foundation Ltd. Antibody having a T-cell receptor-like specificity, yet higher affinity, and the use of same in the detection and treatment of cancer, viral infection and autoimmune disease
DK2508596T3 (en) 2002-02-21 2015-10-19 Inst Virology MN / CA IX-specific monoclonal antibodies generated from MN / CA IX-poor mice, as well as methods of use.
EP1476120B1 (de) * 2002-02-21 2010-09-29 Duke University Behandlungsverfahren unter verwendung von anti-cd22-antikörpern
US20040258678A1 (en) 2002-02-22 2004-12-23 Genentech, Inc. Compositions and methods for the treatment of immune related diseases
US20040025194A1 (en) * 2002-02-22 2004-02-05 Board Of Trustees Of The University Of Illinois Beta chain-associated regulator of apoptosis
EP1478738B1 (de) 2002-02-22 2008-11-12 Progenics Pharmaceuticals, Inc. Anti-ccr5 antikörper
US7662924B2 (en) * 2002-02-22 2010-02-16 The Board Of Trustees Of The University Of Illinois Beta chain-associated regulator of apoptosis
EP1534729A2 (de) * 2002-02-26 2005-06-01 University of Utah Research Foundation Mit bluthochdruck und virusknospung assoziierte nedd4l-varianten
KR101017732B1 (ko) * 2002-03-01 2011-02-28 이뮤노메딕스, 인코오포레이티드 내재화 항-ｃｄ74 항체 및 그 이용방법
US8093357B2 (en) * 2002-03-01 2012-01-10 Xencor, Inc. Optimized Fc variants and methods for their generation
US7317091B2 (en) * 2002-03-01 2008-01-08 Xencor, Inc. Optimized Fc variants
US20090042291A1 (en) * 2002-03-01 2009-02-12 Xencor, Inc. Optimized Fc variants
WO2003073991A2 (en) * 2002-03-01 2003-09-12 Celltech R & D, Inc. Methods to increase or decrease bone density
US20160279239A1 (en) 2011-05-02 2016-09-29 Immunomedics, Inc. Subcutaneous administration of anti-cd74 antibody for systemic lupus erythematosus and autoimmune disease
US20100311954A1 (en) * 2002-03-01 2010-12-09 Xencor, Inc. Optimized Proteins that Target Ep-CAM
US9770517B2 (en) 2002-03-01 2017-09-26 Immunomedics, Inc. Anti-Trop-2 antibody-drug conjugates and uses thereof
US8188231B2 (en) 2002-09-27 2012-05-29 Xencor, Inc. Optimized FC variants
US20040132101A1 (en) 2002-09-27 2004-07-08 Xencor Optimized Fc variants and methods for their generation
US8361464B2 (en) 2002-03-01 2013-01-29 Immunomedics, Inc. Anthracycline-Antibody Conjugates for Cancer Therapy
GB0205022D0 (en) 2002-03-04 2002-04-17 Univ Cambridge Tech Materials and methods for the treatment of cns damage
DE60325564D1 (de) 2002-03-05 2009-02-12 Univ Texas Biospezifische kontrastmittel
IL163812A0 (en) 2002-03-05 2005-12-18 Univ Ramot Immunizing composition and method for inducing an immune response against the -secretase cleavage site of amyloid precursor protein
ES2337566T3 (es) 2002-03-11 2010-04-27 Philogen S.P.A. Anticuerpos derivados de anti ed-b l19 y vasculatura tumoral objetivo.
MY139983A (en) * 2002-03-12 2009-11-30 Janssen Alzheimer Immunotherap Humanized antibodies that recognize beta amyloid peptide
US6703216B2 (en) 2002-03-14 2004-03-09 The Regents Of The University Of California Methods, compositions and apparatuses for detection of gamma-hydroxybutyric acid (GHB)
US20030219436A1 (en) * 2002-03-15 2003-11-27 Ledbetter Jeffrey A. Compositions and methods to regulate an immune response using CD83 gene expressed in tumors and using soluble CD83-Ig fusion protein
WO2003081211A2 (en) * 2002-03-19 2003-10-02 Cengent Therapeutics, Inc. Discrete bayesian analysis of data
WO2003079982A2 (en) * 2002-03-19 2003-10-02 Tularik Inc. Gene amplification in cancer
CA2475529A1 (en) * 2002-03-19 2003-10-02 Abgenix, Inc. Methods for treating chronic obstructive pulmonary disease (copd)
US20030182669A1 (en) * 2002-03-19 2003-09-25 Rockman Howard A. Phosphoinositide 3-kinase mediated inhibition of GPCRs
US7521193B2 (en) 2002-03-20 2009-04-21 Pride Proteomics A/S Human diabetes-mediating proteins
WO2003080808A2 (en) * 2002-03-21 2003-10-02 Sagres Discovery, Inc. Novel compositions and methods in cancer
US7317087B2 (en) * 2002-03-25 2008-01-08 The Uab Research Foundation Members of the FC receptor homolog gene family (FCRH1-3, 6), related reagents, and uses thereof
US7384738B2 (en) * 2002-03-28 2008-06-10 Bremel Robert D Retrovirus-based genomic screening
US20040038304A1 (en) * 2002-03-28 2004-02-26 Gala Design, Inc. Antibody libraries
AU2003218456A1 (en) * 2002-04-01 2003-10-20 Human Genome Sciences, Inc. Antibodies that specifically bind to gmad
GB0207533D0 (en) 2002-04-02 2002-05-08 Oxford Glycosciences Uk Ltd Protein
AU2003243139B2 (en) 2002-04-05 2007-06-21 Amgen Inc. Human anti-OPGL neutralizing antibodies as selective OPGL pathway inhibitors
CA2481920A1 (en) 2002-04-09 2003-10-16 Kyowa Hakko Kogyo Co., Ltd. Antibody composition-containing medicament
ATE369895T1 (de) 2002-04-09 2007-09-15 Sanofi Pasteur Ltd Modifizierte cea nucleinsäure und expressionsvektoren
US7244565B2 (en) * 2002-04-10 2007-07-17 Georgetown University Gene shinc-3 and diagnostic and therapeutic uses thereof
US7138512B2 (en) * 2002-04-10 2006-11-21 Georgetown University Gene SHINC-2 and diagnostic and therapeutic uses thereof
JP2005522514A (ja) 2002-04-10 2005-07-28 ジェネンテック・インコーポレーテッド 抗ｈｅｒ２抗体改変体
WO2003087340A2 (en) * 2002-04-12 2003-10-23 Raven Biotechnologies, Inc. Antibodies that bind to integrin alpha-v-beta-6 and methods of use thereof
EP2270049A3 (de) 2002-04-12 2011-03-09 Medimmune, Inc. Rekombinante Anti-Interleukin-9-Antikörper
US20040016010A1 (en) * 2002-04-17 2004-01-22 Marion Kasaian IL-21 receptor knockout animal and methods of use thereof
KR100994748B1 (ko) 2002-04-19 2010-11-17 더 가버닝 카운실 오브 더 유니버시티 오브 토론토 알쯔하이머병의 치료를 위한 면역학적 방법 및 조성물
SI1501369T1 (sl) 2002-04-26 2015-10-30 Genentech, Inc. Neafinitetno čiščenje proteinov
JP2006511194A (ja) 2002-05-02 2006-04-06 デイビッド ラブジョイ テネウリンｃ末端関連ペプチド（ｔｃａｐ）並びにこれらに関連する方法および使用
CN1662254A (zh) * 2002-05-03 2005-08-31 雷文生物技术公司 Alcam和alcam调制剂
CA2485120C (en) 2002-05-06 2013-02-19 The Government Of The United States Of America, Represented By The Secretary, Department Of Health And Human Services Identification of novel broadly cross-reactive hiv-1 neutralizing human monoclonal antibodies
US20090068178A1 (en) * 2002-05-08 2009-03-12 Genentech, Inc. Compositions and Methods for the Treatment of Tumor of Hematopoietic Origin
ES2375181T3 (es) 2002-05-09 2012-02-27 The Brigham And Women's Hospital, Inc. 1l 1rl-1 como un marcador de enfermedades cardiovasculares.
US20050152899A1 (en) * 2002-05-10 2005-07-14 Kinch Michael S. EphA2 agonistic monoclonal antibodies and methods of use thereof
EP1519956B1 (de) * 2002-05-10 2011-09-21 Medimmune, Inc. Epha2 monoklonale antikörper und deren anwendungsverfahren
EP1575509B1 (de) * 2002-05-10 2011-10-26 Purdue Research Foundation Epha2 agonistische monoklonale antikörper und deren anwendungsverfahren
US20030228317A1 (en) * 2002-05-22 2003-12-11 Prafulla Gokhale Gene BRCC-1 and diagnostic and therapeutic uses thereof
IL149820A0 (en) 2002-05-23 2002-11-10 Curetech Ltd Humanized immunomodulatory monoclonal antibodies for the treatment of neoplastic disease or immunodeficiency
MXPA04011624A (es) 2002-05-24 2005-03-07 Schering Corp Anticuerpo neutralizante humano anti-igfr.
WO2003100000A2 (en) * 2002-05-24 2003-12-04 Tularik Inc. Amplification and overexpression of oncogenes
CA2487932A1 (en) * 2002-05-30 2003-12-11 Macrogenics, Inc. Cd16a binding proteins and use for the treatment of immune disorders
EP1513879B1 (de) * 2002-06-03 2018-08-22 Genentech, Inc. Bibliotheken synthetischer antikörperphagen
US7290215B2 (en) * 2002-06-03 2007-10-30 Microsoft Corporation Dynamic wizard interface system and method
EP2305710A3 (de) 2002-06-03 2013-05-29 Genentech, Inc. Synthetische Antikörperphagenbibliotheken
AU2003274463B2 (en) * 2002-06-10 2009-10-29 University Of Rochester Gene differentially expressed in breast and bladder cancer and encoded polypeptides
US20050221326A1 (en) * 2002-06-12 2005-10-06 Avi Orr-Urtreger Oligonucleotides antibodies and kits including same for treating prostate cancer and determining predisposition thereto
US8518694B2 (en) * 2002-06-13 2013-08-27 Novartis Vaccines And Diagnostics, Inc. Nucleic acid vector comprising a promoter and a sequence encoding a polypeptide from the endogenous retrovirus PCAV
ATE549064T1 (de) 2002-06-14 2012-03-15 Us Gov Health & Human Serv Verfahren zur behandlung und prävention von kolitis, die il-13 und nk-t zellen betrifft
US7893218B2 (en) 2003-06-16 2011-02-22 Stowers Institute For Medical Research Antibodies that specifically bind SOST peptides
US7425618B2 (en) 2002-06-14 2008-09-16 Medimmune, Inc. Stabilized anti-respiratory syncytial virus (RSV) antibody formulations
EP1572950B1 (de) 2002-06-17 2012-10-10 Thrasos, Inc. Einzeldomäne-tdf-verwandte verbindungen und analoge davon
ATE488530T1 (de) 2002-06-19 2010-12-15 Raven Biotechnologies Inc Internalisierende antikörper spezifisch für das raag10 zelloberflächenziel
US8029803B2 (en) 2002-06-20 2011-10-04 Paladin Labs, Inc. Chimeric antigens for eliciting an immune response
US7144950B2 (en) 2003-09-17 2006-12-05 The Regents Of The University Of California Conformationally flexible cationic conjugated polymers
US8025873B2 (en) 2002-06-20 2011-09-27 Paladin Labs, Inc. Chimeric antigens for eliciting an immune response
US7628988B2 (en) * 2002-06-27 2009-12-08 The General Hospital Corporation Methods and compositions for treating type 1 diabetes
US7582313B2 (en) 2002-06-27 2009-09-01 The General Hospital Corporation Methods of organ regeneration using Hox 11-expressing pluripotent cells
EP1532162B1 (de) 2002-06-28 2013-08-07 THE GOVERNMENT OF THE UNITED STATES OF AMERICA, as represented by THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES Humanisierter anti-tag-72 cc49 zur diagnose und therapie humaner tumore
US7455834B2 (en) 2002-06-29 2008-11-25 Genentech, Inc. Methods and compositions for modulating and detecting WISP activity
ATE537842T1 (de) * 2002-07-01 2012-01-15 Wilex Ag Zusammesetzungen von cg250 und il-2 oder von cg250 und ifn-alpha zur krebsbehandlung des nierenzell karzinoms
WO2004004649A2 (en) 2002-07-08 2004-01-15 Genentech, Inc. Compositions and methods for the treatment of immune related diseases
DE60335383D1 (de) 2002-07-15 2011-01-27 Univ Texas Antikörper mit bindung an anionische phospholipide und aminophospholipide und ihre verwendung bei der behandlung von virusinfektionen
MXPA05000655A (es) * 2002-07-15 2006-02-22 Harvard College Metodos y composiciones para modular el desarrollo y la funcion de las celulas t helper (th).
HUP0600340A3 (en) 2002-07-15 2011-06-28 Genentech Inc Methods for identifying tumors that are responsive to treatment with anti-erbb2 antibodies
NZ537277A (en) 2002-07-18 2008-04-30 Crucell Holland Bv Recombinant production of mixtures of antibodies
USRE47770E1 (en) 2002-07-18 2019-12-17 Merus N.V. Recombinant production of mixtures of antibodies
US20040132058A1 (en) 2002-07-19 2004-07-08 Schering Corporation NPC1L1 (NPC3) and methods of use thereof
JP5650876B2 (ja) 2002-07-19 2015-01-07 ベス・イスラエル・ディーコニス・メディカル・センター 子癇前症または子癇の診断方法および治療方法
WO2004009619A2 (en) * 2002-07-19 2004-01-29 Cellzome Ag Protein complexes of the tip60 transcriptional activator protein
US7435419B2 (en) 2002-07-19 2008-10-14 Beth Israel Deaconess Medical Center Methods of diagnosing and treating pre-eclampsia or eclampsia
US7250551B2 (en) * 2002-07-24 2007-07-31 President And Fellows Of Harvard College Transgenic mice expressing inducible human p25
US7794716B2 (en) 2002-07-25 2010-09-14 Glenveigh Pharmaceuticals, Llc Antibody composition and passive immunization against pregnancy-induced hypertension
BR0313033A (pt) * 2002-07-25 2007-07-10 Genentech Inc anticorpos, anticorpos monoclonais, linhagens de células de hibridoma, anticorpos receptores de anti-taci isolados, anticorpos anti -taci, métodos de modulação da atividade biológica
US20040018497A1 (en) * 2002-07-26 2004-01-29 Warden Craig H Human obesity LIPIN3 polynucleotide and polypeptide sequences and methods of use thereof
CN1681920A (zh) * 2002-07-29 2005-10-12 惠氏公司 修饰的admts4分子及其使用方法
ES2369542T3 (es) 2002-07-31 2011-12-01 Seattle Genetics, Inc. Conjugados de auristatina y su uso para tratar cáncer, una enfermedad autoinmune o una enfermedad infecciosa.
ATE541047T1 (de) 2002-08-01 2012-01-15 Univ California Therapeutische monoklonale antikörper zur neutralisierung von botulinum neurotoxinen
US20040142393A1 (en) * 2002-08-01 2004-07-22 Cooper Garth James Smith Methods of use of compounds with preptin function
US20050287648A1 (en) 2002-08-05 2005-12-29 University Of Rochester Protein Transducing Domain/Deaminase Chimeric Proteins, Related Compounds, and Uses Thereof
AU2003257109A1 (en) * 2002-08-05 2004-02-23 Invitrogen Corporation Compositions and methods for molecular biology
WO2004015063A2 (en) * 2002-08-07 2004-02-19 Tularik Inc. Amplification and overexpression of oncogenes
ATE469913T1 (de) * 2002-08-10 2010-06-15 Univ Yale Antagonisten des nogo-rezeptors
US20040067532A1 (en) 2002-08-12 2004-04-08 Genetastix Corporation High throughput generation and affinity maturation of humanized antibody
PT1534335E (pt) 2002-08-14 2012-02-28 Macrogenics Inc Anticorpos específicos de fcγriib e processos para a sua utilização
AU2003264009A1 (en) * 2002-08-15 2004-03-03 Epitomics, Inc. Humanized rabbit antibodies
US20050233473A1 (en) * 2002-08-16 2005-10-20 Zyomyx, Inc. Methods and reagents for surface functionalization
US7972832B2 (en) 2002-08-16 2011-07-05 Danisco Us Inc. Variant Hypocrea jecorina CBH1 cellulases
WO2004016643A2 (en) 2002-08-16 2004-02-26 Yeda Research And Development Co. Ltd. Tumor associated antigen, peptides thereof, and use of same as anti-tumor vaccines
EP2311980A1 (de) 2002-08-20 2011-04-20 Millennium Pharmaceuticals, Inc. Zusammensetzungen, Kits und Verfahren zur Identifizierung, Beurteilung, Vorbeugung und Therapie von Gebärmutterhalskrebs
GB0219524D0 (en) 2002-08-21 2002-10-02 Queen Mary & Westfield College Therapeutic uses of monoclonal antibodies to the angiotensin-II type-1 receptor
US20040247588A1 (en) * 2002-08-28 2004-12-09 Johnson Robert E. Formulations of modified antibodies and methods of making the same
US20040091490A1 (en) * 2002-08-28 2004-05-13 Robert Johnson Stable pH optimized formulation of a modified antibody
JP2006512901A (ja) * 2002-08-29 2006-04-20 ジェネンテック・インコーポレーテッド Ａｃｈａｅｔｅ−Ｓｃｕｔｅ様−２ポリペプチドとそのコード化核酸並びに腫瘍の診断と治療のための方法
US7785608B2 (en) 2002-08-30 2010-08-31 Wyeth Holdings Corporation Immunogenic compositions for the prevention and treatment of meningococcal disease
AU2002328429A1 (en) 2002-09-04 2004-03-29 Chugai Seiyaku Kabushiki Kaisha CONSTRUCTION OF ANTIBODY USING MRL/lpr MOUSE
JP4596916B2 (ja) * 2002-09-05 2010-12-15 メディミューン，エルエルシー Ｃｄ２拮抗薬を投与することによりｔ細胞悪性腫瘍を予防または治療する方法
MXPA05002514A (es) 2002-09-06 2005-05-27 Amgen Inc Anticuerpo monoclonal anti-il-1r1 humano terapeutico.
US20080260744A1 (en) * 2002-09-09 2008-10-23 Omeros Corporation G protein coupled receptors and uses thereof
CA2496400A1 (en) 2002-09-09 2004-03-18 Dana-Farber Cancer Institute, Inc. Bh3 peptides and method of use thereof
EP1581648A2 (de) * 2002-09-09 2005-10-05 Nura, Inc. G-protein-gekoppelte rezeptoren und deren verwendung
JP2006521082A (ja) 2002-09-11 2006-09-21 ジェネンテック・インコーポレーテッド 免疫関連疾患の治療のための新規組成物と方法
EP2277532A1 (de) 2002-09-11 2011-01-26 Genentech, Inc. Neuartige Zusammensetzung und Verfahren zur Behandlung von Immunerkrankungen
PT1543038T (pt) 2002-09-11 2017-07-07 Genentech Inc Purificação de proteína
AU2003291625B2 (en) 2002-09-16 2009-10-08 Genentech, Inc. Compositions and methods for the treatment of immune related diseases
AU2003295330A1 (en) * 2002-09-16 2004-05-04 Elusys Therapeutics, Inc. Bispecific molecule comprising an anti-cr1 antibody cross-linked to an antigen-binding antibody fragment
US20040053363A1 (en) * 2002-09-18 2004-03-18 Thomas Ryll Method for production of a multimeric protein by cell fusion
US20040053359A1 (en) * 2002-09-18 2004-03-18 Thomas Ryll Method for production of a multimeric protein by cell fusion
JP2006516883A (ja) 2002-09-19 2006-07-13 アメリカ合衆国 Ｐ．アリアシポリペプチド、ユウガイサシチョウバエポリペプチド、および使用法
WO2004028479A2 (en) 2002-09-25 2004-04-08 Genentech, Inc. Nouvelles compositions et methodes de traitement du psoriasis
AU2003273633A1 (en) 2002-09-26 2004-04-19 K.U.Leuven Research And Development Integrase cofactor
CA2832136C (en) 2002-09-27 2015-11-17 Xencor Optimized fc variants and methods for their generation
WO2004029287A2 (en) * 2002-09-27 2004-04-08 Oridis Biomed Forschungs- Und Entwicklungs Gmbh Polypeptides and nucleic acids encoding these and their use for the prevention, diagnosis or treatment of liver disorders and epithelial cancer
US20060235208A1 (en) * 2002-09-27 2006-10-19 Xencor, Inc. Fc variants with optimized properties
US20040115814A1 (en) * 2002-09-30 2004-06-17 Protein Design Labs, Inc. Efficient generation of stable expression cell lines through the use of scorable homeostatic reporter genes
US7541440B2 (en) * 2002-09-30 2009-06-02 Immunomedics, Inc. Chimeric, human and humanized anti-granulocyte antibodies and methods of use
CA2499891A1 (en) * 2002-10-03 2004-04-15 Large Scale Biology Corporation Multimeric protein engineering
WO2004033631A2 (en) * 2002-10-04 2004-04-22 Regents Of The University Of Minnesota Nucleic acid and polypeptide sequences from lawsonia intracellularis and methods of using
EP1545615A4 (de) * 2002-10-04 2006-03-01 Rinat Neuroscience Corp Verfahren zur behandlung von herzarrhythmie und zur verhinderung von tod durch herzarrhythmie mit ngf antagonisten
UA80447C2 (en) * 2002-10-08 2007-09-25 Methods for treating pain by administering nerve growth factor antagonist and opioid analgesic
WO2004032870A2 (en) 2002-10-08 2004-04-22 Rinat Neuroscience Corp. Methods for treating post-surgical pain by admisnistering a nerve growth factor antagonist and compositions containing the same
US7255860B2 (en) 2002-10-08 2007-08-14 Rinat Neuroscience Corp. Methods for treating post-surgical pain by administering an anti-nerve growth factor antagonist antibody
AU2003279216A1 (en) * 2002-10-09 2004-05-04 Rinat Neuroscience Corp. Methods of treating alzheimer's disease using antibodies directed against amyloid beta peptide and compositions thereof
GB0228832D0 (en) 2002-12-10 2003-01-15 Novartis Ag Organic compound
US7396913B2 (en) * 2002-10-14 2008-07-08 Abbott Laboratories Erythropoietin receptor binding antibodies
US7229762B2 (en) * 2002-10-15 2007-06-12 Duke University Medical Center Proteomic screening for redox state dependent protein—protein interactions
DK1551876T3 (da) 2002-10-16 2011-06-14 Purdue Pharma Lp Antistoffer, der binder til celle-associerede ca 125/0722P og fremgangsmåder til anvendelse deraf
EP1560597A4 (de) * 2002-10-29 2007-06-27 Pharmacia Corp Differentiell ausgedrückte krebsgene, dabei kodierte polypeptide und verfahren zu ihrer verwendung
DE60327366D1 (de) 2002-10-29 2009-06-04 Fundacao Oswaldo Cruz Lutzomyia longipalpis-polypeptide und verwendungsverfahren
AU2003298607B9 (en) 2002-10-29 2011-08-04 Genentech, Inc. Compositions and methods for the treatment of immune related diseases
MXPA05004677A (es) * 2002-10-31 2005-11-17 Genentech Inc Metodos y composiciones para aumentar la produccion de anticuerpos.
EP1629090B1 (de) * 2002-11-06 2014-03-05 iBio, Inc. Expression von fremdsequenzen in pflanzen unter verwendung eines trans-aktivierungssystems
US8278079B2 (en) 2002-11-07 2012-10-02 Danisco Us Inc. BGL6 β-glucosidase and nucleic acids encoding the same
US7582462B2 (en) * 2002-11-07 2009-09-01 Danisco Us Inc., Genencor Division BGL6 beta-glucosidase and nucleic acids encoding the same
AU2003295401B2 (en) 2002-11-08 2010-04-29 Genentech, Inc. Compositions and methods for the treatment of natural killer cell related diseases
US20050054054A1 (en) * 2002-11-12 2005-03-10 Foss Francine M. Interleukin-7 molecules with altered biological properties
US7692063B2 (en) * 2002-11-12 2010-04-06 Ibio, Inc. Production of foreign nucleic acids and polypeptides in sprout systems
US7683238B2 (en) * 2002-11-12 2010-03-23 iBio, Inc. and Fraunhofer USA, Inc. Production of pharmaceutically active proteins in sprouted seedlings
WO2004043239A2 (en) * 2002-11-13 2004-05-27 Raven Biotechnologies, Inc. Antigen pipa and antibodies that bind thereto
US20060009378A1 (en) 2002-11-14 2006-01-12 Itshak Golan Novel galectin sequences and compositions and methods utilizing same for treating or diagnosing arthritis and other chronic inflammatory diseases
CN100594037C (zh) 2002-11-15 2010-03-17 Musc研究发展基金会 通过补体受体2定向的补体调节剂
US8512701B2 (en) 2002-11-15 2013-08-20 Morehouse School Of Medicine Anti-CXCL13 and anti-CXCR5 antibodies for the prevention and treatment of cancer and cancer cell migration
US20110091451A1 (en) * 2002-11-15 2011-04-21 Kavanaugh William M Methods for preventing and treating cancer metastasis and bone loss associated with cancer metastasis
US9233120B2 (en) 2002-11-15 2016-01-12 Jyant Technologies Anti-CCL25 and anti-CCR9 antibodies for the prevention and treatment of cancer and cancer cell migration
AU2003291002A1 (en) 2002-11-15 2004-06-15 Chiron Corporation Methods for preventing and treating cancer metastasis and bone loss associated with cancer metastasis
US8658377B2 (en) 2002-11-15 2014-02-25 Morehouse School Of Medicine Detecting cancer with anti-CCL25 and anti-CCR9 antibodies
US20040229785A1 (en) * 2002-11-15 2004-11-18 Denise Faustman Screening methods to identify treatments for autoimmune disease
EP1570081A4 (de) * 2002-11-19 2006-05-31 Amgen Inc An krebs beteiligte amplifizierte gene
US7407788B2 (en) * 2002-11-21 2008-08-05 Danisco A/S, Genencor Division BGL7 beta-glucosidase and nucleic acids encoding the same
EP1572976B1 (de) 2002-11-21 2010-09-15 Celltech R & D, Inc. Modulieren von immunantworten
EP2112229A3 (de) 2002-11-25 2009-12-02 Sequenom, Inc. Verfahren zum Identifizieren des Brustkrebsrisikos und zugehörige Behandlungen
WO2004048936A2 (en) * 2002-11-26 2004-06-10 University Of Utah Research Foundation Microporous materials, methods, and articles for localizing and quantifying analytes
EP1572116A4 (de) 2002-11-26 2007-12-12 Genentech Inc Zusammensetzungen und verfahren für die behandlung von immunkrankheiten
MXPA05005558A (es) 2002-11-26 2005-07-26 Protein Design Labs Inc Anticuerpos quimericos y humanizados para integrina ( 5 ( 1 que modulan la angiogenesis.
US7597936B2 (en) * 2002-11-26 2009-10-06 University Of Utah Research Foundation Method of producing a pigmented composite microporous material
JP2007531505A (ja) 2002-11-27 2007-11-08 ミネルバ バイオオテクノロジーズ コーポレーション 癌（ｍｕｃ１）の診断および治療のための技術および組成物
MXPA05005923A (es) 2002-12-06 2005-09-21 Millennium Pharm Inc Metodos para la identificacion, valoracion y tratamiento de pacientes con terapia para la inhibicion de la proteasoma.
US7491699B2 (en) 2002-12-09 2009-02-17 Ramot At Tel Aviv University Ltd. Peptide nanostructures and methods of generating and using the same
US8420086B2 (en) 2002-12-13 2013-04-16 Immunomedics, Inc. Camptothecin conjugates of anti-CD22 antibodies for treatment of B cell diseases
US7056702B2 (en) * 2002-12-16 2006-06-06 Kimberly Clark Co Detecting lipocalin
HUE035898T2 (en) 2002-12-16 2018-05-28 Genentech Inc Immunoglobulin variants and their applications
ATE471946T1 (de) * 2002-12-17 2010-07-15 Merck Patent Gmbh Humanisierter antikörper (h14.18) des maus antikörpers 14.18, der gd2 bindet und seine fusion mit il-2
AU2003299441A1 (en) * 2002-12-19 2004-07-14 Centre National De La Recherche Scientifique - Cnrs Nf-hev compositions and methods of use
AU2002953431A0 (en) * 2002-12-19 2003-01-09 Murdoch University BmpB Novel Nucleotide and Amino Acid Sequences and Diagnostic and Therapeutic Uses Thereof
US9487823B2 (en) * 2002-12-20 2016-11-08 Qiagen Gmbh Nucleic acid amplification
EP2474630B1 (de) 2002-12-20 2016-04-27 Celera Corporation Mit Myokardinfarkt assoziierte genetische Polymorphismen, Nachweisverfahren und deren Verwendungen
US7276372B2 (en) 2002-12-20 2007-10-02 Pdl Biopharma, Inc. Antibodies against GPR64 and uses thereof
WO2004058166A2 (en) 2002-12-23 2004-07-15 Vical Incorporated Codon-optimized polynucleotide-based vaccines against human cytomegalovirus infection
ATE431157T1 (de) * 2002-12-23 2009-05-15 Rinat Neuroscience Corp Verfahren zur behandlung von durch taxol induzierter sensorischer neuropathie
AU2003303384A1 (en) 2002-12-23 2004-07-22 Schering Corporation Uses of mammalian cytokine; related reagents
DK1575517T3 (da) 2002-12-24 2012-05-14 Rinat Neuroscience Corp Anti-ngf-antistoffer og fremgangsmåder til anvendelse af samme
US9498530B2 (en) 2002-12-24 2016-11-22 Rinat Neuroscience Corp. Methods for treating osteoarthritis pain by administering a nerve growth factor antagonist and compositions containing the same
US7569364B2 (en) * 2002-12-24 2009-08-04 Pfizer Inc. Anti-NGF antibodies and methods using same
US20060205924A1 (en) * 2002-12-26 2006-09-14 Marco Muda Spliced variants of lgr6
WO2004060911A2 (en) * 2002-12-30 2004-07-22 Amgen Inc. Combination therapy with co-stimulatory factors
US20050265992A1 (en) 2003-01-03 2005-12-01 The Research Foundation Of State University Of New York F11 receptor (F11R) antagonists as therapeutic agents
US8557957B2 (en) 2003-01-03 2013-10-15 Elizabeth Kornecki Methods of treating disorders by administration of F11 receptor antagonists
WO2004060791A1 (en) 2003-01-07 2004-07-22 Ramot At Tel Aviv University Ltd. Peptide nanostructures encapsulating a foreign material and method of manufacturing same
AU2004204462B2 (en) * 2003-01-09 2012-03-08 Macrogenics, Inc. Dual expression vector system for antibody expression in bacterial and mammalian cells
US7355008B2 (en) 2003-01-09 2008-04-08 Macrogenics, Inc. Identification and engineering of antibodies with variant Fc regions and methods of using same
AU2004205631A1 (en) * 2003-01-16 2004-08-05 Genentech, Inc. Synthetic antibody phage libraries
US7955814B2 (en) * 2003-01-17 2011-06-07 Danisco A/S Method
EP2290085B1 (de) 2003-01-17 2017-12-13 DuPont Nutrition Biosciences ApS Verfahren zur Vor-Ort-Herstellung einer Emulsion in einem Lebensmittel
MXPA05007654A (es) * 2003-01-17 2005-09-30 Danisco Metodo.
US20050196766A1 (en) * 2003-12-24 2005-09-08 Soe Jorn B. Proteins
EP1595129A4 (de) 2003-01-17 2009-03-04 Univ Johns Hopkins Verfahren zur identifizierung von zellglykosylierungsmodulatoren unter verwendung von gtrap3-18
US20040197629A1 (en) * 2003-01-20 2004-10-07 Yasuo Arishima Electric power generating element for fuel cell and fuel cell using the same
US7488475B2 (en) 2003-01-21 2009-02-10 Arius Research, Inc. Antibody therapy of tumors
AU2004206250B8 (en) * 2003-01-21 2009-09-17 Bristol-Myers Squibb Company Polynucleotide encoding a novel acyl coenzyme a, monoacylglycerol acyltransferase-3 (MGAT3), and uses thereof
WO2004065417A2 (en) * 2003-01-23 2004-08-05 Genentech, Inc. Methods for producing humanized antibodies and improving yield of antibodies or antigen binding fragments in cell culture
RS20050577A (sr) * 2003-01-27 2007-09-21 Biogen Idec Ma Inc., PREPARATI I POSTUPCI ZA TRETIRANjE KANCERA KORIŠĆENjEM IGSF9 I LIV-1
DE10303974A1 (de) 2003-01-31 2004-08-05 Abbott Gmbh & Co. Kg Amyloid-β(1-42)-Oligomere, Verfahren zu deren Herstellung und deren Verwendung
KR20050118669A (ko) * 2003-02-01 2005-12-19 뉴랄랩 리미티드 가용성 ａ-베타에 대한 항체를 생성하기 위한 능동 면역화
WO2004070010A2 (en) 2003-02-01 2004-08-19 Tanox, Inc. A method for generating high affinity antibodies
ES2531125T3 (es) 2003-02-03 2015-03-10 Ibio Inc Sistema para la expresión de genes en plantas
JP4824540B2 (ja) 2003-02-07 2011-11-30 ダイアノキュアー インク． サンプル中の前立腺癌を検出する方法
CN110496230A (zh) 2003-02-11 2019-11-26 夏尔人类遗传性治疗公司 使用甲酰-甘氨酸生成酶(fge)对多种硫酸酯酶缺乏症和其它病症进行诊断和治疗
JP2007524362A (ja) 2003-02-14 2007-08-30 サイグレス ディスカバリー， インコーポレイテッド 癌における治療ｇｐｃｒ標的
US7767387B2 (en) * 2003-06-13 2010-08-03 Sagres Discovery, Inc. Therapeutic targets in cancer
EP2241330A1 (de) 2003-02-14 2010-10-20 The Curators Of The University Of Missouri Empfängnisverhütende Verfahren und Zusammensetzungen betreffend proteasomale Störung
WO2004071508A1 (en) * 2003-02-14 2004-08-26 Medical Research Council Ip receptor antagonists for the treatment of pathological uterine conditions
US20070218071A1 (en) * 2003-09-15 2007-09-20 Morris David W Novel therapeutic targets in cancer
US8795672B2 (en) * 2003-02-14 2014-08-05 University Of Southern California Compositions and methods for cancer immunotherapy
US20040170982A1 (en) * 2003-02-14 2004-09-02 Morris David W. Novel therapeutic targets in cancer
KR20050111598A (ko) 2003-02-19 2005-11-25 리나트 뉴로사이언스 코퍼레이션 신경 성장 인자 길항제 및 ｎｓａｉｄ를 투여함으로써통증을 치료하는 방법 및 그것을 함유하는 조성물
US7662387B2 (en) 2003-02-20 2010-02-16 Seattle Genetics Anti-cd70 antibody-drug conjugates and their use for the treatment of cancer and immune disorders
CA2516651C (en) * 2003-02-21 2013-05-07 The Queen's Medical Center Methods of screening for trpm5 modulators
AU2004216176B2 (en) 2003-02-21 2008-04-03 Genentech, Inc. Methods for preventing and treating tissue damage associated with ischemia-reperfusion injury
EP1594541A4 (de) * 2003-02-21 2007-03-28 Rikshospitalet Radiumhospitale Verfahren und zusammensetzungen zur behandlung von meconium-aspirationssyndrom
US8084582B2 (en) 2003-03-03 2011-12-27 Xencor, Inc. Optimized anti-CD20 monoclonal antibodies having Fc variants
US20090010920A1 (en) * 2003-03-03 2009-01-08 Xencor, Inc. Fc Variants Having Decreased Affinity for FcyRIIb
US8388955B2 (en) * 2003-03-03 2013-03-05 Xencor, Inc. Fc variants
US20070275460A1 (en) * 2003-03-03 2007-11-29 Xencor.Inc. Fc Variants With Optimized Fc Receptor Binding Properties
CN102225194B (zh) 2003-03-12 2014-07-16 健泰科生物技术公司 Bv8和/或EG-VEGF促进造血的用途
WO2004081204A1 (ja) 2003-03-12 2004-09-23 Ishihara Sangyo Kaisha, Ltd. 細胞増殖、発生分化が改変された植物細胞及び植物体
US8017113B2 (en) 2003-03-12 2011-09-13 Rappaport Family Institute For Research In The Medical Sciences Compositions and methods for diagnosing and treating an inflammation
US7741065B2 (en) * 2003-03-13 2010-06-22 Ramot At Tel Aviv University Ltd. Non-invasive marker for liver function and disease
US20040180387A1 (en) 2003-03-13 2004-09-16 Fujirebio Diagnostics, Inc. Detection of urinary mesothelin-/megakaryocyte potentiating factor-related peptides for assessment of ovarian cancer
DE10311248A1 (de) * 2003-03-14 2004-09-30 Müller-Hermelink, Hans Konrad, Prof. Dr. Humaner monoklonaler Antikörper
MXPA05009556A (es) * 2003-03-14 2005-11-16 Wyeth Corp Anticuerpos contra receptor de il-21 humano y sus usos.
PL1606409T3 (pl) 2003-03-19 2011-02-28 Biogen Ma Inc Białko wiążące receptor Nogo
WO2004084836A2 (en) * 2003-03-20 2004-10-07 Rinat Neuroscience Corp. Methods for treating taxol-induced gut disorder
JP2006520597A (ja) 2003-03-20 2006-09-14 ノバルティス・フォルシュングスシュティフトゥング・ツヴァイクニーダーラッスング・フリードリッヒ・ミーシェー・インスティトゥート・フォー・バイオメディカル・リサーチ 細胞運動性に関する物質および方法
EP1622941A2 (de) * 2003-03-20 2006-02-08 ImClone Systems Incorporated Methode zur produktion von anti-egfr antikörpern
US20060020119A1 (en) * 2004-03-29 2006-01-26 Stephen Grimes Monoclonal antibodies to gastrin hormone
US7235376B2 (en) * 2003-03-28 2007-06-26 Receptor Biologix, Inc. Gastrin hormone immunoassays
US8043834B2 (en) * 2003-03-31 2011-10-25 Qiagen Gmbh Universal reagents for rolling circle amplification and methods of use
CA2519241A1 (en) 2003-04-01 2004-11-11 Genentech, Inc. Compositions and methods for the diagnosis and treatment of tumor
ATE517926T1 (de) 2003-04-04 2011-08-15 Yeda Res & Dev Antikörper zur hemmung der aktivität von mmp-2 und mmp-9
EP1618897A4 (de) 2003-04-04 2010-09-29 Eisai R&D Man Co Ltd Lipidmembran-struktur mit anti-mt-mmp-monoklonalem antikörper
PT1610820E (pt) 2003-04-04 2010-12-16 Novartis Ag Formulações de elevada concentração de anticorpos e proteínas
ME00426B (me) 2003-04-09 2011-10-10 Genentech Inc Liječenje autoimunih bolesti kod pacijenata sa neadekvatnim odgovorom na tnf-alfa inhibitor
EP1617864A4 (de) * 2003-04-11 2006-06-21 Medimmune Inc Epha2 und nicht-neoplastische hyperproliferative zellstörungen
EP1618184A4 (de) * 2003-04-11 2006-06-21 Medimmune Inc Epha2, hydroproliferative zellstörungen sowie epithel- und endothel-rekonstituierung
KR101224235B1 (ko) 2003-04-11 2013-01-25 메디뮨 엘엘씨 재조합 ｉｌ­９ 항체 및 그의 용도
US20080025977A1 (en) * 2003-04-14 2008-01-31 Arius Research, Inc. Cytotoxicity mediation of cells evidencing surface expression of CD59
US20080213169A1 (en) * 2003-04-14 2008-09-04 Arius Research, Inc. Cytotoxicity mediation of cells evidencing surface expression of CD59
SE0301087D0 (sv) 2003-04-14 2003-04-14 Cartela Ab New monoclonal antibody
US20060140963A1 (en) * 2003-04-14 2006-06-29 Arius Research, Inc. Cytotoxicity mediation of cells evidencing surface expression of CD59
CN1832752A (zh) * 2003-04-16 2006-09-13 耶鲁大学 治疗淀粉样蛋白斑相关性病症的nogo－受体拮抗剂
AT500650B1 (de) 2003-04-17 2009-11-15 Altropus Gmbh Immunogener rekombinanter antikörper
NZ542988A (en) * 2003-04-23 2008-07-31 Medarex Inc Humanised antibodies directed against the IFNAR-1 receptor in which murine CDR sequences have been grafted directly into unmodified human framework sequences, resulting in high affinity, functional antibodies
CA2522957C (en) * 2003-04-23 2013-10-22 Medarex, Inc. Compositions and methods for the therapy of inflammatory bowel disease
US8613922B2 (en) 2003-04-24 2013-12-24 The University Of North Carolina At Chapel Hill Methods for inhibiting diabetic retinopathy with an antibody against integrin associated protein (IAP)
GB2401040A (en) 2003-04-28 2004-11-03 Chugai Pharmaceutical Co Ltd Method for treating interleukin-6 related diseases
PT2829283T (pt) 2003-04-30 2017-09-08 Univ Zuerich Método para tratamento do cancro utilizando uma imunotoxina
WO2004098634A2 (en) * 2003-04-30 2004-11-18 Government Of The United States Of America As Represented By The Sercretary Of The Department Of Health And Human Services National Institutes Of Health Protein arginine n-methyltransferase 2 (prmt-2)
US9051373B2 (en) 2003-05-02 2015-06-09 Xencor, Inc. Optimized Fc variants
TWI353991B (en) 2003-05-06 2011-12-11 Syntonix Pharmaceuticals Inc Immunoglobulin chimeric monomer-dimer hybrids
KR101351122B1 (ko) 2003-05-09 2014-01-14 듀크 유니버시티 Ｃｄ２０-특이적 항체 및 이를 이용한 방법
HUE034760T2 (en) 2003-05-12 2018-02-28 Helion Biotech Aps Masp-2-T binding antibodies
US20070104722A1 (en) * 2003-05-15 2007-05-10 Iogenetics Targeted biocides
US8703134B2 (en) 2003-05-15 2014-04-22 Iogenetics, Llc Targeted cryptosporidium biocides
US7566447B2 (en) 2003-05-15 2009-07-28 Iogenetics, Llc Biocides
US20050014932A1 (en) * 2003-05-15 2005-01-20 Iogenetics, Llc Targeted biocides
US8394379B2 (en) * 2003-05-15 2013-03-12 Iogenetics, Llc Targeted cryptosporidium biocides
EP2266606B1 (de) 2003-05-15 2014-09-10 Genentech, Inc. Verfahren und Zubereitungen zur Prävention und Behandlung von Blutvergiftung
US8080642B2 (en) * 2003-05-16 2011-12-20 Vical Incorporated Severe acute respiratory syndrome DNA compositions and methods of use
US7892563B2 (en) 2003-05-20 2011-02-22 Wyeth Holdings Corporation Methods for treatment of severe acute respiratory syndrome (SARS)
CN1833030B (zh) 2003-05-22 2014-07-23 美国弗劳恩霍夫股份有限公司 用于表达、传递及纯化目标多肽的重组载体分子
EP1635858A4 (de) * 2003-05-29 2009-08-26 Scripps Research Inst Gezielte abgabe an legumain exprimierende zellen
TWI306458B (en) 2003-05-30 2009-02-21 Elan Pharma Int Ltd Humanized antibodies that recognize beta amyloid peptide
US20100069614A1 (en) 2008-06-27 2010-03-18 Merus B.V. Antibody producing non-human mammals
RS20150135A1 (sr) 2003-05-30 2015-08-31 Genentech Inc. Tretman sa anti-vegf antitelima
GB0312481D0 (en) 2003-05-30 2003-07-09 Celltech R&D Ltd Antibodies
US9708410B2 (en) 2003-05-30 2017-07-18 Janssen Biotech, Inc. Anti-tissue factor antibodies and compositions
WO2004106375A1 (en) 2003-05-30 2004-12-09 Merus Biopharmaceuticals B.V. I.O. Fab library for the preparation of anti vegf and anti rabies virus fabs
AU2004251161A1 (en) * 2003-05-30 2005-01-06 Genentech, Inc. Polypeptides that bind an anti-tissue factor antibody and uses thereof
WO2005017149A1 (en) * 2003-06-03 2005-02-24 Cell Genesys, Inc. Compositions and methods for enhanced expression of recombinant polypeptides from a single vector using a peptide cleavage site
US7485291B2 (en) * 2003-06-03 2009-02-03 Cell Genesys, Inc. Compositions and methods for generating multiple polypeptides from a single vector using a virus derived peptide cleavage site, and uses thereof
US20050136035A1 (en) * 2003-06-03 2005-06-23 Derek Ko Cell specific replication-competent viral vectors comprising a self processing peptide cleavage site
US7405274B2 (en) 2003-06-04 2008-07-29 Fibrogen, Inc. Connective tissue growth factor antibodies
ES2537738T3 (es) * 2003-06-05 2015-06-11 Genentech, Inc. Terapia de combinación para trastornos de células B
US20050163775A1 (en) * 2003-06-05 2005-07-28 Genentech, Inc. Combination therapy for B cell disorders
CN1279056C (zh) * 2003-06-06 2006-10-11 马菁 肿瘤相关抗原sm5－1的特异性抗体及其应用
WO2005001486A1 (en) 2003-06-06 2005-01-06 Genentech, Inc. Modulating the interaction between hgf beta chain and c-met
US20050232926A1 (en) * 2003-06-06 2005-10-20 Oncomax Acquisition Corp. Antibodies specific for cancer associated antigen SM5-1 and uses thereof
GB0313259D0 (en) 2003-06-09 2003-07-16 Consejo Superior Investigacion Magnetic nanoparticles
WO2005004794A2 (en) 2003-06-09 2005-01-20 Alnylam Pharmaceuticals Inc. Method of treating neurodegenerative disease
US20040248323A1 (en) * 2003-06-09 2004-12-09 Protometrix, Inc. Methods for conducting assays for enzyme activity on protein microarrays
KR20060015646A (ko) 2003-06-13 2006-02-17 유니버시티 오브 피츠버그 면역, 혈액 및 염증성 질환의 모니터링 방법
IL156495A0 (en) * 2003-06-17 2004-01-04 Prochon Biotech Ltd Use of fgfr3 antagonists for treating t cell mediated diseases
PL2657248T3 (pl) 2003-06-19 2017-09-29 Genzyme Corporation Wiriony AAV o zmniejszonej immunoreaktywności i ich zastosowanie
CN1863556B (zh) * 2003-06-19 2012-05-16 吉宁特有限公司 用于治疗凝血相关紊乱的组合物和方法
AU2004249193A1 (en) * 2003-06-20 2004-12-29 Amgen Inc. Gene amplification and overexpression in cancer
US7700097B2 (en) * 2003-06-27 2010-04-20 Biogen Idec Ma Inc. Purification and preferential synthesis of binding molecules
CN101415724B (zh) 2003-06-30 2015-12-02 特拉维夫大学未来科技开发有限公司 肽、抗肽抗体以及用它们来诊断和治疗淀粉样蛋白相关疾病的方法
GB0315450D0 (en) * 2003-07-01 2003-08-06 Celltech R&D Ltd Biological products
GB0315457D0 (en) * 2003-07-01 2003-08-06 Celltech R&D Ltd Biological products
HRP20120845T1 (hr) * 2003-07-02 2012-11-30 Innate Pharma Protutijela za pan-kir2dl nk-receptor i njihova uporaba u dijagnostici i lijeäśenju
US20090191213A9 (en) * 2003-07-02 2009-07-30 Novo Nordisk A/S Compositions and methods for regulating NK cell activity
DK1641822T3 (da) 2003-07-08 2013-07-22 Genentech Inc Heterologe il-17-a/f-polypeptider og terapeutiske anvendelser deraf.
CA2532250A1 (en) * 2003-07-15 2005-02-03 Barros Research Institute Compositions and methods for immunotherapy of cancer and infectious diseases
GB0407315D0 (en) 2003-07-15 2004-05-05 Cambridge Antibody Tech Human antibody molecules
US20050058658A1 (en) * 2003-07-15 2005-03-17 Barros Research Institute Compositions and methods for immunotherapy of human immunodeficiency virus (HIV)
IL161903A0 (en) * 2003-07-17 2005-11-20 Gamida Cell Ltd Ex vivo progenitor and stem cell expansion for usein the treatment of disease of endodermally- deri ved organs
EA015363B1 (ru) 2003-07-18 2011-06-30 Эмджен Инк. Агенты, специфически связывающие фактор роста гепатоцитов, и их применение
EP1498133A1 (de) 2003-07-18 2005-01-19 Aventis Pharma Deutschland GmbH Verwendung von pak-Inhibitoren zur Behandlung von Gelenkerkrankungen
WO2005007878A2 (en) * 2003-07-22 2005-01-27 Dana-Farber Cancer Institute, Inc. Method of modulating apoptosis and compositions thereof
HUE033129T2 (en) 2003-07-24 2017-11-28 Innate Pharma Sa Methods and compositions for increasing the efficacy of therapeutic antibodies using compounds that potentiate NK cells
US7754209B2 (en) 2003-07-26 2010-07-13 Trubion Pharmaceuticals Binding constructs and methods for use thereof
JP4599355B2 (ja) 2003-07-28 2010-12-15 ジェネンテック， インコーポレイテッド プロテインａアフィニティークロマトグラフィーの間のプロテインａの浸出の低減
WO2005010039A1 (en) * 2003-07-31 2005-02-03 Pfizer Products Inc. Bsep polypeptide variants and uses thereof
US20050026881A1 (en) * 2003-07-31 2005-02-03 Robinson Cynthia B. Combination of dehydroepiandrosterone or dehydroepiandrosterone-sulfate with an anti-IgE antibody for treatment of asthma or chronic obstructive pulmonary disease
US20090263381A1 (en) * 2003-07-31 2009-10-22 Robinson Cynthia B Combination of dehydroepiandrosterone or dehydroepiandrosterone-sulfate with an anti-ige antibody for treatment of asthma or chronic obstructive pulmonary disease
US7709009B2 (en) 2003-07-31 2010-05-04 Novartis Vaccines And Diagnostics, Srl Immunogenic compositions for streptococcus pyogenes
WO2005012877A2 (en) 2003-08-01 2005-02-10 Dna Twopointo Inc. Systems and methods for antibody engineering
US7758859B2 (en) 2003-08-01 2010-07-20 Genentech, Inc. Anti-VEGF antibodies
EP1939779A3 (de) 2003-08-01 2009-04-01 Dna Twopointo Inc. Systeme und Verfahren zur Herstellung von Biopolymeren
US20050106667A1 (en) 2003-08-01 2005-05-19 Genentech, Inc Binding polypeptides with restricted diversity sequences
JP2007501011A (ja) * 2003-08-01 2007-01-25 ジェネンテック・インコーポレーテッド 制限多様性配列を有する結合型ポリペプチド
JP5576010B2 (ja) 2003-08-04 2014-08-20 ザ・ホスピタル・フォー・シック・チルドレン ラフォラ病遺伝子
US8007805B2 (en) * 2003-08-08 2011-08-30 Paladin Labs, Inc. Chimeric antigens for breaking host tolerance to foreign antigens
US20050079131A1 (en) * 2003-08-08 2005-04-14 Lanza Gregory M. Emulsion particles for imaging and therapy and methods of use thereof
EP2128270B1 (de) 2003-08-08 2012-10-03 Genenews Inc. Osteoarthritis-Biomarker und Verwendungen davon
ATE528397T1 (de) 2003-08-08 2011-10-15 Perseus Proteomics Inc Bei krebs überexprimiertes gen
WO2005019258A2 (en) 2003-08-11 2005-03-03 Genentech, Inc. Compositions and methods for the treatment of immune related diseases
US20060035242A1 (en) 2004-08-13 2006-02-16 Michelitsch Melissa D Prion-specific peptide reagents
EP1651674B1 (de) 2003-08-14 2010-09-29 Exelixis, Inc. Ups als den beta-catenin-pfad modifizierende substanzen und anwendungsverfahren
ATE495189T1 (de) 2003-08-15 2011-01-15 Univ Florida Die identifikation von polynukleotiden von porphyromonas gingivalis-virulenz zur diagnose, behandlung und beobachtung von periodontalerkrankungen
US20050131219A1 (en) * 2003-08-18 2005-06-16 Urdea Michael S. Methods for reducing complexity of a sample using small epitope antibodies
US20050042664A1 (en) * 2003-08-22 2005-02-24 Medimmune, Inc. Humanization of antibodies
NZ592039A (en) 2003-08-27 2013-03-28 Ophthotech Corp Combination therapy for the treatment of ocular neovascular disorders
WO2005021594A2 (en) * 2003-08-29 2005-03-10 The Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services Minimally immunogenic variants of sdr-grafted humanized antibody cc49 and their use
CA2537976A1 (en) * 2003-09-05 2005-03-17 The Scripps Research Institute Ozonation products of cholesterol for the treatment and prevention of artherosclerosis and/or cardiovascular diseases
WO2005023831A1 (en) * 2003-09-05 2005-03-17 The Scripps Research Institute Detection of cholesterol ozonation products
US20060216292A1 (en) * 2003-09-05 2006-09-28 Cellzome Ag Treatment of neurodegenerative diseases
AU2004273791A1 (en) * 2003-09-05 2005-03-31 Genentech, Inc. Antibodies with altered effector functions
EP1514561A1 (de) 2003-09-10 2005-03-16 Philogen S.p.A. Tumorvaskulatur Zielrichtung mittels Verwendung eines gegen Fibronectin ED-B radiomarkierten Antikörpers L19
US7046714B2 (en) * 2003-09-10 2006-05-16 Intel Corporation Method and apparatus for Raman ring resonator based laser/wavelength converter
GB0321997D0 (en) 2003-09-19 2003-10-22 Novartis Ag Organic compound
AU2004274487B2 (en) * 2003-09-18 2011-09-01 Macrogenics West, Inc. KID3 and KID3 antibodies that bind thereto
CA2539490A1 (en) 2003-09-18 2005-03-24 Genmab A/S Differentially expressed tumour-specific polypeptides for use in the diagnosis and treatment of cancer
WO2005028512A1 (en) * 2003-09-19 2005-03-31 Leukotech A/S Pro-inflammatory and anti-inflammatory antibodies against the heparin-binding protein (hbp)
US20050282177A1 (en) * 2003-09-22 2005-12-22 Aichi Prefecture Types of lymphoma and method for prognosis thereof
EP1673394A4 (de) * 2003-09-23 2008-03-26 Favrille Inc Modifikation einer b-zellen-pathologie mit eigenen antigenen in verbidnung mit einem spezifisch bindenden zytoreduktiven mittel
US7645602B2 (en) * 2003-09-23 2010-01-12 The University Of North Carolina At Chapel Hill Methods and compositions for producing vitamin K dependent proteins
ATE455174T1 (de) * 2003-09-23 2010-01-15 Univ North Carolina Zellen, die vitamin-k-reduktase und vitamin-k- abhängiges protein coexprimieren und deren anwendung zur verbesserung der produktivität von diesem vitamin-k-abhängigen protein
US9714282B2 (en) 2003-09-26 2017-07-25 Xencor, Inc. Optimized Fc variants and methods for their generation
US8101720B2 (en) * 2004-10-21 2012-01-24 Xencor, Inc. Immunoglobulin insertions, deletions and substitutions
US7803624B2 (en) 2003-09-30 2010-09-28 Cytyc Corporation Automated cytological sample classification
US20070281896A1 (en) * 2003-09-30 2007-12-06 Morris David W Novel compositions and methods in cancer
WO2005031362A2 (en) * 2003-10-02 2005-04-07 Ramot At Tel Aviv University Ltd. Novel antibacterial agents and methods of identifying and utilizing same
IL158287A0 (en) 2003-10-07 2004-05-12 Yeda Res & Dev Antibodies to nik, their preparation and use
WO2005034732A2 (en) 2003-10-07 2005-04-21 Millennium Pharmaceuticals, Inc. Nucleic acid molecules and proteins for the identification, assessment, prevention, and therapy of ovarian cancer
US20050287138A1 (en) * 2003-10-08 2005-12-29 Kyowa Hakko Kogyo Co., Ltd. CCR4-specific antibody composition
US20050226867A1 (en) * 2003-10-08 2005-10-13 Kyowa Hakko Kogyo Co., Ltd. IL-5R-specific antibody composition
US7691810B2 (en) * 2003-10-09 2010-04-06 Kyowa Hakko Kirin Co., Ltd Method of producing recombinant antithrombin III composition
US20060021071A1 (en) * 2003-10-09 2006-01-26 Kyowa Hakko Kogyo Co., Ltd. Cell in which genome is modified
WO2005035548A1 (en) 2003-10-10 2005-04-21 Meditech Research Limited The moduilation of hyaluronan synthesis and degradation in the treatment of disease
EP2272951B1 (de) * 2003-10-14 2014-07-23 Baxter International Inc. VKCORC1 (vitamin k epoxide recycling polypeptide), ein therapeutisches Ziel für Coumarin und deren Derivate
JP5037134B2 (ja) 2003-10-17 2012-09-26 レハブ アル−ジャマル 組織修復
IL158599A0 (en) * 2003-10-26 2004-05-12 Yeda Res & Dev Methods of modulating hematopoiesis
US7304139B2 (en) * 2003-10-28 2007-12-04 University Of Florida Research Foundation, Inc. Polynucleotides and polypeptides of Anaplasma phagocytophilum and methods of using the same
US20070098718A1 (en) 2003-11-04 2007-05-03 Chiron Methods of therapy for b cell-related cancers
DK1680141T3 (da) 2003-11-04 2010-11-01 Novartis Vaccines & Diagnostic Fremgangsmåder til terapi til faste tumorer der udtrykker CD40-celleoverfladeantigenet
PL1682177T3 (pl) 2003-11-04 2011-03-31 Novartis Vaccines & Diagnostics Inc Zastosowanie antagonistycznych przeciwciał anty-CD40 do leczenia przewlekłej białaczki limfocytowej
AU2004287879C1 (en) 2003-11-04 2011-05-26 Novartis Vaccines And Diagnostics, Inc. Antagonist anti-CD40 monoclonal antibodies and methods for their use
PT1684805E (pt) 2003-11-04 2010-10-26 Novartis Vaccines & Diagnostic Utilização de anticorpos monoclonais antagonistas anti-cd40 para o tratamento do mieloma múltiplo
HUE038955T2 (hu) 2003-11-05 2018-12-28 Roche Glycart Ag Antigén-kötõ molekulák fokozott Fc receptor-kötõ affinitással és effektor funkcióval
SG148161A1 (en) 2003-11-05 2008-12-31 Palingen Inc Enhanced b cell cytotoxicity of cdim binding antibody
ES2605443T3 (es) 2003-11-06 2017-03-14 Seattle Genetics, Inc. Conjugados de auristatina con anticuerpos anti-HER2 o anti-CD22 y su uso en terapia
US20050214805A1 (en) * 2003-11-10 2005-09-29 Q-Rna, Inc. Methods of detection employing immuno-Q-Amp technology
PE20090047A1 (es) 2003-11-10 2009-01-26 Schering Corp Anticuerpo recombinante humanizado anti-interleuquina 10
US20060199194A1 (en) * 2003-11-10 2006-09-07 Q-Rna, Inc. Methods of detection using immuno-Q-Amp technology
US20070276049A1 (en) 2003-11-11 2007-11-29 Schlievert Patrick M Regulation of Cell Membrane-Mediated Effects
WO2005047481A2 (en) * 2003-11-12 2005-05-26 Progenics Pharmaceuticals, Inc. Novel sequences encoding hapatitis c virus glycoproteins
WO2005048938A2 (en) * 2003-11-13 2005-06-02 California Pacific Medical Center Anti-pecam therapy for metastasis suppression
US7883703B2 (en) 2003-11-14 2011-02-08 The Brigham And Women's Hospital, Inc. Methods of modulating immunity
NZ576411A (en) 2003-11-17 2010-04-30 Genentech Inc Compositions and methods for the treatment of tumor of hematopoietic origin
DE602004027291D1 (de) 2003-11-25 2010-07-01 Us Gov Health & Human Serv Mutierte anti-cd22-antikörper und immunkonjugate
CN1914226B (zh) * 2003-11-25 2012-02-01 达纳-法伯癌症研究院有限公司 SARS-CoV抗体及其使用方法
EP1711622A2 (de) 2003-11-26 2006-10-18 Applera Corporation Mit kardiovaskulären erkrankungen und dem ansprechen auf medikation in zusammenhang stehende genpolymorphismen, methoden zu deren nachweis und deren verwendung
DE10355904A1 (de) 2003-11-29 2005-06-30 Merck Patent Gmbh Feste Formen von anti-EGFR-Antikörpern
WO2005051423A2 (en) 2003-11-30 2005-06-09 Yeda Research And Development Co. Ltd Methods and agents for immune modulation and methods for identifying immune modulators
EP2361974A1 (de) 2003-12-02 2011-08-31 Institut Pasteur Verwendung von Proteinen und Peptiden, kodiert im Genom eines neuen mit SARS verbunden coronavirus Stammes
WO2005055936A2 (en) * 2003-12-04 2005-06-23 Vaccinex, Inc. Methods of killing tumor cells by targeting internal antigens exposed on apoptotic tumor cells
US20060182742A1 (en) * 2004-08-24 2006-08-17 Ishikawa Muriel Y System and method for magnifying a humoral immune response
US20060122784A1 (en) * 2004-12-03 2006-06-08 Ishikawa Muriel Y System and method for augmenting a humoral immune response
US20060047436A1 (en) * 2004-08-25 2006-03-02 Ishikawa Muriel Y System and method for magnifying an immune response
US20060047434A1 (en) * 2004-08-24 2006-03-02 Ishikawa Muriel Y System and method related to improving an immune system
US20060122783A1 (en) * 2004-08-24 2006-06-08 Ishikawa Muriel Y System and method for heightening a humoral immune response
US20060116824A1 (en) * 2004-12-01 2006-06-01 Ishikawa Muriel Y System and method for modulating a humoral immune response
US20060095211A1 (en) * 2003-12-05 2006-05-04 Searete Llc, A Limited Liability Corporation Of The State Of Delaware System and method for modulating a cell mediated immune response
US20060047435A1 (en) * 2004-08-24 2006-03-02 Ishikawa Muriel Y System and method related to augmenting an immune system
US20060047437A1 (en) * 2004-08-25 2006-03-02 Ishikawa Muriel Y System and method for heightening an immune response
US20070249809A1 (en) * 2003-12-08 2007-10-25 Xencor, Inc. Protein engineering with analogous contact environments
US20060003412A1 (en) * 2003-12-08 2006-01-05 Xencor, Inc. Protein engineering with analogous contact environments
WO2005060368A2 (en) 2003-12-10 2005-07-07 Millennium Pharmaceuticals, Inc. Humanized anti-ccr2 antibodies and methods of use
PT2418220T (pt) 2003-12-10 2017-10-04 Squibb & Sons Llc Anticorpos contra interferão alfa e suas utilizações
DK2383295T3 (en) 2003-12-10 2015-06-15 Squibb & Sons Llc Ip-10 antibodies and uses thereof
US7312320B2 (en) 2003-12-10 2007-12-25 Novimmune Sa Neutralizing antibodies and methods of use thereof
CN1922208A (zh) 2003-12-11 2007-02-28 健泰科生物技术公司 用于抑制c－met二聚化及活化的方法和组合物
US7371381B2 (en) * 2003-12-12 2008-05-13 Amgen Inc. Anti-galanin antibodies and uses thereof
CA2494572A1 (en) * 2003-12-19 2005-06-19 Cytochroma Inc. Cytochrome p450 24 (cyp24) monoclonal antibody and methods and uses thereof
PT1718677E (pt) 2003-12-19 2012-07-18 Genentech Inc Fragmentos de anticorpo monovalentes úteis como agentes terapêuticos
WO2005062916A2 (en) * 2003-12-22 2005-07-14 Centocor, Inc. Methods for generating multimeric molecules
US8586357B2 (en) * 2003-12-23 2013-11-19 Viacyte, Inc. Markers of definitive endoderm
US7985585B2 (en) 2004-07-09 2011-07-26 Viacyte, Inc. Preprimitive streak and mesendoderm cells
MX361174B (es) 2003-12-23 2018-11-29 Genentech Inc Anticuerpos anti-il13 novedosos y sus usos.
US8647873B2 (en) 2004-04-27 2014-02-11 Viacyte, Inc. PDX1 expressing endoderm
EP2722387B1 (de) * 2003-12-23 2019-12-11 Viacyte, Inc. Definitives Endoderm
US7625753B2 (en) * 2003-12-23 2009-12-01 Cythera, Inc. Expansion of definitive endoderm cells
US20050266554A1 (en) * 2004-04-27 2005-12-01 D Amour Kevin A PDX1 expressing endoderm
US7541185B2 (en) * 2003-12-23 2009-06-02 Cythera, Inc. Methods for identifying factors for differentiating definitive endoderm
JP4503617B2 (ja) 2003-12-23 2010-07-14 ライナット ニューロサイエンス コーポレイション アゴニスト抗ｔｒｋＣ抗体および該抗体を用いる方法
US7718408B2 (en) * 2003-12-24 2010-05-18 Danisco A/S Method
GB0716126D0 (en) * 2007-08-17 2007-09-26 Danisco Process
CA2550800A1 (en) 2003-12-24 2005-07-21 Danisco A/S Methods to produce variant glycolipid acyltransferases and variant glycolipid acyltransferases with enhanced activity towards glycolipids.
KR20060133560A (ko) 2003-12-30 2006-12-26 산토리 가부시키가이샤 신규 혈청형 스트렙토코쿠스 뮤탄스 및 그 이용
EP1699821B1 (de) * 2003-12-31 2012-06-20 Merck Patent GmbH Fc-ERYTHROPOIETIN-FUSIONSPROTEIN MIT VERBESSERTER PHARMAKOKINETIK
ES2689328T3 (es) 2004-01-07 2018-11-13 Novartis Vaccines And Diagnostics, Inc. Anticuerpo monoclonal M-CSF-específico y usos del mismo
US20050221429A1 (en) * 2004-01-16 2005-10-06 Cardinal Health Pts, Llc Host cells containing multiple integrating vectors comprising an amplifiable marker
EP1737971B1 (de) 2004-01-20 2017-08-16 Merus N.V. Gemische bindender proteine
EP1715897B2 (de) 2004-01-20 2013-10-30 Sunnybrook and Women's College Health Sciences Centre Hochfrequenz-ultraschall-darstellung mit kontrastmitteln
EP2444805A3 (de) 2004-01-21 2012-06-20 Fujirebio America, Inc. Erkennung von Mesothelin-/Megakaryozyten zur Potenzierung von faktorbezogenen Peptiden in peritonealer Flüssigkeit zur Bewertung des Peritoneum und Peritonealhöhle
EP1716168A4 (de) * 2004-01-21 2009-06-24 Fujirebio America Inc Nachweis von mit dem urinary mesothelin-/ megakaryocyte potentiating factor verwandten peptiden zur untersuchung von mesotheliomen
WO2005069969A2 (en) 2004-01-21 2005-08-04 University Of Utah Research Foundation Mutant sodium channel nav1.7 and methods related thereto
JP2007535913A (ja) * 2004-01-21 2007-12-13 ノボザイムス アクティーゼルスカブ ヘテロカリオン菌類又は菌類宿主細胞におけるモノクローナル抗体の生成
CA2553883C (en) * 2004-01-22 2013-04-02 Merck Patent Gesellschaft Mit Beschraenkter Haftung Anti-cancer antibodies with reduced complement fixation
EP1708752B1 (de) * 2004-01-27 2012-02-22 University Of Southern California Therapeutisches krebsmittel mit polymergebundenem antikörper
US7323551B2 (en) * 2004-01-27 2008-01-29 The Board Of Trustees Of The Leland Stanford Junior University Compositions and methods for inhibiting squamous cell carcinoma
US7875277B2 (en) * 2004-01-27 2011-01-25 The Dept. of Veterans Affairs Office of The General Counsel Compositions and methods for inhibiting squamous cell carcinoma
EP1713900A4 (de) * 2004-01-27 2009-06-17 Compugen Ltd Verfahren und systeme zur kommentierung biomolekularer sequenzen
DE602004011400T2 (de) * 2004-01-29 2009-01-22 Cellzome Ag Behandlung von neurodegenerativen krankheiten mit gpr49
EP1718741A2 (de) * 2004-01-29 2006-11-08 Cellzome Ag Behandlung neurodegenrerativer krankheiten unter verwendung von atp7a
WO2005075511A1 (en) * 2004-01-29 2005-08-18 Genentech, Inc. Variants of the extracellular domain of bcma and uses thereof
CA2555306A1 (en) * 2004-02-06 2005-08-18 Nymox Corporation Humanized antibody
EP1718329A4 (de) * 2004-02-06 2008-09-10 Astellas Us Llc Verfahren zur behandlung von hauterkrankungen
ES2366626T3 (es) 2004-02-06 2011-10-24 University Of Massachusetts Anticuerpos contra toxinas de clostridium difficile y usos de los mismos.
CN102816241B (zh) 2004-02-09 2015-07-22 人类基因科学公司 清蛋白融合蛋白
US7803931B2 (en) 2004-02-12 2010-09-28 Archemix Corp. Aptamer therapeutics useful in the treatment of complement-related disorders
US7481997B1 (en) 2004-02-12 2009-01-27 Montana State University Snow mountain virus genome sequence, virus-like particles and methods of use
US20110171126A1 (en) * 2010-01-11 2011-07-14 Center For Molecular Medicine And Immunology Enhanced Cytotoxicity of Anti-CD74 and Anti-HLA-DR Antibodies with Interferon-Gamma
US9550838B2 (en) 2004-02-13 2017-01-24 Ibc Pharmaceuticals, Inc. Dock-and-lock (DNL) complexes for therapeutic and diagnostic use
US8883160B2 (en) * 2004-02-13 2014-11-11 Ibc Pharmaceuticals, Inc. Dock-and-lock (DNL) complexes for therapeutic and diagnostic use
EP1730173A4 (de) * 2004-02-18 2008-10-08 Merck & Co Inc Nukleinsäuremoleküle, codierend für neue, durch niedrige spannungen aktivierte, als alpha 1h bezeichnete calciumkanalproteine aus der maus, codierte proteine und verfahren zu deren anwendung
EP2168986A3 (de) 2004-02-19 2010-07-28 Genentech, Inc. Antikörper mit korrigiertem CDR
US7807157B2 (en) 2004-02-20 2010-10-05 Intellect Neurosciences Inc. Monoclonal antibodies and use thereof
US7767792B2 (en) 2004-02-20 2010-08-03 Ludwig Institute For Cancer Research Ltd. Antibodies to EGF receptor epitope peptides
ES2532609T3 (es) * 2004-02-20 2015-03-30 Ibio, Inc. Sistemas y métodos para expresión clonales en plantas
CA2560066A1 (en) 2004-03-01 2005-09-15 The Cbr Institute For Biomedical Research, Inc. Natural igm antibodies and inhibitors thereof
GB0405637D0 (en) 2004-03-12 2004-04-21 Danisco Protein
JP2007529718A (ja) * 2004-03-12 2007-10-25 ザ スクリップス リサーチ インスティチュート 蛋白質活性の検出および定量のための蛍光シグナル発光型生細胞バイオセンサー分子ならびに色素
WO2005090406A2 (en) 2004-03-12 2005-09-29 Vasgene Therapeutics, Inc. Antibodies binding to ephb4 for inhibiting angiogenesis and tumor growth
ES2387809T3 (es) * 2004-03-19 2012-10-02 Imclone Llc Anticuerpo frente al receptor del factor de crecimiento epidérmico humano
BRPI0509201A (pt) 2004-03-23 2007-08-28 Biogen Idec Inc agentes de acoplamento de receptor e usos terapêuticos destes
US7276585B2 (en) * 2004-03-24 2007-10-02 Xencor, Inc. Immunoglobulin variants outside the Fc region
EP1786463A4 (de) * 2004-03-26 2009-05-20 Human Genome Sciences Inc Antikörper gegen nogo-rezeptor
US20070161554A1 (en) * 2004-03-26 2007-07-12 Cellzome Ag Treatment of neurodegenerative diseases by the use of laptm4b
US20050260710A1 (en) * 2004-03-31 2005-11-24 Sekisui Chemical Co. Ltd. Methods for producing recombinant polyclonal immunoglobulins
US7479379B2 (en) 2004-03-31 2009-01-20 Centocor, Inc. Methods for altering protein production rates
CN1961003B (zh) * 2004-03-31 2013-03-27 健泰科生物技术公司 人源化抗TGF-β抗体
EP1734996B1 (de) 2004-04-02 2013-05-22 The Regents of The University of California Verfahren und zusammensetzungen für die behandlung und vorbeugung von mit alpha v beta 5-integrin assoziierten krankheiten
WO2005095458A1 (en) * 2004-04-02 2005-10-13 The Talwar Research Foundation CHIMERIC MONOCLONAL ANTIBODY FOR BINDING WITH HIGH AFFINITY SELECTIVELY TO hCG
KR101637908B1 (ko) * 2004-04-07 2016-07-11 리나트 뉴로사이언스 코프. 신경성장인자 길항제의 투여에 의한 골암 통증의 치료방법
US7794713B2 (en) * 2004-04-07 2010-09-14 Lpath, Inc. Compositions and methods for the treatment and prevention of hyperproliferative diseases
US20050227289A1 (en) 2004-04-09 2005-10-13 Reilly Edward B Antibodies to erythropoietin receptor and uses thereof
US7785903B2 (en) * 2004-04-09 2010-08-31 Genentech, Inc. Variable domain library and uses
US20060018902A1 (en) * 2004-04-09 2006-01-26 Reilly Edward B Antibodies to erythropoietin receptor and uses thereof
US20080038265A1 (en) * 2004-04-09 2008-02-14 Reilly Edward B Antibodies to Erythropoietin Receptor and Uses Thereof
WO2005108988A2 (en) 2004-04-09 2005-11-17 University Of Pittsburgh Real time method of detecting acute inflammatory conditions
EP1745149A4 (de) 2004-04-15 2008-08-06 Univ Florida Neurale proteine als biomarker für eine verletzung des nervensystems und andere neurale störungen
US20150017671A1 (en) 2004-04-16 2015-01-15 Yaping Shou Methods for detecting lp-pla2 activity and inhibition of lp-pla2 activity
ZA200608572B (en) * 2004-04-16 2008-06-25 Genentech Inc Assay for antibodies
RU2006140377A (ru) * 2004-04-16 2008-05-27 Дженентек, Инк. (Us) Способ усиления уничтожения в-клеток
BRPI0509412A (pt) * 2004-04-16 2007-09-04 Genentech Inc método de tratamento de policondrite ou mononeurite multiplex em mamìferos e artigo industrializado
AU2005235718B2 (en) 2004-04-23 2011-09-22 Bundesrepublik Deutschland Letztvertreten Durch Das Robert-Koch-Institut Vertreten Durch Seinen Prasidenten Method for the treatment of T cell mediated conditions by depletion of icos-positive cells in vivo
WO2005115435A2 (en) * 2004-04-30 2005-12-08 Bas Medical, Inc. Methods and compositions for control of fetal growth via modulation of relaxin
US7311906B2 (en) * 2004-04-30 2007-12-25 Brigham Young University Anti-viral activity of an anti-thymidine kinase monoclonal antibody
WO2005112568A2 (en) * 2004-05-04 2005-12-01 Genaissance Pharmaceuticals, Inc. Haplotype markers and methods of using the same to determine response to treatment
EP1750747A1 (de) * 2004-05-07 2007-02-14 Astellas US LLC Lösliches lfa-3 polypeptid zur behandlung viraler erkrankungen
WO2005111241A2 (en) 2004-05-07 2005-11-24 Applera Corporation Genetic polymorphisms associated with liver fibrosis methods of detection and uses thereof
EP2214014A1 (de) 2004-05-11 2010-08-04 The University of Pittsburgh Diagnose und überwachung von entzündlichen Krankheiten mittels Messung der Komplementkomponenten von Leukozyten
GB0410627D0 (en) 2004-05-12 2004-06-16 Scancell Ltd Specific binding members
EP1769243A2 (de) * 2004-05-15 2007-04-04 Genentech, Inc. Kreuzscreening-system und verfahren für den nachweis eines moleküls mit bindungsaffinität für ein zielmolekül
US8586294B2 (en) 2004-05-18 2013-11-19 The Board Of Trustees Of The Leland Stanford Junior University Detection of protein translocation by beta-galactosidase reporter fragment complementation
EP1598428A1 (de) 2004-05-18 2005-11-23 Georg Dewald Verfahren und Kits zum Nachweis von erblichen angioedema typ III
EP1789453A2 (de) * 2004-05-18 2007-05-30 Genentech, Inc. Haupthüllproteinvarianten des m13-virus zur c-terminalen und bi-terminalen anzeige eines heterologen proteins
JP5331340B2 (ja) * 2004-05-18 2013-10-30 バイカル インコーポレイテッド インフルエンザウィルスワクチン組成物、及びその使用方法
EP1753458A4 (de) * 2004-05-19 2009-07-22 Wyeth Corp Modulation der immunglobulinproduktion und atopische erkrankungen
BRPI0510909A2 (pt) * 2004-05-19 2008-12-16 Medarex Inc composto de ligaÇço fÁrmaco-ligante citotàxico, formulaÇço farmacÊutica, mÉtodo para matar uma cÉlula e mÉtodo para retardar ou interromper o crescimento de tumor
US7691962B2 (en) * 2004-05-19 2010-04-06 Medarex, Inc. Chemical linkers and conjugates thereof
US8551486B2 (en) * 2004-05-21 2013-10-08 Savoy Pharmaceuticals, Inc. Monoclonal antibodies to human thymidine kinase to treat cancer
US7837998B2 (en) * 2004-05-21 2010-11-23 Nathaniel Lallatin Anti-cancer activity of an anti-thymidine kinase monoclonal antibody
US20100266495A1 (en) * 2004-05-21 2010-10-21 Brigham Young University Anti-Cancer Activity of an Anti-Thymidine Kinase Monoclonal Antibody
US20080276327A1 (en) * 2004-05-21 2008-11-06 University Of Utah Research Foundation Methods and Compositions Related to Delivery of Chemical Compounds to Invertebrate Embryos
RU2381234C2 (ru) 2004-05-28 2010-02-10 Эдженсис, Инк. Антитела и родственные молекулы, связывающиеся с белками psca
NZ551180A (en) 2004-06-01 2009-10-30 Genentech Inc Antibody drug conjugates and methods
US8921528B2 (en) 2004-06-01 2014-12-30 Domantis Limited Bispecific fusion antibodies with enhanced serum half-life
US8222393B2 (en) 2004-06-02 2012-07-17 Tss Biotech Inc. Polypeptide useful for cancer diagnosis and treatment
SG183012A1 (en) 2004-06-04 2012-08-30 Genentech Inc Method for treating multiple sclerosis
KR101295139B1 (ko) 2004-06-07 2013-08-12 레이븐 바이오테크놀로지스, 인코퍼레이티드 트랜스페린 리셉터 항체
US7604947B2 (en) * 2004-06-09 2009-10-20 Cornell Research Foundation, Inc. Detection and modulation of cancer stem cells
US20060018896A1 (en) * 2004-06-10 2006-01-26 University Of Leicester Methods for treating conditions associated with lectin-dependent complement activation
MXPA06014402A (es) * 2004-06-10 2007-03-08 Enkam Pharmaceuticals As Peptido de enlace a heparina.
EP2465534B1 (de) 2004-06-10 2017-03-29 Omeros Corporation Verfahren zur Behandlung von Leiden in Zusammenhang mit MASP-2-abhängiger Komplementaktivierung
US8840893B2 (en) 2004-06-10 2014-09-23 Omeros Corporation Methods for treating conditions associated with MASP-2 dependent complement activation
US7919094B2 (en) 2004-06-10 2011-04-05 Omeros Corporation Methods for treating conditions associated with MASP-2 dependent complement activation
GB0412966D0 (en) 2004-06-10 2004-07-14 Univ Leicester Genetically modified non-human mammals and cells
AU2005255019B2 (en) * 2004-06-12 2011-05-19 Oregon Health And Science University Compositions and methods for diagnosis and treatment of orthopoxviruses
EP2789342A1 (de) 2004-06-17 2014-10-15 Thrasos Innovation, Inc. Verbindungen im Zusammenhang mit TDF und Analoga davon
ES2415665T3 (es) 2004-06-21 2013-07-26 Proteome Sciences Plc Procedimientos de cribado usando c-abl, fyn y sky en combinación con la proteína tau
ES2643237T3 (es) 2004-06-21 2017-11-21 E. R. Squibb & Sons, L.L.C. Anticuerpos del receptor 1 de interferón alfa y sus usos
GB0414054D0 (en) 2004-06-23 2004-07-28 Owen Mumford Ltd Improvements relating to automatic injection devices
PT1776136E (pt) 2004-06-24 2012-12-05 Biogen Idec Inc Tratamento de estados que envolvem desmielinização
WO2006003179A2 (en) 2004-07-01 2006-01-12 Novo Nordisk A/S Antibodies binding to receptors kir2dl1, -2, 3 but not kir2ds4 and their therapeutic use
CA2601417C (en) 2004-07-01 2018-10-30 Novo Nordisk A/S Human anti-kir antibodies
US7973134B2 (en) * 2004-07-07 2011-07-05 Cell Signaling Technology, Inc. Reagents for the detection of protein phosphorylation in anaplastic large cell lymphoma signaling pathways
US7598071B2 (en) * 2004-07-09 2009-10-06 The United States Of America As Represented By The Department Of Health And Human Services Infectious clone of human parvovirus B19 and methods
AU2005256113B2 (en) 2004-07-09 2011-02-10 Chugai Seiyaku Kabushiki Kaisha Anti-glypican 3 antibody
TR201808440T4 (tr) 2004-07-09 2018-07-23 Henry M Jackson Found Advancement Military Medicine Inc Hendra ve nipah virüsü G glikoproteininin çözünebilen formları.
ES2678094T3 (es) * 2004-07-10 2018-08-08 Fox Chase Cancer Center Líneas de células asesinas naturales genéticamente modificadas
CA2573392A1 (en) * 2004-07-12 2006-09-08 Rappaport Family Institute For Research In The Medical Sciences Methods of detecting a phenotype of a polymorphic protein
EP1765846A4 (de) * 2004-07-13 2010-02-17 Cell Genesys Inc Aav-vektorzusammensetzungen und ihr einsatz in verfahren zür erhöhung der immunoglobulin-expression
US20090087376A1 (en) * 2004-07-15 2009-04-02 The General Hospital Corporation Heterocyclic Dye Compounds For In Vivo Imaging And Diagnosis Of Alzheimer's Disease
US20150010550A1 (en) 2004-07-15 2015-01-08 Xencor, Inc. OPTIMIZED Fc VARIANTS
EP3342782B1 (de) 2004-07-15 2022-08-17 Xencor, Inc. Optimierte fc-varianten
US6986264B1 (en) * 2004-07-15 2006-01-17 Carrier Corporation Economized dehumidification system
CN102533440B (zh) * 2004-07-16 2017-09-19 杜邦营养生物科学有限公司 用酶使油脱胶的方法
SI1771474T1 (sl) * 2004-07-20 2010-06-30 Genentech Inc Inhibitorji angiopoetinu podobnega proteina kombinacije in njihova uporaba
US8604185B2 (en) 2004-07-20 2013-12-10 Genentech, Inc. Inhibitors of angiopoietin-like 4 protein, combinations, and their use
US20060024677A1 (en) 2004-07-20 2006-02-02 Morris David W Novel therapeutic targets in cancer
EP1778842B8 (de) 2004-07-22 2012-03-21 Five Prime Therapeutics, Inc. Zusammensetzungen und verfahren zur verwendung von mgd-cdf zur krankheitsbehandlung
WO2006078318A2 (en) 2004-07-29 2006-07-27 Novartis Vaccines And Diagnostics Inc. Immunogenic compositions for gram positive bacteria such as streptococcus agalactiae
AU2005290250A1 (en) * 2004-07-30 2006-04-06 Rinat Neuroscience Corp. Antibodies directed against amyloid-beta peptide and methods using same
JP5014130B2 (ja) 2004-08-02 2012-08-29 ズィナイス オペレーションズ ピーティーワイ．エルティーディー． Ｖｅｇｆ−ｂアンタゴニストを含む癌治療方法
WO2006013552A2 (en) * 2004-08-02 2006-02-09 Ramot At Tel Aviv University Ltd. Articles of peptide nanostructures and method of forming the same
EP1789070B1 (de) 2004-08-03 2012-10-24 Biogen Idec MA Inc. Taj in der neuronalen funktion
WO2006026051A2 (en) * 2004-08-03 2006-03-09 The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Selections of genes and methods of using the same for diagnosis, prognosis and for targeting the therapy of neuroblastoma
ES2381557T3 (es) 2004-08-03 2012-05-29 Innate Pharma Métodos terapéuticos y de diagnóstico y composiciones para determinar 4IG-B7-H3 y su receptor homólogo en las células NK
ES2414460T3 (es) 2004-08-04 2013-07-19 Amgen Inc. Anticuerpos para Dkk-1
US7572600B2 (en) * 2004-08-04 2009-08-11 Chemocentryx, Inc. Enzymatic activities in chemokine-mediated inflammation
ME01803B (me) * 2004-08-05 2010-12-31 Genentech Inc Humanizovani anti-cmet antagonisti
MX2007001509A (es) * 2004-08-05 2007-03-27 Wyeth Corp Antagonismo de la actividad del receptor de interleuquina 21.
CN101061238B (zh) 2004-08-06 2013-11-20 健泰科生物技术公司 使用生物标志的测定法和方法
ES2365719T3 (es) 2004-08-06 2011-10-10 Genentech, Inc. Ensayos y procedimientos que utilizan biomarcadores.
DK1778837T3 (da) * 2004-08-09 2008-08-04 Cellzome Ag Behandling af neurodegenerative sygdomme ved anvendelse af SCD4-inhibitorer
KR20070041781A (ko) * 2004-08-11 2007-04-19 트루비온 파마슈티칼스, 인코포레이티드 결합 도메인 융합 단백질
US20060073168A1 (en) * 2004-08-11 2006-04-06 Stephens David S Neisseria meningitidis serogroup a capsular polysaccharide acetyltransferase, methods and compositions
CA2478458A1 (en) * 2004-08-20 2006-02-20 Michael Panzara Treatment of pediatric multiple sclerosis
US20070265787A1 (en) * 2004-08-24 2007-11-15 Searete Llc,A Limited Liability Corporation Of The State Of Delaware Computational methods and systems for magnifying cell-mediated immune response
US20070198196A1 (en) * 2004-08-24 2007-08-23 Searete Llc, A Limited Liability Corporation Of The State Of Delaware Computational systems and methods relating to ameliorating an immune system
US20070196362A1 (en) * 2004-08-24 2007-08-23 Searete Llc, A Limited Liability Corporation Of The State Of Delaware Computational methods and systems to bolster an immune response
US20070265818A1 (en) * 2004-08-24 2007-11-15 Searete Llc, A Limited Liability Corporation Of The State Of Delaware Computational methods and systems for heightening cell-mediated immune response
US20070265817A1 (en) * 2004-08-24 2007-11-15 Searete Llc, A Limited Liability Corporation Of The State Of Delaware Computational systems and methods relating to fortifying an immune system
US20060047439A1 (en) * 2004-08-24 2006-03-02 Searete Llc, A Limited Liability Corporation Of The State Of Delaware System and method for improving a humoral immune response
US20070207492A1 (en) * 2004-08-24 2007-09-06 Searete Llc, A Limited Liability Corporation Of The State Of Delaware Computational methods and systems to adjust a humoral immune response
US20070265819A1 (en) * 2004-08-24 2007-11-15 Searete Llc, A Limited Liability Corporation Of The State Of Delaware Computational methods and systems for improving cell-mediated immune response
US20070265788A1 (en) * 2004-08-24 2007-11-15 Searete Llc, A Limited Liability Corporation Of The State Of Delaware Computational methods and systems for augmenting cell-mediated immune response
US20070288173A1 (en) * 2004-08-24 2007-12-13 Searete Llc, A Limited Liability Corporation Of The State Of Delware Computational methods and systems to reinforce a humoral immune response
US7300773B2 (en) * 2004-08-27 2007-11-27 Wyeth Research Ireland Limited Production of TNFR-Ig
EP1799868B1 (de) 2004-08-27 2012-01-18 Novartis Vaccines and Diagnostics, Inc. Nichtstrukturelle hcv-proteinmutanten und verwendungsmöglichkeiten dafür
US7294484B2 (en) 2004-08-27 2007-11-13 Wyeth Research Ireland Limited Production of polypeptides
US7335491B2 (en) * 2004-08-27 2008-02-26 Wyeth Research Ireland Limited Production of anti-abeta
WO2006028936A2 (en) * 2004-09-02 2006-03-16 Genentech, Inc. Heteromultimeric molecules
US7662926B2 (en) * 2004-09-02 2010-02-16 Genentech, Inc. Anti-Fc-gamma receptor antibodies, bispecific variants and uses therefor
US7655229B2 (en) * 2004-09-02 2010-02-02 Chan Andrew C Anti-FC-gamma RIIB receptor antibody and uses therefor
ES2377979T3 (es) * 2004-09-03 2012-04-03 Genentech, Inc. Antagonistas anti-beta7 humanizados y utilizaciones para los mismos
US7432359B2 (en) 2004-09-06 2008-10-07 Kirin Pharma Kabushiki Kaisha Anti-A33 antibody
CA2579391C (en) 2004-09-06 2010-10-26 Kirin Beer Kabushiki Kaisha Anti-a33 antibody
US7786086B2 (en) 2004-09-08 2010-08-31 Ramot At Tel-Aviv University Ltd. Peptide nanostructures containing end-capping modified peptides and methods of generating and using the same
US20060051347A1 (en) 2004-09-09 2006-03-09 Winter Charles M Process for concentration of antibodies and therapeutic products thereof
EP1797176A2 (de) * 2004-09-09 2007-06-20 University of Washington All-trans-retinol:all-trans-13,14-dihydroretinol-saturase und verfahren zu ihrer verwendung
US20060074225A1 (en) * 2004-09-14 2006-04-06 Xencor, Inc. Monomeric immunoglobulin Fc domains
WO2006030442A2 (en) * 2004-09-16 2006-03-23 Gamida-Cell Ltd. Methods of ex vivo progenitor and stem cell expansion by co-culture with mesenchymal cells
JP2008513540A (ja) 2004-09-21 2008-05-01 メディミューン，インコーポレーテッド 呼吸器合胞体ウイルスに対する抗体及び該ウイルス用のワクチンを製造する方法
EP2567974A3 (de) 2004-09-22 2013-05-22 Cancer Advances, Inc., Monoklonale Antikörper gegen Progastrin
US20100111856A1 (en) 2004-09-23 2010-05-06 Herman Gill Zirconium-radiolabeled, cysteine engineered antibody conjugates
TR201808537T4 (tr) 2004-09-23 2018-07-23 Genentech Inc Sistein değiştirilmiş antikorlar ve konjugatlar.
JP5270161B2 (ja) 2004-09-24 2013-08-21 ベス イスラエル デアコネス メディカル センター 妊娠合併症を診断および処置する方法
US20080131433A1 (en) * 2004-09-27 2008-06-05 The Uab Research Foundation Fc Receptor Homolog Antibodies And Uses Thereof
US7935790B2 (en) * 2004-10-04 2011-05-03 Cell Singaling Technology, Inc. Reagents for the detection of protein phosphorylation in T-cell receptor signaling pathways
GB0422052D0 (en) 2004-10-04 2004-11-03 Dansico As Enzymes
EA200700751A1 (ru) * 2004-10-05 2008-06-30 Элан Фарма Интернэшнл Лимитед Способы и композиции для улучшения продуцирования рекомбинантного белка
PL1810026T3 (pl) 2004-10-06 2018-08-31 Mayo Foundation For Medical Education And Research B7-H1 i PD-1 w leczeniu raka nerkowokomórkowego
DE602005025005D1 (de) 2004-10-07 2011-01-05 Argos Therapeutics Inc Zusammensetzungen reifer dendritischer zellen und verfahren zu deren kultivierung
WO2006044335A2 (en) * 2004-10-14 2006-04-27 The Board Of Trustees Of The University Of Arkansas Therapy with clostridium perfringens enterotoxin to treat ovarian and uterine cancer
JP4852773B2 (ja) 2004-10-15 2012-01-11 国立大学法人三重大学 肝再生・修復制御剤
GB0423139D0 (en) * 2004-10-18 2004-11-17 Danisco Enzymes
US20080274095A1 (en) * 2004-10-20 2008-11-06 Jane Homan Biocides
JO3000B1 (ar) 2004-10-20 2016-09-05 Genentech Inc مركبات أجسام مضادة .
PT1802334E (pt) 2004-10-21 2012-11-28 Genentech Inc Método para tratamento de doenças neovasculares intraoculares
WO2006047417A2 (en) 2004-10-21 2006-05-04 University Of Florida Research Foundation, Inc. Detection of cannabinoid receptor biomarkers and uses thereof
EP1805320B1 (de) * 2004-10-22 2014-09-03 Amgen Inc. Verfahren zur rückfaltung rekombinanter antikörper
US7910101B2 (en) 2004-10-25 2011-03-22 Centocor, Inc. Melanocortin receptor binding mimetibodies, compositions, methods and uses
JP5024830B2 (ja) 2004-10-25 2012-09-12 ステーテンズ セーラム インスティテュート クラミジア・トラコマチス（Ｃｈｌａｍｙｄｉａｔｒａｃｈｏｍａｔｉｓ）抗原のワクチンおよび診断への使用
WO2006047639A2 (en) 2004-10-27 2006-05-04 Medimmune, Inc. Modulation of antibody specificity by tailoring the affinity to cognate antigens
CA2585970A1 (en) 2004-10-27 2006-05-04 Vanderbilt University Mammalian genes involved in infection
TW200636064A (en) * 2004-10-28 2006-10-16 Centocor Inc Anti-respiratory syncytial virus antibodies, antigens and uses thereof
CN101072578A (zh) * 2004-10-29 2007-11-14 南加州大学 用共刺激分子的联合癌症免疫疗法
CA2585849A1 (en) * 2004-10-29 2006-05-11 Elusys Therapeutics, Inc. Use of cr1-binding molecules in clearance and induction of immune responses
EP1812472A1 (de) * 2004-11-04 2007-08-01 Genentech, Inc. An baff und/oder april bindende polypeptide
AU2005302083A1 (en) * 2004-11-04 2006-05-11 Fibron Limited Treatment of B-cell malignancies
AU2005304973A1 (en) 2004-11-05 2006-05-18 Palingen, Inc. Antibody induced cell membrane wounding
US7462697B2 (en) 2004-11-08 2008-12-09 Epitomics, Inc. Methods for antibody engineering
US7709208B2 (en) * 2004-11-08 2010-05-04 New York University Methods for diagnosis of major depressive disorder
CA2585719A1 (en) 2004-11-08 2006-05-18 Schering Corporation Tumor association of mdl-1 and methods
SI1817345T1 (sl) 2004-11-09 2009-10-31 Philogen Spa Protitelesa proti tenascinu-C
AU2005304771A1 (en) * 2004-11-09 2006-05-18 University Of Southern California Targeted innate immunity
GB0424940D0 (en) 2004-11-11 2004-12-15 Danisco Transcription factors
US8367805B2 (en) * 2004-11-12 2013-02-05 Xencor, Inc. Fc variants with altered binding to FcRn
US9200079B2 (en) 2004-11-12 2015-12-01 Xencor, Inc. Fc variants with altered binding to FcRn
US8546543B2 (en) 2004-11-12 2013-10-01 Xencor, Inc. Fc variants that extend antibody half-life
US20070135620A1 (en) * 2004-11-12 2007-06-14 Xencor, Inc. Fc variants with altered binding to FcRn
JP2008519863A (ja) 2004-11-12 2008-06-12 シアトル ジェネティクス インコーポレイティッド Ｎ末端にアミノ安息香酸単位を有するオーリスタチン
US8802820B2 (en) * 2004-11-12 2014-08-12 Xencor, Inc. Fc variants with altered binding to FcRn
CA2588087A1 (en) * 2004-11-15 2006-05-18 Obe Therapy Biotechnology S.A.S. Methods of reducing body fat
PL2343380T3 (pl) 2004-11-16 2020-03-31 Humanigen, Inc. Wymiana kasety dla regionu zmiennego immunoglobuliny
US8173591B2 (en) * 2004-11-16 2012-05-08 Yeda Research And Development Co. Variants of pigment epithelium derived factor and uses thereof
US20060115862A1 (en) * 2004-11-17 2006-06-01 Duke University Anti-tenascin monoclonal antibody immunoassays and diagnostic kits
US20060127311A1 (en) * 2004-11-17 2006-06-15 Duke University Radiation dosimetry and blocking antibodies and methods and uses therefor in the treatment of cancer
WO2006055638A2 (en) 2004-11-17 2006-05-26 Abgenix, Inc. Fully human monoclonal antibodies to il-13
CA2587597A1 (en) * 2004-11-19 2006-05-26 Biogen Idec Ma Inc. Treatment for multiple sclerosis
EP1812064A4 (de) 2004-11-19 2009-07-08 Cornell Res Foundation Inc Verwendung vaskulärer endothelwachstumsfaktor-rezeptor-1+-zellen bei der behandlung und überwachung von krebs und beim screening bei chemotherapie
WO2006086043A2 (en) * 2004-11-23 2006-08-17 Science & Technology Corporation @ Unm Molecular technologies for improved risk classification and therapy for acute lymphoblastic leukemia in children and adults
US7459529B2 (en) 2004-11-24 2008-12-02 Seoul National University Industry Foundation AIMP2-DX2 and its uses
GB0426146D0 (en) 2004-11-29 2004-12-29 Bioxell Spa Therapeutic peptides and method
AR051836A1 (es) 2004-11-30 2007-02-14 Centocor Inc Antagonistas de receptor 3 simil toll metodos y usos
WO2006058890A2 (en) * 2004-11-30 2006-06-08 Novo Nordisk A/S Method of producing antibodies
JP5185624B2 (ja) 2004-12-02 2013-04-17 ドマンティス リミテッド 血清アルブミンおよびｇｌｐ−１またはｐｙｙを標的とする二重特異性抗体
EP2281841A3 (de) 2004-12-03 2013-10-23 Merck Sharp & Dohme Corp. Biomarker zur Vorauswahl von Patienten für eine Anti-IGF1R Therapie
EP1819732A2 (de) 2004-12-06 2007-08-22 Kirin Beer Kabushiki Kaisha Humane monoklonale influenza-m2-protein-antikörper und verfahren zu deren herstellung und verwendung
JP5139811B2 (ja) 2004-12-08 2013-02-06 アベンティス・ファーマスーティカルズ・インコーポレイテツド ドセタキセル耐性または感受性の測定方法
EP1930046A1 (de) 2004-12-08 2008-06-11 Sirion Therapeutics, Inc. Retinol-Binding-Protein- und Transthyretin-Modulatoren zur Behandlung von Diabetes
WO2006063292A1 (en) * 2004-12-08 2006-06-15 Icos Corporation Recombinant method for making multimeric proteins
EP1838348B1 (de) * 2004-12-15 2013-06-26 Janssen Alzheimer Immunotherapy Humanisierte amyloid-beta-antikörper zur verbesserung der kognition
US20060257396A1 (en) * 2004-12-15 2006-11-16 Jacobsen Jack S Abeta antibodies for use in improving cognition
ES2396555T3 (es) * 2004-12-15 2013-02-22 Janssen Alzheimer Immunotherapy Anticuerpos que reconocen péptido beta amiloide
EP1828250A2 (de) * 2004-12-16 2007-09-05 Genentech, Inc. Methoden zur behandlung von autoimmunkrankheiten
US7504769B2 (en) * 2004-12-16 2009-03-17 E. I. Du Pont De Nemours + Company Aromatic chalcogen compounds and their use
NZ555286A (en) * 2004-12-17 2010-04-30 Genentech Inc Antiangiogenesis therapy of autoimmune disease in patients who have failed prior therapy
CA2591665C (en) * 2004-12-20 2015-05-05 Crucell Holland B.V. Binding molecules capable of neutralizing west nile virus and uses thereof
US7807789B2 (en) * 2004-12-21 2010-10-05 Cell Signaling Technology, Inc. Reagents for the detection of protein phosphorylation in EGFR-signaling pathways
MY146381A (en) 2004-12-22 2012-08-15 Amgen Inc Compositions and methods relating relating to anti-igf-1 receptor antibodies
EP1846444A2 (de) * 2004-12-22 2007-10-24 Lipopeptide AB Das cathelinähnliche protein cap18/ll-37 hemmende mittel
EP2290088A1 (de) 2004-12-22 2011-03-02 Genentech, Inc. Verfahren zur Herstellung von löslichen Multi-Membranproteinen
KR100950635B1 (ko) * 2004-12-23 2010-04-01 에프. 호프만-라 로슈 아게 실험동물의 치료용 항체의 검출
CA2491067A1 (en) 2004-12-24 2006-06-24 Stichting Katholieke Universiteit Mrna rations in urinary sediments and/or urine as a prognostic marker for prostate cancer
CA2531616A1 (en) * 2004-12-28 2006-06-28 Kabushiki Kaisha Kobe Seiko Sho (Kobe Steel, Ltd.) High strength thin steel sheet having high hydrogen embrittlement resisting property and high workability
RU2481356C2 (ru) 2004-12-28 2013-05-10 Иннейт Фарма Моноклональные антитела против nkg2a
US20060154285A1 (en) * 2004-12-29 2006-07-13 Robishaw Janet D Zebrafish heterotrimer G-protein gamma 2 subunit (GNG2)
US7850960B2 (en) 2004-12-30 2010-12-14 University Of Washington Methods for regulation of stem cells
WO2006074399A2 (en) * 2005-01-05 2006-07-13 Biogen Idec Ma Inc. Multispecific binding molecules comprising connecting peptides
PL1835937T3 (pl) 2005-01-06 2012-09-28 Novo Nordisk As Kompozycje i sposoby leczenia infekcji wirusowej
JP5295568B2 (ja) 2005-01-06 2013-09-18 ノヴォ ノルディスク アー／エス Ｋｉｒ結合剤およびその使用方法
US7833725B2 (en) * 2005-01-06 2010-11-16 President And Fellows Of Harvard College Mass spectrometric methods and products
AU2006203882B2 (en) 2005-01-07 2011-05-12 Regeneron Pharmaceuticals, Inc. IGF-1 fusion polypeptides and therapeutic uses thereof
DK1841793T3 (da) 2005-01-07 2010-07-19 Diadexus Inc Ovr110-antistofsammensætninger og fremgangsmåder til anvendelse deraf
CA2595169A1 (en) * 2005-01-12 2006-07-20 Xencor, Inc. Antibodies and fc fusion proteins with altered immunogenicity
EP1846767B1 (de) 2005-01-12 2012-06-06 MacroGenics West, Inc. Kid31 und daran bindende antikörper
US20080102054A1 (en) * 2005-01-18 2008-05-01 Faustman Denise L Compositions Containing Agm Cells And Methods Of Use Thereof
EP3698807A1 (de) 2005-01-21 2020-08-26 Genentech, Inc. Fixe dosierung von her-antikörpern
WO2006081171A1 (en) * 2005-01-24 2006-08-03 Amgen Inc. Humanized anti-amyloid antibody
WO2007094754A2 (en) 2005-01-27 2007-08-23 The Regents Of The University Of Califordnia Therapeutic monoclonal antibodies that neutralize botulinum neurotoxins
GT200600031A (es) 2005-01-28 2006-08-29 Formulacion anticuerpo anti a beta
EP1846032A4 (de) * 2005-01-31 2009-01-28 Raven Biotechnologies Inc Luca2 und daran bindende antikörper
JP5328155B2 (ja) 2005-02-02 2013-10-30 マクロジェニックス ウエスト， インコーポレイテッド Ａｄａｍ−９モジュレータ
US8029783B2 (en) * 2005-02-02 2011-10-04 Genentech, Inc. DR5 antibodies and articles of manufacture containing same
WO2006084078A2 (en) * 2005-02-02 2006-08-10 Raven Biotechnologies, Inc. Jam-3 and antibodies that bind thereto
US7402730B1 (en) 2005-02-03 2008-07-22 Lexicon Pharmaceuticals, Inc. Knockout animals manifesting hyperlipidemia
CA2597171A1 (en) * 2005-02-03 2006-08-10 Raven Biotechnologies, Inc. Antibodies to oncostatin m receptor
BRPI0607450A2 (pt) 2005-02-04 2009-09-01 Raven Biotechnologies Inc anticorpos que se ligam a epha2 e métodos para sua utilização
BRPI0607315B1 (pt) 2005-02-07 2022-05-17 Roche Glycart Ag Molécula de ligação ao antígeno anti-egfr humanizada e seus usos, composição farmacêutica, e método para detectar a presença de egfr em uma amostra
CN103497993A (zh) 2005-02-07 2014-01-08 基因信息公司 轻度骨关节炎生物标志物及其用途
CA2597098C (en) 2005-02-08 2016-08-02 Steven R. Ledbetter Antibodies to tgfbeta
CN101218254A (zh) * 2005-02-14 2008-07-09 惠氏公司 白介素-17f抗体及其它il-17f信号传递拮抗剂和它们的用途
WO2006088925A2 (en) * 2005-02-14 2006-08-24 Wyeth Use of il17-f in diagnosis and therapy of airway inflammation
US20060263357A1 (en) 2005-05-05 2006-11-23 Tedder Thomas F Anti-CD19 antibody therapy for autoimmune disease
PT1853718E (pt) 2005-02-15 2015-11-12 Univ Duke Anticorpos anti-cd19 e usos em oncologia
US20080019905A9 (en) * 2005-02-18 2008-01-24 Strome Scott E Method of using an anti-CD137 antibody as an agent for radioimmunotherapy or radioimmunodetection
US7731965B2 (en) * 2005-02-17 2010-06-08 Abbott Lab Human ring specific BNP antibodies
US8329178B2 (en) 2005-02-18 2012-12-11 Dana-Farber Cancer Institute, Inc. Antibodies against CXCR4 and methods of use thereof
ES2386366T3 (es) * 2005-02-18 2012-08-17 Medarex, Inc. Anticuerpo monoclonal humano contra el antígeno de membrana específico de la próstata (PSMA)
RS53128B (sr) 2005-02-23 2014-06-30 Genentech Inc. Produžavanje vremena progresije bolesti ili preživljavanja kod pacijenata obolelih od kancera jajnika korišćenjem pertuzumaba
US20060193849A1 (en) * 2005-02-25 2006-08-31 Antisoma Plc Biological materials and uses thereof
TW200714289A (en) * 2005-02-28 2007-04-16 Genentech Inc Treatment of bone disorders
US20160355591A1 (en) 2011-05-02 2016-12-08 Immunomedics, Inc. Subcutaneous anti-hla-dr monoclonal antibody for treatment of hematologic malignancies
US9707302B2 (en) 2013-07-23 2017-07-18 Immunomedics, Inc. Combining anti-HLA-DR or anti-Trop-2 antibodies with microtubule inhibitors, PARP inhibitors, bruton kinase inhibitors or phosphoinositide 3-kinase inhibitors significantly improves therapeutic outcome in cancer
US10058621B2 (en) 2015-06-25 2018-08-28 Immunomedics, Inc. Combination therapy with anti-HLA-DR antibodies and kinase inhibitors in hematopoietic cancers
EP1858545A2 (de) * 2005-03-04 2007-11-28 Curedm Inc. Verfahren und pharmazeutische zusammensetzungen zur behandlung von diabetes mellitus typ 1 und anderer erkrankungen
EP1865986B1 (de) 2005-03-08 2016-02-17 Pfizer Products Inc. Anti-ctla-4-antikörperzusammensetzungen
US20060204505A1 (en) * 2005-03-08 2006-09-14 Sliwkowski Mark X Methods for identifying tumors responsive to treatment with HER dimerization inhibitors (HDIs)
MX2007010922A (es) 2005-03-10 2007-10-12 Genentech Inc Metodos y composiciones para modular la integridad vascular.
CN101147066A (zh) 2005-03-11 2008-03-19 塞诺菲-安万特股份有限公司 Mgc4504的用途
EP2113572B1 (de) 2005-03-11 2012-12-05 Celera Corporation Mit koronarer Herzkrankheit assoziierte genetische Polymorphismen, Nachweisverfahren und deren Verwendungen
CA2601574C (en) 2005-03-15 2014-12-02 University Of North Carolina At Chapel Hill Methods and compositions for producing active vitamin k-dependent proteins
EP2551282A3 (de) 2005-03-23 2013-02-13 Genmab A/S Antikörper gegen CD38 zur Behandling von multiplem Myelom
EP1868647A4 (de) 2005-03-24 2009-04-01 Millennium Pharm Inc Ov064-bindende antikörper und verfahren zu ihrer verwendung
JP5238936B2 (ja) 2005-03-25 2013-07-17 ジーアイティーアール，インク． Ｇｉｔｒ結合分子およびその使用
BRPI0608468A2 (pt) * 2005-03-25 2010-01-05 Glycart Biotechnology Ag moléculas de ligação a antìgeno direcionadas a mcsp e tendo afinidade de ligação a receptor de fc e função efetora aumentadas
DK1875244T3 (en) 2005-03-30 2019-04-29 Minerva Biotechnologies Corp Proliferation of MUC1-Expressing Cells
US8859495B2 (en) * 2005-03-30 2014-10-14 Minerva Biotechnologies Corporation Methods for stimulating or enhancing proliferation of non-tumorous cells expressing MUC1 receptors
KR101374454B1 (ko) 2005-03-31 2014-03-17 추가이 세이야쿠 가부시키가이샤 회합제어에 의한 폴리펩티드 제조방법
EP3300739A3 (de) 2005-03-31 2018-07-18 Agensys, Inc. An 161p2f10b-proteine bindende antikörper und zugehörige moleküle
EP1863908B1 (de) * 2005-04-01 2010-11-17 Qiagen GmbH Reverse transkription und amplifikation von rna bei simultaner degradierung von dna
EP3527582B1 (de) 2005-04-04 2022-08-17 IDEXX Laboratories, Inc. Ehrlichia canis diva (unterscheidung infizierter von geimpften tieren)
US8475794B2 (en) 2005-04-06 2013-07-02 Ibc Pharmaceuticals, Inc. Combination therapy with anti-CD74 antibodies provides enhanced toxicity to malignancies, Autoimmune disease and other diseases
US8349332B2 (en) 2005-04-06 2013-01-08 Ibc Pharmaceuticals, Inc. Multiple signaling pathways induced by hexavalent, monospecific and bispecific antibodies for enhanced toxicity to B-cell lymphomas and other diseases
AU2006235276A1 (en) 2005-04-07 2006-10-19 Novartis Vaccines And Diagnostics Inc. CACNA1E in cancer diagnosis, detection and treatment
CA2604844A1 (en) 2005-04-07 2006-10-19 Novartis Vaccines And Diagnostics, Inc. Cancer-related genes
US7714016B2 (en) * 2005-04-08 2010-05-11 Medarex, Inc. Cytotoxic compounds and conjugates with cleavable substrates
WO2006109045A2 (en) 2005-04-09 2006-10-19 Fusion Antibodies Limited Cathepsin s antibody
US8278069B2 (en) 2005-04-11 2012-10-02 National Research Council Of Canada Identification of a β-1,3-N-acetylgalactosaminyltransferase (CGTE) from Campylobacter jejuni LIO87
KR20080009111A (ko) 2005-04-11 2008-01-24 새비언트 파마수티컬즈 인크. 유레이트 옥시다아제의 변이형 및 이의 용도
US20090099340A1 (en) * 2007-10-12 2009-04-16 Cell Signaling Technology, Inc. Reagents for the detection of protein phosphorylation in carcinoma signaling pathways
GT200600148A (es) 2005-04-14 2006-11-22 Metodos para el tratamiento y la prevencion de fibrosis
RU2403261C2 (ru) 2005-04-15 2010-11-10 Дженентек, Инк. Варианты бета-цепи hgf
EA200702239A1 (ru) * 2005-04-15 2008-10-30 Иммьюноджен, Инк. Уничтожение гетерогенной или смешанной клеточной популяции в опухолях
JP5838021B2 (ja) 2005-04-15 2015-12-24 マクロジェニクス，インコーポレーテッド 共有結合型ダイアボディとその使用
US8067546B2 (en) 2005-04-19 2011-11-29 Seattle Genetics, Inc. Humanized anti-CD70 binding agents and uses thereof
EP1871796A4 (de) * 2005-04-20 2009-01-14 Auckland Uniservices Ltd Vesiculine
AR054260A1 (es) * 2005-04-26 2007-06-13 Rinat Neuroscience Corp Metodos de tratamiento de enfermedades de la neurona motora inferior y composiciones utilizadas en los mismos
US7595380B2 (en) 2005-04-27 2009-09-29 Tripath Imaging, Inc. Monoclonal antibodies and methods for their use in the detection of cervical disease
PA8672101A1 (es) 2005-04-29 2006-12-07 Centocor Inc Anticuerpos anti-il-6, composiciones, métodos y usos
PE20061323A1 (es) * 2005-04-29 2007-02-09 Rinat Neuroscience Corp Anticuerpos dirigidos contra el peptido amiloide beta y metodos que utilizan los mismos
US20080248039A1 (en) 2005-04-29 2008-10-09 The Regents Of The University Of California Antibodies Against Histone Modifications for Clinical Diagnosis and Prognosis of Cancer
US20060257317A1 (en) * 2005-05-04 2006-11-16 Duke University Combination therapy in the treatment of cancer
US8034902B2 (en) * 2005-05-04 2011-10-11 Quark Pharmaceuticals, Inc. Recombinant antibodies against CD55 and CD59 and uses thereof
CN101198624B (zh) 2005-05-06 2012-10-10 津莫吉尼蒂克斯公司 Il-31单克隆抗体及使用方法
EP3530736A3 (de) 2005-05-09 2019-11-06 ONO Pharmaceutical Co., Ltd. Humane monoklonale antikörper für den programmierten tod 1 (pd-1) und verfahren zur behandlung von krebs mit pd-1-antikörpern allein oder in kombination mit anderen immunotherapeutika
EP1888649A2 (de) * 2005-05-09 2008-02-20 GlycArt Biotechnology AG Antigen-bindungsmoleküle mit modifizierten fc-regionen und veränderte bindung an fc-rezeptoren
CN101237857A (zh) 2005-05-09 2008-08-06 生物领域医疗公司 使用微球和非离子型造影剂的组合物和方法
EP2377884A1 (de) 2005-05-10 2011-10-19 Neoloch Aps Neuritogene peptide
CA2607930C (en) 2005-05-11 2012-08-21 Dinona Inc. Acute leukemia and lymphoblastic lymphoma-specific cd43 epitope and use thereof
US7622560B2 (en) * 2005-05-11 2009-11-24 Dinona Inc. Monoclonal antibody specific for CD43 epitope
EP1882044A1 (de) * 2005-05-11 2008-01-30 sanofi-aventis Verwendung von gip gene promoter polymorphismus.
AR053272A1 (es) * 2005-05-11 2007-04-25 Hoffmann La Roche Determinacion de responsivos a la quimioterapia
CA2608058C (en) 2005-05-12 2013-09-10 Crucell Holland B.V. Host cell specific binding molecules capable of neutralizing viruses and uses thereof
AR053385A1 (es) 2005-05-12 2007-05-02 Novartis Ag Genes y proteinas novedosos de brachyspira hyodysenteriae y uso de los mismos para diagnostico y terapia
EP2312315A1 (de) 2005-05-18 2011-04-20 Novartis AG Verfahren zur Diagnose und Behandlung von Krankheiten mit einer autoimmunen und/oder entzündlichen Komponente
WO2006127020A1 (en) 2005-05-19 2006-11-30 The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services, Centers For Disease Control And Prevention FUNCTIONAL EPITOPES OF STREPTOCOCCUS PNEUMONIAE PsaA ANTIGEN AND USES THEREOF
JP2008545712A (ja) 2005-05-25 2008-12-18 キュアーディーエム、インク． ペプチド、その誘導体並びに類似体、及びそれらを使用する方法
US8355776B2 (en) 2005-05-27 2013-01-15 Board Of Regents, The University Of Texas System Hemoglobin contrast in magneto-motive optical doppler tomography, optical coherence tomography, and ultrasound imaging methods and apparatus
US8454511B2 (en) * 2005-05-27 2013-06-04 Board Of Regents, The University Of Texas System Magneto-motive ultrasound detection of magnetic nanoparticles
AU2006252509A1 (en) 2005-05-31 2006-12-07 Duska Scientific Co. Inhibition of neuronal damage
WO2006132788A2 (en) 2005-06-06 2006-12-14 Genentech, Inc. Transgenic models for different genes and their use for gene characterization
TW200643171A (en) 2005-06-07 2006-12-16 Temasek Life Sciences Lab Ltd Porcine circovirus type 2 vaccines
US20090028854A1 (en) 2005-06-10 2009-01-29 Chugai Seiyaku Kabushiki Kaisha sc(Fv)2 SITE-DIRECTED MUTANT
CN101238145B (zh) 2005-06-14 2013-04-24 普罗陶克斯有限公司 修饰的成孔蛋白在制备治疗或预防良性前列腺增生的药物中的应用
WO2006138429A2 (en) 2005-06-16 2006-12-28 The Feinstein Institute For Medical Research Antibodies against hmgb1 and fragments thereof
BRPI0611600B8 (pt) 2005-06-17 2021-05-25 Wyeth Corp método para purificação de uma proteína tendo uma região fc a partir de um líquido fonte compreendendo a proteína e uma ou mais impurezas, e kit
ES2547463T3 (es) 2005-06-17 2015-10-06 Merck Sharp & Dohme Corp. Moléculas de unión a ILT3 y usos de las mismas
CA2606084A1 (en) * 2005-06-17 2006-12-28 Abbott Laboratories Improved method of treating degenerative spinal disorders
US20070225242A1 (en) * 2005-06-21 2007-09-27 The Board Of Trustees Of The Leland Stanford Junior University Method and composition for treating and preventing tumor metastasis in vivo
ES2335232T3 (es) 2005-06-21 2010-03-23 Xoma Technology Ltd. Anticuerpos y fragmentos de los mismos que se unen a la il-1 beta.
WO2007094842A2 (en) * 2005-12-02 2007-08-23 Genentech, Inc. Binding polypeptides and uses thereof
KR20080025174A (ko) 2005-06-23 2008-03-19 메디뮨 인코포레이티드 응집 및 단편화 프로파일이 최적화된 항체 제제
WO2006136601A1 (en) * 2005-06-23 2006-12-28 Crucell Holland B.V. Optimization of west nile virus antibodies
CN103145837A (zh) * 2005-06-30 2013-06-12 Abbvie公司 Il-12/p40结合蛋白
CA2613818C (en) 2005-06-30 2013-08-27 Centocor, Inc. Anti-il-23 antibodies, compositions, methods and uses
KR101704734B1 (ko) 2005-07-01 2017-02-09 이. 알. 스퀴부 앤드 선즈, 엘.엘.씨. 예정 사멸 리간드 1 (피디-엘1)에 대한 인간 모노클로날 항체
US20070009976A1 (en) 2005-07-06 2007-01-11 Helmut Lenz Detection of a target antigen irrespective of the presence or absence of a corresponding therapeutic antibody
ES2708763T3 (es) 2005-07-07 2019-04-11 Seattle Genetics Inc Compuestos de monometilvalina que tienen modificaciones de la cadena lateral de fenilalanina en el extremo C
WO2007008848A2 (en) * 2005-07-07 2007-01-18 Seattle Genetics, Inc. Monomethylvaline compounds having phenylalanine carboxy modifications at the c-terminus
EP1904652A2 (de) * 2005-07-08 2008-04-02 Brystol-Myers Squibb Company Mit dosisabhängigem ödem assoziierte einzelnukleotid-polymorphismen und verfahren zur verwendung davon
SI1904104T1 (sl) 2005-07-08 2013-12-31 Biogen Idec Ma Inc. Protitelesa SP35 in njihova uporaba
WO2007008943A2 (en) 2005-07-08 2007-01-18 Xencor, Inc. Optimized anti-ep-cam antibodies
US7780969B2 (en) * 2005-07-15 2010-08-24 University Of Georgia Research Foundation, Inc. Trypanosoma cruzi proteome compositions and methods
HUE035853T2 (en) 2005-07-18 2018-05-28 Seattle Genetics Inc Beta-glucuronide-linker-drug conjugates
US7632509B2 (en) * 2005-07-19 2009-12-15 Biosante Pharmaceuticals, Inc. Methods to express recombinant proteins from lentiviral vectors
SG164379A1 (en) 2005-07-21 2010-09-29 Genmab As Potency assays for antibody drug substance binding to an fc receptor
CN101595228A (zh) 2005-07-21 2009-12-02 艾博特公司 包括sorf构建体的多基因表达和使用多蛋白、前体蛋白和蛋白酶解的方法
RU2486204C2 (ru) 2005-07-22 2013-06-27 Уай'З Терапьютикс Ко., Лтд. Антитела против сd26 и способы их применения
US8211648B2 (en) 2005-07-22 2012-07-03 Kalobios Pharmaceuticals, Inc. Secretion of antibodies without signal peptides from bacteria
EP1910573B1 (de) * 2005-07-22 2013-09-04 CytoDyn, Inc. Verfahren zur reduzierung der viruslast in mit hiv-1 infizierten patienten
AU2006272555B2 (en) * 2005-07-25 2012-03-08 Aptevo Research And Development Llc B-cell reduction using CD37-specific and CD20-specific binding molecules
US8652469B2 (en) * 2005-07-28 2014-02-18 Novartis Ag M-CSF-specific monoclonal antibody and uses thereof
EP2277916A3 (de) * 2005-07-28 2011-04-27 Novartis AG Verwendung von Antikörper zu M-CSF
WO2007016597A2 (en) * 2005-07-29 2007-02-08 The Regents Of The University Of California Targeting tnf-alpha converting enzyme (tace)-dependent growth factor shedding in cancer therapy
US7452979B2 (en) 2005-08-02 2008-11-18 Arius Research, Inc. Cancerous disease modifying antibodies
US7456258B2 (en) 2005-08-02 2008-11-25 Arius Research, Inc. Cancerous disease modifying antibodies
US7494648B2 (en) * 2005-08-02 2009-02-24 Hoffmann-La Roche Inc. Cancerous disease modifying antibodies
US7411046B2 (en) 2005-08-02 2008-08-12 Arius Research Inc Cancerous disease modifying antibodies
US7456259B2 (en) 2005-08-02 2008-11-25 Arius Research, Inc. Cancerous disease modifying antibodies
US7452978B2 (en) * 2005-08-02 2008-11-18 Arius Research, Inc. Cancerous disease modifying antibodies
EP1919504B1 (de) * 2005-08-03 2013-10-16 iBio, Inc. Antikörper gegen bacillus anthracis protektiv antigen
ES2432026T3 (es) 2005-08-05 2013-11-29 Genentech, Inc. Métodos y composiciones para detectar trastornos autoinmunes
CA2615460A1 (en) * 2005-08-08 2007-02-15 Onconon, Llc Antibody compositions, methods for treating neoplastic disease and methods for regulating fertility
DK2573114T3 (en) 2005-08-10 2016-07-04 Macrogenics Inc The identification and production of antibodies with variant Fc regions, and methods of using same
EP1913391B1 (de) 2005-08-11 2010-12-29 Siemens Healthcare Diagnostics Inc. QUANTITATIVE ASSAYS FÜR PDGFR-beta- IN KÖRPERFLÜSSIGKEITEN
US7700299B2 (en) 2005-08-12 2010-04-20 Hoffmann-La Roche Inc. Method for predicting the response to a treatment
WO2007019620A1 (en) * 2005-08-15 2007-02-22 Arana Therapeutics Limited Engineered antibodies with new world primate framework regions
EP1995321A2 (de) 2005-08-15 2008-11-26 Genentech, Inc. Neuartige Genunterbrechungen, dazugehörige Zusammensetzungen und Verfahren in Zusammenhang damit
BRPI0615997A8 (pt) 2005-08-16 2018-05-22 Genentech Inc método para prever a sensibilidade de uma amostra de célula ou tecido, método para induzir apoptose em uma amostra de célula ou tecido e método de tratamento de uma disfunção
KR20140053410A (ko) 2005-08-19 2014-05-07 아보트 러보러터리즈 이원 가변 도메인 면역글로불린 및 이의 용도
US20070202512A1 (en) * 2005-08-19 2007-08-30 Bristol-Myers Squibb Company Human single nucleotide polymorphisms associated with dose-dependent weight gain and methods of use thereof
EP2500353A3 (de) 2005-08-19 2012-10-10 Abbott Laboratories Immunglobuline mit zweifacher variabler Domäne und ihre Verwendung
US7612181B2 (en) * 2005-08-19 2009-11-03 Abbott Laboratories Dual variable domain immunoglobulin and uses thereof
US20090215992A1 (en) * 2005-08-19 2009-08-27 Chengbin Wu Dual variable domain immunoglobulin and uses thereof
AU2006290433B2 (en) 2005-08-26 2012-06-07 Roche Glycart Ag Modified antigen binding molecules with altered cell signaling activity
US20100151495A9 (en) * 2005-08-31 2010-06-17 Cell Signaling Technolgy, Inc. Reagents for the detection of protein phosphorylation in carcinoma signaling pathways
WO2007027906A2 (en) * 2005-08-31 2007-03-08 Cell Signaling Technology, Inc. Reagents for the detection of protein phosphorylation in leukemia signaling pathways
WO2007027867A2 (en) 2005-08-31 2007-03-08 Cell Signaling Technology, Inc. Reagents for the detection of protein phosphorylation in carcinoma signaling pathways
ME02705B (de) 2005-08-31 2017-10-20 Merck Sharp & Dohme Konstruierte anti-il-23-antikörper
AU2006287224A1 (en) 2005-08-31 2007-03-08 Centocor, Inc. Host cell lines for production of antibody constant region with enhanced effector function
EP1928807A4 (de) * 2005-09-02 2011-05-04 Picobella Llc Onkogene regulatorische rnas für diagnostika und therapeutika
EP1762627A1 (de) 2005-09-09 2007-03-14 Qiagen GmbH Verfahren zur Aktivierung einer Nukleinsäure für eine Polymerase-Reaktion
AU2005336263A1 (en) * 2005-09-09 2007-03-15 Glycofi, Inc. Immunoglobulin comprising predominantly a man7GlcNAc2, Man8GlcNAc2 glycoform
EP3031470A3 (de) 2005-09-09 2016-08-10 The Johns Hopkins University Manipulation der regulatorischen t-zell- und dc-funktion durch targeting des neuritin-gens mit antikörpern, agonisten und antagonisten
EP1937307A4 (de) 2005-09-14 2009-05-13 Hutchinson Fred Cancer Res Spezifische entfernung von aktivierten immunzellen
US8299212B2 (en) 2005-09-20 2012-10-30 Thrasos Therapeutics, Inc. TDF-related compounds and analogs thereof, analogs and bioactive fragments
US7799530B2 (en) 2005-09-23 2010-09-21 Celera Corporation Genetic polymorphisms associated with cardiovascular disorders and drug response, methods of detection and uses thereof
EA016577B1 (ru) * 2005-09-26 2012-06-29 Медарекс, Инк. Конъюгаты антитело-лекарство и их применение
EP1934261B1 (de) 2005-09-26 2014-10-29 Medarex, L.L.C. Humane monoklonale antikörper gegen cd70
US20070104689A1 (en) * 2005-09-27 2007-05-10 Merck Patent Gmbh Compositions and methods for treating tumors presenting survivin antigens
DE602006021768D1 (de) 2005-09-28 2011-06-16 Dickinson & Co Nachweis von lysophosphatidylcholin für die prognose oder diagnose eines systemischen entzündungszustands
ES2374942T3 (es) 2005-09-29 2012-02-23 F. Hoffmann-La Roche Ag Reactivo de liberación para compuestos de vitamina d.
EP2264058A3 (de) 2005-09-30 2011-03-23 Seattle Biomedical Research Plasmodium-Leber-Stadium-Antigene
CN101277974A (zh) * 2005-09-30 2008-10-01 阿伯特有限及两合公司 排斥性引导分子(rgm)蛋白质家族的蛋白质的结合结构域及其功能性片段和它们的用途
DK1931709T3 (en) * 2005-10-03 2017-03-13 Xencor Inc FC VARIETIES WITH OPTIMIZED FC RECEPTOR BINDING PROPERTIES
IL172297A (en) 2005-10-03 2016-03-31 Compugen Ltd Soluble vegfr-1 variants for diagnosis of preeclamsia
US7422899B2 (en) * 2005-10-05 2008-09-09 Biogen Idec Ma Inc. Antibodies to the human prolactin receptor
JP4860703B2 (ja) 2005-10-06 2012-01-25 ゼンコー・インコーポレイテッド 最適化された抗ｃｄ３０抗体
AU2006302245A1 (en) * 2005-10-06 2007-04-19 Emthrax, Llc Methods and compositions relating to anthrax spore glycoproteins as vaccines
US8168584B2 (en) 2005-10-08 2012-05-01 Potentia Pharmaceuticals, Inc. Methods of treating age-related macular degeneration by compstatin and analogs thereof
US10004828B2 (en) 2005-10-11 2018-06-26 Romat at Tel-Aviv University Ltd. Self-assembled Fmoc-ff hydrogels
DE102005048898A1 (de) 2005-10-12 2007-04-19 Sanofi-Aventis Deutschland Gmbh EGLN2-Varianten und ihre Verwendung bei der Vorbeugung oder Behandlung thromboembolischer Erkrankungen und koronarer Herzerkrankungen
UA92504C2 (en) 2005-10-12 2010-11-10 Эли Лилли Энд Компани Anti-myostatin monoclonal antibody
EP1948802A4 (de) * 2005-10-13 2009-01-14 Virexx Medical Corp Chimäres antigen mit hepatitis-c-virus-polypeptid und fc-fragment zum hervorrufen einer immunantwort
US8461126B2 (en) 2005-10-14 2013-06-11 Phigenix, Inc. Targeting EN2, PAX2, and/or DEFB1 for treatment of prostate conditions
US8470316B2 (en) 2005-10-14 2013-06-25 Chugai Seiyaku Kabushiki Kaisha Agents for suppressing damage to transplanted islets after islet transplantation
EP1934260B1 (de) 2005-10-14 2017-05-17 Innate Pharma Zusammensetzungen und methoden zur behandlung proliferierender krankheiten
US20100029504A1 (en) 2007-01-16 2010-02-04 Phigenix, Inc. Detecting pax2 for the diagnosis of breast cancer
US7794951B2 (en) * 2005-10-18 2010-09-14 University Of Massachusetts Medical School SREBP2gc transcription factors and uses thereof
KR101323563B1 (ko) 2005-10-18 2013-10-29 니토 보세키 가부시기가이샤 항체를 생산하는 트랜스제닉 누에와 그의 제조방법
EP2532677A1 (de) 2005-10-21 2012-12-12 Novartis AG Menschliche Antikörper gegen IL13 und therapeutische Verwendungen
US20080274469A1 (en) 2005-10-21 2008-11-06 The Regents Of The University Of California C-Kit Oncogene Mutations in Melanoma
ES2642787T3 (es) * 2005-10-21 2017-11-20 Lfb Usa, Inc. Anticuerpos con actividad de citotoxicidad celular dependiente de anticuerpos mejorada, métodos para su producción y uso
US8249814B2 (en) 2005-10-21 2012-08-21 Genenews Inc. Method, computer readable medium, and system for determining a probability of colorectal cancer in a test subject
RU2450830C2 (ru) 2005-10-21 2012-05-20 Чугаи Сейяку Кабусики Кайся Средства для лечения кардиопатии
AR058140A1 (es) * 2005-10-24 2008-01-23 Wyeth Corp Metodo de produccion proteica utilizando compuestos anti-senescencia
EP2862867A3 (de) 2005-10-25 2015-08-05 The Johns Hopkins University Verfahren und Zusammensetzungen zur Behandlung des Marfan-Syndroms und assoziierter Erkrankungen
BRPI0619331A2 (pt) 2005-10-26 2011-09-27 Medarex Inc método para fazer um composto para preparar um análogo de cbi cc-1065, método para preparar um análogo de cbi cc-1065 e composto
ES2435775T3 (es) 2005-10-27 2013-12-23 Janssen Biotech, Inc. Moduladores de receptor tipo Toll 3, procedimientos y usos
US20090074720A1 (en) * 2005-10-28 2009-03-19 Sabbadini Roger A Methods for decreasing immune response and treating immune conditions
JPWO2007049770A1 (ja) 2005-10-28 2009-04-30 明治製菓株式会社 緑膿菌の外膜タンパク質ｐａ５１５８
US20080213274A1 (en) * 2005-10-28 2008-09-04 Sabbadini Roger A Compositions and methods for the treatment and prevention of fibrotic, inflammatory, and neovascularization conditions of the eye
EP2500360B1 (de) 2005-10-31 2015-08-05 Oncomed Pharmaceuticals, Inc. Zusammensetzungen und Verfahren zur Diagnose und Behandlung von Krebs
TW201337266A (zh) 2005-11-01 2013-09-16 Abbott Biotech Ltd 利用生物標記診斷關節黏連脊椎炎之方法及組合物
FR2892724B1 (fr) 2005-11-02 2008-01-04 Lab Francais Du Fractionnement Anticorps cytotoxiques diriges contre des anticorps inhibiteurs du facteur viii.
US20070099246A1 (en) * 2005-11-03 2007-05-03 Sandy John D Antibodies, assays and kits to quantitate cartilage destruction
US7879212B2 (en) * 2005-11-03 2011-02-01 Ramot At Tel-Aviv University Ltd. Peptide nanostructure-coated electrodes
EP1959979A4 (de) 2005-11-04 2010-01-27 Biogen Idec Inc Verfahren zur förderung des axonen-wachstums und des überlebens dopaminergischer neuronen
DK2500030T4 (en) 2005-11-04 2018-10-29 Genentech Inc Use of complement pathway inhibitors for the treatment of eye diseases
EP1957531B1 (de) 2005-11-07 2016-04-13 Genentech, Inc. Bindungspolypeptide mit diversifizierten und konsensus-vh/vl-hypervariablen sequenzen
US20100028358A1 (en) 2005-11-07 2010-02-04 Wolfram Ruf Compositions and Methods for Controlling Tissue Factor Signaling Specificity
AU2006312148B2 (en) 2005-11-07 2012-04-12 The Rockefeller University Reagents, methods and systems for selecting a cytotoxic antibody or variant thereof
UA96139C2 (uk) 2005-11-08 2011-10-10 Дженентек, Інк. Антитіло до нейропіліну-1 (nrp1)
US20070161089A1 (en) * 2005-11-08 2007-07-12 Genentech, Inc. Method of Producing Pan-Specific Antibodies
US7939069B2 (en) 2005-11-09 2011-05-10 Abbott Laboratories Human BNP immunospecific antibodies
US20070207152A1 (en) * 2005-11-09 2007-09-06 Brophy Susan E Human BNP immunospecific antibodies
WO2007059404A2 (en) 2005-11-10 2007-05-24 Medarex, Inc. Duocarmycin derivatives as novel cytotoxic compounds and conjugates
AU2006311458C1 (en) 2005-11-10 2013-05-09 Board Of Supervisors Of Louisiana State University & Agricultural & Mechanical College Compositions and methods for the treatment of addiction and other neuropsychiatric disorders
WO2007055378A1 (ja) 2005-11-14 2007-05-18 Cell Signals Inc. 調節性ｔ細胞の機能異常に基づく疾患の治療方法及び予防方法
SI3045182T1 (en) 2005-11-14 2018-08-31 Teva Pharmaceuticals International Gmbh An antibody to a peptide-associated peptide antagonist to calcitonin for treating a headache in aggregates
EP1951284A4 (de) 2005-11-14 2010-05-05 Yeda Res & Dev Verbesserte varianten des pedf (pigment epithelium derived factor) und ihre verwendungen
ATE547709T1 (de) * 2005-11-14 2012-03-15 Metamol Theranostics Llc Tumorinvasionsfördernde peptidsequenz
WO2007055369A1 (ja) * 2005-11-14 2007-05-18 Riken 活性化形質細胞様樹状細胞に特異的に発現する膜分子
MY149159A (en) 2005-11-15 2013-07-31 Hoffmann La Roche Method for treating joint damage
AR057582A1 (es) 2005-11-15 2007-12-05 Nat Hospital Organization Agentes para suprimir la induccion de linfocitos t citotoxicos
EP1948691A1 (de) * 2005-11-17 2008-07-30 Millennium Pharmaceuticals, Inc. MIT a4ß7-INTEGRIN REAGIERENDES HUMANISIERTES IMMUNOGLOBULIN
PL1948798T3 (pl) 2005-11-18 2015-12-31 Glenmark Pharmaceuticals Sa Przeciwciała przeciwko integrynie alfa2 i ich zastosowania
WO2007062037A2 (en) 2005-11-21 2007-05-31 Laboratoires Serono Sa Compositions and methods of producing hybrid antigen binding molecules and uses thereof
WO2007081608A2 (en) 2005-11-21 2007-07-19 Genentech, Inc. Novel gene disruptions, compositions and methods relating thereto
WO2007081447A2 (en) 2005-11-22 2007-07-19 Novartis Vaccines And Diagnostics, Inc. Norovirus and sapovirus antigens
CA2629306A1 (en) * 2005-11-23 2007-05-31 Genentech, Inc. Methods and compositions related to b cell assays
TWI461436B (zh) 2005-11-25 2014-11-21 Kyowa Hakko Kirin Co Ltd 人類ｃｄ１３４（ｏｘ４０）之人類單株抗體及其製造及使用方法
WO2007061029A1 (ja) 2005-11-25 2007-05-31 Keio University 前立腺癌治療剤
WO2007064759A2 (en) * 2005-11-29 2007-06-07 The Scripps Research Institute Inhibiting tumour cell invasion, metastasis and angiogenesis through targetting legumain
US8846393B2 (en) 2005-11-29 2014-09-30 Gamida-Cell Ltd. Methods of improving stem cell homing and engraftment
PL1976877T5 (pl) 2005-11-30 2017-09-29 Abbvie Inc Przeciwciała monoklonalne przeciwko białku amyloidu beta oraz ich zastosowania
RU2442793C2 (ru) 2005-11-30 2012-02-20 Эбботт Лэборетриз АНТИТЕЛА ПРОТИВ ГЛОБУЛОМЕРА Аβ, ИХ АНТИГЕНСВЯЗЫВАЮЩИЕ ЧАСТИ, СООТВЕТСТВУЮЩИЕ ГИБРИДОМЫ, НУКЛЕИНОВЫЕ КИСЛОТЫ, ВЕКТОРЫ, КЛЕТКИ-ХОЗЯЕВА, СПОСОБЫ ПОЛУЧЕНИЯ УКАЗАННЫХ АНТИТЕЛ, КОМПОЗИЦИИ, СОДЕРЖАЩИЕ УКАЗАННЫЕ АНТИТЕЛА, ПРИМЕНЕНИЯ УКАЗАННЫХ АНТИТЕЛ И СПОСОБЫ ИСПОЛЬЗОВАНИЯ УКАЗАННЫХ АНТИТЕЛ
US20090175872A1 (en) 2005-12-02 2009-07-09 Biogen Idec Ma Inc. Treatment of Conditions Involving Demyelination
EP1979379B1 (de) 2005-12-02 2013-09-18 Dana-Farber Cancer Institute Carboanhydrase ix (g250)-antikörper und verfahren zur verwendung davon
JP2009518314A (ja) 2005-12-02 2009-05-07 ジェネンテック・インコーポレーテッド Ｉｌ−２２に結合する抗体およびｉｌ−２２ｒに結合する抗体を含む、サイトカインシグナリングに関連する疾患および障害の処置のための組成物および方法
WO2007064919A2 (en) * 2005-12-02 2007-06-07 Genentech, Inc. Binding polypeptides with restricted diversity sequences
EA017491B1 (ru) 2005-12-08 2012-12-28 Медарекс, Инк. Человеческие моноклональные антитела к фукозил-gm1 и способы применения антифукозил-gm1 антител
US20070134249A1 (en) * 2005-12-08 2007-06-14 Genitope Corporation Combination therapy and antibody panels
US8105788B2 (en) * 2005-12-08 2012-01-31 The University Of British Columbia Mucopolysaccharidosis (MPS) diagnostic methods, systems, kits and assays associated therewith
US8758773B2 (en) 2005-12-09 2014-06-24 Wisconsin Alumni Research Foundation Vaccine candidates against Johne's disease
DOP2006000277A (es) 2005-12-12 2007-08-31 Bayer Pharmaceuticals Corp Anticuerpos anti mn y métodos para su utilización
GB0525214D0 (en) 2005-12-12 2006-01-18 Bioinvent Int Ab Biological materials and uses thereof
PL1963368T6 (pl) 2005-12-13 2021-02-08 Eli Lilly And Company Przeciwciała anty-IL-17
PL1969003T3 (pl) 2005-12-14 2011-05-31 Herantis Pharma Plc Zastosowanie białka czynnika neurotroficznego
US20070264687A1 (en) 2005-12-15 2007-11-15 Min-Yuan Chou Recombinant triplex scaffold-based polypeptides
EP1973948B1 (de) 2005-12-15 2015-02-11 Genentech, Inc. Verfahren und zusammensetzungen zum targeting von polyubiquitin
US10183986B2 (en) 2005-12-15 2019-01-22 Industrial Technology Research Institute Trimeric collagen scaffold antibodies
US7632498B2 (en) 2005-12-19 2009-12-15 Tripath Imaging, Inc. MCM6 and MCM7 monoclonal antibodies and methods for their use in the detection of cervical disease
US7625759B2 (en) 2005-12-19 2009-12-01 Genentech, Inc. Method for using BOC/CDO to modulate hedgehog signaling
CN101379400A (zh) * 2005-12-22 2009-03-04 诺华有限公司 可溶性人m-csf受体及其应用
WO2007073567A2 (en) * 2005-12-22 2007-06-28 Iq Corporation Compositions and methods of modulating the immune response
SI3219328T1 (sl) 2005-12-29 2020-10-30 Janssen Biotech, Inc. Človeška protitelesa proti-IL-23, sestavki, postopki in uporabe
AR056857A1 (es) 2005-12-30 2007-10-24 U3 Pharma Ag Anticuerpos dirigidos hacia her-3 (receptor del factor de crecimiento epidérmico humano-3) y sus usos
AU2006332155B2 (en) 2005-12-30 2013-01-10 Cancer Research Technology Limited Anti-CD19 antibodies with reduced immunogenicity
US20070286865A1 (en) 2006-01-04 2007-12-13 Richard Moore Use of HE4 and other biochemical markers for assessment of ovarian cancers
US8101365B2 (en) 2006-01-05 2012-01-24 Genentech, Inc. Anti-EphB4 antibodies and methods using same
US20090246208A1 (en) 2006-01-05 2009-10-01 Novartis Ag Methods for preventing and treating cancer metastasis and bone loss associated with cancer metastasis
EP2463305B1 (de) 2006-01-12 2016-05-11 Alexion Pharmaceuticals, Inc. Antikörper zu OX-2/CD200 und deren Verwendungen
EP1973945A4 (de) 2006-01-16 2009-11-18 Compugen Ltd Neue nukleotid- und aminosäuresequenzen und verfahren zu deren anwendung in der diagnose
US20070166306A1 (en) * 2006-01-17 2007-07-19 Fey Georg H M Anti-CD19 antibody composition and method
KR20080089489A (ko) 2006-01-18 2008-10-06 메르크 파텐트 게엠베하 인테그린 리간드를 사용하는 암치료용 특이적 요법
JP5554925B2 (ja) 2006-01-20 2014-07-23 セル・シグナリング・テクノロジー・インコーポレイテツド ヒト非小細胞肺癌における転座及び変異体ｒｏｓキナーゼ
US20120208824A1 (en) 2006-01-20 2012-08-16 Cell Signaling Technology, Inc. ROS Kinase in Lung Cancer
EP2526968A3 (de) 2006-01-27 2013-05-22 Biogen Idec MA Inc. Nogo-Rezeptorantagonisten
JP5033643B2 (ja) 2006-01-27 2012-09-26 学校法人慶應義塾 脈絡膜血管新生を伴う疾患の治療剤
US20080038761A1 (en) * 2006-01-30 2008-02-14 Invitrogen Corporation Compositions and methods for detecting and quantifying toxic substances in disease states
US20070178103A1 (en) * 2006-01-30 2007-08-02 Fey Georg H CD19-specific immunotoxin and treatment method
US20070179094A1 (en) 2006-01-31 2007-08-02 Bayer Schering Pharma Ag Modulation of MDL-1 activity for treatment of inflammatory disease
NZ569988A (en) * 2006-02-01 2011-09-30 Cephalon Australia Pty Ltd Domain antibody construct which binds to human TNF-alpha and contains a modified hinge region sequence and a truncated CH1 domain
ATE491948T1 (de) * 2006-02-06 2011-01-15 Rhode Island Hospital Gpr30-östrogenrezeptor bei mammakarzinomen
JP2009525757A (ja) 2006-02-10 2009-07-16 ザ ユニバーシティ オブ シンシナティ 心機能のレギュレータとしてのホスファターゼインヒビタープロテイン−１
US7790857B2 (en) * 2006-02-10 2010-09-07 Sanofi Pasteur Limited Monoclonal antibodies and uses thereof
US20070249014A1 (en) 2006-02-10 2007-10-25 Invitrogen Corporation Labeling and detection of post translationally modified proteins
WO2008048344A2 (en) * 2006-02-13 2008-04-24 Fraunhofer Usa, Inc. Bacillus anthracis antigens, vaccine compositions, and related methods
WO2007095320A2 (en) * 2006-02-13 2007-08-23 Fraunhofer Usa, Inc. Hpv antigens, vaccine compositions, and related methods
US8124103B2 (en) * 2006-02-13 2012-02-28 Fraunhofer Usa, Inc Influenza antigens, vaccine compositions, and related methods
WO2007093177A2 (en) 2006-02-14 2007-08-23 Vladimir Berezin Metallothionein-derived peptide fragments
CA2638821A1 (en) 2006-02-17 2007-10-11 Genentech, Inc. Gene disruptons, compositions and methods relating thereto
US7750116B1 (en) 2006-02-18 2010-07-06 Seattle Genetics, Inc. Antibody drug conjugate metabolites
TWI417301B (zh) 2006-02-21 2013-12-01 Wyeth Corp 對抗人類介白素-２２（ｉｌ-２２）之抗體及其用途
TW200744634A (en) 2006-02-21 2007-12-16 Wyeth Corp Methods of using antibodies against human IL-22
JP2009531295A (ja) 2006-02-22 2009-09-03 ユニバーシティ オブ チューリッヒ 自己免疫疾患又は脱髄疾患を処置するための方法
US7459280B2 (en) * 2006-02-27 2008-12-02 Picobella, Llc Methods for diagnosing and treating kidney cancer
EP1998792B1 (de) * 2006-03-01 2015-02-18 The University of Utah Research Foundation Verfahren und zusammensetzungen in verbindung mit der synthese zyklischer peptide
US8470965B2 (en) * 2006-03-01 2013-06-25 University Of Utah Research Foundation Methods and compositions related to cyclic peptide synthesis
US7807364B2 (en) 2006-03-03 2010-10-05 University Of Southern California Angiogenesis pathway gene polymorphisms for therapy selection
AU2007223903B2 (en) 2006-03-06 2013-09-05 Medimmune, Llc Humanized anti-CD22 antibodies and their use in treatment of oncology, transplantation and autoimmune disease
EP2650306A1 (de) 2006-03-06 2013-10-16 Aeres Biomedical Limited Humanisierte Anti-CD22-Antikörper und ihre Verwendung bei der Behandlung von Krebs, Transplantationen und Autoimmunerkrankungen
DK1991275T3 (en) 2006-03-08 2014-12-08 Archemix Llc Complement aptamers AND ANTI-C5 AGENTS FOR USE IN THE TREATMENT OF EYE DISEASES
WO2008076139A1 (en) * 2006-03-10 2008-06-26 Tethys Bioscience, Inc. Multiplex protein fractionation
WO2007106536A2 (en) 2006-03-14 2007-09-20 Oregon Health & Science University Methods for producing an immune response to tuberculosis
US7504106B2 (en) 2006-03-14 2009-03-17 Boris Skurkovich Method and composition for treatment of renal failure with antibodies and their equivalents as partial or complete replacement for dialysis
HUE066795T2 (hu) 2006-03-15 2024-09-28 Alexion Pharma Inc Paroxysmalis nocturnalis haemoglobinuriában szenvedõ betegek kezelése egy komplement inhibitorral
DK2374472T3 (en) 2006-03-16 2018-08-13 Dyax Corp Compositions and Methods for the Treatment of Eye Disorders
AR059851A1 (es) 2006-03-16 2008-04-30 Genentech Inc Anticuerpos de la egfl7 y metodos de uso
US9121853B2 (en) * 2006-03-20 2015-09-01 Mayo Foundation For Medical Education And Research B7-H4 expression on tumor vasculature
AR060040A1 (es) 2006-03-21 2008-05-21 Genentech Inc Antagonistas de vefg y de alfa5 beta 1
EP2004230A4 (de) 2006-03-21 2009-05-20 Univ California N-cadherin- und ly6 e:-ziele für die krebsdiagnose und -therapie
US20100278821A1 (en) 2006-03-21 2010-11-04 The Regents Of The University Of California N-cadherin: target for cancer diagnosis and therapy
EP2004221A2 (de) 2006-03-23 2008-12-24 Novartis Pharma AG Antitumorzellenantigen-antikörper-therapeutika
KR101481844B1 (ko) 2006-03-27 2015-01-13 메디뮨 리미티드 Ｇｍ-ｃｓｆ 수용체에 대한 결합 성분
KR20080113239A (ko) 2006-03-30 2008-12-29 메이지 세이카 가부시키가이샤 녹농균의 외막 단백질 ｐａ0427
WO2007123737A2 (en) 2006-03-30 2007-11-01 University Of California Methods and compositions for localized secretion of anti-ctla-4 antibodies
EP2016949A4 (de) 2006-03-31 2009-12-09 Riken Neue verwendung von g-protein-konjugiertem rezeptor und ligand dafür
EP2010911A4 (de) 2006-03-31 2009-05-13 Massachusetts Inst Technology Behandlung von egf-rezeptormutanten exprimierenden tumoren
US20070292922A1 (en) * 2006-03-31 2007-12-20 Cell Genesys, Inc. Regulated expression of recombinant proteins from adeno-associated viral vectors
JP5144499B2 (ja) 2006-03-31 2013-02-13 中外製薬株式会社 二重特異性抗体を精製するための抗体改変方法
WO2007115207A2 (en) * 2006-03-31 2007-10-11 Regents Of The University Of Minnesota Irf-5 haplotypes in systemic lupus erythematosus
US8221966B2 (en) 2006-03-31 2012-07-17 Dana Farber Cancer Institute Methods of determining cellular chemosensitivity
EP4793360A2 (de) 2006-03-31 2026-08-19 Chugai Seiyaku Kabushiki Kaisha Verfahren zur kontrolle der blut-pharmazeutizität von antikörpern
US7919079B2 (en) * 2006-03-31 2011-04-05 Biosante Pharmaceuticals, Inc. Cancer immunotherapy compositions and methods of use
CA2647277A1 (en) 2006-04-05 2007-11-08 Genentech, Inc. Method for using boc/cdo to modulate hedgehog signaling
AU2007235413B2 (en) 2006-04-05 2012-08-02 The Rockefeller University Polypeptides with enhanced anti-inflammatory and decreased cytotoxic properties and relating methods
CN102391358B (zh) 2006-04-05 2016-08-10 艾伯维生物技术有限公司 抗体纯化
US8524454B2 (en) 2006-04-07 2013-09-03 The Research Foundation Of State University Of New York Transcobalamin receptor polypeptides, nucleic acids, and modulators thereof, and related methods of use in modulating cell growth and treating cancer and cobalamin deficiency
JP5754875B2 (ja) 2006-04-07 2015-07-29 国立大学法人大阪大学 筋再生促進剤
AU2007234733A1 (en) * 2006-04-07 2007-10-18 The Government Of The United States Of America As Represented By The Secretary, Department Of Health And Human Services Antibody compositions and methods for treatment of neoplastic disease
ES2828739T3 (es) 2006-04-07 2021-05-27 Aerpio Pharmaceuticals Inc Anticuerpos que se unen a la proteína tirosina fosfatasa beta humana (HPTP-beta) y sus usos
US20070280935A1 (en) * 2006-04-07 2007-12-06 Bernd Bohrmann Antibody that recognizes phosphorylated peptides
BRPI0710055A2 (pt) * 2006-04-10 2011-08-02 Fusion Antibodies Limited métodos de inibir regulação ascendente induzida por quimioterapia de catepsina s, expressão de catepsina s sobre a superfìcie de células de tumor e angiogênese em um grupo de células, um tecido ou um órgão, de tratar doença neoplásica e uma condição associada com atividade de catepsina s em um paciente, de induzir reação citotóxica mediada por célula dependente de anticorpo contra uma célula de tumor, de matar células de tumor, de identificar células de tumor em uma população de células e de avaliar in vitro a resposta de células de tumor de um indivìduo à presença de um agente quimioterápico, usos de um inibidor de catepsina s e um agente quimioterapêutico, de catepsina s, de um anticorpo anti-catepsina s ou um fragmento do mesmo e de uma molécula de anticorpo, composição farmacêutica, kit farmacêutico e molécula de anticorpo ou um ácido nucleico codificando dita molécula de anticorpo
EP2666478A3 (de) 2006-04-10 2014-10-22 AbbVie Biotechnology Ltd Anwendungen und Zusammensetzungen zur Behandlung von Schuppenflechte
EP2343551B1 (de) 2006-04-10 2014-05-28 Genentech, Inc. Dishevelled PDZ-Modulatoren
GB0620255D0 (en) * 2006-10-12 2006-11-22 Fusion Antibodies Ltd Antibody and uses thereof
CA2564435A1 (en) 2006-04-10 2007-10-10 Abbott Biotechnology Ltd. Methods for monitoring and treating intestinal disorders
WO2008063213A2 (en) 2006-04-10 2008-05-29 Abbott Biotechnology Ltd. Uses and compositions for treatment of psoriatic arthritis
KR101288027B1 (ko) * 2006-04-12 2013-07-22 새비언트 파마수티컬즈 인크. 양이온 계면활성제를 이용한 단백질 정제 방법
PL2450437T3 (pl) 2006-04-14 2017-12-29 Cell Signaling Technology Inc Defekty genu i zmutowana kinaza ALK w ludzkich guzach litych
US8784810B2 (en) * 2006-04-18 2014-07-22 Janssen Alzheimer Immunotherapy Treatment of amyloidogenic diseases
CA2649387A1 (en) 2006-04-19 2008-03-27 Genentech, Inc. Novel gene disruptions, compositions and methods relating thereto
AU2007240614B2 (en) 2006-04-20 2013-09-12 The Henry M. Jackson Foundation For The Advancement Of Military Medicine Incorporated Methods and compositions based on Shiga toxin type 1 protein
SMP200800064B (it) 2006-04-21 2009-11-06 Novartis Ag Composizioni farmaceutiche di anticorpi anti-cd40 antagonista
WO2007121522A1 (en) 2006-04-21 2007-11-01 Minister for Primary Industries For And On Behalf Of The State Of New South Wales Pestivirus species
TWI395754B (zh) 2006-04-24 2013-05-11 Amgen Inc 人類化之ｃ-ｋｉｔ抗體
US20070254338A1 (en) * 2006-04-24 2007-11-01 Amgen Inc. Method for making recombinant protein using complementation dependent DHFR mutants
CN101473045B (zh) 2006-04-24 2016-08-03 健泰科生物技术公司 用于检测自身免疫性病症的方法和组合物
US8492097B2 (en) * 2006-04-24 2013-07-23 Diagnostic Hybrids, Inc. Compositions and methods for human metapneumovirus monoclonal antibodies
EP2011513B1 (de) 2006-04-25 2016-10-19 The University of Tokyo Therapeutische mittel gegen alzheimer-krankheit und krebs
US20070258908A1 (en) * 2006-04-27 2007-11-08 Lanza Gregory M Detection and imaging of target tissue
WO2007127335A2 (en) * 2006-04-27 2007-11-08 Cell Signaling Technology, Inc. Reagents for the detection of protein phosphorylation in atm and atr kinase signaling pathways
CA2650730A1 (en) 2006-04-27 2007-11-08 Pikamab, Inc. Methods and compositions for antibody therapy
EP3255149A3 (de) 2006-05-02 2018-04-18 Intrexon Actobiotics NV Mikrobielle intestinale verabreichung von fettsucht verwandten peptiden
US20070258976A1 (en) * 2006-05-04 2007-11-08 Ward Keith W Combination Therapy for Diseases Involving Angiogenesis
DE102006020885A1 (de) * 2006-05-05 2007-11-08 Qiagen Gmbh Einführung von Sequenzelementen in Nukleinsäuren
EP2016101A2 (de) * 2006-05-09 2009-01-21 Genentech, Inc. Bindung von polypeptiden mit optimierten gerüsten
US7727525B2 (en) * 2006-05-11 2010-06-01 City Of Hope Engineered anti-CD20 antibody fragments for in vivo targeting and therapeutics
CA2651962A1 (en) 2006-05-12 2007-12-21 Oklahoma Medical Research Foundation Anthrax compositions and methods of use and production
US20090142259A1 (en) * 2006-05-12 2009-06-04 Genentech, Inc. Compositions and methods for the diagnosis and treatment of bladder and urinary tract tumors
AU2007249698A1 (en) * 2006-05-15 2007-11-22 University Of Kentucky Toll-like receptor (TLR) stimulation for ocular angiogenesis and macular degeneration
US20100062431A1 (en) * 2006-05-18 2010-03-11 Sanofi-Aventis Use of adamts4 gene and protein polymorphisms
EP1918302A3 (de) * 2006-05-18 2009-11-18 AvantGen, Inc. Verfahren zur Identifikation und Isolation von epitopspezifischen Antikörpern
CA2653408C (en) 2006-05-27 2017-08-01 Mitchell A. Winnik Polymer backbone element tags
PT2032606E (pt) 2006-05-30 2014-02-05 Genentech Inc Anticorpos e imunoconjugados e respetivas utilizações
US9274130B2 (en) 2006-05-31 2016-03-01 Lpath, Inc. Prevention and treatment of pain using antibodies to lysophosphatidic acid
US7862812B2 (en) * 2006-05-31 2011-01-04 Lpath, Inc. Methods for decreasing immune response and treating immune conditions
US8796429B2 (en) * 2006-05-31 2014-08-05 Lpath, Inc. Bioactive lipid derivatives, and methods of making and using same
US9217749B2 (en) * 2006-05-31 2015-12-22 Lpath, Inc. Immune-derived moieties reactive against lysophosphatidic acid
US9274129B2 (en) * 2006-05-31 2016-03-01 Lpath, Inc. Methods and reagents for detecting bioactive lipids
EP2024391A2 (de) 2006-06-01 2009-02-18 Genentech, Inc. Kristallstruktur für crig und c3b: crig-komplex
EP2049570B1 (de) * 2006-06-01 2016-08-10 President and Fellows of Harvard College Reinigung von bivalent aktiven antikörpern, mit verwendung von einem nicht-chromatographischen verfahren
MX2008015138A (es) 2006-06-02 2009-01-28 Aveo Pharmaceuticals Inc Proteinas de union al factor de crecimiento de hepatocitos (fch).
US7649083B2 (en) 2006-06-02 2010-01-19 Aveo Pharmaceuticals, Inc. Hepatocyte growth factor (HGF) binding antibody
US8153369B2 (en) 2006-06-05 2012-04-10 Cancer Care Ontario Assessment of risk for colorectal cancer
GB0611116D0 (en) 2006-06-06 2006-07-19 Oxford Genome Sciences Uk Ltd Proteins
AU2007319672B2 (en) * 2006-06-06 2011-06-30 Genentech, Inc. Anti-DLL4 antibodies and methods using same
DK2027155T3 (en) * 2006-06-06 2016-05-09 Crucell Holland Bv HUMAN BINDING MOLECULES with killer activity against staphylococci and uses thereof
JP2009539870A (ja) * 2006-06-06 2009-11-19 ジェネンテック・インコーポレーテッド 血管発生の調節ための組成物および方法
BRPI0712850A8 (pt) 2006-06-07 2018-05-02 Bioalliance Cv anticorpos que reconhecem um epitopo contendo carboidrato em cd-43 e cea expressados em células cancerígenas e métodos de uso dos mesmos
ATE528411T1 (de) 2006-06-07 2011-10-15 Otago Innovation Ltd Diagnoseverfahren und -marker
AT503690A1 (de) 2006-06-09 2007-12-15 Biomay Ag Hypoallergene moleküle
CN105837690A (zh) * 2006-06-12 2016-08-10 新兴产品开发西雅图有限公司 具有效应功能的单链多价结合蛋白
JP2009544761A (ja) 2006-06-14 2009-12-17 マクロジェニクス，インコーポレーテッド 低毒性免疫抑制モノクローナル抗体を用いて自己免疫疾患を治療する方法
KR20090021217A (ko) 2006-06-14 2009-02-27 추가이 세이야쿠 가부시키가이샤 조혈 줄기세포 증가 촉진제
US7858756B2 (en) 2006-06-15 2010-12-28 The Board Of Trustees Of The University Of Arkansas Monoclonal antibodies that selectively recognize methamphetamine and methamphetamine like compounds
US8101721B2 (en) * 2006-06-15 2012-01-24 Fibron Ltd. Antibodies blocking fibroblast growth factor receptor activation and methods of use thereof
WO2008094176A2 (en) * 2006-06-19 2008-08-07 Tolerx, Inc. Ilt3 binding molecules and uses therefor
US8221751B2 (en) 2006-06-21 2012-07-17 Oncotherapy Science, Inc. Tumor-targeting monoclonal antibodies to FZD10 and uses thereof
AU2007260817A1 (en) 2006-06-23 2007-12-27 Myriad Genetics, Inc. DPYD gene variants and use thereof
US8874380B2 (en) 2010-12-09 2014-10-28 Rutgers, The State University Of New Jersey Method of overcoming therapeutic limitations of nonuniform distribution of radiopharmaceuticals and chemotherapy drugs
WO2008000079A1 (en) * 2006-06-26 2008-01-03 The University Of British Columbia Secreted protein acidic and rich in cysteine (sparc) as chemotherapeutic sensitizers
EP2029173B1 (de) 2006-06-26 2016-07-20 MacroGenics, Inc. Fc-riib-spezifische antikörper und verfahren zu ihrer anwendung
FR2902799B1 (fr) 2006-06-27 2012-10-26 Millipore Corp Procede et unite de preparation d'un echantillon pour l'analyse microbiologique d'un liquide
CA2656221A1 (en) 2006-06-28 2008-01-03 Yeda Research And Development Co. Ltd. Caspase-8 and inflammation, infection and wound healing
WO2008005469A2 (en) 2006-06-30 2008-01-10 Schering Corporation Igfbp2 biomarker
DK2038306T3 (en) 2006-06-30 2015-03-09 Novo Nordisk As ANTI-NKG2A ANTIBODIES AND APPLICATIONS THEREOF
CN103316402A (zh) 2006-06-30 2013-09-25 艾伯维生物技术有限公司 自动注射装置
US7572618B2 (en) 2006-06-30 2009-08-11 Bristol-Myers Squibb Company Polynucleotides encoding novel PCSK9 variants
JP5385135B2 (ja) 2006-07-03 2014-01-08 チャールズ デイビッド アデア， 細胞接着分子の発現を調節するための組成物
US20130004480A1 (en) 2006-07-04 2013-01-03 Paul Parren CD20 Binding Molecules for the Treatment of Copd
US8198046B2 (en) * 2006-07-11 2012-06-12 Danisco Us Inc. KEX2 cleavage regions of recombinant fusion proteins
US20080026376A1 (en) 2006-07-11 2008-01-31 Huaming Wang KEX2 cleavage regions of recombinant fusion proteins
JP5066087B2 (ja) 2006-07-12 2012-11-07 株式会社ジーンテクノサイエンス 抗ヒトα９インテグリン抗体とその用途
DK2447275T3 (en) 2006-07-13 2015-06-29 Univ Iowa Res Found Methods and reagents for the treatment of age-related macular degeneration
DK2041270T3 (da) 2006-07-13 2014-01-27 Wyeth Llc Fremstilling af glycoproteiner
ZA200900545B (en) 2006-07-18 2010-03-31 Sanofi Aventis Antagonist antibody against EPHA2 for the treatment of cancer
DK2046809T3 (en) 2006-07-19 2017-03-13 Univ Pennsylvania WSX-1 / IL-27 AS A TARGET OBJECTIVE FOR ANTI-INFLAMMATORY REACTIONS
EP1882697B1 (de) 2006-07-24 2010-04-21 Institut Pasteur Antikörper, Antikörperfragmente und scFv die an posttranslational modifizierte Neurotrophine binden
GB0614780D0 (en) 2006-07-25 2006-09-06 Ucb Sa Biological products
WO2008011713A1 (en) * 2006-07-26 2008-01-31 Diamedica Inc. Methods of diagnosis and treatment for metabolic disorders
RU2009107707A (ru) 2006-08-04 2010-09-10 Новартис АГ (CH) СПЕЦИФИЧНОЕ К EphB3 АНТИТЕЛО И ЕГО ПРИМЕНЕНИЕ
WO2008018472A1 (fr) 2006-08-08 2008-02-14 Kyoto University Nouvel anticorps monoclonal et son utilisation
CA2660286A1 (en) 2006-08-09 2008-02-21 Homestead Clinical Corporation Organ-specific proteins and methods of their use
AR062223A1 (es) * 2006-08-09 2008-10-22 Glycart Biotechnology Ag Moleculas de adhesion al antigeno que se adhieren a egfr, vectores que los codifican, y sus usos de estas
WO2008022035A2 (en) * 2006-08-10 2008-02-21 The Scripps Research Institute Methods for identifying cellular modulators of disaggregation activity or aggregation activity in an animal
JP5244785B2 (ja) 2006-08-11 2013-07-24 小野薬品工業株式会社 ストローマ由来因子−１（ｓｄｆ−１）に対するモノクローナル抗体
US20100316626A1 (en) * 2006-08-11 2010-12-16 The Government Of The United States Of America As Represented By The Secretary Methods for treatment and diagnosis of psychiatric disorders
US7939636B2 (en) * 2006-08-11 2011-05-10 Cell Signaling Technology, Inc. Reagents for the detection of protein phosphorylation in c-Src signaling pathways
AU2007283463B2 (en) 2006-08-11 2012-04-26 Csl Limited Treatment of pulmonary disease conditions
US20090269342A1 (en) * 2006-08-14 2009-10-29 Massachusetts Institute Of Technology Hemagglutinin Polypeptides, and Reagents and Methods Relating Thereto
US9867530B2 (en) 2006-08-14 2018-01-16 Volcano Corporation Telescopic side port catheter device with imaging system and method for accessing side branch occlusions
RS53263B (sr) 2006-08-14 2014-08-29 Xencor Inc. Optimizovana antitela usmerena na cd19
EP2052340A4 (de) * 2006-08-14 2010-11-17 Massachusetts Inst Technology Glycan-datenauswertungssystem
CA2661023C (en) 2006-08-18 2017-08-15 Novartis Ag Prlr-specific antibody and uses thereof
ZA200900954B (en) 2006-08-22 2010-05-26 G2 Inflammation Pty Ltd Ant-C5aR antibodies with improved properties
EP2061900A2 (de) 2006-08-25 2009-05-27 Oncotherapy Science, Inc. Prognostische marker und therapeutische ziele bei lungenkrebs
EP2484696B1 (de) 2006-08-28 2017-08-16 Kyowa Hakko Kirin Co., Ltd. Antagonistische hLIGHT-spezifische menschliche monoklonale Antikörper
EP2471816A1 (de) 2006-08-30 2012-07-04 Genentech, Inc. Multispezifische Antikörper
US20090258442A1 (en) * 2006-08-31 2009-10-15 Cell Signaling Technology, Inc. Reagents for the detection of protein phosphorylation in carcinoma signaling pathways
EP2061811A2 (de) 2006-09-01 2009-05-27 ZymoGenetics, Inc. Sequenzen der variablen region von monoklonalen antikörpern gegen il-31 und anwendungsverfahren
US7951776B2 (en) 2006-09-01 2011-05-31 American Type Culture Collection Methods for treatment of type 1 diabetes
US20090203602A1 (en) 2006-09-01 2009-08-13 Cohava Gelber Compositions and methods for diagnosis and treatment of type 2 diabetes
CN101627055A (zh) 2006-09-05 2010-01-13 梅达雷克斯公司 骨形成蛋白及其受体的抗体以及它们的使用方法
GB0617429D0 (en) 2006-09-05 2006-10-18 Electrophoretics Ltd Markers of renal transplant rejection and renal damage
WO2008030505A2 (en) 2006-09-05 2008-03-13 Alexion Pharmaceuticals, Inc. Methods and compositions for the treatment of antibody mediated neuropathies
US20080064045A1 (en) * 2006-09-07 2008-03-13 Huaiqin Wu Biomarker fragments for the detection of human BNP
EP2089722B1 (de) 2006-09-07 2017-11-08 Otago Innovation Limited Biomarker zur Früherkennung akuter Herzstörungen
HUE052220T2 (hu) 2006-09-08 2021-04-28 Abbvie Bahamas Ltd Interleukin-13 kötõfehérjék
US8034771B2 (en) 2006-09-08 2011-10-11 Amgen Inc. IL-1F6 polypeptides
EP2061906B1 (de) 2006-09-12 2011-08-31 Genentech, Inc. Verfahren und zusammensetzungen zur diagnose und behandlung von lungenkrebs mittels pdgfra-, kit- oder kdg-gen als genmarker
EP2500416A1 (de) 2006-09-13 2012-09-19 Abbott Laboratories Verbesserungen an Zellkulturen
TW201516149A (zh) 2006-09-13 2015-05-01 Abbvie Inc 細胞培養改良
EP2492278A1 (de) 2006-09-18 2012-08-29 Compugen Ltd. Antikörper gegen einen Agonisten von G-Protein-gekoppelten Rezeptoren und deren Verwendung in Diagnose und Therapie
EP2064240A2 (de) 2006-09-18 2009-06-03 Xencor, Inc. Optimierte auf hm1.24 abzielende antikörper
US20080076139A1 (en) 2006-09-21 2008-03-27 Sharat Singh Methods and compositions for detecting the activation states of multiple signal transducers in rare circulating cells
EP2066693A2 (de) 2006-09-22 2009-06-10 St. Jude Children's Research Hospital Modulation der regulatorischen aktivität von t-zellen mittels interleukin-35
PL2081595T3 (pl) 2006-09-26 2019-11-29 Genmab As Anty-cd38 wraz z kortykosteroidami wraz ze środkiem chemioterapeutycznym niebędącym kortykosteroidem, do leczenia guzów nowotworowych
FR2906533B1 (fr) 2006-09-28 2013-02-22 Pf Medicament Procede de generation d'anticorps actifs contre un antigene de resistance,anticorps obtenus par ledit procede et leurs utilisations
CA2664712C (en) 2006-09-29 2019-07-09 Translational Therapeutics, Inc. Eif4e regulon-based diagnostics
HRP20160082T1 (hr) 2006-09-29 2016-02-26 Oncomed Pharmaceuticals, Inc. Sastavi i postupci za dijagnosticiranje i lijeäśenje raka
GB0619291D0 (en) 2006-09-29 2006-11-08 Ucb Sa Altered antibodies
SI2066351T1 (sl) 2006-10-02 2016-02-29 E.R. Squibb & Sons, L.L.C. Humana protitelesa, ki vežejo cxcr4 in njihova uporaba
EP2067041A2 (de) 2006-10-03 2009-06-10 Biogen Idec MA, Inc. Biomarker und testreihen zur behandlung von krebs
CA2664567C (en) 2006-10-04 2016-04-26 Dana-Farber Cancer Institute, Inc. Tumor immunity
DK2457929T3 (en) 2006-10-04 2016-09-05 Genentech Inc Elisa vegf
EP2067791A4 (de) 2006-10-06 2009-11-25 Takeda Pharmaceutical Prophylaktischer oder therapeutischer wirkstoff gegen krebs
AU2007324128B2 (en) 2006-10-10 2013-10-10 The Henry M. Jackson Foundation For The Advancement Of Military Medicine, Inc. Prostate cancer-specific alterations in ERG gene expression and detection and treatment methods based on those alterations
JP5919593B2 (ja) * 2006-10-11 2016-05-18 フージョン アンティボディーズ リミテッド 併用療法
CA2665709C (en) * 2006-10-11 2018-04-03 Janssen Pharmaceutica N.V. Compositions and methods for treating and diagnosing irritable bowel syndrome
NZ576032A (en) 2006-10-12 2012-03-30 Genentech Inc Antibodies to lymphotoxin-alpha
KR20090069330A (ko) * 2006-10-12 2009-06-30 와이어쓰 유백광/응집체를 감소시키기 위한 항체 용액 중의 이온 강도의 변화
JP5247106B2 (ja) * 2006-10-13 2013-07-24 キヤノン株式会社 タンパク質、タンパク質の固定方法、構造体、バイオセンサー、核酸、ベクター及び標的物質検出用キット
EP2064335A4 (de) 2006-10-16 2011-03-30 Medimmune Llc Moleküle mit reduzierter halbwertzeit, zusammensetzungen und ihre verwendung
ES2501947T3 (es) 2006-10-19 2014-10-02 Csl Limited Antagonistas de anticuerpos de alta afinidad del receptor alfa 1 de interleucina
PL2068922T3 (pl) 2006-10-19 2012-11-30 Csl Ltd Przeciwciała anty-IL-13R alfa1 i ich zastosowania
EP1914242A1 (de) 2006-10-19 2008-04-23 Sanofi-Aventis Neue Antikörper gegen CD38 zur Behandlung von Krebs
US8338376B2 (en) * 2006-10-20 2012-12-25 Biogen Idec Ma Inc. Compositions comprising variant LT-B-R-IG fusion proteins
NZ576424A (en) * 2006-10-20 2012-09-28 Biogen Idec Inc Treatment of demyelinating disorders with soluble lymphotoxin-beta-receptor
CA2666346C (en) 2006-10-20 2016-02-23 Celera Corporation Genetic polymorphisms associated with venous thrombosis, methods of detection and uses thereof
US8108030B2 (en) 2006-10-20 2012-01-31 Board Of Regents, The University Of Texas System Method and apparatus to identify vulnerable plaques with thermal wave imaging of heated nanoparticles
WO2008050907A1 (fr) 2006-10-26 2008-05-02 Gene Techno Science Co., Ltd. Anticorps dirigé contre rgd dans une séquence d'acides aminés d'une protéine de matrice extracellulaire et procédé de fabrication et utilisation de celui-ci
EP1916259A1 (de) 2006-10-26 2008-04-30 Institut National De La Sante Et De La Recherche Medicale (Inserm) Anti-Glycoprotein VI SCFV Fragment zur Thrombosebehandlung
US8614103B2 (en) * 2006-10-27 2013-12-24 Lpath, Inc. Compositions and methods for treating sphingosine-1-phosphate (S1P) related ocular diseases and conditions
WO2008070344A2 (en) * 2006-10-27 2008-06-12 Lpath, Inc. Compositions and methods for binding sphingosine-1-phosphate
PT2845866T (pt) 2006-10-27 2017-08-09 Genentech Inc Anticorpos e imunoconjugados e utilizações dos mesmos
GB0621513D0 (en) * 2006-10-30 2006-12-06 Domantis Ltd Novel polypeptides and uses thereof
WO2008133711A2 (en) 2006-10-30 2008-11-06 Functional Genetics, Inc. Random homozygous gene perturbation to enhance antibody production
WO2008136852A2 (en) 2006-11-01 2008-11-13 University Of Rochester Methods and compositions related to the structure and function of apobec3g
WO2008070367A2 (en) * 2006-11-01 2008-06-12 Facet Biotech Corporation Mammalian cell-based immunoglobulin display libraries
WO2008140477A2 (en) 2006-11-02 2008-11-20 Capon Daniel J Hybrid immunoglobulins with moving parts
CA2668410C (en) 2006-11-02 2017-05-16 Mitchell A. Winnik Particles containing detectable elemental code
CN106084055A (zh) 2006-11-02 2016-11-09 健泰科生物技术公司 人源化的抗‑d因子抗体
EP2094733A1 (de) 2006-11-03 2009-09-02 U3 Pharma GmbH Fgfr4-antikörper
MX2009004519A (es) 2006-11-03 2009-05-12 Wyeth Corp Sustancias que inhiben la glucolisis en un cultivo de celulas.
WO2008057501A2 (en) * 2006-11-06 2008-05-15 Whitehead Institute Immunomodulating compositions and methods of use thereof
US9457047B2 (en) 2006-11-06 2016-10-04 Whitehead Institute Immunomodulating compositions and methods of use thereof
EP2094307A4 (de) * 2006-11-08 2015-08-26 Macrogenics West Inc Tes7 und daran bindende antikörper
US20100247552A1 (en) 2006-11-10 2010-09-30 Massachusetts Institute Of Technology Pak modulators
CN101535470A (zh) * 2006-11-13 2009-09-16 霍夫曼-拉罗奇有限公司 修饰癌性疾病的抗体180706-01
CN101595213A (zh) * 2006-11-13 2009-12-02 霍夫曼-拉罗奇有限公司 修饰癌性疾病的抗体
JP2010509244A (ja) * 2006-11-13 2010-03-25 エフ．ホフマン−ラ ロシュ アーゲー 癌性疾患修飾抗体
US7492312B2 (en) * 2006-11-14 2009-02-17 Fam Adly T Multiplicative mismatched filters for optimum range sidelobe suppression in barker code reception
KR20090082480A (ko) 2006-11-14 2009-07-30 제넨테크, 인크. 뉴런 재생의 조절인자
EP2514439A1 (de) * 2006-11-15 2012-10-24 Functional Genetics, Inc. Anti-TSG101-Antikörper und deren Verwendung bei der Behandlung von Virusinfektionen
MX2009005189A (es) 2006-11-15 2009-06-30 Medarex Inc Anticuerpos humanos monoclonales para btla y metodos de uso.
CN103351437A (zh) 2006-11-17 2013-10-16 诺瓦提斯公司 Lingo结合分子及其制药用途
US20080206241A1 (en) 2006-11-21 2008-08-28 Kalobios Pharmaceuticals Inc. Methods of Treating Chronic Inflammatory Diseases Using a GM-CSF Antagonist
WO2008140586A2 (en) 2006-11-21 2008-11-20 The Regents Of The University Of California Modulation of rhamm (cd168) for selective adipose tissue development
US20100062000A1 (en) * 2006-11-21 2010-03-11 The Regents Of The University Of California Rhamm, a Co-Receptor and Its Interactions with Other Receptors in Cancer Cell Motility and the Identification of Cancer Prognitor Cell Populations
US8785400B2 (en) * 2006-11-22 2014-07-22 Curedm Group Holdings, Llc Methods and compositions relating to islet cell neogenesis
AU2007325283B2 (en) 2006-11-27 2012-08-30 Diadexus, Inc. Ovr110 antibody compositions and methods of use
JP2010510772A (ja) 2006-11-27 2010-04-08 パトリス リミテッド 新生細胞における新規なグリコシル化ペプチド標的
WO2008064884A1 (en) 2006-11-28 2008-06-05 U3 Pharma Gmbh Activated her3 as a marker for predicting therapeutic efficacy
DK2102239T3 (da) 2006-11-30 2012-05-29 Res Dev Foundation Forbedrede immunoglobulin-biblioteker
TW200831528A (en) 2006-11-30 2008-08-01 Astrazeneca Ab Compounds
US8455626B2 (en) 2006-11-30 2013-06-04 Abbott Laboratories Aβ conformer selective anti-aβ globulomer monoclonal antibodies
SG177168A1 (en) 2006-12-01 2012-01-30 Medarex Inc Human antibodies that bind cd22 and uses thereof
PL2099823T5 (pl) 2006-12-01 2023-02-20 Seagen Inc. Wariant środków wiążących cel i jego zastosowania
PL2662091T3 (pl) 2006-12-01 2019-05-31 Novartis Ag Przeciwciała skierowane przeciwko selektynie P i sposoby ich zastosowania do leczenia chorób zapalnych
US7858752B2 (en) * 2006-12-05 2010-12-28 Abbott Laboratories Recombinant antibodies against hepatitis C virus and methods of obtaining and using same
CN101678100A (zh) 2006-12-06 2010-03-24 米迪缪尼有限公司 治疗系统性红斑狼疮的方法
MX2009006034A (es) 2006-12-07 2009-10-12 Novartis Ag Anticuerpos antagonistas contra ephb3.
ZA200904022B (en) 2006-12-08 2010-08-25 Lexicon Pharmaceuticals Inc Monoclonal antibodies against ANGPTL3
US20080139790A1 (en) * 2006-12-08 2008-06-12 Jennings Philip A Chimeric antibodies
CL2007003622A1 (es) 2006-12-13 2009-08-07 Medarex Inc Anticuerpo monoclonal humano anti-cd19; composicion que lo comprende; y metodo de inhibicion del crecimiento de celulas tumorales.
AR064333A1 (es) 2006-12-14 2009-04-01 Schering Corp Anticuerpo anti-tslp de diseno
US20100150950A1 (en) 2006-12-14 2010-06-17 Medarex, Inc. Human antibodies that bind cd70 and uses thereof
EP2099827B1 (de) 2006-12-18 2018-11-21 Genentech, Inc. Antagonistische antikörper gegen notch-3 und ihre verwendung zur prävention und behandlung von notch-3-vermittelten krankheiten
US20080248033A1 (en) 2006-12-19 2008-10-09 Genentech, Inc. VEGF-specific antagonists for adjuvant and neoadjuvant therapy and the treatment of early stage tumors
US20090186034A1 (en) * 2006-12-19 2009-07-23 Genetech, Inc. Gene expression markers for inflammatory bowel disease
WO2008077145A2 (en) 2006-12-20 2008-06-26 Xoma Technology Ltd. Treatment of il-1-beta related diseases
US8362217B2 (en) 2006-12-21 2013-01-29 Emd Millipore Corporation Purification of proteins
US8569464B2 (en) 2006-12-21 2013-10-29 Emd Millipore Corporation Purification of proteins
US8163886B2 (en) * 2006-12-21 2012-04-24 Emd Millipore Corporation Purification of proteins
WO2009077483A1 (en) 2007-12-14 2009-06-25 Novo Nordisk A/S Antibodies against human nkg2d and uses thereof
WO2008079849A2 (en) * 2006-12-22 2008-07-03 Genentech, Inc. Antibodies to insulin-like growth factor receptor
US20100129358A1 (en) 2006-12-22 2010-05-27 University Of Utah Research Foundation Method of detecting ocular diseases and pathologic conditions and treatment of same
AR064642A1 (es) 2006-12-22 2009-04-15 Wyeth Corp Polinucleotido vector que lo comprende celula recombinante que comprende el vector polipeptido , anticuerpo , composicion que comprende el polinucleotido , vector , celula recombinante polipeptido o anticuerpo , uso de la composicion y metodo para preparar la composicion misma y preparar una composi
AR064500A1 (es) * 2006-12-22 2009-04-08 Dow Agrosciences Llc Vacunas del virus west nile (wnv) de plantas, vectores y secuencias optimizadas de codones de plantas
US7989173B2 (en) 2006-12-27 2011-08-02 The Johns Hopkins University Detection and diagnosis of inflammatory disorders
TWI412367B (zh) 2006-12-28 2013-10-21 梅達雷克斯有限責任公司 化學鏈接劑與可裂解基質以及其之綴合物
SI3345607T1 (sl) 2006-12-29 2023-03-31 Ossifi-Mab Llc Postopki spreminjanja rasti kosti z dajanjem antagonista ali agonista SOST ali WISE
JP2010514839A (ja) 2007-01-03 2010-05-06 バーナム インスティテュート フォー メディカル リサーチ クロット結合化合物に関連する方法および組成物
CA2674788A1 (en) 2007-01-08 2008-07-17 Government Of The Usa, As Represented By The Secretary, Department Of He Alth And Human Services Slco1b3 genotype
GEP20125693B (en) 2007-01-09 2012-11-26 Biogen Idec Inc Sp35 antibodies and usage thereof
US8128926B2 (en) 2007-01-09 2012-03-06 Biogen Idec Ma Inc. Sp35 antibodies and uses thereof
US20080171710A1 (en) 2007-01-17 2008-07-17 University Of Rochester The Redox/Fyn/c-Cbl Pathway
CA2675366A1 (en) * 2007-01-18 2008-07-24 University Of Southern California Gene polymorphisms predictive for dual tki therapy
EA017864B1 (ru) 2007-01-18 2013-03-29 Мерк Патент Гмбх Специфическая терапия и лекарственное средство на основе интегриновых лигандов для лечения рака
RU2474585C2 (ru) 2007-01-22 2013-02-10 Дженентек, Инк. Осаждение и очистка белков полиэлектролитами
WO2008091908A2 (en) 2007-01-22 2008-07-31 Raven Biotechnologies Human cancer stem cells
MX2009007830A (es) 2007-01-23 2009-10-07 Univ Shinshu Inhibidor de rechazo cronico.
EP2106439B1 (de) * 2007-01-24 2014-11-12 The Regents of the University of Michigan Zusammensetzungen und verfahren zur behandlung und diagnostizierung von pankreaskrebs
US9090693B2 (en) * 2007-01-25 2015-07-28 Dana-Farber Cancer Institute Use of anti-EGFR antibodies in treatment of EGFR mutant mediated disease
CA2673954C (en) * 2007-01-25 2015-09-15 Danisco A/S Production of a lipid acyltransferase from transformed bacillus licheniformis cells
EP2125013A4 (de) * 2007-01-26 2010-04-07 Bioinvent Int Ab Dll4-signalisierungshemmer und ihre verwendungen
CA2676613A1 (en) * 2007-01-29 2008-08-07 Wyeth Immunophilin ligands and methods for modulating immunophilin and calcium channel activity
FI20075059A0 (fi) 2007-01-29 2007-01-29 Valtion Teknillinen Allergeeniä sitovat monoklonaaliset IgE-vasta-aineet ja hypoallergeenit:tyypin l lgE:n ja allergeenin immunokompleksivuorovaikutus
US8143046B2 (en) 2007-02-07 2012-03-27 Danisco Us Inc., Genencor Division Variant Buttiauxella sp. phytases having altered properties
US7834154B2 (en) 2007-02-09 2010-11-16 Genentech, Inc. Anti-ROBO4 antibodies and uses therefor
EP1958645A1 (de) 2007-02-13 2008-08-20 Biomay AG Peptide abgeleitet vom Hauptallergens von Traubenkraut (Ambrosia artemisiifolia) und deren Anwendung
US7883705B2 (en) 2007-02-14 2011-02-08 Kyowa Hakko Kirin Co., Ltd. Anti FGF23 antibody and a pharmaceutical composition comprising the same
AR065368A1 (es) 2007-02-15 2009-06-03 Astrazeneca Ab Anticuerpos para moleculas de ige
WO2008100596A2 (en) * 2007-02-15 2008-08-21 Burnham Institute For Medical Research Biomarkers of neurodegenerative disease
WO2008103292A1 (en) 2007-02-16 2008-08-28 Genzyme Corporation Method of identifying risk for thyroid disorder
NZ579644A (en) 2007-02-16 2012-05-25 Merrimack Pharmaceuticals Inc Antibodies against erbb3 and uses thereof
US8685666B2 (en) * 2007-02-16 2014-04-01 The Board Of Trustees Of Southern Illinois University ARL-1 specific antibodies and uses thereof
US8828665B2 (en) 2007-02-16 2014-09-09 Ark Diagnostics, Inc. Compounds and methods for use in detecting gabapentin
US8114606B2 (en) * 2007-02-16 2012-02-14 The Board Of Trustees Of Southern Illinois University ARL-1 specific antibodies
JP5675109B2 (ja) * 2007-02-20 2015-02-25 アナプティスバイオ インコーポレイティッド ライブラリーの生成方法及びその使用
JP2010519310A (ja) * 2007-02-21 2010-06-03 メダレックス インコーポレイテッド 単一のアミノ酸を有する化学リンカーおよびその複合体
RU2502806C2 (ru) 2007-02-22 2013-12-27 Дженентек, Инк. Способы выявления воспалительного заболевания кишечника
HUE042172T2 (hu) * 2007-02-23 2019-06-28 Merck Sharp & Dohme Genetikailag elõállított anti-il-23P19 antitestek
JP2010519256A (ja) 2007-02-23 2010-06-03 ザ・トラスティーズ・オブ・コランビア・ユニバーシティー・イン・ザ・シティー・オブ・ニューヨーク 免疫疾患を治療するために、ＨＬＡ−Ｅ／Ｑａ−１拘束性ＣＤ８＋Ｔ細胞制御性経路を活性化または遮断する方法
CN103396489A (zh) * 2007-02-23 2013-11-20 默沙东公司 工程改造的抗IL-23p19抗体
WO2008104803A2 (en) 2007-02-26 2008-09-04 Oxford Genome Sciences (Uk) Limited Proteins
EP3118221B1 (de) 2007-02-26 2019-08-21 Oxford BioTherapeutics Ltd Proteine
US8895004B2 (en) * 2007-02-27 2014-11-25 AbbVie Deutschland GmbH & Co. KG Method for the treatment of amyloidoses
CA2679381A1 (en) 2007-02-28 2008-09-04 Schering Corporation Engineered anti-il-23r antibodies
MX2009009167A (es) 2007-02-28 2009-09-04 Schering Corp Terapia de combinacion para el tratamiento de trastornos inmunes.
EP2839839B1 (de) 2007-02-28 2018-01-17 Yeda Research And Development Company Limited Nuklear-Targeting-Sequenzen
CA2678404C (en) 2007-02-28 2019-03-19 The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Brachyury polypeptides and methods for use
MX2009008981A (es) 2007-03-02 2009-09-02 Genentech Inc Prediccion de respuesta a un inhibidor her.
CA2679941C (en) 2007-03-02 2016-09-20 Wyeth Use of copper and glutamate in cell culture for production of polypeptides
AU2008222563A1 (en) 2007-03-05 2008-09-12 Cancer Care Ontario Assessment of risk for colorectal cancer
US8501678B2 (en) 2007-03-06 2013-08-06 Atara Biotherapeutics, Inc. Variant activin receptor polypeptides and uses thereof
TW201718635A (zh) 2007-03-06 2017-06-01 安美基公司 變異之活動素受體多肽及其用途
US9610327B2 (en) 2007-03-06 2017-04-04 Amgen Inc. Variant activin receptor polypeptides, alone or in combination with chemotherapy, and uses thereof
US20090081659A1 (en) 2007-03-07 2009-03-26 Cell Signaling Technology, Inc. Reagents for the detection of protein phosphorylation in carcinoma signaling pathways
EP3199180B1 (de) 2007-03-08 2022-01-05 Humanigen, Inc. Ep ha3-antikörper zur behandlung von soliden tumoren
CL2008000719A1 (es) 2007-03-12 2008-09-05 Univ Tokushima Chugai Seiyaku Agente terapeutico para cancer resistente a agentes quimioterapeuticos que comprende un anticuerpo que reconoce hla de clase i como ingrediente activo; composicion farmaceutica que comprende dicho anticuerpo; y metodo para tratar cancer resistente a
EP2136843A1 (de) 2007-03-12 2009-12-30 Miraculins Inc. Biomarker für prostatakrebs und ihre verwendungen
WO2008112988A2 (en) 2007-03-14 2008-09-18 Novartis Ag Apcdd1 inhibitors for treating, diagnosing or detecting cancer
JP2010521157A (ja) 2007-03-14 2010-06-24 ワシントン ユニバーシティ 糖尿病および肥満の治療薬の同定方法
JP5618549B2 (ja) * 2007-03-15 2014-11-05 ルードヴィッヒ インスティテュート フォー キャンサーリサーチ リミテッド Ｅｇｆｒ抗体及びｓｒｃ阻害剤を用いる治療方法及び関連製剤
EP1972938B1 (de) * 2007-03-19 2014-05-14 Ivoclar Vivadent Teststreifen für die Bestimmung des Kariesrisikos
BRPI0809042B1 (pt) 2007-03-22 2021-08-31 Biogen Ma Inc. Proteína de ligação a cd154 isolada, seu uso, e composição
GB2456236B8 (en) * 2007-03-22 2009-12-09 Heptares Therapeutics Ltd Stable muscarinic receptor mutants
US7960139B2 (en) 2007-03-23 2011-06-14 Academia Sinica Alkynyl sugar analogs for the labeling and visualization of glycoconjugates in cells
WO2008116347A1 (en) 2007-03-26 2008-10-02 General Regeneratives Limited Methods for promoting protection and regeneration of bone marrow using cxcl9 and anti-cxcl9 antibodies
EP1975184A3 (de) 2007-03-26 2008-11-26 Cell Signaling Technology, Inc. Serin- oder Threonin-Phosphorylationsorte
WO2008118324A2 (en) 2007-03-26 2008-10-02 Macrogenics, Inc. Composition and method of treating cancer with an anti-uroplakin ib antibody
AU2008230795B2 (en) 2007-03-27 2014-05-29 Bioassets, Llc Constructs and libraries comprising antibody surrogate light chain sequences
TW200902064A (en) * 2007-03-28 2009-01-16 Wyeth Corp Methods and compositions for modulating IL-17F/IL-17A biological activity
GB0706070D0 (en) 2007-03-28 2007-05-09 Scancell Ltd Nucleic acids
US20080238709A1 (en) * 2007-03-28 2008-10-02 Faramarz Vaziri One-way communication apparatus with dynamic key generation
US8455189B2 (en) * 2007-03-29 2013-06-04 Jeffrey W. Allard Use of HE4 for assessment of breast cancers
CA2682093A1 (en) 2007-03-29 2008-10-09 Technion Research & Development Foundation Ltd. Antibodies, methods and kits for diagnosing and treating melanoma
US20100291024A1 (en) * 2007-03-30 2010-11-18 Xuebin Qin Methods and compositions for the treatment of proliferative and pathogenic diseases
KR101540823B1 (ko) 2007-03-30 2015-07-30 메디뮨 엘엘씨 항체 제제
CA2682851C (en) 2007-04-02 2017-01-17 Philogen S.P.A. A novel antigen associated with the neovasculature of tumour metastases
WO2008122310A1 (en) * 2007-04-04 2008-10-16 Chimera Biotec Gmbh Method for the detection of an analyte in biological matrix
US7807168B2 (en) * 2007-04-10 2010-10-05 Vaccinex, Inc. Selection of human TNFα specific antibodies
AP2009005028A0 (en) 2007-04-10 2009-12-31 Univ Tulane Soluble and membrane-anchored forms of lassa virussubunit proteins
PL2155248T3 (pl) 2007-04-12 2015-12-31 Brigham & Womens Hospital Inc Celowanie w ABCB5 w terapii nowotworowej
WO2008131298A2 (en) * 2007-04-18 2008-10-30 Elan Pharma International Limited Prevention and treatment of cerebral amyloid angiopathy
US8003097B2 (en) * 2007-04-18 2011-08-23 Janssen Alzheimer Immunotherapy Treatment of cerebral amyloid angiopathy
US7977462B2 (en) 2007-04-19 2011-07-12 Cell Signaling Technology, Inc. Tyrosine phosphorylation sites
EP1983003A3 (de) 2007-04-19 2009-03-11 Peter Hornbeck Tyrosinphosphorylationsstellen und spezifische Antikörper
EP2145902A3 (de) 2007-04-19 2010-09-29 Peter Hornbeck Tyrosinphosphorylations-Stellen und spezifische Antikörper
WO2008131216A1 (en) * 2007-04-20 2008-10-30 The Board Of Trustees Of The University Of Arkansas Hapten compounds and compositions and uses thereof
TW200902708A (en) * 2007-04-23 2009-01-16 Wyeth Corp Methods of protein production using anti-senescence compounds
CN101293916A (zh) 2007-04-24 2008-10-29 上海国健生物技术研究院 骨桥蛋白的功能表位、与其特异性结合的单克隆抗体及用途
CN101293924A (zh) 2007-04-24 2008-10-29 上海国健生物技术研究院 骨桥蛋白的功能表位、与其特异性结合的单克隆抗体及其在制备抗肿瘤转移药物中的用途
US20100143336A1 (en) 2007-04-26 2010-06-10 Opsona Therapeutics Limited Toll-like receptor binding epitope and compositions for binding thereto
US20080267977A1 (en) * 2007-04-26 2008-10-30 Friedrich-Alexander University Of Erlangen-Nuremberg Combined immunological agent and sensitizing agent for the treatment of cancer
EP2377952A1 (de) 2007-04-26 2011-10-19 Ludwig Institute For Cancer Research Verfahren zur Diagnostizierung und Behandlung von Astrozytoma
CN101687024A (zh) * 2007-04-28 2010-03-31 美国弗劳恩霍夫股份有限公司 锥虫抗原、疫苗组合物和相关方法
JP5214723B2 (ja) 2007-04-30 2013-06-19 ナノゲン・インコーポレイテッド 多分析物アッセイ
US8629245B2 (en) * 2007-05-01 2014-01-14 Research Development Foundation Immunoglobulin Fc libraries
US20090053831A1 (en) 2007-05-01 2009-02-26 Cell Signaling Technology, Inc. Tyrosine phosphorylation sites
AU2008275513A1 (en) * 2007-05-02 2009-01-15 Emory University Enhancement of glycoprotein incorporation into virus-like particles
PT2164868E (pt) 2007-05-04 2015-08-04 Technophage Investigaçao E Desenvolvimento Em Biotecnologia Sa Domínios variáveis de anticorpos de coelho manipulados e suas utilizações
BRPI0811466A2 (pt) 2007-05-07 2014-10-14 Medimmune Llc Anticorpo anti-icos isolado, ácido nucleico, vetor, célula isolada, métodos para produzir um anticorpo, para tratar uma doença ou distúrbio, para tratar ou prevenir a rejeição em um paciente de transplante humano, para tratar uma malignidade de célula t em um ser humano, para esgotar células t que expressam icos em um paciente humano, para romper a arquitetura do centro germinal em um órgão linfóide secundário de um primata, para esgotar células b centrais germinais de órgão linfóide secundário de um primata, e para esgotar células b comutadas em classes circulantes em um primata, e, composição farmacêutica.
CA2687024A1 (en) 2007-05-09 2009-02-19 Burnham Institute For Medical Research Targeting host proteinases as a therapeutic strategy against viral and bacterial pathogens
US20110091377A1 (en) 2007-05-11 2011-04-21 The Johns Hopkins University Biomarkers for melanoma
EP2160403B1 (de) 2007-05-11 2018-08-08 Genzyme Corporation Verfahren zur herstellung eines sezernierten proteins
PT3072525T (pt) 2007-05-14 2018-04-20 Astrazeneca Ab Métodos para reduzir os níveis de basófilos
SI2173381T1 (sl) 2007-05-14 2014-01-31 Novimmune Sa Fc receptor-vezavni polipeptidi z modificiranimi efektorskimi funkcijami
WO2008144029A1 (en) 2007-05-14 2008-11-27 The University Of Chicago Antibody-light fusion products for cancer therapeutics
ES2541051T3 (es) * 2007-05-17 2015-07-15 Genentech, Inc. Estructuras cristalinas de fragmentos de neuropilina y complejos neuropilina-anticuerpo
DK2164514T3 (en) 2007-05-21 2017-02-27 Alderbio Holdings Llc Antibodies to IL-6 and its use
CN103298950B (zh) 2007-05-21 2015-01-21 健泰科生物技术公司 用于鉴定和治疗狼疮的方法和组合物
CN101688194B (zh) 2007-05-23 2013-09-11 Uab研究基金会 去毒的肺炎球菌神经氨酸酶及其用途
DK2164992T3 (en) * 2007-05-30 2016-08-15 Lpath Inc COMPOSITIONS AND METHODS FOR BONDING OF LYTHOPHOSPHATIC ACID
US20110064744A1 (en) * 2007-05-30 2011-03-17 Sabbadini Roger A Prevention and treatment of pain using antibodies to lysophosphatidic acid
PE20090329A1 (es) * 2007-05-30 2009-03-27 Abbott Lab Anticuerpos humanizados contra el globulomero ab(20-42) y sus usos
US20090232801A1 (en) * 2007-05-30 2009-09-17 Abbot Laboratories Humanized Antibodies Which Bind To AB (1-42) Globulomer And Uses Thereof
US9163091B2 (en) * 2007-05-30 2015-10-20 Lpath, Inc. Compositions and methods for binding lysophosphatidic acid
AU2008255352B2 (en) 2007-05-31 2014-05-22 Genmab A/S Stable IgG4 antibodies
PE20090321A1 (es) 2007-06-04 2009-04-20 Genentech Inc Anticuerpos anti-notch1 nrr, metodo de preparacion y composicion farmaceutica
AU2008262048B2 (en) * 2007-06-07 2013-09-26 Genentech, Inc. C3b antibodies and methods for the prevention and treatment of complement- associated disorders
MX2009012924A (es) 2007-06-08 2010-03-25 Australian Poultry Crc Pty Ltd Toxina clostridial netb.
WO2008154249A2 (en) 2007-06-08 2008-12-18 Genentech, Inc. Gene expression markers of tumor resistance to her2 inhibitor treatment
EP2171451A4 (de) 2007-06-11 2011-12-07 Abbott Biotech Ltd Verfahren zur behandlung juveniler idiopathischer arthritis
US7580304B2 (en) * 2007-06-15 2009-08-25 United Memories, Inc. Multiple bus charge sharing
WO2008151819A2 (en) 2007-06-15 2008-12-18 Deutsches Krebsforschungszentrum Stiftung des öffentlichen Rechts Treatment of tumors using specific anti-l1 antibody
CN103254308B (zh) 2007-06-15 2015-01-21 厦门大学 H5亚型禽流感病毒血凝素蛋白的单克隆抗体或其结合活性片段及其用途
PT2170959E (pt) 2007-06-18 2014-01-07 Merck Sharp & Dohme Anticorpos para o receptor humano de morte programada pd-1
EP2158221B1 (de) 2007-06-21 2018-08-29 MacroGenics, Inc. Kovalente diabodies und deren verwendung
US20080317768A1 (en) * 2007-06-21 2008-12-25 Boeing Company Bioconjugated nanoparticles
EP2173378B1 (de) 2007-06-27 2014-03-19 Admune Therapeutics LLC Komplexe von il-15 und il-15ralpha und ihre verwendungen
CA2691626A1 (en) * 2007-06-29 2009-01-08 Jiro Tanaka Pseudomonas aeruginosa-outer membrane protein pa4710
CL2008001887A1 (es) 2007-06-29 2008-10-03 Amgen Inc Proteinas de union a antigeno que se unen al receptor activado por proteasas 2 (par-2); acido nucleico que las codifica; vector y celula huesped; metodo de produccion; y composicion que las comprende.
ES2694018T3 (es) 2007-07-02 2018-12-17 Oncomed Pharmaceuticals, Inc. Composiciones y métodos para el tratamiento y el diagnóstico del cáncer
UA107557C2 (xx) 2007-07-06 2015-01-26 Композиція антитіла офатумумабу
EP2586788B1 (de) 2007-07-09 2017-11-29 Genentech, Inc. Verhindern der Disulfid-Bindungsreduktion während der rekombinanten Herstellung von Polypeptiden
US8404252B2 (en) 2007-07-11 2013-03-26 Fraunhofer Usa, Inc. Yersinia pestis antigens, vaccine compositions, and related methods
US10219780B2 (en) * 2007-07-12 2019-03-05 Volcano Corporation OCT-IVUS catheter for concurrent luminal imaging
PT2175884T (pt) 2007-07-12 2016-09-21 Gitr Inc Terapias de combinação empregando moléculas de ligação a gitr
AU2008275649B2 (en) 2007-07-12 2013-09-05 Sangamo Therapeutics, Inc. Methods and compositions for inactivating alpha 1,6 fucosyltransferase (FUT 8) gene expression
EP2014681A1 (de) 2007-07-12 2009-01-14 Pierre Fabre Medicament Neue Antikörper zur Hemmung der C-Met-Dimerisation und Verwendungen davon
CA2693651A1 (en) 2007-07-12 2009-01-15 Ronen Shemesh Bioactive peptides and method of using same
EP2178442B1 (de) 2007-07-12 2017-09-06 Volcano Corporation Katheter für in-vivo-bildgebung
US9596993B2 (en) 2007-07-12 2017-03-21 Volcano Corporation Automatic calibration systems and methods of use
IL184627A0 (en) 2007-07-15 2008-12-29 Technion Res & Dev Foundation Agents for diagnosing and modulating metastasis and fibrosis as well as inflammation in a mammalian tissue
AU2008277257B2 (en) 2007-07-15 2014-03-06 Hillman, Yitzchak Mr Disease treatment via antimicrobial peptides or their inhibitors
PT2474557E (pt) 2007-07-16 2014-12-03 Genentech Inc Anticorpos e imunoconjugados anti-cd79b e métodos de utilização
PE20140625A1 (es) 2007-07-16 2014-05-29 Genentech Inc ANTICUERPOS ANTI-CD79b E INMUNOCONJUGADOS HUMANIZADOS
WO2009020748A2 (en) 2007-07-16 2009-02-12 Avaxia Biologics, Inc. Antibody therapy for modulating function of intestinal receptors
CN101809033A (zh) 2007-07-25 2010-08-18 日本国立感染症研究所 对丙型肝炎病毒(hcv)感染具有抑制活性的抗体和其用途
EA017995B1 (ru) 2007-07-25 2013-04-30 Филоджен С.П.А. Антиген, связанный с вариантами рака легкого и лимфомами
EP2174667B1 (de) 2007-07-26 2017-01-04 Osaka University Mittel zur behandlung von augenentzündungen mit interleukin-6-rezeptorhemmer als wirkstoff
ES2498040T3 (es) 2007-07-27 2014-09-24 Janssen Alzheimer Immunotherapy Tratamiento de enfermedades amiloidogénicas con anticuerpos anti-beta humanizados
CN101952312A (zh) 2007-07-31 2011-01-19 米迪缪尼有限公司 多特异性表位结合蛋白及其应用
GB0714963D0 (en) 2007-08-01 2007-09-12 Novartis Ag Compositions comprising antigens
EP2023144A1 (de) * 2007-08-01 2009-02-11 Sanofi-Aventis Neues AS160-Protein, Testsysteme, Verfahren und Verwendungen bei der Identifizierung von Therapeutika gegen Typ-2-Diabetes
CA2693310C (en) 2007-08-02 2018-11-27 Arresto Biosciences, Inc. Lox and loxl2 inhibitors, antibodies and uses thereof
AU2007283667B2 (en) 2007-08-03 2014-09-04 Boehringer Ingelheim Vetmedica Gmbh Genes and proteins of Brachyspira hyodysenteriae and uses thereof
AU2008285626B2 (en) 2007-08-03 2013-09-12 Neuramedy Co., Ltd. Use of TLR-2 antagonists for treatment of reperfusion injury and tissue damage
EP2185688A4 (de) 2007-08-06 2010-08-25 Burnham Inst Medical Research Znf206: ein neuer regulator der selbsterneuerung und pluripotenz embryonaler stammzellen
US20090038182A1 (en) * 2007-08-09 2009-02-12 Lans Maris J Footwear with built-in scale
CN102083861B (zh) * 2007-08-13 2016-04-13 瓦斯基因治疗公司 使用结合EphB4的人源化抗体的癌症治疗
JP5532486B2 (ja) * 2007-08-14 2014-06-25 ルードヴィッヒ インスティテュート フォー キャンサー リサーチ Ｅｇｆ受容体を標的とするモノクローナル抗体１７５ならびにその誘導体および用途
BRPI0814479A2 (pt) 2007-08-15 2016-07-12 Yeda Res & Dev "método para regular uma atividade de metaloproteinase 9 (mm9), método para identificar um agente capaz de regular especificamente a mmp-9, método de tratar a afecção clínica mediada pela mmp-9, molécula capaz de regular especificamente uma atividade da mmp-9, anticorpo humanizado e composição farmacêutica"
US8501929B2 (en) 2007-08-17 2013-08-06 Biochrom Pharma Inc. PTHrP, its isoforms and antagonist thereto in the diagnosis and treatment of disease
US7897139B2 (en) 2007-08-17 2011-03-01 Biochrom Pharma, Inc. PTHrP, its isoforms and antagonist thereto in the diagnosis and treatment of disease
CA2696764A1 (en) * 2007-08-20 2009-02-26 Fraunhofer Usa, Inc. Prophylactic and therapeutic influenza vaccines, antigens, compositions, and methods
EP2860247A1 (de) 2007-08-21 2015-04-15 Nodality, Inc. Diagnose-, Prognose- und Behandlungsverfahren
JP5718640B2 (ja) 2007-08-21 2015-05-13 アムジエン・インコーポレーテツド ヒトｃ−ｆｍｓ抗原結合性タンパク質
EP2190861A4 (de) 2007-08-22 2011-03-30 Univ California Aktivierbare bindende polypeptide und verfahren zu deren identifikation und anwendung
WO2009026496A1 (en) * 2007-08-22 2009-02-26 University Of Southern California Grp78 and tumor angiogenesis
KR20100075452A (ko) 2007-08-24 2010-07-02 온코세라피 사이언스 가부시키가이샤 전립선암 치료 및 진단의 표적 유전자로서의 ｐｋｉｂ 및 ｎａａｌａｄｌ２
JP2010536367A (ja) 2007-08-24 2010-12-02 オンコセラピー・サイエンス株式会社 癌関連遺伝子、ｃｄｃａ５、ｅｐｈａ７、ｓｔｋ３１及びｗｄｈｄ１
US20090087860A1 (en) * 2007-08-24 2009-04-02 Todd John A Highly sensitive system and methods for analysis of prostate specific antigen (psa)
EP2190478B1 (de) 2007-08-24 2016-03-23 Oncotherapy Science, Inc. Dkk1-onkogen als therapeutisches ziel für krebs und diagnostischer marker
WO2009028580A1 (en) 2007-08-24 2009-03-05 Oncotherapy Science, Inc. Ebi3, dlx5, nptx1 and cdkn3 for target genes of lung cancer therapy and diagnosis
JP2010538005A (ja) * 2007-08-28 2010-12-09 ユーエービー リサーチ ファウンデーション 合成アポリポ蛋白質ｅ模倣ポリペプチドおよび使用方法
AU2008296487A1 (en) 2007-08-28 2009-03-12 The Uab Research Foundation Synthetic apolipoprotein E mimicking polypeptides and methods of use
PT2193142E (pt) * 2007-08-30 2015-04-22 Curedm Group Holdings Llc Composições e procedimentos de utilização de peptídeos pro-ilhota e seus análogos
WO2009030254A1 (en) 2007-09-04 2009-03-12 Curevac Gmbh Complexes of rna and cationic peptides for transfection and for immunostimulation
SI2769729T1 (sl) 2007-09-04 2019-06-28 Compugen Ltd. Polipeptidin in polinukleotidi in njihove uporabe kot tarča zdravila za izdelavo zdravil in bioloških zdravil
EP2033971A1 (de) * 2007-09-06 2009-03-11 Abbott GmbH & Co. KG Bone Morphogenetic Protein (BMP)-bindende Domänen von Proteinen der Repulsive Guidance Molecule (RGM) Proteinfamilie und funktionale Fragmente davon sowie deren Verwendung
GB0717337D0 (en) 2007-09-06 2007-10-17 Ucb Pharma Sa Method of treatment
US8287885B2 (en) 2007-09-12 2012-10-16 Novartis Ag GAS57 mutant antigens and GAS57 antibodies
US8877688B2 (en) 2007-09-14 2014-11-04 Adimab, Llc Rationally designed, synthetic antibody libraries and uses therefor
US12529164B2 (en) 2007-09-14 2026-01-20 Adimab, Llc Rationally designed, synthetic antibody libraries and uses therefor
JP5963341B2 (ja) * 2007-09-14 2016-08-10 アムジエン・インコーポレーテツド 均質な抗体集団
WO2009036379A2 (en) 2007-09-14 2009-03-19 Adimab, Inc. Rationally designed, synthetic antibody libraries and uses therefor
CA2699394C (en) 2007-09-17 2020-03-24 The Regents Of The University Of California Internalizing human monoclonal antibodies targeting prostate cancer cells in situ
TW200918553A (en) 2007-09-18 2009-05-01 Amgen Inc Human GM-CSF antigen binding proteins
WO2009039442A1 (en) * 2007-09-21 2009-03-26 California Institute Of Technology Nfia in glial fate determination, glioma therapy and astrocytoma treatment
DE102007045701B3 (de) * 2007-09-24 2009-05-14 Uhde Gmbh Gewinnung von Milchsäure durch Fermentation und Extraktion mit Aminen
US7695963B2 (en) * 2007-09-24 2010-04-13 Cythera, Inc. Methods for increasing definitive endoderm production
AU2008304615A1 (en) 2007-09-24 2009-04-02 Cornell University Immunogenic proteins from genome-derived outer membrane of leptospira and compositions and methods based thereon
EP3127921A1 (de) 2007-09-26 2017-02-08 Chugai Seiyaku Kabushiki Kaisha Verfahren zur modifizierung eines isoelektrischen punkts eines antikörpers über aminosäuresubstition in cdr
ES2687808T3 (es) 2007-09-26 2018-10-29 Chugai Seiyaku Kabushiki Kaisha Región constante de anticuerpo modificado
GB0718843D0 (en) 2007-09-26 2007-11-07 Cancer Rec Tech Ltd Materials and methods relating to modifying the binding of antibodies
EP2535350B1 (de) 2007-09-26 2018-01-24 UCB Biopharma SPRL Antikörperfusionen mit Doppelspezifität
WO2009041501A1 (ja) 2007-09-27 2009-04-02 Virus Ikagaku Kenkyusho Inc. ヘルペスウイルスの潜伏感染に関与する因子及びその利用
KR102069498B1 (ko) 2007-09-28 2020-01-23 포톨라 파마슈티컬스, 인코포레이티드 인자 Ｘａ 저해제에 대한 안티도트 및 그것을 사용하는 방법
KR20150126724A (ko) 2007-09-28 2015-11-12 추가이 세이야쿠 가부시키가이샤 혈장 중 반응속도가 개선된 항-글리피칸-3 항체
EP2365333B1 (de) 2007-10-01 2014-11-26 The University Of British Columbia Diagnostika mit Granzyme A
AU2008308761B2 (en) 2007-10-02 2014-10-16 Genentech, Inc. NLRR-1 antagonists and uses thereof
CN104297506B (zh) 2007-10-02 2017-05-03 赛拉诺斯股份有限公司 模块化现场护理装置及其应用
BRPI0817482B8 (pt) 2007-10-02 2021-05-25 Chugai Pharmaceutical Co Ltd uso de um anticorpo do receptor da interleucina-6 (il-6) no tratamento da doença do enxerto versus hospedeiro (gvhd)
WO2009046168A1 (en) * 2007-10-02 2009-04-09 Avaxia Biologics, Inc. Antibody therapy for use in the digestive tract
US8470560B2 (en) 2007-10-03 2013-06-25 The United States Of America As Represented By The Secretary Of The Army CR-2 binding peptide P28 as molecular adjuvant for DNA vaccines
GB0719231D0 (en) 2007-10-03 2007-11-14 Oxford Genome Sciences Uk Ltd Protein
CA2701189C (en) * 2007-10-11 2017-05-16 Biogen Idec Ma Inc. Methods for treating pressure induced optic neuropathy, preventing neuronal degeneration and promoting neuronal cell survival via administration of lingo-1 antagonists and trkb agonists
AR068767A1 (es) 2007-10-12 2009-12-02 Novartis Ag Anticuerpos contra esclerostina, composiciones y metodos de uso de estos anticuerpos para tratar un trastorno patologico mediado por esclerostina
EP2050764A1 (de) 2007-10-15 2009-04-22 sanofi-aventis Neues polyvalentes bispezifisches Antikörperformat und Verwendung
DK2233149T3 (en) 2007-10-16 2016-05-17 Zymogenetics Inc COMBINATION OF TRANSMEMBRANAKTIVATOR AND CALCIUM MODULATOR AND cyclophilin-LIGAND INTERAKTOR (TACI) AND ANTI-CD20 MEANS FOR TREATMENT OF AUTO-IMMUNE DISEASE
GB0720250D0 (en) 2007-10-17 2007-11-28 Univ Edinburgh Immunogenic compositions containing escherichia coli h7 flagella and methods of use thereof
JO3076B1 (ar) * 2007-10-17 2017-03-15 Janssen Alzheimer Immunotherap نظم العلاج المناعي المعتمد على حالة apoe
EP3072963B1 (de) 2007-10-18 2020-04-01 Cell Signaling Technology, Inc. Translokation und mutations-ros-kinase bei menschlichem nicht-kleinzelligem bronchialkarzinom
RU2010120674A (ru) * 2007-10-22 2011-11-27 Шеринг Корпорейшн (US) Полностью человеческие анти-vegf-антитела и способы их применения
KR20100089851A (ko) 2007-10-23 2010-08-12 노파르티스 아게 호흡기 질환의 치료를 위한 ｔｒｋｂ 항체의 용도
ES2601830T3 (es) 2007-10-23 2017-02-16 The Cleveland Clinic Foundation Apolipoproteína A-1 resistente a oxidantes y péptidos miméticos
FI20070808A0 (fi) 2007-10-25 2007-10-25 Mart Saarma GDNF:n silmukointivariantit ja niiden käytöt
WO2009055656A2 (en) 2007-10-26 2009-04-30 Centocor, Inc. Vectors, host cells, and methods of production and uses
US8361465B2 (en) * 2007-10-26 2013-01-29 Lpath, Inc. Use of anti-sphingosine-1-phosphate antibodies in combination with chemotherapeutic agents
EP2209805B1 (de) 2007-10-30 2017-09-06 Philogen S.p.A. Mit rheumatoider arthritis assoziiertes antigen
HUE024877T2 (en) 2007-10-30 2016-02-29 Genentech Inc Antibody purification by cation exchange chromatography
JP5759724B2 (ja) 2007-10-31 2015-08-05 アイデックス ラボラトリーズ インコーポレイテッド エーリキア・カニス（Ｅｈｒｌｉｃｈｉａｃａｎｉｓ）のＤＩＶＡ（ワクチン接種した動物から感染した動物を区別する）
PE20091163A1 (es) 2007-11-01 2009-08-09 Wyeth Corp Anticuerpos para gdf8
CA2704357C (en) 2007-11-02 2016-06-21 Novartis Ag Improved nogo-a binding molecules and pharmaceutical use thereof
MX2010004761A (es) 2007-11-02 2010-05-19 Novartis Ag Moleculas y metodos para modular la proteina relacionada con el receptor de lipoproteina de baja densidad 6 (lrp6).
AU2008324800B2 (en) 2007-11-05 2014-03-27 Astrazeneca Ab Methods of treating scleroderma
US8039212B2 (en) 2007-11-05 2011-10-18 Celera Corporation Genetic polymorphisms associated with liver fibrosis, methods of detection and uses thereof
KR101620642B1 (ko) 2007-11-07 2016-05-12 제넨테크, 인크. 항-ｃｄ４０ 항체를 사용한 치료에 대한 ｂ-세포 림프종의 반응성 평가를 위한 방법 및 조성물
US20090202475A1 (en) 2007-11-07 2009-08-13 Genentech, Inc. Compositions and methods for treatment of microbial disorders
WO2009061500A1 (en) * 2007-11-08 2009-05-14 Biogen Idec Ma Inc. Use of lingo-4 antagonists in the treatment of conditions involving demyelination
BRPI0820073A2 (pt) 2007-11-12 2015-06-23 U3 Pharma Gmbh Anticorpos anti-axl
AU2008321016B2 (en) * 2007-11-12 2013-03-28 Theraclone Sciences, Inc. Compositions and methods for the therapy and diagnosis of influenza
US20110033476A1 (en) * 2007-11-12 2011-02-10 Theraclone Sciences Inc. Compositions and methods for the therapy and diagnosis of influenza
EP3211011A1 (de) 2007-11-16 2017-08-30 Nuvelo, Inc. Antikörper gegen lrp6
US8637435B2 (en) * 2007-11-16 2014-01-28 Merck Sharp & Dohme Corp. Eukaryotic cell display systems
CA2705486C (en) 2007-11-19 2019-04-02 Celera Corporation Lung cancer markers and uses thereof
US8541543B2 (en) * 2007-11-20 2013-09-24 Academia Sinica Peptides specific for hepatocellular carcinoma cells and applications thereof
BRPI0819743A2 (pt) 2007-11-20 2014-10-07 Pioneer Hi Bred Int Ácido nucléico isolado, cassete de expressão, célula hospedeira, planta transgênica, semente transgênica, método para modular a resposta de etileno em uma planta, proteína isolada
US20090203043A1 (en) 2007-11-21 2009-08-13 Peter Hornbeck Protein phosphorylation by basophilic serine/threonine kinases in insulin signaling pathways
EP2225275A4 (de) * 2007-11-28 2013-04-03 Medimmune Llc Proteinformulierung
WO2015164330A1 (en) 2014-04-21 2015-10-29 Millennium Pharmaceuticals, Inc. Anti-psyk antibody molecules and use of same for syk-targeted therapy
AU2008334095A1 (en) 2007-11-29 2009-06-11 Genentech, Inc. Gene expression markers for inflammatory bowel disease
ES2372236T3 (es) 2007-11-30 2012-01-17 Genentech, Inc. Polimorfismos de vegf y terapia anti-angiogénesis.
TWI468417B (zh) 2007-11-30 2015-01-11 Genentech Inc 抗－ｖｅｇｆ抗體
US8420081B2 (en) 2007-11-30 2013-04-16 Abbvie, Inc. Antibody formulations and methods of making same
US8883146B2 (en) 2007-11-30 2014-11-11 Abbvie Inc. Protein formulations and methods of making same
WO2009070350A1 (en) 2007-11-30 2009-06-04 Siemens Healthcare Diagnostics Inc. Adiponectin receptor fragments and methods of use
WO2010070380A2 (en) * 2007-12-03 2010-06-24 The Government Of The United States Of America, As Represented By The Secretary, Department Of Health Of Human Services, National Institutes Of Health Doc1 compositions and methods for treating cancer
TWI548418B (zh) 2007-12-05 2016-09-11 中外製藥股份有限公司 Anti-NR10 / IL-31RA antibody and its use
WO2009079242A2 (en) 2007-12-05 2009-06-25 Massachusetts Institute Of Technology Aglycosylated immunoglobulin mutants
GB0723797D0 (en) * 2007-12-05 2008-01-16 Immunosolv Ltd Method
EP3524619A1 (de) 2007-12-06 2019-08-14 Dana-Farber Cancer Institute, Inc. Antikörper gegen influenzavirus und verfahren zur verwendung davon
GB0724051D0 (en) * 2007-12-08 2008-01-16 Medical Res Council Mutant proteins and methods for producing them
WO2009075344A1 (ja) 2007-12-12 2009-06-18 Japan As Represented By Director General Of Agency Of National Cancer Center M-csf受容体を分子標的とするmll白血病及びmoz白血病治療剤、およびその利用
JP5737944B2 (ja) 2007-12-17 2015-06-17 ファイザー・リミテッドＰｆｉｚｅｒ Ｌｉｍｉｔｅｄ 間質性膀胱炎の治療
CN105732813A (zh) 2007-12-18 2016-07-06 生物联合公司 识别癌细胞上表达的cd-43和cea的含糖表位的抗体及其使用方法
ES2626634T3 (es) 2007-12-19 2017-07-25 The Henry M. Jackson Foundation For The Advancement Of Military Medicine, Inc. Formas solubles de la glucoproteína F del virus de Hendra y Nipah y usos de la misma
RU2018100129A (ru) 2007-12-20 2019-02-20 Ксома (Сша) Ллс Способы лечения подагры
GB0724860D0 (en) 2007-12-20 2008-01-30 Heptares Therapeutics Ltd Screening
US8092804B2 (en) 2007-12-21 2012-01-10 Medimmune Limited Binding members for interleukin-4 receptor alpha (IL-4Rα)-173
NZ586430A (en) 2007-12-21 2012-09-28 Novartis Ag Mutant forms of streptolysin o (slo)
MX2010006735A (es) 2007-12-21 2010-09-30 Medimmune Ltd Miembros de union para receptor alfa de interleucina-4 (il-4ra) - 173.
WO2009085200A2 (en) 2007-12-21 2009-07-09 Amgen Inc. Anti-amyloid antibodies and uses thereof
US20100291070A1 (en) 2007-12-25 2010-11-18 Meiji Seika Kaisha, Ltd. Type iii secretion system component protein pa1698 of pseudomonas aeruginosa
KR101616758B1 (ko) 2007-12-26 2016-04-29 젠코어 인코포레이티드 ＦｃＲｎ에 대한 변경된 결합성을 갖는 Ｆｃ 변이체
NZ586544A (en) * 2007-12-26 2012-07-27 Vaccinex Inc Anti-c35 antibody in combination with an ani-her2 antibody in cancer therapies and methods
WO2009086514A1 (en) 2007-12-28 2009-07-09 Dana-Farber Cancer Institute, Inc. Humanized monoclonal antibodies and methods of use
WO2009086539A2 (en) 2007-12-28 2009-07-09 Elan Pharmaceuticals, Inc. Treatment and prophylaxis of amyloidosis
EP2077281A1 (de) 2008-01-02 2009-07-08 Bergen Teknologioverforing AS Anti-CD20-Antikörper oder Fragmente davon zur Behandlung von chronischen Ermüdungssyndrom
US7914785B2 (en) * 2008-01-02 2011-03-29 Bergen Teknologieverforing As B-cell depleting agents, like anti-CD20 antibodies or fragments thereof for the treatment of chronic fatigue syndrome
CA2711394A1 (en) 2008-01-11 2009-07-16 Synovex Corporation Cadherin-11 antagonists and methods for the treatment of inflammatory joint disorders
EP2388323B1 (de) 2008-01-11 2016-04-13 Gene Techno Science Co., Ltd. Humanisierte Anti-9-Integrinantikörper und Verwendungen davon
CA2711370C (en) 2008-01-15 2017-06-13 The Board Of Trustees Of The Leland Stanford Junior University Markers of acute myeloid leukemia stem cells
EP2085095B1 (de) 2008-01-17 2012-03-07 Philogen S.p.A. Kombination aus einem Anti-EDb-Fibronectin-Antikörper-IL-2-Fusionsprotein und einem B-Zellen bindenden Molekül, B-Zellen-Vorläufern und/oder deren krebserregendem Gegenspieler
KR20100107501A (ko) 2008-01-18 2010-10-05 메디뮨 엘엘씨 부위 특이적 접합을 위한 시스테인 조작 항체
CA2710398A1 (en) 2008-01-18 2009-10-15 Genentech, Inc. Methods and compositions for targeting polyubiquitin
WO2009093246A2 (en) * 2008-01-22 2009-07-30 Compugen Ltd. Novel clusterin derived peptide
MX2010007935A (es) 2008-01-24 2010-08-23 Novo Nordisk As Anticuerpo monoclonal humanizado anti-nkg2a humano.
KR101720760B1 (ko) 2008-01-25 2017-03-28 오르후스 우니베르시테트 Ｉｇｆｂｐ-4에 대한 ｐａｐｐ-ａ 활성의 선택적 엑소사이트 억제
US20090233295A1 (en) * 2008-01-29 2009-09-17 Elias Georges Trim59 directed diagnostics for neoplastic disease
US9090875B2 (en) 2008-01-29 2015-07-28 Fred Hutchinson Cancer Research Center Identifcation of CD8+ T cells that are CD161hi and/or IL18Rαhi and have rapid drug efflux capacity
TWI472339B (zh) 2008-01-30 2015-02-11 Genentech Inc 包含結合至ｈｅｒ２結構域ii之抗體及其酸性變異體的組合物
DK2657253T3 (en) 2008-01-31 2017-10-09 Genentech Inc Anti-CD79b antibodies and immune conjugates and methods of use
AU2009208607B2 (en) * 2008-01-31 2013-08-01 Compugen Ltd. Polypeptides and polynucleotides, and uses thereof as a drug target for producing drugs and biologics
EP3153526B1 (de) 2008-01-31 2020-09-23 INSERM - Institut National de la Santé et de la Recherche Médicale Antikörper gegen humanes cd39 und verwendung davon zur hemmung der regulatorischen t-zell-aktivität
WO2009100110A1 (en) 2008-02-05 2009-08-13 Medarex, Inc. Alpha 5 - beta 1 antibodies and their uses
MX2010008578A (es) 2008-02-08 2010-11-10 Medimmune Llc Anticuerpos anti-receptor 1 de interferon alfa con afinidad reducida al ligando fc.
GB0802474D0 (en) * 2008-02-11 2008-03-19 Heptares Therapeutics Ltd Mutant proteins and methods for selecting them
EP2245153A4 (de) * 2008-02-13 2011-06-22 Dyax Corp Verbesserte verfahren zur herstellung spezifischer bindungspaare
US8461310B2 (en) 2008-02-14 2013-06-11 Gene Techno Science Co., Ltd. Anti-ADAM-15 antibodies and utilization of the same
US20090221620A1 (en) 2008-02-20 2009-09-03 Celera Corporation Gentic polymorphisms associated with stroke, methods of detection and uses thereof
JO2913B1 (en) 2008-02-20 2015-09-15 امجين إنك, Antibodies directed towards angiopoietin-1 and angiopoietin-2 proteins and their uses
US12492253B1 (en) 2008-02-25 2025-12-09 Xencor, Inc. Anti-human C5 antibodies
ES2553390T3 (es) 2008-02-25 2015-12-09 Nestec S.A. Método para la detección de receptores truncados intracelulares
EP2363407A1 (de) 2008-02-28 2011-09-07 Murdoch University Neuartige Brachyspira-Sequenzen, immunogene Zusammensetzungen, Herstellungsverfahren dafür und Verwendung davon
US20090220991A1 (en) * 2008-02-29 2009-09-03 Cell Signaling Technology, Inc. Reagents for the detection of protein phosphorylation in leukemia signaling pathways
US8962803B2 (en) 2008-02-29 2015-02-24 AbbVie Deutschland GmbH & Co. KG Antibodies against the RGM A protein and uses thereof
JP2011514161A (ja) * 2008-02-29 2011-05-06 ラモット・アット・テル・アビブ・ユニバーシテイ・リミテッド 免疫グロブリン組成物およびその製造方法
CA2715212A1 (en) 2008-03-03 2009-09-11 Glycofi, Inc. Surface display of recombinant proteins in lower eukaryotes
KR101304150B1 (ko) 2008-03-04 2013-09-05 라브리스 바이올로직스 인코포레이티드 만성 통증의 치료 방법
EP2098536A1 (de) 2008-03-05 2009-09-09 4-Antibody AG Isolation und Identifikation antigen- oder ligandenspezifischer Bindungsproteine
US20110112037A1 (en) * 2008-03-05 2011-05-12 Heptares Therapeutics Limited BioPark Crystal structure
WO2009111644A2 (en) * 2008-03-05 2009-09-11 The Regents Of The University Of Michigan Compositions and methods for diagnosing and treating pancreatic cancer
CL2009000545A1 (es) * 2008-03-06 2010-10-15 Genentech Inc Uso de un antagonista de c-met y un antagonista de her para el tratamiento de cancer.
JP5544309B2 (ja) 2008-03-10 2014-07-09 セラクローン サイエンシーズ， インコーポレイテッド サイトメガロウイルス感染の治療および診断のための組成物および方法
CN102037014A (zh) 2008-03-12 2011-04-27 奥塔哥创新有限公司 生物标记物
JP2011512877A (ja) * 2008-03-12 2011-04-28 ワイス・エルエルシー 組換えタンパク質の大スケール産生に適した細胞を同定する方法
AU2009224114B2 (en) 2008-03-12 2013-02-21 Otago Innovation Limited Biomarkers
MY155049A (en) 2008-03-14 2015-08-28 Allergan Inc Immuno-based botolinum toxin serotype a activity assay
WO2009117531A1 (en) 2008-03-18 2009-09-24 Seattle Genetics, Inc. Auristatin drug linker conjugates
US20110020368A1 (en) 2008-03-25 2011-01-27 Nancy Hynes Treating cancer by down-regulating frizzled-4 and/or frizzled-1
EP2105742A1 (de) * 2008-03-26 2009-09-30 Sanofi-Aventis Verwendung von Kathepsin-C
JPWO2009119794A1 (ja) 2008-03-27 2011-07-28 タカラバイオ株式会社 感染症予防、治療剤
AU2009227986C1 (en) 2008-03-27 2014-06-19 Murdoch University Novel sequences of Brachyspira, immunogenic compositions, methods for preparation and use thereof
JP5425180B2 (ja) 2008-03-27 2014-02-26 ザイモジェネティクス， インコーポレイテッド ＰＤＧＦＲβおよびＶＥＧＦ−Ａを阻害するための組成物および方法
NZ601815A (en) 2008-03-31 2014-10-31 Genentech Inc Compositions and methods for treating and diagnosing asthma
CN106349390B (zh) 2008-04-02 2019-12-10 宏观基因有限公司 Bcr-复合体-特异性抗体和其使用方法
WO2009146099A2 (en) 2008-04-02 2009-12-03 Georgia State University Research Foundation, Inc. Contrast agents, methods for preparing contrast agents, and methods of imaging
SG189730A1 (en) 2008-04-02 2013-05-31 Macrogenics Inc Her2/neu-specific antibodies and methods of using same
CN102066552B (zh) 2008-04-04 2014-03-12 麻省理工学院 细胞法产生葡糖二酸
WO2009124294A2 (en) * 2008-04-05 2009-10-08 Lpath, Inc. Pharmaceutical compositions for binding sphingosine-1-phosphate
WO2009126688A2 (en) 2008-04-09 2009-10-15 Genentech, Inc. Novel compositions and methods for the treatment of immune related diseases
AU2009234389B2 (en) 2008-04-10 2014-08-21 Cell Signaling Technology, Inc. Compositions and methods for detecting EGFR mutations in cancer
JP2011522515A (ja) 2008-04-10 2011-08-04 マサチューセッツ インスティテュート オブ テクノロジー 癌幹細胞を標的とする薬剤を同定する方法およびその使用
JP5639039B2 (ja) 2008-04-11 2014-12-10 メリマック ファーマシューティカルズ インコーポレーティッド ヒト血清アルブミンリンカーおよびそのコンジュゲート
NZ603059A (en) * 2008-04-11 2014-07-25 Emergent Product Dev Seattle Cd37 immunotherapeutic and combination with bifunctional chemotherapeutic thereof
TW201920257A (zh) 2008-04-11 2019-06-01 日商中外製藥股份有限公司 重複結合複數個抗原的抗原結合分子
JP2011516609A (ja) * 2008-04-14 2011-05-26 アブラクシス バイオサイエンス リミテッド ライアビリティー カンパニー Ｓｐａｒｃ抗炎症活性及びその使用
AU2008201871A1 (en) * 2008-04-16 2009-11-26 Deutsches Krebsforschungszentrum Stiftung Des Oeffentlichen Rechts Inhibition of angiogenesis and tumor metastasis
EP3062106B1 (de) 2008-04-16 2020-11-11 The Johns Hopkins University Verfahren zur bestimmung von varianten des andorgen rezeptors in prostatakrebs
GB0807018D0 (en) * 2008-04-17 2008-05-21 Fusion Antibodies Ltd Antibodies and treatment
GB0807161D0 (en) * 2008-04-18 2008-05-21 Danisco Process
ES2651924T3 (es) 2008-04-18 2018-01-30 The General Hospital Corporation Inmunoterapias que emplean vacunas autoensamblantes
ES2421719T3 (es) 2008-04-21 2013-09-05 Bio Rad Laboratories Antígeno de gliadina recombinante desamidada
KR101746861B1 (ko) 2008-04-24 2017-06-14 가부시키가이샤 진 테크노 사이언스 세포 외 기질 단백질의 아미노산 서열 ｒｇｄ에 특이적인 인간화된 항체 및 그의 용도
US20090269786A1 (en) * 2008-04-25 2009-10-29 The Board Of Trustees Of The University Of Illinois RHO1-Gamma Amino Butyric Acid C Receptor-Specific Antibodies
KR101824512B1 (ko) 2008-04-28 2018-02-02 휴머니건, 아이엔씨. 과립구-대식세포 콜로니 자극 인자에 대한 항체
CR20170001A (es) 2008-04-28 2017-08-10 Genentech Inc Anticuerpos anti factor d humanizados
US20100260668A1 (en) * 2008-04-29 2010-10-14 Abbott Laboratories Dual Variable Domain Immunoglobulins and Uses Thereof
US20090274696A1 (en) * 2008-04-29 2009-11-05 Wyeth Methods for treating inflammation
EP2282769A4 (de) 2008-04-29 2012-04-25 Abbott Lab Dual-variable- domain-immunglobuline und ihre verwendungen
WO2009133464A2 (en) 2008-04-30 2009-11-05 Danisco A/S Oxidation process
FI20080326A0 (fi) 2008-04-30 2008-04-30 Licentia Oy Neurotroofinen tekijä MANF ja sen käytöt
US20110229460A1 (en) * 2008-05-01 2011-09-22 Gtc Biotherapeutics, Inc. anti-cd137 antibody as an agent in the treatment of inflammatory conditions
PL2282773T3 (pl) 2008-05-02 2014-08-29 Seattle Genetics Inc Sposoby i kompozycje do wytwarzania przeciwciał i pochodnych przeciwciał o obniżonej fukozylacji rdzeniowej
HRP20161580T1 (hr) 2008-05-06 2016-12-30 Genentech, Inc. CRIg-VARIJANTE S RAZVIJENIM AFINITETOM
EP2116261A1 (de) 2008-05-07 2009-11-11 Institut Pasteur Unterbereich eines Plasmodium-Proteins mit verbessertem Impfstoff-Potenzial und medizinische Verwendungen davon
ES2354661B1 (es) 2008-05-08 2012-02-01 Consejo Superior De Investigaciones Científicas (Csic) Método para generar anticuerpos monoclonales que reconocen antígenos de membrana de células progenitoras neurales, anticuerpos producidos por dicho método, y usos.
EP2116555A1 (de) 2008-05-08 2009-11-11 Bayer Schering Pharma Aktiengesellschaft Verwendung eines spezifisch an ED-B Fibronectin bindenden radioaktiv markierten Moleküls bei einem Verfahren zur Behandlung von Hodgkin-Lymphom
EP2281057B1 (de) 2008-05-09 2013-12-25 Akonni Biosystems Mikroarray-system
US8680025B2 (en) * 2008-05-09 2014-03-25 Akonni Biosystems, Inc. Microarray system
CN102089430B (zh) 2008-05-09 2015-02-04 Abbvie公司 针对渐进性糖化终极产物受体(rage)的抗体及其用途
PT2119726E (pt) 2008-05-14 2015-03-30 Immatics Biotechnologies Gmbh Novos e poderosos peptídeos para mhc classe ii derivados de survinina e neurocano
US20110111417A1 (en) 2008-05-14 2011-05-12 Millennium Pharmaceuticals, Inc. Methods and kits for monitoring the effects of immunomodulators on adaptive immunity
AU2009246166B2 (en) 2008-05-15 2014-09-18 Tetherex Pharmaceuticals Corporation Anti-PSGL-1 antibodies and methods of identification and use
WO2009140684A2 (en) * 2008-05-16 2009-11-19 Genentech, Inc. Use of biomarkers for assessing treatment of gastrointestinal inflammatory disorders with beta7integrin antagonists
US9650639B2 (en) 2008-05-19 2017-05-16 Advaxis, Inc. Dual delivery system for heterologous antigens
US9017660B2 (en) 2009-11-11 2015-04-28 Advaxis, Inc. Compositions and methods for prevention of escape mutation in the treatment of Her2/neu over-expressing tumors
JP5757863B2 (ja) 2008-05-19 2015-08-05 アドバクシス インコーポレイテッド 異種抗原のための二重送達システム
US8082730B2 (en) * 2008-05-20 2011-12-27 Caterpillar Inc. Engine system having particulate reduction device and method
US8093018B2 (en) 2008-05-20 2012-01-10 Otsuka Pharmaceutical Co., Ltd. Antibody identifying an antigen-bound antibody and an antigen-unbound antibody, and method for preparing the same
US20090291073A1 (en) * 2008-05-20 2009-11-26 Ward Keith W Compositions Comprising PKC-theta and Methods for Treating or Controlling Ophthalmic Disorders Using Same
AU2009256397B2 (en) 2008-05-29 2014-06-05 The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Expression and assembly of human group C rotavirus-like particles and uses thereof
EP2304439A4 (de) 2008-05-29 2012-07-04 Nuclea Biotechnologies Llc Anti-phospho-akt-antikörper
EP2297209A4 (de) * 2008-06-03 2012-08-01 Abbott Lab Dual-variable- domain-immunglobuline und ihre verwendungen
KR20110016959A (ko) 2008-06-03 2011-02-18 아보트 러보러터리즈 이원 가변 도메인 면역글로불린 및 이의 용도
WO2010033279A2 (en) 2008-06-04 2010-03-25 Macrogenics, Inc. Antibodies with altered binding to fcrn and methods of using same
SG193860A1 (en) 2008-06-04 2013-10-30 Amgen Inc Fgf21 mutants and uses thereof
TW201503898A (zh) 2008-06-05 2015-02-01 Chugai Pharmaceutical Co Ltd 神經浸潤抑制劑
JP5763530B2 (ja) 2008-06-10 2015-08-12 サンガモ バイオサイエンシーズ， インコーポレイテッド Ｂａｘ−およびＢａｋ−欠損細胞株の生成のための方法および組成物
WO2009151514A1 (en) * 2008-06-11 2009-12-17 Millipore Corporation Stirred tank bioreactor
WO2009150623A1 (en) 2008-06-13 2009-12-17 Pfizer Inc Treatment of chronic prostatitis
JP2011524179A (ja) 2008-06-16 2011-09-01 パトリス リミテッド Ｌｍ−１抗体、機能性フラグメント、ｌｍ−１標的抗原、ならびにそれらを作製および使用するための方法
WO2009154770A2 (en) 2008-06-18 2009-12-23 The Texas A & M University System Mesenchymal stem cells, compositions, and methods for treatment of cardiac tissue damage
WO2009155484A2 (en) 2008-06-20 2009-12-23 Wyeth Compositions and methods of use of orf1358 from beta-hemolytic streptococcal strains
WO2009156994A1 (en) * 2008-06-24 2009-12-30 Hadasit Medical Research Services And Development Ltd. Ccl20-specific antibodies for cancer therapy
ES2464459T3 (es) 2008-06-25 2014-06-02 H. Lundbeck A/S Modulación del sistema receptor Trpv:receptor de dominio Vps 10p para el tratamiento del dolor
EP2307571A4 (de) * 2008-06-26 2012-03-07 Univ South Florida Nachweis- und sensibilisierungsverfahren zur platinresistenz von krebserkrankungen
EP2138511A1 (de) 2008-06-27 2009-12-30 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. HER3 als Determinante für eine Melanomprognose
WO2009158432A2 (en) 2008-06-27 2009-12-30 Amgen Inc. Ang-2 inhibition to treat multiple sclerosis
CA2729403A1 (en) 2008-06-30 2010-01-07 Oncotherapy Science, Inc. Anti-cdh3 antibodies labeled with radioisotope label and uses thereof
US8685399B2 (en) * 2008-06-30 2014-04-01 Dako Denmark A/S PAX 5 monoclonal antibody
EP2313507A2 (de) * 2008-07-03 2011-04-27 Pfenex Inc Screening-verfahren mit hohem durchsatz und verwendung davon zur identifizierung einer produktionsplattform für ein multifunktionelles bindungsprotein
FR2933702A1 (fr) * 2008-07-08 2010-01-15 Sanofi Aventis Antagonistes specifiques du recepteur fgf-r4
CN102112490B (zh) 2008-07-08 2014-10-22 昂考梅德药品有限公司 Notch1受体结合剂和其使用方法
US8822645B2 (en) * 2008-07-08 2014-09-02 Abbvie Inc. Prostaglandin E2 dual variable domain immunoglobulins and uses thereof
KR20110040886A (ko) 2008-07-08 2011-04-20 아보트 러보러터리즈 프로스타글란딘 ｅ2 결합 단백질 및 이의 용도
US8067339B2 (en) * 2008-07-09 2011-11-29 Merck Sharp & Dohme Corp. Surface display of whole antibodies in eukaryotes
EP2310525B1 (de) 2008-07-09 2014-02-26 Celera Corporation Mit herz-kreislauf-erkrankungen assoziierte genetische polymorphismen, nachweisverfahren und ihre verwendung
EP2315779A2 (de) 2008-07-09 2011-05-04 Biogen Idec MA Inc. Antikörper gegen lingo oder fragmente davon enthaltende zusammensetzungen
DK2318832T3 (da) 2008-07-15 2014-01-20 Academia Sinica Glycan-arrays på PTFE-lignende aluminiumcoatede objektglas og relaterede fremgangsmåder
US7981627B2 (en) * 2008-07-17 2011-07-19 Ramot At Tel-Aviv University Ltd. Methods for diagnosing and monitoring liver diseases
US8148088B2 (en) * 2008-07-18 2012-04-03 Abgent Regulation of autophagy pathway phosphorylation and uses thereof
EP2323679A4 (de) 2008-07-25 2012-08-22 Univ Colorado Clip-hemmer und verfahren zur modulierung der immunfunktion
CA2732715C (en) 2008-08-01 2015-04-07 Kusuki Nishioka Treatment agent or preventative agent for osteoarthritis
PY09026846A (es) 2008-08-05 2015-09-01 Novartis Ag Composiciones y métodos para anticuerpos que se dirigen a la proteína de complemento c5
EP2307443B1 (de) * 2008-08-07 2013-10-02 Yeda Research And Development Company Ltd. Affinitätsreinigung mittels cohesin-dockerin-interaktion
AR072999A1 (es) 2008-08-11 2010-10-06 Medarex Inc Anticuerpos humanos que se unen al gen 3 de activacion linfocitaria (lag-3) y los usos de estos
WO2010019702A2 (en) 2008-08-12 2010-02-18 Oncomed Pharmaceuticals, Inc. Ddr1-binding agents and methods of use thereof
JP5529869B2 (ja) * 2008-08-14 2014-06-25 メルク・シャープ・アンド・ドーム・コーポレーション プロテインａアフィニティークロマトグラフィーを用いる抗体の精製方法
HUE066562T2 (hu) 2008-08-14 2024-08-28 Genentech Inc Eljárások szennyezés eltávolítására indigén fehérje kiszorításos ioncserés membrán kromatográfia alkalmazásával
AU2008360658B2 (en) 2008-08-15 2015-02-19 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services S0X9, prostaglandin D2 and retinoic acid for treating pigmentary conditions and melanoma
SG10201601279SA (en) 2008-08-18 2016-03-30 Mesoblast Inc Monoclonal Antibody STRO-4
JP5908725B2 (ja) 2008-08-22 2016-04-26 サンガモ バイオサイエンシーズ， インコーポレイテッド 標的一本鎖開裂および標的組込みのための方法、並びに組成物
US20120128684A1 (en) 2008-08-25 2012-05-24 Burnham Institute For Medical Research Conserved Hemagglutinin Epitope, Antibodies to the Epitope and Methods of Use
US8784825B2 (en) 2008-08-28 2014-07-22 Taiga Biotechnologies, Inc. Modulators of MYC, methods of using the same, and methods of identifying agents that modulate MYC
US8790642B2 (en) 2008-08-29 2014-07-29 Genentech, Inc. Cross-reactive and bispecific anti-IL-17A/F antibodies
AR073538A1 (es) 2008-09-03 2010-11-17 Genentech Inc Anticuerpos multiespecificos que se unen especificamente al receptor del factor de crecimiento epidermico humano 2 (her2) y al factor de crecimiento endotelial vascular (vegf)
WO2010027364A1 (en) 2008-09-07 2010-03-11 Glyconex Inc. Anti-extended type i glycosphingolipid antibody, derivatives thereof and use
EP2684570A1 (de) 2008-09-10 2014-01-15 F. Hoffmann-La Roche AG Zusammensetzungen und Verfahren zur Prävention des oxidativen Abbaus von Proteinen
AU2009291747B2 (en) 2008-09-10 2016-05-26 Genentech, Inc. Methods for inhibiting ocular angiogenesis
AU2009290544B2 (en) * 2008-09-12 2015-07-16 Oxford University Innovation Limited PD-1 specific antibodies and uses thereof
TWI445716B (zh) 2008-09-12 2014-07-21 Rinat Neuroscience Corp Ｐｃｓｋ９拮抗劑類
AU2009290543B2 (en) * 2008-09-12 2015-09-03 Oxford University Innovation Limited PD-1 specific antibodies and uses thereof
AR073295A1 (es) 2008-09-16 2010-10-28 Genentech Inc Metodos para tratar la esclerosis multiple progresiva. articulo de fabricacion.
WO2010031749A1 (en) 2008-09-17 2010-03-25 Innate Pharma Compositions and methods for detecting tlr3
SI2331090T1 (en) 2008-09-19 2018-04-30 Pfizer Inc. Stable liquid antibody formulation
US8937046B2 (en) 2008-09-22 2015-01-20 The Regents Of The University Of Colorado, A Body Corporate Modulating the alternative complement pathway
EP2353008A2 (de) 2008-09-22 2011-08-10 Oregon Health and Science University Verfahren zum nachweis einer infektion mit mycobacterium tuberculosis
WO2010039533A2 (en) 2008-09-23 2010-04-08 Wyeth Methods for predicting production of activating signals by cross-linked binding proteins
EP2334300B1 (de) * 2008-09-24 2016-02-17 The Provost, Fellows, Foundation Scholars, & the other members of Board, of the College of the Holy & Undiv. Trinity of Queen Elizabeth near Dublin Zusammensetzung und verfahren zur behandlung von vorzeitigen wehen
WO2010036959A2 (en) 2008-09-26 2010-04-01 Dana-Farber Cancer Institute Human anti-pd-1, pd-l1, and pd-l2 antibodies and uses therefor
WO2010037046A1 (en) 2008-09-28 2010-04-01 Fraunhofer Usa, Inc. Humanized neuraminidase antibody and methods of use thereof
WO2010037408A1 (en) 2008-09-30 2010-04-08 Curevac Gmbh Composition comprising a complexed (m)rna and a naked mrna for providing or enhancing an immunostimulatory response in a mammal and uses thereof
WO2010038610A1 (ja) 2008-09-30 2010-04-08 オリエンタル酵母工業株式会社 新しい軟骨細胞増殖及び分化誘導剤
GB0817891D0 (en) 2008-09-30 2008-11-05 Medical Res Council Antibodies against il-25
ES2536465T3 (es) 2008-10-01 2015-05-25 Immatics Biotechnologies Gmbh Composición de péptidos tumor-asociados y relacionados con la vacuna contra el cáncer para el tratamiento de glioblastoma (GBM) y otros cánceres
US20100082438A1 (en) * 2008-10-01 2010-04-01 Ronnie Jack Garmon Methods and systems for customer performance scoring
EP2679238A1 (de) 2008-10-02 2014-01-01 Celtaxsys, INC. Verfahren zur Modulation der negativen Chemotaxis von Immunzellen
JP2012504961A (ja) 2008-10-06 2012-03-01 ミネルバ バイオテクノロジーズ コーポレーション Ｍｕｃ１＊抗体
EP2346532B1 (de) * 2008-10-07 2020-10-07 Bracco Suisse SA Target-konstrukt mit einem anti-polymer-antikörper und an diesen bindende mikrovesikel
US8481033B2 (en) 2008-10-07 2013-07-09 INSERM (Institute National de la Santé et de la Recherche Médicale) Neutralizing antibodies and fragments thereof directed against platelet factor-4 variant 1 (PF4V1)
KR20160017117A (ko) 2008-10-09 2016-02-15 미네르바 바이오테크놀로지 코포레이션 세포내에서 다능성을 유도하기 위한 방법
NZ592009A (en) 2008-10-10 2012-11-30 Amgen Inc Fgf21 mutants and uses thereof
SMT202000101T1 (it) 2008-10-10 2020-03-13 Childrens Medical Center Vaccino con trimero di env di hiv-1 stabilizzato biochimicamente
WO2010042933A2 (en) 2008-10-10 2010-04-15 Northwestern University Inhibition and treatment of prostate cancer metastasis
AU2009303526B2 (en) 2008-10-14 2015-01-15 Genentech, Inc. Immunoglobulin variants and uses thereof
CA2932207A1 (en) 2008-10-20 2010-12-09 Abbvie Inc. Isolation and purification of antibodies using protein a affinity chromatography
CA2741089A1 (en) 2008-10-22 2010-04-29 Genentech, Inc. Modulation of axon degeneration
WO2010048615A2 (en) 2008-10-24 2010-04-29 The Government Of The United States Of America As Represented By The Secretary, Department Of Health & Human Services, Center For Disease Control And Prevention Human ebola virus species and compositions and methods thereof
US8871202B2 (en) 2008-10-24 2014-10-28 Lpath, Inc. Prevention and treatment of pain using antibodies to sphingosine-1-phosphate
US8168756B2 (en) 2008-10-24 2012-05-01 Ark Diagnostics, Inc. Levetiracetam immunoassays
RU2481824C2 (ru) 2008-10-29 2013-05-20 Аблинкс Н.В Препараты однодоменных антигенсвязывающих молекул
CN105646643A (zh) 2008-10-29 2016-06-08 阿布林克斯公司 单域抗原结合性分子的纯化方法
BRPI0919975A2 (pt) 2008-10-29 2015-12-15 Bg Medicine Inc imunoensaio para galectina-3
ES2732504T3 (es) 2008-10-29 2019-11-22 Circular Commitment Company Procedimientos y agentes para el diagnóstico y tratamiento del carcinoma hepatocelular
US9067981B1 (en) 2008-10-30 2015-06-30 Janssen Sciences Ireland Uc Hybrid amyloid-beta antibodies
KR101683033B1 (ko) 2008-10-31 2016-12-06 얀센 바이오테크 인코포레이티드 톨-유사 수용체 3 길항제
US8574582B2 (en) * 2008-10-31 2013-11-05 Janssen Biotech, Inc. Methods for mediating fibrotic response
AU2009313615B2 (en) 2008-11-05 2012-11-29 Regents Of The University Of Minnesota Multicomponent immunogenic composition for the prevention of beta-hemolytic streptococcal (BHS) disease
JP5775458B2 (ja) * 2008-11-06 2015-09-09 グレンマーク ファーマシューティカルズ， エセ．アー． 抗α２インテグリン抗体を使用する処置
WO2010052288A1 (en) 2008-11-07 2010-05-14 Novartis Forschungsstiftung, Zweigniederlassung, Friedrich Miescher Institute For Biomedical Research Teneurin and cancer
JP6223659B2 (ja) 2008-11-10 2017-11-01 アレクシオン ファーマシューティカルズ， インコーポレイテッド 補体関連障害を処置するための方法および組成物
ES2623128T3 (es) 2008-11-11 2017-07-10 The Regents Of The University Of Michigan Composiciones ANTI-CXCR1 y métodos
WO2010056804A1 (en) 2008-11-12 2010-05-20 Medimmune, Llc Antibody formulation
US8309306B2 (en) * 2008-11-12 2012-11-13 Nodality, Inc. Detection composition
US8329188B2 (en) * 2008-11-12 2012-12-11 Theraclone Sciences, Inc. Human M2e peptide immunogens
CA2742871C (en) 2008-11-13 2018-10-23 Herb Lin Methods and compositions for regulating iron homeostasis by modulation of bmp-6
AU2009313877A1 (en) * 2008-11-13 2011-06-30 Emergent Product Development Seattle, Llc CD37 immunotherapeutic combination therapies and uses thereof
CA2743853C (en) 2008-11-14 2021-04-27 Stephen M. Smith Hiv-2 isolate
US20110229892A1 (en) 2008-11-17 2011-09-22 Yehuda G Assaraf Method for predicting a patient's responsiveness to anti-folate therapy
EP2359852A4 (de) 2008-11-17 2015-05-20 Nat Cancer Ct Neue auf krebs gerichtete therapie mit einem spezifisch an einen tumorstromafaktor bindenden substanzkomplex und antitumirverbindung
CN102282168A (zh) 2008-11-18 2011-12-14 梅里麦克制药股份有限公司 人血清白蛋白接头以及其结合物
WO2010058396A1 (en) 2008-11-19 2010-05-27 Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd. A cd44vra antibody and diagnostic and therapeutic methods using same
AR074369A1 (es) * 2008-11-20 2011-01-12 Genentech Inc Anticuerpos anti-unc 5b (receptor de netrina) y metodos de uso
DK2189539T4 (en) 2008-11-21 2018-09-17 Chimera Biotec Gmbh Conjugate complexes for analyte detection
KR20180117734A (ko) 2008-11-22 2018-10-29 제넨테크, 인크. 유방암의 치료를 위한, 화학요법과 조합된 항-ｖｅｇｆ 항체의 용도
KR20110091780A (ko) 2008-11-25 2011-08-12 앨더 바이오파마슈티컬즈, 인코포레이티드 악액질, 쇠약, 피로 및／또는 발열을 예방하거나 치료하는 ｉｌ­６의 길항제
AU2009319772A1 (en) 2008-11-26 2010-06-03 Centocor Research & Development, Inc. Compositions and methods for regulating collagen and smooth muscle actin expression by SERPINE2
PE20150680A1 (es) 2008-11-26 2015-05-16 Amgen Inc Variantes de polipeptidos receptores de activina iib y aplicaciones de estos
US20110223169A1 (en) * 2008-11-26 2011-09-15 Stern Michael E Il-17 antibody inhibitor for treating dry eye
US8211434B2 (en) * 2008-11-26 2012-07-03 Allergan, Inc. KLK-13 antibody inhibitor for treating dry eye
WO2010061393A1 (en) 2008-11-30 2010-06-03 Compugen Ltd. He4 variant nucleotide and amino acid sequences, and methods of use thereof
US20120070443A1 (en) 2008-12-02 2012-03-22 University Of Utah Research Foundation Pde1 as a target therapeutic in heart disease
US8545839B2 (en) 2008-12-02 2013-10-01 Pierre Fabre Medicament Anti-c-Met antibody
AR074439A1 (es) 2008-12-02 2011-01-19 Pf Medicament Anticuerpo anti-cmet (receptor c-met)
EP2370092A1 (de) 2008-12-03 2011-10-05 Research Development Foundation Modulierung von olfml-3-vermittelter angiogenese
MX2011005915A (es) 2008-12-03 2011-08-17 Proyecto Biomedicina Cima Sl Uso de modulinas solubles en fenol para el desarrollo de vacunas.
CA2743707A1 (en) 2008-12-04 2010-06-10 Pioneer Hi-Bred International, Inc. Methods and compositions for enhanced yield by targeted expression of knotted1
SG171812A1 (en) * 2008-12-04 2011-07-28 Abbott Lab Dual variable domain immunoglobulins and uses thereof
CA2893696C (en) 2008-12-05 2018-09-04 Abraxis Bioscience, Llc Albumin binding peptide-mediated disease targeting
US8401799B2 (en) * 2008-12-05 2013-03-19 Lpath, Inc. Antibody design using anti-lipid antibody crystal structures
NZ623273A (en) 2008-12-05 2015-09-25 Abraxis Bioscience Llc Sparc binding scfvs
EP2374001A4 (de) * 2008-12-05 2013-03-13 Lpath Inc Antikörperdesign unter verwendung von anti-lipid-antikörper-kristallstrukturen
WO2010067308A2 (en) 2008-12-08 2010-06-17 Compugen Ltd. Polypeptides and polynucleotides, and uses thereof as a drug target for producing drugs and biologics
MX356367B (es) 2008-12-09 2018-05-25 Genentech Inc Anticuerpos anti-pd-l1 y su uso para mejorar la funcion de celulas t.
US20110020327A1 (en) * 2008-12-16 2011-01-27 Millipore Corporation Purification of proteins
DK2370561T3 (da) 2008-12-16 2019-10-21 Emd Millipore Corp Omrøringstankreaktor og fremgangsmåde
JP2012512261A (ja) 2008-12-17 2012-05-31 ジェネンテック， インコーポレイテッド Ｃ型肝炎ウイルス併用療法
US20100151457A1 (en) 2008-12-17 2010-06-17 National Tsing Hua University Detection of Unhealthy Cell and Uses Thereof
JP5734201B2 (ja) 2008-12-19 2015-06-17 マクロジェニクス，インコーポレーテッド 共有結合型ダイアボディ及びその使用
GB0823309D0 (en) 2008-12-19 2009-01-28 Univ Bath Functionalising reagents and their uses
WO2010078916A1 (en) 2008-12-19 2010-07-15 Philogen S.P.A. Immunocytokines for tumour therapy with chemotherapeutic agents
US20100159485A1 (en) * 2008-12-19 2010-06-24 Centre For Dna Fingerprinting And Diagnostics Detection of mycobacterium tuberculosis
EP3165537A1 (de) 2008-12-19 2017-05-10 H. Lundbeck A/S Modulation der vps-10-domänen-rezeptor-familie für die behandlung von psychischen und verhaltensstörungen
EP2379710A1 (de) 2008-12-19 2011-10-26 Schering Corporation Futterzusatz für die säugerzellkultur und verwendungsverfahren
CN102264368B (zh) 2008-12-22 2014-09-10 米伦纽姆医药公司 极光激酶抑制剂与抗cd20抗体的组合
WO2010075249A2 (en) 2008-12-22 2010-07-01 Genentech, Inc. A method for treating rheumatoid arthritis with b-cell antagonists
JO3382B1 (ar) 2008-12-23 2019-03-13 Amgen Inc أجسام مضادة ترتبط مع مستقبل cgrp بشري
MX2011006870A (es) 2008-12-23 2011-07-19 Genentech Inc Variantes de inmunoglobulina con union alterada a proteina a.
CA2746120A1 (en) 2008-12-23 2010-07-01 Genentech, Inc. Methods and compositions for diagnostic use in cancer patients
WO2010075540A1 (en) * 2008-12-23 2010-07-01 Burnham Institute For Medical Research Methods and compositions for synaphically-targeted treatment for cancer
CN106008679A (zh) 2008-12-24 2016-10-12 荷兰王国卫生福利和运动部国家公共卫生和环境研究所 修饰的肺炎链球菌溶血素(ply)多肽
US20120009148A1 (en) 2008-12-29 2012-01-12 Yissum Research Development Company Of The Hebrew University Of Jerusalem, Ltd. Methods of predicting responsiveness to interferon treatment and treating hepatitis c infection
WO2010078376A2 (en) 2008-12-30 2010-07-08 Ventana Medical Systems, Inc. Fc-specific polymer-conjugated antibodies and their diagnostic use
CN102341411A (zh) 2008-12-31 2012-02-01 比奥根艾迪克Ma公司 抗-淋巴细胞毒素抗体
US20110142836A1 (en) * 2009-01-02 2011-06-16 Olav Mella B-cell depleting agents for the treatment of chronic fatigue syndrome
US9107935B2 (en) * 2009-01-06 2015-08-18 Gilead Biologics, Inc. Chemotherapeutic methods and compositions
EP2379116B1 (de) 2009-01-07 2015-08-26 Philogen S.p.A. Mit endometriose assoziierte antigene
WO2010078945A2 (en) 2009-01-07 2010-07-15 Philogen S.P.A. Cancer treatment
WO2010080985A1 (en) 2009-01-08 2010-07-15 Dana-Farber Cancer Institute, Inc. Compositions and methods for induced brown fat differentiation
JP2012515158A (ja) 2009-01-12 2012-07-05 武田薬品工業株式会社 癌の予防・治療剤
WO2010079464A1 (en) 2009-01-12 2010-07-15 Novartis Ag Cna_b domain antigens in vaccines against gram positive bacteria
EP3543256A1 (de) 2009-01-12 2019-09-25 Cytomx Therapeutics Inc. Modifizierte antikörperzusammensetzungen, verfahren zur herstellung und verwendung davon
ES2568509T3 (es) 2009-01-15 2016-04-29 Adaptive Biotechnologies Corporation Perfilado de la inmunidad adaptativa y métodos para la generación de anticuerpos monoclonales
CN102348798A (zh) * 2009-01-16 2012-02-08 麻省理工学院 孤独症谱系障碍的诊断和治疗
EP2379720B1 (de) 2009-01-20 2016-08-17 Alona Zilberberg Durch den promoter mir-21 angetriebene gezielte krebstherapie
KR101245929B1 (ko) 2009-01-20 2013-03-22 호메이욘 에이치. 자데흐 항체 매개된 골질 재생
CA2750581A1 (en) 2009-01-21 2010-07-29 Oxford Biotherapeutics Ltd. Pta089 protein
WO2010085345A1 (en) 2009-01-22 2010-07-29 Ludwig Institute For Cancer Research Ltd. Methods and compositions for diagnosis and treatment of malignant and non-malignant gammopathies
ES2453106T3 (es) 2009-01-26 2014-04-04 Electrophoretics Limited Métodos de diagnóstico y pronóstico en relación con la enfermedad de Alzheimer
NZ593905A (en) * 2009-01-29 2013-03-28 Abbott Lab Il-1 binding proteins
US20110165063A1 (en) * 2009-01-29 2011-07-07 Abbott Laboratories Il-1 binding proteins
WO2010086382A1 (en) 2009-01-30 2010-08-05 Pronota N.V. Target for treatment of acute heart failure
US8940501B2 (en) 2009-01-30 2015-01-27 Whitehead Institute For Biomedical Research Methods for ligation and uses thereof
US8530629B2 (en) 2009-01-30 2013-09-10 Ab Biosciences, Inc. Lowered affinity antibodies and uses therefor
WO2010086384A1 (en) 2009-01-30 2010-08-05 Pronota N.V. Target for treatment of acute heart failure
EP2219029A1 (de) 2009-01-30 2010-08-18 Sanofi-Aventis Testsysteme, Verfahren und Verwendungen, die AS160-Protein einbeziehen
WO2010086386A1 (en) 2009-01-30 2010-08-05 Pronota N.V. Protein quantification methods and use thereof for candidate biomarker validation
AU2010209763B2 (en) 2009-01-30 2016-05-12 Mycartis N.V. Biomarker for diagnosis, prediction and/or prognosis of acute heart failure and uses thereof
WO2010086828A2 (en) 2009-02-02 2010-08-05 Rinat Neuroscience Corporation Agonist anti-trkb monoclonal antibodies
WO2010087927A2 (en) 2009-02-02 2010-08-05 Medimmune, Llc Antibodies against and methods for producing vaccines for respiratory syncytial virus
US8309530B2 (en) * 2009-02-04 2012-11-13 Washington State University Compositions and methods for modulating ghrelin-mediated conditions
US9085795B2 (en) * 2009-02-04 2015-07-21 Molecular Innovations, Inc. Methods for screening candidate agents for modulating prorenin and renin, assays for detecting prorenin and antibodies
US20100272736A1 (en) 2009-02-04 2010-10-28 Kalobios Pharmaceuticals, Inc. Combination antibiotic and antibody therapy for the treatment of pseudomonas aeruginosa infection
EP2393787B1 (de) 2009-02-09 2018-01-24 Georgetown University Cadherin-11-inhibitoren und verfahren zu deren anwendung
US9079942B2 (en) * 2009-02-09 2015-07-14 Epitomics, Inc. CDR-anchored amplification method
US20100233733A1 (en) * 2009-02-10 2010-09-16 Nodality, Inc., A Delaware Corporation Multiple mechanisms for modulation of the pi3 kinase pathway
US9110081B2 (en) 2009-02-11 2015-08-18 Cedars-Sinai Medical Center Antibody to cytolethal distending toxin of Campylobacter jejuni
WO2010093450A2 (en) 2009-02-11 2010-08-19 Ludwing Institute For Cancer Research Ltd. Pten phosphorylation-driven resistance to cancer treatment and altered patient prognosis
WO2010093814A1 (en) 2009-02-11 2010-08-19 Kalobios Pharmaceuticals, Inc. Methods of treating dementia using a gm-csf antagonist
IL313131A (en) 2009-02-11 2024-07-01 Caris Mpi Inc Molecular characterization of tumors
EP2396035A4 (de) 2009-02-12 2012-09-12 Human Genome Sciences Inc Verwendung von antagonisten des b-lymphozyten-stimulatorproteins zur förderung von transplantationstoleranz
SI2881402T1 (sl) 2009-02-12 2017-12-29 Cell Signaling Technology, Inc. Ekspresija mutantnega ros pri humanem raku jeter
MX2011008599A (es) 2009-02-16 2011-11-18 Cerenis Therapeutics Sa Peptidos mimeticos de la apolipoproteina a-i.
US20110306069A1 (en) 2009-02-19 2011-12-15 Qingyu Wu Corin As A Marker For Heart Failure
GB0902916D0 (en) 2009-02-20 2009-04-08 Fusion Antibodies Ltd Antibody therapy
WO2010095270A1 (ja) 2009-02-23 2010-08-26 株式会社ジーンテクノサイエンス 抗ヒトα９インテグリン抗体とその用途
US8399219B2 (en) 2009-02-23 2013-03-19 Cytomx Therapeutics, Inc. Protease activatable interferon alpha proprotein
US8030026B2 (en) * 2009-02-24 2011-10-04 Abbott Laboratories Antibodies to troponin I and methods of use thereof
US20120045773A1 (en) 2009-02-24 2012-02-23 University Of Miyazaki Cell adhesion inhibitor and applications thereof
EP2401378B1 (de) 2009-02-25 2013-08-14 Merck Sharp & Dohme Corp. Stoffwechselmanipulation eines galaktoseassimilationswegs bei der glycoengineerten hefe pichia pastoris
GB0903151D0 (en) 2009-02-25 2009-04-08 Bioinvent Int Ab Antibody uses and methods
GB0903168D0 (en) 2009-02-25 2009-04-08 Fusion Antibodies Ltd Diagnostic method and kit
EP2400981A4 (de) * 2009-02-26 2013-02-27 Lpath Inc Desgin für humanisierten thrombozytenaktivierungsfaktor-antikörper mittels anti-lipid-antikörper-templates
EP2403530B1 (de) 2009-02-27 2016-05-11 Massachusetts Institute of Technology Manipulierte proteine mit hoher affinität für dota-chelate
WO2010099472A2 (en) 2009-02-27 2010-09-02 The U.S.A. Of America, As Represented By The Secretary, Department Of Health And Human Services Spanx-b polypeptides and their use
US8435488B2 (en) 2009-02-27 2013-05-07 Genentech, Inc. Methods and compositions for protein labelling
US8716553B2 (en) 2009-03-02 2014-05-06 Pioneer Hi Bred International Inc NAC transcriptional activators involved in abiotic stress tolerance
WO2010100056A2 (en) 2009-03-02 2010-09-10 Stichting Top Institute Pharma Antibodies against a proliferating inducing ligand (april)
JP5816558B2 (ja) 2009-03-05 2015-11-18 メダレックス・リミテッド・ライアビリティ・カンパニーＭｅｄａｒｅｘ， Ｌ．Ｌ．Ｃ． Ｃａｄｍ１に特異的な完全ヒト抗体
NZ594514A (en) 2009-03-05 2013-06-28 Abbott Lab Interleukin-17 BINDING PROTEINS
US20100227335A1 (en) 2009-03-05 2010-09-09 Becton, Dickinson And Company Matrix metalloproteinase-7 (mmp-7) monoclonal antibodies and methods for their use in the detection of ovarian cancer
WO2010102177A1 (en) 2009-03-06 2010-09-10 Becton, Dickinson And Company Glycodelin monoclonal antibodies and methods for their use in the detection of ovarian cancer
WO2010100632A2 (en) 2009-03-06 2010-09-10 Novartis Ag Chlamydia antigens
US8834870B2 (en) 2009-03-06 2014-09-16 Kalobios Pharmaceuticals, Inc. Treatment of leukemias and chronic myeloproliferative diseases with antibodies to EphA3
US9599591B2 (en) 2009-03-06 2017-03-21 California Institute Of Technology Low cost, portable sensor for molecular assays
EP2405920A1 (de) 2009-03-06 2012-01-18 Novartis Forschungsstiftung, Zweigniederlassung Friedrich Miescher Institute For Biomedical Research Neue therapie gegen angstzustände
CN102448473A (zh) 2009-03-10 2012-05-09 Med发现公司 丝氨酸蛋白酶抑制剂在治疗嗜中性粒细胞减少症中的用途
EP2406285B1 (de) 2009-03-10 2016-03-09 Gene Techno Science Co., Ltd. Erzeugung, expression und charakterisierung des humanisierten monoklonalen antikörpers k33n
JP2010213694A (ja) 2009-03-12 2010-09-30 Wyeth Llc ＰＫＮ３／ＲｈｏＣ高分子複合体およびその使用方法
GB0904355D0 (en) 2009-03-13 2009-04-29 Imp Innovations Ltd Biological materials and uses thereof
JP2010210772A (ja) 2009-03-13 2010-09-24 Dainippon Screen Mfg Co Ltd 液晶表示装置の製造方法
JP5826635B2 (ja) 2009-03-13 2015-12-02 アラーガン、インコーポレイテッドＡｌｌｅｒｇａｎ，Ｉｎｃｏｒｐｏｒａｔｅｄ 免疫系調節エンドペプチターゼ活性アッセイ
US20120077696A1 (en) 2009-03-15 2012-03-29 Technion Research And Development Foundation Ltd. Soluble hla complexes for use in disease diagnosis
EP2230515B1 (de) * 2009-03-16 2014-12-17 Agilent Technologies, Inc. Passivierung von Oberflächen nach Ligandenkupplung
US20120064096A1 (en) 2009-03-17 2012-03-15 Universite De La Mediterranee BTLA Antibodies and Uses Thereof
SI3260136T1 (sl) 2009-03-17 2021-05-31 Theraclone Sciences, Inc. Humani imunodeficientni virus (HIV)-nevtralizirajoča protitelesa
US20100286762A1 (en) * 2009-03-18 2010-11-11 Musc Foundation For Research Development Compositions and Methods for Ameliorating Clinical Electrical Disturbances
TWI544077B (zh) 2009-03-19 2016-08-01 中外製藥股份有限公司 Antibody constant region change body
US8420092B2 (en) 2009-03-19 2013-04-16 Ben-Gurion University Of The Negev Research And Development Authority Method of treating diabetes by administering an anti-NKp46 antibody
JP2012521197A (ja) 2009-03-20 2012-09-13 アムジエン・インコーポレーテツド 担体免疫グロブリンおよびその使用
KR20150036824A (ko) 2009-03-20 2015-04-07 제넨테크, 인크. 이중특이적 항-ｈｅｒ 항체
PE20120497A1 (es) 2009-03-20 2012-05-14 Amgen Inc Anticuerpo antagonista especifico para el heterodimero de alfa-4-beta-7
CN201397956Y (zh) * 2009-03-23 2010-02-03 富士康(昆山)电脑接插件有限公司 电连接器组件
US8444983B2 (en) 2009-03-23 2013-05-21 Quark Pharmaceuticals, Inc. Composition of anti-ENDO180 antibodies and methods of use for the treatment of cancer and fibrotic diseases
US8242248B2 (en) * 2009-03-23 2012-08-14 Nodality, Inc. Kits for multiparametric phospho analysis
US9586180B2 (en) 2009-03-24 2017-03-07 Wyeth Llc Membrane evaporation for generating highly concentrated protein therapeutics
WO2010111180A1 (en) 2009-03-24 2010-09-30 Teva Biopharmaceuticals Usa, Inc. Humanized antibodies against light and uses thereof
US20120110684A1 (en) 2009-03-24 2012-05-03 INSERM (Institut National de la Sante st de la Recherche Medicale)- Method for Diagnosing or Predicting a Non Syndromic Autosomal Recessive Optic Atrophy, or a Risk of a Non Syndromic Autosomal Recessive Optic Atrophy
WO2010110838A2 (en) 2009-03-25 2010-09-30 Vet Therapeutics Inc. Antibody constant domain regions and uses thereof
ES2549769T3 (es) 2009-03-25 2015-11-02 Genentech, Inc. Anticuerpos anti-FGFR3 y métodos que emplean los mismos
CN103755808B (zh) 2009-03-25 2016-02-10 霍夫曼-拉罗奇有限公司 抗-α5β1抗体及其应用
CN102574925A (zh) 2009-03-26 2012-07-11 昆腾免疫有限公司 用于诊断及临床应用的癌胚胎抗原/未成熟层粘连蛋白受体抗体
CA2756785A1 (en) * 2009-03-26 2010-09-30 Quantum Immunologics, Inc. Oncofetal antigen/immature laminin receptor peptides for the sensitization of dendritic cells for cancer therapy
US20120020954A1 (en) 2009-03-30 2012-01-26 Anat Achiron Methods of predicting clinical course and treating multiple sclerosis
EP2899212B1 (de) 2009-03-30 2017-07-19 Edimer Biotech S.a. Herstellung von isolierten monoklonalen Agonist-Anti-EDAR-Antikörpern
PL3604510T3 (pl) 2009-03-30 2025-07-28 Alexion Pharmaceuticals, Inc. Antidota na inhibitory czynnika xa i sposoby ich stosowania
WO2010112033A2 (en) 2009-03-31 2010-10-07 Østjysk Innovation A/S Method for estimating the risk of having or developing multiple sclerosis using sequence polymorphisms in a specific region of chromosome x
JP2012522762A (ja) 2009-04-01 2012-09-27 ザ メディカル リサーチ， インフラストラクチャー， アンド ヘルス サーヴィシーズ ファンド オブ ザ テル アヴィヴ メディカル センター ケラチノサイトの増殖および分化を調節する方法
RU2537142C2 (ru) 2009-04-01 2014-12-27 Дженентек, Инк. Лечение нарушений, связанных с инсулинорезистентностью
MA33256B1 (fr) 2009-04-01 2012-05-02 Genentech Inc Anticorps et immunoconjugués anti-fcrh5 et procédés d'utilisation
WO2010112034A2 (en) 2009-04-02 2010-10-07 Aarhus Universitet Compositions and methods for treatment and diagnosis of synucleinopathies
BRPI1014089A2 (pt) 2009-04-02 2016-04-19 Roche Glycart Ag anticorpos multiespecíficos que compreendem anticorpos de comprimento completo e fragmentos fab de cadeia simples
GB0905972D0 (en) 2009-04-06 2009-05-20 Medical Res Council Antibodies against IL-17BR
WO2010116375A1 (en) 2009-04-08 2010-10-14 Yeda Research And Development Co. Ltd. Isolated peptides for regulating apoptosis
WO2010118243A2 (en) 2009-04-08 2010-10-14 Genentech, Inc. Use of il-27 antagonists to treat lupus
ES2581488T3 (es) 2009-04-08 2016-09-06 Lipum Ab Nuevos métodos para el tratamiento de enfermedades inflamatorias
JP2012523438A (ja) 2009-04-10 2012-10-04 タフツ メディカル センター インコーポレイテッド メタロプロテイナーゼ−１（ｍｍｐ−１）によるｐａｒ−１活性化
US8647623B2 (en) 2009-04-10 2014-02-11 Kyowa Hakko Kirin Co., Ltd Method for treatment of blood tumor using anti-TIM-3 antibody
EP2419129A2 (de) 2009-04-14 2012-02-22 Novartis AG Zusammensetzungen zur immunisierung gegen staphylococcus aerus
EP2241323A1 (de) 2009-04-14 2010-10-20 Novartis Forschungsstiftung, Zweigniederlassung Friedrich Miescher Institute For Biomedical Research Tenascin-W und Hirnkrebs
RU2595379C2 (ru) 2009-04-16 2016-08-27 АббВай Биотерапеутикс Инк. АНТИТЕЛА ПРОТИВ TNF-α И ИХ ПРИМЕНЕНИЯ
EP2419446A4 (de) * 2009-04-17 2013-01-23 Lpath Inc Humanisierte antikörperzusammensetzungen und verfahren zur bindung von lysophosphatidsäure
JP5822822B2 (ja) 2009-04-17 2015-11-24 ニューヨーク ユニバーシティ Ｔｎｆファミリー受容体を標的とし、ｔｎｆ作用を拮抗するペプチド、その組成物、方法および使用
MX2011010971A (es) * 2009-04-17 2012-01-19 Biogen Idec Inc Composiciones y metodos para tratar leucemia mielogena aguda.
WO2010121231A1 (en) 2009-04-18 2010-10-21 Genentech, Inc. Methods for assessing responsiveness of b-cell lymphoma to treatment with anti-cd40 antibodies
NZ616382A (en) 2009-04-20 2015-04-24 Oxford Biotherapeutics Ltd Antibodies specific to cadherin-17
FI20090161A0 (fi) 2009-04-22 2009-04-22 Faron Pharmaceuticals Oy Uusi solu ja siihen pohjautuvia terapeuttisia ja diagnostisia menetelmiä
EP3524275A1 (de) 2009-04-22 2019-08-14 Massachusetts Institute Of Technology Angeborene immununterdrückung ermöglicht die wiederholte verabreichung von langen rna-molekülen
EP3444611A1 (de) 2009-04-23 2019-02-20 Siemens Healthcare Diagnostics Inc. Monomere und dimere formen von adiponectin-rezeptor-fragmenten sowie und verfahren zur verwendung davon
WO2010124113A1 (en) 2009-04-23 2010-10-28 Infinity Pharmaceuticals, Inc. Anti-fatty acid amide hydrolase-2 antibodies and uses thereof
CA2759506A1 (en) * 2009-04-23 2010-10-28 Theraclone Sciences, Inc. Granulocyte-macrophage colony-stimulating factor (gm-csf) neutralizing antibodies
US20120294868A1 (en) 2009-04-24 2012-11-22 Edwards James R Anti-tgf-beta induction of bone cell function and bone growth
GB0908770D0 (en) 2009-04-24 2009-07-01 Danisco Method
WO2010125566A2 (en) 2009-04-27 2010-11-04 Technion Research And Development Foundation Ltd. Markers for cancer detection
ES2550639T3 (es) 2009-04-27 2015-11-11 Kyowa Hakko Kirin Co., Ltd. Anticuerpo anti-IL-3Ralfa para su utilización en el tratamiento de un tumor de la sangre
ES2655877T3 (es) 2009-04-27 2018-02-22 Novartis Ag Composiciones y métodos para aumentar el crecimiento muscular
WO2010126590A1 (en) 2009-04-27 2010-11-04 Cold Spring Harbor Laboratory Ptp1b inhibitors
CA2759942A1 (en) 2009-04-27 2010-10-07 Novartis Ag Composition and methods of use for therapeutic antibodies specific for the il-12 receptore betai subunit
US9067986B2 (en) 2009-04-27 2015-06-30 Oncomed Pharmaceuticals, Inc. Method for making heteromultimeric molecules
HUE028021T2 (en) 2009-04-29 2016-11-28 Janssen Biotech Inc Pen-like receptor antagonists
AR076284A1 (es) 2009-04-29 2011-06-01 Bayer Schering Pharma Ag Inmunoconjugados de antimesotelina y usos de los mismos
AU2010242972B2 (en) * 2009-04-29 2015-07-09 Abbvie Biotechnology Ltd Automatic injection device
ES2725356T3 (es) 2009-04-29 2019-09-23 Henry M Jackson Found Advancement Military Medicine Inc Anticuerpos monoclonales de ERG2 y su uso terapéutico
US8367350B2 (en) 2009-04-29 2013-02-05 Morehouse School Of Medicine Compositions and methods for diagnosis, prognosis and management of malaria
ES2668874T3 (es) 2009-04-30 2018-05-22 Tel Hashomer Medical Research Infrastructure And Services Ltd. Anticuerpos anti-CEACAM1 y métodos de uso de los mismos
WO2010127180A2 (en) 2009-04-30 2010-11-04 University Of Rochester Dc-stamp antibodies
JP2012525415A (ja) 2009-05-01 2012-10-22 オプソテツク・コーポレイシヨン 眼科疾患を処置または予防するための方法
ES2514319T3 (es) 2009-05-04 2014-10-28 Abbvie Research B.V. Anticuerpos contra el factor de crecimiento nervioso (NGF) con estabilidad in vivo mejorada
BRPI1011404B1 (pt) 2009-05-05 2022-05-03 Amgen Inc Polipeptídeos mutantes fgf21, polipeptídeo de fusão, multímero, composição farmacêutica, ácido nucleico isolado, vetor e célula hospedeira
AU2010246038A1 (en) 2009-05-05 2011-12-01 Amgen Inc. FGF21 mutants and uses thereof
EP2427203B1 (de) 2009-05-05 2018-10-17 Novimmune S.A. Anti-il-17f-antikörper und deren verwendung
US9023767B2 (en) * 2009-05-07 2015-05-05 Memorial Sloan-Kettering Cancer Center γ-Secretase substrates and methods of use
US8187885B2 (en) * 2009-05-07 2012-05-29 Nodality, Inc. Microbead kit and method for quantitative calibration and performance monitoring of a fluorescence instrument
US9187568B2 (en) 2009-05-07 2015-11-17 Stallergenes S.A. Use of IgG1 immunoglobulins and/or ligands of the CD32 receptor for treating inflammatory diseases and manifestations via the mucosal route
WO2010129609A2 (en) 2009-05-07 2010-11-11 The Regents Of The University Of California Antibodies and methods of use thereof
EP2270053A1 (de) 2009-05-11 2011-01-05 U3 Pharma GmbH Humanisierte AXL-Antikörper
MX2011012047A (es) 2009-05-13 2011-12-14 Genzyme Corp Inmunoglobulinas humanas anti-cd52.
US20120128671A1 (en) 2009-05-13 2012-05-24 Lawrence Horowitz Neutralizing molecules to influenza viruses
GB0908425D0 (en) 2009-05-15 2009-06-24 Medical Res Council Medical use
US20100291706A1 (en) 2009-05-15 2010-11-18 Millipore Corporation Dye conjugates and methods of use
CN102459344A (zh) 2009-05-15 2012-05-16 中外制药株式会社 抗axl抗体
EP2432876A1 (de) 2009-05-19 2012-03-28 Danisco A/S Verwendung von inhibitoren der zdhhc2-aktivität zur modulation der adipogenese
KR101224468B1 (ko) 2009-05-20 2013-01-23 주식회사 파멥신 신규한 형태의 이중표적항체 및 그 용도
US20120128673A1 (en) 2009-05-20 2012-05-24 Schering Corporation Modulation of pilr receptors to treat microbial infections
CA2762302A1 (en) 2009-05-20 2010-11-25 Theraclone Sciences, Inc. Compositions and methods for the therapy and diagnosis of influenza
CA2682429A1 (en) * 2009-05-20 2010-11-20 Gary Levy An assay for measuring plasma fgl-2 and methods and uses thereof
AU2010249470B2 (en) * 2009-05-20 2015-06-25 Novimmune S.A. Synthetic Polypeptide Libraries And Methods For Generating Naturally Diversified Polypeptide Variants
AU2010252280A1 (en) 2009-05-25 2012-01-19 Merck Patent Gmbh Continuous administration of cilengitide in cancer treatments
US8815242B2 (en) 2009-05-27 2014-08-26 Synageva Biopharma Corp. Avian derived antibodies
US20120070449A1 (en) 2009-05-28 2012-03-22 Yeda Research And Development Co. Ltd. Methods of treating inflammation
US8383358B2 (en) * 2009-05-28 2013-02-26 Abraxis Bioscience, Llc Use of 2 anti-SPARC antibodies to predict response to melanoma chemotherapy
US9989533B2 (en) 2009-05-28 2018-06-05 The United States Of America, As Represented By The Secretary, Department Of Health & Human Services Anti-TNF induced apoptosis (ATIA) diagnostic markers and therapies
US20120121586A1 (en) 2009-05-29 2012-05-17 Astrid Kiermaier Modulators for her2 signaling in her2 expressing patients with gastric cancer
US8680055B2 (en) 2009-06-03 2014-03-25 University Of Southern California Methods for decreasing steroidogenesis in prostate cancer cells
EP4218794A3 (de) 2009-06-10 2023-09-13 New York University Immunologisches targeting pathologischer tau-proteine
US20100317539A1 (en) * 2009-06-12 2010-12-16 Guo-Liang Yu Library of Engineered-Antibody Producing Cells
WO2010146059A2 (en) 2009-06-16 2010-12-23 F. Hoffmann-La Roche Ag Biomarkers for igf-1r inhibitor therapy
US9676845B2 (en) 2009-06-16 2017-06-13 Hoffmann-La Roche, Inc. Bispecific antigen binding proteins
JP2012530493A (ja) * 2009-06-17 2012-12-06 アムジエン・インコーポレーテツド キメラポリペプチドおよびその使用
WO2010146511A1 (en) 2009-06-17 2010-12-23 Pfizer Limited Treatment of overactive bladder
US20100322943A1 (en) 2009-06-17 2010-12-23 Thomas Cantor Therapeutic and diagnostic affinity purified specific polyclonal antibodies
RU2567639C2 (ru) 2009-06-17 2015-11-10 АббВай Биотерапеутикс Инк., Антитела против vegf и их применения
WO2010147171A1 (ja) 2009-06-18 2010-12-23 株式会社広島バイオメディカル ニワトリ由来抗lox-1抗体
MX337468B (es) 2009-06-18 2016-03-02 Pfizer Anticuerpos anti notch-1.
GB0910620D0 (en) 2009-06-19 2009-08-05 Immunovia Ab Agents and uses thereof
BRPI1015234A2 (en) 2009-06-22 2018-02-20 Medimmune Llc fc regions designed for site specific conjugation.
GB0910725D0 (en) 2009-06-22 2009-08-05 Heptares Therapeutics Ltd Mutant proteins and methods for producing them
US20110076269A1 (en) * 2009-06-24 2011-03-31 Pebay Alice Marie Methods of increasing neuronal differentiation using antibodies to lysophosphatidic acid
JP2012531596A (ja) 2009-06-25 2012-12-10 サヴィエント・ファーマシューティカルズ・インコーポレイテッド Ｐｅｇ化ウリカーゼ療法における血清尿酸をモニタリングすることにより注入反応の危険性および抗体媒介性効果消失を予測するための方法およびキット
EP2445925A1 (de) 2009-06-25 2012-05-02 Bristol-Myers Squibb Company Proteinaufreinigung mittels präzipitation von caprylsäure (octansäure)
EP2446027A1 (de) 2009-06-25 2012-05-02 Danisco A/S Protein
US8268550B2 (en) * 2009-06-26 2012-09-18 Massachusetts Institute Of Technology Compositions and methods for identification of PARP function, inhibitors, and activators
WO2010151664A2 (en) 2009-06-26 2010-12-29 Massachusetts Institute Of Technology Compositions and methods for treating cancer and modulating stress granule formation
US8435961B2 (en) * 2009-06-26 2013-05-07 Massachusetts Institute Of Technology Methods and compositions for increasing the activity of inhibitory RNA
EP2272979A1 (de) 2009-06-30 2011-01-12 Centre National de la Recherche Scientifique (CNRS) Verfahren zum Testen einer Person, die eine Prädisposition für Krebs aufzuweisen scheint
US20120090043A1 (en) 2009-06-30 2012-04-12 Universite De Liege Targets for retrovirus associated diseases
WO2011001276A1 (en) 2009-06-30 2011-01-06 Philogen S.P.A. Immunocytokines in combination with anti-erbb antibodies for the treatment of cancer
CN102549016B (zh) * 2009-06-30 2015-05-06 研究发展基金会 免疫球蛋白fc多肽
US8487083B2 (en) 2009-06-30 2013-07-16 OOO “Oncomax” Monoclonal antibodies capable of simultaneously binding domains II and IIIc of type 1 fibroblast growth factor receptor
AU2010266129B2 (en) 2009-07-02 2016-04-14 Massachusetts Institute Of Technology Compositions and methods for diagnosing and/or treating influenza infection
JP5871798B2 (ja) 2009-07-02 2016-03-01 エムユーエスシー ファウンデーション フォー リサーチ ディベロップメント 肝再生を刺激する方法
CA2766409C (en) 2009-07-03 2023-04-25 Avipep Pty Ltd Immuno-conjugates and methods for producing them
WO2011004899A1 (en) 2009-07-06 2011-01-13 Takeda Pharmaceutical Company Limited Cancerous disease modifying antibodies
EP2451843A1 (de) 2009-07-07 2012-05-16 F. Hoffmann-La Roche AG Diagnose und behandlung von demyelinisierenden automimmunerkrankungen
US10988511B2 (en) 2009-07-07 2021-04-27 Glaxosmithkline Biologicals Sa Conserved Escherichia bacterial IG-like domain (group 1) protein (ORF405) immunogens
CA2766861A1 (en) 2009-07-09 2011-01-13 F. Hoffmann-La Roche Ag In vivo tumor vasculature imaging
WO2011006001A1 (en) 2009-07-09 2011-01-13 Genentech, Inc. Animal model for the evaluation of adjuvant therapies of cancer
DK2451844T3 (en) 2009-07-10 2015-07-27 Innate Pharma Tlr3-retention agents
WO2011004379A1 (en) 2009-07-10 2011-01-13 Tel Hashomer Medical Research Infrastructure And Services Ltd. Compositions and methods for treating cancer
SG177640A1 (en) 2009-07-13 2012-02-28 Genentech Inc Diagnostic methods and compositions for treatment of cancer
WO2011008959A1 (en) 2009-07-15 2011-01-20 Abbott Laboratories Enhancement of cellular production through mechanotransduction
JP5795311B2 (ja) 2009-07-15 2015-10-14 ネステク ソシエテ アノニム 抗体ベースのアレイを使用する胃癌療法のための薬物選択
EP2453910B1 (de) 2009-07-15 2016-08-31 Portola Pharmaceuticals, Inc. Einzeldosisformulierung von antidoten für faktor-xa-hemmer zur prävention von blutung
US20110033486A1 (en) 2009-07-20 2011-02-10 Abbas Alexander R Gene expression markers for crohn's disease
US9409983B2 (en) 2009-07-23 2016-08-09 The Board Of Trustess Of The University Of Illinois Methods and compositions involving PBEF inhibitors for lung inflammation conditions and diseases
WO2011011689A2 (en) * 2009-07-23 2011-01-27 The Regents Of The University Of Michigan Method for enzymatic production of decarboxylated polyketides and fatty acids
CN105132529A (zh) 2009-07-24 2015-12-09 吉第克生物技术有限公司 子宫内膜癌的标记物
CN106591104B (zh) 2009-07-24 2020-05-22 阿科尼生物系统公司 流通池装置
JP5755647B2 (ja) 2009-07-24 2015-07-29 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア αｖβ５インテグリンに関連する疾患の処置および予防のための方法および組成物
TW201106972A (en) 2009-07-27 2011-03-01 Genentech Inc Combination treatments
TW201109438A (en) * 2009-07-29 2011-03-16 Abbott Lab Dual variable domain immunoglobulins and uses thereof
US9345661B2 (en) 2009-07-31 2016-05-24 Genentech, Inc. Subcutaneous anti-HER2 antibody formulations and uses thereof
ES2513292T3 (es) 2009-07-31 2014-10-24 Genentech, Inc. Inhibición de metástasis tumoral usando anticuerpos anti-G-CSF
CA2769473A1 (en) 2009-07-31 2011-02-03 N.V. Organon Fully human antibodies to btla
EP2459184A1 (de) 2009-07-31 2012-06-06 The Brigham and Women's Hospital, Inc. Modulation der sgk1-expression bei th17-zellen zur modulation von th17-vermittelten immunreaktionen
SG178190A1 (en) 2009-07-31 2012-03-29 Shin Maeda Cancer metastasis inhibitor
CA2769206A1 (en) 2009-07-31 2011-02-03 Amgen Inc. Polypeptides that bind tissue inhibitor of metalloproteinase type three (timp-3), compositions and methods
EP2462163A1 (de) 2009-08-04 2012-06-13 F. Hoffmann-La Roche AG Beta-zellmarker-antikörper
WO2011017492A2 (en) 2009-08-05 2011-02-10 Pioneer Hi-Bred International, Inc. Novel eto1 genes and use of same for reduced ethylene and improved stress tolerance in plants
US8679488B2 (en) 2009-08-05 2014-03-25 Philogen S.P.A. Targeting of bone marrow neovasculature
EP4786482A2 (de) 2009-08-06 2026-08-05 F. Hoffmann-La Roche AG Virusfiltrierungsverfahren
US8536316B2 (en) * 2009-08-07 2013-09-17 Emd Millipore Corporation Methods for purifying a target protein from one or more impurities in a sample
WO2011017294A1 (en) 2009-08-07 2011-02-10 Schering Corporation Human anti-rankl antibodies
WO2011019620A1 (en) 2009-08-10 2011-02-17 Genentech, Inc. Antibodies with enhanced adcc function
US20110038871A1 (en) 2009-08-11 2011-02-17 Veena Viswanth Ccr2 inhibitors for treating conditions of the eye
MX355650B (es) 2009-08-11 2018-04-26 Genentech Inc Produccion de proteinas en medios de cultivo de celulas libres de glutamina.
MX2012001882A (es) 2009-08-13 2012-04-11 Crucell Holland Bv Anticuerpos contra el virus sincitial respiratorio (rsv) humano y metodos de uso.
EP2464661B1 (de) 2009-08-13 2018-01-17 The Johns Hopkins University Verfahren zur modulierung der immunfunktion mittles anti-b7-h7cr antikörper
US20110053223A1 (en) 2009-08-14 2011-03-03 Robert Bayer Cell culture methods to make antibodies with enhanced adcc function
WO2011020107A2 (en) 2009-08-14 2011-02-17 Georgetown University Compositions and methods for detection and treatment of breast cancer
KR20120059553A (ko) 2009-08-14 2012-06-08 제넨테크, 인크. Ｖｅｇｆ 길항제에 대한 환자 반응을 모니터링하기 위한 생물학적 마커
KR20120107069A (ko) 2009-08-15 2012-09-28 제넨테크, 인크. 이전에 치료된 유방암의 치료를 위한 항혈관신생 요법
US8221753B2 (en) 2009-09-30 2012-07-17 Tracon Pharmaceuticals, Inc. Endoglin antibodies
EP2722055A1 (de) 2009-08-17 2014-04-23 Tracon Pharmaceuticals, Inc. Kombination Therapy mit AntiKörpern und therapeutika gegen VEGF für die Behandlung von Krebs
GB0914446D0 (en) 2009-08-18 2009-09-30 King S College London Bioconjugates and their uses in imaging
EP2467492A4 (de) 2009-08-18 2013-01-09 Harvard College Verfahren und zusammensetzungen zur behandlung proliferativer und pathogener erkrankungen
WO2011021146A1 (en) 2009-08-20 2011-02-24 Pfizer Inc. Osteopontin antibodies
GB2472856B (en) 2009-08-21 2012-07-11 Cantargia Ab IL1-RAP modulators and uses thereof
US20110207144A1 (en) * 2009-08-21 2011-08-25 Derek Marshall In vitro screening assays
RU2012110580A (ru) * 2009-08-21 2013-09-27 Джилид Байолоджикс, Инк. Способы скрининга in vivo
WO2011022670A1 (en) * 2009-08-21 2011-02-24 Arresto Biosciences, Inc In vivo screening assays
CA2771702A1 (en) * 2009-08-21 2011-02-24 Gilead Biologics, Inc. Catalytic domains from lysyl oxidase and loxl2
GB0914691D0 (en) 2009-08-21 2009-09-30 Lonza Biologics Plc Immunoglobulin variants
MX2012002271A (es) * 2009-08-21 2012-07-20 Gilead Biologics Inc Metodos y composiciones terapeuticas.
CA2772036A1 (en) 2009-08-24 2011-03-03 Phigenix, Inc. Targeting pax2 for the treatment of breast cancer
BR112012007877A2 (pt) 2009-08-26 2019-09-24 Medizinische Hochschule Hannover meios e métodos para produção de polissacarídeos capsulares artificiais de neisseria meningitidis
EP2292266A1 (de) 2009-08-27 2011-03-09 Novartis Forschungsstiftung, Zweigniederlassung Behandlung von Krebs durch Modulation von Copine III
BR112012004464B8 (pt) 2009-08-28 2021-05-25 Labrys Biologics Inc uso de um anticorpo antagonista anti-cgrp para preparar uma composição farmacêutica para tratar e/ou prevenir dor visceral e/ou um ou mais sintomas de dor visceral, em que a dor visceral está associada á cistite intersticial (ic), e dita composição farmacêutica
CN102002104A (zh) 2009-08-28 2011-04-06 江苏先声药物研究有限公司 一种抗vegf的单克隆抗体及含有该抗体的药物组合物
CA2771575A1 (en) 2009-08-29 2011-03-03 Abbott Laboratories Therapeutic dll4 binding proteins
EP2293072A1 (de) 2009-08-31 2011-03-09 Sanofi-Aventis Verwendung von Kathepsin H
WO2011025542A1 (en) 2009-08-31 2011-03-03 Ludwig Institute For Cancer Research Ltd. Seromic analysis of ovarian cancer
CA2770174A1 (en) * 2009-08-31 2011-03-03 Roche Glycart Ag Affinity-matured humanized anti cea monoclonal antibodies
EP2473523A2 (de) 2009-08-31 2012-07-11 Amplimmune, Inc. Verfahren und zusammensetzungen zur hemmung von transplantatabstossung
MX2012002651A (es) * 2009-09-01 2012-05-22 Abbott Lab Inmunoglobulinas de dominio variable doble y usos de las mismas.
BR112012004697B8 (pt) 2009-09-01 2021-05-25 Genentech Inc método para purificar um polipeptídeo compreendendo uma região ch2/ch3
US9493578B2 (en) 2009-09-02 2016-11-15 Xencor, Inc. Compositions and methods for simultaneous bivalent and monovalent co-engagement of antigens
JP5887270B2 (ja) 2009-09-02 2016-03-16 ジェネンテック， インコーポレイテッド 突然変異体ｓｍｏｏｔｈｅｎｅｄおよびその使用方法
US8178307B2 (en) 2009-09-02 2012-05-15 National Tsing Hua University Methods and compositions for detection of lethal cell and uses thereof
IN2015DN02826A (de) 2009-09-03 2015-09-11 Merck Sharp & Dohme
JP5996429B2 (ja) 2009-09-03 2016-09-21 ジェネンテック， インコーポレイテッド 関節リウマチの治療、診断及びモニターするための方法
WO2011029823A1 (en) 2009-09-09 2011-03-17 Novartis Ag Monoclonal antibody reactive with cd63 when expressed at the surface of degranulated mast cells
WO2011030329A1 (en) 2009-09-10 2011-03-17 Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd. Method of treating tumors
EP2475388B1 (de) 2009-09-10 2017-11-08 Merck Sharp & Dohme Corp. Verwendung von il-33 antagonisten zur behandlung fibrotischer erkrankungen
RU2012114094A (ru) 2009-09-11 2013-10-20 Дженентек, Инк. Способ идентификации пациента с увеличенной вероятностью ответа на противораковый агент
US8293483B2 (en) 2009-09-11 2012-10-23 Epitomics, Inc. Method for identifying lineage-related antibodies
RU2012114005A (ru) 2009-09-11 2013-10-20 Те Гавернмент Оф Те Юнайтед Стейтс Оф Америка Эз Репризентед Бай Те Секретари Оф Те Департмент Хелт Энд Хьюман Сервисез Усовершенствованный экзотоксин а pseudomonas со сниженной иммуногенностью
AR078161A1 (es) 2009-09-11 2011-10-19 Hoffmann La Roche Formulaciones farmaceuticas muy concentradas de un anticuerpo anti cd20. uso de la formulacion. metodo de tratamiento.
EP2477656B1 (de) 2009-09-15 2017-03-29 CSL Limited Behandlung neurologischer erkrankungen
CN102712696A (zh) 2009-09-16 2012-10-03 弗·哈夫曼-拉罗切有限公司 包含卷曲螺旋和/或系链的蛋白质复合体及其用途
KR101557545B1 (ko) 2009-09-17 2015-10-06 에프. 호프만-라 로슈 아게 암 환자에서 진단 용도를 위한 방법 및 조성물
JP2013505268A (ja) 2009-09-18 2013-02-14 アブラクシス バイオサイエンス リミテッド ライアビリティー カンパニー 癌の治療におけるｓｐａｒｃ微小環境シグネチャの使用
EP2480573A1 (de) 2009-09-22 2012-08-01 Novartis Forschungsstiftung, Zweigniederlassung Friedrich Miescher Institute For Biomedical Research Behandlung von krebs durch modulation von mex-3
US20120178910A1 (en) 2009-09-23 2012-07-12 Medarex, Inc. Cation exchange chromatography (methods)
TW201118166A (en) 2009-09-24 2011-06-01 Chugai Pharmaceutical Co Ltd HLA class I-recognizing antibodies
GB201005063D0 (en) 2010-03-25 2010-05-12 Ucb Pharma Sa Biological products
AU2010298036B2 (en) 2009-09-25 2015-05-21 Xoma Technology Ltd. Screening methods
US8926976B2 (en) 2009-09-25 2015-01-06 Xoma Technology Ltd. Modulators
EP2480892A1 (de) 2009-09-25 2012-08-01 Origene Technologies, Inc. Proteinarrays und verwendungen davon
US20110076232A1 (en) * 2009-09-29 2011-03-31 Ludwig Institute For Cancer Research Specific binding proteins and uses thereof
GB0917054D0 (en) 2009-09-29 2009-11-11 Cytoguide As Agents, uses and methods
US8784819B2 (en) 2009-09-29 2014-07-22 Ibio Inc. Influenza hemagglutinin antibodies, compositions and related methods
GB0917044D0 (en) 2009-09-29 2009-11-18 Cytoguide As Agents, uses and methods
WO2011040429A1 (ja) 2009-09-30 2011-04-07 石原産業株式会社 ヒトhig1ポリペプチドに対するモノクローナル抗体
CA2775880A1 (en) 2009-09-30 2011-04-07 Genentech, Inc. Anti-notch3 antagonist antibodies to treat gamma secretase inhibitor responsive and anti-notch1 antagonist antibody unresponsive t-cell leukemias
WO2011038894A1 (en) 2009-10-01 2011-04-07 F. Hoffmann-La Roche Ag Protein a chromatography
WO2011040972A1 (en) 2009-10-02 2011-04-07 Ludwig Institute For Cancer Research Ltd. Anti-fibroblast activation protein antibodies and methods and uses thereof
WO2011040973A2 (en) 2009-10-02 2011-04-07 Ludwig Institute For Cancer Research Ltd. Tnf-immunoconjugates with fibroblast activation protein antibodies and methods and uses thereof
UY32914A (es) 2009-10-02 2011-04-29 Sanofi Aventis Anticuerpos que se usan específicamente al receptor epha2
US20120278908A1 (en) 2009-10-02 2012-11-01 Eric Souied Method for the diagnosis/prognosis of age-related macular degeneration
MX2012004029A (es) 2009-10-07 2012-05-08 Macrogenics Inc Polipeptidos que contienen la region fc que exhiben funcion efectora mejorada debido a alteraciones del grado de fucosilacion, y metodos para su uso.
JP2013507365A (ja) 2009-10-07 2013-03-04 サンフォード−バーナム メディカル リサーチ インスティテュート 血餅結合脂質化合物に関する方法および組成物
EP2486152B1 (de) 2009-10-07 2017-12-06 F. Hoffmann-La Roche AG Verfahren zur diagnose von lupus
US8518405B2 (en) 2009-10-08 2013-08-27 The University Of North Carolina At Charlotte Tumor specific antibodies and uses therefor
US8435516B2 (en) 2009-10-12 2013-05-07 Pfizer Inc. Cancer treatment
US20120231004A1 (en) 2009-10-13 2012-09-13 Oxford Biotherapeutic Ltd. Antibodies
EP2488640B1 (de) 2009-10-14 2018-09-26 Nanyang Technological University Antiproliferationsmittel
AU2010313621C1 (en) 2009-10-14 2015-11-26 Humanigen, Inc. Antibodies to EphA3
US8580714B2 (en) 2009-10-14 2013-11-12 Janssen Biotech, Inc. Methods of affinity maturing antibodies
CA2777717C (en) * 2009-10-15 2021-05-25 Genentech, Inc. Chimeric fibroblast growth factors with altered receptor specificity
AU2010306563B2 (en) 2009-10-15 2013-11-28 Circle 33, Llc Antibody therapeutics with local activity in the digestive tract
WO2011045352A2 (en) 2009-10-15 2011-04-21 Novartis Forschungsstiftung Spleen tyrosine kinase and brain cancers
AR078651A1 (es) 2009-10-15 2011-11-23 Abbott Lab Inmunoglobulinas con dominio variable dual y usos de las mismas
RS57966B1 (sr) 2009-10-16 2019-01-31 Progastrine Et Cancers S A R L Monoklonska antitela na progastrin i njihova upotreba
JPWO2011045945A1 (ja) 2009-10-16 2013-03-04 国立大学法人京都大学 アミロイドβのターン構造を認識する抗体
WO2011047340A1 (en) 2009-10-16 2011-04-21 The United States Of America, As Represented By The Secretary, Department Of Health & Human Services Insertion of foreign genes in rubella virus and their stable expression in a live, attenuated viral vaccine
WO2011045396A2 (en) 2009-10-16 2011-04-21 Novartis Ag Biomarkers of tumor pharmacodynamic response
EP3150635A3 (de) 2009-10-16 2017-06-21 Omeros Corporation Verfahren zur behandlung ausgebreiteter intravaskulärer gerinnung durch hemmung masp-2-abhängiger komplementaktivierung
EP3485908B1 (de) 2009-10-16 2021-08-18 Mereo BioPharma 5, Inc. Therapeutische kombination und verwendung mit dll4-antagonistische antikörper und mittel gegen bluthochdruck
CA2771817A1 (en) 2009-10-19 2011-04-28 Genentech, Inc. Modulators of hepatocyte growth factor activator
US20110206704A1 (en) * 2009-10-19 2011-08-25 Genentech, Inc. Methods and compositions for modulating hepatocyte growth factor activator
DK2491385T3 (en) 2009-10-20 2017-08-28 Diatech Holdings Inc PROXIMITY-MEDIED ASSAYS FOR DETECTING ONCOGEN FUSION PROTEINS
NZ599100A (en) 2009-10-20 2014-07-25 Abbvie Inc Isolation and purification of anti-il-13 antibodies using protein a affinity chromatography
GB0918392D0 (en) 2009-10-20 2009-12-02 Novartis Ag Diagnostic and therapeutic methods
EP2491400B1 (de) 2009-10-21 2015-10-07 MyCartis N.V. Biomarker zur diagnose, vorhersage und/oder prognose eines akuten herzversagens und verwendungen davon
WO2011049082A1 (ja) 2009-10-21 2011-04-28 国立大学法人広島大学 インテグリンα8β1特異的モノクローナル抗体
EP2491059B1 (de) 2009-10-22 2015-02-25 F.Hoffmann-La Roche Ag Anti-hepsin-antikörper sowie verfahren zu ihrer verwendung
RU2539772C2 (ru) 2009-10-22 2015-01-27 Дженентек, Инк. Способы и композиции для модуляции гепсином стимулирующего макрофаги белка
EP2470564A1 (de) 2009-10-22 2012-07-04 Yeda Research and Development Co. Ltd. Zusammensetzungen und verfahren zur behandlung von aspergillose
SG10201406763WA (en) 2009-10-22 2014-11-27 Genentech Inc Modulation of axon degeneration
MY173390A (en) 2009-10-23 2020-01-22 Takeda Pharmaceuticals Co Anti-gcc antibody molecules and related compositions and methods
WO2011056497A1 (en) 2009-10-26 2011-05-12 Genentech, Inc. Activin receptor type iib compositions and methods of use
JO3244B1 (ar) 2009-10-26 2018-03-08 Amgen Inc بروتينات ربط مستضادات il – 23 البشرية
DK2494356T3 (en) * 2009-10-26 2017-05-15 Genentech Inc ASSAYS FOR THE DETECTION OF ANTIBODIES SPECIFIC TO THERAPEUTIC ANTI-IGE ANTIBODIES AND THEIR USE OF ANAPHYLAXY
WO2011056494A1 (en) 2009-10-26 2011-05-12 Genentech, Inc. Activin receptor-like kinase-1 antagonist and vegfr3 antagonist combinations
WO2011056502A1 (en) 2009-10-26 2011-05-12 Genentech, Inc. Bone morphogenetic protein receptor type ii compositions and methods of use
WO2011056561A1 (en) 2009-10-27 2011-05-12 Beth Israel Deaconess Medical Center Methods and compositions for the generation and use of conformation-specific antibodies
GB0922434D0 (en) 2009-12-22 2010-02-03 Ucb Pharma Sa antibodies and fragments thereof
CN102781963B (zh) 2009-10-27 2018-02-16 Ucb医药有限公司 功能修饰性NAv1.7抗体
GB0922435D0 (en) 2009-12-22 2010-02-03 Ucb Pharma Sa Method
US9234037B2 (en) 2009-10-27 2016-01-12 Ucb Biopharma Sprl Method to generate antibodies to ion channels
CA2779223A1 (en) 2009-10-27 2011-05-12 Caris Mpi, Inc. Molecular profiling for personalized medicine
US20110098862A1 (en) 2009-10-27 2011-04-28 ExxonMobil Research Engineering Company Law Department Multi-stage processes and control thereof
JP5774595B2 (ja) 2009-10-28 2015-09-09 ヤンセン バイオテツク，インコーポレーテツド 抗ｇｌｐ−１ｒ抗体及びそれらの使用
US8658175B2 (en) 2009-10-28 2014-02-25 Abbvie Biotherapeutics Inc. Anti-EGFR antibodies and their uses
UY32979A (es) * 2009-10-28 2011-02-28 Abbott Lab Inmunoglobulinas con dominio variable dual y usos de las mismas
US20120213801A1 (en) 2009-10-30 2012-08-23 Ekaterina Gresko Phosphorylated Twist1 and cancer
JP2013509188A (ja) * 2009-10-30 2013-03-14 アボット・ラボラトリーズ Ｓｏｒｆ構築物および複数の遺伝子発現
WO2011053852A1 (en) 2009-10-30 2011-05-05 The Regents Of The University Of California Gna11 mutations in melanoma
CN102596996B (zh) 2009-10-30 2014-06-18 东丽株式会社 对丙型肝炎病毒(hcv)具有感染抑制活性的抗体及其用途
US8420083B2 (en) * 2009-10-31 2013-04-16 Abbvie Inc. Antibodies to receptor for advanced glycation end products (RAGE) and uses thereof
WO2011054007A1 (en) 2009-11-02 2011-05-05 Oxford Biotherapeutics Ltd. Ror1 as therapeutic and diagnostic target
EP2322149A1 (de) 2009-11-03 2011-05-18 Universidad del Pais Vasco Verfahren und Zusammensetzung zur Behandlung von Ischämie
CA2780221A1 (en) 2009-11-04 2011-05-12 Fabrus Llc Methods for affinity maturation-based antibody optimization
US20110165648A1 (en) 2009-11-04 2011-07-07 Menno Van Lookeren Campagne Co-crystal structure of factor D and anti-factor D antibody
EP3594356A1 (de) 2009-11-04 2020-01-15 Merck Sharp & Dohme Corp. Hergestrllte antikoper gegen tslp
KR101968766B1 (ko) 2009-11-05 2019-04-12 제넨테크, 인크. 이종 폴리펩티드의 분비를 위한 방법 및 조성물
US9588121B2 (en) 2009-11-06 2017-03-07 Go Therapeutics, Inc. Method for early detection of cancer
EP2496604B1 (de) 2009-11-06 2017-08-23 IDEXX Laboratories, Inc. Antikörper gegen hunde-cd20
IN2012DN04412A (de) 2009-11-09 2015-08-07 Alexion Pharmaceuticals Inc
GB0919690D0 (en) 2009-11-10 2009-12-23 Guy S And St Thomas S Nhs Foun compositions for immunising against staphylococcus aureus
US9556272B2 (en) 2009-11-11 2017-01-31 The Trustees Of The University Of Pennsylvania Anti-TEM1 antibodies and uses thereof
US10016617B2 (en) 2009-11-11 2018-07-10 The Trustees Of The University Of Pennsylvania Combination immuno therapy and radiotherapy for the treatment of Her-2-positive cancers
WO2011060015A1 (en) 2009-11-11 2011-05-19 Genentech, Inc. Methods and compositions for detecting target proteins
BR112012009997A2 (pt) 2009-11-12 2019-09-24 Genentech Inc ''método para aumentar a densidade de espinhas dentriticas nos neurônios de um paciente com um distúrbios cognitivo ou psiquiatrico,método de manutenção da cognição em um sujeito durante o processo de envelhecimento,uso de um antagonista de dr6 na preparação de um medicamento para uso em um paciente com um disturbio cognitivo uo psiquíatrico e uso de um antagonista de p75 na preparação de um medicamento para uso em um paciente com um distúrbio cognitivo ou psiquiátrico''
KR101806323B1 (ko) 2009-11-13 2017-12-07 다이이치 산쿄 유럽 게엠베하 Ｈｅｒ-３ 관련 질병을 치료하거나 예방하기 위한 물질 및 방법
CA3061784C (en) 2009-11-13 2023-09-26 Dana-Farber Cancer Institute, Inc. Compositions, kits, and methods for the diagnosis, prognosis, monitoring, treatment and modulation of post-transplant lymphoproliferative disorders and hypoxia associated angiogenesis disorders using galectin-1
DK2501822T3 (da) 2009-11-17 2017-11-27 Squibb & Sons Llc Fremgangsmåder til forbedret proteinproduktion
US9260517B2 (en) 2009-11-17 2016-02-16 Musc Foundation For Research Development Human monoclonal antibodies to human nucleolin
GB0920089D0 (en) 2009-11-17 2009-12-30 Danisco Method
GB0920258D0 (en) 2009-11-19 2010-01-06 Alligator Bioscience Ab New medical agents and use thereof
US8961989B2 (en) 2009-11-20 2015-02-24 Oregon Health & Science University Methods for producing an immune response to tuberculosis
WO2011063198A2 (en) 2009-11-20 2011-05-26 St. Jude Children's Research Hospital Methods and compositions for modulating the activity of the interleukin-35 receptor complex
EP2501409A4 (de) 2009-11-20 2015-02-18 Univ California Epithelialmembranenprotein-2 (emp2) und proliferative vitreoretinopathie (pvr)
AU2010321832B2 (en) 2009-11-20 2014-08-14 Amgen Inc. Anti-Orai1 antigen binding proteins and uses thereof
MX2012005595A (es) 2009-11-26 2012-05-29 Hoffmann La Roche Proteina marcadora para diabetes de tipo 2.
TWI507524B (zh) 2009-11-30 2015-11-11 建南德克公司 診斷及治療腫瘤之組合物及方法
WO2011068870A2 (en) 2009-12-01 2011-06-09 President And Fellows Of Harvard College Modulation of nk cell antigen specific effector activity by modulation of cxcr6 (cd186)
WO2011067711A2 (en) 2009-12-01 2011-06-09 Compugen Ltd Novel heparanase splice variant
US10087236B2 (en) 2009-12-02 2018-10-02 Academia Sinica Methods for modifying human antibodies by glycan engineering
MX2012006397A (es) * 2009-12-02 2012-11-30 Amgen Inc PROTEINAS DE ENLACE QUE ENLAZAN A FGFR1C HUMANO, ß-KLOTHO HUMANA Y TANTO FGFR1C HUMANO COMO ß-KLOTHO HUMANA.
US11377485B2 (en) 2009-12-02 2022-07-05 Academia Sinica Methods for modifying human antibodies by glycan engineering
CA2781682A1 (en) 2009-12-04 2011-06-09 Genentech, Inc. Multispecific antibodies, antibody analogs, compositions, and methods
UA109888C2 (uk) 2009-12-07 2015-10-26 ІЗОЛЬОВАНЕ АНТИТІЛО АБО ЙОГО ФРАГМЕНТ, ЩО ЗВ'ЯЗУЄТЬСЯ З β-КЛОТО, РЕЦЕПТОРАМИ FGF І ЇХНІМИ КОМПЛЕКСАМИ
CA2783563A1 (en) 2009-12-07 2011-06-16 Decimmune Therapeutics, Inc. Anti-inflammatory antibodies and uses therefor
EP2509997B1 (de) 2009-12-07 2017-08-30 i2 Pharmaceuticals, Inc. Konjugate mit einem antkörpersurrogatgerüst mit verbesserten pharmakokinetischen eigenschaften
PH12012501070A1 (en) * 2009-12-08 2017-08-23 Abbott Gmbh & Co Kg Monoclonal antibodies against the rgm a protein for use in the treatment of retinal nerve fiber layer degeneration
WO2011069529A1 (en) 2009-12-09 2011-06-16 Curevac Gmbh Mannose-containing solution for lyophilization, transfection and/or injection of nucleic acids
WO2011069528A1 (en) 2009-12-09 2011-06-16 Curevac Gmbh Lyophilization of nucleic acids in lactate-containing solutions
EP2332995A1 (de) 2009-12-10 2011-06-15 Bayer Schering Pharma Aktiengesellschaft Neutralisierende Prolactinrezeptor-Antikörper und deren therapeutische Verwendung
EP2336171A1 (de) 2009-12-11 2011-06-22 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. Neuartige Targets zur Behandlung proliferativer Erkrankungen
AR079336A1 (es) 2009-12-11 2012-01-18 Irm Llc Antagonistas de la pro-proteina convertasa-subtilisina/quexina tipo 9 (pcsk9)
US8486397B2 (en) 2009-12-11 2013-07-16 Genentech, Inc. Anti-VEGF-C antibodies and methods using same
EP2512558A4 (de) * 2009-12-15 2014-08-13 Abbvie Biotechnology Ltd Verbesserter auslöseknopf für automatische injektionsvorrichtung
EP2513148B1 (de) 2009-12-16 2016-08-31 AbbVie Biotherapeutics Inc. Anti-her2-antikörper und ihre verwendung
US20110150891A1 (en) 2009-12-16 2011-06-23 Philip Bosch Methods of Treating Interstitial Cystitis
WO2011084357A1 (en) 2009-12-17 2011-07-14 Schering Corporation Modulation of pilr to treat immune disorders
EP2512497A1 (de) 2009-12-18 2012-10-24 Sanford-Burnham Medical Research Institute Verfahren und zusammensetzungen im zusammenhang mit gerinnselbindenden verbndungen
CN107095846A (zh) 2009-12-21 2017-08-29 霍夫曼-拉罗奇有限公司 抗体配制剂
GB0922377D0 (en) 2009-12-22 2010-02-03 Arab Gulf University The Mutant LDL receptor
GB0922553D0 (en) 2009-12-23 2010-02-10 Fusion Antibodies Ltd Prognostic marker
MX2012007379A (es) 2009-12-23 2012-08-31 Genentech Inc Anticuerpos anti-bv8 y usos de los mismos.
AU2010334809C1 (en) 2009-12-23 2015-02-26 Agenus Inc. Binding members for human cytomegalovirus
ES2573642T3 (es) 2009-12-23 2016-06-09 Synimmune Gmbh Anticuerpos anti-FLT3 y métodos de usar los mismos
TW201125583A (en) * 2009-12-23 2011-08-01 Bioalliance Cv Anti-EpCAM antibodies that induce apoptosis of cancer cells and methods using same
CA2784610C (en) 2009-12-23 2020-07-14 Avipep Pty Ltd Immuno-conjugates and methods for producing them
EP2338492A1 (de) 2009-12-24 2011-06-29 Universidad del Pais Vasco Verfahren und Zusammensetzung zur Behandlung von Alzheimer
CN102781964B (zh) 2009-12-28 2015-11-25 肿瘤疗法科学股份有限公司 抗cdh3抗体及其用途
WO2011080322A1 (en) 2009-12-30 2011-07-07 Institut National De La Sante Et De La Recherche Medicale (Inserm) Method of prognosing the outcome of acquired hemophilia and of treatment of hemophilia
WO2011082345A2 (en) * 2009-12-30 2011-07-07 Brigham Young University Compositions and methods for cancer management using antibodies binding to nucleotide salvage pathway enzymes and complexes thereof
US20110159588A1 (en) 2009-12-30 2011-06-30 Kui Lin Methods for Modulating a PDGF-AA Mediated Biological Response
WO2011084882A2 (en) 2010-01-05 2011-07-14 Contrafect Corporation Methods and compositions for enhanced immunological therapy and targeting of gram-positive bacteria
MX2012008085A (es) 2010-01-13 2012-09-12 Oncomed Pharm Inc Agentes de union notch1 y metodos de uso de los mismos.
WO2011085811A1 (en) 2010-01-14 2011-07-21 Universite Catholique De Louvain Method for evaluating the response of rheumatoid arthritis patients to therapy and for diagnosing disease severity
US20110177107A1 (en) 2010-01-14 2011-07-21 Haplomics, Inc. Predicting and reducing alloimmunogenicity of protein therapeutics
WO2011088385A2 (en) * 2010-01-15 2011-07-21 The Regents Of The University Of California Compositions and methods for detecting cancer
US8362210B2 (en) 2010-01-19 2013-01-29 Xencor, Inc. Antibody variants with enhanced complement activity
AU2011207253B2 (en) 2010-01-20 2015-02-12 Merck Sharp & Dohme Corp. Anti-ILT5 antibodies and ILT5-binding antibody fragments
JP5947727B2 (ja) 2010-01-20 2016-07-06 メルク・シャープ・アンド・ドーム・コーポレーションＭｅｒｃｋ Ｓｈａｒｐ ＆ Ｄｏｈｍｅ Ｃｏｒｐ． 抗ｉｌｔ５抗体およびｉｌｔ５結合抗体断片による免疫調節
WO2011089211A1 (en) 2010-01-22 2011-07-28 Synimmune Gmbh Anti-cd133 antibodies and methods of using the same
AU2011207210A1 (en) 2010-01-22 2012-08-16 Dana-Farber Cancer Institute, Inc. Compositions,kits, and methods for identification, assessment, prevention, and therapy of metabolic disorders
MX344543B (es) 2010-01-26 2016-12-19 Nat Jewish Health Metodos y composiciones para prediccion de riesgo, diagnosis, prognosis y tratamiento de desordenes pulmonares.
CN102822202B (zh) 2010-01-27 2015-07-22 耶达研究及发展有限公司 抑制金属蛋白的抗体
JP6101489B2 (ja) 2010-01-28 2017-03-22 アブ バイオサイエンシズ インコーポレイテッド 親和性が低下した抗体およびそれを作製する方法
AU2011210465A1 (en) 2010-01-29 2012-08-23 Axis Inc. Pharmaceutical composition for treatment or prevention of osteoarthritis, and method of production therefor
CN102821786B (zh) 2010-01-29 2016-01-13 阿克西斯股份有限公司 含有骨关节炎治疗剂的注射液
JP2012246222A (ja) 2010-01-29 2012-12-13 Axis Inc 変形性関節症治療剤または予防剤を製造するための使用
WO2011094759A2 (en) 2010-02-01 2011-08-04 The Regents Of The University Of California Novel diagnostic and therapeutic targets associated with or regulated by n-cadherin expression and/or epithelial to mesenchymal transition (emt) in prostate cancer and other malignancies
FR2955773B1 (fr) 2010-02-01 2017-05-26 Commissariat Energie Atomique Complexe moleculaire de ciblage des antigenes vers les cellules presentatrices d'antigene et ses applications pour la vaccination
JP2013518590A (ja) 2010-02-02 2013-05-23 アボツト・バイオテクノロジー・リミテツド ＴＮＦ−α阻害剤を用いる処置に対する応答性を予測するための方法および組成物
BR112012019693A2 (pt) 2010-02-04 2017-06-20 Gilead Biologics Inc anticorpos que se ligam à lisil oxidase-like 2 (loxl2) e métodos de uso para eles.
TWI518325B (zh) 2010-02-04 2016-01-21 自治醫科大學 對ａｌｋ抑制劑具有先抗性或後抗性癌症的識別、判斷和治療
SI2531527T1 (sl) 2010-02-04 2014-07-31 F. Hoffmann-La Roche Ag Monoklonsko protitelo proti CD44 za uporabo pri zdravljenju skvamoznoceličnega karcinoma glave in vratu
EP2354159A1 (de) 2010-02-05 2011-08-10 RWTH Aachen CCL17-Inhibitoren zur Verwendung bei von T-Helferzellen gesteuerten Erkrankungen
BR112012019780A2 (pt) 2010-02-08 2020-09-01 Agensys, Inc. conjugados de fármaco e anticorpo (adc) que ligam a proteínas 161p2f10b
AR080154A1 (es) 2010-02-10 2012-03-14 Immunogen Inc Anticuerpos cd20 y su utilizacion
MX2012009318A (es) 2010-02-10 2012-09-07 Novartis Ag Metodos y compuestos para el crecimiento muscular.
WO2011103490A2 (en) 2010-02-18 2011-08-25 The Regents Of The University Of California INTEGRIN αVβ8 NEUTRALIZING ANTIBODY
ES2519348T3 (es) 2010-02-18 2014-11-06 Genentech, Inc. Antagonistas de neurregulina y uso de los mismos en el tratamiento del cáncer
US20110207789A1 (en) 2010-02-19 2011-08-25 Ye Fang Methods related to casein kinase ii (ck2) inhibitors and the use of purinosome-disrupting ck2 inhibitors for anti-cancer therapy agents
US8859736B2 (en) 2010-02-19 2014-10-14 The Board Of Regents Of The University Of Oklahoma Monoclonal antibodies that inhibit the wnt signaling pathway and methods of production and use thereof
WO2011103389A1 (en) 2010-02-19 2011-08-25 Cornell University Method to treat autoimmune demyelinating diseases and other autoimmune or inflammatory diseases
WO2011103471A1 (en) 2010-02-22 2011-08-25 Duke University Compositions and methods for the treatment of neurologic and psychiatric conditions
US10369189B2 (en) 2010-02-22 2019-08-06 Duke University Compositions and methods for uncoupling TrkB receptor from PLC gamma 1 for the treatment of epilepsy and anxiety-like disorder
RU2545401C2 (ru) 2010-02-23 2015-03-27 Санофи Антитела к интегрину альфа-2 и их применения
SG10201401123VA (en) 2010-02-23 2014-08-28 Genentech Inc Anti-Angiogenesis Therapy For The Treatment Of Ovarian Cancer
AU2011221226A1 (en) 2010-02-23 2012-08-16 Genentech, Inc. Compositions and methods for the diagnosis and treatment of tumor
AR080291A1 (es) 2010-02-24 2012-03-28 Rinat Neuroscience Corp Anticuerpos antagonistas anti receptor de il-7 y procedimientos
BR112012020882A2 (pt) 2010-02-24 2015-11-03 Merck Sharp & Dohme métodos para produzir uma glicoproteína heteróloga e para produzir uma composição de glicoproteína, célula hospedeira, composição de glicoproteína, e, uso da pichia pastoris recombinante.
CN105777907B (zh) 2010-02-24 2020-03-17 伊缪诺金公司 叶酸受体1抗体与免疫缀合物以及其用途
WO2011106104A2 (en) 2010-02-26 2011-09-01 Memorial Sloan-Kettering Cancer Center Methods and compositions for the detection and treatment of cancer involving mirnas and mirna inhibitors and targets
SI3409289T1 (sl) 2010-02-26 2020-12-31 Novo Nordisk A/S Stabilni sestavki, ki vsebujejo protitelo
GB201003333D0 (en) 2010-02-26 2010-04-14 Novartis Ag Immunogenic proteins and compositions
US20110212088A1 (en) * 2010-02-26 2011-09-01 Sabbadini Roger A Anti-paf antibodies
WO2011107939A1 (en) 2010-03-01 2011-09-09 Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd. Methods of predicting efficacy of an anti-vegfa treatment for solid tumors
PT2542257T (pt) 2010-03-01 2017-10-09 Bayer Healthcare Llc Anticorpos monoclonais otimizados contra inibidor da via do fator tecidual (tfpi)
WO2011109298A2 (en) 2010-03-02 2011-09-09 Abbott Laboratories Therapeutic dll4 binding proteins
MX2012009942A (es) * 2010-03-02 2012-09-21 Hoffmann La Roche Vector de expresion.
EP2542571B1 (de) 2010-03-03 2016-05-25 The University of British Columbia Oligomer-spezifisches amyloid-beta-epitop und antikörper dazu
EP2542258A4 (de) 2010-03-04 2013-08-21 Vet Therapeutics Inc Auf cd52 gerichtete monoklonale antikörper
DK2542256T3 (da) 2010-03-04 2019-08-26 Macrogenics Inc Antistoffer reagerende med b7-h3, immunologisk aktive fragmenter deraf og anvendelser deraf
EP2543730B1 (de) 2010-03-04 2018-10-31 Chugai Seiyaku Kabushiki Kaisha Variante einer konstanten antikörperregion
GB201003630D0 (en) 2010-03-04 2010-04-21 Novartis Ag Avian rotavirus
PH12012501751A1 (en) 2010-03-04 2012-11-12 Macrogenics Inc Antibodies reactive with b7-h3, immunologically active fragments thereof and uses thereof
US20110236386A1 (en) * 2010-03-04 2011-09-29 Zimering Mark B Novel method for prediction of cardiovascular disease risk in type 2 diabetes
EP2543388A4 (de) 2010-03-04 2013-11-27 Dainippon Sumitomo Pharma Co Arzneimittel für entzündliche darmerkrankungen
BR112012022338A2 (pt) 2010-03-04 2017-02-14 Vet Therapeutics Inc anticorpos monoclonais direcionados a cd20
US8993524B2 (en) 2010-03-05 2015-03-31 The Johns Hopkins University Compositions and methods for targeted immunomodulatory antibodies and fusion proteins
GB201003701D0 (en) 2010-03-05 2010-04-21 Cilian Ag System for the expression of a protein
WO2011109280A1 (en) 2010-03-05 2011-09-09 Lerner Research Institute Methods and compositions to treat immune-mediated disorders
US20130004519A1 (en) 2010-03-05 2013-01-03 Ruth Chiquet-Ehrismann Smoci, tenascin-c and brain cancers
EP2544715A2 (de) 2010-03-09 2013-01-16 Board Of Regents, University Of Texas System Verfahren und zusammensetzung für chlamydia-antigen zur diagnose und behandlung einer chlamydieninfektion und -erkranung
US20110223208A1 (en) 2010-03-09 2011-09-15 Beth Hill Non-Aqueous High Concentration Reduced Viscosity Suspension Formulations
EP2544704A4 (de) 2010-03-11 2013-08-28 Abraxis Bioscience Llc Angiogene sparc-domäne und anwendungsverfahren dafür
NZ602220A (en) 2010-03-11 2014-10-31 Rinat Neuroscience Corp Antibodies with ph dependent antigen binding
LT2544719T (lt) 2010-03-12 2019-10-25 Debiopharm Int Sa Cd37 surišančios molekulės, ir jų imunokonjugatai
EP2368428A1 (de) 2010-03-16 2011-09-28 Institut National De La Recherche Agronomique Erhalt eines Rex-Tiers durch molekulare Verfahren auf Grundlage der Änderung der LIPH-Funktion
KR20130031247A (ko) 2010-03-17 2013-03-28 애보트 리서치 비.브이. 항―신경 성장 인자（ｎｇｆ） 항체 조성물
WO2011114251A1 (en) 2010-03-18 2011-09-22 Danisco A/S Foodstuff
GB201004551D0 (en) 2010-03-19 2010-05-05 Immatics Biotechnologies Gmbh NOvel immunotherapy against several tumors including gastrointestinal and gastric cancer
WO2011113118A1 (en) 2010-03-19 2011-09-22 Katholieke Universiteit Leuven Drug tolerance/persistence of fungal biofilms
KR101878369B1 (ko) 2010-03-22 2018-07-16 제넨테크, 인크. 단백질-함유 제제의 안정화에 유용한 조성물 및 방법
WO2011119549A1 (en) 2010-03-22 2011-09-29 President And Fellows Of Harvard College Trioxacarcins and uses thereof
WO2011119484A1 (en) 2010-03-23 2011-09-29 Iogenetics, Llc Bioinformatic processes for determination of peptide binding
KR101899835B1 (ko) 2010-03-24 2018-09-19 제넨테크, 인크. 항-ｌｒｐ６ 항체
GB201005064D0 (en) 2010-03-25 2010-05-12 Ucb Pharma Sa Biological products
WO2011117653A1 (en) 2010-03-25 2011-09-29 Ucb Pharma S.A. Disulfide stabilized dvd-lg molecules
CN103119054B (zh) 2010-03-26 2017-01-18 达特茅斯大学理事会 Vista调节性t细胞介体蛋白、vista结合剂及其用途
CA2793753C (en) 2010-03-26 2018-06-05 Memorial Sloan-Kettering Cancer Center Antibodies to muc16 and methods of use thereof
US20110237513A1 (en) 2010-03-26 2011-09-29 Pronota N.V. Ltbp2 as a biomarker for renal dysfunction
US10745467B2 (en) 2010-03-26 2020-08-18 The Trustees Of Dartmouth College VISTA-Ig for treatment of autoimmune, allergic and inflammatory disorders
TW201138821A (en) 2010-03-26 2011-11-16 Roche Glycart Ag Bispecific antibodies
US20150231215A1 (en) 2012-06-22 2015-08-20 Randolph J. Noelle VISTA Antagonist and Methods of Use
US20130108623A1 (en) 2010-03-29 2013-05-02 Zymeworks Inc Antibodies with Enhanced or Suppressed Effector Function
TWI667346B (zh) 2010-03-30 2019-08-01 中外製藥股份有限公司 促進抗原消失之具有經修飾的FcRn親和力之抗體
PL2552961T3 (pl) 2010-03-30 2018-04-30 Janssen Biotech, Inc. Humanizowane przeciwciała il-25
EP2796467B1 (de) 2010-03-31 2018-03-28 Boehringer Ingelheim International GmbH Anti-CD40-Antikörper
GB201005625D0 (en) 2010-04-01 2010-05-19 Novartis Ag Immunogenic proteins and compositions
EP4450523A3 (de) 2010-04-02 2025-03-12 Amunix Pharmaceuticals, Inc. Bindungsfusionsproteine, bindungsfusionsprotein-arzneimittelkonjugate, xten-arzneimittelkonjugate sowie verfahren zur herstellung und verwendung davon
CA2793778A1 (en) 2010-04-05 2011-11-13 Wyeth Llc Biomarkers for p13k-driven cancer
US9441032B2 (en) 2010-04-07 2016-09-13 Agency For Science, Technology And Research Binding molecules against Chikungunya virus and uses thereof
EP2374816B1 (de) 2010-04-07 2016-09-28 Agency For Science, Technology And Research Bindemoleküle gegen Chikungunya-Virus und Verwendungen davon
KR101764453B1 (ko) 2010-04-09 2017-08-02 아베오 파마슈티컬즈, 인크. 항-erbb3 항체
RU2684724C2 (ru) 2010-04-09 2019-04-11 Критикал Кэа Дайэгностикс, Инк. Антитела против растворимого st-2 человека и способы анализа
WO2011130332A1 (en) 2010-04-12 2011-10-20 Academia Sinica Glycan arrays for high throughput screening of viruses
GB201006096D0 (en) 2010-04-13 2010-05-26 Alligator Bioscience Ab Novel compositions and uses thereof
CN103038645B (zh) 2010-04-13 2016-05-04 迈卡蒂斯股份有限公司 用于妊娠的高血压疾病的生物标志物
WO2011130377A2 (en) 2010-04-15 2011-10-20 Abbott Laboratories Amyloid-beta binding proteins
US8383793B2 (en) 2010-04-15 2013-02-26 St. Jude Children's Research Hospital Methods and compositions for the diagnosis and treatment of cancer resistant to anaplastic lymphoma kinase (ALK) kinase inhibitors
PT2528625E (pt) 2010-04-15 2013-10-17 Spirogen Sarl Pirrolobenzodiazepinas e conjugados das mesmas
WO2011130417A2 (en) 2010-04-15 2011-10-20 Amgen Inc. HUMAN FGF RECEPTOR AND β-KLOTHO BINDING PROTEINS
ES2912934T3 (es) 2010-04-16 2022-05-30 Biogen Ma Inc Anticuerpos anti VLA-4
WO2011132182A1 (en) 2010-04-18 2011-10-27 Yeda Research And Development Co. Ltd. MOLECULES AND METHODS OF USING SAME FOR TREATING ErbB/ErbB LIGANDS ASSOCIATED DISEASES
US8785385B2 (en) 2010-04-19 2014-07-22 Research Development Foundation RTEF-1 variants and uses thereof
US20110269735A1 (en) 2010-04-19 2011-11-03 Celera Corporation Genetic polymorphisms associated with statin response and cardiovascular diseases, methods of detection and uses thereof
EP2561076A1 (de) 2010-04-19 2013-02-27 Novartis Forschungsstiftung, Zweigniederlassung Friedrich Miescher Institute For Biomedical Research Modulation von xrn1
KR102071212B1 (ko) 2010-04-21 2020-01-30 애브비 바이오테크놀로지 리미티드 치료제의 제어된 전달을 위한 착용형 자동 주사 디바이스
WO2011133931A1 (en) 2010-04-22 2011-10-27 Genentech, Inc. Use of il-27 antagonists for treating inflammatory bowel disease
GB201006768D0 (en) 2010-04-22 2010-06-09 Cancer Rec Tech Ltd Method for obtaining dendritic cells
WO2011133886A2 (en) 2010-04-23 2011-10-27 Genentech, Inc. Production of heteromultimeric proteins
BR112012027531A2 (pt) 2010-04-29 2017-08-08 Hadasit Medical Res Service And Development Co Ltd método de tratamento e/ou prevenção de progresso e/ou atraso de desenvolvimento de hepatite em um indivíduo, uso de uma molécula imunológica anti-cd3 e composição farmacêutica
AU2011245117B2 (en) 2010-04-30 2015-03-12 Alexion Pharmaceuticals, Inc. Anti-C5a antibodies and methods for using the antibodies
EP2563394B1 (de) 2010-04-30 2018-03-21 Beth Israel Deaconess Medical Center Verfahren und zusammensetzungen zur behandlung von zöliakie
BR112012027828A2 (pt) 2010-05-03 2016-08-09 Genentech Inc composição de matéria, artigo de fabricação e método de redução da viscosidade de uma formulação contendo proteína e de preparação de uma formulação aquosa contendo proteína
CN102958941A (zh) 2010-05-03 2013-03-06 霍夫曼-拉罗奇有限公司 用于肿瘤诊断和治疗的组合物和方法
EP2566891B1 (de) 2010-05-03 2016-11-02 University Of Rochester Passive immunisierung gegen glucosaminidase für staphylococcus aureus-infektionen
EP3943154A1 (de) 2010-05-04 2022-01-26 Five Prime Therapeutics, Inc. Antikörper zur bindung von csf1r
WO2011140254A1 (en) 2010-05-04 2011-11-10 Adimab, Llc Antibodies against epidermal growth factor receptor (egfr) and uses thereof
WO2011140151A1 (en) 2010-05-04 2011-11-10 Dyax Corp. Antibodies against epidermal growth factor receptor (egfr)
SG185416A1 (en) 2010-05-06 2012-12-28 Novartis Ag Compositions and methods of use for therapeutic low density lipoprotein -related protein 6 (lrp6) antibodies
MX2012012927A (es) 2010-05-06 2013-05-01 Novartis Ag Composiciones y metodos de uso para anticuerpos multivalentes terapeuticos de proteina relacionada con lipoproteina de baja densidad 6 (lrp6).
DK2568976T3 (en) 2010-05-10 2016-01-11 Academia Sinica Zanamivir-phosphonate congener with the anti-influenza activity, and determining the sensitivity oseltamivir in influenza viruses
WO2011141823A2 (en) 2010-05-14 2011-11-17 Orega Biotech Methods of treating and/or preventing cell proliferation disorders with il-17 antagonists
WO2011143545A1 (en) 2010-05-14 2011-11-17 Rinat Neuroscience Corporation Heterodimeric proteins and methods for producing and purifying them
US8623375B2 (en) 2010-05-14 2014-01-07 Baxter International Inc. Chimeric OspA genes, proteins, and methods of use thereof
TWI500427B (zh) 2010-05-14 2015-09-21 Abbvie Inc Ｉｌ－１結合蛋白
CN102892791B (zh) 2010-05-17 2017-05-17 Emd密理博公司 用于纯化生物分子的刺激响应性聚合物
US20110287018A1 (en) 2010-05-19 2011-11-24 Philip Bosch Methods of Treating Interstitial Cystitis
WO2011146568A1 (en) 2010-05-19 2011-11-24 Genentech, Inc. Predicting response to a her inhibitor
CA2796576C (en) 2010-05-20 2015-06-23 F. Hoffmann-La Roche Ag Release reagent for vitamin d compounds
WO2011145085A2 (en) 2010-05-21 2011-11-24 Procognia (Israel) Ltd Novel antibodies and methods of use for the treatment and diagnosis of cancer
GB201008541D0 (en) 2010-05-21 2010-07-07 Univ Geneve Diagnostic methods
HRP20171095T4 (hr) 2010-05-25 2022-07-22 F. Hoffmann - La Roche Ag Postupci pročišćavanja polipeptida
WO2011147834A1 (en) 2010-05-26 2011-12-01 Roche Glycart Ag Antibodies against cd19 and uses thereof
CA2800744C (en) 2010-05-27 2018-09-04 Centocor Ortho Biotech Inc. Insulin-like growth factor 1 receptor binding peptides
WO2011149461A1 (en) 2010-05-27 2011-12-01 Medtronic, Inc. Anti-amyloid beta antibodies conjugated to sialic acid-containing molecules
RS63800B1 (sr) 2010-05-28 2022-12-30 Chugai Pharmaceutical Co Ltd Poboljšanje antitumorskog odgovora t ćelije
JP5904552B2 (ja) 2010-05-28 2016-04-13 国立研究開発法人国立がん研究センター 膵癌治療剤
RU2012153786A (ru) 2010-05-28 2014-07-10 Ново Нордиск А/С Стабильные многодозовые композиции, содержащие антитело и консервант
JP6050226B2 (ja) 2010-05-28 2016-12-21 ジェネンテック， インコーポレイテッド Ｌｄｈ及びｐｄｈｋ発現を下方制御することによる乳酸レベルの低下及びポリペプチド生産の増加
US9169329B2 (en) 2010-06-01 2015-10-27 Ludwig Institute For Cancer Research Antibodies directed to the receptor tyrosine kinase c-Met
WO2011153243A2 (en) 2010-06-02 2011-12-08 Genentech, Inc. Anti-angiogenesis therapy for treating gastric cancer
EP3957653A1 (de) 2010-06-02 2022-02-23 Dana Farber Cancer Institute, Inc. Humanisierte monoklonale antikörper und verfahren zu ihrer verwendung
EP2578232A4 (de) 2010-06-02 2013-11-20 Dainippon Sumitomo Pharma Co Behandlungsmittel für autoimmun-erkrankungen und allergische erkrankungen
WO2011153224A2 (en) 2010-06-02 2011-12-08 Genentech, Inc. Diagnostic methods and compositions for treatment of cancer
AU2011261240A1 (en) 2010-06-03 2013-01-10 Abraxis Bioscience, Llc Use of the SPARC microenvironment signature in the treatment of cancer
NZ701208A (en) 2010-06-03 2016-05-27 Genentech Inc Immuno-pet imaging of antibodies and immunoconjugates and uses thereof
EP3845904A1 (de) 2010-06-03 2021-07-07 Idexx Laboratories, Inc. Marker für nierenerkrankung
MX2012014080A (es) 2010-06-03 2013-05-01 Abbvie Biotechnology Ltd Usos y composiciones para el tratamiento de hidradenitis superativa (hs).
CN103037891A (zh) 2010-06-03 2013-04-10 雷蒙特亚特特拉维夫大学有限公司 治疗糖尿病的方法和能够治疗糖尿病的组合物
US8795664B2 (en) 2010-06-04 2014-08-05 Georg-August-Universität Göttingen Stiftung Öffentlichen Rechts, Universitätsmedizin Monoclonal antibodies targeting amyloid beta oligomers
GB201009455D0 (en) 2010-06-04 2010-07-21 King S College London Nanoparticles and their uses in molecular imaging
CA3220104A1 (en) 2010-06-08 2011-12-15 Genentech, Inc. Cysteine engineered antibodies and conjugates
WO2011156617A2 (en) 2010-06-09 2011-12-15 Aveo Pharmaceuticals, Inc. Anti-egfr antibodies
EP2580241B1 (de) 2010-06-09 2020-11-04 Queen Mary & Westfield College, University of London Annexin-1-antikörper
US20130089538A1 (en) 2010-06-10 2013-04-11 Novartis Forschungsstiftung, Zweigniederlassung Friedrich Miescher Institute forBiomedical Researh Treating cancer by modulating mammalian sterile 20-like kinase 3
GB201009861D0 (en) 2010-06-11 2010-07-21 Novartis Ag OMV vaccines
BR112012032206A2 (pt) 2010-06-16 2016-10-04 Abbvie Inc comparações de amostras de proteínas
US20110311527A1 (en) 2010-06-16 2011-12-22 Allergan, Inc. IL23p19 ANTIBODY INHIBITOR FOR TREATING OCULAR AND OTHER CONDITIONS
CN103080136B (zh) 2010-06-18 2015-08-12 霍夫曼-拉罗奇有限公司 抗Axl抗体及使用方法
NZ603581A (en) 2010-06-19 2015-05-29 Sloan Kettering Inst Cancer Anti-gd2 antibodies
BR112012033119A2 (pt) 2010-06-22 2016-10-25 Univ Colorado Regents anticorpos para o fragamento c3d do componente do complemento 3.
CA2803391C (en) 2010-06-22 2021-11-09 Neogenix Oncology, Inc. Npc1 antibodies that bind a muc5ac epitope
WO2011161119A1 (en) 2010-06-22 2011-12-29 F. Hoffmann-La Roche Ag Antibodies against insulin-like growth factor i receptor and uses thereof
JP6152944B2 (ja) 2010-06-23 2017-06-28 モナシュ、ユニバーシティＭｏｎａｓｈ Ｕｎｉｖｅｒｓｉｔｙ 束縛免疫原性組成物およびその用途
KR101924653B1 (ko) 2010-06-24 2018-12-03 제넨테크, 인크. 단백질-함유 제제를 안정화시키기 위한 알킬글리코시드 함유 조성물 및 방법
WO2011161189A1 (en) 2010-06-24 2011-12-29 F. Hoffmann-La Roche Ag Anti-hepsin antibodies and methods of use
CN103068400A (zh) 2010-06-25 2013-04-24 阿斯顿大学 具有脂类动员性质的糖蛋白及其治疗用途
WO2012003493A2 (en) 2010-07-01 2012-01-05 The Regents Of The University Of California Protein kinase ck2 gene mutations, amplifications and polymorphisms in human cancers and methods of use
WO2012003472A1 (en) 2010-07-02 2012-01-05 Aveo Pharmaceuticals, Inc. Anti-notch1 antibodies
WO2012004565A1 (en) 2010-07-06 2012-01-12 Robert White Cancer biomarker brf1
JP2013533746A (ja) 2010-07-06 2013-08-29 アベオ ファーマシューティカルズ， インコーポレイテッド 抗ｒｏｎ抗体
GB201011513D0 (en) 2010-07-08 2010-08-25 Danisco Method
US9485812B2 (en) 2010-07-08 2016-11-01 Honda Motor Co., Ltd. High frequency heating coil
CA2802305A1 (en) 2010-07-08 2012-01-12 Pronota N.V. Biomarker for hypertensive disorders of pregnancy
US20120009196A1 (en) 2010-07-08 2012-01-12 Abbott Laboratories Monoclonal antibodies against hepatitis c virus core protein
UY33492A (es) 2010-07-09 2012-01-31 Abbott Lab Inmunoglobulinas con dominio variable dual y usos de las mismas
EP2591000B1 (de) 2010-07-09 2017-05-17 Janssen Vaccines & Prevention B.V. Antikörper gegen humanes respiratorisches syncytialvirus (rsv) und ihre verwendung
NZ605449A (en) 2010-07-09 2015-03-27 Genentech Inc Anti-neuropilin antibodies and methods of use
CA2804550C (en) 2010-07-09 2021-01-05 Bionovion Holding B.V. Agonistic antibody to cd27
PT2591006T (pt) 2010-07-09 2019-07-29 Bioverativ Therapeutics Inc Moléculas de cadeia simples processáveis e polipéptidos preparados utilizando as mesmas
GB201011771D0 (en) 2010-07-13 2010-08-25 Bioinvent Int Ab Biological material and particular uses thereof
EP2593551B1 (de) 2010-07-15 2016-09-14 Technion Research & Development Foundation Ltd. Isolierte hochaffine einheiten mit t-zell-rezeptorähnlicher spezifität gegenüber nativen komplexen der mhc-klasse ii und autoantigenen gad-peptiden
EP3345925A3 (de) 2010-07-15 2018-09-26 Adheron Therapeutics, Inc. Auf die ec1-domäne von cadherin-11 gerichtete humanisierte antikörper sowie zugehörige zusammensetzungen und verfahren
AR082163A1 (es) 2010-07-15 2012-11-14 Hoffmann La Roche Anticuerpos especificamente ligantes del tslpr humano y metodos de utilizacion de los mismos
WO2012009705A1 (en) 2010-07-15 2012-01-19 Zyngenia, Inc. Ang-2 binding complexes and uses thereof
CA2805478A1 (en) 2010-07-15 2012-01-19 Technion Research & Development Foundation Ltd. Isolated high affinity entities with t-cell receptor like specificity towards native complexes of mhc class ii and diabetes-associated autoantigenic peptides
WO2012007137A1 (en) 2010-07-16 2012-01-19 Merck Patent Gmbh Peptide for use in the treatment of breast cancer and/or bone metastases
AU2011277983C1 (en) 2010-07-16 2016-09-29 Ablynx Nv Modified single domain antigen binding molecules and uses thereof
CN104634971A (zh) 2010-07-19 2015-05-20 霍夫曼-拉罗奇有限公司 鉴定响应抗癌疗法的可能性升高的患者的方法
JP6087816B2 (ja) 2010-07-19 2017-03-01 オタゴ イノベーション リミテッド シグナルバイオマーカー
WO2012010549A1 (en) 2010-07-19 2012-01-26 F. Hoffmann-La Roche Ag Method to identify a patient with an increased likelihood of responding to an anti-cancer therapy
JP5972871B2 (ja) 2010-07-20 2016-08-17 テバ・ファーマシューティカルズ・オーストラリア・ピーティワイ・リミテッド 抗ｉｌ−２３ヘテロ二量体特異的抗体
WO2012010582A1 (en) 2010-07-21 2012-01-26 Roche Glycart Ag Anti-cxcr5 antibodies and methods of use
EP2595637B1 (de) 2010-07-22 2017-11-01 Cellect Biotherapeutics Ltd. Immunregulatorische zellen mit verstärkter gezielter zelltodwirkung
SG187592A1 (en) 2010-07-23 2013-03-28 Univ Boston Anti-despr inhibitors as therapeutics for inhibition of pathological angiogenesis and tumor cell invasiveness and for molecular imaging and targeted delivery
EP2596025B1 (de) 2010-07-23 2018-06-20 INSERM (Institut National de la Santé et de la Recherche Médicale) Gegen co-029 gerichtete krebstherapieverfahren
EP2412724A1 (de) 2010-07-29 2012-02-01 Centre National de la Recherche Scientifique (C.N.R.S) Regulierung der Glypican-4-Aktivität zur Modulierung des Schicksals von Stammzellen und Verwendungen davon
JP2013533286A (ja) 2010-07-30 2013-08-22 セントルイス ユニバーシティ 疼痛を治療する方法
BR112013002334A2 (pt) 2010-07-30 2016-05-24 Medimmune Llc método para purificar polipeptídeos ou imunoconjugados ativos.
ES2667100T3 (es) 2010-08-02 2018-05-09 Macrogenics, Inc. Diacuerpos covalentes y sus usos
KR20130045914A (ko) 2010-08-03 2013-05-06 에프. 호프만-라 로슈 아게 만성 림프구성 백혈병(cll) 생체지표
KR20130100118A (ko) 2010-08-03 2013-09-09 아비에 인코포레이티드 이원 가변 도메인 면역글로불린 및 이의 용도
WO2012019024A2 (en) 2010-08-04 2012-02-09 Immunogen, Inc. Her3-binding molecules and immunoconjugates thereof
US8901074B2 (en) 2010-08-04 2014-12-02 Ramot At Tel-Aviv University Methods of treating autoimmune diseases of the central nervous system (CNS) and neurodegenerative diseases
WO2012019061A2 (en) 2010-08-05 2012-02-09 Stem Centrx, Inc. Novel effectors and methods of use
BR112013002532A2 (pt) 2010-08-05 2016-05-31 Hoffmann La Roche proteína de fusão de citocina anti-viral do anticorpo anti-mhc
CA2807552A1 (en) 2010-08-06 2012-02-09 Moderna Therapeutics, Inc. Engineered nucleic acids and methods of use thereof
US20120101108A1 (en) 2010-08-06 2012-04-26 Cell Signaling Technology, Inc. Anaplastic Lymphoma Kinase In Kidney Cancer
JP5899213B2 (ja) 2010-08-06 2016-04-06 マイカーティス エヌ．ヴェ．ＭｙＣａｒｔｉｓ ＮＶ 腎機能不全のバイオマーカーとしてのパールカン
AU2011286407A1 (en) 2010-08-06 2013-02-21 Amgen Use of HER3 binding agents in prostate treatment
US20140072983A1 (en) 2010-08-10 2014-03-13 Amgen Inc. Dual function in vitro target binding assay for the detection of neutralizing antibodies against target antibodies
EP2420250A1 (de) 2010-08-13 2012-02-22 Universitätsklinikum Münster Anti-Syndecan-4-Antikörper
EP2603237A4 (de) 2010-08-12 2014-05-21 Theraclone Sciences Inc Anti-hämagglutinin-antikörperzusammensetzungen und verfahren zu ihrer anwendung
US20130137627A1 (en) 2010-08-12 2013-05-30 Christophe Delacourt Methods and kits for identifying a premature infant at risk of having or developing bronchopulmonary dysplasia
PE20171512A1 (es) 2010-08-13 2017-10-20 Roche Glycart Ag Anticuerpos anti-fap
BR112013002444A2 (pt) 2010-08-13 2016-05-24 Roche Glycart Ag anticorpo, polinucleotídeo e polipeotídeo isolados, composição, vetor, cécula hospedeira, conjulgado de anticorpo, formulação farmacêutica, uso do anticorpo, métodos para produzir um anticorpo, tratar um indivíduo, induzir a lise celular de uma célula tumorosa e diagnosticar uma doença em um indivíduo
CN104474546A (zh) 2010-08-13 2015-04-01 弗·哈夫曼-拉罗切有限公司 用于疾病治疗的针对IL-1β和IL-18的抗体
US9062101B2 (en) 2010-08-14 2015-06-23 AbbVie Deutschland GmbH & Co. KG Amyloid-beta binding proteins
PH12013500315A1 (en) 2010-08-16 2013-04-29 Amgen Inc Antibodies that bind myostatin, compositions and methods
WO2012022734A2 (en) 2010-08-16 2012-02-23 Medimmune Limited Anti-icam-1 antibodies and methods of use
WO2012023622A1 (ja) 2010-08-16 2012-02-23 国立大学法人九州大学 腫瘍の検査用試薬及び腫瘍の予防用医薬組成物
NZ604510A (en) 2010-08-17 2013-10-25 Csl Ltd Dilutable biocidal compositions and methods of use
EP2606071B1 (de) 2010-08-17 2019-12-18 F.Hoffmann-La Roche Ag Humaner anti-igg1-antikörper
KR101234807B1 (ko) 2010-08-18 2013-02-19 한국원자력의학원 혈관신생 촉진용 약학 조성물 및 혈관신생 촉진용 활성물질을 스크리닝하는 방법
ES2555864T3 (es) 2010-08-19 2016-01-11 F. Hoffmann-La Roche Ag Ensayo para la medición de anticuerpos de unión a un anticuerpo monoclonal terapéutico
ES2665954T3 (es) 2010-08-19 2018-04-30 Zoetis Belgium S.A. Anticuerpos anti-NGF y su uso
GB201014033D0 (en) 2010-08-20 2010-10-06 Ucb Pharma Sa Biological products
EP2606119A1 (de) 2010-08-20 2013-06-26 Wyeth LLC Zellkultur aus wachstumsfaktorfreien adaptierten zellen
ME02637B (de) 2010-08-20 2017-06-20 Novartis Ag Antikörper für den epidermalen wachstumsfaktorrezeptor 3 (her 3)
CA2808975C (en) 2010-08-23 2018-10-30 Wyeth Llc Stable formulations of neisseria meningitidis rlp2086 antigens
LT2609118T (lt) 2010-08-23 2017-04-25 Board Of Regents, The University Of Texas System Anti-ox40 antikūnai ir jų panaudojimo būdai
CN103068846B9 (zh) 2010-08-24 2016-09-28 弗·哈夫曼-拉罗切有限公司 包含二硫键稳定性Fv片段的双特异性抗体
WO2012027440A1 (en) 2010-08-24 2012-03-01 Abbott Laboratories Hiv core protein specific antibodies and uses thereof
KR101603001B1 (ko) 2010-08-25 2016-03-11 에프. 호프만-라 로슈 아게 Il-18r1에 대한 항체 및 그의 용도
US9068006B2 (en) 2010-08-25 2015-06-30 President And Fellows Of Harvard College Glycated CD59 peptides, their preparation, and uses thereof
US9046513B2 (en) 2010-08-26 2015-06-02 Abbvie Inc. Dual variable domain immunoglobulins and uses thereof
WO2012027721A2 (en) 2010-08-27 2012-03-01 Gilead Biologics, Inc Antibodies to matrix metalloproteinase 9
SG10201506782XA (en) 2010-08-27 2015-10-29 Stem Centrx Inc Notum protein modulators and methods of use
SG10201408229WA (en) 2010-08-31 2015-02-27 Genentech Inc Biomarkers and methods of treatment
CA3201524C (en) 2010-08-31 2026-01-13 International Aids Vaccine Initiative Human immunodeficiency virus (hiv)-neutralizing antibodies
CA2809568C (en) 2010-09-01 2019-06-11 Genzyme Corporation Treatment of myocardial infarction using tgf - beta antagonists
EP2426213A1 (de) 2010-09-03 2012-03-07 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. Marker zur Sunitnibresistenzbildung
CA2809864A1 (en) 2010-09-03 2012-03-08 Stem Centrx, Inc. Identification and enrichment of cell subpopulations
WO2012030512A1 (en) 2010-09-03 2012-03-08 Percivia Llc. Flow-through protein purification process
CN106620693A (zh) 2010-09-03 2017-05-10 艾伯维施特姆森特克斯有限责任公司 新型调节剂及使用方法
WO2013119964A2 (en) 2012-02-08 2013-08-15 Stem Centrx, Inc. Identification and enrichment of cell subpopulations
WO2012032043A1 (en) 2010-09-07 2012-03-15 Areva Med Llc 212 pb imaging
CN103502466A (zh) 2010-09-07 2014-01-08 斯隆－凯特林纪念癌症中心 用于γ-分泌酶测定的方法和组合物
EP2614083A2 (de) 2010-09-08 2013-07-17 Yeda Research and Development Co. Ltd Immunsuppresive wirkstoffkombination für stabiles und langfristiges anwachsen
NZ729044A (en) 2010-09-09 2020-07-31 Pfizer 4-1bb binding molecules
KR101584871B1 (ko) 2010-09-10 2016-01-22 와이어쓰 엘엘씨 네이세리아 메닝기티디스 orf2086 항원의 비-지질화된 변이체
US20130171159A1 (en) 2010-09-10 2013-07-04 Brian Arthur Hemmings Phosphorylated twist1 and metastasis
US8551479B2 (en) 2010-09-10 2013-10-08 Oncomed Pharmaceuticals, Inc. Methods for treating melanoma
EP2616807A1 (de) 2010-09-13 2013-07-24 Abbvie Inc. Hochsensitiver test für den nachweis von monoklonalen antikörperresten
EP2616100B1 (de) 2010-09-17 2016-08-31 Compugen Ltd. Zusammensetzungen und verfahren zur behandlung von wirkstoffresistentem multiplem myelom
CA2810909A1 (en) 2010-09-20 2012-03-29 Abbvie Inc. Purification of antibodies using simulated moving bed chromatography
AU2011305371B2 (en) 2010-09-21 2015-05-21 Massachusetts Institute Of Technology Human-adapted HA polypeptides, vaccines, and influenza treatment
CA2885176C (en) 2010-09-22 2018-10-23 Amgen Inc. Carrier immunoglobulins and uses thereof
CA2812644A1 (en) 2010-09-27 2012-04-05 Zestagen, S.A. Compositions and methods for treating neoplasia
EP2621950A4 (de) 2010-09-27 2015-09-02 Janssen Biotech Inc Antikörper zur bindung von humanem kollagen ii
ES2874306T3 (es) 2010-09-29 2021-11-04 Agensys Inc Conjugados de anticuerpos y fármacos (CAF) que se unen a las proteínas 191P4D12
ES2537017T3 (es) 2010-09-29 2015-06-01 Nb Health Laboratory Co. Ltd. Anticuerpo dirigido contra el receptor EP4 de la prostaglandina E2 humano
US8530427B2 (en) 2010-09-30 2013-09-10 Mayo Foundation For Medical Education And Research Methods for modulating resistance to apoptosis using KLK6
US9675693B2 (en) 2010-09-30 2017-06-13 Riken Methods and drugs targeting Eva1 or Ceacam1 gene expression for treatment and diagnosing of glioma
CN107412756A (zh) 2010-10-01 2017-12-01 宾夕法尼亚大学理事会 李斯特菌疫苗载体用于在寄生虫感染的个体中扭转免疫无应答的用途
US9228023B2 (en) 2010-10-01 2016-01-05 Oxford Biotherapeutics Ltd. Anti-ROR1 antibodies and methods of use for treatment of cancer
EP2857499A1 (de) 2010-10-01 2015-04-08 Moderna Therapeutics, Inc. Manipulierte Nukleinsäuren und Verfahren zur Verwendung davon
UA112062C2 (uk) 2010-10-04 2016-07-25 Бьорінгер Інгельхайм Інтернаціональ Гмбх Cd33-зв'язувальний агент
AU2011312178B2 (en) 2010-10-04 2016-05-12 Massachusetts Institute Of Technology Hemagglutinin polypeptides, and reagents and methods relating thereto
EP2625203A1 (de) 2010-10-05 2013-08-14 Novartis AG Anti-il12rbeta1-antikörper und ihre verwendung zur behanldung von autoimmun- und entzündungserkrankungen
US8481680B2 (en) 2010-10-05 2013-07-09 Genentech, Inc. Mutant smoothened and methods of using the same
ES2562274T3 (es) 2010-10-06 2016-03-03 Fundació Institut De Recerca Biomèdica (Irb Barcelona) Procedimiento para el diagnóstico, pronóstico y tratamiento de metástasis de cáncer de mama
FR2965810B1 (fr) 2010-10-06 2012-12-28 Commissariat Energie Atomique Anticorps antagoniste du sous-type b des recepteurs aux endothelines et ses utilisations
JP2013545969A (ja) 2010-10-15 2013-12-26 ユニヴェルシテ リブル ドゥ ブリュッセル エストロゲン受容体αポリペプチド配列、並びにその診断および治療用途
CA2813796C (en) 2010-10-18 2019-01-15 Mediapharma S.R.L. Erbb3 binding antibody
WO2012054077A2 (en) 2010-10-19 2012-04-26 Mayo Foundation For Medical Education And Research Human antibodies and diagnostic and therapeutic uses thereof for the treatment of neurological disease
CA2812785A1 (en) 2010-10-20 2012-04-26 Genentech, Inc. Methods and compositions for modulating the wnt pathway
JP6121906B2 (ja) 2010-10-22 2017-04-26 シアトル ジェネティクス，インコーポレーテッド アウリスタチン系抗体薬物複合体とＰＩ３Ｋ−ＡＫＴｍＴＯＲ経路インヒビターの間の相乗効果
AU2011323784A1 (en) 2010-10-25 2013-05-30 Regents Of The University Of Minnesota Therapeutic composition for treatment of glioblastoma
EP3214442A1 (de) 2010-10-25 2017-09-06 F. Hoffmann-La Roche AG Behandlung von gastrointestinalen entzündungen und psoriasis und asthmaentzündung und psoriasis a
EP3838922A1 (de) 2010-10-27 2021-06-23 Amgen Inc. Dkk1-antikörper-zusammensetzungen und verfahren zur verwendung
WO2012058418A2 (en) 2010-10-27 2012-05-03 The Research Foundation Of State University Of New York Compositions targeting the soluble extracellular domain of e-cadherin and related methods for cancer therapy
CN103370337B (zh) 2010-10-28 2015-12-09 耶达研究及发展有限公司 用于产生针对金属酶的抗体的方法
KR20130130732A (ko) 2010-11-01 2013-12-02 제넨테크, 인크. 다유전자 스코어를 이용한 진행성 노인성 황반 변성으로의 진행 예측
US20120108651A1 (en) 2010-11-02 2012-05-03 Leiden University Medical Center (LUMC) Acting on Behalf of Academic Hospital Leiden (AZL) Genetic polymorphisms associated with venous thrombosis and statin response, methods of detection and uses thereof
KR102049223B1 (ko) 2010-11-04 2019-11-28 베링거 인겔하임 인터내셔날 게엠베하 항－ｉｌ－２３ 항체
CA2816763A1 (en) 2010-11-05 2012-05-10 Transbio Ltd Markers of endothelial progenitor cells and uses thereof
CN103429620B (zh) 2010-11-05 2018-03-06 酵活有限公司 在Fc结构域中具有突变的稳定异源二聚的抗体设计
WO2012064743A2 (en) 2010-11-08 2012-05-18 The Johns Hopkins University Methods for improving heart function
KR101933197B1 (ko) 2010-11-08 2018-12-27 제넨테크, 인크. 피하 투여용 항―ｉｌ―6 수용체 항체
AU2011326564A1 (en) 2010-11-10 2013-05-09 Genentech, Inc. Methods and compositions for neural disease immunotherapy
GB201019118D0 (en) 2010-11-11 2010-12-29 King S College Conjugates and their uses in molecular imaging
US9297813B2 (en) 2010-11-11 2016-03-29 Agency For Science, Technology And Research Targeting metabolic enzymes in human cancer
CN103282385A (zh) 2010-11-12 2013-09-04 美国洛克菲勒大学 用于hiv治疗的融合蛋白
EP2640738A1 (de) 2010-11-15 2013-09-25 Novartis Forschungsstiftung, Zweigniederlassung Friedrich Miescher Institute For Biomedical Research Antimykotische wirkstoffe
EP2640831A1 (de) 2010-11-17 2013-09-25 Sea Lane Biotechnologies,llc. Die bindungsstelle eines influenzaneutralisierenden antikörpers nachahmende influenzavirusneutralisierungsmittel
EP2640727B1 (de) 2010-11-17 2015-05-13 Genentech, Inc. Alaninylmaytansinol-antikörperkonjugate
EP2641967B1 (de) 2010-11-18 2016-10-12 National University Corporation Okayama University Verfahren zur herstellung einer b-zelle die humane antikörper produziert
WO2012068463A2 (en) 2010-11-18 2012-05-24 Beth Israel Deaconess Medicall Center, Inc. Methods of treating obesity by inhibiting nicotinamide n-methyl transferase (nnmt)
MX361929B (es) 2010-11-19 2018-12-19 Eisai R&D Man Co Ltd Star Anticuerpos anti-ligando de quimiocina cc 20 (ccl20) neutralizantes.
MX351887B (es) 2010-11-23 2017-11-01 Glaxo Group Ltd Proteinas de union a antigeno para oncostatina m (osm).
CA2818827C (en) 2010-11-23 2024-02-13 Pantheryx, Inc. Compositions and methods for treatment in broad-spectrum, undifferentiated or mixed clinical applications
US8992908B2 (en) 2010-11-23 2015-03-31 Alderbio Holdings Llc Anti-IL-6 antibodies for the treatment of oral mucositis
MX385858B (es) 2010-11-24 2025-03-18 Lexicon Pharmaceuticals Inc Anticuerpos que se unen a notum pectinacetilesterasa.
WO2012071436A1 (en) 2010-11-24 2012-05-31 Genentech, Inc. Method of treating autoimmune inflammatory disorders using il-23r loss-of-function mutants
CN103415615B (zh) 2010-11-24 2015-11-25 高红 扩增造血干细胞
WO2012069466A1 (en) 2010-11-24 2012-05-31 Novartis Ag Multispecific molecules
TWI654203B (zh) 2010-11-30 2019-03-21 Chugai Seiyaku Kabushiki Kaisha 具有鈣依存性的抗原結合能力之抗體
WO2012075111A1 (en) 2010-11-30 2012-06-07 Novartis Ag Uses of anti-cd40 antibodies in combination therapy for b cell-related cancers
CN103443125B (zh) 2010-11-30 2019-05-03 霍夫曼-拉罗奇有限公司 低亲和力血脑屏障受体抗体及其用途
WO2012075173A2 (en) 2010-12-01 2012-06-07 Board Of Regents The University Of Texas System Compositions and method for deimmunization of proteins
WO2012072769A1 (en) 2010-12-01 2012-06-07 Novartis Ag Pneumococcal rrgb epitopes and clade combinations
US9783601B2 (en) 2010-12-01 2017-10-10 Alderbio Holdings Llc Methods of preventing inflammation and treating pain using anti-NGF compositions
WO2012075333A2 (en) 2010-12-02 2012-06-07 Prometheus Laboratories Inc. Her2delta16 peptides
CA2819886A1 (en) 2010-12-06 2012-06-14 Pronota N.V. Biomarkers and parameters for hypertensive disorders of pregnancy
PH12013501137A1 (en) 2010-12-08 2021-06-02 Abbvie Stemcentrx Llc Novel modulators and methods of use
WO2012102793A2 (en) 2010-12-10 2012-08-02 Zirus, Inc. Mammalian genes involved in toxicity and infection
PL2651975T3 (pl) 2010-12-14 2018-04-30 Dso Nat Laboratories Ludzkie przeciwciało monoklonalne o swoistości względem białka e wirusa denga serotypu 1 i jego zastosowania
WO2012080926A2 (en) 2010-12-15 2012-06-21 Wyeth Llc Anti-notch1 antibodies
WO2012080769A1 (en) 2010-12-15 2012-06-21 INSERM (Institut National de la Santé et de la Recherche Médicale) Anti-cd277 antibodies and uses thereof
KR101615420B1 (ko) 2010-12-16 2016-04-26 제넨테크, 인크. Th2 억제에 관한 진단 및 치료
TW201239097A (en) 2010-12-17 2012-10-01 Sanofi Sa MiRNAs in joint disease
TW201238974A (en) 2010-12-17 2012-10-01 Sanofi Sa MiRNAs in joint disease
TW201241179A (en) 2010-12-17 2012-10-16 Sanofi Sa MiRNAs in joint disease
TW201238973A (en) 2010-12-17 2012-10-01 Sanofi Sa MiRNAs in joint disease
AU2011349443B2 (en) 2010-12-20 2015-12-24 Genentech, Inc. Anti-mesothelin antibodies and immunoconjugates
WO2012087928A2 (en) 2010-12-20 2012-06-28 The Rockefeller University Modulating agonistic tnfr antibodies
BR112013015508B1 (pt) 2010-12-20 2022-04-05 Medimmune Limited Molécula de anticorpo para il-18 humana, domínio vh isolado e domínio vl isolado, composição, uso de uma molécula de anticorpo ou do domínio vh isolado e do domínio vl isolado, molécula de ácido nucleico isolada, célula hospedeira procariótica recombinante, método para produzir um anticorpo, e método in vitro para medir il-18 em uma amostra de um indivíduo
US9631002B2 (en) 2010-12-21 2017-04-25 The University Of North Carolina At Chapel Hill Methods and compositions for producing active vitamin K-dependent proteins
MX2013007332A (es) 2010-12-21 2014-01-23 Abbvie Inc Inmunoglobulinas de dominio variable doble biespecificas de il-1 alfa y beta y su uso.
WO2012088094A2 (en) 2010-12-21 2012-06-28 Abbott Laboratories Il-1 binding proteins
EP3222635A1 (de) 2010-12-21 2017-09-27 Selexys Pharmaceuticals Corporation Anti-p-selectin-antikörper und verfahren zu ihrer verwendung und identifizierung
WO2012085132A1 (en) 2010-12-22 2012-06-28 Orega Biotech Antibodies against human cd39 and use thereof
CN103261230A (zh) 2010-12-22 2013-08-21 霍夫曼-拉罗奇有限公司 抗pcsk9抗体及使用方法
AU2011349049B2 (en) 2010-12-22 2016-08-11 Teva Pharmaceuticals Australia Pty Ltd Modified antibody with improved half-life
EP2655413B1 (de) 2010-12-23 2019-01-16 F.Hoffmann-La Roche Ag Polypeptid-polynukleotid-komplex und verwendung bei der gezielten effektorrest-bereitstellung
SG191230A1 (en) 2010-12-23 2013-07-31 Nestec Sa Drug selection for malignant cancer therapy using antibody-based arrays
US11141063B2 (en) 2010-12-23 2021-10-12 Philips Image Guided Therapy Corporation Integrated system architectures and methods of use
MX2013007527A (es) 2010-12-27 2014-02-27 Japan Health Science Found Anticuerpo monoclonal que reconoce la proteina l2 de virus de papiloma humano y metodo para medir el titulo del anticuerpo neutralizante de vph utilizando el mismo.
WO2012090939A1 (ja) 2010-12-27 2012-07-05 国立大学法人名古屋大学 受容体型チロシンキナーゼが仲介する癌細胞の生存促進性シグナルを抑制する方法
US20140038842A1 (en) 2010-12-28 2014-02-06 Xoma Technology Cell surface display using pdz domains
EP2471554A1 (de) 2010-12-28 2012-07-04 Hexal AG Pharmazeutische Formulierung mit biopharmazeutischem Arzneimittel
WO2012092374A2 (en) 2010-12-31 2012-07-05 Short Jay M Express humanization of antibodies
WO2012092539A2 (en) 2010-12-31 2012-07-05 Takeda Pharmaceutical Company Limited Antibodies to dll4 and uses thereof
AU2011352207B2 (en) * 2010-12-31 2016-03-03 Bioatla, Llc Comprehensive monoclonal antibody generation
US11040140B2 (en) 2010-12-31 2021-06-22 Philips Image Guided Therapy Corporation Deep vein thrombosis therapeutic methods
US20120171195A1 (en) 2011-01-03 2012-07-05 Ravindranath Mepur H Anti-hla-e antibodies, therapeutic immunomodulatory antibodies to human hla-e heavy chain, useful as ivig mimetics and methods of their use
JP2014502607A (ja) 2011-01-03 2014-02-03 エフ．ホフマン−ラ ロシュ アーゲー 抗ｄｉｇ抗体およびペプチドと結合体化しているジゴキシゲニンの複合体の薬学的組成物
WO2012093340A2 (en) 2011-01-07 2012-07-12 Bioscience Slovakia Viral diagnostics
US20140080153A1 (en) 2011-01-07 2014-03-20 Chugai Seiyaku Kabushiki Kaisha Method for improving physical properties of antibody
KR20200023495A (ko) 2011-01-10 2020-03-04 더 리젠츠 오브 더 유니버시티 오브 미시간 줄기 세포 인자 억제제
EP3467487A1 (de) 2011-01-11 2019-04-10 The Governing Council Of The University Of Toronto Proteinnachweisverfahren
US20140065154A1 (en) 2011-01-12 2014-03-06 Innate Pharma Tlr3 binding agents
WO2012097238A2 (en) 2011-01-14 2012-07-19 Five Prime Therapeutics, Inc. Il-27 antagonists for treating inflammatory diseases
US20120196294A1 (en) 2011-01-17 2012-08-02 Life Technologies Corporation Workflow for detection of ligands using nucleic acids
WO2012099983A1 (en) 2011-01-18 2012-07-26 Amgen Inc. Nav1.7 knockout mice and uses thereof
JP5940093B2 (ja) 2011-01-19 2016-06-29 カンタージア アクチエボラーグ 抗ｉｌ−１ｒａｐ抗体及びヒトを処置するためのそれらの使用
CN103477197B (zh) 2011-01-21 2016-08-17 提拉诺斯公司 样品使用最大化的系统和方法
WO2012101125A1 (en) 2011-01-24 2012-08-02 INSERM (Institut National de la Santé et de la Recherche Médicale) Specific antibodies against human cxcl4 and uses thereof
SG192119A1 (en) 2011-01-24 2013-08-30 Abbvie Biotechnology Ltd Automatic injection devices having overmolded gripping surfaces
US20120189633A1 (en) 2011-01-26 2012-07-26 Kolltan Pharmaceuticals, Inc. Anti-kit antibodies and uses thereof
US20140050728A1 (en) 2011-01-28 2014-02-20 Board Of Regents Of The University Of Nebraska Methods and compositions for inhibiting cyclophilin d for the treatment and prevention of obesity and kidney indications
WO2012106556A2 (en) 2011-02-02 2012-08-09 Amgen Inc. Methods and compositons relating to inhibition of igf-1r
US9669092B2 (en) 2011-02-02 2017-06-06 Emory University Antagonism of the VIP signaling pathway
TW201244737A (en) 2011-02-03 2012-11-16 Alexion Pharma Inc Use of an anti-CD200 antibody for prolonging the survival of allografts
WO2012106615A1 (en) 2011-02-03 2012-08-09 Xoma Technology Ltd. Methods and materials for enhancing functional protein expression in bacteria
US10689447B2 (en) 2011-02-04 2020-06-23 Genentech, Inc. Fc variants and methods for their production
WO2012106669A2 (en) 2011-02-04 2012-08-09 John Wayne Cancer Institute Foxc1 antibodies and methods of their use
AR085138A1 (es) 2011-02-04 2013-09-11 Genentech Inc VARIANTES DE Fc Y METODOS PARA SU PRODUCCION
RU2440142C1 (ru) 2011-02-07 2012-01-20 Общество С Ограниченной Ответственностью "Онкомакс" Антитело, останавливающее или замедляющее рост опухоли (варианты), способ подавления роста опухоли, способ диагностики злокачественных образований
CA2826467C (en) 2011-02-07 2019-11-12 Research Development Foundation Engineered immunoglobulin fc polypeptides
EP2487242A1 (de) 2011-02-09 2012-08-15 Ruprecht-Karls-Universität Heidelberg B-Plexin-Antagonisten und Verwendungen davon
RU2013139267A (ru) 2011-02-10 2015-03-20 Рош Гликарт Аг Улучшенная иммунотерапия
MX2013009258A (es) 2011-02-11 2013-10-17 Novartis Ag Antagonistas de pcsk9.
WO2012107589A1 (en) 2011-02-11 2012-08-16 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and pharmaceutical compositions for the treatment and prevention of hcv infections
AU2012217867A1 (en) 2011-02-14 2013-09-05 Theraclone Sciences, Inc. Compositions and methods for the therapy and diagnosis of influenza
WO2012112842A2 (en) 2011-02-17 2012-08-23 The Government Of The United States Of America, As Represented By The Secretary, Department Of Health & Human Services Compositions and methods for treating poliovirus
WO2012110824A1 (en) 2011-02-18 2012-08-23 Astrazeneca Ab Binding agents with specificity for a nucleic acid modification
SA112330278B1 (ar) 2011-02-18 2015-10-09 ستيم سينتركس، انك. مواد ضابطة جديدة وطرق للاستخدام
WO2012110843A1 (en) 2011-02-18 2012-08-23 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and pharmaceutical compositions for promoting fibrinolysis and thrombolysis
WO2012113718A1 (en) 2011-02-21 2012-08-30 Roche Diagnostics Gmbh A diagnostic method for type ii diabetes
US20130330349A1 (en) 2011-02-23 2013-12-12 Rappaport Family Institute For Research In The Medical Sciences High affinity molecules capable of binding a type a plexin receptor and uses of same
CN103582815A (zh) 2011-02-24 2014-02-12 佛米利昂公司 用于卵巢癌的生物标志物组、诊断方法和测试试剂盒
FR2972006B1 (fr) 2011-02-24 2016-03-25 Centre Nat Rech Scient Nouveaux fragments d'il-33 superactifs et leurs utilisations
SG10201609665PA (en) 2011-02-25 2017-01-27 Chugai Pharmaceutical Co Ltd FcɣRIIb-SPECIFIC Fc ANTIBODY
US10842849B2 (en) 2011-02-28 2020-11-24 The Schepens Eye Research Institute, Inc. Methods for promoting neuronal outgrowth by insulin-like growth factor binding protein-like 1 (IGFBPL-1) in glaucoma or leber's optic neuropathy
US20140105898A1 (en) 2011-02-28 2014-04-17 Istituto Di Ricovero E Cura A Carattere Scientific Materno-Infantile Burlo Garo Apoptosis-inducing molecules and uses therefor
RU2013140975A (ru) 2011-02-28 2015-04-10 Дженентек, Инк. Биологические маркеры и способы прогнозирования восприимчивости к антагонистам в-клеток
JP5768147B2 (ja) 2011-02-28 2015-08-26 エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ 一価抗原結合タンパク質
WO2012118693A1 (en) 2011-02-28 2012-09-07 Northshore University Healthsystem Methods of diagnosing clostridium difficile infection
JP2014509588A (ja) 2011-03-01 2014-04-21 アムジエン・インコーポレーテツド 二特異性結合剤
EP2680925B1 (de) 2011-03-02 2019-11-20 Berg LLC Interrogatorische zellbasierte assays und verwendung derselben
KR101981342B1 (ko) 2011-03-02 2019-05-22 로슈 글리카트 아게 Cea 항체
EP2681314B1 (de) 2011-03-03 2017-11-01 Quark Pharmaceuticals, Inc. Zusammensetzungen und verfahren zur behandlung von lungenerkrankungen und läsionen
WO2012119989A2 (en) 2011-03-04 2012-09-13 Oryzon Genomics, S.A. Methods and antibodies for the diagnosis and treatment of cancer
JP6100704B2 (ja) 2011-03-07 2017-03-22 エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト 治療用抗体についてのインビボ試験の手段および方法
WO2012120004A1 (en) 2011-03-07 2012-09-13 F. Hoffmann-La Roche Ag In vivo selection of therapeutically active antibodies
US9061006B2 (en) 2011-03-08 2015-06-23 Ramot At Tel-Aviv University Ltd. Compositions and methods for diagnosing and treating phenylketonuria (PKU)
EP2684045B2 (de) 2011-03-09 2023-03-29 INSERM (Institut National de la Santé et de la Recherche Médicale) Verfahren zur charakterisierung von patienten mit hämolyse
AU2012225310B2 (en) 2011-03-09 2017-08-03 Cell Signaling Technology, Inc. Methods and reagents for creating monoclonal antibodies
CN103619876A (zh) 2011-03-10 2014-03-05 Hco抗体股份有限公司 双特异性三链抗体样分子
WO2012122512A1 (en) 2011-03-10 2012-09-13 Hco Antibody, Inc. Recombinant production of mixtures of single chain antibodies
HUE065915T2 (hu) 2011-03-11 2024-06-28 Beth Israel Deaconess Medical Ct Inc Anti-CD40 antitestek és alkalmazásaik
CA2829960A1 (en) 2011-03-11 2012-09-20 John Rothman Listeria-based adjuvants
WO2012122590A1 (en) 2011-03-14 2012-09-20 Cellmid Limited Antibody recognizing n-domain of midkine
US20120238730A1 (en) 2011-03-15 2012-09-20 Abbott Laboratories Integrated approach to the isolation and purification of antibodies
AU2012229188A1 (en) 2011-03-15 2013-09-26 Theraclone Sciences, Inc. Compositions and methods for the therapy and diagnosis of influenza
WO2012125775A1 (en) 2011-03-16 2012-09-20 Sanofi Uses of a dual v region antibody-like protein
EP4086338A1 (de) 2011-03-17 2022-11-09 Minerva Biotechnologies Corporation Verfahren zur herstellung pluripotenter stammzellen
EP2686348B1 (de) 2011-03-17 2015-12-30 Ramot at Tel-Aviv University Ltd. Bi- und monospezifische, asymetrische Antikörper und Methoden zu deren Herstellung
JP2014523398A (ja) 2011-03-23 2014-09-11 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア 抗−インテグリンを用いた抗血管新生療法を改良するための方法及び組成物
TW201239355A (en) 2011-03-23 2012-10-01 Abbott Lab Methods and systems for the analysis of protein samples
US9555108B2 (en) 2011-03-24 2017-01-31 Texas Tech University System TCR mimic antibodies as vascular targeting tools
US9051619B2 (en) 2011-03-25 2015-06-09 Florida Agricultural and Mechanical University (FAMU) Methods and compositions for prostate cancer metastasis
PL2697369T3 (pl) 2011-03-25 2018-12-31 F.Hoffmann-La Roche Ag Nowe sposoby oczyszczania białek
LT2691417T (lt) 2011-03-29 2018-10-25 Roche Glycart Ag Antikūno fc variantai
AU2012237287B2 (en) 2011-03-30 2016-09-08 Ablynx Nv Methods of treating immune disorders with single domain antibodies against TNF-alpha
MX2013011130A (es) 2011-03-31 2013-10-30 Genentech Inc Metodos de administracion de antagonistas de integrina beta7.
WO2012133914A1 (ja) 2011-03-31 2012-10-04 オリエンタル酵母工業株式会社 Ranklアンタゴニストを含む癌免疫増強剤
KR102023661B1 (ko) 2011-03-31 2019-09-23 인쎄름 (엥스띠뛰 나씨오날 드 라 쌍떼 에 드 라 흐쉐르슈 메디깔) Icos에 대한 항체 및 이의 용도
CA2831613A1 (en) 2011-03-31 2012-10-04 Moderna Therapeutics, Inc. Delivery and formulation of engineered nucleic acids
CN103826657A (zh) 2011-04-04 2014-05-28 衣阿华大学研究基金会 改进疫苗免疫原性的方法
US9790262B2 (en) 2011-04-05 2017-10-17 Longevity Biotech, Inc. Compositions comprising glucagon analogs and methods of making and using the same
WO2012138694A2 (en) 2011-04-07 2012-10-11 Emory University Compositions comprising saccharide binding moieties and methods for targeted therapy
JP5908972B2 (ja) 2011-04-07 2016-04-26 アムジエン・インコーポレーテツド 新規な抗原結合タンパク質
CA2828890A1 (en) 2011-04-07 2012-10-11 Genentech, Inc. Anti-fgfr4 antibodies and methods of use
EP2694537A1 (de) 2011-04-08 2014-02-12 Danisco US Inc. Zusammensetzungen
CA2832565A1 (en) 2011-04-08 2012-10-11 Biogen Idec Ma Inc. Biomarkers predictive of therapeutic responsiveness to ifn.beta. and uses thereof
US20140186340A1 (en) 2011-04-08 2014-07-03 Gilead Biologics, Inc. Methods and Compositions for Normalization of Tumor Vasculature by Inhibition of LOXL2
DK2694108T3 (en) 2011-04-08 2018-08-20 Univ Leicester METHODS OF TREATING DISEASES ASSOCIATED WITH MASP-2 DEPENDENT COMPLEMENT ACTIVATION
US9644035B2 (en) 2011-04-08 2017-05-09 Omeros Corporation Methods for treating conditions associated with MASP-2 dependent complement activation
WO2012142164A1 (en) 2011-04-12 2012-10-18 The United States Of America, As Represented By The Secretary, Department Of Health & Human Services Human monoclonal antibodies that bind insulin-like growth factor (igf) i and ii
EP2511293A1 (de) 2011-04-13 2012-10-17 LEK Pharmaceuticals d.d. Verfahren zur Steuerung der Hauptkomplex-N-Glycan-Strukturen und der sauren Varianten und Variabilität in Bioprozessen, die rekombinante Proteine produzieren
US20140157443A1 (en) 2011-04-14 2014-06-05 St. Jude Children's Research Hospital Methods and compositions for detecting and modulating a novel mtor complex
RU2623161C2 (ru) 2011-04-15 2017-06-22 Компуджен Лтд. Полипептиды и полинуклеотиды и их применение для лечения иммунологических нарушений и рака
EP2514831A1 (de) 2011-04-19 2012-10-24 Pronota NV Neuer Biomarker zur Messung der Betazellaktivität
US20140178368A1 (en) 2011-04-19 2014-06-26 Leslie Lynne SHARP Combinations of anti-4-1bb antibodies and adcc-inducing antibodies for the treatment of cancer
KR101589135B1 (ko) 2011-04-20 2016-01-29 주식회사 셀앤바이오 인간화 항-ｅｍａｐｉｉ 항체 및 이의 용도
EP3699286A1 (de) 2011-04-20 2020-08-26 The Trustees of the University of Pennsylvania Dosierpläne und zusammensetzungen zur aav-vermittelten passiven immunisierung von luftbürtigen krankheitserregern
CA2833636A1 (en) 2011-04-20 2012-10-26 Amplimmune, Inc. Antibodies and other molecules that bind b7-h1 and pd-1
US9956345B2 (en) 2011-04-21 2018-05-01 Abbvie Inc. Wearable automatic injection device for controlled administration of therapeutic agents
MX383544B (es) 2011-04-21 2025-03-14 Univ Rockefeller Lisinas de bacteriofago de streptococcus para la deteccion y tratamiento de bacterias gram positivas
CA2833404A1 (en) 2011-04-21 2012-10-26 Garvan Institute Of Medical Research Modified variable domain molecules and methods for producing and using them b
EP2699256B1 (de) 2011-04-21 2017-09-27 The Regents of the University of Colorado, a body corporate Zusammensetzungen und verfahren zur behandlung von neuromyelitis optica
SG194567A1 (en) 2011-04-21 2013-12-30 Seattle Genetics Inc Novel binder-drug conjugates (adcs) and their use
JP6407714B2 (ja) 2011-04-25 2018-10-17 アドヴァンスド バイオサイエンス ラボラトリーズ インコーポレイテッド 短縮型ｈｉｖエンベロープタンパク質（ｅｎｖ）、前記に関連する方法及び組成物
EP2518157A1 (de) 2011-04-26 2012-10-31 Sanofi Testsysteme und Verfahren zur Identifizierung einer Verbindung, die die zelluläre DDR-Aktivität verändert
US10487114B2 (en) 2011-04-27 2019-11-26 Beth Israel Deaconess Medical Center, Inc. Methods for administering peptides for the generation of effective c/s conformation-specific antibodies to a human subject in need thereof
GB2490655A (en) 2011-04-28 2012-11-14 Univ Aston Modulators of tissue transglutaminase
US20140056912A1 (en) 2011-04-29 2014-02-27 Novartis Ag Methods of treating squamous cell carcinoma
WO2012146630A1 (en) 2011-04-29 2012-11-01 F. Hoffmann-La Roche Ag N-terminal acylated polypeptides, methods for their production and uses thereof
EA201391582A1 (ru) 2011-04-29 2014-03-31 Бристол-Майерс Сквибб Компани Режимы повышения дозы антител против ip-10
UA116189C2 (uk) 2011-05-02 2018-02-26 Мілленніум Фармасьютікалз, Інк. КОМПОЗИЦІЯ АНТИ-α4β7 АНТИТІЛА
UY34054A (es) 2011-05-02 2012-11-30 Millennium Pharm Inc FORMULACIÓN PARA ANTICUERPO ANTI-a(alfa)4B(Beta)7
WO2012151317A1 (en) 2011-05-03 2012-11-08 Genentech, Inc. Vascular disruption agents and uses thereof
WO2012151465A1 (en) 2011-05-04 2012-11-08 Pop Test, Llc Diagnostic device
HUE049154T2 (hu) 2011-05-04 2020-09-28 Omeros Corp Készítmények a MASP-2-függõ komplement-aktiválás gátlására
WO2015067913A1 (en) 2013-11-07 2015-05-14 Diagnodus Limited Biomarkers
GB201107467D0 (en) 2011-05-05 2011-06-15 Univ Leuven Kath Novel treatment of pain
EP2704739B1 (de) 2011-05-06 2017-07-12 The Government of the United States of America, as represented by the Secretary of the Department of Health and Human Services Gegen mesothelin gerichtetes rekombinantes immuntoxin
DK2707031T3 (da) 2011-05-08 2019-10-07 Legochem Biosciences Inc Protein-active agent conjugates and method for preparing the same
US9598496B2 (en) 2011-05-09 2017-03-21 Perseus Proteomics Inc. Antibody capable of specifically recognizing transferrin receptor
WO2012154889A1 (en) 2011-05-09 2012-11-15 The Cleveland Clinic Foundation Serum s100b and uses thereof
EP2707389B1 (de) 2011-05-12 2019-10-30 The Johns Hopkins University Testreagenzien für eine neurogranin-diagnosekit
EP2707723B1 (de) 2011-05-12 2016-02-10 Genentech, Inc. Lc-ms/ms-verfahren mit mehrfachreaktionsüberwachung zur erkennung therapeutischer antikörper in tierischen proben mittels rahmensignaturpeptiden
WO2012158704A1 (en) 2011-05-16 2012-11-22 Genentech, Inc. Fgfr1 agonists and methods of use
JP6400470B2 (ja) 2011-05-16 2018-10-03 ジェネロン（シャンハイ）コーポレイション リミテッド 多重特異性Ｆａｂ融合タンパク質および使用法
CN112225798B (zh) 2011-05-17 2023-07-18 洛克菲勒大学 人类免疫缺陷病毒中和抗体及其使用方法
EP2524699A1 (de) 2011-05-17 2012-11-21 Trion Research GmbH Impfstoffzubereitung mit trifunktionalen Antikörpern mit Antigenimmunogenität verbessernden Eigenschaften
WO2012156430A1 (en) 2011-05-17 2012-11-22 Trion Research Gmbh Vaccine preparation containing trifunctional antibodies with antigen immunogenicity enhancer properties
EP2710041A4 (de) 2011-05-18 2014-11-05 Parkinson S Inst Assay zur bestimmung der lrrk2-aktivität bei morbus parkinson
WO2012156447A1 (en) 2011-05-18 2012-11-22 Pronota N.V. New biomarker for the classification of ovarian tumours
ES2748577T3 (es) 2011-05-19 2020-03-17 Univ Michigan Regents Agentes de fijación de la integrina alfa-2 y uso de los mismos para inhibir la proliferación de las células de cáncer
US9127065B2 (en) 2011-05-19 2015-09-08 Institut National De La Sante Et De La Recherche Medicale (Inserm) Anti-human HER3 antibodies and uses thereof
EA033109B1 (ru) 2011-05-20 2019-08-30 Олдербайо Холдингз Ллк Способы ингибирования, профилактики или лечения диареи и/или поддержания соответствующих уровней электролитов и жидкости в толстой кишке субъекта, подвергающегося связанному с диареей состоянию, с помощью антитела против cgrp или фрагмента антитела против cgrp
PT3495392T (pt) 2011-05-20 2021-09-22 H Lundbeck As Composições anti-cgrp e a sua utilização
CN108014334B (zh) 2011-05-20 2021-11-30 H.伦德贝克公司 抗cgrp抗体和抗体片段用于在有需要的受试者中预防或抑制畏光或厌光的用途
WO2012162067A2 (en) 2011-05-21 2012-11-29 Macrogenics, Inc. Cd3-binding molecules capable of binding to human and non-human cd3
US9376495B2 (en) 2011-05-21 2016-06-28 Macrogenics, Inc. Deimmunized serum-binding domains and their use in extending serum half-life
DK2714738T3 (en) 2011-05-24 2019-01-28 Zyngenia Inc MULTIVALENT AND MONOVALENT MULTISPECIFIC COMPLEXES AND THEIR APPLICATIONS
US9067997B2 (en) 2011-05-25 2015-06-30 Innate Pharma Sa Anti-KIR antibodies for the treatment of inflammatory and autoimmune disorders
AR086543A1 (es) 2011-05-25 2014-01-08 Bg Medicine Inc Inhibidores de galectina-3 y metodos de uso de los mismos, composicion farmaceutica
EP2714737A1 (de) 2011-05-27 2014-04-09 Glaxo Group Limited Bcma (cd269/tnfrsf17)-bindende proteine
WO2012163848A1 (en) 2011-05-27 2012-12-06 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and pharmaceutical compositions for the treatment of crohn's disease
KR20140049993A (ko) 2011-06-02 2014-04-28 메사추세츠 인스티튜트 오브 테크놀로지 메타핵 줄기 세포의 dsRNA/DNA 하이브리드 게놈 복제 중간체
EP2530089A1 (de) 2011-06-03 2012-12-05 Bayer Pharma Aktiengesellschaft Neutralisierender Antikörper Mat3 gegen den Prolactinrezeptor und dessen therapeutische Verwendung
EP2714735B1 (de) 2011-06-03 2021-07-21 XOMA Technology Ltd. Tgf-beta-spezifische antikörper
US8691231B2 (en) 2011-06-03 2014-04-08 Merrimack Pharmaceuticals, Inc. Methods of treatment of tumors expressing predominantly high affinity EGFR ligands or tumors expressing predominantly low affinity EGFR ligands with monoclonal and oligoclonal anti-EGFR antibodies
WO2012170071A1 (en) 2011-06-06 2012-12-13 Elan Pharmaceuticas, Inc Mcam antagonists and methods of treatment
US9574002B2 (en) 2011-06-06 2017-02-21 Amgen Inc. Human antigen binding proteins that bind to a complex comprising β-Klotho and an FGF receptor
EP2717911A1 (de) 2011-06-06 2014-04-16 Novartis Forschungsstiftung, Zweigniederlassung Proteintyrosinphosphatase, nicht-rezeptor typ 11 (ptpn11) und dreifach negativer brustkrebs
US9244074B2 (en) 2011-06-07 2016-01-26 University Of Hawaii Biomarker of asbestos exposure and mesothelioma
US9561274B2 (en) 2011-06-07 2017-02-07 University Of Hawaii Treatment and prevention of cancer with HMGB1 antagonists
WO2012168399A1 (en) 2011-06-08 2012-12-13 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods for predicting, treating and modelling hormone resistance
CA2873852A1 (en) * 2011-06-08 2012-12-13 Indiana University Research And Technology Corporation Monoclonal antibody and antigens for diagnosing and treating lung disease and injury
BR112013031262A2 (pt) 2011-06-09 2016-11-22 Us Health "exotoxinas a de pseudomonas com menos epítopos imunogênicos de célula b e t, e seu uso no tratamento e prevenção de câncer, bem como molécula quimérica, ácido nucleico, vetor de expressão, células, composição farmacêutica e métodos para inibir crescimento de célula-alvo e de produção de endotoxinas a de pseudomonas e de molécula quimérica".
AU2012267732A1 (en) 2011-06-10 2014-01-09 Medimmune Limited Anti-Pseudomonas Psl binding molecules and uses thereof
EP2718728A1 (de) 2011-06-10 2014-04-16 Université Libre de Bruxelles Targets und wirkstoffe zur behandlung beeinträchtigter knochenbruchheilung
WO2012170607A2 (en) 2011-06-10 2012-12-13 Novartis Ag Use of pcsk9 antagonists
WO2012168491A1 (en) 2011-06-10 2012-12-13 Novartis Ag Pharmaceutical formulations of pcsk9 antagonists
CA2838833A1 (en) 2011-06-10 2012-12-13 Biogen Idec Ma Inc. Pro-coagulant compounds and methods of use thereof
GB201109966D0 (en) 2011-06-10 2011-07-27 Cancer Res Inst Royal Materials and methods for treating pten mutated or deficient cancer
DK2718714T3 (en) 2011-06-10 2015-09-28 Université Libre de Bruxelles Markers for impaired fracture healing
GB201109965D0 (en) 2011-06-10 2011-07-27 Cancer Res Inst Royal Materials and methods for treating estrogen receptor alpher(ER) positive cancer
RU2605595C2 (ru) 2011-06-13 2016-12-20 СиЭсЭл Лимитид Антитела против g-csfr и их применение
WO2012172555A1 (en) 2011-06-14 2012-12-20 Yeda Research And Development Co. Ltd. Combination therapy to prevent dcis formation and progression to breast cancer
WO2012172495A1 (en) 2011-06-14 2012-12-20 Novartis Ag Compositions and methods for antibodies targeting tem8
CN103596976A (zh) 2011-06-15 2014-02-19 霍夫曼-拉罗奇有限公司 结合abca1多肽的抗体
WO2012171996A1 (en) 2011-06-15 2012-12-20 F. Hoffmann-La Roche Ag Anti-human epo receptor antibodies and methods of use
JP2014520123A (ja) 2011-06-17 2014-08-21 アムジエン・インコーポレーテツド Ｃｌｅｃ−２を使用して代謝性障害を治療または改善させる方法
WO2012175613A1 (en) 2011-06-21 2012-12-27 Innate Pharma NKp46-MEDIATED NK CELL TUNING
AU2012273955A1 (en) 2011-06-22 2014-01-09 Inserm (Institut National De La Sante Et De La Recherche Medicale) Anti-Axl antibodies and uses thereof
WO2012175691A1 (en) 2011-06-22 2012-12-27 INSERM (Institut National de la Santé et de la Recherche Médicale) Anti-axl antibodies and uses thereof
PL2723773T3 (pl) 2011-06-22 2018-07-31 F.Hoffmann-La Roche Ag Eliminacja komórek docelowych przez obecne w krążeniu, swoiste dla wirusa, cytotoksyczne limfocyty T z wykorzystaniem kompleksów zawierających MHC klasy I
EP2537532A1 (de) 2011-06-22 2012-12-26 J. Stefan Institute Cathepsinbindende Verbindungen, die an ein Nanogerät gebunden sind, und deren diagnostische und therapeutische Verwendung
EP2726494B1 (de) 2011-06-28 2017-01-04 Whitehead Institute For Biomedical Research Verwendung von sortasen zur installation von click-chemie-handles für proteinligation
US9447178B2 (en) 2011-06-28 2016-09-20 Oxford Biotherapeutics Ltd. Therapeutic and diagnostic target
EA031181B1 (ru) 2011-06-28 2018-11-30 Оксфорд Байотерепьютикс Лтд. Антитело, которое специфически связывается с bst1, или его антигенсвязывающий фрагмент, нуклеиновые кислоты, кодирующие его цепи, клетка-хозяин, способ получения этого антитела и применение для лечения рака и воспалительных заболеваний
EP2726503B1 (de) 2011-06-30 2019-09-04 Compugen Ltd. Polypetide und ihre verwendung zur behandlung von autoimmunerkrankungen und infektionen
AU2012277185A1 (en) 2011-06-30 2014-02-13 Gene Techno Science Co., Ltd. Soluble integrin alpha4 mutant
RU2013155695A (ru) 2011-06-30 2015-08-10 Дженентек, Инк. Препараты антител против с-мет
WO2013002362A1 (ja) 2011-06-30 2013-01-03 中外製薬株式会社 ヘテロ二量化ポリペプチド
RU2657440C2 (ru) 2011-06-30 2018-06-13 Джензим Корпорейшн Ингибиторы т-клеточной активации
JP2013040160A (ja) 2011-07-01 2013-02-28 Genentech Inc 自己免疫疾患を治療するための抗ｃｄ８３アゴニスト抗体の使用
JP6472999B2 (ja) 2011-07-01 2019-02-20 ノバルティス アーゲー 代謝障害を治療するための方法
CN102268089A (zh) 2011-07-05 2011-12-07 上海交通大学 Agr2阻断抗体及其用途
EP2543679A1 (de) 2011-07-08 2013-01-09 INSERM (Institut National de la Santé et de la Recherche Médicale) Antikörper zur Behandlung und Vorbeugung von Thrombose
EP2543678A1 (de) 2011-07-08 2013-01-09 INSERM (Institut National de la Santé et de la Recherche Médicale) Antikörper zur Behandlung und Vorbeugung von Thrombose
EP2543677A1 (de) 2011-07-08 2013-01-09 INSERM (Institut National de la Santé et de la Recherche Médicale) Antikörper zur Behandlung und Vorbeugung von Thrombose
WO2013009491A2 (en) 2011-07-08 2013-01-17 Nripen Singh Improved depth filters for disposable biotechnological processes
KR102119840B1 (ko) 2011-07-11 2020-06-09 아이크노스 사이언스 에스. 아. Ox40에 결합하는 항체 및 이들의 용도
WO2013009767A2 (en) 2011-07-12 2013-01-17 Epitomics, Inc. Facs-based method for obtaining an antibody sequence
SG10201505454SA (en) 2011-07-13 2015-09-29 Abbvie Inc Methods and compositions for treating asthma using anti-il-13 antibodies
GB201112091D0 (en) 2011-07-14 2011-08-31 Gt Biolog Ltd Bacterial strains isolated from pigs
US9835621B2 (en) 2011-07-14 2017-12-05 University Of Kentucky Research Foundation Process for detection of alzheimer's disease from a serum sample
US9238689B2 (en) 2011-07-15 2016-01-19 Morpho Sys AG Antibodies that are cross-reactive for macrophage migration inhibitory factor (MIF) and D-dopachrome tautomerase (D-DT)
WO2013012733A1 (en) 2011-07-15 2013-01-24 Biogen Idec Ma Inc. Heterodimeric fc regions, binding molecules comprising same, and methods relating thereto
WO2013012747A1 (en) 2011-07-15 2013-01-24 Oncomed Pharmaceuticals, Inc. Rspo binding agents and uses thereof
WO2013012855A1 (en) 2011-07-18 2013-01-24 Amgen Inc. Apelin antigen-binding proteins and uses thereof
EP2548891A1 (de) 2011-07-18 2013-01-23 Universiteit Maastricht Humaner monoklonaler Antikörper gegen die Gamma-Untereinheit des Acetylcholin-Rezeptors zur Verwendung bei der Behandlung von Rhabdomyosarkom
CA2842195A1 (en) 2011-07-18 2013-01-24 Immunomedics, Inc. Fty720 increases cd74 expression and sensitizes cancer cells to anti-cd74 antibody-mediated cell death
WO2013011072A1 (en) 2011-07-20 2013-01-24 INSERM (Institut National de la Santé et de la Recherche Médicale) Carbapenemase and antibacterial treatment
US9120858B2 (en) 2011-07-22 2015-09-01 The Research Foundation Of State University Of New York Antibodies to the B12-transcobalamin receptor
US20130022551A1 (en) 2011-07-22 2013-01-24 Trustees Of Boston University DEspR ANTAGONISTS AND AGONISTS AS THERAPEUTICS
WO2013015821A1 (en) 2011-07-22 2013-01-31 The Research Foundation Of State University Of New York Antibodies to the b12-transcobalamin receptor
US20150125533A1 (en) 2011-07-25 2015-05-07 American University In Cairo Single-domain antibodies and graphene coated magnetic metal nanoparticles conjugate and methods for using the same
CN103842503A (zh) 2011-07-26 2014-06-04 独立行政法人产业技术综合研究所 上皮性卵巢癌标志物检测用抗体和上皮性卵巢癌判定方法
EP2738252B1 (de) 2011-07-26 2019-07-10 National Institute of Advanced Industrial Science And Technology Antikörper zum nachweis von markern für epithelialen eierstockkrebs und verfahren zur diagnose von epithelialem eierstockkrebs
WO2013014262A1 (en) 2011-07-27 2013-01-31 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods for diagnosing and treating myhre syndrome
ES2872964T3 (es) 2011-07-27 2021-11-03 Philogen Spa Inmunoconjugado de IL-12
CN104010494B (zh) 2011-07-28 2017-07-04 霍夫曼-拉罗奇有限公司 Pik3ca h1047r敲入非人动物乳腺癌模型
CA2842860A1 (en) 2011-07-28 2013-01-31 Sea Lane Biotechnologies, Llc Sur-binding proteins
BR112014002353B1 (pt) 2011-08-01 2022-09-27 Genentech, Inc Usos de antagonistas de ligação do eixo pd-1 e inibidores de mek, composições farmacêuticas, e kit
WO2013017656A1 (en) 2011-08-02 2013-02-07 Medizinische Universität Wien Antagonists of ribonucleases for treating obesity
CN103975241B (zh) 2011-08-03 2016-01-20 奎德尔公司 用于提高a型链球菌免疫测定法的特异性的n-乙酰基-d-葡糖胺
WO2013017691A1 (en) 2011-08-04 2013-02-07 Medizinische Universität Innsbruck Cahgt1p inhibitors for use in the treatment of candidiasis
HUE039009T2 (hu) 2011-08-05 2018-12-28 Res Found Dev Javított eljárások és készítmények Olfml3-mediált angiogenesis modulálására
WO2013021228A1 (en) 2011-08-10 2013-02-14 Institut National De La Sante Et De La Recherche Medicale (Inserm) Early childhood membranous nephropathy due to cationic bovine serum albumin
WO2013022091A1 (ja) 2011-08-11 2013-02-14 小野薬品工業株式会社 Ｐｄ－１アゴニストからなる自己免疫疾患治療剤
WO2013023994A1 (en) 2011-08-12 2013-02-21 Pronota N.V. New biomarker for the classification of ovarian tumours
EP2743699A4 (de) 2011-08-12 2015-04-08 Nat Inst Infectious Diseases Verfahren zum testen auf, verhindern und behandeln der infektionserkrankung aspergillus fumigatus und zusammensetzung
WO2013024022A1 (en) 2011-08-12 2013-02-21 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and pharmaceutical compositions for treatment of pulmonary hypertension
US9676854B2 (en) 2011-08-15 2017-06-13 Medimmune, Llc Anti-B7-H4 antibodies and their uses
WO2013025479A1 (en) 2011-08-16 2013-02-21 Emory University Jaml specific binding agents, antibodies, and uses related thereto
BR112014003431A2 (pt) 2011-08-17 2017-06-13 Genentech Inc anticorpo, ácido nucleico, célula hospedeira, método de produção de um anticorpo, imunoconjugado, formulação farmacêutica, agente farmacêutico, uso do anticorpo, método de tratamento de um indivíduo que tem câncer e método de aumento de tempo para recorrência de tumor
JP2014525412A (ja) 2011-08-17 2014-09-29 ジェネンテック， インコーポレイテッド 難治性腫瘍における血管新生の阻害
MX350335B (es) 2011-08-17 2017-09-04 Univ California Anticuerpos que enlazan alfa-v beta-8 integrina.
WO2013025936A1 (en) 2011-08-18 2013-02-21 Cornell University Detection and treatment of metastatic disease
WO2013023251A1 (en) 2011-08-18 2013-02-21 Affinity Biosciences Pty Ltd Soluble polypeptides
US9096648B2 (en) 2011-08-19 2015-08-04 Emd Millipore Corporation Methods of reducing level of one or more impurities in a sample during protein purification
US9505847B2 (en) 2011-08-22 2016-11-29 Cnj Holdings Inc Clostridium difficile antibodies
JP2014534806A (ja) 2011-08-23 2014-12-25 ロシュ グリクアート アーゲー 抗ｍｃｓｐ抗体
WO2013028817A1 (en) 2011-08-23 2013-02-28 Foundation Medicine , Inc. Novel kif5b-ret fusion molecules and uses thereof
KR101886983B1 (ko) 2011-08-23 2018-08-08 로슈 글리카트 아게 2 개의 ｆａｂ 단편을 포함하는 fc-부재 항체 및 이용 방법
KR101870555B1 (ko) 2011-08-23 2018-06-22 로슈 글리카트 아게 T 세포 활성화 항원 및 종양 항원에 대해 특이적인 이중특이적 항체 및 이의 사용 방법
GB201114923D0 (en) 2011-08-30 2011-10-12 Novartis Ag Immunogenic proteins and compositions
WO2013033069A1 (en) 2011-08-30 2013-03-07 Theraclone Sciences, Inc. Human rhinovirus (hrv) antibodies
WO2013033592A1 (en) 2011-08-31 2013-03-07 Volcano Corporation Optical-electrical rotary joint and methods of use
ES2684173T3 (es) 2011-09-01 2018-10-01 Eisai R&D Management Co., Ltd. Anticuerpos anti-XCR1 humano
KR101851425B1 (ko) 2011-09-02 2018-04-23 네스텍 소시에테아노님 치료 효능 결정을 위한 신호 경로 단백질의 프로파일링
US20130058947A1 (en) 2011-09-02 2013-03-07 Stem Centrx, Inc Novel Modulators and Methods of Use
EP2753359B1 (de) 2011-09-06 2018-02-28 Translational Sciences Inc. Serpinf2-bindemoleküle und verfahren zu ihrer anwendung
JP6077997B2 (ja) 2011-09-07 2017-02-08 中外製薬株式会社 癌幹細胞の分離
GB201115529D0 (en) 2011-09-08 2011-10-26 Imp Innovations Ltd Antibodies, uses and methods
US20140378537A1 (en) 2011-09-09 2014-12-25 Genentech, Inc. Treatment of th17 mediated inflammatory diseases
WO2013036799A2 (en) 2011-09-09 2013-03-14 Fred Hutchinson Cancer Research Center Methods and compositions involving nkg2d inhibitors and cancer
AU2012305807B2 (en) 2011-09-09 2015-08-20 Department of Medical Sciences (DMSc) Dengue-virus serotype neutralizing antibodies
MX362457B (es) 2011-09-12 2019-01-18 Janssen Biotech Inc Antagonistas del receptor tipo toll 3.
UY34317A (es) 2011-09-12 2013-02-28 Genzyme Corp Anticuerpo antireceptor de célula T (alfa)/ß
US9464124B2 (en) 2011-09-12 2016-10-11 Moderna Therapeutics, Inc. Engineered nucleic acids and methods of use thereof
US20140170735A1 (en) 2011-09-25 2014-06-19 Elizabeth A. Holmes Systems and methods for multi-analysis
US8475739B2 (en) 2011-09-25 2013-07-02 Theranos, Inc. Systems and methods for fluid handling
US9664702B2 (en) 2011-09-25 2017-05-30 Theranos, Inc. Fluid handling apparatus and configurations
US8840838B2 (en) 2011-09-25 2014-09-23 Theranos, Inc. Centrifuge configurations
US8435738B2 (en) 2011-09-25 2013-05-07 Theranos, Inc. Systems and methods for multi-analysis
US9632102B2 (en) 2011-09-25 2017-04-25 Theranos, Inc. Systems and methods for multi-purpose analysis
CA2848368C (en) 2011-09-13 2023-02-14 Dana-Farber Cancer Institute, Inc. Compositions and methods for brown fat induction and activity using fndc5
US9619627B2 (en) 2011-09-25 2017-04-11 Theranos, Inc. Systems and methods for collecting and transmitting assay results
US9268915B2 (en) 2011-09-25 2016-02-23 Theranos, Inc. Systems and methods for diagnosis or treatment
US20130108641A1 (en) 2011-09-14 2013-05-02 Sanofi Anti-gitr antibodies
WO2013038412A2 (en) 2011-09-15 2013-03-21 Vaxil Bio Therapeutics Ltd. Antibodies directed against signal peptides, methods and uses thereof
CN103930781A (zh) 2011-09-15 2014-07-16 霍夫曼-拉罗奇有限公司 促进分化的方法
ES2656505T3 (es) 2011-09-16 2018-02-27 The U.S.A. As Represented By The Secretary, Department Of Health And Human Services Exotoxina A de Pseudomonas con epítopos de linfocitos B menos inmunogénicos
EP2771349B1 (de) 2011-09-16 2020-02-26 Iogenetics, LLC. Bioinformatikverfahren zur bestimmung von peptidbindungen
AU2012312515A1 (en) 2011-09-19 2014-03-13 Genentech, Inc. Combination treatments comprising c-met antagonists and B-raf antagonists
BR112014006535A2 (pt) 2011-09-20 2017-03-28 Univ North Carolina Chapel Hill regulação dos canais de sódio através das proteínas plunc
EP2759551B1 (de) 2011-09-21 2019-05-22 Fujirebio Inc. Antikörper die an einen affinitätskomplex binden der 25oh-vitamin d2 oder d3 und einen dagegen gerichteten antikörper enthält
HK1200850A1 (en) 2011-09-23 2015-08-14 罗氏格黎卡特股份公司 Bispecific anti-egfr/anti igf-1r antibodies
TWI583699B (zh) 2011-09-23 2017-05-21 安可美德藥物股份有限公司 Ｖｅｇｆ／ｄｌｌ４結合劑類及彼等之用途
AU2012310328A1 (en) 2011-09-23 2014-04-10 Technophage, Investigação E Desenvolvimento Em Biotecnologia, S.A. Anti-Tumor Necrosis Factor-alpha agents and uses thereof
MX2014003313A (es) 2011-09-23 2014-07-09 Amgen Res Munich Gmbh Moleculas de union biespecificas para 5t4 y cd3.
US9810704B2 (en) 2013-02-18 2017-11-07 Theranos, Inc. Systems and methods for multi-analysis
US10012664B2 (en) 2011-09-25 2018-07-03 Theranos Ip Company, Llc Systems and methods for fluid and component handling
US9250229B2 (en) 2011-09-25 2016-02-02 Theranos, Inc. Systems and methods for multi-analysis
ES2762179T3 (es) 2011-09-26 2020-05-22 Philogen Spa Terapia de combinación de inmunocitocinas
EP2748198A2 (de) 2011-09-27 2014-07-02 The United States of America, as represented by The Secretary, Department of Health and Human Services Verfahren zur behandlung von multipler sklerose mittels intrathekalen abreicherung von b-zellen und biomarkern zur auswahl von patienten mit progressiver multipler sklerose
GB2495113A (en) 2011-09-29 2013-04-03 Bioinvent Int Ab Anti-ICAM-1 antibody for treating multiple-myeloma-related disorders
CA2850178C (en) 2011-09-30 2020-02-25 Sarcotein Diagnostics, Llc Bin1 expression as a marker of cancer
DK2760471T3 (en) 2011-09-30 2017-05-08 Dana Farber Cancer Inst Inc THERAPEUTIC PEPTIDES
TW201817745A (zh) 2011-09-30 2018-05-16 日商中外製藥股份有限公司 具有促進抗原清除之ＦｃＲｎ結合域的治療性抗原結合分子
JP6322411B2 (ja) 2011-09-30 2018-05-09 中外製薬株式会社 複数の生理活性を有する抗原の消失を促進する抗原結合分子
EP3495389A1 (de) 2011-09-30 2019-06-12 Teva Pharmaceuticals Australia Pty Ltd Antikörper gegen tl1a und verwendungen davon
PT3682905T (pt) 2011-10-03 2022-04-07 Modernatx Inc Nucleósidos, nucleótidos e ácidos nucleicos modificados e respetivas utilizações
AR088048A1 (es) 2011-10-04 2014-05-07 Univ Columbia Señuelos notch1 humanos
EP2765192A4 (de) 2011-10-05 2015-04-15 Chugai Pharmaceutical Co Ltd Antigenbindendes molekül zur herstellung eines abstands zwischen einem plasma und einem antigen mit einer saccharidkettenrezeptor-bindenden domäne
CA2851270C (en) 2011-10-05 2023-03-14 The Rockefeller University Dimeric bacteriophage lysins
WO2013050441A1 (en) 2011-10-05 2013-04-11 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and pharmaceutical composition for inhibiting or preventing platelet aggregation
US20130089562A1 (en) 2011-10-05 2013-04-11 Genenthech, Inc. Methods of treating liver conditions using notch2 antagonists
GB201117313D0 (en) 2011-10-07 2011-11-16 Gt Biolog Ltd Bacterium for use in medicine
CN103906767A (zh) 2011-10-10 2014-07-02 米迪缪尼有限公司 对类风湿关节炎的治疗
US9575073B2 (en) 2011-10-10 2017-02-21 Rutgers, The State University Of New Jersey Detection of high-risk intraductal papillary mucinous neoplasm and pancreatic adenocarcinoma
SI2766397T1 (sl) 2011-10-11 2018-09-28 F. Hoffmann-La Roche Ag Izboljšano sestavljanje bispecifičnih protiteles
WO2013054320A1 (en) 2011-10-11 2013-04-18 Tel Hashomer Medical Research Infrastructure And Services Ltd. Antibodies to carcinoembryonic antigen-related cell adhesion molecule (ceacam)
WO2013055908A1 (en) 2011-10-12 2013-04-18 The Scripps Research Institute An hiv-1 gp120 mini v3 loop and uses thereof
EP2766041B1 (de) 2011-10-12 2018-12-05 Children's Medical Center Corporation Kombinatorische zusammensetzungen und verfahren zur behandlung von hämoglobinopathien
EP3501536B1 (de) 2011-10-13 2025-12-24 EyePoint Pharmaceuticals, Inc. Behandlung von augenerkrankungen
MX363351B (es) 2011-10-13 2019-03-20 Aerpio Therapeutics Inc Un agente de unión a hptp?-ecd para usarse en el tratamiento de síndrome de fuga vascular.
ES2769786T3 (es) 2011-10-14 2020-06-29 Recordati Ag Anticuerpos y métodos para enfermedades relacionadas con la vía Wnt
US10378060B2 (en) 2011-10-14 2019-08-13 Dana-Farber Cancer Institute, Inc. ZNF365/ZFP365 biomarker predictive of anti-cancer response
MX355128B (es) 2011-10-14 2018-04-06 Genentech Inc Péptidos inhibidores de bace1 y uso de los mismos para el tratamiento de enfermedades o trastornos neurológicos.
JP6104257B2 (ja) 2011-10-14 2017-03-29 メドイミューン・リミテッドMedImmune Limited ピロロベンゾジアゼピンおよびそのコンジュゲート
WO2013056178A2 (en) 2011-10-14 2013-04-18 Foundation Medicine, Inc. Novel estrogen receptor mutations and uses thereof
EP2766734A1 (de) 2011-10-14 2014-08-20 Pronota NV Procathepsin-l und cathepsin-l als biomarker für ischämie
EP2581388A1 (de) 2011-10-14 2013-04-17 Centre National de la Recherche Scientifique (CNRS) Antikörper gegen sPLA2-V und Gebrauch davon
HUE044352T2 (hu) 2011-10-14 2019-10-28 Hoffmann La Roche Pertuzumab, Trastuzumab, Docetaxel és Carboplatin korai stádiumú mellrák kezelésére
PE20141562A1 (es) 2011-10-14 2014-11-12 Genentech Inc Anticuerpos anti-htra1 y metodos de uso
US9358250B2 (en) 2011-10-15 2016-06-07 Genentech, Inc. Methods of using SCD1 antagonists
EP2768945B1 (de) 2011-10-17 2022-01-05 Minerva Biotechnologies Corporation Medien zur stammzellenproliferation und -induzierung
EP2768971A1 (de) 2011-10-20 2014-08-27 Institut National de la Santé et de la Recherche Médicale (INSERM) Verfahren zur erkennung und behandlung von kardialer remodellierung
WO2013059531A1 (en) 2011-10-20 2013-04-25 Genentech, Inc. Anti-gcgr antibodies and uses thereof
WO2013059740A1 (en) 2011-10-21 2013-04-25 Foundation Medicine, Inc. Novel alk and ntrk1 fusion molecules and uses thereof
EP2768944B2 (de) 2011-10-21 2023-11-22 Pfizer Inc. Zugabe von eisen zur verbesserung der zellkultur
AR088513A1 (es) 2011-10-24 2014-06-18 Abbvie Inc Inmunoenlazantes dirigidos contra esclerostina
BR112014010009A2 (pt) 2011-10-26 2017-04-25 Univ California "anticorpo que se liga a cd44, seus métodos de produção e usos no tratamento ou prevenção de malignidade hematológica ou leucemia linfocítica crônica, método de alvejar anticorpo, kit de detecção, bem como composição farmacêutica, molécula de ácido nucleico e vetor de expressão"
US9790280B2 (en) 2011-10-26 2017-10-17 Elanco Tiergesundheit Ag Monoclonal canine CD20 antibodies and methods of use
US9145559B2 (en) 2011-10-27 2015-09-29 Yeda Research And Development Co. Ltd. Methods of treating cancer
CA2862580A1 (en) 2011-10-28 2013-05-02 Millennium Pharmaceuticals, Inc. Biomarkers of response to nae inhibitors
EP3603671A3 (de) 2011-10-28 2020-07-29 Chugai Seiyaku Kabushiki Kaisha Krebstammzellenspezifisches molekül
DK2771037T3 (en) 2011-10-28 2016-11-14 Fredax Ab Therapeutics and uses thereof
KR20140097205A (ko) 2011-10-28 2014-08-06 제넨테크, 인크. 흑색종을 치료하는 치료 조합물 및 방법
JP2015504413A (ja) 2011-10-28 2015-02-12 パトリス リミテッド Ｐａｔ−ｌｍ１エピトープおよびそれを使用するための方法
US9272002B2 (en) 2011-10-28 2016-03-01 The Trustees Of The University Of Pennsylvania Fully human, anti-mesothelin specific chimeric immune receptor for redirected mesothelin-expressing cell targeting
BR112014010257A2 (pt) 2011-10-31 2017-04-18 Chugai Pharmaceutical Co Ltd molécula de ligação ao antígeno tendo conjugação regulada entre cadeias pesadas e cadeias leves
AU2012332767C1 (en) 2011-10-31 2017-02-02 Genentech, Inc. Antibody formulations
WO2013067060A1 (en) 2011-11-01 2013-05-10 Bionomics, Inc. Anti-gpr49 antibodies
HK1201855A1 (en) 2011-11-01 2015-09-11 Bionomics, Inc. Antibodies and methods of treating cancer
ES2697674T3 (es) 2011-11-01 2019-01-25 Bionomics Inc Procedimientos para bloquear el crecimiento de células madre cancerosas
EP2773664A1 (de) 2011-11-01 2014-09-10 Bionomics, Inc. Anti-gpr49-antikörper
KR20140091721A (ko) 2011-11-02 2014-07-22 제넨테크, 인크. 오버로드 및 용리 크로마토그래피
CA2853943C (en) 2011-11-02 2015-12-08 University Of Rochester Anti-glucosaminidase passive immunization for staphylococcus aureus infections
US9422351B2 (en) 2011-11-03 2016-08-23 The Trustees Of The University Of Pennsylvania Isolated B7-H4 specific compositions and methods of use thereof
US9574010B2 (en) 2011-11-04 2017-02-21 Zymeworks Inc. Stable heterodimeric antibody design with mutations in the Fc domain
WO2013067639A1 (en) 2011-11-07 2013-05-16 UNIVERSITé LAVAL Use of rank/rankl antagonists for treating neuromuscular disorders, genetic myopathies and/or non genetic myopathies and/or for regulating skeletal and cardiac muscle disuse, diseases and aging
WO2013070615A1 (en) 2011-11-07 2013-05-16 Medlmmune, Llc. Combination therapies using anti- pseudomonas psl and pcrv binding molecules
WO2013068431A1 (en) 2011-11-08 2013-05-16 Novartis Forschungsstiftung, Zweigniederlassung, Friedrich Miescher Institute For Biomedical Research New treatment for neurodegenerative diseases
EP2592103A1 (de) 2011-11-08 2013-05-15 Adriacell S.p.A. Polymeraldehydderivate
WO2013070468A1 (en) 2011-11-08 2013-05-16 The Trustees Of The University Of Pennsylvania Glypican-3-specific antibody and uses thereof
US20140294732A1 (en) 2011-11-08 2014-10-02 Novartis Forschungsstiftung, Zweigniederlassung, Friedrich Miescher Institute Early diagnostic of neurodegenerative diseases
WO2013071233A1 (en) 2011-11-10 2013-05-16 The United States Of America, As Represented By The Secretary, Department Of Health & Human Services Methods for detecting infectious agents and a novel virus detected thereby
JP6411214B2 (ja) 2011-11-11 2018-10-24 ユーシービー バイオファルマ エスピーアールエル アルブミン結合抗体及びその結合断片
CN104039328B (zh) 2011-11-11 2018-10-09 米伦纽姆医药公司 对蛋白酶体抑制剂的反应的生物标记
EP2776586B1 (de) 2011-11-11 2018-03-07 Millennium Pharmaceuticals, Inc. Biomarker der reaktion auf proteasomenhemmer
SG11201401699WA (en) 2011-11-11 2014-09-26 Rinat Neuroscience Corp Antibodies specific for trop-2 and their uses
TWI679212B (zh) 2011-11-15 2019-12-11 美商安進股份有限公司 針對ｂｃｍａ之e3以及ｃｄ３的結合分子
SI2780373T1 (sl) 2011-11-16 2019-12-31 Boehringer Ingelheim International Gmbh Protitelesa proti IL-36R
EP2780039B9 (de) 2011-11-17 2018-04-18 Pfizer Inc Zytotoxische peptide und antikörperwirkstoffkonjugate dafür
KR102108582B1 (ko) 2011-11-18 2020-05-08 에프. 호프만-라 로슈 아게 비타민 d 화합물용 방출 시약
SG11201402485UA (en) 2011-11-21 2014-06-27 Genentech Inc Purification of anti-c-met antibodies
WO2013078122A1 (en) 2011-11-22 2013-05-30 President And Fellows Of Harvard College Diabetes diagnosis through the detection of glycated proteins in urine
EP2782933A1 (de) 2011-11-22 2014-10-01 Institut National de la Santé et de la Recherche Médicale (INSERM) Verfahren und pharmazeutische zusammensetzungen zur verringerung von atemwegüberreaktion
CN108424456B (zh) 2011-11-23 2022-04-26 医学免疫有限责任公司 特异于her3的结合分子及其用途
HK1202877A1 (en) 2011-11-23 2015-10-09 伊格尼卡生物治疗公司 Anti-cd98 antibodies and methods of use thereof
BR112014012819B1 (pt) 2011-11-28 2022-08-16 Merck Patent Gmbh Anticorpo anti-pd-l1 ou fragmento de ligação ao antígeno do mesmo e composição
US9381229B2 (en) 2011-11-28 2016-07-05 Inserm (Institut National De La Sante Et De La Recherche Medicale) Pharmaceutical composition for use in the treatment of dysfunction associated with aging
US20130143237A1 (en) 2011-11-29 2013-06-06 Genentech, Inc. Compositions and methods for prostate cancer analysis
EP2599496A1 (de) 2011-11-30 2013-06-05 Kenta Biotech AG Neuartige Targets von Acinetobacter baumannii
WO2013079973A1 (en) 2011-12-02 2013-06-06 Di Cara Danielle Marie Antibodies against hgf - receptor and uses
CN107353342B (zh) 2011-12-05 2021-08-10 X 博迪生物科学公司 PDGF受体β结合多肽
US9192664B2 (en) 2011-12-05 2015-11-24 Immunomedics, Inc. Therapeutic use of anti-CD22 antibodies for inducing trogocytosis
EP2788382A2 (de) 2011-12-05 2014-10-15 Novartis AG Antikörper für epidermalen wachstumsfaktor-rezeptor 3 (her3) gegen domäne ii von her3
US9757458B2 (en) 2011-12-05 2017-09-12 Immunomedics, Inc. Crosslinking of CD22 by epratuzumab triggers BCR signaling and caspase-dependent apoptosis in hematopoietic cancer cells
CN108341873B (zh) 2011-12-05 2022-03-25 诺华股份有限公司 表皮生长因子受体3(her3)的抗体
EP2788024A1 (de) 2011-12-06 2014-10-15 F.Hoffmann-La Roche Ag Antikörper-formulierung
EP2602265A1 (de) 2011-12-07 2013-06-12 Centre National de la Recherche Scientifique (CNRS) Antikörper gegen Anti-sPLA2-X und Verwendungen damit
WO2013086443A1 (en) 2011-12-08 2013-06-13 Amgen Inc. Agonistic human lcat antigen binding proteins and their use in therapy
AU2012349753A1 (en) 2011-12-08 2014-06-19 Novartis Ag Clostridium difficile toxin-based vaccine
US20150045245A1 (en) 2011-12-08 2015-02-12 Biocartis Nv Biomarkers and test panels useful in systemic inflammatory conditions
US20140329251A1 (en) 2011-12-09 2014-11-06 Pronota N.V. Ltbp2 as a biomarker for lung injury
GB201121301D0 (en) 2011-12-12 2012-01-25 Novartis Ag Method
WO2013088136A1 (en) 2011-12-12 2013-06-20 Ahrens Susan Ligand for dngr-1 receptor
GB201121564D0 (en) 2011-12-14 2012-01-25 Queen Mary & Westfield College Use of antibody
CN104136462B (zh) 2011-12-14 2017-06-09 艾伯维德国有限责任两合公司 用于诊断和治疗铁相关病症的组合物和方法
MX2014007121A (es) 2011-12-14 2014-09-04 Seattle Genetics Inc Nuevos conjugados de principio activo-ligante (adc) y su uso.
MX357708B (es) 2011-12-14 2018-07-20 Abbvie Deutschland Composicion y metodo para el diagnostico y tratamiento de trastornos relacionados con hierro.
AU2012352454A1 (en) 2011-12-15 2014-07-17 The University Of Chicago Methods and compositions for cancer therapy using mutant light molecules with increased affinity to receptors
AU2012351504C1 (en) 2011-12-15 2018-04-26 Mycartis N.V. Biomarkers and parameters for preeclampsia
ES2923757T3 (es) 2011-12-16 2022-09-30 Modernatx Inc Composiciones de ARNm modificado
CN104144946A (zh) 2011-12-19 2014-11-12 爱克索马美国有限责任公司 治疗痤疮的方法
GB201121891D0 (en) 2011-12-20 2012-02-01 Bakhiet Abdelmoiz Applications of an immune system-released activating agent (ISRAA)
CA2859665C (en) 2011-12-20 2024-05-21 Janssen Biotech, Inc. Anti-phf-tau antibodies and their uses
SG10201703249PA (en) 2011-12-21 2017-05-30 Novartis Ag Compositions and methods for antibodies targeting factor p
CN107881196A (zh) 2011-12-22 2018-04-06 弗·哈夫曼-拉罗切有限公司 表达载体组织、新的生产用细胞产生方法及其在重组产生多肽中的用途
EP2794662A1 (de) 2011-12-22 2014-10-29 F.Hoffmann-La Roche Ag System zur anzeige eines antikörpers in voller länge für eukaryotische zellen und seine verwendung
WO2013093693A1 (en) 2011-12-22 2013-06-27 Rinat Neuroscience Corp. Staphylococcus aureus specific antibodies and uses thereof
US9975956B2 (en) 2011-12-22 2018-05-22 I2 Pharmaceuticals, Inc. Surrogate binding proteins which bind DR4 and/or DR5
SG10201700169PA (en) 2011-12-22 2017-02-27 Hoffmann La Roche Expression vector element combinations, novel production cell generation methods and their use for the recombinant production of polypeptides
RU2014123030A (ru) 2011-12-22 2016-02-20 Ринат Ньюросайенс Корп. Антагонистические антитела против человеческого рецептора гормона роста и способы их применения
WO2013091903A1 (en) 2011-12-22 2013-06-27 Novo Nordisk A/S Anti-crac channel antibodies
PL2794635T3 (pl) 2011-12-22 2019-02-28 F.Hoffmann-La Roche Ag Membranowa chromatografia jonowymienna
GB201122325D0 (en) 2011-12-23 2012-02-01 Cytoguide As Novel formulations
FR2984750B1 (fr) 2011-12-23 2014-01-10 Lfb Biotechnologies Nouvelles compositions pharmaceutiques comprenant un anticorps liant le recepteur humain de l'hormone anti-mullerienne de type ii
EP3539982B1 (de) 2011-12-23 2025-02-19 Pfizer Inc. Konstante regionen gentechnisch hergestellter antikörper für stellenspezifische konjugation sowie verfahren und verwendungen dafür
CA2858806A1 (en) 2011-12-23 2013-06-27 Innate Pharma Enzymatic conjugation of polypeptides
AR089434A1 (es) 2011-12-23 2014-08-20 Genentech Inc Procedimiento para preparar formulaciones con alta concentracion de proteinas
WO2013096812A1 (en) 2011-12-23 2013-06-27 Genentech, Inc. Articles of manufacture and methods for co-administration of antibodies
US9823246B2 (en) 2011-12-28 2017-11-21 The Board Of Trustees Of The Leland Stanford Junior University Fluorescence enhancing plasmonic nanoscopic gold films and assays based thereon
WO2013101771A2 (en) 2011-12-30 2013-07-04 Genentech, Inc. Compositions and method for treating autoimmune diseases
AR089529A1 (es) 2011-12-30 2014-08-27 Abbvie Inc Proteinas de union especificas duales dirigidas contra il-13 y/o il-17
WO2013098813A1 (en) 2012-01-01 2013-07-04 Qbi Enterprises Ltd. Endo180-targeted particles for selective delivery of therapeutic and diagnostic agents
WO2013102825A1 (en) 2012-01-02 2013-07-11 Novartis Ag Cdcp1 and breast cancer
BR112014016587A2 (pt) 2012-01-05 2020-10-27 Novartis Ag células fúngicas filamentosas deficientes de protease e métodos de uso das mesmas
EP2800976A2 (de) 2012-01-06 2014-11-12 BG Medicine, Inc. Verwendung von galectin-3 für risikobewertung und nachweis von präeklampsie und verwandten leiden
US20140050720A1 (en) 2012-01-09 2014-02-20 The Scripps Research Institute Ultralong complementarity determining regions and uses thereof
EP2802601B1 (de) 2012-01-09 2019-11-13 The Scripps Research Institute Humanisierte antikörper mit ultralangem cdr3s
CN104159922B (zh) 2012-01-10 2018-03-02 比奥根Ma公司 对转运治疗性分子穿过血脑屏障的增强
CN102571433B (zh) 2012-01-11 2014-07-30 华为技术有限公司 呈现网络路径的方法和装置
US10800847B2 (en) 2012-01-11 2020-10-13 Dr. Mepur Ravindranath Anti-HLA class-IB antibodies mimic immunoreactivity and immunomodulatory functions of intravenous immunoglobulin (IVIG) useful as therapeutic IVIG mimetics and methods of their use
CA2862999A1 (en) 2012-01-11 2013-07-18 Arizona Board Of Regents, A Body Corporate Of The State Of Arizona Acting For And On Behalf Of Arizona State University Bispecific antibody fragments for neurological disease proteins and methods of use
US20130177574A1 (en) 2012-01-11 2013-07-11 Paul I. Terasaki Foundation Laboratory ANTI-HLA CLASS-Ib ANTIBODIES MIMIC IMMUNOREACTIVITY AND IMMUNOMODULATORY FUNCTIONS OF INTRAVENOUS IMMUNOGLOBULIN (IVIg) USEFUL AS THERAPEUTIC IVIg MIMETICS AND METHODS OF THEIR USE
WO2013104798A1 (en) 2012-01-12 2013-07-18 Cemm - Center For Molecular Medicine Of The Austrian Academy Of Sciences Modulators of immune responses
CA2862835A1 (en) 2012-01-13 2013-07-18 Genentech, Inc. Biological markers for identifying patients for treatment with vegf antagonists
SG10201601747XA (en) 2012-01-18 2016-04-28 Genentech Inc Anti-LRP5 Antibodies And Methods Of Use
RU2014133547A (ru) 2012-01-18 2016-03-10 Дженентек, Инк. Способы применения модуляторов fgf19
BR112014017814A8 (pt) 2012-01-20 2017-07-11 Genzyme Corp Anticorpos anti-cxcr3
US10238698B2 (en) 2012-01-25 2019-03-26 Dnatrix, Inc. Biomarkers and combination therapies using oncolytic virus and immunomodulation
GB201201314D0 (en) 2012-01-26 2012-03-07 Isis Innovation Composition
AU2013211939C1 (en) 2012-01-27 2018-06-07 AbbVie Deutschland GmbH & Co. KG Composition and method for diagnosis and treatment of diseases associated with neurite degeneration
WO2013113755A1 (en) 2012-01-30 2013-08-08 Fundació Institut D'investigació Biomèdica De Bellvitge (Idibell) Reagents and methods for the treatment of diseases based on the inhibition of calcineurin - nfat signalling pathway
WO2013116287A1 (en) 2012-01-31 2013-08-08 Genentech, Inc. Anti-ig-e m1' antibodies and methods using same
AU2013216320A1 (en) 2012-02-01 2014-04-03 Compugen Ltd. C10RF32 antibodies, and uses thereof for treatment of cancer
US9896695B2 (en) 2012-02-02 2018-02-20 Consejo Nacional De Investigaciones Cientificas Y Tecnicas (Conicet) HAHB11 provides improved plant yield and tolerance to abiotic stress
ME03512B (de) 2012-02-06 2020-04-20 Inhibrx Inc Cd47-antikörper und verfahren zur verwendung davon
WO2013119419A1 (en) 2012-02-08 2013-08-15 North Carolina State University Treatment of allergic diseases with recombinant antibodies
WO2013120012A2 (en) 2012-02-08 2013-08-15 Igm Biosciences Inc. Cdim binding proteins and uses thereof
EP4624490A3 (de) 2012-02-09 2025-11-05 Chugai Seiyaku Kabushiki Kaisha Modifizierte fc-region eines antikörpers
AU2013216863B2 (en) 2012-02-10 2018-09-06 Seagen Inc. Detection and treatment of CD30+ cancers
MX2014009565A (es) 2012-02-10 2014-11-10 Genentech Inc Anticuerpos monocatenarios y otros heteromultimeros.
BR112014019741A2 (pt) 2012-02-11 2020-12-22 Genentech, Inc Usos de um antagonista da via wnt, uso de uma terapia anticâncer, método de identificação de um indivíduo com câncer, métodos para prever, método de inibição da proliferação de uma célula de câncer, uso de um antagonista da translocação de r-spondina e antagonista da translocação de r-spondina isolado
WO2013121426A1 (en) 2012-02-13 2013-08-22 Gamida-Cell Ltd. Culturing of mesenchymal stem cells
JP6411218B2 (ja) 2012-02-15 2018-10-24 ノヴォ ノルディスク アー／エス 骨髄細胞で発現されるトリガー受容体１（ｔｒｅｍ−１）に結合し、それを遮断する抗体
KR102069397B1 (ko) 2012-02-15 2020-01-22 에프. 호프만-라 로슈 아게 Ｆｃ-수용체 기재 친화성 크로마토그래피
US9550830B2 (en) 2012-02-15 2017-01-24 Novo Nordisk A/S Antibodies that bind and block triggering receptor expressed on myeloid cells-1 (TREM-1)
RS57827B1 (sr) 2012-02-15 2018-12-31 Novo Nordisk As Antitela koja vezuju protein 1 prepoznavanja peptidoglikana
GB201203071D0 (en) 2012-02-22 2012-04-04 Ucb Pharma Sa Biological products
GB201203051D0 (en) 2012-02-22 2012-04-04 Ucb Pharma Sa Biological products
US20150201588A1 (en) 2012-02-22 2015-07-23 Amgen Inc. Autologous Mammalian Models Derived from Induced Pluripotent Stem Cells and Related Methods
SG11201404991YA (en) 2012-02-23 2014-09-26 Stage Cell Therapeutics Gmbh Chromatographic isolation of cells and other complex biological materials
CN104520324A (zh) 2012-02-24 2015-04-15 施特姆森特Rx股份有限公司 Dll3调节剂及其使用方法
SG11201405305PA (en) 2012-02-29 2014-09-26 Gilead Biologics Inc Antibodies to matrix metalloproteinase 9
MD20140108A2 (ro) 2012-02-29 2015-03-31 Gilead Biologics, Inc. Anticorpi împotriva metaloproteinazei 9 matriciale
JP6407726B2 (ja) 2012-03-01 2018-10-24 アムゲン リサーチ （ミュンヘン） ゲーエムベーハーＡＭＧＥＮ Ｒｅｓｅａｒｃｈ（Ｍｕｎｉｃｈ）ＧｍｂＨ 長寿命ポリペプチド結合分子
WO2013132495A1 (en) 2012-03-07 2013-09-12 Yeda Research And Development Co. Ltd. Compositions for inhibition of quiescin sulfhydryl oxidase (qsox1) and uses of same
WO2013131983A1 (en) 2012-03-07 2013-09-12 Novartis Ag Adjuvanted formulations of streptococcus pneumoniae antigens
JP5859148B2 (ja) 2012-03-08 2016-02-10 エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ Ａβ抗体製剤
CA2866612C (en) 2012-03-08 2018-01-16 Halozyme, Inc. Conditionally active ph-dependent cetuximab variant anti-epidermal growth factor receptor antibodies and method of use thereof
SA115360586B1 (ar) 2012-03-09 2017-04-12 فايزر انك تركيبات لعلاج الالتهاب السحائي البكتيري وطرق لتحضيرها
CA2865745C (en) 2012-03-09 2018-01-09 Pfizer Inc. Neisseria meningitidis compositions and methods thereof
WO2013151664A1 (en) 2012-04-02 2013-10-10 modeRNA Therapeutics Modified polynucleotides for the production of proteins
BR112014022662A2 (pt) 2012-03-12 2017-10-03 Advaxis Inc Inibição da função de célula supressora seguindo tratamento de vacina de listeria
PL2825558T3 (pl) 2012-03-13 2019-11-29 Hoffmann La Roche Terapia skojarzona w leczeniu raka jajnika
AU2013234046B2 (en) 2012-03-16 2017-09-07 University Health Network Methods and compositions for modulating Toso activity
CN104470942B (zh) 2012-03-20 2018-12-14 奥塔哥创新有限公司 生物标志物
WO2013140393A1 (en) 2012-03-21 2013-09-26 Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd. Peptides derived from the d1 - domain of nkp46
WO2013139956A1 (en) 2012-03-22 2013-09-26 Thrombogenics Nv Antibodies abrogating cell binding to lactadherin
US9334308B2 (en) 2012-03-22 2016-05-10 Ramot At Tel-Aviv University Ltd. PLIF multimeric peptides and uses thereof
EP2641916A1 (de) 2012-03-23 2013-09-25 Centre National de la Recherche Scientifique (C.N.R.S) Neue Antikörper gegen Anti-sPLA2-IIA und Verwendungen damit
US9592289B2 (en) 2012-03-26 2017-03-14 Sanofi Stable IgG4 based binding agent formulations
WO2013148315A1 (en) 2012-03-27 2013-10-03 Genentech, Inc. Diagnosis and treatments relating to her3 inhibitors
WO2013148232A1 (en) 2012-03-27 2013-10-03 Genentech, Inc. Methods of prognosing, diagnosing and treating idiopathic pulmonary fibrosis
SG11201406112TA (en) 2012-03-27 2014-10-30 Genentech Inc Improved harvest operations for recombinant proteins
WO2013148296A1 (en) 2012-03-28 2013-10-03 Sanofi Antibodies to bradykinin b1 receptor ligands
HK1206759A1 (en) 2012-03-28 2016-01-15 F. Hoffmann-La Roche Ag Anti-hcmv idiotypic antibodies and uses thereof
CA2875200C (en) 2012-03-28 2024-02-20 Hiroshima University Fibrosis suppression by inhibiting integrin alpha8beta1 function
US20150266961A1 (en) 2012-03-29 2015-09-24 Novartis Forschungsstiftung, Zweigniederlassung, Fridrich Miescher Institute Inhibition of interleukin-8 and/or its receptor cxcr1 in the treatment of her2/her3-overexpressing breast cancer
HUE037613T2 (hu) 2012-03-29 2018-09-28 Novimmune Sa Anti-TLR4 antitestek és azok felhasználása
MX2014011582A (es) 2012-03-30 2014-11-21 Genentech Inc Metodos y composiciones de diagnostico para el tratamiento de cancer.
AR090549A1 (es) 2012-03-30 2014-11-19 Genentech Inc Anticuerpos anti-lgr5 e inmunoconjugados
HK1206610A1 (en) 2012-03-30 2016-01-15 Sorrento Therapeutics, Inc. Fully human antibodies that bind to vegfr2
ES2702278T3 (es) 2012-04-01 2019-02-28 Technion Res & Dev Foundation Péptidos de inductor de metaloproteinasa de matriz extracelular (emmprin) y anticuerpos de unión
US9494597B2 (en) 2012-04-02 2016-11-15 Ab Biosciences, Inc. Human control antibodies and uses therefor
US9572897B2 (en) 2012-04-02 2017-02-21 Modernatx, Inc. Modified polynucleotides for the production of cytoplasmic and cytoskeletal proteins
BR112014024537A2 (pt) 2012-04-02 2017-08-08 Berg Llc métodos para identificar moduladores de um sistema biológico, de um processo de doença, e de angiogênese
US10501512B2 (en) 2012-04-02 2019-12-10 Modernatx, Inc. Modified polynucleotides
US9283287B2 (en) 2012-04-02 2016-03-15 Moderna Therapeutics, Inc. Modified polynucleotides for the production of nuclear proteins
WO2013151649A1 (en) 2012-04-04 2013-10-10 Sialix Inc Glycan-interacting compounds
WO2013152352A1 (en) 2012-04-06 2013-10-10 The United States Of America, As Represented By The Secretary, Department Of Health And Human Servic Live, attenuated rubella vector to express vaccine antigens
NZ629675A (en) 2012-04-06 2017-02-24 Omeros Corp Compositions and methods of inhibiting masp-1, masp-2 and/or masp-3 for treatment of paroxysmal nocturnal hemoglobinuria
EP2650682A1 (de) 2012-04-09 2013-10-16 Fundació Privada Institut de Recerca Biomèdica Asymmetrische Ester von als Schmiermittel geeigneten Fettsäuren
US9493744B2 (en) 2012-06-20 2016-11-15 Genentech, Inc. Methods for viral inactivation and other adventitious agents
WO2013153083A1 (en) 2012-04-11 2013-10-17 INSERM (Institut National de la Santé et de la Recherche Médicale) Method for diagnosing a skeletal ciliopathy
EP2836514A4 (de) 2012-04-13 2015-12-30 Childrens Medical Center Tiki-inhibitoren
US10130714B2 (en) 2012-04-14 2018-11-20 Academia Sinica Enhanced anti-influenza agents conjugated with anti-inflammatory activity
US9914767B2 (en) 2012-04-17 2018-03-13 Arsanis Biosciences Gmbh Cross-reactive Staphylococcus aureus antibody
BR112014025898A2 (pt) 2012-04-17 2017-11-07 Mayo Found Medical Education & Res anticorpos humanos e sequências de ligação específica, para uso em acidente vascular cerebral e isquemia ou condições isquêmicas
JP6224077B2 (ja) 2012-04-17 2017-11-01 エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ 改変された核酸を用いてポリペプチドを発現させるための方法
US10114023B2 (en) 2012-04-18 2018-10-30 Massachusetts Institute Of Technology Method of enhancing the efficacy of anti-hepatocyte growth factor receptor breast cancer therapy by administering an inhibitor of menaINV
WO2013158859A1 (en) 2012-04-18 2013-10-24 Cell Signaling Technology, Inc. Egfr and ros1 in cancer
US9150645B2 (en) 2012-04-20 2015-10-06 Abbvie, Inc. Cell culture methods to reduce acidic species
US9181572B2 (en) 2012-04-20 2015-11-10 Abbvie, Inc. Methods to modulate lysine variant distribution
WO2013158275A1 (en) 2012-04-20 2013-10-24 Abbvie Inc. Cell culture methods to reduce acidic species
WO2013157953A1 (en) 2012-04-20 2013-10-24 Merus B.V. Methods and means for the production of ig-like molecules
EP2843051B1 (de) 2012-04-23 2018-06-06 GeneFrontier Corporation Anti-human-cd69-antikörper und verwendung davon für medizinische zwecke
AU2013254690B2 (en) 2012-04-24 2017-12-07 Thrombogenics N.V. Anti-PDGF-C antibodies
US20130281355A1 (en) 2012-04-24 2013-10-24 Genentech, Inc. Cell culture compositions and methods for polypeptide production
SG10201608980YA (en) 2012-04-26 2016-12-29 Novartis Ag Antigens and antigen combinations
US10279026B2 (en) 2012-04-26 2019-05-07 Glaxosmithkline Biologicals Sa Antigens and antigen combinations
US9156915B2 (en) 2012-04-26 2015-10-13 Thomas Jefferson University Anti-GCC antibody molecules
CN104507968B (zh) 2012-04-27 2019-02-05 诺和诺德股份有限公司 人cd30配体抗原结合蛋白
WO2013162748A1 (en) 2012-04-27 2013-10-31 The Trustees Of The University Of Pennsylvania Anti-tumor endothelial marker-1 (tem1) antibody variants and uses thereof
KR20150006000A (ko) 2012-05-01 2015-01-15 제넨테크, 인크. 항-pmel17 항체 및 면역접합체
EP2844287A4 (de) 2012-05-02 2016-01-27 Univ New York Verfahren zur behandlung und prävention von staphylococcus-aureus-infektionen und verwandten erkrankungen
CN109206516A (zh) 2012-05-03 2019-01-15 勃林格殷格翰国际有限公司 抗IL-23p19抗体
US9480449B2 (en) 2012-05-03 2016-11-01 Fibrogen, Inc. Methods for treating idiopathic pulmonary fibrosis
AU2013256010B2 (en) 2012-05-04 2018-01-04 Dana-Farber Cancer Institute, Inc. Affinity matured anti-CCR4 humanized monoclonal antibodies and methods of use
WO2013166290A1 (en) 2012-05-04 2013-11-07 Abbvie Biotherapeutics Inc. P21 biomarker assay
US20150072880A1 (en) 2012-05-09 2015-03-12 David A. Calderwood Rapid detection of analytes in liquid samples
US9783614B2 (en) 2012-05-10 2017-10-10 Bayer Pharma Aktiengesellschaft Antibodies capable of binding to the coagulation Factor XI and/or its activated form factor Xia and uses thereof
DK3269736T3 (da) 2012-05-10 2020-01-13 Georg August Univ Goettingen Stiftung Oeffentlichen Rechts Univsmedizin Konformationsspecifikke antistoffer mod oligomerer af amyloid beta
AU2013260123A1 (en) 2012-05-10 2014-11-13 Massachusetts Institute Of Technology Agents for influenza neutralization
US9273140B2 (en) 2012-05-10 2016-03-01 Fujita Health University Antibody for detecting DNA damage in cells utilizing cell membrane surface antigen Ly6D
WO2013170191A1 (en) 2012-05-11 2013-11-14 Genentech, Inc. Methods of using antagonists of nad biosynthesis from nicotinamide
US9416189B2 (en) 2012-05-11 2016-08-16 Microbial Chemistry Research Foundation Anti-CXADR antibody
KR20150018533A (ko) 2012-05-11 2015-02-23 파이브 프라임 테라퓨틱스, 인크. 콜로니 자극 인자 1 수용체(csf1r)에 결속하는 항체들에 의한 질병 상태의 치료 방법
US9796780B2 (en) 2012-05-14 2017-10-24 Biogen Ma Inc. LINGO-2 antagonists for treatment of conditions involving motor neurons
EP3184542A1 (de) 2012-05-14 2017-06-28 Novo Nordisk A/S Stabilisierte proteinlösungen
CN104822656B (zh) 2012-05-15 2018-05-01 西雅图基因公司 自稳定接头偶联物
JP6122948B2 (ja) 2012-05-15 2017-04-26 モルフォテック， インコーポレイテッド 胃癌の治療のための方法
EP2850207B1 (de) 2012-05-16 2017-01-04 Institut National de la Santé et de la Recherche Médicale (INSERM) Verfahren zur diagnose und behandlung von familiären aneurysmen der a. thoracica durch tgfb2-funktionsverlustmutationen
WO2013173582A1 (en) 2012-05-17 2013-11-21 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Hepatitis c virus neutralizing antibody
MX349035B (es) 2012-05-17 2017-07-07 Extend Biosciences Inc Portadores para el suministro mejorado de farmaco.
WO2013173266A1 (en) 2012-05-17 2013-11-21 The Johns Hopkins University Methods for identifying patterns of ifn induced expression and use in diagnosis, monitoring and therapy
US20130309223A1 (en) 2012-05-18 2013-11-21 Seattle Genetics, Inc. CD33 Antibodies And Use Of Same To Treat Cancer
SI2849723T1 (sl) 2012-05-18 2018-09-28 Genentech, Inc. Formulacije z visoko koncentracijo monoklonskih protiteles
WO2013177062A2 (en) 2012-05-21 2013-11-28 Genentech, Inc. Methods for improving safety of blood-brain barrier transport
TW201348247A (zh) 2012-05-21 2013-12-01 Abbvie Inc 利用蛋白質ａ親和性層析之非人類抗體之新穎純化
WO2013174834A1 (en) 2012-05-22 2013-11-28 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods for diagnosing and treating focal segmental glomerulosclerosis
US9844582B2 (en) 2012-05-22 2017-12-19 Massachusetts Institute Of Technology Synergistic tumor treatment with extended-PK IL-2 and therapeutic agents
DK2852610T3 (en) 2012-05-23 2018-09-03 Glykos Finland Oy PRODUCTION OF FUCOSYLED GLYCOPROTEIN
EP2852840B1 (de) 2012-05-23 2019-10-09 F.Hoffmann-La Roche Ag Auswahlverfahren für therapeutika
WO2013175276A1 (en) 2012-05-23 2013-11-28 Argen-X B.V Il-6 binding molecules
US9249182B2 (en) 2012-05-24 2016-02-02 Abbvie, Inc. Purification of antibodies using hydrophobic interaction chromatography
SG11201408330XA (en) 2012-05-24 2015-01-29 Mountgate Group Ltd Compositions and methods related to prevention and treatment of rabies infection
WO2013177386A1 (en) 2012-05-24 2013-11-28 Abbvie Biotherapeutics Inc. Biomarkers for predicting response to tweak receptor (tweakr) agonist therapy
US10502737B2 (en) 2012-05-25 2019-12-10 The University Of Vermont And State Agriculture College Anti-thrombotic compositions and methods for assaying platelet reactivity and treatment selection
US20130315891A1 (en) 2012-05-25 2013-11-28 Matthew Charles Formulations of human tissue kallikrein-1 for parenteral delivery and related methods
WO2013177481A1 (en) 2012-05-25 2013-11-28 Immunogen, Inc. Benzodiazepines and conjugates thereof
MX361773B (es) 2012-05-31 2018-12-17 Innate Pharma Agentes de ligación a tlr3.
ES2742379T3 (es) 2012-05-31 2020-02-14 Hoffmann La Roche Procedimientos de tratamiento del cáncer usando antagonistas de unión al eje de PD-1 y antagonistas de VEGF
US20130323222A1 (en) 2012-06-04 2013-12-05 Matthew Charles Human tissue kallikrein 1 glycosylation isoforms
WO2013184900A2 (en) 2012-06-06 2013-12-12 Sanofi Pasteur Biologics, Llc Immunogenic compositions and related methods
US9617334B2 (en) 2012-06-06 2017-04-11 Zoetis Services Llc Caninized anti-NGF antibodies and methods thereof
MX2014014951A (es) 2012-06-06 2015-03-13 Oncomed Pharm Inc Agentes aglutinantes que modulan la trayectoria hippo y sus usos.
CA2875451A1 (en) 2012-06-08 2013-12-12 Kinki University Antibody against transporter and use thereof
UA113879C2 (xx) 2012-06-08 2017-03-27 ГУМАНІЗОВАНЕ АНТИТІЛО ПРОТИ ТrkА З АМІНОКИСЛОТНИМИ ЗАМІЩЕННЯМИ
AU2013270682A1 (en) 2012-06-08 2014-12-11 Biogen Ma Inc. Procoagulant compounds
AU2013270683A1 (en) 2012-06-08 2014-12-11 Biogen Ma Inc. Chimeric clotting factors
US9738724B2 (en) 2012-06-08 2017-08-22 Sutro Biopharma, Inc. Antibodies comprising site-specific non-natural amino acid residues, methods of their preparation and methods of their use
ES2834072T3 (es) 2012-06-11 2021-06-16 Univ Xiamen Polipéptidos y anticuerpos para el tratamiento de la infección por vhb y enfermedades relacionadas
JP2015525230A (ja) 2012-06-11 2015-09-03 アムジエン・インコーポレーテツド デュアル受容体アンタゴニスト性抗原結合タンパク質およびその使用
US20130330761A1 (en) 2012-06-12 2013-12-12 Celcuity, LLC Whole cell assays and methods
US10155987B2 (en) 2012-06-12 2018-12-18 Dana-Farber Cancer Institute, Inc. Methods of predicting resistance to JAK inhibitor therapy
EP2892924B1 (de) 2012-06-14 2020-11-25 Therapix Biosciences Ltd. Humanisierte antikörper gegen differenzierungscluster 3 (cd 3)
EP4310191A3 (de) 2012-06-14 2024-05-15 Chugai Seiyaku Kabushiki Kaisha Antigenbindendes molekül mit modifizierter fc-region
MX2014015205A (es) 2012-06-14 2015-08-14 Ambrx Inc Anticuerpos anti-psma conjugados a polipeptidos de ligando de receptor nuclear.
AR091462A1 (es) 2012-06-15 2015-02-04 Genentech Inc Anticuerpos anti-pcsk9, formulaciones, dosificacion y metodos de uso
WO2013188693A1 (en) 2012-06-15 2013-12-19 Imaginab, Inc. Antigen binding constructs to cd3
PT2861246T (pt) 2012-06-18 2021-04-05 Univ Leicester Composições e métodos para inibir masp-1 e/ou masp-2 e/ou masp-3 para o tratamento de várias doenças e perturbações
MX2014015557A (es) 2012-06-21 2015-02-24 Univ Indiana Res & Tech Corp Polipeptidos de fusion de region fc de polipeptido de ligando receptor de incretina y conjugados con función efectora fc alterada.
CN104619722B (zh) 2012-06-22 2022-10-04 达特茅斯大学理事会 新型vista-ig构建体和vista-ig用于治疗自身免疫性、过敏性和炎性疾病的用途
US9890215B2 (en) 2012-06-22 2018-02-13 King's College London Vista modulators for diagnosis and treatment of cancer
WO2014004586A1 (en) 2012-06-25 2014-01-03 Zymeworks Inc. Process and methods for efficient manufacturing of highly pure asymmetric antibodies in mammalian cells
WO2014003830A1 (en) 2012-06-25 2014-01-03 Emory University Particle-nucleic acid conjugates and therapeutic uses related thereto
WO2014001368A1 (en) 2012-06-25 2014-01-03 Orega Biotech Il-17 antagonist antibodies
EP3135690A1 (de) 2012-06-26 2017-03-01 Sutro Biopharma, Inc. Modifizierte fc-proteine mit stellenspezifischen nichtnatürlichen aminosäureresten, konjugate daraus, verfahren zu deren herstellung und verfahren zu deren verwendung
KR20150030744A (ko) 2012-06-27 2015-03-20 에프. 호프만-라 로슈 아게 표적에 특이적으로 결합하는 하나 이상의 결합 단위를 포함하는 항체 Ｆｃ－영역 접합체의 제조 방법 및 그의 용도
CA2871386A1 (en) 2012-06-27 2014-01-03 F. Hoffmann-La Roche Ag Method for the selection and production of tailor-made, selective and multi-specific therapeutic molecules comprising at least two different targeting entities and uses thereof
ES2597228T3 (es) 2012-06-27 2017-01-17 F. Hoffmann-La Roche Ag Procedimiento para la selección y la producción de entidades de objetivación, como dianas, altamente selectivas y multiespecíficas, personalizadas, las cuales contienen por lo menos dos entidades de unión diferentes, y utilización de éstas
US9457071B2 (en) 2012-06-28 2016-10-04 Hiroshima University Histamine releaser contained in human sweat
EP2682168A1 (de) 2012-07-02 2014-01-08 Millipore Corporation Reinigung biologischer Moleküle
JP6182210B2 (ja) 2012-06-29 2017-08-16 イー・エム・デイー・ミリポア・コーポレイシヨン タンパク質精製プロセス中のウイルスの不活性化方法
WO2014001482A1 (en) 2012-06-29 2014-01-03 Novartis Forschungsstiftung, Zweigniererlassung, Friedrich Miescher Institute For Biomedical Research Treating diseases by modulating a specific isoform of mkl1
AR091649A1 (es) 2012-07-02 2015-02-18 Bristol Myers Squibb Co Optimizacion de anticuerpos que se fijan al gen de activacion de linfocitos 3 (lag-3) y sus usos
JP6246199B2 (ja) 2012-07-02 2017-12-13 ザ ヘンリー エム． ジャクソン ファウンデーション フォー ザ アドヴァンスメント オブ ミリタリー メディシン インコーポレイテッド パラミクソウイルスおよび使用方法
EP2869837B1 (de) 2012-07-04 2016-09-14 F. Hoffmann-La Roche AG Anti-theophyllin-antikörper und verwendungsverfahren
SG11201407420RA (en) 2012-07-04 2015-02-27 Hoffmann La Roche Covalently linked antigen-antibody conjugates
MX354303B (es) 2012-07-04 2018-02-23 Hoffmann La Roche Anticuerpos de anti-biotina y metodos de uso.
US20150184154A1 (en) 2012-07-05 2015-07-02 Novartis Forschungsstiftung, Zweigniederlassung Friedrich Miescher Institute For Biomedical Resear New treatment for neurodegenerative diseases
WO2014008475A2 (en) 2012-07-05 2014-01-09 The Ohio State University Compositions and methods related to viral vaccines
US10656156B2 (en) 2012-07-05 2020-05-19 Mepur Ravindranath Diagnostic and therapeutic potential of HLA-E monospecific monoclonal IgG antibodies directed against tumor cell surface and soluble HLA-E
PL2870247T3 (pl) 2012-07-05 2019-10-31 Hoffmann La Roche Układ ekspresji i wydzielania
US20150224190A1 (en) 2012-07-06 2015-08-13 Mohamed Bentires-Alj Combination of a phosphoinositide 3-kinase inhibitor and an inhibitor of the IL-8/CXCR interaction
WO2014006217A1 (en) 2012-07-06 2014-01-09 Genmab B.V. Dimeric protein with triple mutations
AU2013288932A1 (en) 2012-07-09 2014-12-11 Genentech, Inc. Immunoconjugates comprising anti - CD79b antibodies
EP2684896A1 (de) 2012-07-09 2014-01-15 International-Drug-Development-Biotech Antikörper gegen die DR5-Familie, bispezifische oder multivalente Antikörper gegen die DR5-Familie und Verfahren zu deren Verwendung
CA2874904A1 (en) 2012-07-09 2014-01-16 Genentech, Inc. Immunoconjugates comprising anti-cd22 antibodies
BR112015000437A2 (pt) 2012-07-09 2017-06-27 Genentech Inc imunoconjugados, formulação farmacêutica, métodos de tratamento e de inbir a proliferação de uma célula
KR20150027829A (ko) 2012-07-09 2015-03-12 제넨테크, 인크. 항-cd22 항체를 포함하는 면역접합체
WO2014011908A1 (en) 2012-07-11 2014-01-16 Esperion Therapeutics, Inc. Apolipoprotein mixtures
AR091755A1 (es) 2012-07-12 2015-02-25 Abbvie Inc Proteinas de union a il-1
KR20150029714A (ko) 2012-07-13 2015-03-18 더 트러스티스 오브 더 유니버시티 오브 펜실바니아 이중특이적 항체의 공-도입에 의한 ｃａｒ 세포의 활성 증강
SI3495387T1 (sl) 2012-07-13 2021-12-31 Roche Glycart Ag Bispecifična protitelesa proti VEGF/proti ANG-2 in njihova uporaba pri zdravljenju bolezni očesnih žil
EP2872894B1 (de) 2012-07-13 2019-04-17 Innate Pharma Screening von konjugierten antikörpern
US20140024015A1 (en) 2012-07-18 2014-01-23 Idexx Laboratories, Inc. Boone Cardiovirus
EP2875049B1 (de) 2012-07-18 2018-12-26 Institut National de la Sante et de la Recherche Medicale (INSERM) Verfahren zur vorbeugung und behandlung chronische niereninsuffizienz (ckd)
CA2879443A1 (en) 2012-07-19 2014-01-23 Zoetis Llc Bovine influenza virus compositions
US9567569B2 (en) 2012-07-23 2017-02-14 Gamida Cell Ltd. Methods of culturing and expanding mesenchymal stem cells
US9175266B2 (en) 2012-07-23 2015-11-03 Gamida Cell Ltd. Enhancement of natural killer (NK) cell proliferation and activity
ES2817897T3 (es) 2012-07-23 2021-04-08 La Jolla Inst Allergy & Immunology PTPRS y proteoglicanos en enfermedad autoinmune
WO2014018274A1 (en) 2012-07-27 2014-01-30 Baxter International, Inc. Compositions comprising chimeric ospa molecules and methods of use thereof
WO2014018724A1 (en) 2012-07-27 2014-01-30 Zoetis Llc Tick toxin compositions
AU2013297478B2 (en) 2012-07-30 2018-12-20 Medical & Biological Laboratories Co., Ltd. Monoclonal antibody against human midkine
WO2014020293A1 (en) 2012-07-31 2014-02-06 Imperial Innovations Limited Assay
GB201213652D0 (en) 2012-08-01 2012-09-12 Oxford Biotherapeutics Ltd Therapeutic and diagnostic target
EP4678239A3 (de) 2012-08-01 2026-04-08 Ikaika Therapeutics, Inc. Abschwächung von gewebeschäden und fibrose über latentes transformierendes wachstumsfaktor-beta-bindendes protein (ltbp4)
CA2876096A1 (en) 2012-08-02 2014-02-06 Petra Rueger Method for producing soluble fcr as fc-fusion with inert immunoglobulin fc-region and uses thereof
EP3613765B1 (de) 2012-08-03 2024-10-02 Dana-Farber Cancer Institute, Inc. Antikörper gegen das abstossende wegweisermolekül b (rgmb)
PL3434695T3 (pl) 2012-08-07 2021-05-17 Roche Glycart Ag Ulepszona immunoterapia
EP3446709A1 (de) 2012-08-07 2019-02-27 F. Hoffmann-La Roche AG Kombinationstherapie zur behandlung von glioblastomen
FR2994390B1 (fr) 2012-08-10 2014-08-15 Adocia Procede d'abaissement de la viscosite de solutions de proteines a concentration elevee
WO2014027959A1 (en) 2012-08-14 2014-02-20 Nanyang Technological University Angiopoietin-like 4 antibody and a method of its use in cancer treatment
EP2885010B1 (de) 2012-08-16 2020-01-01 Ipierian, Inc. Verfahren zur behandlung einer tauopathie
US9645151B2 (en) 2012-08-17 2017-05-09 California Institute Of Technology Targeting phosphofructokinase and its glycosylation form for cancer
US9989538B2 (en) 2012-08-17 2018-06-05 Hiroshima University Monoclonal IgE antibody that binds to sweat allergy antigen protein
US9914956B2 (en) 2012-08-18 2018-03-13 Academia Sinica Cell-permeable probes for identification and imaging of sialidases
JP6211084B2 (ja) 2012-08-21 2017-10-11 アカデミア シニカＡｃａｄｅｍｉａ Ｓｉｎｉｃａ ベンゾシクロオクチン化合物およびその使用
US20140056901A1 (en) 2012-08-21 2014-02-27 The Institute For Molecular Medicine Anti-tau antibodies and compositions for and methods of making and using in treatment, diagnosis and monitoring of tauopathies
TR201900694T4 (tr) 2012-08-23 2019-02-21 Agensys Inc 158p1d7 proteinlerine bağlanan antikor ilaç konjugatları (adc).
JP6774164B2 (ja) 2012-08-24 2020-10-21 中外製薬株式会社 マウスＦｃγＲＩＩ特異的Ｆｃ抗体
TWI855488B (zh) 2012-08-24 2024-09-11 日商中外製藥股份有限公司 FcγRIIb特異性Fc區域變異體
EP3260464A1 (de) 2012-08-28 2017-12-27 Novartis AG Verfahren zur reinigung von antikörpern mit aliphatischen alkoholen
MX367126B (es) 2012-08-29 2019-08-06 Hoffmann La Roche Transporte para atravesar la barrera hematoencefálica.
JP6233932B2 (ja) 2012-08-30 2017-11-22 国立大学法人広島大学 ＢＢＦ２Ｈ７（ＢＢＦ２ ｈｕｍａｎ ｈｏｍｏｌｏｇｕｅ ｏｎ ｃｈｒｏｍｏｓｏｍｅ７）部分アミノ酸配列を有するペプチドまたはそれに結合する抗体を含む細胞増殖調節用組成物
US9345766B2 (en) 2012-08-30 2016-05-24 Merrimack Pharmaceuticals, Inc. Combination therapies comprising anti-ERBB3 agents
CN107759690A (zh) 2012-08-31 2018-03-06 戊瑞治疗有限公司 用结合群落刺激因子1受体(csf1r)的抗体治疗病状的方法
US8883979B2 (en) 2012-08-31 2014-11-11 Bayer Healthcare Llc Anti-prolactin receptor antibody formulations
US8613919B1 (en) 2012-08-31 2013-12-24 Bayer Healthcare, Llc High concentration antibody and protein formulations
US9592297B2 (en) 2012-08-31 2017-03-14 Bayer Healthcare Llc Antibody and protein formulations
SG11201500938XA (en) 2012-08-31 2015-04-29 Immunogen Inc Diagnostic assays and kits for detection of folate receptor 1
WO2014036562A2 (en) 2012-08-31 2014-03-06 University Of Virginia Patent Foundation Target peptides for immunotherapy and diagnostics
ES2684552T3 (es) 2012-09-03 2018-10-03 Inserm - Institut National De La Santé Et De La Recherche Médicale Anticuerpos dirigidos contra ICOS para tratar la enfermedad de injerto contra hospedador
UA115789C2 (uk) 2012-09-05 2017-12-26 Трейкон Фармасутікалз, Інк. Композиція антитіла до cd105 та її застосування
HK1212236A1 (en) 2012-09-05 2016-06-10 University Of Virginia Patent Foundation Target peptides for colorectal cancer therapy and diagnostics
WO2014036608A1 (en) 2012-09-06 2014-03-13 Adelaide Research & Innovation Pty Ltd Methods and products for preventing and/or treating metastatic cancer
US9376489B2 (en) 2012-09-07 2016-06-28 Novartis Ag IL-18 binding molecules
CA2884704C (en) 2012-09-07 2023-04-04 Randolph J. Noelle Vista modulators for diagnosis and treatment of cancer
FR2995214B1 (fr) 2012-09-10 2014-11-21 Adocia Solution a viscosite reduite de proteine a concentration elevee
TWI595007B (zh) 2012-09-10 2017-08-11 Neotope Biosciences Ltd 抗ｍｃａｍ抗體及相關使用方法
WO2014040025A2 (en) 2012-09-10 2014-03-13 International Aids Vaccine Initiative Immunogens of hiv-1 broadly neutralizing antibodies, methods of generation and uses thereof
WO2014041544A1 (en) 2012-09-12 2014-03-20 Ramot At Tel-Aviv University Ltd. Immunoparticles and methods of generating and using same
EP2896291B1 (de) 2012-09-13 2019-03-20 Chugai Seiyaku Kabushiki Kaisha Nichtmenschliches gen-knock-in-tier
WO2014043518A1 (en) 2012-09-14 2014-03-20 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Brachyury protein, non-poxvirus non-yeast vectors encoding brachyury protein, and their use
DK178233B1 (en) 2012-09-17 2015-09-14 Novartis Tiergesundheit Ag Fiskevaccine
WO2014047342A1 (en) 2012-09-19 2014-03-27 Dana-Farber Cancer Institute, Inc. Dynamic bh3 profiling
WO2014046730A1 (en) 2012-09-24 2014-03-27 Ventana Medical Systems, Inc. Method of identifying treatment responsive non-small cell lung cancer using anaplastic lymphoma kinase (alk) as a marker
EA031631B1 (ru) 2012-09-27 2019-01-31 Чугаи Сеияку Кабушики Каиша Способ лечения или предупреждения злокачественного новообразования, способ отбора пациента, способ тестирования предрасположенности к злокачественному новообразованию у субъекта, гибридный полипептид и его применения
BR112015006824A2 (pt) 2012-09-27 2017-07-04 Merus B V anticorpo igg biespecífico, método para produzir um anticorpo igg biespecífico, anticorpo, composição farmacêutica e uso de um anticorpo igg biespecífico
PL2900686T3 (pl) 2012-09-28 2021-01-25 The University Of North Carolina At Chapel Hill Wektory aav ukierunkowane na oligodendrocyty
WO2014055442A2 (en) 2012-10-01 2014-04-10 The Trustees Of The University Of Pennsylvania Compositions and methods for targeting stromal cells for the treatment of cancer
NO2760138T3 (de) 2012-10-01 2018-08-04
US10662477B2 (en) 2012-10-01 2020-05-26 Millennium Pharmaceuticals, Inc. Biomarkers and methods to predict response to inhibitors and uses thereof
US20140094383A1 (en) 2012-10-02 2014-04-03 Ohio State Innovation Foundation Tethered Lipoplex nanoparticle Biochips And Methods Of Use
EP2904015A4 (de) 2012-10-02 2016-10-05 Univ Rutgers Gezielte freisetzung von mit antikörpern gegen aktivierte matriptase konjugierten toxinen
EP2904093B1 (de) 2012-10-03 2019-04-10 Zymeworks Inc. Verfahren zur quantitativen bestimmung von schwer- und leichtkettigen polypeptidpaaren
EP2903629B1 (de) 2012-10-03 2019-07-10 Philogen S.p.A. Antikörperkonjugat zur verwendung bei der behandlung von entzündlichen darmerkrankungen
BR112015007672A2 (pt) 2012-10-04 2017-08-08 Dana Farber Cancer Inst Inc anticorpos anti-pd-l1 monoclonais humanos e métodos de uso
US9324141B2 (en) 2012-10-05 2016-04-26 Volcano Corporation Removal of A-scan streaking artifact
US10070827B2 (en) 2012-10-05 2018-09-11 Volcano Corporation Automatic image playback
US9286673B2 (en) 2012-10-05 2016-03-15 Volcano Corporation Systems for correcting distortions in a medical image and methods of use thereof
US9307926B2 (en) 2012-10-05 2016-04-12 Volcano Corporation Automatic stent detection
US9292918B2 (en) 2012-10-05 2016-03-22 Volcano Corporation Methods and systems for transforming luminal images
CA2887421A1 (en) 2012-10-05 2014-04-10 David Welford Systems and methods for amplifying light
KR101850591B1 (ko) 2012-10-05 2018-04-19 제넨테크, 인크. 염증성 장 질환의 진단 및 치료 방법
US9367965B2 (en) 2012-10-05 2016-06-14 Volcano Corporation Systems and methods for generating images of tissue
US9858668B2 (en) 2012-10-05 2018-01-02 Volcano Corporation Guidewire artifact removal in images
US20140100454A1 (en) 2012-10-05 2014-04-10 Volcano Corporation Methods and systems for establishing parameters for three-dimensional imaging
US10568586B2 (en) 2012-10-05 2020-02-25 Volcano Corporation Systems for indicating parameters in an imaging data set and methods of use
US11272845B2 (en) 2012-10-05 2022-03-15 Philips Image Guided Therapy Corporation System and method for instant and automatic border detection
US9598489B2 (en) 2012-10-05 2017-03-21 The Trustees Of The Univeristy Of Pennsylvania Human alpha-folate receptor chimeric antigen receptor
EP3677310A1 (de) 2012-10-08 2020-07-08 St. Jude Children's Research Hospital Therapien auf der basis der steuerung der stabilität und funktion regulatorischer t-zellen über eine neuropilin-1:semaphorin-achse
MX2015003616A (es) 2012-10-08 2015-06-05 Roche Glycart Ag Anticuerpos sin fc que comprenden dos fragmentos fab y metodos de uso.
MX2015004436A (es) 2012-10-09 2015-06-24 Biogen Idec Inc Tratamientos conjuntos y usos para tratar trastornos desmielinizantes.
SG11201502757QA (en) 2012-10-09 2015-05-28 Igenica Biotherapeutics Inc Anti-c16orf54 antibodies and methods of use thereof
WO2014057490A1 (en) 2012-10-09 2014-04-17 Ramot At Tel-Aviv University Ltd. Methods and kits for predicting prognosis of cancer using soluble mortalin in blood
WO2014059034A2 (en) 2012-10-09 2014-04-17 President And Fellows Of Harvard College Nad biosynthesis and precursors for the treatment and prevention of cancer and proliferation
WO2014057114A1 (en) 2012-10-12 2014-04-17 Adc Therapeutics Sàrl Pyrrolobenzodiazepine-anti-psma antibody conjugates
WO2014059251A1 (en) 2012-10-12 2014-04-17 The Brigham And Women's Hospital, Inc. Enhancement of the immune response
BR112015008238A2 (pt) 2012-10-12 2017-11-28 Adc Therapeutics Sarl conjugados de pirrolbenzodiazepina-anticorpo anti-cd22
PT2906253T (pt) 2012-10-12 2018-11-05 Medimmune Ltd Conjugados de anticorpo anti-psma de pirrolobenzodiazepina
EP2906297B1 (de) 2012-10-12 2017-12-06 ADC Therapeutics SA Pyrrolobenzodiazepin-antikörper-konjugate
DK2906298T3 (en) 2012-10-12 2018-12-17 Adc Therapeutics Sa Pyrrolobenzodiazepine-antibody conjugates
DK2839860T3 (da) 2012-10-12 2019-06-17 Medimmune Ltd Pyrrolobenzodiazepiner og konjugater deraf
PT2906248T (pt) 2012-10-12 2019-03-04 Medimmune Ltd Pirrolobenzodiazepinas e conjugados das mesmas
KR101995620B1 (ko) 2012-10-12 2019-07-03 에이디씨 테라퓨틱스 에스에이 피롤로벤조디아제핀-항체 컨주게이트
EP2906249B1 (de) 2012-10-12 2018-06-27 MedImmune Limited Synthese und zwischenprodukte pyrrolobenzodiazepinderivaten zur konjugation
KR102308915B1 (ko) 2012-10-15 2021-10-06 메디뮨 리미티드 아밀로이드 베타에 대한 항체
PT2908912T (pt) 2012-10-18 2020-09-04 Univ Rockefeller Anticorpos anti-hiv amplamente neutralizantes
WO2014063097A1 (en) 2012-10-19 2014-04-24 Danisco Us Inc. Stabilization of biomimetic membranes
US9395369B2 (en) 2012-10-19 2016-07-19 Regents Of The University Of Minnesota Guinea pig cytomegalovirus (CIDMTR strain)
US9840734B2 (en) 2012-10-22 2017-12-12 Raindance Technologies, Inc. Methods for analyzing DNA
JP2015536933A (ja) 2012-10-23 2015-12-24 オンコメッド ファーマシューティカルズ インコーポレイテッド Ｗｎｔ経路結合剤を用いて神経内分泌腫瘍を処置する方法
WO2014064682A1 (en) 2012-10-24 2014-05-01 Yeda Research And Development Co. Ltd. Combinations of epidermal growth factor receptor targeting antibodies for treating cancer
CA2888345C (en) 2012-10-24 2020-04-21 Research Development Foundation Jam-c antibodies and methods for treatment of cancer
CN104704359A (zh) 2012-10-25 2015-06-10 生命科技公司 糖蛋白酶介导位点特异性放射性标记的方法和组合物
WO2014066744A2 (en) 2012-10-25 2014-05-01 True North Therapeutics, Inc. Anti-complement c1s antibodies and uses thereof
US20150246118A1 (en) 2012-10-26 2015-09-03 INSERM (Institut National de la Santé et de la Recherche Médicale) Lyve-1 antagonists for preventing or treating a pathological condition associated with lymphangiogenesis
AU2013334075B2 (en) 2012-10-26 2018-11-29 Memorial Sloan-Kettering Cancer Center Androgen receptor variants and methods for making and using
US9751931B2 (en) 2012-10-26 2017-09-05 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Hepatitis C virus neutralizing antibodies and methods
WO2014063205A1 (en) 2012-10-26 2014-05-01 The University Of Queensland Use of endocytosis inhibitors and antibodies for cancer therapy
WO2014070786A1 (en) 2012-10-29 2014-05-08 The University Of North Carolina At Chapel Hill Compositions and methods for inhibiting pathogen infection
AR093297A1 (es) 2012-10-31 2015-05-27 Amgen Res Munich Gmbh Formulacion liquida que comprende un compuesto neutralizante de gm-csf
CA2889638A1 (en) 2012-10-31 2014-05-08 Oncomed Pharmaceuticals, Inc. Methods and monitoring of treatment with a dll4 antagonist
US9833410B2 (en) 2012-10-31 2017-12-05 Takeda Gmbh Lyophilized formulation comprising GM-CSF neutralizing compound
PE20151179A1 (es) 2012-11-01 2015-09-12 Abbvie Inc Inmunoglobulinas de dominio variable dual anti-vegf/dll4 y usos de las mismas
EP2914628A1 (de) 2012-11-01 2015-09-09 Max-Delbrück-Centrum für Molekulare Medizin Antikörper mit bindung von cd269 (bcma) zur behandlung von plasmazellenkrankheiten wie multiplem myelom und autoimmunerkrankungen
ES2912396T3 (es) 2012-11-02 2022-05-25 Bioverativ Usa Inc Anticuerpos anti-C1s del complemento y uso de los mismos
WO2014070975A1 (en) 2012-11-02 2014-05-08 Novartis Ag Flavivirus associated with theiler's disease
EP4223770A3 (de) 2012-11-05 2023-10-18 Foundation Medicine, Inc. Neuartige fusionsmoleküle und verwendungen davon
HK1214521A1 (zh) 2012-11-05 2016-07-29 Genzyme Corporation 用於治療蛋白質病的組合物和方法
MX340090B (es) 2012-11-05 2016-06-23 Pfizer Analogos de spliceostatina.
EP2914621B1 (de) 2012-11-05 2023-06-07 Foundation Medicine, Inc. Neuartige ntrk1-fusionsmoleküle und verwendungen davon
TW201726746A (zh) 2012-11-07 2017-08-01 輝瑞股份有限公司 抗切口３（ａｎｔｉ-ｎｏｔｃｈ３）抗體及抗體-藥物共軛體
CN104755500B (zh) 2012-11-08 2020-10-02 霍夫曼-拉罗奇有限公司 结合HER3 β-发夹的HER3抗原结合蛋白
EP2917347B1 (de) 2012-11-08 2019-01-02 Institut National de la Sante et de la Recherche Medicale (INSERM) Verfahren und pharmazeutische zusammensetzungen zur behandlung von knochenmetastasen
DK2918603T3 (en) 2012-11-08 2018-10-15 Univ Miyazaki ANTIBODY STANDING TO SPECIFICALLY RECOGNIZE TRANSFERRIN RECEPTOR
KR102149206B1 (ko) 2012-11-08 2020-08-31 세센 바이오, 아이엔씨. 인터루킨-6의 길항제 및 이의 용도
RU2015115956A (ru) 2012-11-09 2017-01-10 Пфайзер Инк. Антитела, специфичные в отношении фактора роста тромбоцитов в, и их композиции и применения
EP2916872B1 (de) 2012-11-09 2019-02-27 Innate Pharma Kennungen für tgase-vermittelte konjugation
CN104937099B (zh) 2012-11-09 2018-03-30 基因先端领域株式会社 用于治疗癌症的抗adam28抗体
CN104884056A (zh) 2012-11-12 2015-09-02 雷德伍德生物科技股份有限公司 用于制备缀合物的化合物和方法
BR112015010817A8 (pt) 2012-11-13 2018-01-23 Genentech Inc anticorpos anti-hemaglutinina isolado, método de tratamento, inibição ou prevenção de infecções, composição, composição farmacêutica, ácido nucleico isolado, célula hospedeira, método de produção de anticorpos e uso do anticorpo anti-hemaglutinina
JP2015537212A (ja) 2012-11-15 2015-12-24 ジェネンテック， インコーポレイテッド イオン強度媒介のｐｈ勾配イオン交換クロマトグラフィー
US10035822B2 (en) 2012-11-15 2018-07-31 Apellis Pharmaceuticals, Inc. Cell-reactive, long-acting, or targeted compstatin analogs and related compositions and methods
EP2733153A1 (de) 2012-11-15 2014-05-21 INSERM (Institut National de la Santé et de la Recherche Médicale) Verfahren zur Herstellung von Immunkonjugaten und Verwendungen davon
WO2014078733A1 (en) 2012-11-16 2014-05-22 The Regents Of The University Of California Pictet-spengler ligation for protein chemical modification
US9310374B2 (en) 2012-11-16 2016-04-12 Redwood Bioscience, Inc. Hydrazinyl-indole compounds and methods for producing a conjugate
PT3199552T (pt) 2012-11-20 2020-03-25 Sanofi Sa Anticorpos anti-ceacam5 e suas utilizações
EP2735874A1 (de) 2012-11-21 2014-05-28 Fundación Para La Investigación Biomédica Del Hospital Universitario Puerta De Hierro Verfahren zur Diagnose und Therapiemittel zur Behandlung von Prostatakrebs
GB201220924D0 (en) 2012-11-21 2013-01-02 Cancer Res Inst Royal Materials and methods for determining susceptibility or predisposition to cancer
US10131682B2 (en) 2012-11-24 2018-11-20 Hangzhou Dac Biotech Co., Ltd. Hydrophilic linkers and their uses for conjugation of drugs to a cell binding molecules
PT2922554T (pt) 2012-11-26 2022-06-28 Modernatx Inc Arn modificado nas porções terminais
US9775915B2 (en) 2012-11-26 2017-10-03 President And Fellows Of Harvard College Trioxacarcins, trioxacarcin-antibody conjugates, and uses thereof
FR2998579B1 (fr) 2012-11-27 2015-06-19 Commissariat Energie Atomique Methode pour obtenir des anticorps humains specifiques d'un antigene par immunisation in vitro
US9914785B2 (en) 2012-11-28 2018-03-13 Zymeworks Inc. Engineered immunoglobulin heavy chain-light chain pairs and uses thereof
MX2015004626A (es) 2012-11-29 2015-07-14 Yeda Res & Dev Metodos para prevenir metastasis de tumor, tratar y pronosticar cancer e identificar agentes que son inhibidores putativos de metastasis.
US20140154255A1 (en) 2012-11-30 2014-06-05 Abbvie Biotherapeutics Inc. Anti-vegf antibodies and their uses
WO2014084859A1 (en) 2012-11-30 2014-06-05 Novartis Ag Molecules and methods for modulating tmem16a activities
US10407503B2 (en) 2012-11-30 2019-09-10 The Regents Of The University Of California Fully human antibodies and fragments recognizing human c-Met
US20150322152A1 (en) 2012-11-30 2015-11-12 Institut Pasteur Use of anti-fcyri and/or anti-fcyriia antibodies for treating arthritis, inflammation, thrombocytopenia and allergic shock
RU2693078C2 (ru) 2012-12-03 2019-07-01 Новиммун С.А. Анти-cd47 антитела и способы их применения
US9353150B2 (en) 2012-12-04 2016-05-31 Massachusetts Institute Of Technology Substituted pyrazino[1′,2′:1 ,5]pyrrolo[2,3-b]-indole-1,4-diones for cancer treatment
DK2928921T3 (da) 2012-12-05 2021-04-19 Novartis Ag Sammensætninger og fremgangsmåder til antistoffer målrettet epo
CA2891504A1 (en) 2012-12-07 2014-06-12 Danisco Us Inc. Compositions and methods of use
UA118255C2 (uk) 2012-12-07 2018-12-26 Санофі Композиція, яка містить антитіло до cd38 і леналідомід
US9879245B2 (en) 2012-12-07 2018-01-30 Danisco Us Inc. Polypeptides having beta-mannanase activity and methods of use
US9383357B2 (en) 2012-12-07 2016-07-05 Northwestern University Biomarker for replicative senescence
US10342869B2 (en) 2012-12-07 2019-07-09 The Regents Of The University Of California Compositions comprising anti-CD38 antibodies and lenalidomide
ES2664095T3 (es) 2012-12-07 2018-04-18 Pfizer Inc. Fragmentos de anticuerpos monoméricos diseñados mediante ingeniería genética
WO2014093417A1 (en) 2012-12-12 2014-06-19 University Of Virginia Patent Foundation Compositions and methods for regulating erythropoiesis
EP3290515A1 (de) 2012-12-12 2018-03-07 Danisco US Inc. Varianten von cellobiohydrolasen
WO2014093855A1 (en) 2012-12-13 2014-06-19 University Of Virginia Patent Foundation Target peptides for ovarian cancer therapy and diagnostics
JP6322210B2 (ja) 2012-12-13 2018-05-09 ボルケーノ コーポレイション 標的化された挿管のためのデバイス、システム、および方法
WO2015012904A2 (en) 2012-12-13 2015-01-29 Immunomedics, Inc. Antibody-sn-38 immunoconjugates with a cl2a linker
US10413539B2 (en) 2012-12-13 2019-09-17 Immunomedics, Inc. Therapy for metastatic urothelial cancer with the antibody-drug conjugate, sacituzumab govitecan (IMMU-132)
US12310958B2 (en) 2012-12-13 2025-05-27 Immunomedics, Inc. Antibody-drug conjugates and uses thereof
US20240148873A1 (en) 2012-12-13 2024-05-09 Immunomedics, Inc. Dosages of immunoconjugates of antibodies and sn-38 for improved efficacy and decreased toxicity
US10137196B2 (en) 2012-12-13 2018-11-27 Immunomedics, Inc. Dosages of immunoconjugates of antibodies and SN-38 for improved efficacy and decreased toxicity
US9492566B2 (en) 2012-12-13 2016-11-15 Immunomedics, Inc. Antibody-drug conjugates and uses thereof
UA117466C2 (uk) 2012-12-13 2018-08-10 Мерк Шарп Енд Доме Корп. СТАБІЛЬНИЙ СКЛАД У ВИГЛЯДІ РОЗЧИНУ АНТИТІЛА ДО IL-23p19
CN107753954A (zh) 2012-12-13 2018-03-06 免疫医疗公司 功效改进且毒性降低的抗体与sn‑38的免疫缀合物的剂量
US10744129B2 (en) 2012-12-13 2020-08-18 Immunomedics, Inc. Therapy of small-cell lung cancer (SCLC) with a topoisomerase-I inhibiting antibody-drug conjugate (ADC) targeting Trop-2
US9931417B2 (en) 2012-12-13 2018-04-03 Immunomedics, Inc. Antibody-SN-38 immunoconjugates with a CL2A linker
US10206918B2 (en) 2012-12-13 2019-02-19 Immunomedics, Inc. Efficacy of anti-HLA-DR antiboddy drug conjugate IMMU-140 (hL243-CL2A-SN-38) in HLA-DR positive cancers
EP2931749B1 (de) 2012-12-17 2019-04-24 Laboratoire Francais du Fractionnement et des Biotechnologies Societe Anonyme Verwendung monoklonaler antikörper zur behandlung von entzündungen und bakteriellen infektionen
KR20150095684A (ko) 2012-12-18 2015-08-21 노파르티스 아게 히알루로난에 결합하는 펩티드 태그를 이용하는 조성물 및 방법
JP6408487B2 (ja) 2012-12-18 2018-10-24 ザ ロックフェラー ユニバーシティ Ｈｉｖの防止および療法のためのグリカン修飾された抗ｃｄ４抗体
WO2014100095A1 (en) 2012-12-19 2014-06-26 Genentech, Inc. Methods and compositions for radiohalogen protein labeling
ES2737649T3 (es) 2012-12-19 2020-01-15 Aveo Pharmaceuticals Inc Anticuerpos anti-Notch3
AU2013361275B2 (en) 2012-12-19 2016-11-24 Amplimmune, Inc. Anti-human B7-H4 antibodies and their uses
US9709379B2 (en) 2012-12-20 2017-07-18 Volcano Corporation Optical coherence tomography system that is reconfigurable between different imaging modes
WO2014100602A1 (en) 2012-12-20 2014-06-26 Hospital For Special Surgery Treatment of egf-receptor dependent pathologies
WO2014113188A2 (en) 2012-12-20 2014-07-24 Jeremy Stigall Locating intravascular images
CN105007937B (zh) 2012-12-20 2019-11-19 米迪缪尼有限公司 生产免疫偶联物的方法
US10942022B2 (en) 2012-12-20 2021-03-09 Philips Image Guided Therapy Corporation Manual calibration of imaging system
US10595820B2 (en) 2012-12-20 2020-03-24 Philips Image Guided Therapy Corporation Smooth transition catheters
US11406498B2 (en) 2012-12-20 2022-08-09 Philips Image Guided Therapy Corporation Implant delivery system and implants
US10939826B2 (en) 2012-12-20 2021-03-09 Philips Image Guided Therapy Corporation Aspirating and removing biological material
EP2934280B1 (de) 2012-12-21 2022-10-19 Mai, Jerome Ultraschallbildgebung mit variabler liniendichte
JP2016502884A (ja) 2012-12-21 2016-02-01 ダグラス メイヤー， 延在カテーテル本体テレスコープを有する回転可能超音波撮像カテーテル
JP6475167B2 (ja) 2012-12-21 2019-02-27 エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ ジスルフィド結合した多価ｍｈｃクラスｉを含む多機能タンパク質
WO2015097928A1 (ja) 2013-12-24 2015-07-02 中外製薬株式会社 可溶性ｇｐｃ３タンパク質の測定方法
AR093984A1 (es) 2012-12-21 2015-07-01 Merck Sharp & Dohme Anticuerpos que se unen a ligando 1 de muerte programada (pd-l1) humano
US10058284B2 (en) 2012-12-21 2018-08-28 Volcano Corporation Simultaneous imaging, monitoring, and therapy
US9486143B2 (en) 2012-12-21 2016-11-08 Volcano Corporation Intravascular forward imaging device
GB201223172D0 (en) 2012-12-21 2013-02-06 Immunocore Ltd Method
US9550986B2 (en) 2012-12-21 2017-01-24 Abbvie Inc. High-throughput antibody humanization
ES3066738T3 (en) 2012-12-21 2026-05-14 Aveo Pharmaceuticals Inc Anti-gdf15 antibodies
JP6359031B2 (ja) 2012-12-21 2018-07-18 メディミューン，エルエルシー 抗ｈ７ｃｒ抗体
AU2013366493B2 (en) 2012-12-21 2017-08-24 Medimmune Limited Pyrrolobenzodiazepines and conjugates thereof
WO2014100530A1 (en) 2012-12-21 2014-06-26 Whiseant Chester System and method for catheter steering and operation
US9567340B2 (en) 2012-12-21 2017-02-14 Medimmune Limited Unsymmetrical pyrrolobenzodiazepines-dimers for use in the treatment of proliferative and autoimmune diseases
EP2936426B1 (de) 2012-12-21 2021-10-13 Jason Spencer System und verfahren zur grafischen verarbeitung medizinischer daten
US9612105B2 (en) 2012-12-21 2017-04-04 Volcano Corporation Polarization sensitive optical coherence tomography system
CA2896004A1 (en) 2012-12-21 2014-06-26 Nathaniel J. Kemp Power-efficient optical buffering using optical switch
WO2014099672A1 (en) 2012-12-21 2014-06-26 Andrew Hancock System and method for multipath processing of image signals
KR20210132742A (ko) 2012-12-21 2021-11-04 알트루바이오 인코퍼레이티드 친수성 자기-희생 링커 및 그것의 포합체
EP2936626A4 (de) 2012-12-21 2016-08-17 David Welford Systeme und verfahren zur verengung einer wellenlängenlichtemission
SG11201504920SA (en) 2012-12-27 2015-07-30 Sanofi Sa Anti-lamp1 antibodies and antibody drug conjugates, and uses thereof
CN105102618B (zh) 2012-12-27 2018-04-17 中外制药株式会社 异源二聚化多肽
EP3336104A1 (de) 2012-12-28 2018-06-20 Precision Biologics, Inc. Humanisierte monoklonale antikörper und verfahren zur verwendung zur diagnose und behandlung von darm- und pankreaskrebs
EP2939026B1 (de) 2012-12-28 2017-07-05 Ventana Medical Systems, Inc. Bildanalyse zur brustkrebsprognose
WO2014106602A1 (en) 2013-01-02 2014-07-10 Glenmark Pharmaceuticals S.A. Antibodies that bind to tl1a and their uses
WO2014107739A1 (en) 2013-01-07 2014-07-10 Eleven Biotherapeutics, Inc. Antibodies against pcsk9
GB201300346D0 (en) 2013-01-09 2013-02-20 Biolnvent Internat Ab BiologIcal materials and uses thereof
WO2014108854A1 (en) 2013-01-09 2014-07-17 Fusimab Ltd. Monospecific anti-hgf and anti-ang2 antibodies and bispecific anti-hgf/anti-ang2 antibodies
HUE038915T2 (hu) 2013-01-17 2018-12-28 Arsanis Biosciences Gmbh MDR E. colira fajlagos antitest
CA2898326C (en) 2013-01-18 2022-05-17 Foundation Medicine, Inc. Methods of treating cholangiocarcinoma
WO2014113717A1 (en) 2013-01-18 2014-07-24 Ark Diagnostics, Inc. Voriconazole immunoassays
WO2014116749A1 (en) 2013-01-23 2014-07-31 Genentech, Inc. Anti-hcv antibodies and methods of using thereof
JO3519B1 (ar) 2013-01-25 2020-07-05 Amgen Inc تركيبات أجسام مضادة لأجل cdh19 و cd3
EP2948478B1 (de) 2013-01-25 2019-04-03 Amgen Inc. Antikörper gegen cdh19 für melanome
WO2014118705A1 (en) 2013-01-31 2014-08-07 Novartis Ag Methods of treating chronic kidney disease-mineral and bone disorder using sclerostin antagonists
EP2951199A4 (de) 2013-01-31 2016-07-20 Univ Jefferson Fusionsproteine zur modulation von regulatorischen und effektor-t-zellen
US20150377888A1 (en) 2013-02-01 2015-12-31 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods for Predicting and Preventing Metastasis in Triple Negative Breast Cancers
AU2014213009B2 (en) 2013-02-01 2019-01-03 Kira Biotech Pty Limited Anti-CD83 antibodies and use thereof
KR20150136061A (ko) 2013-02-01 2015-12-04 산타 마리아 바이오테라퓨틱스, 인코포레이티드 대상에 항-액티빈-a 화합물의 투여
US10568975B2 (en) 2013-02-05 2020-02-25 The Johns Hopkins University Nanoparticles for magnetic resonance imaging tracking and methods of making and using thereof
EP2762496A1 (de) 2013-02-05 2014-08-06 EngMab AG Verfahren zur Auswahl von Antikörpern gegen BCMA
JP6636803B2 (ja) 2013-02-05 2020-01-29 エンクマフ エスアーエールエル Ｂｃｍａに対する抗体の選択のための方法
EP2762497A1 (de) 2013-02-05 2014-08-06 EngMab AG Bispezifische Antikörper gegen CD3-epsilon und BCMA
SG10201706383XA (en) 2013-02-06 2017-09-28 Inhibrx Lp Non-platelet depleting and non-red blood cell depleting cd47 antibodies and methods of use thereof
PT2953971T (pt) 2013-02-07 2023-05-02 Csl Ltd Proteínas de ligação à il-11r e suas utilizações
WO2014124319A2 (en) 2013-02-07 2014-08-14 Massachusetts Institute Of Technology Human adaptation of h5 influenza
US8877202B2 (en) 2013-02-07 2014-11-04 Immunomedics, Inc. Pro-drug form (P2PDOX) of the highly potent 2-pyrrolinodoxorubicin conjugated to antibodies for targeted therapy of cancer
JP6367836B2 (ja) 2013-02-07 2018-08-01 ザ ジェネラル ホスピタル コーポレイション Ｔ制御性細胞の増殖または枯渇方法
LT2953969T (lt) 2013-02-08 2019-12-10 Novartis Ag Anti-il-17a antikūnai ir jų panaudojimas autoimuninių ir uždegiminių ligų gydymui
JP2016514091A (ja) 2013-02-08 2016-05-19 ミスフォールディング ダイアグノスティクス， インコーポレイテッド トランスサイレチン抗体およびその使用
WO2014124280A1 (en) 2013-02-08 2014-08-14 Institute For Myeloma & Bone Cancer Research Improved diagnostic, prognostic, and monitoring methods for multiple myeloma, chronic lymphocytic leukemia, and b-cell non-hodgkin lymphoma
WO2014123227A1 (ja) 2013-02-08 2014-08-14 株式会社医学生物学研究所 ヒトｎｒｇ１タンパク質に対する抗体
GB201302447D0 (en) 2013-02-12 2013-03-27 Oxford Biotherapeutics Ltd Therapeutic and diagnostic target
EP2956003A2 (de) 2013-02-13 2015-12-23 Laboratoire Français du Fractionnement et des Biotechnologies Proteine mit modifizierter glykosylierung und verfahren zur herstellung davon
WO2014126861A1 (en) 2013-02-13 2014-08-21 Ark Diagnostics, Inc. Posaconazole immunoassays
KR20160002713A (ko) 2013-02-13 2016-01-08 라보라토이레 프란카이즈 듀 프락티온네먼트 에트 데스 바이오테크놀로지스 고도로 갈락토실화된 항-tnf-알파 항체 및 이의 용도
WO2014125041A1 (en) 2013-02-14 2014-08-21 Innate Pharma Treatment of peripheral t cell lymphoma
DK3896088T3 (da) 2013-02-20 2025-09-29 Innate Pharma Behandling af perifert t-cellelymfom
WO2014130635A1 (en) 2013-02-20 2014-08-28 Novartis Ag Effective targeting of primary human leukemia using anti-cd123 chimeric antigen receptor engineered t cells
SG11201505896YA (en) 2013-02-20 2015-09-29 Novartis Ag Treatment of cancer using humanized anti-egfrviii chimeric antigen receptor
ES2731681T3 (es) 2013-02-22 2019-11-18 Abbvie Stemcentrx Llc Conjugados de anticuerpo anti-DLL3 y PBD y usos de los mismos
SG11201506052PA (en) 2013-02-22 2015-09-29 Curevac Gmbh Combination of vaccination and inhibition of the pd-1 pathway
WO2014128235A1 (en) 2013-02-22 2014-08-28 F. Hoffmann-La Roche Ag Methods of treating cancer and preventing drug resistance
EP3578200A1 (de) 2013-02-22 2019-12-11 CureVac AG Kombination von impfung und hemmung des pd-1-pfades
RU2015140573A (ru) 2013-02-25 2017-03-30 Дженентек, Инк. Способы и композиции для обнаружения и лечения устойчивого к лекарственным средствам мутанта акт
MX2015010789A (es) 2013-02-26 2015-11-26 Roche Glycart Ag Anticuerpos anti-pcsm.
EP3339327A3 (de) 2013-02-28 2018-09-19 National Cancer Center Antikörper gegen unlösliches fibrin
EP2961853B1 (de) 2013-02-28 2018-09-19 The Board of Regents of The University of Texas System Verfahren zur klassifizierung einer krebserkrankung als anfälligkeit für tmepai-gerichtete therapien und zur heilung solcher krebserkrankungen
US9487587B2 (en) 2013-03-05 2016-11-08 Macrogenics, Inc. Bispecific molecules that are immunoreactive with immune effector cells of a companion animal that express an activating receptor and cells that express B7-H3 and uses thereof
JP2016510751A (ja) 2013-03-06 2016-04-11 ジェネンテック， インコーポレイテッド 抗がん剤耐性を治療及び予防する方法
WO2014138555A1 (en) 2013-03-07 2014-09-12 Bernhard Sturm Multimodal segmentation in intravascular images
US10226597B2 (en) 2013-03-07 2019-03-12 Volcano Corporation Guidewire with centering mechanism
CA2903716C (en) 2013-03-08 2019-04-09 Pfizer Inc. Immunogenic fusion polypeptides
WO2014164472A1 (en) 2013-03-10 2014-10-09 The Board Of Regents Of The University Of Texas System Biomarkers for chagas disease related cardiomyopathy
EP2975054A4 (de) 2013-03-12 2016-11-23 Zenyaku Kogyo Kk Antikörper gegen staphylokokken, verfahren zur herstellung davon und verwendung davon
US20140276923A1 (en) 2013-03-12 2014-09-18 Volcano Corporation Vibrating catheter and methods of use
US11084860B2 (en) 2013-03-12 2021-08-10 The General Hospital Corporation Modified Mullerian inhibiting substance (MIS) proteins and uses thereof for the treatment of diseases
EP2778176A1 (de) 2013-03-12 2014-09-17 Sanofi Zusammensetzungen und Verfahren zur Analyse der Histidinphosphorylierung
US10638939B2 (en) 2013-03-12 2020-05-05 Philips Image Guided Therapy Corporation Systems and methods for diagnosing coronary microvascular disease
PH12022550138A1 (en) 2013-03-13 2023-03-06 Amgen Inc Proteins specific for baff and b7rp1 and uses thereof
SG11201507043SA (en) 2013-03-13 2015-10-29 Genentech Inc Formulations with reduced oxidation
JP6339170B2 (ja) 2013-03-13 2018-06-06 ジンヒョン パーク 回転式血管内超音波装置から画像を生成するためのシステム及び方法
ES2687439T3 (es) 2013-03-13 2018-10-25 Medimmune Limited Pirrolobenzodiazepinas y conjugados de las mismas
KR102066318B1 (ko) 2013-03-13 2020-01-14 메디뮨 리미티드 피롤로벤조디아제핀 및 그의 컨쥬게이트
HK1212613A1 (zh) 2013-03-13 2016-06-17 豪夫迈‧罗氏有限公司 具有降低的氧化的配制物
US10653779B2 (en) 2013-03-13 2020-05-19 Genentech, Inc. Formulations with reduced oxidation
US9458246B2 (en) 2013-03-13 2016-10-04 Amgen Inc. Proteins specific for BAFF and B7RP1
US11026591B2 (en) 2013-03-13 2021-06-08 Philips Image Guided Therapy Corporation Intravascular pressure sensor calibration
US9301687B2 (en) 2013-03-13 2016-04-05 Volcano Corporation System and method for OCT depth calibration
MX363787B (es) 2013-03-13 2019-04-03 Medimmune Ltd Pirrolobenzodiazepinas y conjugados de los mismos.
KR20150131208A (ko) 2013-03-13 2015-11-24 이미지냅 인코포레이티드 Cd８에의 항원 결합 구조체들
US9023353B2 (en) 2013-03-13 2015-05-05 The Board Of Trustees Of The University Of Arkansas Anti-(+)—methamphetamine monoclonal antibodies
US10550201B2 (en) 2013-03-13 2020-02-04 Bioventures, Llc Antibody-nanoparticle conjugates for the treatment of drug abuse
SG10201913777XA (en) 2013-03-13 2020-03-30 Sanofi Sa Compositions comprising anti-cd38 antibodies and carfilzomib
US10023608B1 (en) 2013-03-13 2018-07-17 Amgen Inc. Protein purification methods to remove impurities
US20140314778A1 (en) 2013-03-13 2014-10-23 Genentech, Inc. Formulations with reduced oxidation
MX365567B (es) 2013-03-13 2019-06-07 Genentech Inc Formulaciones de anticuerpo.
MX362075B (es) 2013-03-14 2019-01-07 Abbott Lab Ensayo de combinación de antígeno-anticuerpo del virus de la hepatitis c (vhc) y métodos y composiciones para usarlo.
BR112015017307A2 (pt) 2013-03-14 2017-11-21 Abbvie Inc composições de espécies com baixa acidez e métodos para produção e uso das mesmas
EP2968550B1 (de) 2013-03-14 2018-11-14 Ffe Therapeutics LLC Zusammensetzungen und verfahren zur behandlung von angiogenesebedingten erkrankungen
WO2014153056A2 (en) 2013-03-14 2014-09-25 Parkash Gill Cancer treatment using antibodies that bing cell surface grp78
US9302005B2 (en) 2013-03-14 2016-04-05 Mayo Foundation For Medical Education And Research Methods and materials for treating cancer
US10219887B2 (en) 2013-03-14 2019-03-05 Volcano Corporation Filters with echogenic characteristics
CN105378099B (zh) 2013-03-14 2021-05-11 雅培制药有限公司 Hcv核心脂质结合结构域单克隆抗体
WO2014143342A1 (en) 2013-03-14 2014-09-18 Abbott Laboratories Hcv ns3 recombinant antigens and mutants thereof for improved antibody detection
CA2904170A1 (en) 2013-03-14 2014-09-25 University Of Maryland, Baltimore Androgen receptor down-regulating agents and uses thereof
US9562099B2 (en) 2013-03-14 2017-02-07 Genentech, Inc. Anti-B7-H4 antibodies and immunoconjugates
MX2015011945A (es) 2013-03-14 2015-12-01 Shire Human Genetic Therapies Evaluacion cuantitativa para la eficacia de los casquetes de arn mensajero.
EP2968565A2 (de) 2013-03-14 2016-01-20 Genentech, Inc. Verfahren zur behandlung von krebs und prävention einer antikrebsmittelresistenz
WO2014159764A1 (en) 2013-03-14 2014-10-02 Amgen Inc. Chrdl-1 antigen binding proteins and methods of treatment
MX2015010777A (es) 2013-03-14 2016-04-25 Genentech Inc Anticuerpos e inmunoconjugados anti-b7-h4.
WO2014152358A2 (en) 2013-03-14 2014-09-25 Genentech, Inc. Combinations of a mek inhibitor compound with an her3/egfr inhibitor compound and methods of use
US10292677B2 (en) 2013-03-14 2019-05-21 Volcano Corporation Endoluminal filter having enhanced echogenic properties
WO2014159554A1 (en) 2013-03-14 2014-10-02 Abbvie Inc. Low acidic species compositions and methods for producing the same using displacement chromatography
US20160030151A1 (en) 2013-03-14 2016-02-04 Volcano Corporation Filters with echogenic characteristics
US12343198B2 (en) 2013-03-14 2025-07-01 Philips Image Guided Therapy Corporation Delivery catheter having imaging capabilities
WO2014159239A2 (en) 2013-03-14 2014-10-02 Novartis Ag Antibodies against notch 3
WO2014142882A1 (en) 2013-03-14 2014-09-18 Abbvie Inc. Protein purification using displacement chromatography
WO2014159961A1 (en) 2013-03-14 2014-10-02 Beth Israel Deaconess Medical Center, Inc. Measurement of fgf21 as a biomarker of fructose metabolism and metabolic disease
CA2906566C (en) 2013-03-14 2024-09-10 Macrogenics, Inc. Immunoreactive bispecific molecules at immune effector cells expressing an activation receptor
EP4292657A3 (de) 2013-03-15 2024-03-20 Dana Farber Cancer Institute, Inc. Flavi-virus-neutralisierende antikörper und verfahren zur verwendung davon
ES2835716T3 (es) 2013-03-15 2021-06-23 Beth Israel Deaconess Medical Ct Inc Procedimientos y composiciones para la generación y el uso de anticuerpos específicos de conformación
SG10201809452RA (en) 2013-03-15 2018-11-29 Genentech Inc Cell culture compositions with antioxidants and methods for polypeptide production
CN111366434A (zh) 2013-03-15 2020-07-03 赛拉诺斯知识产权有限责任公司 用于使样品中的细胞破裂的自动化测定装置
EP2970489A2 (de) 2013-03-15 2016-01-20 AbbVie Biotechnology Ltd Anti-cd25-antikörper und deren verwendungen
ES2769574T3 (es) 2013-03-15 2020-06-26 Michael C Milone Reconocimiento de células citotóxicas con receptores quiméricos para inmunoterapia adoptiva
US10077439B2 (en) 2013-03-15 2018-09-18 Modernatx, Inc. Removal of DNA fragments in mRNA production process
PL2970422T3 (pl) 2013-03-15 2018-09-28 F.Hoffmann-La Roche Ag Polipeptydy IL-22 i białka fuzyjne IL-22 Fc i sposoby zastosowania
CA2904357C (en) 2013-03-15 2020-09-22 Intrinsic Lifesciences Llc Anti-hepcidin antibodies and uses thereof
BR112015022963A8 (pt) 2013-03-15 2018-01-16 Los Angeles Biomedical Res Inst Harbor Ucla Medical Ct composições e métodos para tratar patógenos fúngicos e bacterianos.
AR095374A1 (es) 2013-03-15 2015-10-14 Amgen Res Munich Gmbh Moléculas de unión para bcma y cd3
HK1220626A1 (zh) 2013-03-15 2017-05-12 The Centre For Drug Research And Development 具细胞毒性和抗有丝分裂的化合物以及其使用方法
ES2699599T3 (es) 2013-03-15 2019-02-11 Abbvie Biotherapeutics Inc Variantes de Fc
AU2014227732A1 (en) 2013-03-15 2015-09-17 Abbvie Inc. Dual specific binding proteins directed against IL-1 beta and IL-17
HK1214533A1 (zh) 2013-03-15 2016-07-29 基因泰克公司 治疗癌症和预防癌症耐药性的方法
MX374811B (es) 2013-03-15 2025-03-06 Ac Immune Sa Anticuerpos anti-tau y métodos de uso.
WO2014152391A1 (en) 2013-03-15 2014-09-25 Apellis Pharmaceuticals, Inc. Cell-penetrating compstatin analogs and uses thereof
US9446105B2 (en) 2013-03-15 2016-09-20 The Trustees Of The University Of Pennsylvania Chimeric antigen receptor specific for folate receptor β
MX2015011444A (es) 2013-03-15 2015-12-16 Genentech Inc Composiciones y metodos para el diagnostico y tratamiento del cancer hepatico.
CA2903589A1 (en) 2013-03-15 2014-09-18 Genentech, Inc. Cell culture media and methods of antibody production
KR20150131269A (ko) 2013-03-15 2015-11-24 제넨테크, 인크. Pd-1 및 pd-l1 관련 상태를 치료하기 위한 바이오마커 및 방법
WO2014145718A2 (en) 2013-03-15 2014-09-18 Longevity Biotech, Inc. Peptides comprising non-natural amino acids and methods of making and using the same
UY35460A (es) 2013-03-15 2014-10-31 Bayer Healthcare Llc Formulaciones de anticuerpos anti-receptor de prolactina
US9505849B2 (en) 2013-03-15 2016-11-29 Amgen Research (Munich) Gmbh Antibody constructs for influenza M2 and CD3
US8980864B2 (en) 2013-03-15 2015-03-17 Moderna Therapeutics, Inc. Compositions and methods of altering cholesterol levels
US10611824B2 (en) 2013-03-15 2020-04-07 Innate Pharma Solid phase TGase-mediated conjugation of antibodies
KR102215405B1 (ko) 2013-03-15 2021-02-10 암젠 인크 인간 pac1 항체
US20140283157A1 (en) 2013-03-15 2014-09-18 Diadexus, Inc. Lipoprotein-associated phospholipase a2 antibody compositions and methods of use
US9856313B2 (en) 2013-03-15 2018-01-02 Xiamen University Epitope of RSV fusion protein and antibody recognizing the same
WO2014144292A2 (en) 2013-03-15 2014-09-18 Sanofi Pasteur Biologics , Llc Antibodies against clostridium difficile toxins and methods of using the same
AR095199A1 (es) 2013-03-15 2015-09-30 Genzyme Corp Anticuerpos anti-cd52
WO2014144791A2 (en) 2013-03-15 2014-09-18 Dana-Farber Cancer Institute, Inc. Therapeutic peptides
US9469686B2 (en) 2013-03-15 2016-10-18 Abbott Laboratories Anti-GP73 monoclonal antibodies and methods of obtaining the same
UY35484A (es) 2013-03-15 2014-10-31 Amgen Res Munich Gmbh Molécula de unión de cadena simple que comprenden ABP de extremo N
US9850297B2 (en) 2013-03-15 2017-12-26 Amgen Inc. Secreted frizzle-related protein 5 (SFRP5) binding proteins
BR112015021521A2 (pt) 2013-03-15 2017-10-10 Genentech Inc anticorpos anti-crth2 e métodos para seu uso
AU2014233478A1 (en) 2013-03-15 2015-09-24 Abbvie Biotechnology Ltd. Anti-CD25 antibodies and their uses
MX2015013163A (es) 2013-03-15 2016-04-04 Zyngenia Inc Complejos multiespecificos multivalente y monovalentes y sus usos.
AU2014228772B2 (en) 2013-03-15 2019-02-28 Memorial Sloan Kettering Cancer Center High affinity anti-GD2 antibodies
UY35468A (es) 2013-03-16 2014-10-31 Novartis Ag Tratamiento de cáncer utilizando un receptor quimérico de antígeno anti-cd19
US10233249B2 (en) 2013-03-19 2019-03-19 Beijing Shenogen Pharma Group Ltd. Antibodies and methods for treating estrogen receptor-associated diseases
IL225380A (en) 2013-03-21 2014-04-30 Savyon Diagnostics Ltd Bacterial training test and kit
US9447193B2 (en) 2013-03-24 2016-09-20 Development Center For Biotechnology Methods for suppressing cancer by inhibition of TMCC3
JP6615745B2 (ja) 2013-03-27 2019-12-04 ジェネンテック， インコーポレイテッド ベータ７インテグリンアンタゴニストによる胃腸炎症障害の治療を評価するためのバイオマーカーの使用
WO2014165524A2 (en) 2013-04-01 2014-10-09 The Regents Of The University Of California Methods and compositions for treating and preventing disease associated with avb8 integrin
WO2014161483A1 (zh) 2013-04-02 2014-10-09 厦门大学 识别流感病毒血凝素蛋白ha1结构域的广谱单克隆抗体
SG11201508170TA (en) 2013-04-02 2015-11-27 Chugai Pharmaceutical Co Ltd Fc REGION VARIANT
WO2014165422A1 (en) 2013-04-02 2014-10-09 Merck Sharp & Dohme Corp. Immunohistochemical assay for detecting expression of programmed death ligand 1 (pd-l1) in tumor tissue
WO2014165818A2 (en) 2013-04-05 2014-10-09 T Cell Therapeutics, Inc. Compositions and methods for preventing and treating prostate cancer
EP2789630A1 (de) 2013-04-09 2014-10-15 EngMab AG Bispezifische Antikörper gegen CD3e und ROR1
US20160053023A1 (en) 2013-04-09 2016-02-25 Annexon, Inc. Methods of treatment for neuromyelitis optica
GB201306536D0 (en) 2013-04-10 2013-05-22 Gt Biolog Ltd Polypeptide and immune modulation
WO2014172434A1 (en) 2013-04-16 2014-10-23 The Johns Hopkins University Diagnostic and prognostic test for sturge-weber syndrome, klippel-trenaunay-weber syndrome, and port-wine stains (pwss)
JP2016518126A (ja) 2013-04-19 2016-06-23 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア ローンスターウイルス
WO2014174596A1 (ja) 2013-04-23 2014-10-30 株式会社医学生物学研究所 ヘパリン結合上皮増殖因子様増殖因子に対する機能性モノクローナル抗体
TW201920285A (zh) 2013-04-29 2019-06-01 瑞士商赫孚孟拉羅股份公司 遏止FcRn結合之抗IGF-1R抗體及其治療血管性眼疾之用途
CA2904805A1 (en) 2013-04-29 2014-11-06 F. Hoffmann-La Roche Ag Fc-receptor binding modified asymmetric antibodies and methods of use
CA2904806C (en) 2013-04-29 2021-11-23 F. Hoffmann-La Roche Ag Human fcrn-binding modified antibodies and methods of use
WO2014176696A1 (en) 2013-04-30 2014-11-06 Université de Montréal Novel biomarkers for acute myeloid leukemia
HRP20201914T1 (hr) 2013-05-06 2021-01-22 Scholar Rock, Inc. Sastavi i postupci za modulaciju faktora rasta
CN105189560A (zh) 2013-05-07 2015-12-23 瑞纳神经科学公司 抗胰高血糖素受体抗体和其使用方法
GB201308259D0 (en) 2013-05-08 2013-06-12 Iles Raymond K Cancer diagnosis and monitoring
WO2014182972A2 (en) 2013-05-10 2014-11-13 The Regents Of The University Of California Diagnostic and monitoring system for huntington's disease
US10260038B2 (en) 2013-05-10 2019-04-16 Whitehead Institute For Biomedical Research Protein modification of living cells using sortase
CA2912526C (en) 2013-05-16 2021-09-14 Kyoto University Method for determining prognosis of cancer
WO2014184384A1 (en) 2013-05-17 2014-11-20 Centre National De La Recherche Scientifique (Cnrs) Anti-cxcl1, cxcl7 and cxcl8 antibodies and their applications
WO2014183885A1 (en) 2013-05-17 2014-11-20 INSERM (Institut National de la Santé et de la Recherche Médicale) Antagonist of the btla/hvem interaction for use in therapy
SG11201509566RA (en) 2013-05-20 2015-12-30 Genentech Inc Anti-transferrin receptor antibodies and methods of use
EP2999717B1 (de) 2013-05-21 2018-08-08 Yissum Research Development Company of the Hebrew University of Jerusalem Ltd. Behandlung von mastzellen-vermittelten erkrankungen
JP6560195B2 (ja) 2013-05-21 2019-08-14 アルサニス・バイオサイエンスズ・ゲゼルシャフト・ミト・ベシュレンクテル・ハフツング 黄色ブドウ球菌のＬｕｋＧＨ（ＬｕｋＡＢ）毒素を中和する、非常に強力な抗体の生成
EA201591993A1 (ru) 2013-05-23 2016-05-31 Шир Хьюман Дженетик Терапис, Инк. Лечение склеродермии с применением комбинированной терапии антителами анти-ccl2 и анти-loxl2
AU2014268298B2 (en) 2013-05-24 2019-01-17 Medlmmune, Llc Anti-B7-H5 antibodies and their uses
CA2913108A1 (en) 2013-05-24 2014-11-27 Nestec S.A. Pathway specific assays for predicting irritable bowel syndrome diagnosis
EP3004174B1 (de) 2013-05-31 2019-04-17 Zymeworks Inc. Heteromultimere mit reduzierter oder gedämpfter effektorfunktion
US10526375B2 (en) 2013-06-05 2020-01-07 Massachusetts Institute Of Technology Human Adaptation of H7 HA
EP3003390B1 (de) 2013-06-06 2021-07-07 Pierre Fabre Médicament Anti-c10orf54-antikörper und verwendungen davon
WO2014197866A1 (en) 2013-06-06 2014-12-11 Igenica Biotherapeutics, Inc. Modified antibodies and related compounds, compositions, and methods of use
AU2014275166B2 (en) 2013-06-06 2020-09-10 Dana-Farber Cancer Institute, Inc. Compositions and methods for identification, assessment prevention, and treatment of cancer using PD-L1 isoforms
EP3003372B1 (de) 2013-06-07 2019-10-09 Duke University Inhibitoren des komplementfaktors h
SMT202000401T1 (it) 2013-06-10 2020-11-10 Ipierian Inc Metodi di trattamento di una taupatia
EP3009518B1 (de) 2013-06-11 2020-08-12 National Center of Neurology and Psychiatry Verfahren zur vorhersage einer posttherapeutischen prognose von patienten mit schubförmig remittierender multipler sklerose (rrms) und verfahren zur bestimmung der anwendbarkeit der neuartigen therapie
US9783576B2 (en) 2013-06-11 2017-10-10 Sanford-Burnham Medical Research Institute Compositions and methods for targeted endometriosis treatment
US9587032B2 (en) 2013-06-12 2017-03-07 The Board Of Trustees Of The Leland Stanford Junior University IgE antibodies for the inhibition of tumor metastasis
CN105658810B (zh) 2013-06-13 2020-08-21 南澳大学 用于检测前列腺癌的方法
US9428748B2 (en) 2013-06-17 2016-08-30 Hong Gao Method of expanding hematopoietic stem cells
CA2952390A1 (en) 2013-06-20 2014-12-24 The Trustees Of The University Of Pennsylvania Methods for diagnosing pancreatic cancer
US9890369B2 (en) 2013-06-20 2018-02-13 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Cytolethal distending toxin subunit B conjugated or fused to Bacillus anthracis toxin lethal factor
WO2014202773A1 (en) 2013-06-20 2014-12-24 Innate Pharma Enzymatic conjugation of polypeptides
KR20160042871A (ko) 2013-06-21 2016-04-20 이나뜨 파르마, 에스.아. 폴리펩티드의 효소적 콘쥬게이션
AR096601A1 (es) 2013-06-21 2016-01-20 Novartis Ag Anticuerpos del receptor 1 de ldl oxidado similar a lectina y métodos de uso
WO2014210397A1 (en) 2013-06-26 2014-12-31 Academia Sinica Rm2 antigens and use thereof
EP3013347B1 (de) 2013-06-27 2019-12-11 Academia Sinica Glykankonjugate und verwendung davon
US10221239B2 (en) 2013-06-28 2019-03-05 Singapore Health Services Pte Ltd TRPM4 channel inhibitors for stroke treatment
EP2818484A1 (de) 2013-06-28 2014-12-31 Universitat Autònoma de Barcelona Synergistische Kombination eines Anti-IgE-Antikörpers und eines EP2-Rezeptoragonisten
RU2016103373A (ru) 2013-07-04 2017-08-10 Новартис Аг Клетки нитчатых грибов с дефицитом о-маннозилтрансферазы и способы их применения
WO2015001082A1 (en) 2013-07-05 2015-01-08 INSERM (Institut National de la Santé et de la Recherche Médicale) Novel alternative splice transcripts for mhc class i related chain alpha (mica) and uses thereof
SG11201510316UA (en) 2013-07-09 2016-01-28 Annexon Inc Anti-complement factor c1q antibodies and uses thereof
US20160153019A1 (en) 2013-07-10 2016-06-02 Novartis Ag Production of Glycoproteins Having Increased N-Glycosylation Site Occupancy
WO2015006554A1 (en) 2013-07-10 2015-01-15 The Regents Of The University Of Michigan Therapeutic antibodies and uses thereof
WO2015006555A2 (en) 2013-07-10 2015-01-15 Sutro Biopharma, Inc. Antibodies comprising multiple site-specific non-natural amino acid residues, methods of their preparation and methods of their use
KR102251127B1 (ko) 2013-07-12 2021-05-11 제넨테크, 인크. 이온 교환 크로마토그래피 입력 최적화의 설명
CA2912765C (en) 2013-07-12 2018-05-01 Emd Millipore Corporation A method of determining virus removal from a sample containing a target protein using activated carbon
US10208125B2 (en) 2013-07-15 2019-02-19 University of Pittsburgh—of the Commonwealth System of Higher Education Anti-mucin 1 binding agents and uses thereof
TWI888366B (zh) 2013-07-16 2025-07-01 美商建南德克公司 利用pd-1軸結合拮抗劑及tigit抑制劑治療癌症之方法
WO2015017146A2 (en) 2013-07-18 2015-02-05 Fabrus, Inc. Antibodies with ultralong complementarity determining regions
JP6687520B2 (ja) 2013-07-18 2020-04-22 トーラス バイオサイエンシズ リミテッド ライアビリティ カンパニー 極めて長い相補性決定領域を有するヒト化抗体
US10005838B2 (en) 2013-07-19 2018-06-26 The Regents Of The University Of California Milk fat globule epidermal growth factor 8 regulates fatty acid uptake
JP6480926B2 (ja) 2013-07-23 2019-03-13 バイオコン・リミテッド タンパク質におけるフコシル化レベルを制御するための方法
US11253606B2 (en) 2013-07-23 2022-02-22 Immunomedics, Inc. Combining anti-HLA-DR or anti-Trop-2 antibodies with microtubule inhibitors, PARP inhibitors, Bruton kinase inhibitors or phosphoinositide 3-kinase inhibitors significantly improves therapeutic outcome in cancer
WO2015015489A1 (en) 2013-07-30 2015-02-05 Biolinerx Ltd. Antibody for treating diabetes and autoimmune diseases
US10195289B2 (en) 2013-07-31 2019-02-05 Rinat Neuroscience Corp. Engineered polypeptide conjugates using transglutaminase
JP2015030666A (ja) 2013-07-31 2015-02-16 学校法人順天堂 抗ヒトｃｄ２６モノクローナル抗体又はその抗原結合性断片
CA2919477A1 (en) 2013-07-31 2015-02-05 Dana-Farber Cancer Institute, Inc. Compositions and methods for modulating thermogenesis using pth-related and egf-related molecules
AU2014298373B2 (en) 2013-08-01 2019-12-05 Ludwig Institute For Cancer Research Ltd Anti-GARP protein and uses thereof
AR097161A1 (es) 2013-08-01 2016-02-24 Agensys Inc Conjugados de fármacos anticuerpo (adc) que se unen a las proteínas cd37
MX374785B (es) 2013-08-01 2025-03-06 Five Prime Therapeutics Inc Anticuerpos anti-fgfr2iiib afucosilados.
CN105682683A (zh) 2013-08-02 2016-06-15 阿杜罗生物科技控股有限公司 结合cd27激动剂以及免疫检查点抑制以用于免疫刺激
US10227370B2 (en) 2013-08-02 2019-03-12 California Institute Of Technology Heparan sulfate/heparin mimetics with anti-chemokine and anti-inflammatory activity
US9770461B2 (en) 2013-08-02 2017-09-26 California Institute Of Technology Tailored glycopolymers as anticoagulant heparin mimetics
MX371455B (es) 2013-08-02 2020-01-28 Pfizer Anticuerpos anti-cxcr4 y conjugados de anticuerpo y farmaco.
TWI714869B (zh) 2013-08-05 2021-01-01 德商伊瑪提克斯生物科技有限公司 新穎肽類，細胞及其用於治療多種腫瘤的用途，其製造方法及包含其等之醫藥組成物
EP3030249B1 (de) 2013-08-07 2019-12-25 Rigshospitalet, Copenhagen University Hospital Antikörper, verbindungen und derivate davon zur verwendung in der behandlung männlicher unfruchtbarkeit
US20160178610A1 (en) 2013-08-07 2016-06-23 Friedrich Miescher Institute For Biomedical Research New screening method for the treatment Friedreich's ataxia
EP3030268B1 (de) 2013-08-09 2022-07-27 The Trustees Of The University Of Pennsylvania Kombination von ifn-gamma mit anti-erbb-antikörpern zur krebsbehandlung
MX2016001854A (es) 2013-08-12 2016-09-06 Genentech Inc Composiciones y metodo para tratar condiciones asociadas con el complemento.
BR112016002829A2 (pt) 2013-08-12 2017-09-19 Genentech Inc Composto e processo para preparar o composto de conjugado anticorpo-¿droga, composição farmacêutica, método de tratamento do câncer, kit para o tratamento do câncer, intermediário ligante¿-droga, porção e composto de porção droga de dímero cbi
KR20160058774A (ko) 2013-08-12 2016-05-25 토카이 파마슈티컬, 아이엔씨. 안드로겐-표적 치료제를 이용하는 종양 질환 치료를 위한 바이오마커
BR112016002753A2 (pt) 2013-08-13 2017-11-21 Sanofi Sa anticorpos contra o inibidor-1 de ativador de plasminogênio (pai-1) e usos dos mesmos
TW201722994A (zh) 2013-08-13 2017-07-01 賽諾菲公司 胞漿素原活化素抑制劑-１（ｐａｉ-１）之抗體及其用途
AU2014306564B2 (en) 2013-08-14 2019-10-17 Antlera Therapeutics Inc. Antibodies against frizzled proteins and methods of use thereof
WO2015022658A2 (en) 2013-08-14 2015-02-19 Novartis Ag Methods of treating sporadic inclusion body myositis
AU2014309199B2 (en) 2013-08-20 2018-04-19 Merck Sharp & Dohme Llc Treating cancer with a combination of a PD-1 antagonist and dinaciclib
AR097306A1 (es) 2013-08-20 2016-03-02 Merck Sharp & Dohme Modulación de la inmunidad tumoral
WO2015027120A1 (en) 2013-08-21 2015-02-26 Jiang Jean X Compositions and methods for targeting connexin hemichannels
JP2016531915A (ja) 2013-08-28 2016-10-13 ステムセントリックス， インコーポレイテッド 部位特異的抗体コンジュゲーション方法および組成物
CA2922529A1 (en) 2013-08-28 2015-03-05 Stemcentrx, Inc. Novel sez6 modulators and methods of use
KR102522346B1 (ko) 2013-08-29 2023-04-17 시티 오브 호프 세포침투 콘주게이트 및 이의 사용 방법
US10617755B2 (en) 2013-08-30 2020-04-14 Genentech, Inc. Combination therapy for the treatment of glioblastoma
NZ717140A (en) 2013-08-30 2022-05-27 Immunogen Inc Antibodies and assays for detection of folate receptor 1
RU2714919C2 (ru) 2013-08-30 2020-02-21 Такеда Гмбх Антитела, нейтрализующие gm-csf, для применения в лечении ревматоидного артрита или в качестве анальгетиков
US10456470B2 (en) 2013-08-30 2019-10-29 Genentech, Inc. Diagnostic methods and compositions for treatment of glioblastoma
TW201605896A (zh) 2013-08-30 2016-02-16 安美基股份有限公司 Gitr抗原結合蛋白
US20160251410A1 (en) 2013-09-03 2016-09-01 Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd. Compositions and methods for expressing recombinant polypeptides
WO2015035044A2 (en) 2013-09-04 2015-03-12 Abbvie Biotherapeutics Inc. Fc VARIANTS WITH IMPROVED ANTIBODY-DEPENDENT CELL-MEDIATED CYTOTOXICITY
JP2016531920A (ja) 2013-09-05 2016-10-13 アデュロ・バイオテック・ホールディングス・ヨーロッパ・ベスローテン・フエンノートシャップＡｄｕｒｏ Ｂｉｏｔｅｃｈ Ｈｏｌｄｉｎｇｓ， Ｅｕｒｏｐｅ Ｂ．Ｖ． Ｃｄ７０結合ペプチドおよびそれに関連する方法、プロセスおよび用途
EP3041593B1 (de) 2013-09-05 2025-01-29 F. Hoffmann-La Roche AG Reinigungsverfahren eines chromatographiematerials für seine wiederverwendung
CN105722855B (zh) 2013-09-05 2021-04-23 Igm生物科学股份有限公司 恒定链经修饰的双特异性五价和六价Ig-M抗体
CN105917235A (zh) 2013-09-06 2016-08-31 赛拉诺斯股份有限公司 用于检测感染性疾病的系统和方法
NL2011406C2 (en) 2013-09-06 2015-03-10 Bionovion Holding B V Method for obtaining april-binding peptides, process for producing the peptides, april-binding peptides obtainable with said method/process and use of the april-binding peptides.
EP3041484B1 (de) 2013-09-06 2021-03-03 Academia Sinica Humane inkt-zell-aktivierung mittels glykolipiden mit veränderten glycosylgruppen
RU2662968C2 (ru) 2013-09-08 2018-07-31 Пфайзер Инк. Иммуногенная композиция против neisseria meningitidis (варианты)
IL312865B2 (en) 2013-09-11 2025-06-01 Eagle Biologics Inc Liquid protein formulations containing viscosity-lowering agents
WO2015038984A2 (en) 2013-09-12 2015-03-19 Halozyme, Inc. Modified anti-epidermal growth factor receptor antibodies and methods of use thereof
PL3044323T3 (pl) 2013-09-13 2022-06-27 F.Hoffmann-La Roche Ag Sposoby wykrywania i ilościowego oznaczania białka komórki gospodarza w liniach komórkowych
SG11201601823TA (en) 2013-09-13 2016-04-28 Genentech Inc Methods and compositions comprising purified recombinant polypeptides
AR097648A1 (es) 2013-09-13 2016-04-06 Amgen Inc Combinación de factores epigenéticos y compuestos biespecíficos que tienen como diana cd33 y cd3 en el tratamiento de leucemia mieloide
WO2015037009A1 (en) 2013-09-16 2015-03-19 Plexicure Ltd. Isolated proteins capable of binding plexin-a4 and methods of producing and using same
US20160271230A1 (en) 2013-09-17 2016-09-22 University Health Network (Uhn): Technology Development And Commercialization Agents directed against a cis rgma/neogenin interaction or lipid rafts and use of the same in methods of treatment
EP3046588B1 (de) 2013-09-17 2022-03-02 OBI Pharma, Inc. Zusammensetzungen aus einem kohlenhydratimpfstoff zur induktion von immunreaktionen und verwendungen davon bei der krebsbehandlung
BR112016004450A2 (pt) 2013-09-17 2017-10-17 Genentech Inc métodos para tratar uma doença, para aumentar a eficácia de um tratamento, para adiar e/ou prevenir desenvolvimento da reincidência e/ou resistência de uma doença, para aumentar a sensibilidade a um inibidor, para estender o período de sensibilidade a um inibidor e para estender a duração de resposta a um inibidor
AU2014323526B2 (en) 2013-09-19 2020-07-23 Dana-Farber Cancer Institute, Inc. Methods of BH3 profiling
CA2925087C (en) 2013-09-24 2024-02-13 The Feinstein Institute For Medical Research Peptides inhibiting cold-inducible rna binding protein activity
WO2015048531A1 (en) 2013-09-26 2015-04-02 Beth Israel Deaconess Medical Center, Inc. Inhibition of sgk1 in the treatment of heart conditions
EP3049442A4 (de) 2013-09-26 2017-06-28 Costim Pharmaceuticals Inc. Verfahren zur behandlung von blutkrebs
CA2925256C (en) 2013-09-27 2023-08-15 Chugai Seiyaku Kabushiki Kaisha Method for producing polypeptide heteromultimer
GB201317207D0 (en) 2013-09-27 2013-11-13 Univ Glasgow Materials and methods for modulating disc1 turnover
DK3049441T3 (da) 2013-09-27 2020-02-03 Hoffmann La Roche Anti-PDL1-antistofformuleringer
WO2015044083A1 (en) 2013-09-27 2015-04-02 F. Hoffmann-La Roche Ag Thermus thermophilus slyd fkbp domain specific antibodies
US9243294B2 (en) 2013-09-30 2016-01-26 Hadasit Medical Research Services And Development Ltd. Modulation of NLGn4 expression, NK cell activity in non-alcoholic fatty liver disease (NAFLD)
US10023626B2 (en) 2013-09-30 2018-07-17 Modernatx, Inc. Polynucleotides encoding immune modulating polypeptides
AU2014324426A1 (en) 2013-09-30 2016-04-21 The Regents Of The University Of California Anti-alphavbeta1 integrin compounds and methods
WO2015050959A1 (en) 2013-10-01 2015-04-09 Yale University Anti-kit antibodies and methods of use thereof
EP3470081A1 (de) 2013-10-01 2019-04-17 Mayo Foundation for Medical Education and Research Verfahren zur behandlung von krebs bei patienten mit erhöhten bim-werten
SG11201602522VA (en) 2013-10-02 2016-04-28 Medimmune Llc Neutralizing anti-influenza a antibodies and uses thereof
KR20160067219A (ko) 2013-10-03 2016-06-13 모더나 세라퓨틱스, 인코포레이티드 저밀도 지단백질 수용체를 암호화하는 폴리뉴클레오타이드
CA2926215A1 (en) 2013-10-06 2015-04-09 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Modified pseudomonas exotoxin a
JP6463744B2 (ja) 2013-10-08 2019-02-06 イミュノジェン， インコーポレイテッド 抗ｆｏｌｒ１免疫抱合体投薬レジメン
AU2014331938A1 (en) 2013-10-09 2016-04-28 University Of Miami Perforin-2 activators and inhibitors as drug targets for infectious disease and gut inflammation
JP2016539350A (ja) 2013-10-09 2016-12-15 ユニバーシティー オブ ロチェスター マルチプレックスな肺炎連鎖球菌血清学のためのチップ、検出システム、及び方法
WO2015054427A1 (en) 2013-10-10 2015-04-16 Beth Israel Deaconess Medical Center, Inc. Tm4sf1 binding proteins and methods of using same
BR112016006929A2 (pt) 2013-10-11 2017-09-19 Hoffmann La Roche Anticorpo, ácido nucleico, vetor de expressão, célula hospedeira, métodos de preparação de anticorpo, de tratamento de pacientes e de geração de um anticorpo, composição farmacêutica e uso do anticorpo
WO2015054670A1 (en) 2013-10-11 2015-04-16 Genentech, Inc. Nsp4 inhibitors and methods of use
WO2015052535A1 (en) 2013-10-11 2015-04-16 Spirogen Sàrl Pyrrolobenzodiazepine-antibody conjugates
US10010624B2 (en) 2013-10-11 2018-07-03 Medimmune Limited Pyrrolobenzodiazepine-antibody conjugates
WO2015052534A1 (en) 2013-10-11 2015-04-16 Spirogen Sàrl Pyrrolobenzodiazepine-antibody conjugates
GB201317981D0 (en) 2013-10-11 2013-11-27 Spirogen Sarl Pyrrolobenzodiazepines and conjugates thereof
GB201317982D0 (en) 2013-10-11 2013-11-27 Spirogen Sarl Pyrrolobenzodiazepines and conjugates thereof
CR20160156A (es) 2013-10-11 2016-11-01 Oxford Biotherapeutics Ltd Anticuerpos conjugados contra ly75 para el tratamiento del cáncer
EP2860243A1 (de) 2013-10-14 2015-04-15 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. Neuprogrammierung von Endothelzellen für die Knochenangiogenese und -osteogenese
PT3057585T (pt) 2013-10-15 2020-10-21 Seagen Inc Fármaco-ligadores peguilados para farmacocinética melhorada de conjugados de fármaco-ligando
CA2927525C (en) 2013-10-15 2023-01-31 Genefrontier Corporation Human antibody against aggrecanase-type adamts species for therapeutics of aggrecanase-related diseases
WO2015055796A1 (en) 2013-10-16 2015-04-23 Université Libre de Bruxelles Formulations useful in the treatment of proliferative diseases affecting the respiratory tract
RS61351B1 (sr) 2013-10-17 2021-02-26 Omeros Corp Postupci za lečenje stanja udruženih sa aktivacijom komplementa zavisnom od masp-2
WO2015057968A2 (en) 2013-10-17 2015-04-23 The General Hospital Corporation Methods of identifying subjects responsive to treatment for an autoimmune disease and compositions for treating the same
CN105873946A (zh) 2013-10-17 2016-08-17 阿尔萨尼斯生物科学有限责任公司 交叉反应性金黄色葡萄球菌抗体序列
US20150147333A1 (en) 2013-10-18 2015-05-28 Genentech, Inc. Anti-rspo antibodies and methods of use
JP6715767B2 (ja) 2013-10-23 2020-07-01 ジェネンテック， インコーポレイテッド 好酸球性疾患の診断及び治療方法
EP3733868A3 (de) 2013-10-28 2021-01-13 DOTS Technology Corp. Allergennachweis
GB201319374D0 (en) 2013-11-01 2013-12-18 Univ Nottingham Glycans as functional cancer targets abd antibodies thereto
WO2015062738A1 (en) 2013-11-01 2015-05-07 Curevac Gmbh Modified rna with decreased immunostimulatory properties
GB201319446D0 (en) 2013-11-04 2013-12-18 Immatics Biotechnologies Gmbh Personalized immunotherapy against several neuronal and brain tumors
WO2015068781A1 (ja) 2013-11-06 2015-05-14 国立大学法人大阪大学 インフルエンザウイルスａ型のグループ１に対して広域な中和活性を有する抗体
WO2015067986A1 (en) 2013-11-07 2015-05-14 INSERM (Institut National de la Santé et de la Recherche Médicale) Neuregulin allosteric anti-her3 antibody
US20160272673A1 (en) 2013-11-07 2016-09-22 Abbvie Inc. Isolation and purification of dvd-igs
EP2871189A1 (de) 2013-11-07 2015-05-13 Institut Pasteur Hochaffiner, monoklonaler Anti-Strep-Tag-Antikörper
WO2015070014A1 (en) 2013-11-08 2015-05-14 Biogen Idec Ma Inc. Procoagulant fusion compound
US20170002064A1 (en) 2013-11-08 2017-01-05 The Board Of Regents Of The University Of Texas System Vh4 antibodies against gray matter neuron and astrocyte
WO2015070207A2 (en) 2013-11-11 2015-05-14 The Government Of The United States, As Represented By The Secretary Of The Army Ama-1 epitopes, antibodies, compositions, and methods of making and using the same
CA2929044A1 (en) 2013-11-11 2015-05-14 Chugai Seiyaku Kabushiki Kaisha Antigen-binding molecule containing modified antibody variable region
CN105814081B (zh) 2013-11-13 2021-02-02 辉瑞大药厂 肿瘤坏死因子样配体1a特异性抗体及其组合物和用途
EP3068892A4 (de) 2013-11-13 2017-05-31 Zymeworks Inc. Monovalente antigenbindende konstrukte zum targeting von egfr und/oder her2 und verwendungen davon
GB201320061D0 (en) 2013-11-13 2013-12-25 Electrophoretics Ltd Materials nad methods for diagnosis and prognosis of liver cancer
WO2015071701A1 (en) 2013-11-15 2015-05-21 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and pharmaceutical compositions for the treatment of pancreatic cancers
CN115177759B (zh) 2013-11-15 2024-07-23 豪夫迈·罗氏有限公司 使用环保洗涤剂的病毒灭活方法
KR102283408B1 (ko) 2013-11-15 2021-07-29 앵스티띠 파스퇴르 플라스모듐 팔시파룸 아르테미시닌 내성의 분자 마커
EP2873740A1 (de) 2013-11-19 2015-05-20 Oncodiag Verfahren zur Überwachung, Diagnose und Untersuchung von Blasenkrebs
WO2015075445A1 (en) 2013-11-19 2015-05-28 Fredax Ab Humanised anti kallikrein-2 antibody
LT3071597T (lt) 2013-11-21 2020-10-12 F. Hoffmann-La Roche Ag Antikūnai prieš alfa-sunukleiną ir jų naudojimo būdai
ES2980417T3 (es) 2013-11-25 2024-10-01 Famewave Ltd Composiciones que comprenden anticuerpos anti-CEACAM1 y anti-PD para la terapia del cáncer
EP4053560A1 (de) 2013-11-26 2022-09-07 The Brigham and Women's Hospital, Inc. Zusammensetzungen und verfahren zur modulierung einer immunreaktion
BR112016010454A2 (pt) 2013-11-27 2017-12-05 Ipierian Inc métodos para tratar uma taupatia
CN115504924A (zh) 2013-11-27 2022-12-23 雷德伍德生物科技股份有限公司 肼基-吡咯并化合物及用于生成缀合物的方法
LT3074424T (lt) * 2013-11-27 2025-05-26 Zymeworks Bc Inc. Bispecifiniai antigeną surišantys konstruktai, nukreipti į her2
TR201900665T4 (tr) 2013-11-28 2019-02-21 B Creative Sweden Ab Diyabetik nefropatinin tedavi yöntemi.
EP3077412B1 (de) 2013-12-02 2023-01-04 Baylor College of Medicine Identifizierung eines neuen polypeptidhormons zur aufrechterhaltung eines optimalen körpergewichts und glucosewerts
CN105934671B (zh) 2013-12-03 2019-04-19 哈佛大学董事会 用于评估妊娠糖尿病的方法和试剂
US9321834B2 (en) 2013-12-05 2016-04-26 Leidos, Inc. Anti-malarial compositions
MX371187B (es) 2013-12-06 2020-01-22 Dana Farber Cancer Inst Inc Péptidos terapéuticos.
US10335494B2 (en) 2013-12-06 2019-07-02 Millennium Pharmaceuticals, Inc. Combination of aurora kinase inhibitors and anti-CD30 antibodies
CN105980405A (zh) 2013-12-08 2016-09-28 派特塞尔有限公司 Hiv抗原和抗体及其组合物、方法和用途
AU2014363987A1 (en) 2013-12-09 2016-06-30 Janssen Biotech, Inc. Compositions and methods for phagocyte delivery of anti-staphylococcal agents
KR20210125114A (ko) 2013-12-09 2021-10-15 알라코스 인크. 항-Siglec-8 항체 및 그의 사용 방법
WO2015087187A1 (en) 2013-12-10 2015-06-18 Rinat Neuroscience Corp. Anti-sclerostin antibodies
CN105979780A (zh) 2013-12-11 2016-09-28 斯隆-凯特林癌症研究院 治疗前列腺癌的糖皮质激素抑制剂
US11135269B2 (en) 2013-12-11 2021-10-05 The General Hospital Corporation Use of mullerian inhibiting substance (MIS) proteins for contraception and ovarian reserve preservation
WO2015089380A2 (en) 2013-12-12 2015-06-18 Celcuity Llc Assays and methods for determining the responsiveness of an individual subject to a therapeutic agent
WO2015088346A1 (en) 2013-12-13 2015-06-18 Rijksuniversiteit Groningen Antibodies against staphylococcus aureus and uses thereof.
JP2017505756A (ja) 2013-12-13 2017-02-23 ザ ジェネラル ホスピタル コーポレイション 可溶性高分子量（ｈｍｗ）タウ種およびその用途
AR098743A1 (es) 2013-12-13 2016-06-08 Genentech Inc Anticuerpos e inmunoconjugados anti-cd33
ES2754209T3 (es) 2013-12-13 2020-04-16 Stora Enso Oyj Cartón multicapa
UA118113C2 (uk) 2013-12-16 2018-11-26 Дженентек, Інк. Пептидоміметичні сполуки та їх кон'югати антитіла з лікарським засобом
JP6980384B2 (ja) 2013-12-16 2021-12-15 ジェネンテック， インコーポレイテッド １−（クロロメチル）−２，３−ジヒドロ−１ｈ−ベンゾ［ｅ］インドール二量体抗体−薬物コンジュゲート化合物、並びに使用及び処置の方法
BR112016012410A2 (pt) 2013-12-16 2017-09-26 Genentech Inc conjugado de droga e anticorpo, composto conjugado de droga e anticorpo, composto não-peptídico, método de tratamento de doenças em seres humanos e composição farmacêutica
EP2883883A1 (de) 2013-12-16 2015-06-17 Cardio3 Biosciences S.A. Therapeutische Ziele und Mittel zur Behandlung von ischämiebedingten Reperfusionsschäden
WO2015095143A1 (en) 2013-12-16 2015-06-25 The University Of North Carolina At Chapel Hill Depletion of plasmacytoid dendritic cells
US9914769B2 (en) 2014-07-15 2018-03-13 Kymab Limited Precision medicine for cholesterol treatment
US9045545B1 (en) 2014-07-15 2015-06-02 Kymab Limited Precision medicine by targeting PD-L1 variants for treatment of cancer
US8980273B1 (en) 2014-07-15 2015-03-17 Kymab Limited Method of treating atopic dermatitis or asthma using antibody to IL4RA
US8986691B1 (en) 2014-07-15 2015-03-24 Kymab Limited Method of treating atopic dermatitis or asthma using antibody to IL4RA
US9067998B1 (en) 2014-07-15 2015-06-30 Kymab Limited Targeting PD-1 variants for treatment of cancer
ES2763429T5 (es) 2013-12-17 2023-06-21 Hoffmann La Roche Procedimientos de tratamiento de cánceres usando antagonistas de la unión al eje de PD-1 y taxanos
HUE050159T2 (hu) 2013-12-17 2020-11-30 Genentech Inc Anti-CD3 antitestek és alkalmazási eljárások
US8992927B1 (en) 2014-07-15 2015-03-31 Kymab Limited Targeting human NAV1.7 variants for treatment of pain
US8986694B1 (en) 2014-07-15 2015-03-24 Kymab Limited Targeting human nav1.7 variants for treatment of pain
MX2016007965A (es) 2013-12-17 2016-10-28 Genentech Inc Terapia de combinacion que comprende agonistas de union a ox40 y antagonistas de union al eje pd-1.
US20150210772A1 (en) 2013-12-17 2015-07-30 Genentech, Inc. Methods of treating cancer using pd-1 axis binding antagonists and an anti-cd20 antibody
WO2015091653A2 (en) 2013-12-17 2015-06-25 Westfaelische Wilhelms-Universitaet Muenster Means and methods for treating a pruritus-like skin-disease
EP3084003A4 (de) 2013-12-17 2017-07-19 Merck Sharp & Dohme Corp. Ifn-gamma-gensignaturbiomarker der tumorreaktion auf pd-1 antagonisten
CN105979965B (zh) 2013-12-18 2021-07-09 杰特有限公司 治疗伤口的方法
HUE060643T2 (hu) 2013-12-19 2023-04-28 Seagen Inc Metilén-karbamát-linkerek célzott hatóanyag-konjgátumokkal közös alkalmazásra
DK3083936T3 (en) 2013-12-19 2018-10-22 Danisco Us Inc USE OF HYDROPHOBINES TO INCREASE GAS TRANSFER IN AEROBE FERMENTATION PROCESSES
US10137170B2 (en) 2013-12-20 2018-11-27 Indiana University Research And Technology Corporation Lipidated incretin receptor ligand human immunoglobulin Fc-region fusion polypeptides
BR112016011027A2 (pt) 2013-12-20 2017-12-05 Genentech Inc método de produção de um anticorpo, anticorpos, composição farmacêutica, polinucleotídeo, vetor, célula hospedeira, método de tratamento de asma e método de tratamento de um distúrbio
WO2015095868A1 (en) 2013-12-20 2015-06-25 Wake Forest University Health Sciences Methods and compositions for increasing protective antibody levels induced by pneumococcal polysaccharide vaccines
WO2015090229A1 (en) 2013-12-20 2015-06-25 Novartis Ag Regulatable chimeric antigen receptor
AU2014368453B2 (en) 2013-12-20 2020-04-16 Intervet International B.V. Caninized murine anti-canine PD-1 antibodies
CR20160270A (es) 2013-12-20 2016-09-05 Hoffmann La Roche ANTICUERPOS ANTI-TAU (pS422) HUMANIZADOS Y MÉTODOS DE UTILIZACIÓN
TWI728373B (zh) 2013-12-23 2021-05-21 美商建南德克公司 抗體及使用方法
AU2014372833B2 (en) 2013-12-23 2019-08-22 Bayer Pharma Aktiengesellschaft Antibody drug conjugates (ADCs) with kinesin spindel protein (KSP)
EP2960252A1 (de) 2014-06-26 2015-12-30 Institut Pasteur Phospholipase zur Behandlung von Immunosuppression
US10273301B2 (en) 2013-12-24 2019-04-30 Janssen Pharmaceutica Nv Anti-vista antibodies and fragments
US11014987B2 (en) 2013-12-24 2021-05-25 Janssen Pharmaceutics Nv Anti-vista antibodies and fragments, uses thereof, and methods of identifying same
HUE064292T2 (hu) 2013-12-26 2024-03-28 Mitsubishi Tanabe Pharma Corp Humán anti-IL-33 semlegesítõ monoklonális antitest
WO2015099127A1 (ja) 2013-12-27 2015-07-02 中外製薬株式会社 Ｆｇｆｒゲートキーパー変異遺伝子およびそれを標的とする医薬
KR102384740B1 (ko) 2013-12-27 2022-04-07 자임워크스 인코포레이티드 약물 접합체를 위한 설폰아마이드-함유 연결 시스템
WO2015100459A2 (en) 2013-12-27 2015-07-02 Merrimack Pharmaceuticals, Inc. Biomarker profiles for predicting outcomes of cancer therapy with erbb3 inhibitors and/or chemotherapies
WO2015098113A1 (ja) 2013-12-27 2015-07-02 独立行政法人医薬基盤研究所 悪性腫瘍の治療薬
JP2017502672A (ja) 2013-12-30 2017-01-26 メディシナル バイオコンバージェンス リサーチ センター 抗ｋｒｓモノクロナル抗体及びこれの用途
US10188650B2 (en) 2014-01-03 2019-01-29 The Regents Of The University Of Michigan Treatment of neurological disorders
BR112016014945A2 (pt) 2014-01-03 2018-01-23 F. Hoffmann-La Roche Ag conjugado, formulação farmacêutica e uso
EP3089758B1 (de) 2014-01-03 2021-01-27 F.Hoffmann-La Roche Ag Kovalent verknüpfte helikar-/anti-helikar-antikörperkonjugate und verwendungen davon
WO2015101586A1 (en) 2014-01-03 2015-07-09 F. Hoffmann-La Roche Ag Bispecific anti-hapten/anti-blood brain barrier receptor antibodies, complexes thereof and their use as blood brain barrier shuttles
PL3092251T3 (pl) 2014-01-06 2021-08-02 F. Hoffmann-La Roche Ag Jednowartościowe moduły transportera wahadłowego przez barierę krew-mózg
US10344073B2 (en) 2014-01-09 2019-07-09 Hadasit Medical Research Services And Development Ltd. Cell compositions and methods for cancer therapy
WO2015108907A2 (en) 2014-01-14 2015-07-23 Dana-Farber Cancer Institute, Inc. Compositions and methods for identification, assessment, prevention, and treatment of melanoma using pd-l1 isoforms
AU2015206788B2 (en) 2014-01-14 2019-10-24 The Medical College Of Wisconsin, Inc. Targeting CLPTM1L for treatment and prevention of cancer
CN110903398B (zh) 2014-01-15 2023-08-15 豪夫迈·罗氏有限公司 具有修饰的FCRN和保持的蛋白A结合性质的Fc区变体
KR20160104727A (ko) 2014-01-16 2016-09-05 아카데미아 시니카 암의 치료 및 검출을 위한 조성물 및 방법
WO2016114819A1 (en) 2015-01-16 2016-07-21 Academia Sinica Compositions and methods for treatment and detection of cancers
US10150818B2 (en) 2014-01-16 2018-12-11 Academia Sinica Compositions and methods for treatment and detection of cancers
EP2896400A1 (de) 2014-01-17 2015-07-22 Université Catholique De Louvain Verfahren zur Erhöhung der Bioverfügbarkeit von inhaliertem Verbindungen
WO2015109212A1 (en) 2014-01-17 2015-07-23 Pfizer Inc. Anti-il-2 antibodies and compositions and uses thereof
EP3097117B1 (de) 2014-01-21 2023-10-04 Novartis Ag Verbessertes antigen mit car-t-zellfähigkeit durch co-einführung von co-stimulatorischen molekülen
RS60593B1 (sr) 2014-01-24 2020-08-31 Ngm Biopharmaceuticals Inc Antitela koja vezuju domen 2 beta-kloto i postupci za njihovu upotrebu
WO2015112909A1 (en) 2014-01-24 2015-07-30 Genentech, Inc. Methods of using anti-steap1 antibodies and immunoconjugates
UA122479C2 (uk) 2014-01-24 2020-11-25 Дана-Фарбер Кенсер Інстітьют, Інк. Виділена молекула антитіла, яка зв’язується з людським білком програмованої смерті-1 (pd-1)
SG11201605437YA (en) 2014-01-27 2016-08-30 Pfizer Bifunctional cytotoxic agents
EP3100054B1 (de) 2014-01-28 2022-02-23 Quest Diagnostics Investments Incorporated Verfahren und zusammensetzungen zum nachweis eines adenoma-adenokarzinom-übergangs bei krebs
CN106132992B (zh) 2014-01-29 2020-08-07 达娜-法勃肿瘤研究所公司 针对muc1-c/胞外结构域(muc1-c/ecd)的抗体
CA2934965A1 (en) 2014-01-31 2016-03-17 Boehringer Ingelheim International Gmbh Novel anti-baff antibodies
WO2015116902A1 (en) 2014-01-31 2015-08-06 Genentech, Inc. G-protein coupled receptors in hedgehog signaling
PL3099717T3 (pl) 2014-01-31 2019-10-31 Novartis Ag Cząsteczki przeciwciała dla TIM-3 i ich zastosowanie
JP2017506259A (ja) 2014-02-03 2017-03-02 イッスム・リサーチ・ディベロップメント・カンパニー・オブ・ザ・ヘブルー・ユニバーシティ・オブ・エルサレム・リミテッドＹｉｓｓｕｍ Ｒｅｓｅａｒｃｈ Ｄｅｖｅｌｏｐｍｅｎｔ Ｃｏｍｐａｎｙ Ｏｆ Ｔｈｅ Ｈｅｂｒｅｗ Ｕｎｉｖｅｒｓｉｔｙ Ｏｆ Ｊｅｒｕｓａｌｅｍ Ｌｔｄ． 幹細胞を枯渇させるためのカゼインキナーゼｉ阻害剤の使用
US10570202B2 (en) 2014-02-04 2020-02-25 Pfizer Inc. Combination of a PD-1 antagonist and a VEGFR inhibitor for treating cancer
AU2015214146B2 (en) 2014-02-04 2020-09-17 Contrafect Corporation Antibodies useful in passive influenza immunization, and compositions, combinations and methods for use thereof
US20170044232A1 (en) 2014-02-04 2017-02-16 Genentech, Inc. Mutant smoothened and methods of using the same
PH12020550847A1 (en) 2014-02-04 2022-05-11 Incyte Corp Combination of a pd-1 antagonist and an ido1 inhibitor for treating cancer
KR102301188B1 (ko) 2014-02-06 2021-09-13 엑스4 파마슈티컬스 (오스트리아) 게엠베하 이. 콜라이 특이성 항체 서열
CN106573976B (zh) 2014-02-06 2020-05-05 耶达研究及发展有限公司 抗cd84抗体、包含所述抗体的组合物及其用途
NZ723884A (en) 2014-02-08 2023-02-24 Genentech Inc Methods of treating alzheimer’s disease
TW202239429A (zh) 2014-02-08 2022-10-16 美商建南德克公司 治療阿茲海默症之方法
WO2015120474A1 (en) 2014-02-10 2015-08-13 Igm Biosciences, Inc. Iga multi-specific binding molecules
MX2016010295A (es) 2014-02-11 2016-10-17 Seattle Genetics Inc Reduccion selectiva de proteinas.
JP6764348B2 (ja) 2014-02-11 2020-09-30 ビステラ， インコーポレイテッド デングウイルスに対する抗体分子およびその使用
EP3105252B1 (de) 2014-02-12 2019-07-24 Michael Uhlin Bispezifische antikörper zur verwendung in der stammzelltransplantation
SI3105253T1 (sl) 2014-02-12 2018-10-30 F. Hoffmann-La Roche Ag Protitelesa anti-Jagged1 in načini njihove uporabe
JP2017506640A (ja) 2014-02-14 2017-03-09 セントローズ， エルエルシー 細胞外標的化薬物共役体
EP3107557B1 (de) 2014-02-17 2021-06-09 Seagen Inc. Hydrophile antikörper-wirkstoff-konjugate
EP3108255B1 (de) 2014-02-18 2020-08-12 INSERM (Institut National de la Santé et de la Recherche Médicale) Verfahren und pharmazeutische zusammensetzungen zur behandlung von durch den nrp-1/obr-komplexsignalweg vermittelten krankheiten
WO2015124570A1 (en) 2014-02-18 2015-08-27 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and pharmaceutical composition for the treatment of influenza a virus infection
SG10201806481XA (en) 2014-02-19 2018-09-27 Emergent Biosolutions Canada Inc Marburg monoclonal antibodies
CA3265373A1 (en) 2014-02-20 2025-10-30 H. Lundbeck A/S Anti-acth antibodies and use thereof
CA3177696A1 (en) 2014-02-20 2015-08-27 Allergan, Inc. Complement component c5 antibodies
JP2017507939A (ja) 2014-02-21 2017-03-23 ジェネンテック， インコーポレイテッド 抗ｉｌ−１３／ｉｌ−１７二重特異性抗体及びその使用
EP3107576A4 (de) 2014-02-21 2017-09-06 Abbvie Stemcentrx LLC Anti-dll3-antikörper und arzneimittelkonjugate zur verwendung in melanomen
GB201403115D0 (en) 2014-02-21 2014-04-09 Qbd Qs Ip Ltd Red blood cell detection
NZ723328A (en) 2014-02-24 2018-01-26 Glycovaxyn Ag Compositions comprising e. coli o25b antigen, uses thereof and methods of manufacture
WO2015130805A1 (en) 2014-02-26 2015-09-03 Arizona Board Of Regents On Behalf Of Arizona State University Dna gridiron compositions and methods
CN106062001A (zh) 2014-02-27 2016-10-26 吉利德科学公司 基质金属蛋白酶9的抗体及其使用方法
AU2015223056B2 (en) 2014-02-27 2020-10-01 Allergan, Inc. Complement Factor Bb antibodies
DK3805268T3 (da) 2014-02-28 2025-01-20 Merus Nv Antistof, der binder erbb-2 og erbb-3
JP6417421B2 (ja) 2014-02-28 2018-11-07 ハンジョウ ディーエーシー バイオテック シーオー．，エルティディ．Ｈａｎｇｚｈｏｕ Ｄａｃ Ｂｉｏｔｅｃｈ Ｃｏ．，Ｌｔｄ． 荷電連結体及び共役体のためのその使用
CA2941030C (en) 2014-02-28 2025-05-13 Merus N.V. ANTIBODIES THAT BIND TO EGFR AND ERBB3
JP6825909B2 (ja) 2014-02-28 2021-02-03 アラコス インコーポレイテッド シグレック−８関連疾患を処置するための方法および組成物
GB201403815D0 (en) 2014-03-04 2014-04-16 Mologic Ltd Assay
GB201403775D0 (en) 2014-03-04 2014-04-16 Kymab Ltd Antibodies, uses & methods
GB201403875D0 (en) 2014-03-05 2014-04-16 Cantargia Ab Novel antibodies and uses thereof
NZ711451A (en) 2014-03-07 2016-05-27 Alexion Pharma Inc Anti-c5 antibodies having improved pharmacokinetics
WO2015132672A2 (en) 2014-03-07 2015-09-11 University Health Network Methods and compositions for detection of targets involved in cancer metastasis
CA2935878C (en) 2014-03-12 2023-05-02 Curevac Ag Combination of vaccination and ox40 agonists
US9738702B2 (en) 2014-03-14 2017-08-22 Janssen Biotech, Inc. Antibodies with improved half-life in ferrets
EP3116903A2 (de) 2014-03-14 2017-01-18 Dana-Farber Cancer Institute, Inc. Impfstoffzusammensetzungen und verfahren zur wiederherstellung der nkg2d-wegfunktion gegen krebs
SG11201607519VA (en) 2014-03-14 2016-10-28 Genentech Inc Methods and compositions for secretion of heterologous polypeptides
EA201691765A1 (ru) 2014-03-14 2016-12-30 Новартис Аг Молекулы антител против lag-3 и их применения
CN122399016A (zh) 2014-03-15 2026-07-17 诺华股份有限公司 使用嵌合抗原受体治疗癌症
WO2015142661A1 (en) 2014-03-15 2015-09-24 Novartis Ag Regulatable chimeric antigen receptor
EP3119804A2 (de) 2014-03-19 2017-01-25 Dana-Farber Cancer Institute, Inc. Immungenetisch beschränkung der induzierung von antikörpern
EP3119876B1 (de) 2014-03-19 2024-12-18 Pfizer Inc. Zellkultur-verfahren
WO2015143335A1 (en) 2014-03-20 2015-09-24 The University Of North Carolina At Chapel Hill Methods and compositions for chimeric coronavirus spike proteins
US20170107294A1 (en) 2014-03-21 2017-04-20 Nordlandssykehuset Hf Anti-cd14 antibodies and uses thereof
RU2688349C2 (ru) 2014-03-21 2019-05-21 Ф. Хоффманн-Ля Рош Аг In vitro прогнозирование времени полужизни антител in vivo
US10556945B2 (en) 2014-03-21 2020-02-11 Teva Pharmaceuticals International Gmbh Antagonist antibodies directed against calcitonin gene-related peptide and methods using same
MX378344B (es) 2014-03-21 2025-03-10 Teva Pharmaceuticals Int Gmbh Anticuerpos antagonistas dirigidos contra el peptido relacionado con el gen de calcitonina y metodos que usan los mismos.
WO2015140351A1 (en) 2014-03-21 2015-09-24 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and pharmaceutical compositions for enhancing myelination
CA2943242A1 (en) 2014-03-21 2015-09-24 X-Body, Inc. Bi-specific antigen-binding polypeptides
EP3122900A1 (de) 2014-03-24 2017-02-01 F. Hoffmann-La Roche AG Krebsbehandlung mit c-met-antagonisten und korrelation desselben mit hgf-expression
SG11201607929PA (en) 2014-03-25 2016-10-28 Genentech Inc Methods of preparing a poloxamer for use in cell culture medium
ES2884930T3 (es) 2014-03-26 2021-12-13 Siemens Healthcare Diagnostics Inc Inmunoensayo de canalización de oxígeno luminiscente utilizando tres anticuerpos y métodos de producción y uso de los mismos
EP3122768A2 (de) 2014-03-27 2017-02-01 Yeda Research and Development Co. Ltd. T-zell-rezeptor-cdr3-peptide und -antikörper
TWI797430B (zh) 2014-03-27 2023-04-01 中央研究院 反應性標記化合物及其用途
JP7054990B2 (ja) 2014-03-27 2022-04-15 ジェネンテック， インコーポレイテッド 炎症性腸疾患の診断及び治療のための方法
CA2944456C (en) 2014-03-31 2023-10-31 The Johns Hopkins University Use of bacteria, bacterial products, and other immunoregulatory entities in combination with anti-ctla-4 and/or anti-pd-1 antibodies to treat solid tumor malignancies
SG11201607969XA (en) 2014-03-31 2016-10-28 Genentech Inc Anti-ox40 antibodies and methods of use
WO2015150900A2 (en) 2014-03-31 2015-10-08 Debiopharm International Sa Fgfr fusions
KR20160146747A (ko) 2014-03-31 2016-12-21 제넨테크, 인크. 항혈관신생제 및 ox40 결합 효능제를 포함하는 조합 요법
SG10202107077QA (en) 2014-04-02 2021-07-29 Hoffmann La Roche Method for detecting multispecific antibody light chain mispairing
US9995746B2 (en) 2014-04-02 2018-06-12 The United States Of America, As Represented By The Secretary Of The Army Rapid dual direct fluorescent antibody assay for the identification of Bacillus antrhacis
EP4011910A1 (de) 2014-04-03 2022-06-15 IGM Biosciences, Inc. Modifizierte j-kette
EP3125943B1 (de) 2014-04-04 2026-04-22 Merck Sharp & Dohme LLC Phosphatbasierte linker für intrazelluläre verabreichung von arzneimittelkonjugaten
CA2944649C (en) 2014-04-04 2022-06-21 Bionomics, Inc. Humanized antibodies that bind lgr5
EP4050103A1 (de) 2014-04-07 2022-08-31 Minerva Biotechnologies Corporation Anti-nme-antikörper
SG10202109752XA (en) 2014-04-07 2021-10-28 Novartis Ag Treatment of cancer using anti-cd19 chimeric antigen receptor
AU2015244025B2 (en) 2014-04-08 2019-03-21 Boston Pharmaceuticals Inc. Binding molecules specific for IL-21 and uses thereof
ES2772817T3 (es) 2014-04-10 2020-07-08 Obi Pharma Inc Anticuerpos de unión a antígenos de carbohidrato asociados a tumor, composiciones farmacéuticas y sus usos
CA2943299A1 (en) 2014-04-11 2015-10-15 Medimmune, Llc Bispecific her2 antibodies
GB201406767D0 (en) 2014-04-15 2014-05-28 Cancer Rec Tech Ltd Humanized anti-Tn-MUC1 antibodies anf their conjugates
RU2689145C2 (ru) 2014-04-16 2019-05-24 Биокон Лтд. Стабильные белковые препараты, содержащие молярный избыток сорбитола
EP3131929B1 (de) 2014-04-16 2022-06-01 INSERM (Institut National de la Santé et de la Recherche Médicale) Antikörper zur prophylaxe oder behandlung von blutungsepisoden
EP2933640A1 (de) 2014-04-17 2015-10-21 eXcorLab GmbH Verfahren zur Früherkennung der chronischen Niereninsuffizienz durch Detektion von posttransalationalen Modifikationen an Albumin mittels ELISA-Technik
US10407703B2 (en) 2014-04-17 2019-09-10 Medizinische Hochschule Hannover Means and methods for producing Neisseria meningitidis capsular polysaccharides of low dispersity
EP3131931B1 (de) 2014-04-18 2020-10-21 Acceleron Pharma Inc. Verfahren zur erhöhung der erythrozytenkonzentration und behandlung der sichelzellenanämie
GB201407132D0 (en) 2014-04-23 2014-06-04 Velgene Biotechnology Marker for neurodegenerative disorders
WO2015164615A1 (en) 2014-04-24 2015-10-29 University Of Oslo Anti-gluten antibodies and uses thereof
TW201622746A (zh) 2014-04-24 2016-07-01 諾華公司 改善或加速髖部骨折術後身體復原之方法
EP3134546A4 (de) 2014-04-24 2017-12-06 Dana-Farber Cancer Institute, Inc. Tumorsuppressor und onkogene biomarker zur vorhersage der anti-immun-checkpoint-inhibitorreaktion
JP6792454B2 (ja) 2014-04-25 2020-11-25 ザ ブリガム アンド ウィメンズ ホスピタル インコーポレイテッドＴｈｅ Ｂｒｉｇｈａｍ ａｎｄ Ｗｏｍｅｎ’ｓ Ｈｏｓｐｉｔａｌ， Ｉｎｃ． アルファ−フェトプロテイン（ａｆｐ）を操作するための方法
WO2015164865A1 (en) 2014-04-25 2015-10-29 Dana-Farber Cancer Institute, Inc. Middle east respiratory syndrome coronavirus neutralizing antibodies and methods of use thereof
US20170045528A1 (en) 2014-04-25 2017-02-16 The Brigham And Women's Hospital, Inc. Compositions and methods for treating subjects with immune-mediated diseases
KR20190072663A (ko) 2014-04-25 2019-06-25 리나트 뉴로사이언스 코프. 약물이 고도로 로딩된 항체-약물 접합체
JP6805428B2 (ja) 2014-04-27 2021-01-06 フェイムウェイヴ リミテッド Ｃｅａｃａｍ１に対するヒト化抗体
US11427647B2 (en) 2014-04-27 2022-08-30 Famewave Ltd. Polynucleotides encoding humanized antibodies against CEACAM1
US10087259B1 (en) 2014-04-28 2018-10-02 Memorial Sloan Kettering Cancer Center Depleting tumor-specific tregs
US9753036B2 (en) 2014-04-29 2017-09-05 Edp Biotech Corporation Methods and compositions for screening and detecting biomarkers
SMT202100146T1 (it) 2014-04-30 2021-05-07 Pfizer Coniugati di anticorpo anti-ptk7-farmaco
US9388239B2 (en) 2014-05-01 2016-07-12 Consejo Nacional De Investigation Cientifica Anti-human VEGF antibodies with unusually strong binding affinity to human VEGF-A and cross reactivity to human VEGF-B
SG11201608868PA (en) 2014-05-01 2016-11-29 Genentech Inc Anti-factor d antibody variants and uses thereof
RU2728703C2 (ru) 2014-05-02 2020-07-31 Рисерч Инститьют Эт Нэшнуайд Чилдрен`С Хоспитал Композиции и способы для анти-lyst иммуномодуляции
ES2899754T3 (es) 2014-05-02 2022-03-14 Medimmune Ltd Moduladores de canales iónicos y usos de los mismos
EP2942627A1 (de) 2014-05-05 2015-11-11 MicroBPlex, Inc. MIT VON NEULICH PROLIFERIERTEN ANTIKöRPER SEKRETIERENDEN ZELLEN NEU SYNTHETISIERTEN ANTIKÖRPERN (MENSA) ELABORIERTE MEDIEN UND VERWENDUNGEN DAVON
PL3140392T3 (pl) 2014-05-06 2023-11-27 F. Hoffmann-La Roche Ag Produkcja białek heteromultimerycznych z wykorzystaniem komórek ssaków
WO2015171723A1 (en) 2014-05-06 2015-11-12 Research Development Foundation Methods for treating insulin resistance and for sensitizing patients to glp1 agonist therapy
US11173208B2 (en) 2014-05-07 2021-11-16 Takeda Gmbh Liquid formulation comprising GM-CSF neutralizing compound
GB201408255D0 (en) 2014-05-09 2014-06-25 Immatics Biotechnologies Gmbh Novel immunotherapy against several tumours of the blood, such as acute myeloid leukemia (AML)
ES2851451T3 (es) 2014-05-13 2021-09-07 Bavarian Nordic As Terapia de combinación para tratar cáncer con un poxvirus que expresa un antígeno de tumor y un anticuerpo monoclonal contra TIM-3
FR3020947B1 (fr) 2014-05-14 2018-08-31 Adocia Composition aqueuse comprenant au moins une proteine et un agent solubilisant, sa preparation et ses utilisations
WO2015176010A1 (en) 2014-05-15 2015-11-19 The United States Of America, As Represented By The Secretary, Departmentof Health & Human Services Treatment or prevention of an intestinal disease or disorder
WO2015175861A1 (en) 2014-05-16 2015-11-19 Amgen Inc. Assay for detecting th1 and th2 cell populations
JP6832709B2 (ja) 2014-05-16 2021-02-24 メディミューン，エルエルシー 新生児Ｆｃ受容体結合が改変されて治療および診断特性が強化された分子
US9903868B2 (en) 2014-05-16 2018-02-27 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Method for the detection and quantitation of biomarkers
WO2015179404A1 (en) 2014-05-19 2015-11-26 The Johns Hopkins University Methods for identifying androgen receptor splice variants in subjects having castration resistant prostate cancer
RU2696490C2 (ru) 2014-05-19 2019-08-02 Пфайзер Инк. Замещенные-6,8-диоксабицикло[3.2.1.]октан-2,3-диольные соединения в качестве агентов, нацеленных на ASGPR
WO2015179236A1 (en) 2014-05-21 2015-11-26 Pfizer Inc. Combination of an anti-ccr4 antibody and a 4-1bb agonist for treating cancer
WO2015179627A1 (en) 2014-05-21 2015-11-26 Dana-Farber Cancer Institute, Inc. Methods for treating cancer with anti bip or anti mica antibodies
JP2017522861A (ja) 2014-05-22 2017-08-17 ジェネンテック， インコーポレイテッド 抗ｇｐｃ３抗体及びイムノコンジュゲート
US10302653B2 (en) 2014-05-22 2019-05-28 Mayo Foundation For Medical Education And Research Distinguishing antagonistic and agonistic anti B7-H1 antibodies
KR20170005016A (ko) 2014-05-23 2017-01-11 제넨테크, 인크. MiT 바이오마커 및 그의 사용 방법
KR20170010003A (ko) 2014-05-27 2017-01-25 아카데미아 시니카 박테로이드 기원의 푸코시다제 및 이의 사용 방법
EP4116329A1 (de) 2014-05-27 2023-01-11 Academia Sinica Anti-her2-glykoantikörper und verwendungen davon
US10695406B2 (en) 2014-05-27 2020-06-30 The University Of Queensland Modulation of cellular stress using a B-cell oxidative and/or endoplasmic reticulum stress inhibitor and a targeting agent
US10118969B2 (en) 2014-05-27 2018-11-06 Academia Sinica Compositions and methods relating to universal glycoforms for enhanced antibody efficacy
JP2017518989A (ja) 2014-05-27 2017-07-13 アカデミア シニカＡｃａｄｅｍｉａ Ｓｉｎｉｃａ 抗ｃｄ２０糖操作抗体群およびその使用
LT3148579T (lt) 2014-05-28 2021-05-25 Agenus Inc. Anti-gitr antikūnai ir jų panaudojimo būdai
JP7063538B2 (ja) 2014-05-28 2022-05-09 アカデミア シニカ 抗ＴＮＦα糖操作抗体群およびその使用
US10647768B2 (en) 2014-05-29 2020-05-12 Macrogenics, Inc. Multi-chain polypeptide-containing tri-specific binding molecules
EP3613433B1 (de) 2014-05-30 2022-01-05 Shanghai Henlius Biotech, Inc. Antikörper gegen den epidermalen wachstumsfaktor-rezeptor (egfr)
US20170253881A1 (en) 2014-06-02 2017-09-07 Technion Research & Development Foundation Limited Compositions and methods of selectively inhibiting irp1 and treating inflammation
WO2015187499A1 (en) 2014-06-03 2015-12-10 Gilead Sciences, Inc. Use of an ask1 inhibitor for the treatment of liver disease, optionally in combination with a loxl2 inhibitor
AU2015271100B2 (en) 2014-06-06 2020-07-30 Redwood Bioscience, Inc. Anti-HER2 antibody-maytansine conjugates and methods of use thereof
PL3151921T3 (pl) 2014-06-06 2020-02-28 Bristol-Myers Squibb Company Przeciwciała przeciwko receptorowi indukowanego glukokortykoidami czynnika martwicy nowotworu (gitr) i ich zastosowania
US11033620B2 (en) 2014-06-09 2021-06-15 Biomed Valley Discoveries, Inc. Combination therapies targeting tumor-associated stroma or tumor cells and microtubules
WO2015191617A2 (en) 2014-06-09 2015-12-17 Biomed Valley Discoveries, Inc. Combination therapies using anti-metabolites and agents that target tumor-associated stroma or tumor cells
WO2015191568A2 (en) 2014-06-09 2015-12-17 Biomed Valley Discoveries, Inc. Combination therapies using agents that target tumor-associated stroma or tumor cells and tumor vasculature
US10758526B2 (en) 2014-06-09 2020-09-01 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services National Institutes Of Health Combination therapies using agents that target tumor-associated stroma or tumor cells and other pathways
US10758614B2 (en) 2014-06-09 2020-09-01 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services National Institutes Of Health Combination therapies targeting tumor-associated stroma or tumor cells and topoisomerase
WO2015191596A1 (en) 2014-06-09 2015-12-17 Biomed Valley Discoveries, Inc. Combination therapies using platinum agents and agents that target tumor-associated stroma or tumor cells
WO2015191615A2 (en) 2014-06-09 2015-12-17 Biomed Valley Discoveries, Inc. Combination therapies using agents that target tumor-associated stroma or tumor cells and alkylating agents
DK3845245T3 (da) 2014-06-09 2025-09-15 Ultragenyx Pharmaceutical Inc Effektiv og virkningsfuld kontrol af serumphosphat til optimal knogledannelse
MX2016016233A (es) 2014-06-11 2017-03-31 Genentech Inc Anticuerpos anti-lgr5 y sus usos.
JP6997619B2 (ja) 2014-06-11 2022-01-17 キャシー・エイ・グリーン 液性免疫の抑制または増進のための、ｖｉｓｔａアゴニスト及びｖｉｓｔａアンタゴニストの使用
EA201692202A1 (ru) 2014-06-11 2017-06-30 Джилид Сайэнс, Инк. Способы лечения сердечно-сосудистых заболеваний
CN114699529A (zh) 2014-06-13 2022-07-05 阿塞勒隆制药公司 用于治疗溃疡的方法和组合物
WO2015191986A1 (en) 2014-06-13 2015-12-17 Genentech, Inc. Methods of treating and preventing cancer drug resistance
EP3154579A1 (de) 2014-06-13 2017-04-19 Friedrich Miescher Institute for Biomedical Research Neue behandlung gegen das influenzavirus
ES2694296T3 (es) 2014-06-17 2018-12-19 Centre National De La Recherche Scientifique (Cnrs) Anticuerpos monoclonales anti-pVHL y usos de los mismos
ES2779412T3 (es) 2014-06-17 2020-08-17 Medimmune Ltd Anticuerpos Alfa-V Beta-8 mejorados
TWI695011B (zh) 2014-06-18 2020-06-01 美商梅爾莎納醫療公司 抗ｈｅｒ２表位之單株抗體及其使用之方法
GB201411037D0 (en) 2014-06-20 2014-08-06 Immatics Biotechnologies Gmbh Novel immunotherapy against several tumors of the blood, in particular chronic lymphoid leukemai (CLL)
CA2952032C (en) 2014-06-20 2023-03-14 Aveo Pharmaceuticals, Inc. Treatment of chronic kidney disease and other renal dysfunction using a gdf15 modulator
JP6910800B2 (ja) 2014-06-20 2021-07-28 アベオ ファーマシューティカルズ， インコーポレイテッド Ｇｄｆ１５調節剤を用いたうっ血性心不全及びその他の心機能不全の治療
KR20170020868A (ko) 2014-06-20 2017-02-24 바이오얼라이언스 씨.브이. 항-폴레이트 수용체 알파 (fra) 항체-약물 컨쥬게이트 및 그것의 사용 방법
EP3157535A1 (de) 2014-06-23 2017-04-26 Friedrich Miescher Institute for Biomedical Research Verfahren zur auslösung der novo-bildung von heterochromatin und/oder zur epigenetischen abschaltung mit kleinen rnas
EP3157957A1 (de) 2014-06-23 2017-04-26 Five Prime Therapeutics, Inc. Verfahren zur behandlung von erkrankungen mit antikörpern zur bindung des koloniestimulationsfaktor-1-rezeptors (csf1r)
WO2015199976A1 (en) 2014-06-24 2015-12-30 The United States Of America, As Represented By The Secretary, Department Of Health & Human Services Target activated microdissection
WO2015198320A1 (en) 2014-06-24 2015-12-30 Insight Biopharmaceuticals Ltd. Methods of purifying antibodies
US20170327553A1 (en) 2014-06-25 2017-11-16 Novartis Ag Compositions and methods for long acting proteins
EP3161001A2 (de) 2014-06-25 2017-05-03 Novartis AG Il17-a spezifische antikörper die mit hyaluronan bindenden peptid-marker fusioniert sind
US20170290876A1 (en) 2014-06-25 2017-10-12 Novartis Ag Compositions and methods for long acting proteins
AR100978A1 (es) 2014-06-26 2016-11-16 Hoffmann La Roche LANZADERAS CEREBRALES DE ANTICUERPO HUMANIZADO ANTI-Tau(pS422) Y USOS DE LAS MISMAS
TWI693232B (zh) 2014-06-26 2020-05-11 美商宏觀基因股份有限公司 與pd-1和lag-3具有免疫反應性的共價結合的雙抗體和其使用方法
CN106687476B (zh) 2014-06-26 2020-11-13 豪夫迈·罗氏有限公司 抗brdu抗体及使用方法
TW201628647A (zh) 2014-06-27 2016-08-16 賽諾菲公司 抗－ｉｌ４－ｉｌ１３雙特異性抗體
WO2015200905A2 (en) 2014-06-28 2015-12-30 Oligasis, Llc Dual pdgf/vegf antagonists
TW201623329A (zh) 2014-06-30 2016-07-01 亞佛瑞司股份有限公司 針對骨調素截斷變異體的疫苗及單株抗體暨其用途
US20170165261A1 (en) 2014-07-01 2017-06-15 Brian Arthur Hemmings Combination of a brafv600e inhibitor and mertk inhibitor to treat melanoma
MX2016017393A (es) 2014-07-01 2017-09-05 Pfizer Diacuerpos heterodimericos biespecificos y sus usos.
CA2953149A1 (en) 2014-07-03 2016-01-07 Yale University Dickkopf2 (dkk2) inhibition suppresses tumor formation
WO2016004383A1 (en) 2014-07-03 2016-01-07 City Of Hope Tumor-selective ctla-4 antagonists
HRP20192243T1 (hr) 2014-07-03 2020-03-06 F. Hoffmann - La Roche Ag Polipeptidni ekspresijski sustavi
US20160000791A1 (en) 2014-07-07 2016-01-07 Mayo Foundation For Medical Education And Research Par1 modulation to alter myelination
CN107001451A (zh) * 2014-07-07 2017-08-01 阿勒根公司 检测组织样品中裂解的snap25的方法
CN106686977B (zh) 2014-07-09 2022-03-25 豪夫迈·罗氏有限公司 Ph调整以改善细胞库的解冻复苏
JP6876601B2 (ja) 2014-07-10 2021-05-26 アフィリス・アクチェンゲゼルシャフトＡｆｆｉｒｉｓ Ａｇ ハンチントン病の予防および／または処置における使用のための物質および方法
EP3166627A1 (de) 2014-07-11 2017-05-17 Genentech, Inc. Notch-signalweghemmung
CN106604933B (zh) 2014-07-11 2021-08-10 文塔纳医疗系统公司 抗pd-l1抗体及其诊断用途
US10166304B2 (en) 2014-07-11 2019-01-01 Regents Of The University Of Minnesota Antibody fragments for detecting cancer and methods of use
JP2017523776A (ja) 2014-07-14 2017-08-24 ジェネンテック， インコーポレイテッド 膠芽腫の診断方法及びその治療用組成物
WO2016011035A2 (en) 2014-07-15 2016-01-21 Medlmmune, Llc Neutralizing anti-influenza b antibodies and uses thereof
BR112017000672A2 (pt) 2014-07-15 2017-11-14 Genentech Inc composições para tratamento de câncer utilizando antagonistas de ligação de eixo pd-1 e inibidores de mek
HUE049261T2 (hu) 2014-07-15 2020-09-28 Yissum Research And Development Company Of The Hebrew Univ Of Jerusalem Ltd CD44 izolált polipeptidek és alkalmazásaik
US9139648B1 (en) 2014-07-15 2015-09-22 Kymab Limited Precision medicine by targeting human NAV1.9 variants for treatment of pain
CN106536559B (zh) 2014-07-17 2021-04-27 诺和诺德股份有限公司 定点诱变trem-1抗体以降低黏度
US20170227541A1 (en) 2014-07-17 2017-08-10 The Trustees Of The University Of Pennsylvania Methods for using exosomes to monitor transplanted organ status
WO2016011357A1 (en) 2014-07-18 2016-01-21 Advaxis, Inc. Combination of a pd-1 antagonist and a listeria-based vaccine for treating prostate cancer
JP6831777B2 (ja) 2014-07-21 2021-02-17 ノバルティス アーゲー Ｃｄ３３キメラ抗原受容体を使用する癌の処置
WO2016014553A1 (en) 2014-07-21 2016-01-28 Novartis Ag Sortase synthesized chimeric antigen receptors
AU2015292744C1 (en) 2014-07-21 2021-01-21 Novartis Ag Treatment of cancer using humanized anti-BCMA chimeric antigen receptor
JP2017528433A (ja) 2014-07-21 2017-09-28 ノバルティス アーゲー 低い免疫増強用量のｍＴＯＲ阻害剤とＣＡＲの組み合わせ
EP3172233B1 (de) 2014-07-22 2019-09-11 Sutro Biopharma, Inc. Anti-cd74-antikörper, zusammensetzungen mit anti-cd74-antikörpern und verfahren zur verwendung von anti-cd74-antikörpern
US10517875B2 (en) 2014-07-23 2019-12-31 Mayo Foundation for Medical Engineering and Research Targeting DNA-PKcs and B7-H1 to treat cancer
CA2956161A1 (en) 2014-07-23 2016-01-28 Ohio State Innovation Foundation Methods and compositions related to antibody fragments that bind to tumor-associated glycoprotein 72 (tag-72)
EP3172339A1 (de) 2014-07-24 2017-05-31 Boehringer Ingelheim International GmbH Biomarker zur verwendung bei der behandlung von erkrankungen im zusammenhang mit il-23a
CA2956385A1 (en) 2014-07-25 2016-01-28 Theravectys Lentiviral vectors for regulated expression of a chimeric antigen receptor molecule
US20170348402A1 (en) 2014-07-30 2017-12-07 The Research Foundation For The State University Of New York System and method for delivering genetic material or protein to cells
WO2016019300A1 (en) 2014-07-31 2016-02-04 Novartis Ag Subset-optimized chimeric antigen receptor-containing t-cells
ES2980787T3 (es) 2014-07-31 2024-10-03 Amgen Res Munich Gmbh Constructo de anticuerpo de cadena sencilla biespecífico con distribución tisular potenciada
JP7081923B2 (ja) 2014-07-31 2022-06-07 ユーエイビー リサーチ ファンデーション アポｅ模倣ペプチド及び血漿コレステロールを取り除くためのより高い効果
ES2743809T3 (es) 2014-07-31 2020-02-20 Amgen Res Munich Gmbh Constructos de anticuerpo monocatenarios biespecificos específicos de especies cruzadas optimizados
AR101669A1 (es) 2014-07-31 2017-01-04 Amgen Res Munich Gmbh Constructos de anticuerpos para cdh19 y cd3
ES3036749T3 (en) 2014-08-01 2025-09-23 Massachusetts Inst Technology Modified alginates for anti-fibrotic materials and applications
AU2015296135A1 (en) 2014-08-01 2017-02-16 The Johns Hopkins University MrgprX2/MrgprB2 expressing cell based assay to detect pseudo-allergic drug reactions and to identify blockers to prevent the adverse reactions
CN105296433B (zh) 2014-08-01 2018-02-09 中山康方生物医药有限公司 一种ctla4抗体、其药物组合物及其用途
EP2982692A1 (de) 2014-08-04 2016-02-10 EngMab AG Bispezifische Antikörper gegen CD3-Epsilon und BCMA
US10072097B2 (en) 2014-08-04 2018-09-11 Academia Sinica Compositions and methods for detection of protein S-nitrosylation and oxidation
US9982052B2 (en) 2014-08-05 2018-05-29 MabQuest, SA Immunological reagents
PT3177644T (pt) 2014-08-05 2021-01-13 MabQuest SA Reagentes imunológicos que se ligam a pd-1
GB201413913D0 (en) 2014-08-06 2014-09-17 Cantargia Ab Novel antibodies and uses thereof
EA201790336A1 (ru) 2014-08-07 2017-06-30 Новартис Аг Антитела к ангиопоэтинподобному белку 4 и способы применения
TW201613977A (en) 2014-08-07 2016-04-16 Novartis Ag Angiopoetin-like 4 (ANGPTL4) antibodies and methods of use
EA201790342A1 (ru) 2014-08-08 2017-07-31 ЭЛЕКТОР ЭлЭлСи Антитела к trem2 и способы их применения
CN106794246B (zh) 2014-08-08 2021-10-15 OncoQuest制药有限公司 肿瘤抗原特异性抗体和tlr3刺激以增强检查点干扰癌症疗法的性能
CA2954463C (en) 2014-08-08 2023-11-07 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Photo-controlled removal of targets in vitro and in vivo
EP3180024B1 (de) 2014-08-11 2022-05-18 University of Massachusetts Anti-ospa-antikörper und verfahren zur verwendung
WO2016025647A1 (en) 2014-08-12 2016-02-18 Massachusetts Institute Of Technology Synergistic tumor treatment with il-2, a therapeutic antibody, and a cancer vaccine
US10278986B2 (en) 2014-08-14 2019-05-07 The Regents Of The University Of Colorado, A Body Corporate Antibody-siRNA conjugates and uses therefor
EP3180359A1 (de) 2014-08-14 2017-06-21 Novartis AG Behandlung von krebs mit einem chimären gfr-alpha-4-antigenrezeptor
CA2957722C (en) 2014-08-19 2022-05-31 Merck Sharp & Dohme Corp. Anti-tigit antibodies
JO3663B1 (ar) 2014-08-19 2020-08-27 Merck Sharp & Dohme الأجسام المضادة لمضاد lag3 وأجزاء ربط الأنتيجين
EP3712171A1 (de) 2014-08-19 2020-09-23 Novartis AG Behandlung von krebs mit einem chimären cd123-antigenrezeptor
EP3185004A4 (de) * 2014-08-20 2018-05-30 Chugai Seiyaku Kabushiki Kaisha Verfahren zur messung der viskosität einer proteinlösung
US10961298B2 (en) 2014-08-21 2021-03-30 The Government Of The United States, Represented By The Secretary Of The Army Monoclonal antibodies for treatment of microbial infections
WO2016026978A1 (en) 2014-08-22 2016-02-25 Universite Nice Sophia Antipolis Methods and pharmaceutical compositions for treating drug addiction
WO2016026143A1 (en) 2014-08-22 2016-02-25 Huiru Wang Saccharide-based biomarkers and therapeutics
WO2016033114A1 (en) 2014-08-25 2016-03-03 The Johns Hopkins University Methods and compositions related to prostate cancer therapeutics
US10695426B2 (en) 2014-08-25 2020-06-30 Pfizer Inc. Combination of a PD-1 antagonist and an ALK inhibitor for treating cancer
WO2016030488A1 (en) 2014-08-27 2016-03-03 Innate Pharma Treatment of celiac disease
DK3186284T3 (da) 2014-08-28 2022-05-09 Bioatla Inc Betinget aktive kimæriske antigenreceptorer til modificerede t-celler
EP3186281B1 (de) 2014-08-28 2019-04-10 Halozyme, Inc. Kombinationstherapie mit einer hyaluronanabbauendem enzym und einem immun-checkpoint-hemmer
HUE049325T2 (hu) 2014-08-28 2020-09-28 Pfizer Stabilitás modulátor linker antitest-hatóanyag konjugátumokhoz történõ alkalmazásra
BR112017004270B1 (pt) 2014-09-04 2023-03-07 Stemcell Technologies Inc Método de ativação de células t ou células nk
TW201617368A (zh) 2014-09-05 2016-05-16 史坦森特瑞斯公司 新穎抗ｍｆｉ２抗體及使用方法
WO2016038610A1 (en) 2014-09-08 2016-03-17 Yeda Research And Development Co. Ltd. Compositions and methods for treating cancer resistant to a tyrosine kinase inhibitor (tki)
EP3191500A4 (de) 2014-09-08 2018-04-11 Academia Sinica Aktivierung menschlicher inkt-zellen mithilfe von glykolipiden
US10526416B2 (en) 2014-09-08 2020-01-07 Yeda Research And Development Co. Ltd. Anti-HER3 antibodies and uses of same
EP3193940A1 (de) 2014-09-10 2017-07-26 Medimmune Limited Pyrrolobenzodiazepine und konjugate daraus
JP2017531620A (ja) 2014-09-12 2017-10-26 ジェネンテック， インコーポレイテッド システイン操作抗体及びコンジュゲート
MA40579A (fr) 2014-09-12 2016-03-17 Genentech Inc Anticorps anti-cll-1 et immunoconjugués
WO2016040767A2 (en) 2014-09-12 2016-03-17 Amgen Inc. Chrdl-1 epitopes and antibodies
US20160075772A1 (en) 2014-09-12 2016-03-17 Regeneron Pharmaceuticals, Inc. Treatment of Fibrodysplasia Ossificans Progressiva
GB201416112D0 (en) 2014-09-12 2014-10-29 Medimmune Ltd Pyrrolobenzodiazepines and conjugates thereof
SI3191135T1 (sl) 2014-09-12 2021-01-29 Genentech, Inc. Anti-HER2 protitelesa in imunokonjugati
US10149913B2 (en) 2014-09-12 2018-12-11 Genentech, Inc. Anthracycline disulfide intermediates, antibody-drug conjugates and methods
TW201625689A (zh) 2014-09-12 2016-07-16 建南德克公司 抗－ｂ７－ｈ４抗體及免疫結合物
EP3191126B1 (de) 2014-09-13 2020-05-13 Novartis AG Kombinationstherapien aus alk-hemmern
IL234638A0 (en) 2014-09-14 2014-12-02 Yeda Res & Dev NMDA receptor antagonists for the treatment of Gaucher disease
ES2949173T3 (es) 2014-09-15 2023-09-26 Hoffmann La Roche Formulaciones de anticuerpo
WO2016043577A1 (en) 2014-09-16 2016-03-24 Academisch Medisch Centrum Ig-like molecules binding to bmp4
CA2944085C (en) 2014-09-16 2018-04-10 Ease Charm Limited Anti-egfr antibody and uses of same
ES2905569T3 (es) 2014-09-17 2022-04-11 Zymeworks Inc Compuestos citotóxicos y antimitóticos y métodos para utilizarlos
CA2957148A1 (en) 2014-09-17 2016-03-24 Genentech, Inc. Immunoconjugates comprising anti-her2 antibodies and pyrrolobenzodiazepines
US10577417B2 (en) 2014-09-17 2020-03-03 Novartis Ag Targeting cytotoxic cells with chimeric receptors for adoptive immunotherapy
JP2017533887A (ja) 2014-09-17 2017-11-16 ジェネンテック， インコーポレイテッド ピロロベンゾジアゼピン類及びその抗体ジスルフィドコンジュゲート
US9616114B1 (en) 2014-09-18 2017-04-11 David Gordon Bermudes Modified bacteria having improved pharmacokinetics and tumor colonization enhancing antitumor activity
US10080790B2 (en) 2014-09-19 2018-09-25 The Regents Of The University Of Michigan Staphylococcus aureus materials and methods
US10222386B2 (en) 2014-09-19 2019-03-05 The Johns Hopkins University Biomarkers of congnitive dysfunction
CA2961917A1 (en) 2014-09-22 2016-03-31 Intrinsic Lifesciences Llc Humanized anti-hepcidin antibodies and uses thereof
CA2979671C (en) 2014-09-23 2020-03-10 Genentech, Inc. Methods of using anti-cd79b immunoconjugates
WO2016046768A1 (en) 2014-09-24 2016-03-31 Friedrich Miescher Institute For Biomedical Research Lats and breast cancer
EP3851122A1 (de) 2014-09-25 2021-07-21 Aveo Pharmaceuticals Inc. Verfahren zur umkehrung von kachexie und verlängerung der überlebensdauer mit der verabreichung eines gdf15-modulators und eines antikrebsmittels
EA201790719A1 (ru) 2014-09-26 2017-07-31 Макродженикс, Инк. Биспецифические моновалентные диатела, которые способны связывать cd19 и cd3, а также их применения
MA40764A (fr) 2014-09-26 2017-08-01 Chugai Pharmaceutical Co Ltd Agent thérapeutique induisant une cytotoxicité
WO2016054101A1 (en) 2014-09-29 2016-04-07 Duke University Bispecific molecules comprising an hiv-1 envelope targeting arm
US20170211053A1 (en) 2014-09-30 2017-07-27 Danisco Us Inc. Compositions comprising beta mannanase and methods of use
WO2016054176A1 (en) 2014-09-30 2016-04-07 Danisco Us Inc Compositions comprising beta-mannanase and methods of use
EP3201334A1 (de) 2014-09-30 2017-08-09 Danisco US Inc. Zusammensetzungen mit beta-mannanase und verfahren zur verwendung
US20170211054A1 (en) 2014-09-30 2017-07-27 Dansico Us Inc. Compositions comprising beta mannanase and methods of use
EP3200822B1 (de) 2014-09-30 2021-04-14 Deutsches Krebsforschungszentrum, Stiftung des öffentlichen Rechts Bindungsmoleküle, insbesondere antikörper die sich an l1cam (cd171) binden
EP3201333A1 (de) 2014-09-30 2017-08-09 Danisco US Inc. Zusammensetzungen mit beta-mannanase und verfahren zur verwendung
SG11201702614SA (en) 2014-10-01 2017-04-27 Eagle Biolog Inc Polysaccharide and nucleic acid formulations containing viscosity-lowering agents
US10365280B2 (en) 2014-10-02 2019-07-30 Dana-Farber Cancer Institute, Inc. Compositions and methods for treating malignancies
RU2017115315A (ru) 2014-10-03 2018-11-08 Дана-Фарбер Кэнсер Инститьют, Инк. Антитела к рецептору глюкокортикоид-индуцированного фактора некроза опухоли (gitr) и способы их применения
KR20170066546A (ko) 2014-10-03 2017-06-14 노파르티스 아게 조합 요법
CA2962949C (en) 2014-10-06 2024-03-05 Dana-Farber Cancer Institute, Inc. Humanized cc chemokine receptor 4 (ccr4) antibodies and methods of use thereof
US20170248603A1 (en) 2014-10-06 2017-08-31 Dana-Farber Cancer Institute, Inc. Angiopoiten-2 biomarkers predictive of anti-immune checkpoint response
MA41044A (fr) 2014-10-08 2017-08-15 Novartis Ag Compositions et procédés d'utilisation pour une réponse immunitaire accrue et traitement contre le cancer
US9921230B2 (en) 2014-10-08 2018-03-20 Rhode Island Hospital Methods for diagnosis and treatment of concussion or brain injury
AU2015328163B2 (en) 2014-10-09 2020-10-15 Dana-Farber Cancer Institute, Inc. Multiple-variable IL-2 dose regimen for treating immune disorders
EP3204415B1 (de) 2014-10-09 2020-06-17 EngMab Sàrl Bispezifische antikörper gegen cd3epsilon und ror1
WO2016055609A1 (en) 2014-10-10 2016-04-14 Innate Pharma Cd73 blockade
SG11201702401RA (en) 2014-10-14 2017-04-27 Novartis Ag Antibody molecules to pd-l1 and uses thereof
EP3207146B1 (de) 2014-10-15 2021-09-29 Amgen Inc. Promotor und regulatorische elemente zur verbesserten expression von heterologen genen in wirtszellen
JP2017536102A (ja) 2014-10-16 2017-12-07 ジェネンテック， インコーポレイテッド 抗アルファ−シヌクレイン抗体及び使用方法
US20170247460A1 (en) 2014-10-18 2017-08-31 Pfizer Inc. Anti-il-7r antibody compositions
US9585934B2 (en) 2014-10-22 2017-03-07 Extend Biosciences, Inc. Therapeutic vitamin D conjugates
US9789197B2 (en) 2014-10-22 2017-10-17 Extend Biosciences, Inc. RNAi vitamin D conjugates
WO2016065052A1 (en) 2014-10-22 2016-04-28 Extend Biosciences, Inc. Insulin vitamin d conjugates
WO2016061632A1 (en) 2014-10-23 2016-04-28 La Trobe University Fn14-binding proteins and uses thereof
AU2015336931B2 (en) 2014-10-23 2021-04-29 Kira Biotech Pty Limited CD83 binding proteins and uses thereof
WO2016065329A1 (en) 2014-10-24 2016-04-28 The Board Of Trustees Of The Leland Stanford Junior University Compositions and methods for inducing phagocytosis of mhc class i positive cells and countering anti-cd47/sirpa resistance
EP3172329A1 (de) 2014-10-24 2017-05-31 Danisco US Inc. Verfahren zur herstellung von alkoholen durch verwendung einer tripeptidylpeptidase
CN107105707B (zh) 2014-10-24 2022-07-22 杜邦营养生物科学有限公司 脯氨酸耐受性三肽基肽酶及其用途
GB201419108D0 (en) 2014-10-27 2014-12-10 Glythera Ltd Materials and methods relating to linkers for use in antibody drug conjugates
HUE054012T2 (hu) 2014-10-29 2021-08-30 Five Prime Therapeutics Inc Kombinációs terápia rák ellen
EP3212233B1 (de) 2014-10-31 2020-06-24 Oncomed Pharmaceuticals, Inc. Kombinationstherapie zur behandlung einer krankheit
PL3212225T3 (pl) 2014-10-31 2026-03-30 The Trustees Of The University Of Pennsylvania Sposoby i kompozycje zmodyfikowanych limfocytów t
CA2966005C (en) 2014-10-31 2021-04-27 Abbvie Biotherapeutics Inc. Anti-cs1 antibodies and antibody drug conjugates
KR102546296B1 (ko) 2014-10-31 2023-06-21 더 트러스티스 오브 더 유니버시티 오브 펜실베니아 변형된 t 세포에서 유전자 발현의 변경 및 그의 용도
EP3015475A1 (de) 2014-10-31 2016-05-04 Novartis AG Säugetierzellen zur Expression von Cytomegalovirus-Antigenen
EP3217989B1 (de) 2014-10-31 2022-01-05 The Trustees of the University of Pennsylvania Zusammensetzungen und verfahren zur stimulierung und vermehrung von t-zellen
CA2966507A1 (en) 2014-11-03 2016-05-12 Genentech, Inc. Methods and biomarkers for predicting efficacy and evaluation of an ox40 agonist treatment
KR20170086540A (ko) 2014-11-03 2017-07-26 제넨테크, 인크. T 세포 면역 하위세트를 검출하기 위한 검정 및 그의 사용 방법
US10738078B2 (en) 2014-11-03 2020-08-11 Bristol-Myers Squibb Company Use of caprylic acid precipitation for protein purification
WO2016073184A1 (en) 2014-11-04 2016-05-12 Dana Farber Cancer Institute, Inc. Compositions and methods for treating multiple myeloma
PL3215527T3 (pl) 2014-11-05 2025-04-28 Annexon, Inc. Humanizowane przeciwciała przeciwko czynnikowi dopełniacza C1Q i ich zastosowanie
RU2739500C2 (ru) 2014-11-05 2020-12-25 Дженентек, Инк. Способы получения двуцепочечных белков в бактериях
CN107110851B (zh) 2014-11-05 2019-10-22 纳迈达斯生物科技中心 用于增强成像的金属复合物
CN108064308B (zh) 2014-11-05 2023-06-09 豪夫迈·罗氏有限公司 细菌中产生双链蛋白的方法
CA2961439A1 (en) 2014-11-05 2016-05-12 Genentech, Inc. Anti-fgfr2/3 antibodies and methods using same
PT3215528T (pt) 2014-11-06 2019-10-11 Hoffmann La Roche Variantes da região fc com ligação modificada ao fcrn e métodos de utilização
WO2016073157A1 (en) 2014-11-06 2016-05-12 Genentech, Inc. Anti-ang2 antibodies and methods of use thereof
WO2016073747A1 (en) 2014-11-06 2016-05-12 The Trustees Of The University Of Pennsylvania Atomic description of immune complex that causes heparin-induced thrombocytopenia
RU2713131C1 (ru) 2014-11-06 2020-02-03 Ф. Хоффманн-Ля Рош Аг ВАРИАНТЫ Fc-ОБЛАСТИ С МОДИФИЦИРОВАННЫМИ СВОЙСТВАМИ СВЯЗЫВАНИЯ FcRn И БЕЛКА А
CA2963974A1 (en) 2014-11-06 2016-05-12 Genentech, Inc. Combination therapy comprising ox40 binding agonists and tigit inhibitors
WO2016073853A1 (en) 2014-11-06 2016-05-12 Scholar Rock, Inc. Anti-pro/latent-myostatin antibodies and uses thereof
WO2016073894A1 (en) 2014-11-07 2016-05-12 Eleven Biotherapeutics, Inc. Therapeutic agents with increased ocular retention
SI3215530T1 (sl) 2014-11-07 2020-02-28 Sesen Bio, Inc. Izboljšana protitelesa IL-6
JP6929771B2 (ja) 2014-11-10 2021-09-01 ジェネンテック， インコーポレイテッド 抗インターロイキン−３３抗体及びその使用
JP2018500882A (ja) 2014-11-10 2018-01-18 ジェネンテック， インコーポレイテッド 腎症の動物モデルおよびそれを治療するための薬剤
RS62003B2 (sr) 2014-11-10 2025-01-31 Medimmune Ltd Vezujući molekuli specifični za cd73 i njihove upotrebe
EP3789403A1 (de) 2014-11-11 2021-03-10 MedImmune Limited Therapeutische kombinationen mit anti-cd73-antikörpern und a2a-rezeptorinhibitoren sowie verwendungen davon
US11154615B2 (en) 2014-11-11 2021-10-26 Chugai Seiyaku Kabushiki Kaisha Library of antigen-binding molecules including modified antibody variable region
US9926375B2 (en) 2014-11-12 2018-03-27 Tracon Pharmaceuticals, Inc. Anti-endoglin antibodies and uses thereof
CA2967222C (en) 2014-11-12 2023-10-31 Rinat Neuroscience Corp. Inhibitory chimeric antigen receptors
MX2017006167A (es) 2014-11-12 2018-03-23 Siamab Therapeutics Inc Compuestos que interactúan con glicanos y métodos de uso.
AU2015346444A1 (en) 2014-11-12 2017-05-04 Tracon Pharmaceuticals, Inc. Anti-endoglin antibodies and uses thereof
CN106999583A (zh) 2014-11-17 2017-08-01 豪夫迈·罗氏有限公司 包含ox40结合激动剂和pd‑1轴结合拮抗剂的组合疗法
WO2016079736A2 (en) 2014-11-17 2016-05-26 Yeda Research And Development Co. Ltd. Methods of treating diseases related to mitochondrial function
US9982057B2 (en) 2014-11-17 2018-05-29 Pelican Therapeutics, Inc. Human TNFRSF25 antibody
WO2016081423A1 (en) 2014-11-18 2016-05-26 Janssen Pharmaceutica Nv Cd47 antibodies, methods, and uses
JP6779876B2 (ja) 2014-11-19 2020-11-04 ジェネンテック， インコーポレイテッド 抗トランスフェリン受容体抗体及びその使用方法
EP3221349B1 (de) 2014-11-19 2020-11-04 Axon Neuroscience SE Humanisierte tau-antikörper bei alzheimer-krankheit
EP3221364B1 (de) 2014-11-19 2020-12-16 Genentech, Inc. Antikörper gegen bace1 und deren verwendung zur immuntherapie von nervenerkrankungen
WO2016079708A1 (en) 2014-11-19 2016-05-26 Nestec S.A. Antibodies against serotonin, tryptophan and kynurenine metabolites and uses thereof
EP3221361B1 (de) 2014-11-19 2021-04-21 Genentech, Inc. Multispezifische anti-transferrin-rezeptor- / anti-bace1-antikörper und verfahren zur verwendung
EP3023437A1 (de) 2014-11-20 2016-05-25 EngMab AG Bispezifische Antikörper gegen CD3epsilon und BCMA
SG11201704056XA (en) 2014-11-20 2017-06-29 Hoffmann La Roche Combination therapy of t cell activating bispecific antigen binding molecules cd3 abd folate receptor 1 (folr1) and pd-1 axis binding antagonists
EP3221445B1 (de) 2014-11-20 2021-07-14 The Regents of The University of California Zusammensetzungen und verfahren in zusammenhang mit hämatologischer erholung
AU2015349759B2 (en) 2014-11-21 2022-01-06 The University Of North Carolina At Chapel Hill Aav vectors targeted to the central nervous system
EP3222637A4 (de) * 2014-11-21 2018-10-31 Astellas Pharma Inc. Neuartiges bispezifisches antikörperformat
JP6805142B2 (ja) 2014-11-21 2020-12-23 ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ Ｃｄ７３に対する抗体およびその使用
GB201420852D0 (en) 2014-11-24 2015-01-07 Genevillage Kft Method
WO2016084062A1 (en) 2014-11-25 2016-06-02 Rappaport Family Institute For Research In The Medical Sciences Novel epitope as a target for therapy of inflammatory autoimmune diseases and graft rejection
CN107148285B (zh) 2014-11-25 2022-01-04 Adc治疗股份有限公司 吡咯并苯并二氮杂䓬-抗体缀合物
WO2016086036A2 (en) 2014-11-25 2016-06-02 Bristol-Myers Squibb Company Methods and compositions for 18f-radiolabeling of biologics
EP3224280A1 (de) 2014-11-26 2017-10-04 Millennium Pharmaceuticals, Inc. Vedolizumab zur behandlung von fistelbildendem morbus crohn
FI3223848T3 (fi) 2014-11-27 2025-02-28 Zymeworks Bc Inc Menetelmiä käyttää bispesifisiä antigeenia sitovia rakenteita, jotka kohdistuvat her2:een
KR101760467B1 (ko) 2014-12-01 2017-07-24 중앙대학교 산학협력단 수태능력 관련 단백질 마커를 이용한 동물의 산자수 예측 방법과 클로르테트라사이클린 염색법을 이용한 동물의 정액 품질 및 산자수의 예측 방법
WO2016087514A1 (en) 2014-12-02 2016-06-09 Cemm - Forschungszentrum Für Molekulare Medizin Gmbh Anti-mutant calreticulin antibodies and their use in the diagnosis and therapy of myeloid malignancies
WO2016087889A1 (en) 2014-12-03 2016-06-09 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and pharmaceutical compositions using orexins (oxa, oxb) for the treatment of prostate cancers
WO2016087416A1 (en) 2014-12-03 2016-06-09 F. Hoffmann-La Roche Ag Multispecific antibodies
US20180334490A1 (en) 2014-12-03 2018-11-22 Qilong H. Wu Methods for b cell preconditioning in car therapy
MA41119A (fr) 2014-12-03 2017-10-10 Acceleron Pharma Inc Méthodes de traitement de syndromes myélodysplasiques et d'anémie sidéroblastique
CA2969689A1 (en) 2014-12-03 2016-06-09 Genentech, Inc. Quaternary amine compounds and antibody-drug conjugates thereof
ES2935274T3 (es) 2014-12-05 2023-03-03 Merck Patent Gmbh Anticuerpo con intercambio de dominios
MX386587B (es) 2014-12-05 2025-03-19 Genentech Inc ANTICUERPOS ANTI-CD79b Y MÉTODOS DE USO.
EP3227337A1 (de) 2014-12-05 2017-10-11 F. Hoffmann-La Roche AG Verfahren und zusammensetzungen zur krebsbehandlung mit pd-1-achsenantagonisten und hpk1-antagonisten
MX2017007136A (es) 2014-12-05 2017-12-04 Immunext Inc Identificacion de vsig8 como el receptor vista putativo y su uso para producir moduladores vista/vsig8.
KR102657306B1 (ko) 2014-12-08 2024-04-12 버그 엘엘씨 전립선암의 진단 및 치료에서 필라민을 포함하는 마커의 용도
AU2015360903B2 (en) 2014-12-08 2021-03-25 Dana-Farber Cancer Institute, Inc. Methods for upregulating immune responses using combinations of anti-RGMB and anti-PD-1 agents
EP3031822A1 (de) 2014-12-08 2016-06-15 Novartis AG Cytomegalovirus-Antigene
TWI595006B (zh) 2014-12-09 2017-08-11 禮納特神經系統科學公司 抗ｐｄ－１抗體類和使用彼等之方法
EP3229844B1 (de) 2014-12-09 2020-03-04 AbbVie Inc. Antikörper-wirkstoff-konjugate mit zelldurchlässigen bcl-xl-inhibitoren
RU2017123942A (ru) 2014-12-09 2019-01-11 Эббви Инк. Ингибирующие bcl-xl соединения, обладающие низкой клеточной проницаемостью, и коньюгаты антитело-лекарственное средство, включающие их
MX2017007535A (es) 2014-12-09 2017-08-10 Merck Sharp & Dohme Sistema y metodos para derivar biomarcadores de firmas geneticas de la respuesta a antagonistas de muerte programada 1 (pd-1).
SG11201703750XA (en) 2014-12-10 2017-06-29 Genentech Inc Blood brain barrier receptor antibodies and methods of use
KR102693806B1 (ko) 2014-12-11 2024-08-09 피에르 파브르 메디카먼트 항-c10orf54 항체들 및 그들의 용도들
KR20170093182A (ko) 2014-12-11 2017-08-14 인바이오모션 에스.엘. 인간 c-maf에 대한 결합 구성원
US10093733B2 (en) 2014-12-11 2018-10-09 Abbvie Inc. LRP-8 binding dual variable domain immunoglobulin proteins
EP3699589A1 (de) 2014-12-12 2020-08-26 Celcuity Inc. Verfahren zur messung der aktivität des erbb-signalwegs zur diagnose und behandlung von krebspatienten
JP6743015B2 (ja) 2014-12-15 2020-08-19 バイエル ファーマ アクチエンゲゼルシャフト Ｋｓｐ阻害剤の脱グリコシル化抗ｔｗｅａｋｒ抗体との抗体薬物複合体（ａｄｃ類）
BR112017011170A2 (pt) 2014-12-18 2018-02-27 Hoffmann La Roche método para determinar a citotoxicidade dependente do complemento de uma composição
WO2016100825A1 (en) 2014-12-18 2016-06-23 Danisco Us Inc Engineered multifunctional enzymes and methods of use
WO2016100615A2 (en) 2014-12-18 2016-06-23 The University Of Chicago Methods and composition for neutralization of influenza
US20170362621A1 (en) 2014-12-18 2017-12-21 Danisco Us Inc. Engineered multifunctional enzymes and methods of use
US10961580B2 (en) 2014-12-19 2021-03-30 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods for predicting graft alterations
EP3233916A4 (de) 2014-12-19 2018-06-06 Alder Biopharmaceuticals, Inc. Humanisierte anti-acth-antikörper und verwendungen davon
EP3233120A4 (de) 2014-12-19 2018-05-30 Monash University Il-21-antikörper
EA201791366A1 (ru) 2014-12-19 2018-02-28 Чугаи Сейяку Кабусики Кайся Антитела к c5 и способы их применения
EP3233918A1 (de) 2014-12-19 2017-10-25 Novartis AG Kombinationstherapien
UY36449A (es) 2014-12-19 2016-07-29 Novartis Ag Composiciones y métodos para anticuerpos dirigidos a bmp6
MX2017005774A (es) 2014-12-19 2017-07-28 Chugai Pharmaceutical Co Ltd Anticuerpos antimiostatina, polipeptidos que contienen regiones fc variantes, y metodos de uso.
US10040858B2 (en) 2014-12-22 2018-08-07 Five Prime Therapeutics, Inc. Anti-CSF1R antibodies for treating PVNS
CA2971734C (en) 2014-12-22 2025-11-18 Pd-1 Acquisition Group, Llc Anti-pd-1 antibodies
AR103172A1 (es) 2014-12-22 2017-04-19 Novartis Ag Reducción selectiva de residuos de cisteina en anticuerpos il-17
EP3789039A1 (de) 2014-12-22 2021-03-10 The Rockefeller University Anti-mertk-antikörper und verwendungen davon
AR103173A1 (es) 2014-12-22 2017-04-19 Novarits Ag Productos farmacéuticos y composiciones líquidas estables de anticuerpos il-17
DK3193901T3 (en) 2014-12-23 2018-05-28 4D Pharma Res Ltd PIRIN POLYPEPTIDE AND IMMUNMODULATION
AR103268A1 (es) 2014-12-23 2017-04-26 Bristol Myers Squibb Co Anticuerpos contra tigit
MA50819A (fr) 2014-12-23 2021-04-07 Immatics Biotechnologies Gmbh Nouveaux peptides et combinaison de peptides à utiliser dans l'immunothérapie contre le carcinome hépatocellulaire (hcc) et d'autres cancers
GB201501017D0 (en) 2014-12-23 2015-03-04 Immatics Biotechnologies Gmbh Novel peptides and combination of peptides for use in immunotherapy against hepatocellular carcinoma (HCC) and other cancers
PE20171138A1 (es) 2014-12-23 2017-08-09 4D Pharma Res Ltd Modulacion inmunitaria
US20170360929A1 (en) 2014-12-23 2017-12-21 Pfizer Inc. Stable aqueous antibody formulation for anti tnf alpha antibodies
JP6904905B2 (ja) 2014-12-24 2021-07-21 ミレニアム ファーマシューティカルズ， インコーポレイテッドＭｉｌｌｅｎｎｉｕｍ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． 抗α４β７インテグリン抗体による治療の結果の予測
HUE053145T2 (hu) 2014-12-31 2021-06-28 Checkmate Pharmaceuticals Inc Kombinált tumor immunterápia
US20160200815A1 (en) 2015-01-05 2016-07-14 Jounce Therapeutics, Inc. Antibodies that inhibit tim-3:lilrb2 interactions and uses thereof
WO2016112270A1 (en) 2015-01-08 2016-07-14 Biogen Ma Inc. Lingo-1 antagonists and uses for treatment of demyelinating disorders
NL2014108B1 (en) 2015-01-09 2016-09-30 Aduro Biotech Holdings Europe B V Altered april binding antibodies.
WO2016112916A1 (en) 2015-01-12 2016-07-21 Rigshospitalet Copenhagen University Hospital Antibodies, compounds and derivatives thereof for use in the treatment of male infertility
WO2016115275A1 (en) 2015-01-13 2016-07-21 City Of Hope Ctla4-binding protein peptide-linker masks
SG11201705721WA (en) 2015-01-14 2017-08-30 Brigham & Womens Hospital Inc Treatment of cancer with anti-lap monoclonal antibodies
CN107405410B (zh) 2015-01-15 2021-08-10 OncoQuest制药有限公司 增加抗癌剂向靶递送的方法
AU2016206475B2 (en) 2015-01-16 2021-11-04 City Of Hope Cell penetrating antibodies
US10495645B2 (en) 2015-01-16 2019-12-03 Academia Sinica Cancer markers and methods of use thereof
US9975965B2 (en) 2015-01-16 2018-05-22 Academia Sinica Compositions and methods for treatment and detection of cancers
US20180016327A1 (en) 2015-01-22 2018-01-18 Chugai Seiyaku Kabushiki Kaisha A Combination of Two or More Anti-C5 Antibodies and Methods of Use
EP3048114A1 (de) 2015-01-22 2016-07-27 Novartis AG Cytomegalovirus-Antigene und Verwendungen davon
AR103488A1 (es) 2015-01-23 2017-05-10 Sanofi Sa Anticuerpos anti-cd3, anticuerpos anti-cd123 y anticuerpos biespecíficos que se unen específicamente a cd3 y/o cd123
EP3047856A1 (de) 2015-01-23 2016-07-27 Novartis AG Cmv-antigene und ihre verwendungen
EP3247281B1 (de) 2015-01-23 2020-12-02 The University of North Carolina at Chapel Hill Vorrichtungen, systeme und verfahren zur vorklinischen ultraschallabbildung von patienten
TWI710571B (zh) 2015-01-24 2020-11-21 中央研究院 腫瘤標記及其使用方法
AU2015378564A1 (en) 2015-01-24 2017-07-13 Academia Sinica Novel glycan conjugates and methods of use thereof
CN107250161A (zh) 2015-01-26 2017-10-13 宏观基因有限公司 包含dr5‑结合结构域的多价分子
JP6846351B2 (ja) 2015-01-27 2021-03-24 ザ・ジョンズ・ホプキンス・ユニバーシティー 粘膜表面における活性薬剤の増強された輸送のための低張ヒドロゲル製剤
EP3250927B1 (de) 2015-01-28 2020-02-19 H. Hoffnabb-La Roche Ag Genexpressionsmarker und behandlung von multipler sklerose
WO2016120753A1 (en) 2015-01-28 2016-08-04 Pfizer Inc. Stable aqueous anti- vascular endothelial growth factor (vegf) antibody formulation
AU2016210835B2 (en) 2015-01-29 2021-01-21 Technophage, Investigação E Desenvolvimento Em Biotecnologia, Sa Antibody molecules and peptide delivery systems for use in alzheimer's disease and related disorders
CN114702581B (zh) 2015-01-30 2025-08-01 台湾地区“中央研究院” 增进抗体功效的通用糖型组合物及方法
WO2016122865A1 (en) 2015-01-30 2016-08-04 Salk Institute For Biological Studies Compositions and methods for treating age-related diabetes and related disorders
AU2015380397B2 (en) 2015-01-31 2021-10-21 The Trustees Of The University Of Pennsylvania Compositions and methods for T cell delivery of therapeutic molecules
CN104593416A (zh) * 2015-02-02 2015-05-06 上海交通大学 pHAb-FAST人源抗体表达载体系统及其使用方法
WO2016126608A1 (en) 2015-02-02 2016-08-11 Novartis Ag Car-expressing cells against multiple tumor antigens and uses thereof
WO2016125017A1 (en) 2015-02-03 2016-08-11 Universite Catholique De Louvain Anti-garp protein and uses thereof
EP3254110B1 (de) 2015-02-03 2020-03-18 Ventana Medical Systems, Inc. Histochemischer test zur beurteilung der expression des liganden 1 für programmierten zelltod (pd-l1)
CN107636170A (zh) 2015-02-04 2018-01-26 健泰科生物技术公司 突变型Smoothened及其使用方法
KR20170120616A (ko) 2015-02-04 2017-10-31 베링거 인겔하임 인터내셔날 게엠베하 염증성 질환의 치료 방법
CN114773469B (zh) 2015-02-05 2025-12-19 中外制药株式会社 包含离子浓度依赖性的抗原结合结构域的抗体，fc区变体，il-8-结合抗体及其应用
JP6724023B2 (ja) 2015-02-09 2020-07-15 リサーチ ディベロップメント ファウンデーション 改善された補体活性化を示す操作された免疫グロブリンｆｃポリペプチド
WO2016128349A1 (en) 2015-02-09 2016-08-18 INSERM (Institut National de la Santé et de la Recherche Médicale) Antibodies specific to glycoprotein (gp) of ebolavirus and uses for the treatment and diagnosis of ebola virus infection
CN105461809B (zh) 2015-02-11 2018-10-12 康融东方（广东）医药有限公司 Pcsk9抗体、其药物组合物及其用途
WO2016128523A1 (en) 2015-02-12 2016-08-18 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods for predicting the responsiveness of a patient affected with malignant hematological disease to chemotherapy treatment and methods of treatment of such disease
WO2016131503A1 (en) 2015-02-17 2016-08-25 Arsanis Biosciences Gmbh Antibodies targeting a galactan-based o-antigen of k. pneumoniae
US11000548B2 (en) 2015-02-18 2021-05-11 Enlivex Therapeutics Ltd Combination immune therapy and cytokine control therapy for cancer treatment
US11596652B2 (en) 2015-02-18 2023-03-07 Enlivex Therapeutics R&D Ltd Early apoptotic cells for use in treating sepsis
US11318163B2 (en) 2015-02-18 2022-05-03 Enlivex Therapeutics Ltd Combination immune therapy and cytokine control therapy for cancer treatment
US11304976B2 (en) 2015-02-18 2022-04-19 Enlivex Therapeutics Ltd Combination immune therapy and cytokine control therapy for cancer treatment
US11497767B2 (en) 2015-02-18 2022-11-15 Enlivex Therapeutics R&D Ltd Combination immune therapy and cytokine control therapy for cancer treatment
US11512289B2 (en) 2015-02-18 2022-11-29 Enlivex Therapeutics Rdo Ltd Combination immune therapy and cytokine control therapy for cancer treatment
KR20190049940A (ko) 2015-02-19 2019-05-09 화이자 인코포레이티드 나이세리아 메닌지티디스 조성물 및 그의 방법
US10202444B2 (en) 2015-02-24 2019-02-12 Rpeptide, Llc Anti-tau antibodies
US10479825B2 (en) 2015-02-25 2019-11-19 Vanderbilt University Antibody-mediated neutralization of Marburg virus
KR20170132171A (ko) 2015-02-26 2017-12-01 메르크 파텐트 게엠베하 암 치료를 위한 ｐｄ­１ ／ ｐｄ­ｌ１ 저해제
EP3978530A1 (de) 2015-02-26 2022-04-06 F. Hoffmann-La Roche AG Integrin-beta7-antagonisten und verfahren zur behandlung von morbus crohn
CA2977607A1 (en) 2015-02-26 2016-09-01 Jacob Schneiderman Methods and compositions relating to leptin antagonists
EP3061826A1 (de) 2015-02-27 2016-08-31 Novartis AG Flavivirus-replikons
TWI759261B (zh) 2015-02-27 2022-04-01 日商中外製藥股份有限公司 Ｉｌ－６受體抗體用於製備醫藥組成物的用途
AR103726A1 (es) 2015-02-27 2017-05-31 Merck Sharp & Dohme Cristales de anticuerpos monoclonales anti-pd-1 humanos
HK1246394A1 (zh) 2015-03-02 2018-09-07 Sarcotein Diagnostics Llc 13+/17+bin1表达作为心脏病症的标记
WO2016141111A1 (en) 2015-03-03 2016-09-09 Xoma (Us) Llc Treatment of post-prandial hyperinsulinemia and hypoglycemia after bariatric surgery
PL3265123T3 (pl) 2015-03-03 2023-03-13 Kymab Limited Przeciwciała, zastosowania i sposoby
EP3761036B1 (de) 2015-03-03 2025-11-19 ARK Diagnostics, Inc. Pregabalinimmunoassays
US9139653B1 (en) 2015-04-30 2015-09-22 Kymab Limited Anti-human OX40L antibodies and methods of treatment
MX386547B (es) 2015-03-04 2025-03-19 Merck Sharp & Dohme Combinación de un antagonista con muerte programada 1 (pd-1) y eribulina para el tratamiento de cáncer.
KR102357312B1 (ko) 2015-03-04 2022-02-03 아이쥐엠 바이오사이언스 인코포레이티드 Ｃｄ20 결합 분자 및 그의 용도
KR20240064733A (ko) 2015-03-04 2024-05-13 머크 샤프 앤드 돔 코포레이션 암을 치료하기 위한 pd-1 길항제 및 vegfr/fgfr/ret 티로신 키나제 억제제의 조합
WO2016141230A1 (en) 2015-03-05 2016-09-09 Sirenas Llc Cyclic peptide analogs and conjugates thereof
US11447569B2 (en) 2015-03-06 2022-09-20 Public University Corporation Yokohama City University Anti-PAD4 antibody
MA41636A (fr) 2015-03-06 2018-01-09 Millennium Pharm Inc Méthode de traitement de la cholangite sclérosante primitive
SG11201706659WA (en) 2015-03-06 2017-09-28 Csl Behring Recombinant Facility Ag Modified von willebrand factor having improved half-life
HK1248812A1 (zh) 2015-03-06 2018-10-19 Dana-Farber Cancer Institute, Inc. 预测在食管胃癌中pd-1通路抑制剂响应的pd-l2生物标记
HRP20192217T1 (hr) 2015-03-06 2020-02-21 F. Hoffmann - La Roche Ag ULTRA-PROČIŠĆENI DsbA I DsbC TE POSTUPCI NJIHOVE IZRADE I UPORABE
GB201503967D0 (en) 2015-03-09 2015-04-22 Univ Glasgow Biocompatible implants for use in tendon therapy
CA2978631C (en) 2015-03-09 2023-06-27 Agensys, Inc. Antibody drug conjugates (adc) that bind to flt3 proteins
AU2016228852A1 (en) 2015-03-10 2017-10-19 The Regents Of The University Of California Anti-alphavbeta1 integrin inhibitors and methods of use
WO2016142385A1 (en) 2015-03-11 2016-09-15 INSERM (Institut National de la Santé et de la Recherche Médicale) Method for diagnosing ocular anterior chamber dysgenesis
BR112017018365A2 (pt) 2015-03-13 2018-04-10 Bristol-Myers Squibb Company uso de lavagens alcalinas durante cromatografia para remoção de impurezas
EP3067062A1 (de) 2015-03-13 2016-09-14 Ipsen Pharma S.A.S. Kombination von tasquinimod oder einem pharmazeutisch zulässigen salz davon und pd1 und/oder pdl1-hemmer zur verwendung als medikament
EP3271723A1 (de) 2015-03-16 2018-01-24 F. Hoffmann-La Roche AG Verfahren für den nachweis und die quantifizierung von il-13 und verwendungen in der diagnostik und behandlung von th2-assoziierten erkrankungen
KR102618312B1 (ko) 2015-03-17 2023-12-28 메모리얼 슬로안 케터링 캔서 센터 항muc16 항체 및 그의 용도
WO2016145536A1 (en) 2015-03-18 2016-09-22 Immunobiochem Corporation Conjugates for the treatment of cancer targeted at intracellular tumor-associated antigens
KR20170128256A (ko) 2015-03-18 2017-11-22 시애틀 지네틱스, 인크. Cd48 항체 및 이의 접합체
IL237852A0 (en) 2015-03-19 2016-03-24 Yeda Res & Dev Antibodies against amphigoline, medical preparations containing them and their use
WO2016146833A1 (en) 2015-03-19 2016-09-22 F. Hoffmann-La Roche Ag Biomarkers for nad(+)-diphthamide adp ribosyltransferase resistance
KR102046862B1 (ko) 2015-03-20 2019-11-20 화이자 인코포레이티드 Cti 약물작용발생단을 함유하는 이관능성 세포독성제
US20180105554A1 (en) 2015-03-20 2018-04-19 Bristol-Myers Squibb Company Use of dextran sulfate to enhance protein a affinity chromatography
US20180105555A1 (en) 2015-03-20 2018-04-19 Bristol-Myers Squibb Company Use of dextran for protein purification
MA53297A (fr) 2015-03-23 2022-05-04 Jounce Therapeutics Inc Anticorps anti-icos
EP3273981B1 (de) 2015-03-24 2020-04-29 INSERM - Institut National de la Santé et de la Recherche Médicale Verfahren und pharmazeutische zusammensetzung zur verwendung bei der behandlung von diabetes
EP3274468B1 (de) 2015-03-25 2019-02-20 Alexion Pharmaceuticals, Inc. Verfahren zur bestimmung der c3- und c5- konvertase protease-aktivität im alternativen komplement-pfad
EP3274724A1 (de) 2015-03-25 2018-01-31 Alexion Pharmaceuticals, Inc. Verfahren zur messung der proteaseaktivität von faktor d des alternativen komplementweges
EP4218771A1 (de) 2015-03-27 2023-08-02 Yeda Research and Development Co. Ltd Verfahren zur behandlung von motoneuronenerkrankungen
IL301919A (en) 2015-03-27 2023-06-01 Immatics Biotechnologies Gmbh Innovative peptides and a combination of peptides for use in immunotherapy against various tumors
CA2981504C (en) 2015-03-30 2023-10-24 City Of Hope Mechanically interlocking complexes
GB201505585D0 (en) 2015-03-31 2015-05-13 Immatics Biotechnologies Gmbh Novel peptides and combination of peptides and scaffolds for use in immunotherapy against renal cell carinoma (RCC) and other cancers
EP3277306B1 (de) 2015-04-01 2023-02-22 Hadasit Medical Research Services and Development Ltd. Inhibitoren der neuroligin-4-neurexin-1-beta-protein-protein-wechselwirkung zur verwendung in der behandlung von lebererkrankungen
KR20170134525A (ko) 2015-04-02 2017-12-06 메모리얼 슬로안-케터링 캔서 센터 Tnfrsf14 / hvem 단백질 및 이의 이용 방법
EP3954710A3 (de) 2015-04-02 2022-07-20 Intervet International B.V. Antikörper gegen interleukin-4-rezeptor-alpha des hundes
CN114456272A (zh) 2015-04-03 2022-05-10 优瑞科生物技术公司 靶向afp肽/mhc复合体的构建体及其用途
US11279768B1 (en) 2015-04-03 2022-03-22 Precision Biologics, Inc. Anti-cancer antibodies, combination therapies, and uses thereof
ES2820768T3 (es) 2015-04-03 2021-04-22 Xoma Technology Ltd Tratamiento del cáncer usando inhibidores de TGF-beta y PD-1
MA41919A (fr) 2015-04-06 2018-02-13 Acceleron Pharma Inc Hétéromultimères alk4:actriib et leurs utilisations
EP3280435B1 (de) 2015-04-06 2021-06-02 Acceleron Pharma Inc. Heteromultimere des tgf-beta-superfamilie-typ-i- und typ-ii-rezeptors und verwendungen davon
HK1256681A1 (zh) 2015-04-06 2019-10-04 President And Fellows Of Harvard College 用於非清髓性预处理的组合物和方法
EP4212175A1 (de) 2015-04-06 2023-07-19 Bioverativ USA Inc. Humanisierte anti-c1s-antikörper und verfahren zur verwendung davon
ES2912276T3 (es) 2015-04-07 2022-05-25 Ela Pharma Ltd Composiciones para tratar y/o prevenir necrosis celular o tisular que seleccionan como diana específicamente catepsina C y/o CELA1 y/o CELA3A y/o enzimas estructuralmente relacionadas con las mismas
MX2017012805A (es) 2015-04-07 2018-04-11 Genentech Inc Complejo de unión a antígenos con actividad agonista y métodos de uso.
EP3991748A3 (de) 2015-04-07 2022-08-24 Alector LLC Anti-sortilin-antikörper und verfahren zur verwendung davon
WO2016164608A1 (en) 2015-04-07 2016-10-13 Alector Llc Methods of screening for sortilin binding antagonists
WO2016162368A1 (en) 2015-04-07 2016-10-13 INSERM (Institut National de la Santé et de la Recherche Médicale) Non-invasive imaging of tumor pd-l1 expression
PL3280729T3 (pl) 2015-04-08 2022-08-22 Novartis Ag Terapie cd20, terapie cd22 i terapie skojarzone komórką eksprymującą chimeryczny receptor antygenowy (car) cd19
US11135282B2 (en) 2015-04-08 2021-10-05 Dana-Farber Cancer Institute, Inc. Humanized influenza monoclonal antibodies and methods of use thereof
EP3281016A1 (de) 2015-04-10 2018-02-14 Applied Proteomics Inc. Proteinbiomarkertafeln zur detektion von kolorektalkrebs und fortgeschrittenem adenom
JP6957035B2 (ja) 2015-04-10 2021-11-02 トーマス・ジェファーソン・ユニバーシティ 対象への移植用の免疫原性拡散チャンバおよびその調製方法
HUE057285T2 (hu) 2015-04-13 2022-04-28 Pfizer Terápiás ellenanyagok és alkalmazásaik
CA2980460A1 (en) 2015-04-13 2016-10-20 Five Prime Therapeutics, Inc. Combination therapy for cancer
TWI700298B (zh) 2015-04-13 2020-08-01 美商輝瑞股份有限公司 靶向ｂ細胞成熟抗原之嵌合型抗原受體類
ES2841437T3 (es) 2015-04-13 2021-07-08 Inst Nat Sante Rech Med Métodos y composiciones farmacéuticas para el tratamiento de enfermedades hemorrágicas
MX2017013156A (es) 2015-04-14 2018-02-21 Boehringer Ingelheim Int Metodos para tratar enfermedades.
GB201506411D0 (en) 2015-04-15 2015-05-27 Bergenbio As Humanized anti-axl antibodies
GB201506402D0 (en) 2015-04-15 2015-05-27 Berkel Patricius H C Van And Howard Philip W Site-specific antibody-drug conjugates
WO2016169807A1 (en) 2015-04-22 2016-10-27 Nestec S.A. Biomarkers for predicting degree of weight loss in female subjects
AU2016249837A1 (en) 2015-04-17 2017-09-28 Arsanis Biosciences Gmbh Anti-staphylococcus aureus antibody combination preparation
WO2016168133A1 (en) 2015-04-17 2016-10-20 Merck Sharp & Dohme Corp. Blood-based biomarkers of tumor sensitivity to pd-1 antagonists
PL3283524T3 (pl) 2015-04-17 2023-06-12 Amgen Research (Munich) Gmbh Konstrukty biswoistego przeciwciała dla cdh3 i cd3
AU2016252609B2 (en) 2015-04-20 2022-06-30 Sumitomo Pharma Oncology, Inc. Predicting response to alvocidib by mitochondrial profiling
US10954515B2 (en) 2015-04-21 2021-03-23 Institut Gustave Roussy Therapeutic methods, products and compositions inhibiting ZNF555
JP6815331B2 (ja) 2015-04-21 2021-01-20 ジェネンテック， インコーポレイテッド 前立腺がんの分析のための組成物及び方法
JP6803339B2 (ja) 2015-04-21 2020-12-23 エンリヴェックス セラピューティクス リミテッド 治療用のプールされた血液アポトーシス細胞調製物及びそれらの使用
GB201506869D0 (en) 2015-04-22 2015-06-03 Ucb Biopharma Sprl Method
WO2016169806A1 (en) 2015-04-22 2016-10-27 Nestec S.A. Biomarkers for predicting degree of weight loss in male subjects
EP3286224A4 (de) 2015-04-22 2018-11-14 Immunomedics, Inc. Isolierung, detektion, diagnose und/oder charakterisierung von zirkulierenden trop-2-positiven krebszellen
WO2016170027A1 (en) 2015-04-22 2016-10-27 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and pharmaceutical compositions for the treatment of th17 mediated diseases
GB201506870D0 (en) 2015-04-22 2015-06-03 Ucb Biopharma Sprl Method
WO2016172583A1 (en) 2015-04-23 2016-10-27 Novartis Ag Treatment of cancer using chimeric antigen receptor and protein kinase a blocker
EP3286315B1 (de) 2015-04-24 2021-05-26 F. Hoffmann-La Roche AG Verfahren zur identifizierung von bakterien mit bindenden polypeptiden
CA2980189A1 (en) 2015-04-24 2016-10-27 Genentech, Inc. Multispecific antigen-binding proteins
TWI728953B (zh) 2015-04-24 2021-06-01 美商安美基公司 治療或預防偏頭痛之方法
GB201507030D0 (en) 2015-04-24 2015-06-10 Immatics Biotechnologies Gmbh Immunotherapy against lung cancers, in particular NSCLC
AU2016255749B2 (en) 2015-04-27 2021-10-14 Dana-Farber Cancer Institute, Inc. Compositions and methods for assessing toxicity using Dynamic BH3 profiling
KR20170140318A (ko) 2015-04-29 2017-12-20 리제너론 파마슈티칼스 인코포레이티드 진행성 골화성 섬유이형성증의 치료
EP3778640A1 (de) 2015-05-01 2021-02-17 Genentech, Inc. Maskierte anti-cd3-antikörper und verfahren zur verwendung
EP3288977B1 (de) 2015-05-01 2021-11-17 Dana-Farber Cancer Institute, Inc. Verfahren zur vermittlung der cytokinexpression mit anti-ccr4-antikörpern
WO2016179194A1 (en) 2015-05-04 2016-11-10 Jounce Therapeutics, Inc. Lilra3 and method of using the same
GB201507719D0 (en) 2015-05-06 2015-06-17 Immatics Biotechnologies Gmbh Novel peptides and combination of peptides and scaffolds thereof for use in immunotherapy against colorectal carcinoma (CRC) and other cancers
EA201792442A1 (ru) 2015-05-06 2018-06-29 Янссен Байотек, Инк. Биспецифические агенты, связывающие простатический специфический мембранный антиген (psma), и их применение
EP3292152A1 (de) 2015-05-07 2018-03-14 Agenus Inc. Anti-ox40-antikörper und verfahren zur verwendung davon
US10676723B2 (en) 2015-05-11 2020-06-09 David Gordon Bermudes Chimeric protein toxins for expression by therapeutic bacteria
CN116196414A (zh) 2015-05-11 2023-06-02 豪夫迈·罗氏有限公司 治疗狼疮性肾炎的组合物和方法
EP3294280A1 (de) 2015-05-11 2018-03-21 Yeda Research and Development Co., Ltd. Citrinhemmer zur behandlung von krebs
DK3294770T4 (da) 2015-05-12 2024-05-21 Hoffmann La Roche Terapeutiske og diagnostiske fremgangsmåder til cancer
US12595297B2 (en) 2015-05-12 2026-04-07 In3Bio Ltd. Methods and compositions for inhibition of EGF/EGFR pathway in combination with tyrosine kinase inhibitors
WO2016200543A2 (en) 2015-05-13 2016-12-15 The Trustees Of The University Of Pennsylvania Aav-mediated expression of anti-inluenza antibodies and methods of use thereof
DK3447075T3 (da) 2015-05-15 2023-11-13 Massachusetts Gen Hospital Antagonistiske antistoffer af antitumornekrosefaktorreceptor-superfamilien
CN107849102B (zh) 2015-05-15 2022-05-13 希望之城 嵌合抗原受体组合物
ES3063952T3 (en) 2015-05-18 2026-04-21 Agensys Inc Antibodies that bind to axl proteins
WO2016187354A1 (en) 2015-05-18 2016-11-24 Agensys, Inc. Antibodies that bind to axl proteins
EP3770168A1 (de) 2015-05-18 2021-01-27 TCR2 Therapeutics Inc. Zusammensetzungen und verfahren zur tcr-reprogrammierung mithilfe von fusionsproteinen
HUE045585T2 (hu) 2015-05-18 2020-01-28 Tolero Pharmaceuticals Inc Megnövelt biológiai hozzáférhetõséggel rendelkezõ Alvocidib gyógyszer-elõanyagok
WO2016185457A1 (en) 2015-05-19 2016-11-24 Yeda Research And Development Co. Ltd. Methods of promoting lymphangiogenesis
WO2016185481A2 (en) 2015-05-20 2016-11-24 Yeda Research And Development Co. Ltd. Method of targeting senescent cells
EP3297672B1 (de) 2015-05-21 2021-09-01 Harpoon Therapeutics, Inc. Trispezifische bindungsproteine und verfahren zur verwendung
CN107921126A (zh) 2015-05-22 2018-04-17 转化药物开发有限责任公司 苯甲酰胺和活性化合物的组合物及其使用方法
EP3303391A1 (de) 2015-05-26 2018-04-11 INSERM (Institut National de la Santé et de la Recherche Médicale) Verfahren und pharmazeutische zusammensetzungen (ntsr1-inhibitoren) zur behandlung von hepatozellulären karzinomen
ES2823033T3 (es) 2015-05-28 2021-05-05 Genentech Inc Ensayo basado en células para detectar homodímeros anti-CD3
US20160347848A1 (en) 2015-05-28 2016-12-01 Medimmune Limited Therapeutic combinations and methods for treating neoplasia
WO2016189118A1 (en) 2015-05-28 2016-12-01 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods of prognosis and treatment of patients suffering from acute myeloid leukemia
JP6518917B2 (ja) 2015-05-29 2019-05-29 アッヴィ・インコーポレイテッド 抗ｃｄ４０抗体およびその使用
EP3302563A1 (de) 2015-05-29 2018-04-11 H. Hoffnabb-La Roche Ag Humanisierte anti-ebola-virus-glycoprotein-antikörper und verfahren zur verwendung
MX388405B (es) 2015-05-29 2025-03-19 Genentech Inc Un anticuerpo anti-pd-l1 para usarse en el tratamiento de cáncer en sujetos que tienen nivel medio o bajo de metilación en la región promotora pd-l1.
EP3302501B1 (de) 2015-05-29 2021-09-22 Merck Sharp & Dohme Corp. Kombination aus einem pd-1-antagonisten und cpg-c-typ-oligonukleotid zur behandlung von krebs
DK3303394T3 (da) 2015-05-29 2020-07-06 Agenus Inc Anti-ctla-4-antistoffer og fremgangsmåder til anvendelse deraf
EP3303632B2 (de) 2015-05-29 2023-05-10 F. Hoffmann-La Roche AG Therapeutische und diagnostische verfahren für krebs
AU2016271111B2 (en) 2015-05-29 2022-04-28 Bristol-Myers Squibb Company Antibodies against OX40 and uses thereof
JP2018080114A (ja) 2015-05-29 2018-05-24 株式会社アールテック・ウエノ 抗ヒトｖａｐ−１モノクローナル抗体
MX389708B (es) 2015-06-01 2025-03-20 Medimmune Llc Neutralizacion de moleculas de union anti-influenza y usos de las mismas.
HK1253064A1 (zh) 2015-06-01 2019-06-06 The University Of Chicago 通过操纵共生微生物菌群对癌症的治疗
HK1249016A1 (zh) 2015-06-02 2018-10-26 豪夫迈‧罗氏有限公司 使用抗il-34抗体治疗神经疾病的组合物和方法
WO2016191811A1 (en) 2015-06-03 2016-12-08 The University Of Queensland Mobilizing agents and uses therefor
US10184006B2 (en) 2015-06-04 2019-01-22 Merrimack Pharmaceuticals, Inc. Biomarkers for predicting outcomes of cancer therapy with ErbB3 inhibitors
NZ775762A (en) 2015-06-05 2025-02-28 Genentech Inc Anti-tau antibodies and methods of use
SG11201707815RA (en) 2015-06-05 2017-12-28 Novartis Ag Antibodies targeting bone morphogenetic protein 9 (bmp9) and methods therefor
AU2016274585A1 (en) 2015-06-08 2017-12-14 Genentech, Inc. Methods of treating cancer using anti-OX40 antibodies
TWI773646B (zh) 2015-06-08 2022-08-11 美商宏觀基因股份有限公司 結合lag-3的分子和其使用方法
EP3303397A1 (de) 2015-06-08 2018-04-11 H. Hoffnabb-La Roche Ag Verfahren zur krebsbehandlung mit anti-ox40-antikörpern und pd-1-achsen-bindungsantagonisten
NL2014935B1 (en) 2015-06-08 2017-02-03 Applied Immune Tech Ltd T cell receptor like antibodies having fine specificity.
EP3307772B1 (de) 2015-06-12 2020-09-09 Ludwig Institute For Cancer Research Limited Tgf-beta-3-spezifische antikörper und verfahren sowie verwendungen davon
EP3307779A2 (de) 2015-06-12 2018-04-18 Alector LLC Anti-cd33-antikörper und verfahren zur verwendung davon
AU2016276981B2 (en) 2015-06-12 2022-10-06 Alector Llc Anti-CD33 antibodies and methods of use thereof
TWI870335B (zh) 2015-06-12 2025-01-21 美商宏觀基因股份有限公司 變異的嵌合4d5抗體及其與抗pd-1抗體聯合用於治療癌症的應用
TW201709932A (zh) 2015-06-12 2017-03-16 西雅圖遺傳學公司 Ｃｄ１２３抗體及其共軛物
MA41010B1 (fr) 2015-06-15 2020-01-31 4D Pharma Res Ltd Compositions comprenant des souches bactériennes
LT3360559T (lt) 2015-06-15 2019-12-27 4D Pharma Research Limited Kompozicijos, apimančios bakterijų kamienus
PE20180243A1 (es) 2015-06-15 2018-01-31 4D Pharma Res Ltd Composiciones que comprenden cepas bacterianas
US10017577B2 (en) 2015-06-15 2018-07-10 Genentech, Inc. Antibodies and immunoconjugates
TW201710286A (zh) 2015-06-15 2017-03-16 艾伯維有限公司 抗ｖｅｇｆ、ｐｄｇｆ及／或其受體之結合蛋白
EP3662917A1 (de) 2015-06-15 2020-06-10 4D Pharma Research Limited Zusammensetzungen mit bakterienstämmen
MA41060B1 (fr) 2015-06-15 2019-11-29 4D Pharma Res Ltd Compositions comprenant des souches bactériennes
EP3310811B1 (de) 2015-06-16 2021-06-16 Genentech, Inc. Anti-cd3-antikörper und verfahren zur verwendung
US10323094B2 (en) 2015-06-16 2019-06-18 Genentech, Inc. Humanized and affinity matured antibodies to FcRH5 and methods of use
TW201718647A (zh) 2015-06-16 2017-06-01 建南德克公司 抗-cll-1抗體及使用方法
RU2766890C2 (ru) 2015-06-16 2022-03-16 Мерк Патент Гмбх Комбинированные способы лечения антагонистами pd-l1
HRP20260689T1 (hr) 2015-06-17 2026-07-17 F. Hoffmann-La Roche Ag Postupci za liječenje lokalno uznapredovalog ili metastatskog raka dojke primjenom antagonista vezivanja osi pd-1 i taksana
WO2016205704A2 (en) 2015-06-17 2016-12-22 International Aids Vaccine Initiative Engineered outer domain (eod) of hiv gp120, mutants and use thereof
ES3043088T3 (en) 2015-06-17 2025-11-24 Hoffmann La Roche Anti-her2 antibodies and methods of use
HK1254432A1 (zh) 2015-06-17 2019-07-19 Allakos Inc. 用於治疗纤维性疾病的方法和组合物
US11384104B2 (en) 2015-06-19 2022-07-12 Centurion Biopharma Corporation Delivery systems for controlled drug release
SG11201710639YA (en) 2015-06-22 2018-01-30 Bayer Pharma AG Antibody drug conjugates (adcs) and antibody prodrug conjugates (apdcs) with enzymatically cleavable groups
CA2990394A1 (en) 2015-06-23 2016-12-29 Bayer Pharma Aktiengesellschaft Antibody drug conjugates of kinesin spindel protein (ksp) inhibitors with anti-tweakr-antibodies
WO2016207104A1 (de) 2015-06-23 2016-12-29 Bayer Pharma Aktiengesellschaft Antikörper-wirkstoff-konjugate (adcs) von ksp-inhibitoren mit anti-b7h3-antikörpern
AU2016282334B2 (en) 2015-06-24 2022-07-21 F. Hoffmann-La Roche Ag Anti-transferrin receptor antibodies with tailored affinity
EP3722314A1 (de) 2015-06-24 2020-10-14 Janssen Pharmaceutica NV Anti-vista-antikörper und -fragmente
JP7021955B2 (ja) 2015-06-24 2022-03-03 エフ・ホフマン－ラ・ロシュ・アクチェンゲゼルシャフト Ｈｅｒ２及び血液脳関門受容体に特異的な三重特異性抗体及び使用方法
ES2809728T3 (es) 2015-06-24 2021-03-05 Hoffmann La Roche Anticuerpos anti-tau(pS422) humanizados y procedimientos de uso
GB201511196D0 (en) 2015-06-25 2015-08-12 Cytosystems Ltd Monoclonal antibodies
US10195175B2 (en) 2015-06-25 2019-02-05 Immunomedics, Inc. Synergistic effect of anti-Trop-2 antibody-drug conjugate in combination therapy for triple-negative breast cancer when used with microtubule inhibitors or PARP inhibitors
CA2990822A1 (en) 2015-06-26 2016-12-29 Dupont Nutrition Biosciences Aps Aminopeptidases for protein hydrlyzates
CN108026172B (zh) 2015-06-26 2022-04-29 赛诺菲生物技术公司 单克隆抗il-1racp抗体
JOP20160131B1 (ar) 2015-06-26 2022-03-14 Novartis Ag الأجسام المضادة للعامل xi وطرق الاستخدام
CN108139375A (zh) 2015-06-26 2018-06-08 贝斯以色列女执事医疗中心股份有限公司 靶向髓样衍生的抑制细胞中的四跨膜蛋白33(tspan33)的癌症疗法
JP6786529B2 (ja) 2015-06-29 2020-11-18 バイオメッド バレー ディスカバリーズ，インコーポレイティド Ｌｐｔ−７２３と免疫チェックポイント阻害剤との組み合わせおよび処置の方法
SMT202100092T1 (it) 2015-06-29 2021-03-15 Immunogen Inc Anticorpi anti-cd123 e loro coniugati e derivati
ES2878316T3 (es) 2015-06-29 2021-11-18 Ventana Med Syst Inc Materiales y procedimientos para realizar ensayos histoquímicos de pro-epirregulina y anfirregulina humanas
WO2017004091A1 (en) 2015-06-29 2017-01-05 Genentech, Inc. Type ii anti-cd20 antibody for use in organ transplantation
MX2017016502A (es) 2015-06-29 2018-03-12 Univ Rockefeller Anticuerpos contra cd40 con actividad agonista mejorada.
GB201511546D0 (en) 2015-07-01 2015-08-12 Immatics Biotechnologies Gmbh Novel peptides and combination of peptides for use in immunotherapy against ovarian cancer and other cancers
IL308735A (en) 2015-07-01 2024-01-01 Immatics Biotechnologies Gmbh Novel peptides and combination of peptides for use in immunotherapy against ovarian cancer and other cancers
SG10202010735PA (en) 2015-07-06 2020-11-27 UCB Biopharma SRL Tau-binding antibodies
PT3319985T (pt) 2015-07-06 2021-01-06 Immatics Biotechnologies Gmbh Novos péptidos e combinação de péptidos para uso em imunoterapia do cancro do esófago e outros cancros
CA2991264C (en) 2015-07-06 2023-10-10 Ucb Biopharma Sprl Tau-binding antibodies
FR3038517B1 (fr) 2015-07-06 2020-02-28 Laboratoire Francais Du Fractionnement Et Des Biotechnologies Utilisation de fragments fc modifies en immunotherapie
EP3319990A1 (de) 2015-07-07 2018-05-16 Institut National de la Sante et de la Recherche Medicale (INSERM) Antikörper mit spezifität gegen myosin 18a und verwendungen davon
US10287338B2 (en) 2015-07-10 2019-05-14 Miran NERSISSIAN Factor VIII protein compositions and methods of treating of hemophilia A
WO2017010874A1 (en) 2015-07-10 2017-01-19 Merus N.V. Human cd3 binding antibody
CA2991973C (en) 2015-07-12 2021-12-07 Suzhou M-Conj Biotech Co., Ltd. Bridge linkers for conjugation of a cell-binding molecule
US9839687B2 (en) 2015-07-15 2017-12-12 Suzhou M-Conj Biotech Co., Ltd. Acetylenedicarboxyl linkers and their uses in specific conjugation of a cell-binding molecule
MX2017016844A (es) 2015-07-16 2018-08-15 Biokine Therapeutics Ltd Composiciones y procedimientos para tratar cancer.
WO2017015334A1 (en) 2015-07-21 2017-01-26 Saint Louis University Compositions and methods for diagnosing and treating endometriosis-related infertility
US20190030153A1 (en) 2015-07-22 2019-01-31 University Of Saskatchewan Mycoplasma vaccines and uses thereof
US11066481B2 (en) 2015-07-23 2021-07-20 The Regents Of The University Of California Antibodies to coagulation factor XIa and uses thereof
ES2699526T3 (es) 2015-07-28 2019-02-11 Hoffmann La Roche Prueba de endotoxinas bacterianas mejorada para la determinación de endotoxinas
EP3328418A1 (de) 2015-07-29 2018-06-06 Novartis AG Kombinationstherapien mit antikörpermolekülen gegen pd-1
US20180207273A1 (en) 2015-07-29 2018-07-26 Novartis Ag Combination therapies comprising antibody molecules to tim-3
US20180340025A1 (en) 2015-07-29 2018-11-29 Novartis Ag Combination therapies comprising antibody molecules to lag-3
PE20231958A1 (es) 2015-07-30 2023-12-06 Macrogenics Inc Moleculas de union a pd-1 y metodos de uso de las mismas
TWI829617B (zh) 2015-07-31 2024-01-21 德商安美基研究（慕尼黑）公司 Ｆｌｔ３及ｃｄ３抗體構築體
TWI717375B (zh) 2015-07-31 2021-02-01 德商安美基研究（慕尼黑）公司 Ｃｄ７０及ｃｄ３抗體構築體
TWI744242B (zh) 2015-07-31 2021-11-01 德商安美基研究（慕尼黑）公司 Egfrviii及cd3抗體構築體
US10940204B2 (en) 2015-07-31 2021-03-09 Research Institute At Nationwide Children's Hospital Peptides and antibodies for the removal of biofilms
TWI793062B (zh) 2015-07-31 2023-02-21 德商安美基研究（慕尼黑）公司 Ｄｌｌ３及ｃｄ３抗體構築體
TWI796283B (zh) 2015-07-31 2023-03-21 德商安美基研究（慕尼黑）公司 Ｍｓｌｎ及ｃｄ３抗體構築體
EA039859B1 (ru) 2015-07-31 2022-03-21 Эмджен Рисерч (Мюник) Гмбх Биспецифические конструкты антител, связывающие egfrviii и cd3
EP3331536A4 (de) 2015-08-03 2019-03-27 The Regents of The University of California Zusammensetzungen und verfahren zur modulierung der abhd2-aktivität
CA2992797A1 (en) 2015-08-03 2017-02-09 Engmab Sarl Monoclonal antibodies against bcma
EP3331914A1 (de) 2015-08-03 2018-06-13 Novartis AG Verfahren zur behandlung von fgf21-vermittelten erkrankungen
AU2016301315C1 (en) 2015-08-03 2022-07-07 Sumitomo Pharma Oncology, Inc. Combination therapies for treatment of cancer
TW202440903A (zh) 2015-08-04 2024-10-16 美商再生元醫藥公司 補充牛磺酸之細胞培養基及用法（一）
WO2017024171A1 (en) 2015-08-04 2017-02-09 Acceleron Pharma Inc. Methods for treating myeloproliferative disorders
EP3331553B1 (de) 2015-08-05 2022-06-29 Acticor Biotech Neuartige anti-human-gpvi-antikörper und verwendungen davon
JO3620B1 (ar) 2015-08-05 2020-08-27 Amgen Res Munich Gmbh مثبطات نقطة فحص مناعية للاستخدام في علاج سرطانات محمولة عبر الدم
GB201513921D0 (en) 2015-08-05 2015-09-23 Immatics Biotechnologies Gmbh Novel peptides and combination of peptides for use in immunotherapy against prostate cancer and other cancers
EP3331543A4 (de) 2015-08-06 2019-03-20 City of Hope Zellpenetrierende proteinantikörperkonjugate und verfahren zur verwendung
JP2018532693A (ja) 2015-08-06 2018-11-08 ゾーマ （ユーエス） リミテッド ライアビリティ カンパニー インスリン受容体に対する抗体断片及び低血糖を治療するためのその使用
WO2017025458A1 (en) 2015-08-07 2017-02-16 Gamamabs Pharma Antibodies, antibody drug conjugates and methods of use
CN108136012B (zh) 2015-08-07 2022-10-04 伊麦吉纳博公司 靶向分子的抗原结合构建体
WO2017025179A1 (en) 2015-08-07 2017-02-16 Merck Patent Gmbh A transglutamine tag for efficient site-specific bioconjugation
EP3331544A4 (de) 2015-08-07 2019-03-27 University Of Virginia Patent Foundation Identifizierung von mit klasse-1-mhc assoziierten glycopeptiden als ziele zur krebsimmuntherapie
US11667691B2 (en) 2015-08-07 2023-06-06 Novartis Ag Treatment of cancer using chimeric CD3 receptor proteins
CN105384825B (zh) 2015-08-11 2018-06-01 南京传奇生物科技有限公司 一种基于单域抗体的双特异性嵌合抗原受体及其应用
US11453697B1 (en) 2015-08-13 2022-09-27 Merck Sharp & Dohme Llc Cyclic di-nucleotide compounds as sting agonists
DK3334454T3 (da) 2015-08-14 2022-11-14 Zoetis Services Llc Mycoplasma-Bovis-sammensætninger
SI3769781T1 (sl) 2015-08-19 2023-06-30 Astrazeneca Ab Stabilna formulacija proti-IFNAR1
JP2018528191A (ja) 2015-08-19 2018-09-27 ラトガーズ， ザ ステイト ユニバーシティ オブ ニュー ジャージー 抗体を生成する新規な方法
WO2018036117A1 (zh) 2016-08-22 2018-03-01 复旦大学 靶向于组织因子的抗体、其制备方法和用途
KR102601323B1 (ko) 2015-08-20 2023-11-10 에프. 호프만-라 로슈 아게 페길화 분석물-특이적 결합제를 사용하는 입자-기반 면역어세이
GB201514928D0 (en) 2015-08-21 2015-10-07 King S College London PDD compounds
TWI715617B (zh) 2015-08-24 2021-01-11 比利時商葛蘭素史密斯克藍生物品公司 對抗腸道外病原性大腸桿菌之免疫保護之方法及組合物
US11091559B2 (en) 2015-08-27 2021-08-17 Celldex Therapeutics, Inc. Anti-ALK antibodies and methods for use thereof
WO2017040195A1 (en) 2015-08-28 2017-03-09 The Trustees Of The University Of Pennsylvania Methods and compositions for cells expressing a chimeric intracellular signaling molecule
CN115960235A (zh) 2015-08-28 2023-04-14 艾利妥 抗siglec-7抗体及其使用方法
WO2017040312A1 (en) 2015-08-28 2017-03-09 The General Hospital Corporation Agonistic anti-tumor necrosis factor receptor 2 antibodies
WO2017040324A1 (en) 2015-08-28 2017-03-09 The Trustees Of The University Of Pennsylvania Methods and compositions for cells expressing a chimeric intracellular signaling molecule
JP6869987B2 (ja) 2015-09-01 2021-05-12 アジェナス インコーポレイテッド 抗ｐｄ−１抗体及びその使用方法
BR112018001907A2 (pt) 2015-09-01 2018-09-25 Boehringer Ingelheim Int uso de anticorpos anti-cd40 para o tratamento de nefrite lúpica
CA2997179A1 (en) 2015-09-02 2017-03-09 The Regents Of The Unversity Of Colorado, A Body Corporate Compositions and methods for modulating t-cell mediated immune response
RU2760582C2 (ru) 2015-09-02 2021-11-29 Иммутеп С.А.С. Анти-LAG-3 антитела
US10946095B2 (en) 2015-09-02 2021-03-16 Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd. Antibodies specific to human T-cell immunoglobulin and ITIM domain (TIGIT)
WO2017040932A1 (en) 2015-09-04 2017-03-09 Primatope Therapeutics Inc. Humanized anti-cd40 antibodies and uses thereof
EP3344806A4 (de) 2015-09-04 2019-03-20 OBI Pharma, Inc. Glycanarrays und verfahren zur verwendung
EP3842457A1 (de) 2015-09-09 2021-06-30 Novartis AG Moleküle zur bindung von thymus-stroma-lymphopoietin (tslp) und verfahren zur verwendung der moleküle
EA038332B1 (ru) 2015-09-09 2021-08-10 Новартис Аг Молекулы, связывающиеся с тимусным стромальным лимфопоэтином (tslp), и способы применения таких молекул
EP3347721B1 (de) 2015-09-09 2020-06-10 Medizinische Hochschule Hannover Diagnose und behandlung von peripartaler kardiomyopathie durch die höhe des plasminogen-aktivator-inhibitors
WO2017042816A1 (en) 2015-09-10 2017-03-16 Yeda Research And Development Co. Ltd. Ablation of perforin positive dendritic cells in cancer treatment
JP2018531625A (ja) 2015-09-11 2018-11-01 ナセント バイオテック インコーポレイテッド 脳への向上した薬物送達の方法
EA038146B1 (ru) 2015-09-15 2021-07-13 Сколар Рок, Инк. Антитела к про-/латентному миостатину и их применения
KR20180050744A (ko) 2015-09-17 2018-05-23 히스티드 아게 신생물성 세포를 비-신생물성 세포로 전환시키기 위한 약제학적 회합물 및 이것의 용도
CN122075735A (zh) 2015-09-17 2026-05-26 伊缪诺金公司 包含抗folr1免疫缀合物的治疗组合
EP3349778B1 (de) 2015-09-17 2021-09-01 Histide AG Pharmazeutische assoziation von wachstumsfaktorrezeptoragonist und adhäsionsproteininhibtor zur umwandlung einer neoplastischen zelle in eine nicht-neoplastische zelle und verwendungen davon
PE20181336A1 (es) 2015-09-18 2018-08-21 Chugai Pharmaceutical Co Ltd Anticuerpos que se unen a interleucina 8 (il-8) y sus usos
TWI811716B (zh) 2015-09-18 2023-08-11 德商百靈佳殷格翰國際股份有限公司 治療發炎性疾病之方法
CA2999083A1 (en) 2015-09-18 2017-03-23 The General Hospital Corporation Dba Massachusetts General Hospital Localized delivery of anti-fugetactic agent for treatment of cancer
HK1251480A1 (zh) 2015-09-21 2019-02-01 Aptevo Research And Development Llc Cd3结合多肽
ES2940360T3 (es) 2015-09-22 2023-05-05 Inst Nat Sante Rech Med Polipéptidos capaces de inhibir la unión entre leptina y neuropilina-1
EP3353288A1 (de) 2015-09-22 2018-08-01 H. Hoffnabb-La Roche Ag Expression von fc-haltigen proteinen
JP6904947B2 (ja) 2015-09-22 2021-07-21 スプリング バイオサイエンス コーポレーション 抗ｏｘ４０抗体及びその診断用途
US11339213B2 (en) 2015-09-23 2022-05-24 Mereo Biopharma 5, Inc. Methods and compositions for treatment of cancer
JP6959912B2 (ja) 2015-09-23 2021-11-05 ジェネンテック， インコーポレイテッド 抗ｖｅｇｆ抗体の最適化変異体
WO2017051347A2 (en) 2015-09-23 2017-03-30 Pfizer Inc. Cells and method of cell culture
ES2768957T3 (es) 2015-09-24 2020-06-24 Abvitro Llc Composiciones de anticuerpos contra el VIH y métodos de uso
SG10202007764TA (en) 2015-09-25 2020-09-29 Genentech Inc Anti-tigit antibodies and methods of use
EP4071477B1 (de) 2015-09-25 2026-01-21 QIAGEN Sciences, LLC Zusammensetzungen und verfahren zur diagnose der lyme-krankheit und zur vorhersage der lyme-krankheits-spirochäten-eliminierung nach der behandlung
RU2638457C2 (ru) 2015-09-28 2017-12-13 Общество С Ограниченной Ответственностью "Онкомакс" Антитела, специфически связывающие рецептор 1 типа фактора роста фибробластов, применение антител для лечения онкологического заболевания, способ получения антител
BR112018006237A2 (pt) 2015-09-29 2018-10-09 Celgene Corp proteínas de ligação a pd-1 e métodos de uso das mesmas
ES2839212T3 (es) 2015-09-29 2021-07-05 Inst Nat Sante Rech Med Métodos para determinar el estado metabólico de linfomas B
WO2017059132A1 (en) 2015-09-29 2017-04-06 The General Hospital Corporation Methods of treating and diagnosing disease using biomarkers for bcg therapy
JP2018529719A (ja) 2015-09-30 2018-10-11 メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツングＭｅｒｃｋ Ｐａｔｅｎｔ Ｇｅｓｅｌｌｓｃｈａｆｔ ｍｉｔ ｂｅｓｃｈｒａｅｎｋｔｅｒ Ｈａｆｔｕｎｇ Ａｌｋ陰性がんを処置するためのｐｄ−１系結合アンタゴニストおよびａｌｋ阻害剤の組合せ
ES2819870T3 (es) 2015-09-30 2021-04-19 Igm Biosciences Inc Moléculas de unión con cadena J modificada
PT3355913T (pt) 2015-09-30 2024-12-18 Igm Biosciences Inc Moléculas de ligação com cadeia j modificada
CA3000697A1 (en) 2015-10-01 2017-04-06 Amgen Inc. Treatment of bile acid disorders
WO2017055966A1 (en) 2015-10-01 2017-04-06 Pfizer Inc. Low viscosity antibody compositions
EP3150636A1 (de) 2015-10-02 2017-04-05 F. Hoffmann-La Roche AG Tetravalente multispezifische antikörper
SI3356404T1 (sl) 2015-10-02 2021-11-30 F. Hoffmann-La Roche Ag Protitelesa proti PD1 in postopki uporabe
CR20180243A (es) 2015-10-02 2018-07-31 Genentech Inc Conjugados de anticuerpo-fármaco de pirrolobenzodiazepina y métodos de uso
AR106189A1 (es) 2015-10-02 2017-12-20 Hoffmann La Roche ANTICUERPOS BIESPECÍFICOS CONTRA EL A-b HUMANO Y EL RECEPTOR DE TRANSFERRINA HUMANO Y MÉTODOS DE USO
MA43028B1 (fr) 2015-10-02 2021-09-30 Hoffmann La Roche Anticorps bispécifiques pour pd1 et tim3
MX2018003822A (es) 2015-10-02 2018-06-22 Hoffmann La Roche Anticuerpos biespecificos contra el cd20 humano y el receptor de transferrina humano y metodos de uso.
US10800826B2 (en) 2015-10-05 2020-10-13 Merck Sharp & Dohme Corp. Antibody peptide conjugates that have agonist activity at both the glucagon and glucagon-like peptide 1 receptors
JP2018529747A (ja) 2015-10-06 2018-10-11 ジェネンテック， インコーポレイテッド 多発性硬化症を治療するための方法
WO2017062271A2 (en) 2015-10-06 2017-04-13 Merck Sharp & Dohme Corp. Antibody drug conjugate for anti-inflammatory applications
JP7725185B2 (ja) 2015-10-06 2025-08-19 アレクトル エルエルシー 抗ｔｒｅｍ２抗体及びその使用方法
KR20180090785A (ko) 2015-10-07 2018-08-13 아펠리스 파마슈티컬스 인코포레이티드 투여 요법
AU2016335842A1 (en) 2015-10-07 2018-04-12 Obi Pharma, Inc. Novel carbohydrate antibodies, pharmaceutical compositions and uses thereof
UA128469C2 (uk) 2015-10-08 2024-07-24 Макродженікс, Інк. Спосіб лікування в7-н3-експресуючого раку
CN108283001B (zh) 2015-10-08 2022-08-19 酵活有限公司 包含κ和λ轻链的抗原结合多肽构建体及其用途
WO2017060397A1 (en) 2015-10-09 2017-04-13 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods for predicting the survival time of subjects suffering from melanoma metastases
AU2016334401A1 (en) 2015-10-10 2018-04-26 Intrexon Corporation Improved therapeutic control of proteolytically sensitive, destabilized forms of interleukin-12
WO2017060322A2 (en) 2015-10-10 2017-04-13 Bayer Pharma Aktiengesellschaft Ptefb-inhibitor-adc
WO2017064034A1 (en) 2015-10-12 2017-04-20 INSERM (Institut National de la Santé et de la Recherche Médicale) An agent capable of depleting cd8 t cells for the treatment of myocardial infarction or acute myocardial infarction
WO2017064043A1 (en) 2015-10-12 2017-04-20 Innate Pharma Cd73 blocking agents
US11161912B2 (en) 2015-10-13 2021-11-02 Technion Research & Development Foundation Limited Heparanase-neutralizing monoclonal antibodies
EP3365027B1 (de) 2015-10-14 2022-03-30 Research Institute at Nationwide Children's Hospital Hu-spezifische antikörper und deren verwendeng zur hemmung von biofilm
MA43354A (fr) 2015-10-16 2018-08-22 Genentech Inc Conjugués médicamenteux à pont disulfure encombré
WO2017064302A1 (en) 2015-10-16 2017-04-20 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and pharmaceutical compositions for the treatment of autoimmune inflammatory diseases
US20180298084A1 (en) 2015-10-16 2018-10-18 Arsanis Biosciences Gmbh Bactericidal monoclonal antibody targeting klebsiella pneumoniae
WO2017066561A2 (en) 2015-10-16 2017-04-20 President And Fellows Of Harvard College Regulatory t cell pd-1 modulation for regulating t cell effector immune responses
WO2017067944A1 (en) 2015-10-19 2017-04-27 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods for predicting the survival time of subjects suffering from triple negative breast cancer
JP6852065B2 (ja) 2015-10-20 2021-03-31 ジェネンテック， インコーポレイテッド カリケアマイシン−抗体−薬物コンジュゲート及び使用方法
GB201518675D0 (en) 2015-10-21 2015-12-02 Cellcap Technologies Ltd Detection of structural forms of proteins
SMT202500064T1 (it) 2015-10-21 2025-03-12 Redcoat Solutions Inc Dispositivo per il rilevamento delle cimici dei letti
CA3041460A1 (en) 2015-10-21 2017-04-27 Redcoat Solutions, Inc. Anti-bed bug monoclonal antibodies and methods of making and uses thereof
US10968277B2 (en) 2015-10-22 2021-04-06 Jounce Therapeutics, Inc. Gene signatures for determining ICOS expression
MA45489A (fr) 2015-10-22 2018-08-29 Juno Therapeutics Gmbh Procédés de culture de cellules, kits et appareil associés
US10604577B2 (en) 2015-10-22 2020-03-31 Allakos Inc. Methods and compositions for treating systemic mastocytosis
RU2761555C2 (ru) 2015-10-22 2021-12-09 Джуно Терапьютикс Гмбх Способы, наборы, средства и устройства для трансдукции
US20170114127A1 (en) 2015-10-22 2017-04-27 Massachusetts Institute Of Technology Vegf-a-binding proteins and her2-binding proteins with enhanced stability against aggregation
JP7296728B2 (ja) 2015-10-23 2023-06-23 メルス ナムローゼ フェンノートシャップ 癌の成長を抑制する結合分子
US10149887B2 (en) 2015-10-23 2018-12-11 Canbas Co., Ltd. Peptides and peptidomimetics in combination with t cell activating and/or checkpoint inhibiting agents for cancer treatment
EP3365369A1 (de) 2015-10-23 2018-08-29 Pfizer Inc Anti-il-2-antikörper sowie zusammensetzungen und verwendungen davon
MX2018004721A (es) 2015-10-23 2018-07-06 Eureka Therapeutics Inc Construcciones quimericas anticuerpo/receptor de celulas t y usos de las mismas.
EP3365376A1 (de) 2015-10-25 2018-08-29 Yeda Research and Development Co., Ltd. Auf quiescin-sulfhydryl-oxidase (qsox1) abzielende antikörper und verwendungen davon
US20180348224A1 (en) 2015-10-28 2018-12-06 Friedrich Miescher Institute For Biomedical Resear Ch Tenascin-w and biliary tract cancers
WO2017074774A1 (en) 2015-10-28 2017-05-04 Yale University Humanized anti-dkk2 antibody and uses thereof
EP4015533A1 (de) 2015-10-29 2022-06-22 F. Hoffmann-La Roche AG Antikörper gegen variante fc-regionen und verfahren zur verwendung
JO3555B1 (ar) 2015-10-29 2020-07-05 Merck Sharp & Dohme جسم مضاد يبطل فعالية فيروس الالتهاب الرئوي البشري
SG11201803567XA (en) 2015-10-29 2018-05-30 Alector Llc Anti-siglec-9 antibodies and methods of use thereof
EP3184547A1 (de) 2015-10-29 2017-06-28 F. Hoffmann-La Roche AG Anti-tpbg-antikörper und verfahren zur verwendung
EP3368157B1 (de) 2015-10-29 2022-06-29 Dana-Farber Cancer Institute, Inc. Verfahren zur identifizierung, beurteilung, prävention und behandlung von stoffwechselerkrankungen mit verwendung von pm20d1 und n-lipidierten aminosäuren
WO2017075045A2 (en) 2015-10-30 2017-05-04 Mayo Foundation For Medical Education And Research Antibodies to b7-h1
JP2018536650A (ja) 2015-10-30 2018-12-13 ジェネンテック， インコーポレイテッド 抗ｄ因子抗体変異体コンジュゲート及びその使用
WO2017075259A1 (en) 2015-10-30 2017-05-04 Genentech, Inc. Anti-factor d antibody formulations
TW201730211A (zh) 2015-10-30 2017-09-01 建南德克公司 抗因子d抗體及結合物
BR112018007703A2 (pt) 2015-10-30 2018-11-06 Genentech Inc anticorpos, ácido nucleico isolado, métodos de produção de um anticorpo e de tratamento de um distúrbio, composição farmacêutica, terapia de combinação e uso do anticorpo
SI3368579T1 (sl) 2015-10-30 2022-04-29 F.Hoffmann-La Roche Ag Tečajni modificirani fragmenti protitelesa in metode priprave
CA3003738C (en) 2015-11-01 2021-01-12 Massachusetts Institute Of Technology Materials with improved properties
ES2978718T3 (es) 2015-11-01 2024-09-18 Massachusetts Inst Technology Alginatos modificados para materiales antifibróticos y aplicaciones
CA3001131A1 (en) 2015-11-02 2017-05-11 Five Prime Therapeutics, Inc. Cd80 extracellular domain polypeptides and their use in cancer treatment
CN108431026B (zh) 2015-11-02 2023-02-17 豪夫迈·罗氏有限公司 制备岩藻糖基化和去岩藻糖基化形式的蛋白质的方法
AU2016349897B2 (en) 2015-11-03 2021-11-04 Regents Of The University Of Minnesota CD200 inhibitors and methods of use thereof
TWI660741B (zh) 2015-11-03 2019-06-01 財團法人工業技術研究院 抗體藥物複合物及其製造方法
US20180320136A1 (en) 2015-11-03 2018-11-08 GlycoMimitics, Inc. Methods and compositions for the production of monoclonal antibodies, hematopoietic stem cells, and methods of using the same
EP3370754B1 (de) 2015-11-04 2026-04-29 Acceleron Pharma, Inc. Verfahren zur erhöhung der erythrozytenkonzentration und behandlung von ineffizienter erythropoiese
US20190209697A1 (en) 2015-11-05 2019-07-11 The Regents Of The University Of California Cells labelled with lipid conjugates and methods of use thereof
WO2017079768A1 (en) 2015-11-08 2017-05-11 Genentech, Inc. Methods of screening for multispecific antibodies
WO2017083306A1 (en) 2015-11-09 2017-05-18 R.P. Scherer Technologies, Llc Anti-cd22 antibody-maytansine conjugates and methods of use thereof
CN117398458A (zh) 2015-11-09 2024-01-16 奥默罗斯公司 用于治疗与masp-2依赖性补体活化相关的病况的方法
WO2017083296A1 (en) 2015-11-09 2017-05-18 The Children's Hospital Of Philadelphia Glypican 2 as a cancer marker and therapeutic target
PL3374398T3 (pl) 2015-11-10 2020-08-24 Medimmune, Llc Cząsteczki wiążące swoiste dla ASCT2 i ich zastosowanie
US11168131B2 (en) 2015-11-10 2021-11-09 Visterra, Inc. Antibody molecule-drug conjugates and uses thereof
KR102810368B1 (ko) 2015-11-10 2025-05-19 예일 유니버시티 자가면역 질환 및 암을 치료하기 위한 조성물 및 방법
CA3002097A1 (en) 2015-11-12 2017-05-18 Siamab Therapeutics, Inc. Glycan-interacting compounds and methods of use
MX2018006072A (es) 2015-11-19 2018-08-01 Squibb Bristol Myers Co Anticuerpos contra receptor de factor de necrosis de tumor inducido por glucocorticoides (gitr) y usos de los mismos.
US20190330336A1 (en) 2015-11-19 2019-10-31 Sutro Biopharma, Inc. Anti-lag3 antibodies, compositions comprising anti-lag3 antibodies and methods of making and using anti-lag3 antibodies
MA41013A (fr) 2015-11-20 2017-08-30 4D Pharma Res Ltd Compositions comprenant des souches bactériennes
GB201520497D0 (en) 2015-11-20 2016-01-06 4D Pharma Res Ltd Compositions comprising bacterial strains
GB201520544D0 (en) 2015-11-23 2016-01-06 Immunocore Ltd & Adaptimmune Ltd Peptides
GB201520592D0 (en) 2015-11-23 2016-01-06 Immunocore Ltd & Adaptimmune Ltd Peptides
GB201520546D0 (en) 2015-11-23 2016-01-06 Immunocore Ltd & Adaptimmune Ltd Peptides
GB201520543D0 (en) 2015-11-23 2016-01-06 Immunocore Ltd & Adaptimmune Ltd Peptides
SG10201913538VA (en) 2015-11-23 2020-02-27 Five Prime Therapeutics Inc Fgfr2 inhibitors alone or in combination with immune stimulating agents in cancer treatment
GB201520562D0 (en) 2015-11-23 2016-01-06 Immunocore Ltd & Adaptimmune Ltd Peptides
GB201520536D0 (en) 2015-11-23 2016-01-06 Immunocore Ltd & Adaptimmune Ltd Peptides
GB201520603D0 (en) 2015-11-23 2016-01-06 Immunocore Ltd & Adaptimmune Ltd Peptides
GB201607534D0 (en) 2016-04-29 2016-06-15 Immunocore Ltd & Adaptimmune Ltd Peptides
GB201520638D0 (en) 2015-11-23 2016-01-06 4D Pharma Res Ltd Compositions comprising bacterial strains
GB201520565D0 (en) 2015-11-23 2016-01-06 Immunocore Ltd & Adaptimmune Ltd Peptides
GB201520545D0 (en) 2015-11-23 2016-01-06 Immunocore Ltd & Adaptimmune Ltd Peptides
CN106729743B (zh) 2015-11-23 2021-09-21 四川科伦博泰生物医药股份有限公司 抗ErbB2抗体-药物偶联物及其组合物、制备方法和应用
GB201520563D0 (en) 2015-11-23 2016-01-06 Immunocore Ltd & Adaptimmune Ltd Peptides
GB201520557D0 (en) 2015-11-23 2016-01-06 Immunocore Ltd & Adaptimmune Ltd Peptides
GB201520541D0 (en) 2015-11-23 2016-01-06 Immunocore Ltd & Adaptimmune Ltd Peptides
GB201520558D0 (en) 2015-11-23 2016-01-06 Immunocore Ltd & Adaptimmune Ltd Peptides
GB201520570D0 (en) 2015-11-23 2016-01-06 Immunocore Ltd & Adaptimmune Ltd Peptides
GB201520568D0 (en) 2015-11-23 2016-01-06 Immunocore Ltd Peptides
WO2018083505A1 (en) 2016-11-07 2018-05-11 Immunocore Limited Peptides
GB201520583D0 (en) 2015-11-23 2016-01-06 Immunocore Ltd & Adaptimmune Ltd Peptides
WO2017089786A1 (en) 2015-11-23 2017-06-01 Immunocore Limited Peptides
GB201520566D0 (en) 2015-11-23 2016-01-06 Immunocore Ltd & Adaptimmune Ltd Peptides
GB201520595D0 (en) 2015-11-23 2016-01-06 Immunocore Ltd & Adaptimmune Ltd Peptides
GB201520550D0 (en) 2015-11-23 2016-01-06 Immunocore Ltd & Adaptimmune Ltd Peptides
GB201520548D0 (en) 2015-11-23 2016-01-06 Immunocore Ltd & Adaptimmune Ltd Peptides
GB201520579D0 (en) 2015-11-23 2016-01-06 Immunocore Ltd & Adaptimmune Ltd Peptides
GB201607535D0 (en) 2016-04-29 2016-06-15 Immunocore Ltd & Adaptimmune Ltd Peptides
GB201520597D0 (en) 2015-11-23 2016-01-06 Immunocore Ltd & Adaptimmune Ltd Peptides
GB201520539D0 (en) 2015-11-23 2016-01-06 Immunocore Ltd & Adaptimmune Ltd Peptides
JP7072507B2 (ja) 2015-11-23 2022-05-20 アクセルロン ファーマ インコーポレイテッド 眼の障害を処置するための方法
GB201520567D0 (en) 2015-11-23 2016-01-06 Immunocore Ltd & Adaptimmune Ltd Peptides
GB201520575D0 (en) 2015-11-23 2016-01-06 Immunocore Ltd & Adaptimmune Ltd Peptides
GB201520542D0 (en) 2015-11-23 2016-01-06 Immunocore Ltd & Adaptimmune Ltd Peptides
GB201520559D0 (en) 2015-11-23 2016-01-06 Immunocore Ltd & Adaptimmune Ltd Peptides
GB201520564D0 (en) 2015-11-23 2016-01-06 Immunocore Ltd & Adaptimmune Ltd Peptides
GB201604468D0 (en) 2016-03-16 2016-04-27 Immunocore Ltd & Adaptimmune Ltd Peptides
GB201520589D0 (en) 2015-11-23 2016-01-06 Immunocore Ltd & Adaptimmune Ltd Peptides
GB201520631D0 (en) 2015-11-23 2016-01-06 4D Pharma Res Ltd Compositions comprising bacterial strains
FI3380518T3 (fi) 2015-11-24 2026-05-29 Annexon Inc Antikomplementtitekijä-C1Q:n Fab-fragmentteja ja niiden käyttöjä
US20170145086A1 (en) 2015-11-25 2017-05-25 Visterra, Inc. Antibody molecules to april and uses thereof
HUE067016T2 (hu) 2015-11-25 2024-09-28 Ligachem Biosciences Inc Önfeláldozó csoportokat tartalmazó konjugátumok és ezekkel kapcsolos eljárások
AU2016361462B2 (en) 2015-11-27 2023-09-21 Csl Limited CD131 binding proteins and uses thereof
JP2019501124A (ja) 2015-11-30 2019-01-17 アッヴィ・インコーポレイテッド 抗ｈｕＬＲＲＣ１５抗体薬物コンジュゲート及びその使用方法
EP3383909B1 (de) 2015-11-30 2020-06-17 AbbVie Inc. Anti-hulrrc15-antikörper-wirkstoff-konjugate und verfahren zu deren verwendung
US10556948B2 (en) 2015-11-30 2020-02-11 Bristol-Myers Squibb Company IP-10 antibodies and their uses
EP3383920B1 (de) 2015-11-30 2024-01-10 The Regents of the University of California Freisetzung von tumorspezifischer nutzlast und immunaktivierung mit einem menschlichen antikörper gegen hochspezifisches tumorzellenoberflächenantigen
KR102803158B1 (ko) 2015-12-02 2025-05-08 주식회사 에스티큐브앤컴퍼니 Btn1a1에 면역특이적으로 결합하는 항체와 분자 및 그의 치료 용도
EP3176183A1 (de) 2015-12-02 2017-06-07 Yeda Research and Development Co. Ltd Zusammensetzungen und verfahren zur behandlung von krebs ohne resistenz gegen einen tyrosinkinasehemmer (tki)
JP7227007B2 (ja) 2015-12-02 2023-02-21 ストサイエンシス， インコーポレイテッド グリコシル化ｂｔｌａ（ｂ－及びｔ－リンパ球減弱因子）に特異的な抗体
US20180271998A1 (en) 2015-12-04 2018-09-27 Merrimack Pharmaceuticals, Inc. Disulfide-stabilized fabs
US10144768B2 (en) 2015-12-04 2018-12-04 Novartis Ag Antibody cytokine engrafted compositions and methods of use for immunoregulation
US11793880B2 (en) 2015-12-04 2023-10-24 Seagen Inc. Conjugates of quaternized tubulysin compounds
US11229708B2 (en) 2015-12-04 2022-01-25 Seagen Inc. Conjugates of quaternized tubulysin compounds
CA3045756A1 (en) 2015-12-05 2017-06-08 Centre Hospitalier Universitaire Vaudois Hiv binding agents
EP3178848A1 (de) 2015-12-09 2017-06-14 F. Hoffmann-La Roche AG Type ii anti-cd20 antikörper zur verringerung der bildung von antikörpern gegen medikamente
IL313608A (en) 2015-12-09 2024-08-01 Hoffmann La Roche Antibody against CD20 type II to reduce the formation of antibodies against drugs
CN108603037B (zh) 2015-12-10 2020-11-17 希望之城 细胞穿透花青偶联抗体
CN108367069B (zh) 2015-12-14 2022-08-23 宏观基因有限公司 对于pd-1和ctla-4具有免疫反应性的双特异性分子及其使用方法
AU2016370648B2 (en) 2015-12-15 2023-03-09 OncoC4, Inc. Chimeric and humanized anti-human CTLA4 monoclonal antibodies and uses thereof
BR112018012352A2 (pt) 2015-12-16 2018-12-11 Merck Sharp & Dohme Corp. anticorpos anti-lag3 e fragmentos de ligação ao antígeno
CN108495651A (zh) 2015-12-17 2018-09-04 诺华股份有限公司 抗pd-1的抗体分子及其用途
US11007251B2 (en) 2015-12-17 2021-05-18 The Johns Hopkins University Ameliorating systemic sclerosis with death receptor agonists
CN108697794A (zh) 2015-12-17 2018-10-23 诺华股份有限公司 C-met抑制剂和抗pd-1抗体分子的组合及其用途
WO2017106566A1 (en) 2015-12-17 2017-06-22 Gilead Sciences, Inc. Combination of a jak inhibitor and an mmp9 binding protein for treating inflammatory disorders
EA201891420A1 (ru) 2015-12-18 2019-02-28 Чугаи Сейяку Кабусики Кайся Антитела к миостатину, полипептиды, содержащие варианты fc-областей, и способы их применения
CN108401431B (zh) 2015-12-18 2022-01-25 中外制药株式会社 抗-c5抗体及使用方法
TW201731872A (zh) 2015-12-18 2017-09-16 諾華公司 標靶CD32b之抗體及其使用方法
WO2017106806A1 (en) 2015-12-18 2017-06-22 Federica Cavallo COMPOSITIONS AND METHODS RELATED TO xCT PEPTIDES
GB201522667D0 (en) 2015-12-22 2016-02-03 Immatics Biotechnologies Gmbh Novel peptides and combination of peptides for use in immunotherapy against breast cancer and other cancers
CN117106085A (zh) 2015-12-23 2023-11-24 美国安进公司 使用gipr结合蛋白与glp-1激动剂的组合来治疗或改善代谢病症的方法
EP3184544A1 (de) 2015-12-23 2017-06-28 Julius-Maximilians-Universität Würzburg Glycoprotein-v-inhibitoren zur verwendung als koagulansien
AU2016379425B2 (en) 2015-12-24 2021-11-11 Corvus Pharmaceuticals, Inc. Methods of treating cancer
US10561706B2 (en) 2015-12-28 2020-02-18 B. G. Negev Technologies And Applications Isolated polypeptide and compositions comprising same
IL290457B2 (en) 2015-12-30 2025-02-01 Kodiak Sciences Inc Antibodies and their conjugates
SG10202103844WA (en) 2015-12-30 2021-06-29 Genentech Inc Use of tryptophan derivatives for protein formulations
US10525137B2 (en) 2015-12-30 2020-01-07 Genentech, Inc. Formulations with reduced degradation of polysorbate
WO2017118634A1 (en) 2016-01-04 2017-07-13 INSERM (Institut National de la Santé et de la Recherche Médicale) Use of pd-1 and tim-3 as a measure for cd8+ cells in predicting and treating renal cell carcinoma
CA3010593C (en) 2016-01-05 2024-02-13 University Of Leicester Methods for inhibiting fibrosis in a subject in need thereof
CN107531795B (zh) 2016-01-05 2021-01-19 江苏恒瑞医药股份有限公司 Pcsk9抗体、其抗原结合片段及其医药用途
AU2017204950A1 (en) 2016-01-06 2018-08-16 Yeda Research And Development Co. Ltd. Compositions and methods for treating malignant, autoimmune and inflammatory diseases
WO2017120479A1 (en) 2016-01-07 2017-07-13 The Schepens Eye Research Institute, Inc. Therapeutics for ocular immunoinflammatory diseases
WO2017120534A1 (en) 2016-01-08 2017-07-13 Bioalliance C.V. Tetravalent anti-psgl-1 antibodies and uses thereof
US11103589B2 (en) 2016-01-08 2021-08-31 Apg Therapeutics, Inc. Polyethylenimine (PEI)-polypeptide conjugates and methods of use thereof
CN115814077A (zh) 2016-01-08 2023-03-21 供石公司 抗-原肌生长抑制素/潜伏肌生长抑制素抗体及其使用方法
US20170198290A1 (en) 2016-01-08 2017-07-13 Northwestern University Anti-inflammatory treatment via inhibition of endothelial cell kinesin light chain 1, variant 1 (klc1c)
BR112018011029A2 (pt) 2016-01-08 2018-11-21 Hoffmann La Roche métodos para tratar ou atrasar a progressão do câncer e para melhorar a função imune em um indivíduo com câncer, usos de um antagonista de ligação e de um anticorpo biespecífico, composições e kits
WO2017120557A1 (en) 2016-01-09 2017-07-13 Arbele Limited Cadherin-17 specific antibodies and cytotoxic cells for cancer treatment
EP3411409B1 (de) 2016-01-10 2025-10-08 Neotx Therapeutics Ltd. Antikörper anti-pd-1/anti-pd-l1 zur stimulierung der durch superantigene vermittelten krebs immuntherapie
WO2017122203A1 (en) 2016-01-11 2017-07-20 Technion Research & Development Foundation Limited Methods of determining prognosis of sepsis and treating same
DK3402515T3 (da) 2016-01-12 2021-11-15 Oncotracker Inc Forbedrede fremgangsmåder til monitorering af et individs immunstatus
US20190309060A1 (en) 2016-01-15 2019-10-10 Philogen S.P.A. Intestinal antigens for pharmacodelivery applications
EP3405489A1 (de) 2016-01-20 2018-11-28 Genentech, Inc. Hochdosierte behandlungen für morbus alzheimer
ES2904593T3 (es) 2016-01-21 2022-04-05 Pfizer Anticuerpos monoespecíficos y biespecíficos para la variante III del receptor del factor de crecimiento epidérmico y CD3 y sus usos
EP3851457A1 (de) 2016-01-21 2021-07-21 Novartis AG Gegen cll-1 gerichtete multispezifische moleküle
BR112018014585A2 (pt) 2016-01-21 2018-12-11 Pfizer receptores de antígeno quiméricos que direcionam o receptor do fator de crescimento epidérmico variante iii
PL3964529T3 (pl) 2016-01-22 2025-10-27 MabQuest SA Nieblokujące przeciwciała specyficzne względem pd1
US11214617B2 (en) 2016-01-22 2022-01-04 MabQuest SA Immunological reagents
US10053515B2 (en) 2016-01-22 2018-08-21 Merck Sharp & Dohme Corp. Anti-coagulation factor XI antibodies
WO2017130076A1 (en) 2016-01-25 2017-08-03 Pfizer Inc. Combination of an ox40 agonist and a 4-1bb agonist monoclonal antibody for treating cancer
WO2017129558A1 (en) 2016-01-25 2017-08-03 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods for predicting or treating myelopoiesis-driven cardiometabolic diseases and sepsis
EP3408671B1 (de) 2016-01-25 2023-11-01 F. Hoffmann-La Roche AG Verfahren zum testen t-zell-abhängiger bispezifischer antikörper
GB201601431D0 (en) 2016-01-26 2016-03-09 Medimmune Ltd Pyrrolobenzodiazepines
ES2823173T3 (es) 2016-01-27 2021-05-06 Just Biotherapeutics Inc Promotor híbrido y usos del mismo
AU2017212739B2 (en) 2016-01-27 2024-03-21 Sutro Biopharma, Inc. Anti-CD74 antibody conjugates, compositions comprising anti-CD74 antibody conjugates and methods of using anti-CD74 antibody conjugates
JP6902040B2 (ja) 2016-01-28 2021-07-14 アンスティチュ ナショナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシュ メディカル 免疫チェックポイント阻害剤の効力を増強する方法
WO2017129763A1 (en) 2016-01-28 2017-08-03 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and pharmaceutical compositions for the treatment of signet ring cell gastric cancer
JP6970099B2 (ja) 2016-01-28 2021-11-24 アンスティチュ ナショナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシュ メディカル ガンの処置のための方法及び医薬組成物
ES2986360T3 (es) 2016-01-29 2024-11-11 Yuhan Corp Proteínas de unión a antígeno que se unen a PD-L1
EP3407916B1 (de) 2016-01-29 2023-12-20 Merck Sharp & Dohme LLC Phosphonat-linker und deren verwendung zur erleichterung der zellulären retention von verbindungen
US10983135B2 (en) 2016-02-01 2021-04-20 Prevencio, Inc. Diagnostic and prognostic methods for cardiovascular diseases and events
CA3012960A1 (en) 2016-02-01 2017-08-10 Pfizer Inc. Tubulysin analogs and methods for their preparation
UA126657C2 (uk) 2016-02-03 2023-01-11 Емджен Рісерч (Мюнік) Ґмбг ОДНОЛАНЦЮГОВА КОНСТРУКЦІЯ АНТИТІЛА ДО BCMA І CD3<font face="Symbol">e</font>
US20190038720A1 (en) 2016-02-03 2019-02-07 President And Fellows Of Harvard College Methods of treating inflammatory bowel disease and parasite infection
AR107582A1 (es) 2016-02-03 2018-05-16 Amgen Res Munich Gmbh Constructos de anticuerpo biespecíficos para psma y cd3 que se ligan a células t
AU2017213826A1 (en) 2016-02-04 2018-08-23 Curis, Inc. Mutant smoothened and methods of using the same
US10465003B2 (en) 2016-02-05 2019-11-05 Janssen Biotech, Inc. Anti-TNF antibodies, compositions, methods and use for the treatment or prevention of type 1 diabetes
EP3410849B1 (de) 2016-02-05 2023-07-05 Institut Pasteur Verwendung von inhibitoren von adam12 als adjuvanzien in tumortherapien
EP3202788A1 (de) 2016-02-05 2017-08-09 MediaPharma S.r.l. Endosialinbindender antikörper
AU2017214541B2 (en) 2016-02-05 2024-03-21 NanoView Biosciences, Inc. Detection of exosomes having surface markers
GB201602356D0 (en) 2016-02-10 2016-03-23 Medimmune Ltd Pyrrolobenzodiazepine Conjugates
CN108601841A (zh) 2016-02-10 2018-09-28 免疫医疗公司 Abcg2抑制剂与sacituzumab govitecan(immu-132)的组合克服表达trop-2的癌中对sn-38的抗性
GB201602359D0 (en) 2016-02-10 2016-03-23 Medimmune Ltd Pyrrolobenzodiazepine Conjugates
KR20180101462A (ko) 2016-02-10 2018-09-12 화이자 인코포레이티드 치료제를 포함하는 치료 나노입자 및 그의 제조 및 사용 방법
EP3414339A4 (de) 2016-02-12 2019-08-28 The Regents of The University of California Systeme und zusammensetzungen zur diagnose einer pathogenen pilzinfektion und verfahren zur verwendung davon
US10899836B2 (en) 2016-02-12 2021-01-26 Janssen Pharmaceutica Nv Method of identifying anti-VISTA antibodies
WO2017138008A2 (en) 2016-02-14 2017-08-17 Yeda Research And Development Co. Ltd. Methods of modulating protein exocytosis and uses of same in therapy
WO2017140684A2 (en) 2016-02-15 2017-08-24 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and pharmaceutical compositions for the treatment of post-operative cognitive dysfunction
EP3416641A1 (de) 2016-02-16 2018-12-26 Deutsches Krebsforschungszentrum Stiftung des Öffentlichen Rechts Modulatoren von ccr9 zur behandlung von tumorresistenz gegenüber immunreaktionen
WO2017140803A1 (en) 2016-02-16 2017-08-24 Deutsches Krebsforschungszentrum Stiftung des öffentlichen Rechts Modulators of tumor immune resistance for the treatment of cancer
EP3207937A1 (de) 2016-02-17 2017-08-23 Royal College of Surgeons in Ireland Verfahren zur behandlung oder prävention von sepsis
MA44254A (fr) 2016-02-17 2018-12-26 Seattle Genetics Inc Anticorps bcma et leur utilisation pour traiter le cancer et les troubles immunologiques
AR108034A1 (es) 2016-02-17 2018-07-11 Macrogenics Inc Moléculas de unión a ror1, y métodos de uso de las mismas
JP6884155B2 (ja) 2016-02-18 2021-06-09 エンリヴェックス セラピューティクス リミテッド 癌治療のための併用免疫療法及びサイトカイン制御療法
WO2017139975A1 (en) 2016-02-19 2017-08-24 Huiru Wang Antibodies against n-acetylglucosamine and n-acetyl-galactosamine
GB201602918D0 (en) 2016-02-19 2016-04-06 Immatics Biotechnologies Gmbh Novel peptides and combination of peptides for use in immunotherapy against NHL and other cancers
GB201603002D0 (en) 2016-02-22 2016-04-06 Univ Manchester Inflammation biomarker
BR112018017031A2 (pt) 2016-02-23 2019-01-22 Sesen Bio Inc formulações de antagonista de il-6 e usos das mesmas
MX2018009216A (es) 2016-02-25 2018-11-09 Dupont Nutrition Biosci Aps Metodo para producir un hidrolizado de proteina empleando una tripeptidil peptidasa de aspergillus fumigatus.
CA3013333A1 (en) 2016-02-26 2017-08-31 Inserm (Institut National De La Sante Et De La Recherche Medicale) Antibodies having specificity for btla and uses thereof
AU2017224122B2 (en) 2016-02-26 2024-04-11 The Board Of Regents Of The University Of Texas System Connexin (Cx) 43 hemichannel-binding antibodies and uses thereof
US10941447B2 (en) 2016-02-29 2021-03-09 Rhode Island Hospital Diagnostics for pulmonary arterial hypertension and sudden cardiac death
US11725247B2 (en) 2016-02-29 2023-08-15 Foundation Medicine, Inc. Methods of treating cancer
WO2017151502A1 (en) 2016-02-29 2017-09-08 Genentech, Inc. Therapeutic and diagnostic methods for cancer
PE20181583A1 (es) 2016-03-01 2018-10-04 Immatics Biotechnologies Gmbh Peptido recombinante derivado de la proteina duoxa2
RU2756275C2 (ru) 2016-03-01 2021-09-29 Юссум Рисёрч Девелопмент Компани Оф Зэ Хибру Юниверсити Оф Иерусалим Лтд. Антитела, специфические к рецептору полиовируса (pvr) человека
MY199595A (en) 2016-03-02 2023-11-08 Eisai R&D Man Co Ltd Eribulin-based antibody-drug conjugates and methods of use
KR102424496B1 (ko) 2016-03-02 2022-07-25 아이덱스 래보러토리즈, 인코포레이티드 신장 질환 및 치주 질환의 검출 및 진단을 위한 방법 및 조성물
GB201612191D0 (en) 2016-07-13 2016-08-24 4D Pharma Plc Compositions comprising bacterial strains
MX373290B (es) 2016-03-04 2020-06-18 4D Pharma Plc Composiciones que comprenden cepas bacterianas.
JP7023853B2 (ja) 2016-03-04 2022-02-22 アレクトル エルエルシー 抗ｔｒｅｍ１抗体及びその使用方法
CN116063494A (zh) 2016-03-04 2023-05-05 洛克菲勒大学 具有增强的激动剂活性的cd40的抗体
AU2017228470A1 (en) 2016-03-04 2018-08-30 Bristol-Myers Squibb Company Combination therapy with anti-CD73 antibodies
SG11201807489PA (en) 2016-03-04 2018-09-27 Novartis Ag Cells expressing multiple chimeric antigen receptor (car) molecules and uses therefore
US10443054B2 (en) 2016-03-06 2019-10-15 Massachusetts Institute Of Technology Methods for identifying and treating invasive/metastatic breast cancers
WO2017153982A1 (en) 2016-03-06 2017-09-14 Yeda Research And Development Co. Ltd. Method for modulating myelination
US11357849B2 (en) 2016-03-07 2022-06-14 Musc Foundation For Research Development Anti-nucleolin antibodies
CN108699158B (zh) 2016-03-08 2022-06-03 依奈特制药公司 Siglec中和抗体
US12128102B2 (en) 2016-03-08 2024-10-29 Takeda Pharmaceutical Company Limited Constrained conditionally activated binding proteins
CN109195996A (zh) 2016-03-08 2019-01-11 中央研究院 N-聚醣及其阵列的模组化合成方法
GB201603987D0 (en) 2016-03-08 2016-04-20 Immatics Biotechnologies Gmbh Uterine cancer treatments
US11921116B2 (en) 2016-03-09 2024-03-05 Memorial Sloan Kettering Cancer Center Enigma and CDH18 as companion diagnostics for CDK4 inhibitors
US11014088B2 (en) 2016-03-09 2021-05-25 The Board Of Regents Of The University Of Texas System Sensitive ELISA for disease diagnosis on surface modified poly(methyl methacrylate) (PMMA) microfluidic microplates
US20170260286A1 (en) 2016-03-10 2017-09-14 The General Hospital Corporation Antigen-Binding Fusion Proteins with Modified HSP70 Domains
CA3015277A1 (en) 2016-03-10 2017-09-14 Acceleron Pharma Inc. Activin type 2 receptor binding proteins and uses thereof
ES2951648T3 (es) 2016-03-11 2023-10-24 Scholar Rock Inc Inmunoglobulinas de unión a Tgfbeta1 y uso de las mismas
WO2017158421A1 (en) 2016-03-14 2017-09-21 University Of Oslo Anti-viral engineered immunoglobulins
CN109071631B (zh) 2016-03-14 2023-07-14 奥斯陆大学 具有改变的FcRn结合的工程化免疫球蛋白
WO2017157305A1 (en) 2016-03-15 2017-09-21 Generon (Shanghai) Corporation Ltd. Multispecific fab fusion proteins and use thereof
BR112018068461A2 (pt) 2016-03-15 2019-01-22 Mersana Therapeutics Inc conjugado, composição farmacêutica, métodos para preparação de um conjugado e para alívio de um sintoma de um câncer.
CN109153719B (zh) 2016-03-15 2022-12-30 中外制药株式会社 使用pd-1轴结合拮抗剂和抗gpc3抗体治疗癌症的方法
PL3779447T3 (pl) 2016-03-15 2023-06-26 INSERM (Institut National de la Santé et de la Recherche Médicale) Sposób aktywowania przeciwnowotworowej odpowiedzi komórek t cd8+ u pacjenta dotknego nowotworem
WO2017158396A1 (en) 2016-03-16 2017-09-21 INSERM (Institut National de la Santé et de la Recherche Médicale) Cytidine deaminase inhibitors for the treatment of pancreatic cancer
EP3430046A4 (de) 2016-03-16 2019-10-23 Abeome Corporation Neutralisierende monoklonale antikörper gegen il-25 und verwendungen davon
KR20170108203A (ko) 2016-03-16 2017-09-27 주식회사 피플바이오 응집형-형성 폴리펩타이드의 응집형을 검출하는 방법
WO2017161206A1 (en) 2016-03-16 2017-09-21 Halozyme, Inc. Conjugates containing conditionally active antibodies or antigen-binding fragments thereof, and methods of use
EA039201B1 (ru) 2016-03-17 2021-12-16 Нумаб Инновейшн Аг Антитела к фно и их функциональные фрагменты
IL261793B2 (en) 2016-03-17 2025-04-01 Numab Therapeutics AG ANTI-TNFALPHA ANTIBODIES AND THEIR FUNCTIONAL PARTS
EA039323B1 (ru) 2016-03-17 2022-01-13 Нумаб Инновейшн Аг Антитела к фно и их функциональные фрагменты
EP3219727B1 (de) 2016-03-17 2020-12-16 Tillotts Pharma AG Anti-tnf-alpha-antikörper und funktionale fragmente davon
WO2017158436A1 (en) 2016-03-17 2017-09-21 Oslo Universitetssykehus Hf Fusion proteins targeting tumour associated macrophages for treating cancer
PT3219726T (pt) 2016-03-17 2020-12-15 Tillotts Pharma Ag Alfa-anticorpos anti-tnf e fragmentos funcionais dos mesmos
US11291721B2 (en) 2016-03-21 2022-04-05 Marengo Therapeutics, Inc. Multispecific and multifunctional molecules and uses thereof
US20190086392A1 (en) 2016-03-21 2019-03-21 Inserm (Institut National De La Sante Et De La Recherch Medicale) Methods for diagnosis and treatment of solar lentigo
US10745487B2 (en) 2016-03-22 2020-08-18 Bionomics Limited Method of treating cancer by administering an anti-LGR5 monoclonal antibody
JP7080213B2 (ja) 2016-03-23 2022-06-03 スーチョウ トランセンタ セラピューティクス カンパニー，リミテッド 新規抗ｐｄ－ｌ１抗体
EP3432924A1 (de) 2016-03-23 2019-01-30 Novartis AG Zellsekretierte minikörper und verwendungen davon
KR102448456B1 (ko) 2016-03-23 2022-09-28 프로틱스 비브이 인자 xi의 활성 부위에 대한 모노클로날 항체 및 이의 용도
SG10202008909VA (en) 2016-03-24 2020-10-29 Bayer Pharma AG Prodrugs of cytotoxic active agents having enzymatically cleavable groups
EP3433278A4 (de) 2016-03-25 2019-11-06 Seattle Genetics, Inc. Verfahren zur herstellung von pegylierten wirkstoff-linkern und zwischenprodukten davon
EP3433274A1 (de) 2016-03-25 2019-01-30 Visterra, Inc. Formulierung von antikörpermolekülen gegen das denguevirus
CN108700598A (zh) 2016-03-25 2018-10-23 豪夫迈·罗氏有限公司 多路总抗体和抗体缀合的药物量化测定法
EP3436475A1 (de) 2016-03-29 2019-02-06 STCube & Co., Inc. Verfahren zur auswahl von antikörpern, die spezifisch glykosylierte immunkontrollpunktproteine binden
US10980894B2 (en) 2016-03-29 2021-04-20 Obi Pharma, Inc. Antibodies, pharmaceutical compositions and methods
EP3225997A1 (de) 2016-03-29 2017-10-04 Universitätsklinikum Hamburg-Eppendorf Thsd7a als neues target für die krebstherapie und krebsdiagnose
AU2017239637A1 (en) 2016-03-29 2018-11-15 Obi Pharma, Inc. Antibodies, pharmaceutical compositions and methods
CN109195991B (zh) 2016-03-29 2023-10-31 斯特库比股份有限公司 对糖基化pd-l1特异的双重功能抗体及其使用方法
EP3436477A2 (de) 2016-03-29 2019-02-06 Janssen Biotech, Inc. Verfahren zur behandlung von psoriasis mit erhöhter intervalldosierung von anti-il12- und/oder -23-antikörper
JP2019510517A (ja) 2016-03-29 2019-04-18 ジェルター， インコーポレイテッド 細胞質内体積に対するペリプラズム体積の比率が０．５：１および１０：１の間にあるグラム陰性細菌におけるタンパク質の発現
WO2017173091A1 (en) 2016-03-30 2017-10-05 Musc Foundation For Research Development Methods for treatment and diagnosis of cancer by targeting glycoprotein a repetitions predominant (garp) and for providing effective immunotherapy alone or in combination
WO2017173327A1 (en) 2016-03-31 2017-10-05 The Schepens Eye Research Institute, Inc. Endomucin inhibitor as an anti-angiogenic agent
NZ745531A (en) 2016-03-31 2020-09-25 Omeros Corp Methods for inhibiting angiogenesis in a subject in need thereof
CN117986363A (zh) 2016-03-31 2024-05-07 恩格姆生物制药公司 结合蛋白及其使用方法
US10836720B2 (en) 2016-04-01 2020-11-17 The Regents Of The University Of California Inhibitors of integrin alpha 5 beta 1 and methods of use
AU2017246794B2 (en) 2016-04-04 2024-07-04 Genzyme Corporation Anti-complement factor Bb antibodies and uses thereof
EP3440190B1 (de) 2016-04-05 2024-08-28 Pfizer Inc. Zellkulturverfahren
BR112018070452A2 (pt) 2016-04-05 2019-02-05 Baliopharm Ag um inibidor do receptor de hutnfr1, uma preparação farmacêutica compreendendo o referido inibidor, um método de produção do referido inibidor, uso do referido inibidor na fabricação de um produto para tratamento de um indivíduo humano, um ácido nucleico isolado que codifica o referido inibidor, vetor de expressão e células hospedeiras compreendendo o referido ácido nucleico
US20170306027A1 (en) 2016-04-06 2017-10-26 Acceleron Pharma Inc. Alk7 antagonists and uses thereof
EP3440468B1 (de) 2016-04-06 2021-12-01 Nestle Sa Biomarker zur vorhersage des grads des gewichtsverlusts
US20200330459A1 (en) 2016-04-06 2020-10-22 Inserm (Institut National De La Santé Et La Recherche Médicale) Methods and pharmaceutical compositions for the treatment of age-related cardiometabolic diseases
US11262358B2 (en) 2016-04-06 2022-03-01 Technion Research & Development Foundation Limited Infiltrating immune cell proportions predict anti-TNF response in colon biopsies
SG10202110335PA (en) 2016-04-06 2021-10-28 Immatics Biotechnologies Gmbh Novel peptides and combination of peptides for use in immunotherapy against aml and other cancers
CN109195620B (zh) 2016-04-07 2022-06-28 约翰霍普金斯大学 用死亡受体激动剂治疗胰腺炎和疼痛的组合物和方法
WO2017175058A1 (en) 2016-04-07 2017-10-12 Janssen Pharmaceutica Nv Anti-vista antibodies and fragments, uses thereof, and methods of identifying same
KR102611444B1 (ko) 2016-04-08 2023-12-06 지엘바이오, 인크. 플렉틴-1 결합 항체 및 그의 용도
JP2019513737A (ja) 2016-04-08 2019-05-30 ギリアード サイエンシーズ， インコーポレイテッド がん、炎症性疾患および自己免疫疾患を処置するための組成物および方法
EP3443004A1 (de) 2016-04-14 2019-02-20 H. Hoffnabb-La Roche Ag Anti-rspo3-antikörper und verfahren zur verwendung
EP4656204A3 (de) 2016-04-15 2026-06-03 BioAtla, Inc. Anti-axl-antikörper, antikörperfragmente und deren immunkonjugate und verwendungen davon
WO2017181079A2 (en) 2016-04-15 2017-10-19 Genentech, Inc. Methods for monitoring and treating cancer
CN109069633A (zh) 2016-04-15 2018-12-21 宏观基因有限公司 新颖的b7-h3-结合分子、其抗体药物缀合物及其使用方法
AU2017250583A1 (en) 2016-04-15 2018-08-16 Boehringer Ingelheim International Gmbh Methods of treating inflammatory diseases
PE20190115A1 (es) 2016-04-15 2019-01-16 Immunext Inc Anticuerpos vista antihumanos y su uso
SG10202109691UA (en) 2016-04-15 2021-10-28 Alder Biopharmaceuticals Inc Anti-pacap antibodies and uses thereof
US20230071283A1 (en) 2016-04-15 2023-03-09 Aimee S. Payne Compositions and methods for selective protein expression
WO2017181098A2 (en) 2016-04-15 2017-10-19 Visterra, Inc. Antibody molecules to zika virus and uses thereof
PL3443350T3 (pl) 2016-04-15 2021-05-31 F. Hoffmann-La Roche Ag Sposoby monitorowania i leczenia nowotworu
JOP20170091B1 (ar) 2016-04-19 2021-08-17 Amgen Res Munich Gmbh إعطاء تركيبة ثنائية النوعية ترتبط بـ cd33 وcd3 للاستخدام في طريقة لعلاج اللوكيميا النخاعية
EP3445393B1 (de) 2016-04-20 2026-01-14 Merck Sharp & Dohme LLC Cmv-neutralisierende antigenbindende proteine
WO2017182609A1 (en) 2016-04-22 2017-10-26 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and pharmaceutical composition for the treatment of inflammatory skin diseases associated with desmoglein-1 deficiency
JP7103950B2 (ja) 2016-04-22 2022-07-20 アクセレロン ファーマ インコーポレーテッド Ａｌｋ７結合性タンパク質及びその使用
BR112018071612A2 (pt) 2016-04-22 2019-02-19 Alligator Bioscience Ab polipeptídeos biespecíficos inovadores contra cd137
IL262296B2 (en) 2016-04-22 2024-09-01 Obi Pharma Inc Cancer immunotherapy by immune activation or immune modulation via globo series antigens
WO2017189805A1 (en) 2016-04-27 2017-11-02 Abbvie Inc. Methods of treatment of diseases in which il-13 activity is detrimental using anti-il-13 antibodies
RU2725292C2 (ru) 2016-04-27 2020-06-30 Иммьюномедикс, Инк. Эффективность конъюгатов антитела против trop-2 с лекарственным средством sn-38 для терапии рецидивирующих/рефрактерных к ингибиторам контрольной точки опухолей
US11410746B2 (en) 2016-04-27 2022-08-09 Massachusetts Institute Of Technology Stable nanoscale nucleic acid assemblies and methods thereof
US11514331B2 (en) 2016-04-27 2022-11-29 Massachusetts Institute Of Technology Sequence-controlled polymer random access memory storage
GB201607478D0 (en) 2016-04-29 2016-06-15 Medimmune Ltd Pyrrolobenzodiazepine Conjugates
JP6675017B2 (ja) 2016-05-02 2020-04-01 エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ コントースボディ−単鎖標的結合物質
EP3452512B1 (de) 2016-05-03 2023-03-08 Institut National de la Santé et de la Recherche Médicale (INSERM) Verfahren und pharmazeutische zusammensetzungen zur behandlung von gewebeläsionen
US11376269B2 (en) 2016-05-06 2022-07-05 Inserm Pharmaceutical compositions for the treatment of chemoresistant acute myeloid leukemia (AML)
US10968279B2 (en) 2016-05-09 2021-04-06 Bristol-Myers Squibb Company TL1A antibodies and uses thereof
US11142548B2 (en) 2016-05-10 2021-10-12 Sorbonne Universite Agents that activate CD47 and their use in the treatment of inflammation
US20190151346A1 (en) 2016-05-10 2019-05-23 INSERM (Institute National de la Santé et de la Recherche Médicale) Combinations therapies for the treatment of cancer
BR112018073133A2 (pt) 2016-05-10 2019-04-30 Genentech Inc métodos de diminuição das ligações trissulfeto durante a produção recombinante de polipeptídeos
US10918627B2 (en) 2016-05-11 2021-02-16 Massachusetts Institute Of Technology Convergent and enantioselective total synthesis of Communesin analogs
JP6972022B2 (ja) 2016-05-11 2021-11-24 アムジエン・インコーポレーテツド グルタミンシンセターゼ遺伝子内相補ベクターを用いた高レベルのヘテロマータンパク質発現細胞の直接選択
TWI794171B (zh) 2016-05-11 2023-03-01 美商滬亞生物國際有限公司 Ｈｄａｃ抑制劑與ｐｄ-ｌ１抑制劑之組合治療
JP7089483B2 (ja) 2016-05-11 2022-06-22 エフ・ホフマン－ラ・ロシュ・アクチェンゲゼルシャフト 修飾された抗テネイシン抗体及び使用方法
TWI808055B (zh) 2016-05-11 2023-07-11 美商滬亞生物國際有限公司 Hdac 抑制劑與 pd-1 抑制劑之組合治療
KR20250007678A (ko) 2016-05-13 2025-01-14 더 제너럴 하스피탈 코포레이션 길항성 항-종양 괴사 인자 수용체 슈퍼패밀리 항체
EP4122958A1 (de) 2016-05-13 2023-01-25 BioAtla, Inc. Anti-ror2-antikörper, antikörperfragmente, deren immunkonjugate und verwendungen davon
EP3458853B1 (de) 2016-05-16 2022-09-07 Onco Tracker, Inc. Verbesserte verfahren zur überwachung des immunstatus einer person
RS61659B1 (sr) 2016-05-17 2021-04-29 Abbvie Biotherapeutics Inc Konjugati antitelo lek anti-cmet i metode za njihovu upotrebu
CA3024465A1 (en) 2016-05-17 2017-11-23 Genentech, Inc. Stromal gene signatures for diagnosis and use in immunotherapy
CN107400165A (zh) 2016-05-18 2017-11-28 上海开拓者生物医药有限公司 一种il‑13抗体及其制备方法和应用
CN109152843A (zh) 2016-05-20 2019-01-04 豪夫迈·罗氏有限公司 Protac抗体缀合物及其使用方法
US11623958B2 (en) 2016-05-20 2023-04-11 Harpoon Therapeutics, Inc. Single chain variable fragment CD3 binding proteins
KR102530742B1 (ko) 2016-05-20 2023-05-09 하푼 테라퓨틱스, 인크. 단일 도메인 혈청 알부민 결합 단백질
WO2017202962A1 (en) 2016-05-24 2017-11-30 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and pharmaceutical compositions for the treatment of non small cell lung cancer (nsclc) that coexists with chronic obstructive pulmonary disease (copd)
WO2017202813A1 (en) 2016-05-24 2017-11-30 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and pharmaceutical compositions for the treatment of pulmonary bacterial infections
WO2017202814A1 (en) 2016-05-24 2017-11-30 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and pharmaceutical compositions for the treatment of neuropathological disorders characterized by a loss of cortical neurons
IL245861A0 (en) 2016-05-25 2016-09-04 Yeda Res & Dev Use of substances to treat drug-resistant tumors
TW201802121A (zh) 2016-05-25 2018-01-16 諾華公司 抗因子XI/XIa抗體之逆轉結合劑及其用途
CA3025264A1 (en) 2016-05-25 2017-11-30 Inbiomotion S.L. Therapeutic treatment of breast cancer based on c-maf status
WO2017203051A1 (en) 2016-05-26 2017-11-30 University College Cork - National University Of Ireland, Cork An engineered gram positive bacterium
CA3025391A1 (en) 2016-05-26 2017-11-30 Merck Patent Gmbh Pd-1 / pd-l1 inhibitors for cancer treatment
CA3024618A1 (en) 2016-05-27 2017-11-30 Alexion Pharmaceuticals, Inc. Methods for treatment of refractory generalized myasthenia gravis
WO2017201731A1 (en) 2016-05-27 2017-11-30 Beijing Vdjbio Co., Ltd. Antibodies, composition and kits comprising same, and methods of use thereof
CN109313200B (zh) 2016-05-27 2022-10-04 豪夫迈·罗氏有限公司 用于表征位点特异性抗体-药物缀合物的生物分析性方法
KR102543118B1 (ko) 2016-05-27 2023-06-14 아게누스 인코포레이티드 항-tim-3 항체 및 이의 사용 방법
WO2017202890A1 (en) 2016-05-27 2017-11-30 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and compositions for predicting and treating myeloma
US10875921B2 (en) 2016-05-27 2020-12-29 Abbvie Biotherapeutics Inc. Anti-4-1BB antibodies and their uses
SMT202100721T1 (it) 2016-05-27 2022-01-10 Abbvie Biotherapeutics Inc Anticorpi anti-cd40 e loro usi
WO2017210335A1 (en) 2016-06-01 2017-12-07 Bristol-Myers Squibb Company Imaging methods using 18f-radiolabeled biologics
US10851159B2 (en) 2016-06-02 2020-12-01 Bloom Diagnostics Ag Antibodies that bind to human anti-Müllerian hormone (AMH) and their uses
WO2017210617A2 (en) 2016-06-02 2017-12-07 Porter, David, L. Therapeutic regimens for chimeric antigen receptor (car)- expressing cells
EP3252078A1 (de) 2016-06-02 2017-12-06 F. Hoffmann-La Roche AG Typ ii anti-cd20 antikörper und anti-cd20/cd3 bispecific antikörper zur behandlung von krebs
JP7599819B2 (ja) 2016-06-02 2024-12-16 イムノコア リミテッド ｇｐ１００特異的ＴＣＲ－抗ＣＤ３ ｓｃＦｖ融合タンパク質の投薬レジメン
RS62040B1 (sr) 2016-06-02 2021-07-30 Abbvie Inc Agonist receptora glukokortikoida i njegovi imunokonjugati
JP7043425B2 (ja) 2016-06-06 2022-03-29 ジェネンテック， インコーポレイテッド シルベストロール抗体－薬物コンジュゲート及び使用方法
JP6921943B2 (ja) 2016-06-06 2021-08-18 エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ 増加した眼球保持を伴う眼科用融合タンパク質
US11274345B2 (en) 2016-06-07 2022-03-15 The Board Of Trustees Of The Leland Stanford Junior University Methods for diagnosis of bacterial and viral infections
US12048718B2 (en) 2016-06-07 2024-07-30 Max-Delbrück-Centrum für Molekulare Medizin in der Helmholtz-Geminschaft Chimeric antigen receptor and CAR-T cells that bind BCMA
MX2018015268A (es) 2016-06-08 2019-08-12 Abbvie Inc Anticuerpos anti-cd98 y conjugados de anticuerpo y farmaco.
JP2019526529A (ja) 2016-06-08 2019-09-19 アッヴィ・インコーポレイテッド 抗ｂ７−ｈ３抗体及び抗体薬物コンジュゲート
WO2017214456A1 (en) 2016-06-08 2017-12-14 Abbvie Inc. Anti-cd98 antibodies and antibody drug conjugates
CN109641962A (zh) 2016-06-08 2019-04-16 艾伯维公司 抗b7-h3抗体和抗体药物偶联物
MX2018015272A (es) 2016-06-08 2019-08-12 Abbvie Inc Anticuerpos anti-cd98 y conjugados de anticuerpo y farmaco.
RS61828B1 (sr) 2016-06-08 2021-06-30 Abbvie Inc Anti-b7-h3 antitela i antitelske konjugacije lekova
CA3026490A1 (en) 2016-06-09 2017-12-14 University Of Leicester Monoclonal antibodies, compositions and methods for detecting mucin-like protein (mlp) as a biomarker for ovarian and pancreatic cancer
RU2746314C2 (ru) 2016-06-09 2021-04-12 Пеликан Терапьютикс, Инк. Антитела анти-tnfrsf25
GB201610198D0 (en) 2016-06-10 2016-07-27 Ucb Biopharma Sprl Anti-ige antibodies
WO2017218434A1 (en) 2016-06-12 2017-12-21 Millennium Pharmaceuticals, Inc. Method of treating inflammatory bowel disease
US10059769B2 (en) 2016-06-13 2018-08-28 I-Mab Anti-PD-L1 antibodies and uses thereof
IL263481B2 (en) 2016-06-14 2024-06-01 Regeneron Pharma Anti-c5 antibodies and uses thereof
EA201892716A1 (ru) 2016-06-14 2019-05-31 Мерк Шарп И Доум Корп. Антитела к фактору свертывания xi
WO2017218698A1 (en) 2016-06-15 2017-12-21 Sutro Biopharma, Inc. Antibodies with engineered ch2 domains, compositions thereof and methods of using the same
WO2017216724A1 (en) 2016-06-15 2017-12-21 Novartis Ag Methods for treating disease using inhibitors of bone morphogenetic protein 6 (bmp6)
WO2017216028A1 (en) 2016-06-15 2017-12-21 Bayer Pharma Aktiengesellschaft Specific antibody-drug-conjugates (adcs) with ksp inhibitors and anti-cd123-antibodies
CA3026518A1 (en) 2016-06-17 2017-12-21 Genentech, Inc. Purification of multispecific antibodies
WO2017218891A1 (en) 2016-06-17 2017-12-21 Life Technologies Corporation Site-specific crosslinking of antibodies
TWI760396B (zh) 2016-06-17 2022-04-11 日商中外製藥股份有限公司 抗肌抑素抗體及使用方法
KR102379464B1 (ko) 2016-06-20 2022-03-29 키맵 리미티드 항-pd-l1 항체
JP7085709B2 (ja) 2016-06-20 2022-06-17 エフ－スター セラピューティクス リミテッド Ｐｄ－ｌ１及びｌａｇ－３に結合する結合分子
EP3471761A2 (de) 2016-06-21 2019-04-24 University Of Oslo Hla-bindende impfstoffeinheiten und verwendungen davon
IL299221A (en) 2016-06-21 2023-02-01 Teneobio Inc Cd3 binding antibodies
WO2017221255A1 (en) 2016-06-23 2017-12-28 Memed Diagnostics Ltd. Measuring trail by lateral flow immunoassay
JP7133477B2 (ja) 2016-06-24 2022-09-08 ジェネンテック， インコーポレイテッド 抗ポリユビキチン多重特異性抗体
FR3053042B1 (fr) 2016-06-24 2018-08-10 Commissariat A L'energie Atomique Et Aux Energies Alternatives Anticorps dirige contre le sous-type b des recepteurs aux endothelines et ses utilisations
EP3264087B1 (de) 2016-06-27 2020-04-22 Chimera Biotec GmbH Verfahren und vorrichtung zur quantifizierung von zielmolekülen
KR20230047507A (ko) 2016-06-27 2023-04-07 더 리젠츠 오브 더 유니버시티 오브 캘리포니아 암 치료 조합
WO2018001844A1 (en) 2016-06-28 2018-01-04 Nestec S.A. Biomarkers of blood-brain barrier dysfunction
GB201611530D0 (en) 2016-07-01 2016-08-17 Alligator Bioscience Ab Novel polypeptides
US20190263919A1 (en) 2016-07-01 2019-08-29 Five Prime Therapeutics, Inc. Combined anti tumor therapy with a gitr agonist and cpg
JP6983824B2 (ja) 2016-07-04 2021-12-17 エフ.ホフマン−ラ ロシュ アーゲーF. Hoffmann−La Roche Aktiengesellschaft 新規抗体フォーマット
EA038617B1 (ru) * 2016-07-06 2021-09-23 Онкоиммьюн, Инк. Химерные и гуманизированные античеловеческие ctla-4 моноклональные антитела и их использование
CA3030219A1 (en) 2016-07-07 2018-01-11 Berg Llc Lipid, protein, and metabolite markers for the diagnosis and treatment of prostate cancer
WO2018007999A1 (en) 2016-07-08 2018-01-11 Staten Biotechnology B.V. Anti-apoc3 antibodies and methods of use thereof
WO2018011691A1 (en) 2016-07-12 2018-01-18 Nestec S.A. Competitive immunoassay methods
TWI802545B (zh) 2016-07-13 2023-05-21 英商４Ｄ製藥有限公司 包含細菌菌株之組合物
WO2018013714A1 (en) 2016-07-13 2018-01-18 Biogen Ma Inc. Dosage regimens of lingo-1 antagonists and uses for treatment of demyelinating disorders
AU2017295704B2 (en) 2016-07-13 2023-07-13 President And Fellows Of Harvard College Antigen-presenting cell-mimetic scaffolds and methods for making and using the same
US20190248893A1 (en) 2016-07-14 2019-08-15 Bristol-Myers Squibb Company Antibodies against tim3 and uses thereof
EP3484455A2 (de) 2016-07-15 2019-05-22 Novartis AG Behandlung und prävention von zytokin-freisetzungssyndrom unter verwendung eines chimären antigenrezeptors in kombination mit einem kinasehemmer
AU2017296040C1 (en) 2016-07-15 2023-06-22 Acceleron Pharma Inc. Compositions and methods for treating pulmonary hypertension
EP3484517B1 (de) 2016-07-18 2025-07-02 Ramot at Tel-Aviv University Ltd. Modulare plattform für gezielte therapeutika
WO2018017814A1 (en) 2016-07-20 2018-01-25 President And Fellows Of Harvard College Peptidoglycan glycosyltransferase inhibitors of sed proteins for treating bacterial infections
US11365252B2 (en) 2016-07-20 2022-06-21 University Of Utah Research Foundation CD229 CAR T cells and methods of use thereof
WO2018014260A1 (en) 2016-07-20 2018-01-25 Nanjing Legend Biotech Co., Ltd. Multispecific antigen binding proteins and methods of use thereof
US11746152B2 (en) 2016-07-20 2023-09-05 Stcube, Inc. Methods of cancer treatment and therapy using a combination of antibodies that bind glycosylated PD-L1
US20200148750A1 (en) 2016-07-21 2020-05-14 Emory University Ebola Virus Antibodies and Binding Agents Derived Therefrom
JP2019531332A (ja) 2016-07-22 2019-10-31 ドイチェス ツェントルム フュール ノイロデゲネラティフェ アークランクンゲン エー．ファウ．（デーツェットエンエー） Ｔｒｅｍ２切断モジュレーター及びその使用
CA3031194A1 (en) 2016-07-22 2018-01-25 Dana-Farber Cancer Institute, Inc. Glucocorticoid-induced tumor necrosis factor receptor (gitr) antibodies and methods of use thereof
US11285191B2 (en) 2016-07-26 2022-03-29 The Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical College Immunostimulatory compositions and uses therefor
LT3490582T (lt) 2016-07-27 2024-07-25 Acceleron Pharma Inc. Kompozicijos, skirtos naudoti gydant mielofibrozę
KR20190067765A (ko) 2016-07-27 2019-06-17 오비아이 파머 인코퍼레이티드 면역원성/치료 글리칸 조성물 및 그의 용도
EP3491387A1 (de) 2016-07-28 2019-06-05 Institut National de la Sante et de la Recherche Medicale (INSERM) Verfahren zur behandlung von krebserkrankungen durch abzielen auf tumor-assoziierte makrophagen
KR102528998B1 (ko) 2016-07-29 2023-05-03 오비아이 파머 인코퍼레이티드 인간 항체, 제약 조성물 및 방법
MA45784A (fr) 2016-07-29 2019-06-05 Juno Therapeutics Inc Anticorps anti-idiotypes dirigés contre anti-cd19 anticorps
GB201613167D0 (en) 2016-07-29 2016-09-14 Univ Southampton Cancer and b-cell related disease therapy
CA3027018A1 (en) 2016-07-29 2018-02-01 Chugai Seiyaku Kabushiki Kaisha Bispecific antibody exhibiting increased alternative fviii-cofactor-function activity
EP3491022B1 (de) 2016-07-29 2025-09-10 Institut National de la Santé et de la Recherche Médicale (INSERM) Antikörper gegen tumor-assoziierte makrophagen und verwendungen davon
NL2017267B1 (en) 2016-07-29 2018-02-01 Aduro Biotech Holdings Europe B V Anti-pd-1 antibodies
CN118530358A (zh) 2016-08-01 2024-08-23 佐马美国有限公司 甲状旁腺激素受体1（pth1r）抗体和其用途
JOP20170154B1 (ar) 2016-08-01 2023-03-28 Omeros Corp تركيبات وطرق لتثبيط masp-3 لعلاج أمراض واضطرابات مختلفة
SG11201900885VA (en) 2016-08-01 2019-02-27 Novartis Ag Treatment of cancer using a chimeric antigen receptor in combination with an inhibitor of a pro-m2 macrophage molecule
WO2018026953A1 (en) 2016-08-02 2018-02-08 TCR2 Therapeutics Inc. Compositions and methods for tcr reprogramming using fusion proteins
NL2017270B1 (en) 2016-08-02 2018-02-09 Aduro Biotech Holdings Europe B V New anti-hCTLA-4 antibodies
CA3032820A1 (en) 2016-08-02 2018-03-22 Visterra, Inc. Engineered polypeptides and uses thereof
JP2018058822A (ja) 2016-08-03 2018-04-12 ファイザー・インク ヘテロアリールスルホンをベースとするコンジュゲーションハンドル、これらの調製のための方法、および抗体薬物コンジュゲートの合成におけるこれらの使用
EP3493845A4 (de) 2016-08-03 2020-04-15 The Board of Trustees of the Leland Stanford Junior University Unterbrechung des fc-rezeptor-einsatzes auf makrophagen zur verbesserung der wirksamkeit der anti-sirpalpha-antikörpertherapie
BR112019002039A2 (pt) 2016-08-05 2019-05-07 Medimmune, Llc anticorpos anti-o2 e uso dos mesmos
EP3494139B1 (de) 2016-08-05 2022-01-12 F. Hoffmann-La Roche AG Multivalente und multiepitopische anitikörper mit agonistischer wirkung und verfahren zur verwendung
CN116271014A (zh) 2016-08-05 2023-06-23 中外制药株式会社 用于预防或治疗il-8相关疾病的组合物
CN109562153A (zh) 2016-08-07 2019-04-02 诺华股份有限公司 mRNA介导的免疫方法
WO2018029124A1 (en) 2016-08-08 2018-02-15 F. Hoffmann-La Roche Ag Therapeutic and diagnostic methods for cancer
KR20240010534A (ko) 2016-08-09 2024-01-23 씨젠 인크. 개선된 물리화학적 특성을 갖는 자기 안정화 링커를 구비한 약물 접합체
ES2919927T3 (es) 2016-08-10 2022-07-29 Pasteur Institut Métodos y reactivos para la detección del paludismo por Plasmodium falciparum resistente a la piperaquina
PL3896091T3 (pl) 2016-08-10 2024-04-29 Legend Biotech Ireland Limited Chimeryczne receptory antygenowe nakierowane na bcma i sposoby ich zastosowania
WO2018031662A1 (en) 2016-08-11 2018-02-15 Genentech, Inc. Pyrrolobenzodiazepine prodrugs and antibody conjugates thereof
CN109689102A (zh) 2016-08-12 2019-04-26 基因泰克公司 Mek抑制剂,pd-1轴抑制剂,和vegf抑制剂的组合疗法
EP3497125A1 (de) 2016-08-12 2019-06-19 ARSANIS Biosciences GmbH Auf klebsiella pneumoniae abzielende monoklonale anti-galactan-ii-antikörper
JP2019530646A (ja) 2016-08-12 2019-10-24 ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ タンパク質精製法
US10759848B2 (en) 2016-08-12 2020-09-01 Arsanis Biosciences Gmbh Klebsiella pneumoniae O3 specific antibodies
CN115598231B (zh) 2016-08-15 2025-11-18 豪夫迈·罗氏有限公司 定量包含非离子表面活性剂和多肽的组合物中非离子表面活性剂的层析方法
EP4252847A3 (de) 2016-08-15 2023-11-15 Novartis AG Therapiepläne und verfahren zur behandlung von multipler sklerose mittels ofatumumab
US11630103B2 (en) 2016-08-17 2023-04-18 The Broad Institute, Inc. Product and methods useful for modulating and evaluating immune responses
US11225689B2 (en) 2016-08-17 2022-01-18 The Broad Institute, Inc. Method for determination and identification of cell signatures and cell markers
CN106938051B (zh) 2016-08-22 2019-10-11 复旦大学 靶向于组织因子的抗体-药物偶联物
WO2018038046A1 (ja) 2016-08-22 2018-03-01 中外製薬株式会社 ヒトｇｐｃ３ポリペプチドを発現する遺伝子改変非ヒト動物
CA3034057A1 (en) 2016-08-22 2018-03-01 CHO Pharma Inc. Antibodies, binding fragments, and methods of use
CN106967172B (zh) 2016-08-23 2019-01-08 康方药业有限公司 抗ctla4-抗pd-1 双功能抗体、其药物组合物及其用途
CN109863171B (zh) 2016-08-23 2023-08-04 免疫医疗有限公司 抗vegf-a和抗ang2抗体及其用途
WO2018035710A1 (en) 2016-08-23 2018-03-01 Akeso Biopharma, Inc. Anti-ctla4 antibodies
CN106977602B (zh) 2016-08-23 2018-09-25 中山康方生物医药有限公司 一种抗pd1单克隆抗体、其药物组合物及其用途
JP6949106B2 (ja) 2016-08-23 2021-10-13 メディミューン リミテッド 抗ｖｅｇｆ−ａ抗体ならびにそれらの使用
TW202304970A (zh) 2016-08-26 2023-02-01 德商英麥提克生物技術股份有限公司 用於頭頸鱗狀細胞癌和其他癌症免疫治療的新型肽和支架
SG10201913074WA (en) 2016-08-30 2020-03-30 Regeneron Pharma Methods of treating severe insulin resistance by interfering with glucagon receptor signaling
GB201614627D0 (en) 2016-08-30 2016-10-12 Glaxosmithkline Ip Dev Ltd Antigen binding proteins
AU2017318907B2 (en) 2016-08-31 2023-07-06 Oncotherapy Science, Inc. Monoclonal antibody against MELK and utilization thereof
WO2018045245A1 (en) 2016-09-02 2018-03-08 Sirenas Llc Cyclic peptide analogs and conjugates thereof
CA3035081A1 (en) 2016-09-02 2018-03-08 Dana-Farber Cancer Institute, Inc. Composition and methods of treating b cell disorders
US20190225682A1 (en) 2016-09-02 2019-07-25 180 Therapeutics Lp Method of treating localized fibrotic disorders using an il-33/tnf bispecific antibody
WO2018045213A1 (en) 2016-09-02 2018-03-08 180 Therapeutics Lp Method of treating systemic fibrotic disorders using an il-33/tnf bispecific antibody
EP3509633A1 (de) 2016-09-06 2019-07-17 Dana-Farber Cancer Institute, Inc. Verfahren zur behandlung oder vorbeugung einer zika-virus-infektion
WO2018049027A1 (en) 2016-09-07 2018-03-15 Trustees Of Tufts College Combination therapies using immuno-dash inhibitors and pge2 antagonists
US11168148B2 (en) 2016-09-07 2021-11-09 The Regents Of The University Of California Antibodies to oxidation-specific epitopes
JP2020501506A (ja) 2016-09-07 2020-01-23 イッサム リサーチ デベロップメント カンパニー オブ ザ ヘブリュー ユニバーシティー オブ エルサレム エルティーディー． 抗ＮＫｐ４６抗体およびその治療的使用
TW201825511A (zh) 2016-09-09 2018-07-16 美商艾斯合顧問有限公司 表現免疫檢查點調節子的溶瘤病毒
EP3293271A1 (de) 2016-09-12 2018-03-14 The Provost, Fellows, Foundation Scholars, & the other members of Board, of the College of the Holy & Undiv. Trinity of Queen Elizabeth near Dublin Marker und target als eine diagnosevariable und target zur therapie von metastatischem krebs
EP3512883A1 (de) 2016-09-13 2019-07-24 Humanigen, Inc. Epha3-antikörper zur behandlung von lungenfibrose
MX2019002946A (es) 2016-09-14 2019-09-26 Abbvie Biotherapeutics Inc Anticuerpos anti-pd-1 y sus usos.
CR20220578A (es) 2016-09-14 2023-01-17 Teneobio Inc Anticuerpos de unión a cd3
US11202818B2 (en) 2016-09-14 2021-12-21 President And Fellows Of Harvard College Methods and compositions for modulating erythropoiesis
SG10201607778XA (en) 2016-09-16 2018-04-27 Chugai Pharmaceutical Co Ltd Anti-Dengue Virus Antibodies, Polypeptides Containing Variant Fc Regions, And Methods Of Use
SI4339615T1 (sl) 2016-09-16 2026-01-30 Shanghai Henlius Biotech, Inc. Protitelesa anti-pd-1 za uporabo pri zdravljenju raka
DK3328887T3 (da) 2016-09-19 2021-09-20 I Mab Biopharma Hangzhou Co Ltd Anti-GM-CSF antistoffer og anvendelser deraf
WO2018053508A1 (en) 2016-09-19 2018-03-22 The University Of North Carolina At Chapel Hill Methods and compositions for inducing an immune response
EP3515943A4 (de) 2016-09-19 2020-05-06 Celgene Corporation Verfahren zur behandlung von vitiligo mithilfe von pd-1-bindenden proteinen
EP3515944A4 (de) 2016-09-19 2020-05-06 Celgene Corporation Verfahren zur behandlung von immunerkrankungen unter verwendung von pd-1 bindenden proteinen
CN116731197A (zh) 2016-09-19 2023-09-12 豪夫迈·罗氏有限公司 基于补体因子的亲和层析
AU2017329780B2 (en) 2016-09-20 2024-11-14 Merck Patent Gmbh Diagnostic anti-PD-L1 antibody and use thereof
CA3034643A1 (en) 2016-09-20 2018-03-29 Ellen Weisberg Compositions and methods for identification, assessment, prevention, and treatment of aml using usp10 biomarkers and modulators
EP4360714A3 (de) 2016-09-21 2024-07-24 Nextcure, Inc. Antikörper für siglec-15 und verfahren zur verwendung davon
KR102644544B1 (ko) 2016-09-21 2024-03-11 넥스트큐어 인코포레이티드 Siglec-15를 위한 항체 및 이의 사용 방법
JOP20190009A1 (ar) 2016-09-21 2019-01-27 Alx Oncology Inc أجسام مضادة ضد بروتين ألفا منظم للإشارات وطرق استخدامها
EP3516071B1 (de) 2016-09-22 2021-02-17 INSERM (Institut National de la Santé et de la Recherche Médicale) Verfahren und pharmazeutische zusammensetzungen zur behandlung von lungenkrebs
CA3034105A1 (en) 2016-09-23 2018-03-29 Csl Limited Coagulation factor binding proteins and uses thereof
SMT202600087T1 (it) 2016-09-23 2026-03-09 Teva Pharmaceuticals Int Gmbh Trattamento dell’emicrania refrattaria
EP3515488A1 (de) 2016-09-23 2019-07-31 Teva Pharmaceuticals International GmbH Behandlung von cluster-kopfschmerzen
EP3516390A1 (de) 2016-09-23 2019-07-31 Stichting Het Nederlands Kanker Instituut- Antoni van Leeuwenhoek Ziekenhuis Manipulation der immunaktivität durch modulation der expression
TWI787203B (zh) 2016-09-23 2022-12-21 美商建南德克公司 Il-13拮抗劑用於治療異位性皮炎之用途
CA3036564A1 (en) 2016-09-23 2018-03-29 Elstar Therapeutics, Inc. Multispecific antibody molecules comprising lambda and kappa light chains
JOP20190055A1 (ar) 2016-09-26 2019-03-24 Merck Sharp & Dohme أجسام مضادة ضد cd27
EP3515494B1 (de) 2016-09-26 2026-02-25 The Brigham and Women's Hospital, Inc. Regulatoren der b-zellvermittelten immunsuppression
US10906957B2 (en) 2016-09-27 2021-02-02 Epicentrx, Inc. Immunomodulatory fusion proteins
US10858428B2 (en) 2016-09-28 2020-12-08 Xoma (Us) Llc Antibodies that bind interleukin-2 and uses thereof
CN109862913B (zh) 2016-09-29 2023-09-05 加利福尼亚大学董事会 用于免疫疗法的αvβ8整联蛋白复合物的中和抗体
IL307684B2 (en) 2016-09-29 2025-04-01 Amgen Inc Low viscosity antigen binding proteins and methods for preparing them
WO2018064299A1 (en) 2016-09-29 2018-04-05 Genentech, Inc. Combination therapy with a mek inhibitor, a pd-1 axis inhibitor, and a taxane
EP3519049B1 (de) 2016-09-30 2025-12-03 Janssen Biotech, Inc. Sicheres und effizientes verfahren zur behandlung von psoriasis mit anti-il23-spezifischem antikörper
CA3036714A1 (en) 2016-10-03 2018-04-12 Abbott Laboratories Improved methods of assessing uch-l1 status in patient samples
EP3523330A1 (de) 2016-10-04 2019-08-14 Fairbanks Pharmaceuticals, Inc. Anti-fstl3-antikörper und verwendungen davon
WO2018067740A1 (en) 2016-10-05 2018-04-12 Acceleron Pharma, Inc. Compositions and method for treating kidney disease
CN109952369B (zh) 2016-10-05 2024-03-22 弗罗里达中央大学研究基金会 涉及nk细胞和抗pdl1癌症治疗的方法和组合物
JP7050770B2 (ja) 2016-10-05 2022-04-08 エフ・ホフマン－ラ・ロシュ・アクチェンゲゼルシャフト 抗体薬物コンジュゲートの調製方法
BR112019006504A2 (pt) 2016-10-06 2019-06-25 Pfizer Inc. regime de dosagem de avelumabe para o tratamento de câncer
KR102804118B1 (ko) 2016-10-06 2025-05-09 제넨테크, 인크. 암에 대한 치료 및 진단 방법
TWI762516B (zh) 2016-10-06 2022-05-01 日商腫瘤療法 科學股份有限公司 針對ｆｚｄ１０之單株抗體及其用途
US12447213B2 (en) 2016-10-07 2025-10-21 The Broad Institute, Inc. Modulation of novel immune checkpoint targets
BR112019007100A2 (pt) 2016-10-07 2019-06-25 Tcr2 Therapeutics Inc composições e métodos para reprogramação de receptores de célula t com o uso de proteínas de fusão
JP7467117B2 (ja) 2016-10-07 2024-04-15 ノバルティス アーゲー 癌の治療のためのキメラ抗原受容体
WO2018068201A1 (en) 2016-10-11 2018-04-19 Nanjing Legend Biotech Co., Ltd. Single-domain antibodies and variants thereof against ctla-4
KR20230133934A (ko) 2016-10-11 2023-09-19 아게누스 인코포레이티드 항-lag-3 항체 및 이의 사용 방법
IL326479A (en) 2016-10-12 2026-04-01 Bioverativ Usa Inc Anti-c1s antibodies and methods of use thereof
US20190233512A1 (en) 2016-10-12 2019-08-01 Sutro Biopharma, Inc. Anti-folate receptor antibodies, compositions comprising anti-folate receptor antibodies and methods of making and using anti-folate receptor antibodies
CN110621774A (zh) 2016-10-14 2019-12-27 儿童医疗中心有限公司 用于治疗中枢神经系统疾病和病症的组合物和方法
GB201617466D0 (en) 2016-10-14 2016-11-30 Medimmune Ltd Pyrrolobenzodiazepine conjugates
SG11201902974PA (en) 2016-10-14 2019-05-30 Merck Sharp & Dohme Combination of a pd-1 antagonist and eribulin for treating urothelial cancer
WO2018071504A2 (en) 2016-10-14 2018-04-19 Boehringer Ingelheim International Gmbh Methods of treating diseases
WO2018071809A1 (en) 2016-10-14 2018-04-19 Ariad Pharmaceuticals, Inc. Inducible t-cell system and uses thereof
WO2018075564A1 (en) 2016-10-17 2018-04-26 University Of Maryland, College Park Multispecific antibodies targeting human immunodeficiency virus and methods of using the same
EA201990890A1 (ru) 2016-10-18 2019-10-31 Целевая доставка ингибиторов реутилизационного пути никотинамидадениндинуклеотида
CA3039686A1 (en) 2016-10-19 2018-04-26 Medimmune, Llc Anti-o1 antibodies and uses thereof
EP3529268B1 (de) 2016-10-19 2025-02-26 The Scripps Research Institute Chimäre antigenrezeptor-effektorzellen-switches mit humanisierten targeting-einheiten und/oder optimierten chimären antigen-rezeptor-interaktionsdomänen und verwendungen davon
US20200140565A1 (en) 2016-10-20 2020-05-07 I-Mab Novel cd47 monoclonal antibodies and uses thereof
US11286295B2 (en) 2016-10-20 2022-03-29 Sanofi Anti-CHIKV monoclonal antibodies directed against the E2 structural protein
SMT202100555T1 (it) 2016-10-21 2021-11-12 Inst Nat Sante Rech Med Metodi per promuovere la risposta di cellule t
WO2018073363A1 (en) 2016-10-21 2018-04-26 Innate Pharma Treatment with anti-kir3dl2 agents
AR109621A1 (es) 2016-10-24 2018-12-26 Janssen Pharmaceuticals Inc Formulaciones de vacunas contra glucoconjugados de expec
CN110121508A (zh) 2016-10-25 2019-08-13 法国国家健康和医学研究院 与cd160跨膜同种型结合的单克隆抗体
BR112019007856A8 (pt) 2016-10-28 2023-04-11 Merck Sharp & Dohme Composição, e, método para remover anticorpos de tirosina sulfatada ou fragmentos de ligação a antígeno dos mesmos
WO2018081531A2 (en) 2016-10-28 2018-05-03 Ariad Pharmaceuticals, Inc. Methods for human t-cell activation
JP2020500508A (ja) 2016-10-28 2020-01-16 バンヤン・バイオマーカーズ・インコーポレーテッド ユビキチンｃ末端ヒドロラーゼｌ１（ｕｃｈ−ｌ１）およびグリア線維酸性タンパク質（ｇｆａｐ）に対する抗体および関連する方法
EP3532091A2 (de) 2016-10-29 2019-09-04 H. Hoffnabb-La Roche Ag Anti-mic-antikörper und verfahren zur verwendung
US11124577B2 (en) 2016-11-02 2021-09-21 Engmab Sàrl Bispecific antibody against BCMA and CD3 and an immunological drug for combined use in treating multiple myeloma
EP3534953A4 (de) 2016-11-02 2020-10-07 Vanderbilt University Humane zirka-virus-antikörper und verfahren zur verwendung davon
LT3535298T (lt) 2016-11-02 2021-12-27 Jounce Therapeutics, Inc. Antikūnai prieš pd-1 ir jų panaudojimas
AU2017355402A1 (en) 2016-11-02 2019-05-30 Health Research, Inc. Combination treatment with antibody-drug conjugates and PARP inhibitors
WO2018083248A1 (en) 2016-11-03 2018-05-11 Kymab Limited Antibodies, combinations comprising antibodies, biomarkers, uses & methods
CA3040812A1 (en) 2016-11-04 2018-05-11 Novimmune Sa Anti-cd19 antibodies and methods of use thereof
US20200055947A1 (en) 2016-11-04 2020-02-20 Memorial Sloan Kettering Cancer Center Bi-specific activators for tumor therapy
CN109906030B (zh) 2016-11-04 2022-03-18 安健基因公司 用于产生仅重链抗体的经基因修饰的非人动物和方法
EP3535294B1 (de) 2016-11-07 2025-02-12 Neuracle Science Co., Ltd. Anti-familie mit sequenzähnlichkeit 19, element a5-antikörper und verfahren zur verwendung davon
JP7127859B2 (ja) 2016-11-09 2022-08-30 ノース カロライナ ステート ユニバーシティ キメラタンパク質を用いたアレルギー疾患の治療
US11103592B2 (en) 2016-11-09 2021-08-31 Philogen S.P.A. IL2 and TNF mutant immunoconjugates
EP3538551A4 (de) 2016-11-10 2020-11-11 Fortis Therapeutics, Inc. Cd46-specifische effektorzellen und verwendungen davon
WO2018087285A1 (en) 2016-11-10 2018-05-17 Deutsches Krebsforschungszentrum Stiftung des öffentlichen Rechts Or10h1 antigen binding proteins and uses thereof
DK3321280T3 (da) 2016-11-10 2021-02-22 Deutsches Krebsforschungszentrum Stiftung Des Oeffentlichen Rechts Immunmodulatorer til reduktion af immunresistens i et melanom og andre proliferative sygdomme
US11434301B2 (en) 2016-11-11 2022-09-06 The Regents Of The University Of California Anti-CD46 antibodies and methods of use
WO2018089386A1 (en) 2016-11-11 2018-05-17 The Broad Institute, Inc. Modulation of intestinal epithelial cell differentiation, maintenance and/or function through t cell action
CN116637177A (zh) 2016-11-11 2023-08-25 好利恩治疗美国公司 泼尼松和尿酸酶分子的组合疗法及其用途
KR20220147719A (ko) 2016-11-14 2022-11-03 항저우 디에이씨 바이오테크 씨오, 엘티디 결합 링커, 그러한 결합 링커를 함유하는 세포 결합 분자-약물 결합체, 링커를 갖는 그러한 결합체의 제조 및 사용
WO2018089967A1 (en) 2016-11-14 2018-05-17 Virginia Commonwealth University Inhibitors of cancer invasion, attachment, and/or metastasis
CN109996809A (zh) 2016-11-14 2019-07-09 诺华股份有限公司 与促融合蛋白minion相关的组合物、方法和治疗用途
WO2018093797A1 (en) 2016-11-15 2018-05-24 The Schepens Eye Research Institute, Inc. Compositions and methods for the treatment of aberrant angiogenesis
EP3541843A1 (de) 2016-11-15 2019-09-25 Genentech, Inc. Dosierung zur behandlung mit anti-cd20/anti-cd3-bispezifischen antikörpern
JP7645607B2 (ja) 2016-11-16 2025-03-14 ヤンセン バイオテツク，インコーポレーテツド 抗ｉｌ２３特異的抗体で乾癬を治療する方法
WO2018094143A1 (en) 2016-11-17 2018-05-24 Siamab Therapeutics, Inc. Glycan-interacting compounds and methods of use
WO2018094275A1 (en) 2016-11-18 2018-05-24 Tolero Pharmaceuticals, Inc. Alvocidib prodrugs and their use as protein kinase inhibitors
TW201829463A (zh) 2016-11-18 2018-08-16 瑞士商赫孚孟拉羅股份公司 抗hla-g抗體及其用途
JOP20190100A1 (ar) 2016-11-19 2019-05-01 Potenza Therapeutics Inc بروتينات ربط مولد ضد مضاد لـ gitr وطرق استخدامها
GB201619648D0 (en) 2016-11-21 2017-01-04 Alligator Bioscience Ab Novel antibodies and uses thereof
CA3036983A1 (en) 2016-11-21 2018-05-24 Cureab Gmbh Anti-gp73 antibodies and immunoconjugates
WO2018091720A1 (en) 2016-11-21 2018-05-24 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and pharmaceutical compositions for the prophylactic treatment of metastases
CN109937034B (zh) 2016-11-21 2022-09-16 济世-伊沃泰克生物制品有限公司 阿柏西普制剂及其用途
WO2018094414A1 (en) 2016-11-21 2018-05-24 Obi Pharma, Inc. Conjugated biological molecules, pharmaceutical compositions and methods
CN110177803A (zh) 2016-11-22 2019-08-27 T细胞受体治疗公司 用于使用融合蛋白进行tcr重新编程的组合物和方法
US10780080B2 (en) 2016-11-23 2020-09-22 Translational Drug Development, Llc Benzamide and active compound compositions and methods of use
AU2017363309A1 (en) 2016-11-23 2019-07-11 Bioverativ Therapeutics Inc. Mono- and bispecific antibodies binding to coagulation factor IX and coagulation factor X
KR102275008B1 (ko) 2016-11-23 2021-07-13 하푼 테라퓨틱스, 인크. 전립선 특이 막 항원 결합 단백질
WO2018098370A1 (en) 2016-11-23 2018-05-31 Immunoah Therapeutics, Inc. 4-1bb binding proteins and uses thereof
JP7215997B2 (ja) 2016-11-23 2023-01-31 ハープーン セラピューティクス，インク． 前立腺特異的膜抗原（ｐｓｍａ）を標的とする三重特異性タンパク質と使用方法
AU2017364818C1 (en) 2016-11-28 2025-05-15 Chugai Seiyaku Kabushiki Kaisha Ligand-binding molecule having adjustable ligand binding activity
WO2018102746A1 (en) 2016-12-02 2018-06-07 Rigel Pharmaceuticals, Inc. Antigen binding molecules to tigit
WO2018100190A1 (en) 2016-12-02 2018-06-07 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and compositions for diagnosing renal cell carcinoma
US11198723B2 (en) 2016-12-05 2021-12-14 The Administrators Of The Tulane Educational Fund Arenavirus monoclonal antibodies and uses
EP3551220B1 (de) 2016-12-07 2025-01-29 Genentech, Inc. Anti-tau antikörper und derern verwendung
US11180535B1 (en) 2016-12-07 2021-11-23 David Gordon Bermudes Saccharide binding, tumor penetration, and cytotoxic antitumor chimeric peptides from therapeutic bacteria
EP3551655A2 (de) 2016-12-07 2019-10-16 Genentech, Inc. Anti-tau-antikörper und verfahren zu deren verwendung
IL307242B1 (en) 2016-12-07 2026-07-01 Agenus Inc Anti-CTLA-4 antibodies and methods of using them
CN110300599B (zh) 2016-12-07 2024-07-02 艾吉纳斯公司 抗体和其使用方法
US11129906B1 (en) 2016-12-07 2021-09-28 David Gordon Bermudes Chimeric protein toxins for expression by therapeutic bacteria
CA3045944A1 (en) 2016-12-07 2018-06-14 Progenity, Inc. Gastrointestinal tract detection methods, devices and systems
GB201621123D0 (en) 2016-12-12 2017-01-25 4D Pharma Plc Compositions comprising bacterial strains
WO2018112032A1 (en) 2016-12-13 2018-06-21 President And Fellows Of Harvard College Methods and compositions for targeting tumor-infiltrating tregs using inhibitors of ccr8 and tnfrsf8
WO2018112232A1 (en) 2016-12-14 2018-06-21 Progenity Inc. Treatment of a disease of the gastrointestinal tract with an il-12/il-23 inhibitor released using an ingestible device
US20200315540A1 (en) 2016-12-14 2020-10-08 Progenity, Inc. Treatment of a disease of the gastrointestinal tract with an il-1 inhibitor
EP3554345A1 (de) 2016-12-14 2019-10-23 Progenity, Inc. Behandlung von erkrankungen des gastrointestinaltraktes mit einem smad7-inhibitor
US11523772B2 (en) 2016-12-14 2022-12-13 Biora Therapeutics, Inc. Treatment of a disease of the gastrointestinal tract with an immunosuppressant
WO2018112237A1 (en) 2016-12-14 2018-06-21 Progenity Inc. Treatment of a disease of the gastrointestinal tract with an il-6r inhibitor
AU2017378393B2 (en) 2016-12-14 2023-03-09 Bt Bidco, Inc. Treatment of a disease of the gastrointestinal tract with a TNF inhibitor
WO2018112223A1 (en) 2016-12-14 2018-06-21 Progenity Inc. Treatment of a disease of the gastrointestinal tract with a tlr modulator
JP7244987B2 (ja) 2016-12-14 2023-03-23 シージェン インコーポレイテッド 多剤抗体薬物コンジュゲート
CA3045310A1 (en) 2016-12-14 2018-06-21 Progenity, Inc. Treatment of a disease of the gastrointestinal tract with a chemokine/chemokine receptor inhibitor
CN116712540A (zh) 2016-12-14 2023-09-08 比奥拉治疗股份有限公司 使用整联蛋白抑制剂治疗胃肠道疾病
CA3045666A1 (en) 2016-12-14 2018-06-21 Progenity, Inc. Treatment of a disease of the gastrointestinal tract with a jak inhibitor and devices
UY37523A (es) 2016-12-15 2018-07-31 Abbvie Biotherapeutics Inc Anticuerpos anti-ox40 y sus usos
JP2020514256A (ja) 2016-12-15 2020-05-21 ザ ナショナル インスティチュート フォー バイオテクノロジー イン ザ ネゲヴ，リミテッド 抗ｐｃｎａモノクローナル抗体及びその使用
JP7252627B2 (ja) 2016-12-15 2023-04-05 デューク ユニバーシティ 制御性ｂ１０細胞を枯渇させる抗体および方法並びに免疫チェックポイント阻害剤との併用における使用
WO2018112364A1 (en) 2016-12-16 2018-06-21 Evelo Biosciences, Inc. Combination therapies for treating melanoma
WO2018112360A1 (en) 2016-12-16 2018-06-21 Evelo Biosciences, Inc. Combination therapies for treating cancer
CA3047557A1 (en) 2016-12-19 2018-06-28 Tolero Pharmaceuticals, Inc. Profiling peptides and methods for sensitivity profiling
US20200157190A1 (en) 2016-12-19 2020-05-21 Abcam Plc Monovalent and divalent binding proteins
EP3559248B2 (de) 2016-12-21 2024-11-20 F. Hoffmann-La Roche AG In vitro glycoengineering von antikörpern
EP3559035A1 (de) 2016-12-21 2019-10-30 TeneoBio, Inc. Nur schwerketten-anti-bcma-antikörper
US12059472B2 (en) 2016-12-21 2024-08-13 Bayer Aktiengesellschaft Prodrugs of cytotoxic active agents having enzymatically cleavable groups
US11433140B2 (en) 2016-12-21 2022-09-06 Bayer Pharma Aktiengesellschaft Specific antibody drug conjugates (ADCs) having KSP inhibitors
MX2019007411A (es) 2016-12-21 2019-08-29 Hoffmann La Roche Reuso de enzimas en glucomanipulacion in vitro de anticuerpos.
GB201621806D0 (en) 2016-12-21 2017-02-01 Philogen Spa Immunocytokines with progressive activation mechanism
MX2019006123A (es) 2016-12-21 2019-08-12 Hoffmann La Roche Metodo para glicomanipulacion in vitro de anticuerpos.
AU2017380871C1 (en) 2016-12-21 2025-05-15 Bayer Aktiengesellschaft Antibody drug conjugates (ADCs) having enzymatically cleavable groups
CN106519034B (zh) 2016-12-22 2020-09-18 鲁南制药集团股份有限公司 抗pd-1抗体及其用途
WO2018115485A1 (en) 2016-12-22 2018-06-28 Pierfrancesco Tassone A monoclonal antibody targeting a unique sialoglycosilated cancer-associated epitope of cd43
WO2018118887A1 (en) 2016-12-22 2018-06-28 Wake Forest University Health Sciences Sirp-gamma targeted agents for use in the treatment of cancer
MD3558391T2 (ro) 2016-12-23 2022-05-31 Immunogen Inc Imunoconjugate care țintesc ADAM9 și procedee de utilizare a acestora
JOP20190134A1 (ar) 2016-12-23 2019-06-02 Potenza Therapeutics Inc بروتينات رابطة لمولد ضد مضادة لنيوروبيلين وطرق استخدامها
KR102616666B1 (ko) 2016-12-23 2023-12-27 노파르티스 아게 인자 xi 항체 및 사용 방법
EP3559029A2 (de) 2016-12-23 2019-10-30 Bristol-Myers Squibb Company Design von therapeutischem immunglobulin g4 für verbesserte bioanalytische und bioverarbeitungseigenschaften
IL315727A (en) 2016-12-23 2024-11-01 Visterra Inc Binding polypeptides and methods for their preparation
BR112019012950A2 (pt) 2016-12-23 2019-11-26 Macrogenics, Inc. molécula de ligação a adam9, composição farmacêutica, uso da molécula de ligação a adam9 e método para tratar uma doença ou condição associada ou caracterizada pela expressão de adam9 em um indivíduo
JP6982075B2 (ja) 2016-12-27 2021-12-17 エフ.ホフマン−ラ ロシュ アーゲーF. Hoffmann−La Roche Aktiengesellschaft 新規のビオチン特異的モノクローナル抗体およびその使用
KR20210126135A (ko) 2016-12-27 2021-10-19 에프. 호프만-라 로슈 아게 신규한 비오틴-특이적 단일클론 항체 및 그 용도
KR102413013B1 (ko) 2016-12-27 2022-06-23 에프. 호프만-라 로슈 아게 신규한 비오틴-특이적 단일클론 항체 및 그 용도
WO2018122245A1 (en) 2016-12-28 2018-07-05 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods of predicting the survival time of patients suffering from cms3 colorectal cancer
KR102085798B1 (ko) 2016-12-28 2020-03-06 주식회사 인투셀 베타-갈락토사이드가 도입된 자가-희생 기를 포함하는 화합물
WO2018122249A1 (en) 2016-12-28 2018-07-05 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods for predicting the survival time of patients suffering from a microsatellite stable colorectal cancer
JP6914336B2 (ja) 2016-12-28 2021-08-04 ジェネンテック， インコーポレイテッド 進行したｈｅｒ２発現がんの治療
JP6888764B2 (ja) 2016-12-29 2021-06-16 ディヴェロップメント センター フォー バイオテクノロジー 糖タンパク質−薬物コンジュゲートを調製する方法
EP3565589A1 (de) 2017-01-04 2019-11-13 Research Institute at Nationwide Children's Hospital Dnabii-impfstoffe und antikörper mit erhöhter aktivität
WO2018129040A1 (en) 2017-01-04 2018-07-12 President And Fellows Of Harvard College Modulating nudix homology domain (nhd) with nicotinamide mononucleotide analogs and derivatives of same
TW201825515A (zh) 2017-01-04 2018-07-16 美商伊繆諾金公司 Ｍｅｔ抗體以及其免疫結合物及用途
AU2018206560B9 (en) 2017-01-04 2025-04-03 Research Institute At Nationwide Children's Hospital Antibody fragments for the treatment of biofilm-related disorders
CN116120454A (zh) 2017-01-05 2023-05-16 上海煦顼技术有限公司 人源化抗cd19抗体及其与嵌合抗原受体的用途
WO2018129395A1 (en) 2017-01-06 2018-07-12 Scholar Rock, Inc. Methods for treating metabolic diseases by inhibiting myostatin activation
HRP20230308T1 (hr) 2017-01-06 2023-05-12 Scholar Rock, Inc. Liječenje metaboličkih bolesti putem inhibiranja aktivacije miostatina
US12049493B2 (en) 2017-01-06 2024-07-30 Abl Bio Inc. Anti-alpha-synuclein antibodies and uses thereof
WO2018128454A1 (ko) 2017-01-06 2018-07-12 에이비엘바이오 주식회사 항 α-SYN 항체 및 그 용도
EP3565845A4 (de) 2017-01-06 2020-10-07 Biosion, Inc. Erbb2-antikörper und deren verwendungen
CN110382530A (zh) 2017-01-06 2019-10-25 供石公司 亚型特异性、背景许可性TGFβ1抑制剂及其用途
EP3346001A1 (de) 2017-01-06 2018-07-11 TXCell Monospezifische regulatorische t-zellpopulation mit zytotoxizität gegenüber b-zellen
WO2018127585A1 (en) 2017-01-06 2018-07-12 Txcell Monospecific regulatory t cell population with cytotoxicity for b cells
TW201833140A (zh) 2017-01-09 2018-09-16 美商莫瑞麥克製藥公司 抗fgfr抗體及使用方法
GB201700345D0 (en) 2017-01-09 2017-02-22 F-Star Beta Ltd Conditional agonists of immune responses
TW201831517A (zh) 2017-01-12 2018-09-01 美商優瑞科生物技術公司 靶向組織蛋白h3肽/mhc複合體之構築體及其用途
WO2018132768A1 (en) 2017-01-13 2018-07-19 Sanna Pietro P Methods and compositions for treating hpa hyperactivity
DK3570884T3 (da) 2017-01-17 2020-11-30 Genentech Inc Subkutane HER2-antistofformuleringer
JP7225115B2 (ja) 2017-01-17 2023-02-20 ザ チルドレンズ メディカル センター コーポレーション リソソーム蓄積症およびリソソーム蓄積障害を処置するための組成物および方法
EP4480537A3 (de) 2017-01-17 2025-03-12 Amgen Inc. Verfahren zur behandlung oder linderung von stoffwechselerkrankungen mit glp-1-rezeptoragonisten, die mit antagonisten für den magenhemmenden peptidrezeptor (gipr) konjugiert sind
WO2018136626A1 (en) 2017-01-18 2018-07-26 Visterra, Inc. Antibody molecule-drug conjugates and uses thereof
MX2019008348A (es) 2017-01-18 2019-10-21 Genentech Inc Anticuerpos idiotipo contra anticuerpos anti-pd-l1 y usos de estos solicitudes relacionadas.
JP7275030B2 (ja) 2017-01-20 2023-05-17 タユー ファシャ バイオテック メディカル グループ カンパニー， リミテッド 抗ｐｄ－１抗体およびその使用
CA3045376C (en) 2017-01-24 2022-08-30 I-Mab Anti-cd73 antibodies and uses thereof
EP3573995A1 (de) 2017-01-24 2019-12-04 Pfizer Inc. Calicheamicin-derivate und antikörper-wirkstoff-konjugate davon
AU2018213823B2 (en) 2017-01-24 2024-11-07 Innate Pharma NKp46 binding agents
US11535662B2 (en) 2017-01-26 2022-12-27 Novartis Ag CD28 compositions and methods for chimeric antigen receptor therapy
EP3574012A1 (de) 2017-01-27 2019-12-04 Memorial Sloan Kettering Cancer Center Bispezifische her2- und cd3-bindende moleküle
WO2018138257A1 (en) 2017-01-27 2018-08-02 Immatics Biotechnologies Gmbh Novel peptides and combination of peptides for use in immunotherapy against ovarian cancer and other cancers
US20190367600A1 (en) 2017-01-27 2019-12-05 A-Clip Institute, Co., Ltd. Prophylactic and/or therapeutic agent of infectious diseases or inflammatory diseases
CN110234351A (zh) 2017-01-30 2019-09-13 詹森生物科技公司 用于治疗活动性银屑病关节炎的抗tnf抗体、组合物和方法
WO2018144425A1 (en) 2017-01-31 2018-08-09 Vanderbilt University Generation of human allergen-and helminth-specific ige monoclonal antibodies for diagnostic and therapeutic use
SG11201906519RA (en) 2017-01-31 2019-08-27 Pfizer Neisseria meningitidis compositions and methods thereof
US20190375815A1 (en) 2017-01-31 2019-12-12 Novartis Ag Treatment of cancer using chimeric t cell receptor proteins having multiple specificities
JP7068323B2 (ja) 2017-02-02 2022-05-16 エフ．ホフマン－ラ ロシュ アーゲー 少なくとも２種のペグ化された分析物特異的結合剤を使用する免疫アッセイ
SG11201905259SA (en) 2017-02-02 2019-08-27 Merck Patent Gmbh Preferred pairing of antibody domains
CR20190408A (es) 2017-02-02 2020-01-31 Amgen Inc Composición farmacéutica de bajo ph que comprende construcciones de anticuerpos que activan linfocitos t antecedentes
KR102633644B1 (ko) 2017-02-03 2024-02-05 액티코어 바이오테크 항-인간 gpvi 항체를 이용한 혈소판 응집의 억제
WO2018141959A1 (en) 2017-02-06 2018-08-09 Innate Pharma Immunomodulatory antibody drug conjugates binding to a human mica polypeptide
US20180221476A1 (en) 2017-02-06 2018-08-09 Oncoquest Nc. Treatment of cancer with therapeutic monoclonal antibody specific for a tumor associated antigen and an immune adjuvant
KR20240038148A (ko) 2017-02-07 2024-03-22 얀센 바이오테크 인코포레이티드 활성 강직성 척추염의 치료를 위한 항-tnf 항체, 조성물, 및 방법
WO2018146199A1 (en) 2017-02-08 2018-08-16 Adc Therapeutics Sa Pyrrolobenzodiazepine-antibody conjugates
GB201702031D0 (en) 2017-02-08 2017-03-22 Medlmmune Ltd Pyrrolobenzodiazepine-antibody conjugates
CA3052911A1 (en) 2017-02-08 2018-08-16 Novartis Ag Fgf21 mimetic antibodies and uses thereof
RS61795B1 (sr) 2017-02-08 2021-06-30 Adc Therapeutics Sa Konjugati pirolobenzodiazepin antitela
WO2018148223A1 (en) 2017-02-09 2018-08-16 Memorial Sloan Kettering Cancer Center Anti-kir3dl1 antibodies
CN116715775A (zh) 2017-02-10 2023-09-08 豪夫迈·罗氏有限公司 抗类胰蛋白酶抗体、其组合物及其用途
EP3579872A1 (de) 2017-02-10 2019-12-18 INSERM (Institut National de la Santé et de la Recherche Médicale) Verfahren und pharmazeutische zusammensetzungen zur behandlung von krebs in verbindung mit aktivierung der mapk-leitungsbahn
WO2018151820A1 (en) 2017-02-16 2018-08-23 Elstar Therapeutics, Inc. Multifunctional molecules comprising a trimeric ligand and uses thereof
WO2018152496A1 (en) 2017-02-17 2018-08-23 The Usa, As Represented By The Secretary, Dept. Of Health And Human Services Compositions and methods for the diagnosis and treatment of zika virus infection
JP7136790B2 (ja) 2017-02-17 2022-09-13 ブリストル－マイヤーズ スクイブ カンパニー アルファ－シヌクレインに対する抗体およびその使用
CN108456251A (zh) 2017-02-21 2018-08-28 上海君实生物医药科技股份有限公司 抗pd-l1抗体及其应用
EP3585813A1 (de) 2017-02-22 2020-01-01 Sutro Biopharma, Inc. Pd-1/tim-3 bi-spezifische antikörper, zusammensetzungen davon und verfahren zur herstellung und verwendung davon
US11124575B2 (en) 2017-02-22 2021-09-21 University Of Saskatchewan EGFR-binding agents and uses thereof
BR112019017628A2 (pt) 2017-02-24 2020-07-07 Macrogenics, Inc. molécula de ligação a cd137 x ta, composições farmacêuticas, uso da molécula de ligação a cd137 x ta, molécula de ligação a cd137, uso da molécula de ligação a cd137, molécula de ligação a her2/neu, uso da molécula de ligação a her2/neu, e uso de uma composição
WO2018160754A2 (en) 2017-02-28 2018-09-07 Harpoon Therapeutics, Inc. Inducible monovalent antigen binding protein
RS65241B1 (sr) 2017-02-28 2024-03-29 Univ Pennsylvania Vektor adeno-asociranih virusa (aav) iz podgrupe f i njegove upotrebe
JOP20190200A1 (ar) 2017-02-28 2019-08-27 Univ Pennsylvania تركيبات نافعة في معالجة ضمور العضل النخاعي
TW201837170A (zh) 2017-02-28 2018-10-16 賓州大學委員會 新穎ａａｖ媒介的流感疫苗
KR20240144261A (ko) 2017-02-28 2024-10-02 사노피 치료적 rna
MX2019010295A (es) 2017-03-01 2019-11-21 Genentech Inc Métodos de diagnóstico y terapéuticos para el cáncer.
EP3597217A4 (de) 2017-03-01 2021-01-13 Institute for Rheumatic Diseases Co., Ltd. Prophylaktisches und/oder therapeutisches mittel gegen autoimmunkrankheit und impfstoff
EP3589650A1 (de) 2017-03-02 2020-01-08 Novartis AG Manipulierte heterodimere proteine
HUE064898T2 (hu) 2017-03-02 2024-04-28 Genentech Inc HER2-pozitív emlõrák adjuváns kezelése
US11274160B2 (en) 2017-03-02 2022-03-15 INSERM (Institut National de la Santé et de la Recherche Médicale Antibodies having specificity to Nectin-4 and uses thereof
JP7195262B2 (ja) 2017-03-02 2022-12-23 ベス イスラエル デアコネス メディカル センター インコーポレイティッド カルシトニン遺伝子関連ペプチドを指向する抗体に応答性の頭痛患者の選択方法
KR20240044544A (ko) 2017-03-03 2024-04-04 씨젠 인크. 글리칸-상호작용 화합물 및 사용 방법
US11198735B2 (en) 2017-03-03 2021-12-14 Rinat Neuroscience Corp. Anti-GITR antibodies and methods of use thereof
AU2018230478B2 (en) 2017-03-09 2025-01-23 Diamedica Inc. Dosage forms of tissue kallikrein 1
KR20190124270A (ko) 2017-03-10 2019-11-04 에프. 호프만-라 로슈 아게 다중특이적 항체의 생산 방법
GB201703876D0 (en) 2017-03-10 2017-04-26 Berlin-Chemie Ag Pharmaceutical combinations
WO2018165649A1 (en) 2017-03-10 2018-09-13 Embera Neurotherapeutics, Inc. Pharmaceutical compositions and uses thereof
SG11201907583TA (en) 2017-03-14 2019-09-27 Bioverativ Usa Inc Methods for treating complement-mediated diseases and disorders
KR20240005989A (ko) 2017-03-15 2024-01-12 큐 바이오파마, 인크. 면역 반응을 조절하는 방법
CN114940713B (zh) 2017-03-15 2024-04-30 清华大学 抗trkb抗体
EP3595445B1 (de) 2017-03-15 2024-09-04 The Research Institute at Nationwide Children's Hospital Zusammensetzung und verfahren zur brechung bakterieller biofilme ohne begleitentzündung
AU2018235092B2 (en) 2017-03-16 2024-09-19 Innate Pharma Compositions and methods for treating cancer
WO2018167621A1 (en) 2017-03-16 2018-09-20 Pfizer Inc. Tyrosine prototrophy
TWI771389B (zh) 2017-03-16 2022-07-21 美商健生生物科技公司 抗phf-tau抗體及其用途
EP3596467B1 (de) 2017-03-16 2023-09-27 Université Libre de Bruxelles Nachweis, quantifizierung und/oder isolierung zirkulierender tumorzellen mittels der expression des cd321-markers
WO2018167283A1 (en) 2017-03-17 2018-09-20 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods for the diagnosis and treatment of pancreatic ductal adenocarcinoma associated neural remodeling
CA3050614A1 (en) 2017-03-17 2018-09-20 Curevac Ag Rna vaccine and immune checkpoint inhibitors for combined anticancer therapy
US10941178B2 (en) 2017-03-17 2021-03-09 Gilead Sciences, Inc. Method of purifying an antibody
EP3879269A3 (de) 2017-03-20 2021-11-17 Celcuity Inc. Verfahren zur messung der signalwegaktivität zur auswahl von therapeutischen mitteln
EP3378872A1 (de) 2017-03-20 2018-09-26 Institut National De La Sante Et De La Recherche Medicale (Inserm) Antikörper gegen die humane extrazelluläre fshr-domäne
TWI808963B (zh) 2017-03-22 2023-07-21 法商賽諾菲公司 使用人類化抗ｃｘｃｒ５抗體治療狼瘡
EP3600442A1 (de) 2017-03-22 2020-02-05 Genentech, Inc. Optimierte antikörperzusammensetzungen zur behandlung von augenkrankheiten
JP7216006B2 (ja) 2017-03-22 2023-01-31 ジェネンテック， インコーポレイテッド ヒドロゲル架橋ヒアルロン酸プロドラッグ組成物及び方法
JP7346300B2 (ja) 2017-03-23 2023-09-19 アボット・ラボラトリーズ 早期バイオマーカーであるユビキチンカルボキシ末端ヒドロラーゼｌ１を使用する、ヒト対象における外傷性脳損傷の程度の診断及び決定の一助となるための方法
KR102628323B1 (ko) 2017-03-24 2024-01-22 노바르티스 아게 심장질환 예방 및 치료 방법
JP7527787B2 (ja) 2017-03-24 2024-08-05 シージェン インコーポレイテッド グルクロニド薬物－リンカーの調製のためのプロセスおよびその中間体
EP3604340A4 (de) 2017-03-24 2021-01-06 Zenyaku Kogyo Co., Ltd Anti-igm/b-zelloberflächenantigen-bispezifischer antikörper
WO2018172508A1 (en) 2017-03-24 2018-09-27 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and compositions for treating melanoma
EP3599843A4 (de) 2017-03-24 2021-01-13 The Regents of the University of California Proteoglycan-irregularitäten in abnormalen fibroblasten und darauf basierende therapien
EP3601350A1 (de) 2017-03-27 2020-02-05 Boehringer Ingelheim International GmbH Kombinationstherapie gegen il-36r-antikörper
EP3601351A1 (de) 2017-03-27 2020-02-05 Celgene Corporation Verfahren und zusammensetzungen zur reduzierung der immunogenität
WO2018178030A1 (en) 2017-03-27 2018-10-04 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and compositions for treating degenerative muscular and/or neurological conditions or diseases
RU2758234C2 (ru) 2017-03-27 2021-10-26 Иммьюномедикс, Инк. ЛЕЧЕНИЕ ТРИЖДЫ НЕГАТИВНОГО РАКА МОЛОЧНОЙ ЖЕЛЕЗЫ, ХАРАКТЕРИЗУЮЩЕГОСЯ ЭКСПРЕССИЕЙ Trop-2, С ПОМОЩЬЮ САЦИТУЗУМАБА ГОВИТЕКАНА И ИНГИБИТОРА Rad51
WO2018178029A1 (en) 2017-03-27 2018-10-04 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and compositions for treating degenerative muscular and/or neurological conditions or diseases
CN117205311A (zh) 2017-03-28 2023-12-12 基因泰克公司 治疗神经退行性疾病的方法
WO2018183932A1 (en) 2017-03-30 2018-10-04 Progenity Inc. Treatment of a disease of the gastrointestinal tract with a il-13 inhibitor
JP2020515267A (ja) 2017-03-30 2020-05-28 ザ ボード オブ トラスティーズ オブ ザ レランド スタンフォード ジュニア ユニバーシティー 多重アイソタイプ特異的抗体の検出
CN110506060B (zh) 2017-03-30 2024-05-07 昆士兰大学 嵌合分子及其用途
JP7022328B2 (ja) 2017-03-30 2022-02-18 日油株式会社 自壊性アセタールリンカーを有する親水性ポリマー誘導体及びそれを用いた複合体
SG11201909064RA (en) 2017-03-30 2019-10-30 Merck Patent Gmbh Combination of an anti-pd-l1 antibody and a dna-pk inhibitor for the treatment of cancer
JP6990355B2 (ja) 2017-03-30 2022-01-12 日油株式会社 ヘテロ二官能性単分散ポリエチレングリコール及びそれを用いた複合体
CA3054156A1 (en) 2017-03-30 2018-10-04 Progenity Inc. Treatment of a disease of the gastrointestinal tract with il-10 or an il-10 agonist
WO2018183934A1 (en) 2017-03-30 2018-10-04 Progenity Inc. Treatment of a disease of the gastrointestinal tract with a chst15 inhibitor
JOP20190203A1 (ar) 2017-03-30 2019-09-03 Potenza Therapeutics Inc بروتينات رابطة لمولد ضد مضادة لـ tigit وطرق استخدامها
WO2018183941A2 (en) 2017-03-30 2018-10-04 Progenity Inc. Treatment of a disease of the gastrointestinal tract with live biotherapeutics
WO2018178237A1 (en) 2017-03-30 2018-10-04 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods for the treatment of mitochondrial genetic diseases
CA3054632A1 (en) 2017-03-30 2018-10-04 Progenity, Inc. Treatment of a disease of the gastrointestinal tract with an immune modulatory agent released using an ingestible device
US20190048055A1 (en) 2017-03-31 2019-02-14 Altor Bioscience Corporation Alt-803 in combination with anti-cd38 antibody for cancer therapies
JP7737220B2 (ja) 2017-03-31 2025-09-10 メルス ナムローゼ フェンノートシャップ ＮＲＧ１融合遺伝子を有する細胞の処置における使用のためのＥｒｂＢ－２及びＥｒｂＢ３結合二重特異性抗体
EP3601353A1 (de) 2017-03-31 2020-02-05 Five Prime Therapeutics, Inc. Kombinationstherapie gegen krebs mit anti-gitr-antikörpern
CA3044082A1 (en) 2017-04-03 2018-10-11 Immunomedics, Inc. Subcutaneous administration of antibody-drug conjugates for cancer therapy
US11726091B2 (en) 2017-04-03 2023-08-15 The Regents Of The University Of California Compositions and methods of diagnosing pancreatic cancer
US20200024351A1 (en) 2017-04-03 2020-01-23 Jounce Therapeutics, Inc. Compositions and Methods for the Treatment of Cancer
KR20200020662A (ko) 2017-04-03 2020-02-26 온콜로지, 인크. 면역-종양학 제제와 함께 ps-표적화 항체를 사용하여 암을 치료하는 방법
UA128387C2 (uk) 2017-04-05 2024-07-03 Ф. Хоффманн-Ля Рош Аг Антитіло до lag3
CA3052532A1 (en) 2017-04-05 2018-10-11 F. Hoffmann-La Roche Ag Bispecific antibodies specifically binding to pd1 and lag3
WO2018185516A1 (en) 2017-04-05 2018-10-11 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and pharmaceutical compositions for treating cardiovascular toxicity induced by anti-cancer therapy
TWI796329B (zh) 2017-04-07 2023-03-21 美商默沙東有限責任公司 抗－ilt4抗體及抗原結合片段
BR112019020955A2 (pt) 2017-04-07 2020-05-05 Apellis Pharmaceuticals, Inc. regimes de dosagem e composições e métodos relacionados
TWI788340B (zh) 2017-04-07 2023-01-01 美商必治妥美雅史谷比公司 抗icos促效劑抗體及其用途
TW201841937A (zh) 2017-04-10 2018-12-01 德商英麥提克生物技術股份有限公司 用於白血病和其他癌症免疫治療的新穎肽和肽組合物
TW201841934A (zh) 2017-04-10 2018-12-01 德商英麥提克生物技術股份有限公司 用於治療癌症免疫治療的新穎肽及其肽組合物
CR20210160A (es) 2017-04-10 2021-04-26 Immatics Biotechnologies Gmbh Péptidos y combinaciones de los mismos para el uso en la inmunoterapia contra diversos tipos de cáncer (divisional de solicitud 2019-0508)
US12590288B2 (en) 2017-04-12 2026-03-31 The Broad Institute, Inc. Method of treating an inflammatory disease by administering an agent which binds a surface receptor on a tuft cell that induces an ILC class 2 inflammatory response
EP3609917A1 (de) 2017-04-12 2020-02-19 Amgen Inc. Behandlung von asthma mit anti-tslp-antikörper
WO2018191520A1 (en) 2017-04-12 2018-10-18 The Broad Institute, Inc. Respiratory and sweat gland ionocytes
EP3609915A1 (de) 2017-04-12 2020-02-19 Pfizer Inc Antikörper mit bedingter affinität und verfahren zur verwendung dafür
US20200088732A1 (en) 2017-04-13 2020-03-19 INSERM (Institut National de la Santé et de la Recherche Mèdicale) Methods for the diagnosis and treatment of pancreatic ductal adenocarcinoma
KR20190136076A (ko) 2017-04-13 2019-12-09 에프. 호프만-라 로슈 아게 암 치료 방법에 사용하기 위한 인터루킨-2 면역접합체, cd40 작용제 및 임의적인 pd-1 축 결합 길항제
JP7160833B2 (ja) 2017-04-13 2022-10-25 サイロパ ビー．ブイ． 抗ｓｉｒｐアルファ抗体
BR112019017241A2 (pt) 2017-04-13 2020-04-14 Agenus Inc. anticorpos anti-cd137 e métodos de uso dos mesmos
WO2018189403A1 (en) 2017-04-14 2018-10-18 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and pharmaceutical compositions for the treatment of cancer
EP3610018B1 (de) 2017-04-14 2023-06-07 Arizona Board of Regents on Behalf of the University of Arizona Zusammensetzungen und verfahren zur behandlung pulmonaler fibrose
CA3059938A1 (en) 2017-04-14 2018-10-18 Kodiak Sciences Inc. Complement factor d antagonist antibodies and conjugates thereof
BR112019021495A8 (pt) 2017-04-14 2023-05-02 Inst Curie Compostos de ligação ao amhrii para prevenção ou tratamento de cânceres de pulmão
BR112019021520A2 (pt) 2017-04-14 2020-08-04 Tollnine, Inc. oligonucleotídeo, composto, polinucleotídeo imunomodulador, composição, conjugado, método para modular um receptor, método de tratamento de um tumor, método de tratamento de câncer, método para tratar um tumor, método de prevenção de câncer, método para induzir uma resposta imune
WO2018189379A1 (en) 2017-04-14 2018-10-18 Gamamabs Pharma Amhrii-binding compounds for preventing or treating cancers
EP3610268B1 (de) 2017-04-15 2025-09-24 Abbott Laboratories Verfahren zur unterstützung der diagnose und der bestimmung von traumatischen gehirnschäden bei menschen mithilfe frühen biomarkern
RU2665790C1 (ru) 2017-04-17 2018-09-04 Закрытое Акционерное Общество "Биокад" Моноклональное антитело к pd-l1
CA3058290A1 (en) 2017-04-18 2018-10-25 Universite Libre De Bruxelles Biomarkers and targets for proliferative diseases
SMT202200490T1 (it) 2017-04-18 2023-01-13 Medimmune Ltd Coniugati di pirrolobenzodiazepina
EP3617221A4 (de) 2017-04-19 2021-04-14 Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. Cytotoxin und konjugat, verwendungen davon und herstellungsverfahren dafür
EP3612563A1 (de) 2017-04-19 2020-02-26 Elstar Therapeutics, Inc. Multispezifische moleküle und verwendungen davon
CA3057744A1 (en) 2017-04-20 2018-10-25 Adc Therapeutics Sa Combination therapy with an anti-cd25 antibody-drug conjugate
WO2018193102A1 (en) 2017-04-20 2018-10-25 Adc Therapeutics Sa Combination therapy with an anti-axl antibody-drug conjugate
TW201841656A (zh) 2017-04-21 2018-12-01 美商建南德克公司 Ｋｌｋ５拮抗劑用於治療疾病之用途
JOP20190248A1 (ar) 2017-04-21 2019-10-20 Amgen Inc بروتينات ربط مولد ضد trem2 واستخداماته
WO2018193427A1 (en) 2017-04-21 2018-10-25 Staten Biotechnology B.V. Anti-apoc3 antibodies and methods of use thereof
EP3612556B8 (de) 2017-04-22 2024-11-20 Immunomic Therapeutics, Inc. Verbesserte lamp konstrukte
EP3396378A1 (de) 2017-04-24 2018-10-31 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. Verfahren zur bestimmung von myeloischen natürlichen killerzellen (nk) und verwendung davon
EP4230649A3 (de) 2017-04-25 2023-10-25 The U.S.A. As Represented By The Secretary, Department Of Health And Human Services Antikörper und verfahren zur diagnose und behandlung von epstein barr-virusinfektion
WO2018200582A1 (en) 2017-04-26 2018-11-01 Eureka Therapeutics, Inc. Chimeric antibody/t-cell receptor constructs and uses thereof
EP3615574B1 (de) 2017-04-26 2026-06-24 Eureka Therapeutics, Inc. Spezifisch glypican 3 erkennende konstrukte und deren verwendung
US12569497B2 (en) 2017-04-27 2026-03-10 The University Of Hong Kong Use of HCN inhibitors for treatment of cancer
AU2018260380B2 (en) 2017-04-27 2025-02-13 Juno Therapeutics Gmbh Oligomeric particle reagents and methods of use thereof
TWI791519B (zh) 2017-04-27 2023-02-11 美商提薩羅有限公司 針對淋巴細胞活化基因-3（lag-3）之抗體藥劑及其用途
WO2018201087A1 (en) 2017-04-27 2018-11-01 Seattle Genetics, Inc. Quaternized nicotinamide adenine dinucleotide salvage pathway inhibitor conjugates
JP7080899B2 (ja) 2017-04-28 2022-06-06 アボット・ラボラトリーズ 同じヒト対象に由来する少なくとも２つの試料に対して早期バイオマーカーを使用する、外傷性脳損傷の超急性の診断及び決定の一助となるための方法
MA48461A (fr) 2017-04-28 2020-03-04 Amgen Inc Excipients pour réduire la viscosité de formulations d'anticorps et compositions de formulation
MX2019012741A (es) 2017-04-28 2020-01-21 Merck Sharp & Dohme Biomarcadores para agentes terapeuticos contra el cancer.
EP3615055A1 (de) 2017-04-28 2020-03-04 Novartis AG Zellen, die einen auf bcma abzielenden chimären antigenrezeptor exprimieren, und kombinationsbehandlung mit einem gamma-sekretase-inhibitor
EP3615068A1 (de) 2017-04-28 2020-03-04 Novartis AG Auf bcma abzielender wirkstoff und kombinationstherapie mit einem gamma-sekretase-inhibitor
IL270201B2 (en) 2017-04-28 2026-05-01 Millennium Pharm Inc A method for treating childhood disorders
WO2018199318A1 (ja) 2017-04-28 2018-11-01 国立大学法人高知大学 抗ｇｐｃ－１抗体
EP4328241A3 (de) 2017-04-28 2024-06-05 Marengo Therapeutics, Inc. Multispezifische moleküle mit einer nichtimmunglobulin-heterodimerisierungsdomäne und verwendungen davon
LT3618863T (lt) 2017-05-01 2023-10-10 Agenus Inc. Anti-tigit antikūnai ir jų panaudojimo būdai
CN110913906A (zh) 2017-05-02 2020-03-24 默沙东公司 抗lag3抗体的制剂和抗lag3抗体与抗pd-1抗体的共制剂
EP3620531A4 (de) 2017-05-02 2021-03-17 National Center of Neurology and Psychiatry Verfahren zur vorhersage und beurteilung der therapeutischen wirkung bei erkrankungen im zusammenhang mit il-6 und neutrophilen
WO2018204534A1 (en) 2017-05-02 2018-11-08 Immunomic Therapeutics, Inc. Lamp (lysosomal associated membrane protein) constructs comprising cancer antigens
CA3060695A1 (en) 2017-05-02 2018-11-08 Merck Sharp & Dohme Corp. Stable formulations of anti-ctla4 antibodies alone and in combination with programmed death receptor 1 (pd-1) antibodies and methods of use thereof
JOP20190260A1 (ar) 2017-05-02 2019-10-31 Merck Sharp & Dohme صيغ ثابتة لأجسام مضادة لمستقبل الموت المبرمج 1 (pd-1) وطرق استخدامها
US11597774B2 (en) 2017-05-04 2023-03-07 City Of Hope Antibody variable domains and antibody constructs
BR112019022912A2 (pt) 2017-05-05 2020-05-26 Allakos Inc. Métodos e composições para tratar doenças oculares alérgicas
US10865238B1 (en) 2017-05-05 2020-12-15 Duke University Complement factor H antibodies
MA48763A (fr) 2017-05-05 2020-04-08 Amgen Inc Composition pharmaceutique comprenant des constructions d'anticorps bispécifiques pour un stockage et une administration améliorés
IL252151A0 (en) 2017-05-07 2017-07-31 Fainzilber Michael Treatment of stress disorders
EP3401332A1 (de) 2017-05-08 2018-11-14 MAB Discovery GmbH Anti-il-1r3 antikörper zur verwendung bei entzündungskrankheiten
WO2018207184A2 (en) 2017-05-10 2018-11-15 Ariel Scientific Innovations Ltd. Methods of purifying antibodies
US11932650B2 (en) 2017-05-11 2024-03-19 Massachusetts Institute Of Technology Potent agelastatin derivatives as modulators for cancer invasion and metastasis
US12226479B2 (en) 2017-05-11 2025-02-18 The General Hospital Corporation Methods and compositions of use of CD8+ tumor infiltrating lymphocyte subtypes and gene signatures thereof
GB201707561D0 (en) 2017-05-11 2017-06-28 Argenx Bvba GARP-TGF-beta antibodies
WO2018209301A1 (en) 2017-05-11 2018-11-15 Cytodyn Inc. Methods for treating or preventing graft-versus-host disease involving the administration of anti-ccr5 receptor agents
ES2924499T3 (es) 2017-05-11 2022-10-07 Inst Nat Sante Rech Med Método de selección de terapia para pacientes que padecen glioblastoma
SG10202107880XA (en) 2017-05-12 2021-09-29 Harpoon Therapeutics Inc Mesothelin binding proteins
JOP20190256A1 (ar) 2017-05-12 2019-10-28 Icahn School Med Mount Sinai فيروسات داء نيوكاسل واستخداماتها
US10730954B2 (en) 2017-05-12 2020-08-04 Harpoon Therapeutics, Inc. MSLN targeting trispecific proteins and methods of use
EP3623368A4 (de) 2017-05-12 2021-04-07 Riken Modifikator einer verbindung mit klasse-a-gpcr-bindung
WO2018209175A2 (en) 2017-05-12 2018-11-15 The Trustees Of The University Of Pennsylvania Fully humanized anti-platelet factor 4 antibodies that treat heparin-induced thrombocytopenia
WO2018213097A1 (en) 2017-05-15 2018-11-22 University Of Rochester Broadly neutralizing anti-influenza monoclonal antibody and uses thereof
DK3624837T3 (da) 2017-05-16 2025-09-29 Five Prime Therapeutics Inc Anti-fgfr2-antistoffer i kombination med kemoterapeutiske midler til kræftbehandling
US10646569B2 (en) 2017-05-16 2020-05-12 Bhami's Research Laboratory, Pvt. Ltd. High concentration protein formulations with reduced viscosity
PT3625259T (pt) 2017-05-16 2024-07-04 Synthon Biopharmaceuticals Bv Anticorpos anti-sirpalfa
EP3403649A1 (de) 2017-05-16 2018-11-21 Bayer Pharma Aktiengesellschaft Inhibitoren und antagonisten von gpr84 zur behandlung von endometriose
EP3625258A1 (de) 2017-05-16 2020-03-25 Alector LLC Anti-siglec-5-antikörper und verfahren zur verwendung davon
EP3625264B9 (de) 2017-05-17 2023-10-25 Merus N.V. Kombination eines erbb-2 / erbb-3-bispezifischen antikörpers mit endokrin-therapie für brustkrebs
WO2018211126A1 (en) 2017-05-19 2018-11-22 Philip Morris Products S.A. Diagnostic test for distinguishing the smoking status of a subject
MA48940A (fr) 2017-05-22 2020-04-08 4D Pharma Res Ltd Compositions comprenant des souches bactériennes
US10914729B2 (en) 2017-05-22 2021-02-09 The Trustees Of Princeton University Methods for detecting protein binding sequences and tagging nucleic acids
EP3634991A1 (de) 2017-05-23 2020-04-15 Technion Research & Development Foundation Limited Mittel zur hemmung von gads-dimerisierung und verfahren zur verwendung davon
KR20200010491A (ko) 2017-05-23 2020-01-30 신톤 바이오파머슈티칼즈 비.브이. 항체-약물 접합체를 제조하기 위한 이중 접합 방법
US20200362058A1 (en) 2017-05-24 2020-11-19 Novartis Ag Antibody-cytokine engrafted proteins and methods of use
MA41708A (fr) 2017-05-24 2020-04-08 4D Pharma Res Ltd Compositions comprenant des souches bactériennes
US20200079850A1 (en) 2017-05-24 2020-03-12 Sutro Biopharma, Inc. Pd-1/lag3 bi-specific antibodies, compositions thereof, and methods of making and using the same
WO2018215937A1 (en) 2017-05-24 2018-11-29 Novartis Ag Interleukin-7 antibody cytokine engrafted proteins and methods of use in the treatment of cancer
EP3406253A1 (de) 2017-05-24 2018-11-28 Bayer Aktiengesellschaft Inhibitoren und antagonisten von humanem pycr1
JOP20190271A1 (ar) 2017-05-24 2019-11-21 Novartis Ag بروتينات مطعّمة بسيتوكين- الجسم المضاد وطرق الاستخدام للاضطرابات المتعلقة بالمناعة
KR102920712B1 (ko) 2017-05-24 2026-01-30 노파르티스 아게 항체-사이토카인 생착된 단백질 및 암 치료에 있어서의 사용 방법
US10866251B2 (en) 2017-05-25 2020-12-15 Abbott Laboratories Methods for aiding in the determination of whether to perform imaging on a human subject who has sustained or may have sustained an injury to the head using early biomarkers
US11260117B2 (en) 2017-05-26 2022-03-01 Novimmune Sa Anti-CD47 x anti-mesothelin antibodies and methods of use thereof
US20200140547A1 (en) 2017-05-26 2020-05-07 The Johns Hopkins University Multifunctional antibody-ligand traps to modulate immune tolerance
CN111010867B (zh) 2017-05-30 2023-05-12 俄克拉何马大学董事会 抗双皮层蛋白样激酶1抗体及其使用方法
WO2018222783A1 (en) 2017-05-30 2018-12-06 Abbott Laboratories Methods for aiding in diagnosing and evaluating a mild traumatic brain injury in a human subject using cardiac troponin i and early biomarkers
EP3630836A1 (de) 2017-05-31 2020-04-08 Elstar Therapeutics, Inc. Multispezifische moleküle, die an myeloproliferatives leukämie (mlp)-protein binden, und deren verwendungen
JOP20190259A1 (ar) 2017-05-31 2019-10-31 Amgen Inc بروتينات ربط مولد ضد مضادة لـ jagged1
CN111148762A (zh) 2017-05-31 2020-05-12 斯特库伯株式会社 免疫特异性结合至btn1a1的抗体和分子及其治疗性用途
CN111051346A (zh) 2017-05-31 2020-04-21 斯特库伯株式会社 使用免疫特异性结合btn1a1的抗体和分子治疗癌症的方法
JP7234142B2 (ja) 2017-06-02 2023-03-07 ファイザー・インク Ｆｌｔ３に特異的な抗体およびその使用
JP2020521791A (ja) 2017-06-02 2020-07-27 エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト がんの治療のためのｉｉ型抗ｃｄ２０抗体及び抗ｃｄ２０／ｃｄ３０二重特異性抗体
PE20241587A1 (es) 2017-06-02 2024-08-01 Pfizer Receptores de antigenos quimericos que se dirigen a flt3
WO2018226690A1 (en) 2017-06-05 2018-12-13 The University Of Chicago Microbiome biomarkers of immunotherapy responsiveness: diagnostic, prognostic and therapeutic uses thereof
JP2020522562A (ja) 2017-06-06 2020-07-30 ストキューブ アンド シーオー．， インコーポレイテッド Ｂｔｎ１ａ１又はｂｔｎ１ａ１リガンドに結合する抗体及び分子を用いて癌を治療する方法
WO2018226750A1 (en) 2017-06-06 2018-12-13 Relinia, Inc. Single-chain tnf receptor 2 agonist fusion proteins
WO2018226685A2 (en) 2017-06-06 2018-12-13 Dana-Farber Cancer Institute, Inc. Methods for sensitizing cancer cells to t cell-mediated killing by modulating molecular pathways
EP3634999A1 (de) 2017-06-07 2020-04-15 Philogen S.p.A. Gefässendothelwachstumsfaktor-/antifibronectin-antikörper-fusionsproteine
JP7321101B2 (ja) 2017-06-08 2023-08-04 エンリヴェックス セラピューティクス アールディーオー リミテッド 癌治療のための治療的アポトーシス細胞
US10793634B2 (en) 2017-06-09 2020-10-06 Boehringer Ingelheim International Gmbh Anti-TrkB antibodies
CN107271674B (zh) 2017-06-13 2019-05-07 首都医科大学附属北京地坛医院 一种用于脂肪性肝炎检测的靶标志物gp73及检测应用方法
WO2018232020A1 (en) 2017-06-13 2018-12-20 TCR2 Therapeutics Inc. Compositions and methods for tcr reprogramming using fusion proteins
US11635435B2 (en) 2017-06-13 2023-04-25 Oncotracker, Inc. Diagnostic, prognostic, and monitoring methods for solid tumor cancers
KR102442736B1 (ko) 2017-06-14 2022-09-16 에이디씨 테라퓨틱스 에스에이 항-cd19 adc의 투여를 위한 투약량 체제
KR20200028950A (ko) 2017-06-14 2020-03-17 에이디씨 테라퓨틱스 에스에이 항-cd25 adc의 투여를 위한 투약량 체제
JP2020523383A (ja) 2017-06-14 2020-08-06 ダナ−ファーバー キャンサー インスティテュート，インコーポレイテッド Ｂ細胞成熟抗原（ｂｃｍａ）指向性ナノ粒子
TWI767013B (zh) 2017-06-14 2022-06-11 英商4D製藥研究有限公司 包含細菌品系之組成物
JP2020523326A (ja) 2017-06-14 2020-08-06 フォーディー ファーマ リサーチ リミテッド４Ｄ Ｐｈａｒｍａ Ｒｅｓｅａｒｃｈ Ｌｉｍｉｔｅｄ 細菌株を含む組成物
PL3638271T3 (pl) 2017-06-14 2021-03-22 4D Pharma Research Limited Kompozycje zawierające szczepy bakteryjne
WO2018228875A1 (en) 2017-06-15 2018-12-20 Nestec S.A. Micro-rna biomarkers of blood-brain barrier dysfunction
US12150978B2 (en) 2017-06-15 2024-11-26 Cancer Advances Inc. Compositions and methods for preventing tumors and cancer
EP4491746A3 (de) 2017-06-15 2025-07-09 Miradx Biomarker zur vorhersage der tumorreaktion auf und toxizität einer immuntherapie
IL271427B2 (en) 2017-06-15 2025-08-01 Cancer Advances Inc Compositions and methods for inducing humoral and cellular immunities against tumors and cancer
WO2018229715A1 (en) 2017-06-16 2018-12-20 Novartis Ag Compositions comprising anti-cd32b antibodies and methods of use thereof
US11325957B2 (en) 2017-06-19 2022-05-10 Cell Design Labs, Inc. Methods and compositions for reducing the immunogenicity of chimeric notch receptors
EP3641929A2 (de) 2017-06-19 2020-04-29 Massachusetts Institute Of Technology Automatisierte verfahren zur skalierbaren, parallelisierten enzymatischen biopolymersynthese und modifikation unter verwendung von mikrofluidischen vorrichtungen
JP7240335B2 (ja) 2017-06-20 2023-03-15 テネオワン， インコーポレイテッド 抗ｂｃｍａ重鎖のみ抗体
CA3062194A1 (en) 2017-06-20 2018-12-27 Amgen Inc. Method of treating or ameliorating metabolic disorders using binding proteins for gastric inhibitory peptide receptor (gipr) in combination with glp-1 agonists
CN110891971B (zh) 2017-06-20 2024-01-12 特尼奥生物股份有限公司 仅有重链的抗bcma抗体
WO2018237010A2 (en) 2017-06-20 2018-12-27 The Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical College Vaccine compositions and methods of using the same
JP7250706B2 (ja) 2017-06-21 2023-04-03 アムジエン・インコーポレーテツド 胃抑制ペプチド受容体（ｇｉｐｒ）に対するアンタゴニスト結合タンパク質／ｇｌｐ－１受容体アゴニスト融合タンパク質を使用した代謝障害の治療又は寛解方法
WO2018234843A1 (en) 2017-06-22 2018-12-27 INSERM (Institut National de la Santé et de la Recherche Médicale) METHODS AND PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OF FIBROSIS WITH AGENTS CAPABLE OF INHIBITING THE ACTIVATION OF MOSES-ASSOCIATED INVARIANT T CELLS (MAIT)
MX2019015885A (es) 2017-06-22 2020-09-10 Novartis Ag Moleculas de anticuerpo que se unen a cd73 y usos de las mismas.
US20200172628A1 (en) 2017-06-22 2020-06-04 Novartis Ag Antibody molecules to cd73 and uses thereof
EP3645741A4 (de) 2017-06-25 2021-08-25 Systimmune, Inc. Anti-4-1bb-antikörper und verfahren zur herstellung und verwendung
WO2019000223A1 (en) 2017-06-27 2019-01-03 Nanjing Legend Biotech Co., Ltd. ENABLERS OF IMMUNE EFFECTOR CELLS OF CHIMERIC ANTIBODIES AND METHODS OF USE THEREOF
AU2018290749A1 (en) 2017-06-27 2019-12-12 Dana-Farber Cancer Institute, Inc. Compositions and methods for identifying and treating resistance to CTLA4 antagonists in leukemia
BR112019027729A2 (pt) 2017-06-27 2020-08-18 Neuracle Science Co., Ltd anticorpos anti-fam19a5 e seus usos
CN111050791A (zh) 2017-06-27 2020-04-21 诺华股份有限公司 用于抗tim-3抗体的给药方案及其用途
EP3645564A1 (de) 2017-06-28 2020-05-06 Novartis AG Verfahren zur prävention und behandlung von harninkontinenz
WO2019002548A1 (en) 2017-06-29 2019-01-03 INSERM (Institut National de la Santé et de la Recherche Médicale) TREATMENT OF MIGRAINE WITH TREK1, TREK2 AGONIZATION OR HETEROMERS COMPRISING SAME
WO2019005503A1 (en) 2017-06-29 2019-01-03 Rutgers, The State University Of New Jersey COMPOSITIONS AND METHODS TARGETING G12 SIGNALING FOR BRONCHODILATORY THERAPY
EP3649474A1 (de) 2017-07-03 2020-05-13 Abbott Laboratories Verbesserte verfahren zur messung von ubiquitin-carboxy-terminalen hydrolase-l1-konzentrationen in blut
KR20200026898A (ko) 2017-07-07 2020-03-11 이매틱스 바이오테크놀로지스 게엠베하 Nsclc, sclc 등 폐암 및 기타 암에 대한 면역요법에서의 사용을 위한 신규 펩티드 및 펩티드의 조합
WO2019007974A1 (en) 2017-07-07 2019-01-10 Immatics Biotechnologies Gmbh NOVEL PEPTIDES AND COMBINATION OF PEPTIDES FOR USE IN IMMUNOTHERAPY OF LUNG CANCER, INCLUDING NSCLC, CPPC AND OTHER CANCERS
CN111263769B (zh) 2017-07-10 2024-01-02 先天制药公司 Siglec-9中和性抗体
PE20200481A1 (es) 2017-07-10 2020-03-03 Bayer Pharma AG Anticuerpo del receptor de prolactina para la perdida de cabello con patrones masculinos y femeninos
WO2019011852A1 (en) 2017-07-10 2019-01-17 Innate Pharma POLYTHERAPY USING ANTIBODY AGAINST SIGLEC-9 HUMAN AND ANTIBODY AGAINST NKG2A HUMAN FOR THE TREATMENT OF CANCER
WO2019014581A1 (en) 2017-07-14 2019-01-17 The Broad Institute, Inc. METHODS AND COMPOSITIONS FOR MODULATING THE ACTIVITY OF A CYTOTOXIC LYMPHOCYTE
EP3654993A4 (de) 2017-07-17 2021-08-25 The Broad Institute, Inc. Zellatlas des gesunden menschlichen dickdarms und menschlichen dickdarms mit colitis ulcerosa
US11827669B2 (en) 2017-07-19 2023-11-28 The Usa, As Represented By The Secretary, Dept. Of Health And Human Services Antibodies and methods for the diagnosis and treatment of hepatitis b virus infection
EP3431496A1 (de) 2017-07-19 2019-01-23 Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung e.V. Anti-isoasp7-amyloid-beta-antikörper und verwendungen davon
WO2019018729A1 (en) 2017-07-20 2019-01-24 Dana-Farber Cancer Institute, Inc. COMPOSITIONS AND METHODS FOR IDENTIFICATION AND TREATMENT OF NEUROENDOCRINE METASTATIC TUMORS OF INTESTINAL HAIL
WO2019016310A1 (en) 2017-07-20 2019-01-24 INSERM (Institut National de la Santé et de la Recherche Médicale) METHODS AND COMPOSITIONS FOR TREATING CANCERS
WO2019018647A1 (en) 2017-07-20 2019-01-24 Pfizer Inc. ANTI-GD3 ANTIBODIES AND CONJUGATES ANTIBODY-MEDICATION
WO2019018730A1 (en) 2017-07-20 2019-01-24 Novartis Ag DOSAGE REGIMES FOR ANTI-LAG3 ANTIBODIES AND USES THEREOF
AU2018304458B2 (en) 2017-07-21 2021-12-09 Foundation Medicine, Inc. Therapeutic and diagnostic methods for cancer
EP3658581A1 (de) 2017-07-24 2020-06-03 INSERM (Institut National de la Santé et de la Recherche Médicale) Antikörper und peptide zur behandlung von erkrankungen im zusammenhang mit hcmv
US11926664B2 (en) 2017-07-25 2024-03-12 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and pharmaceutical compositions for modulating monocytopoiesis
EP3658589B1 (de) 2017-07-26 2023-09-27 Forty Seven, Inc. Anti-sirp-alpha-antikörper und verwandte verfahren
EP3658588A1 (de) 2017-07-26 2020-06-03 Sutro Biopharma, Inc. Verfahren zur verwendung von anti-cd74-antikörpern und antikörperkonjugaten bei der behandlung von t-zell-lymphomen
SG11202000634UA (en) 2017-07-27 2020-02-27 Nomocan Pharmaceuticals Llc Antibodies to m(h)dm2/4 and their use in diagnosing and treating cancer
ES2965486T3 (es) 2017-07-27 2024-04-15 Alexion Pharma Inc Formulaciones de anticuerpos anti-C5 de alta concentración
US11285149B2 (en) 2017-07-28 2022-03-29 Dana-Farber Cancer Institute, Inc. Enhanced immunotherapy of cancer using targeted transcriptional modulators
WO2019020807A1 (en) 2017-07-28 2019-01-31 Gene Signal International Sa CD9P-1 TARGETING ANTIBODIES AND USES THEREOF
EP3658583A1 (de) 2017-07-28 2020-06-03 Scholar Rock, Inc. Ltbp-komplex-spezifische inhibitoren von tgf-beta 1 und verwendungen davon
US11680110B2 (en) 2017-07-31 2023-06-20 Hoffmann-La Roche Inc. Three-dimensional structure-based humanization method
WO2019028096A1 (en) 2017-08-02 2019-02-07 The Wistar Institute Of Anatomy And Biology METHODS AND COMPOSITIONS FOR THE TREATMENT OF CANCER
MY205541A (en) 2017-08-03 2024-10-25 Alector Llc Anti-cd33 antibodies and methods of use thereof
HUE062436T2 (hu) 2017-08-03 2023-11-28 Alector Llc Anti-trem2 antitestek és alkalmazási módszereik
MA68842B1 (fr) 2017-08-04 2025-01-31 Amgen Inc. Procédé de conjugaison de cys-mabs
RS66708B9 (sr) 2017-08-09 2025-08-29 Merus Nv Antitela koja se vezuju za egfr i cmet
WO2019033043A2 (en) 2017-08-11 2019-02-14 Genentech, Inc. ANTI-CD8 ANTIBODIES AND USES THEREOF
WO2019036363A1 (en) 2017-08-14 2019-02-21 Progenity Inc. TREATMENT OF GASTROINTESTINAL TRACT DISEASE WITH GLATIRAMER OR A PHARMACEUTICALLY ACCEPTABLE SALT THEREOF
TWI818919B (zh) 2017-08-15 2023-10-21 美商歐米諾斯公司 用於治療和／ 或預防與造血幹細胞移植有關的移植物抗宿主病和／ 或瀰漫性肺泡出血和／ 或靜脈閉塞性病的方法
WO2019035938A1 (en) 2017-08-16 2019-02-21 Elstar Therapeutics, Inc. MULTISPECIFIC MOLECULES BINDING TO BCMA AND USES THEREOF
WO2019035034A1 (en) 2017-08-16 2019-02-21 The Broad Institute, Inc. NEURONAL DOSAGE METHOD INVOLVING CALCINEURIN
EP3444275A1 (de) 2017-08-16 2019-02-20 Exiris S.r.l. Monoklonaler antikörper anti-fgfr4
MY199833A (en) 2017-08-17 2023-11-24 Just Evotec Biologics Inc Method of purifying glycosylated protein from host cell galectins and other contaminants
SI3668874T1 (sl) 2017-08-18 2022-04-29 Medimmune Limited Pirolobenzodiazepinski konjugati
AU2017428737B2 (en) 2017-08-21 2024-02-15 Adagene Inc. Dynamic human heavy chain antibody libraries
CN111511762B (zh) 2017-08-21 2025-05-06 天演药业公司 抗cd137分子及其用途
SG11202001549UA (en) 2017-08-21 2020-03-30 Adagene Inc Dynamic human antibody light chain libraries
US12139546B2 (en) 2017-08-22 2024-11-12 Regeneron Pharmaceuticals, Inc. Methods of treating urea cycle disorders by interfering with glucagon receptor signaling
CA3072859A1 (en) 2017-08-23 2019-02-28 Max-Delbruck-Centrum Fur Molekulare Medizin In Der Helmholtz-Gemeinscht Chimeric antigen receptor and car-t cells that bind cxcr5
AU2018321893A1 (en) 2017-08-23 2020-03-19 Wayne State University In vivo immunoimaging of interferon-gamma
MX2020002241A (es) 2017-08-28 2020-09-03 Angiex Inc Anticuerpos anti-tm4sf y métodos de uso de los mismos.
US20210332141A1 (en) 2017-08-30 2021-10-28 Amgen Inc. Insulin-like growth factor-1 receptor (igf-1r) binding proteins and methods of use
US11085929B2 (en) 2017-08-31 2021-08-10 Arizona Board Of Regents On Behalf Of Arizona State University Nanoshell-structured material as co-matrix for peptide characterization in mass spectrometry
WO2019045075A1 (ja) 2017-08-31 2019-03-07 田辺三菱製薬株式会社 Ｉｌ－３３アンタゴニストを含む子宮内膜症治療剤
US11266674B2 (en) 2017-09-01 2022-03-08 Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. Pharmaceutical composition for tumor treatment or prevention, method, and use thereof
JP7604226B2 (ja) 2017-09-05 2024-12-23 イミュノジェン， インコーポレイテッド 患者の試料中のヒト葉酸受容体１を検出するための方法
EP3679061A4 (de) 2017-09-06 2021-06-09 University of Cincinnati Verfahren zur prognose von brustläsionen im frühstadium
JP7795860B2 (ja) 2017-09-07 2026-01-08 オーガスタ ユニバーシティ リサーチ インスティテュート，インコーポレーテッド プログラム細胞死タンパク質１に対する抗体
CN111356700A (zh) 2017-09-08 2020-06-30 马弗里克治疗公司 受约束的条件性活化的结合蛋白
WO2019050362A2 (ko) 2017-09-08 2019-03-14 주식회사 와이바이오로직스 인간 dlk1에 대한 항체 및 이의 용도
KR102755742B1 (ko) 2017-09-11 2025-01-15 모나쉬 유니버시티 인간 트롬빈 수용체 par4 결합 단백질
JP7196160B2 (ja) 2017-09-12 2022-12-26 スミトモ ファーマ オンコロジー， インコーポレイテッド Ｍｃｌ－１阻害剤アルボシジブを用いた、ｂｃｌ－２阻害剤に対して非感受性である癌の治療レジメン
WO2019055796A1 (en) 2017-09-15 2019-03-21 Bristol-Myers Squibb Company ONLINE BIOMASS CAPACITY MONITORING DURING LARGE SCALE PRODUCTION OF POLYPEPTIDES OF INTEREST
WO2019055825A1 (en) 2017-09-15 2019-03-21 The Regents Of The University Of California INHIBITION OF AMINOACYLASE 3 (AA3) IN THE TREATMENT OF CANCER
CN111344403B (zh) 2017-09-15 2025-05-06 利兰斯坦福初级大学董事会 遗传工程细胞的多元性产生和条形码编制
HUE059339T2 (hu) 2017-09-15 2022-11-28 Amgen Inc Eljárás terápiás fehérje liofilizált gyógyászati kiszerelésére
US12025615B2 (en) 2017-09-15 2024-07-02 Arizona Board Of Regents On Behalf Of Arizona State University Methods of classifying response to immunotherapy for cancer
MA50265A (fr) 2017-09-18 2020-07-29 Sutro Biopharma Inc Conjugués anticorps-récepteur alpha anti-folate et leurs utilisations
KR102742220B1 (ko) 2017-09-19 2024-12-17 더 유니버시티 오브 브리티쉬 콜롬비아 항-hla-a2 항체 및 그 사용 방법
WO2019057742A1 (en) 2017-09-20 2019-03-28 INSERM (Institut National de la Santé et de la Recherche Médicale) METHODS AND PHARMACEUTICAL COMPOSITIONS FOR MODULATION OF AUTOPHAGIA
EP3685166A2 (de) 2017-09-20 2020-07-29 Mersana Therapeutics, Inc. Zusammensetzungen und verfahren zur vorhersage des ansprechens auf eine napi2b-gerichtete therapie
US11814432B2 (en) 2017-09-20 2023-11-14 The University Of British Columbia Anti-HLA-A2 antibodies, related chimeric antigen receptors, and uses thereof
JP7382922B2 (ja) 2017-09-20 2023-11-17 中外製薬株式会社 Ｐｄ－１系結合アンタゴニストおよびｇｐｃ３標的化剤を使用する併用療法のための投与レジメン
KR102764182B1 (ko) 2017-09-21 2025-02-07 임체크 테라퓨틱스 Ｂｔｎ２에 대해 특이성을 갖는 항체 및 이의 용도
WO2019057816A1 (en) 2017-09-22 2019-03-28 F. Hoffmann-La Roche Ag MULOMALENT MONO- OR BISPECIFIC RECOMBINANT ANTIBODIES FOR ANALYTICAL PURPOSES
TW201922780A (zh) 2017-09-25 2019-06-16 美商健生生物科技公司 以抗ｉｌ１２／ｉｌ２３抗體治療狼瘡之安全且有效之方法
KR20240017986A (ko) 2017-09-26 2024-02-08 더 리전트 오브 더 유니버시티 오브 캘리포니아 암 치료를 위한 조성물 및 방법
KR102757384B1 (ko) 2017-09-27 2025-01-20 에피센트알엑스, 인코포레이티드 면역조절 융합 단백질
US11897917B2 (en) 2017-09-27 2024-02-13 The University Of York Bioconjugation of polypeptides
EP3687629A4 (de) 2017-09-27 2021-10-06 University of Georgia Research Foundation Behandlung und nachweis einer mit verschiedenen pilzpathogenen assoziierten infektion und erkrankung
US11180541B2 (en) 2017-09-28 2021-11-23 Geltor, Inc. Recombinant collagen and elastin molecules and uses thereof
WO2019067792A1 (en) 2017-09-28 2019-04-04 Celularity, Inc. TUMOR CONTROL WITH INTERMEDIATE NATURAL KILLER CELLS DERIVED FROM HUMAN PLACENTA (PINK) IN COMBINATION WITH ANTIBODY
WO2019067015A1 (en) 2017-09-29 2019-04-04 City Of Hope RECEPTORS OF CHIMERIC ANTIGENS AND BISPECIFIC ANTIBODIES FOR THE TREATMENT OF COAT CELL LYMPHOMA
CA3071236A1 (en) 2017-09-29 2019-04-04 Chugai Seiyaku Kabushiki Kaisha Multispecific antigen-binding molecule having blood coagulation factor viii (fviii) cofactor function-substituting activity, and pharmaceutical formulation containing said moleculeas active ingredient
EP3689903A4 (de) 2017-09-30 2022-01-12 Hefei Lifeon Pharmaceutical Co. Ltd. Bindung von protein an fibronectin-b-domäne
EP3461841B1 (de) 2017-10-02 2019-09-11 Certest Biotec, S.L. Antikörper gegen dps und testvorrichtungen zum nachweis von bakterien der gattung campylobacter
IL320863A (en) 2017-10-02 2025-07-01 Visterra Inc Antibodies to CD138 and their uses
EA039662B1 (ru) 2017-10-03 2022-02-24 Закрытое Акционерное Общество "Биокад" Антитела, специфичные к cd47 и pd-l1
RU2698048C2 (ru) 2017-10-03 2019-08-21 Закрытое Акционерное Общество "Биокад" МОНОКЛОНАЛЬНОЕ АНТИТЕЛО К IL-5Rα
JP7543134B2 (ja) 2017-10-03 2024-09-02 メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツング システイン操作された抗原結合分子
AU2018344859A1 (en) 2017-10-04 2020-04-30 Hesperix SA Articles and methods directed to personalized therapy of cancer
EP3693013A4 (de) 2017-10-06 2021-06-30 Ono Pharmaceutical Co., Ltd. Bispezifischer antikörper
CN111787930B (zh) 2017-10-06 2024-12-20 芝加哥大学 针对癌症特异性抗原对t淋巴细胞的筛选
CA3078434A1 (en) 2017-10-10 2019-04-18 Medicenna Therapeutics, Inc. Il-4-fusion formulations for treatment of central nervous system (cns) tumors
WO2019075090A1 (en) 2017-10-10 2019-04-18 Tilos Therapeutics, Inc. ANTI-LAP ANTIBODIES AND USES THEREOF
EP3694545A4 (de) 2017-10-11 2021-12-01 Board Of Regents, The University Of Texas System Menschliche pd-l1-antikörper und verfahren zu ihrer verwendung
CN119264274A (zh) 2017-10-12 2025-01-07 免疫苏醒公司 Vegfr-抗体轻链融合蛋白
US10640508B2 (en) 2017-10-13 2020-05-05 Massachusetts Institute Of Technology Diazene directed modular synthesis of compounds with quaternary carbon centers
CA3078969A1 (en) 2017-10-13 2019-04-18 Harpoon Therapeutics, Inc. Trispecific proteins and methods of use
IL315737A (en) 2017-10-13 2024-11-01 Harpoon Therapeutics Inc B-cell maturation antigen-binding proteins
AU2018347331A1 (en) 2017-10-13 2020-04-09 Merck Patent Gmbh Combination of a PARP inhibitor and a PD-1 axis binding antagonist
EA202090565A1 (ru) 2017-10-13 2020-10-13 Мерк Шарп энд Доум Корп. Композиции и способы лечения диффузной в-крупноклеточной лимфомы
KR102715492B1 (ko) 2017-10-18 2024-10-11 씨에스엘 리미티드 인간 혈청 알부민 변이체 및 이의 용도
BR112020004351A2 (pt) 2017-10-19 2020-09-08 Curevac Ag moléculas de ácido nucleico artificial
KR20200072507A (ko) 2017-10-19 2020-06-22 데비오팜 인터네셔날 에스 에이 암 치료를 위한 조합 제품
EP3697811A1 (de) 2017-10-20 2020-08-26 Institut Curie Hakenfusionsprotein zur regulierung der zellulären transportsteuerung eines zielproteins
WO2019078344A1 (ja) 2017-10-20 2019-04-25 学校法人兵庫医科大学 抗ｉｌ－６受容体抗体を含有する術後の癒着を抑制するための医薬組成物
EP3697809A1 (de) 2017-10-20 2020-08-26 Institut Curie Für rush angepasste dap10/12-basierte cars
KR101966362B1 (ko) * 2017-10-20 2019-04-05 주식회사 녹십자 항-msln 항체 및 이를 포함하는 암 치료용 약학적 조성물
WO2019083904A1 (en) 2017-10-23 2019-05-02 Chan Zuckerberg Biohub, Inc. AFUCOSYLATED IGG FC GLYCANES MEASUREMENT AND METHODS OF TREATMENT THEREOF
WO2019081456A1 (en) 2017-10-24 2019-05-02 Bayer Aktiengesellschaft USE OF SGC ACTIVATORS AND STIMULATORS COMPRISING A BETA2 SUBUNIT
WO2019081983A1 (en) 2017-10-25 2019-05-02 Novartis Ag CD32B TARGETING ANTIBODIES AND METHODS OF USE
US11897969B2 (en) 2017-10-26 2024-02-13 The Regents Of The University Of California Inhibition of oxidation-specific epitopes to treat ischemic reperfusion injury
JP7518764B2 (ja) 2017-10-26 2024-07-18 アレクシオン ファーマシューティカルズ， インコーポレイテッド 発作性夜間ヘモグロビン尿症（ＰＮＨ）および非典型溶血性尿毒症症候群（ａＨＵＳ）の処置のための抗Ｃ５抗体の投薬量および投与
KR20200078483A (ko) 2017-10-27 2020-07-01 머크 샤프 앤드 돔 코포레이션 간암 치료를 위한 조성물 및 방법
IL274071B2 (en) 2017-10-30 2025-10-01 Hoffmann La Roche Method for generating in vivo multispecific antibodies from monospecific antibodies
CN111315772A (zh) 2017-10-31 2020-06-19 斯塔顿生物技术有限公司 抗apoc3抗体及其使用方法
TW201922294A (zh) 2017-10-31 2019-06-16 美商伊繆諾金公司 抗體-藥物結合物與阿糖胞苷之組合治療
WO2019088658A1 (ko) 2017-10-31 2019-05-09 주식회사 컴워스파마 Scf 및 갈렉틴-1을 표적으로 하는 이중표적항체 및 그 용도
PE20210844A1 (es) 2017-11-01 2021-05-10 Hoffmann La Roche Contorsbodies 2 + biespecificos
BR112020008031A2 (pt) 2017-11-01 2020-10-27 F. Hoffmann-La Roche Ag anticorpo multiespecíficos, método para a preparação do anticorpo multiespecífico, conjunto de ácidos nucleicos, vetor de expressão, célula hospedeira e composição farmacêutica
CN111295392A (zh) 2017-11-01 2020-06-16 豪夫迈·罗氏有限公司 Compbody–多价靶结合物
CN111246884A (zh) 2017-11-01 2020-06-05 豪夫迈·罗氏有限公司 新颖的含有tnf家族配体三聚体的抗原结合分子
EP3704154A1 (de) 2017-11-02 2020-09-09 Oxford BioTherapeutics Ltd Antikörper und verfahren zur verwendung
MX2020004716A (es) 2017-11-06 2020-11-06 Janssen Biotech Inc Método seguro y eficaz para tratar la artritis psoriásica con el anticuerpo específico anti-il23.
WO2019090263A1 (en) 2017-11-06 2019-05-09 Genentech, Inc. Diagnostic and therapeutic methods for cancer
CN111587123A (zh) 2017-11-09 2020-08-25 品通治疗有限公司 用于生成和使用人源化构象特异性磷酸化的τ抗体的方法和组合物
WO2019094928A1 (en) 2017-11-10 2019-05-16 Massachusetts Institute Of Technology Microbial production of pure single stranded nucleic acids
US12171783B2 (en) 2017-11-13 2024-12-24 The Broad Institute, Inc. Methods and compositions for targeting developmental and oncogenic programs in H3K27M gliomas
MA50102A (fr) 2017-11-14 2020-07-15 Univ Virginia Patent Foundation Compositions et méthodes de fabrication et d'utilisation d'anticorps bispécifiques
AU2018368431B2 (en) 2017-11-14 2024-03-21 Arcellx, Inc. Multifunctional immune cell therapies
CA3082643A1 (en) 2017-11-14 2019-05-23 The Schepens Eye Research Institute, Inc. Runx1 inhibition for treatment of proliferative vitreoretinopathy and conditions associated with epithelial to mesenchymal transition
EP4640703A3 (de) 2017-11-14 2026-04-08 Chugai Seiyaku Kabushiki Kaisha Anti-c1s-antikörper und verfahren zur verwendung
IL255664A0 (en) 2017-11-14 2017-12-31 Shachar Idit Hematopoietic stem cells with enhanced properties
MX2020004756A (es) 2017-11-16 2020-08-20 Novartis Ag Terapias de combinacion.
JP7194481B2 (ja) 2017-11-17 2022-12-22 メルク・シャープ・アンド・ドーム・エルエルシー 免疫グロブリン様転写産物３（ｉｌｔ３）に特異的な抗体およびその使用
MY202872A (en) 2017-11-20 2024-05-28 Just Evotec Biologics Inc Aflibercept formulations containing a lysine salt as tonicifying agent and uses thereof
CA3082728A1 (en) 2017-11-22 2019-05-31 Inbiomotion S.L. Therapeutic treatment of breast cancer based on c-maf status
WO2019101995A1 (en) 2017-11-27 2019-05-31 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and pharmaceutical compositions for cardiac regeneration
WO2019102456A1 (en) 2017-11-27 2019-05-31 University Of Rijeka Faculty Of Medicine Immunotoxins for treating cancer
CN111727075B (zh) 2017-11-27 2024-04-05 普渡制药公司 靶向人组织因子的人源化抗体
KR20200089312A (ko) 2017-11-28 2020-07-24 추가이 세이야쿠 가부시키가이샤 리간드 결합 활성을 조정 가능한 리간드 결합 분자
US20210179721A1 (en) 2017-11-29 2021-06-17 Csl Limited Method of treating or preventing ischemia-reperfusion injury
JP7402158B2 (ja) 2017-11-30 2023-12-20 ジェネンテック， インコーポレイテッド 抗ｐｄ－ｌ１抗体及びｐｄ－ｌ１を検出するためにそれを使用する方法
BR112020009836A2 (pt) 2017-11-30 2020-10-13 Centurion Biopharma Corporation pró-drogas de ligação a albumina de derivados de auristatina e
IL305268A (en) 2017-11-30 2023-10-01 Centurion Biopharma Corp Maytansinoid-based drug delivery systems
WO2019108477A1 (en) 2017-11-30 2019-06-06 The Johns Hopkins University Body mountable robot
CN111615520A (zh) 2017-12-01 2020-09-01 辉瑞大药厂 抗cxcr5抗体及其组合物和用途
WO2019106126A1 (en) 2017-12-01 2019-06-06 INSERM (Institut National de la Santé et de la Recherche Médicale) Mdm2 modulators for the diagnosis and treatment of liposarcoma
WO2019110706A1 (en) 2017-12-08 2019-06-13 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods for predicting the risk of developing a sepsis or a systemic inflammatory response syndrome (sirs)
JP7348899B2 (ja) 2017-12-08 2023-09-21 マレンゴ・セラピューティクス，インコーポレーテッド 多重特異性分子及びその使用
WO2019112860A1 (en) 2017-12-09 2019-06-13 Abbott Laboratories Methods for aiding in diagnosing and evaluating a traumatic brain injury in a human subject using a combination of gfap and uch-l1
WO2019113525A2 (en) 2017-12-09 2019-06-13 Abbott Laboratories Methods for aiding in the diagnosis and evaluation of a subject who has sustained an orthopedic injury and that has or may have sustained an injury to the head, such as mild traumatic brain injury (tbi), using glial fibrillary acidic protein (gfap) and/or ubiquitin carboxy-terminal hydrolase l1 (uch-l1)
AU2018383679C1 (en) 2017-12-11 2026-05-28 Amgen Inc. Continuous manufacturing process for bispecific antibody products
CA3084315A1 (en) 2017-12-11 2019-06-20 Abalone Bio, Inc. Yeast display of proteins in the periplasmic space
WO2019118318A1 (en) 2017-12-12 2019-06-20 Calico Biolabs, Inc. Recombinant antibody comprising heavy chain genetically fused to signature peptide and uses thereof
US11795226B2 (en) 2017-12-12 2023-10-24 Macrogenics, Inc. Bispecific CD16-binding molecules and their use in the treatment of disease
AU2018383751B2 (en) 2017-12-13 2025-05-08 Regeneron Pharmaceuticals, Inc. Anti-C5 antibody combinations and uses thereof
EP3723770A4 (de) 2017-12-13 2021-11-24 North Carolina State University Zusammensetzungen mit chemotherapeutika und checkpoint-inhibitoren und verfahren zur verwendung
BR112020011875A2 (pt) 2017-12-14 2020-11-24 Abl Bio Inc. anticorpo biespecífico ao a-syn/igf1r e uso do mesmo
CN119219654A (zh) 2017-12-15 2024-12-31 四川科伦博泰生物医药股份有限公司 生物活性物偶联物及其制备方法和用途
JP2021507884A (ja) 2017-12-15 2021-02-25 アペリス・ファーマシューティカルズ・インコーポレイテッドＡｐｅｌｌｉｓ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ，Ｉｎｃ． 投与レジメンならびに関連組成物および方法
EP3498293A1 (de) 2017-12-15 2019-06-19 Institut National De La Sante Et De La Recherche Medicale (Inserm) Behandlung monogener erkrankungen mit einem anti-cd45rc-antikörper
TW201938165A (zh) 2017-12-18 2019-10-01 美商輝瑞股份有限公司 治療癌症的方法及組合療法
CA3086045A1 (en) 2017-12-19 2019-06-27 Akouos, Inc. Aav-mediated delivery of therapeutic antibodies to the inner ear
EA202091521A1 (ru) 2017-12-19 2020-10-22 Дзе Рокфеллер Юниверсити ВАРИАНТЫ ДОМЕНА Fc IgG ЧЕЛОВЕКА С УЛУЧШЕННОЙ ЭФФЕКТОРНОЙ ФУНКЦИЕЙ
EP3502139A1 (de) 2017-12-19 2019-06-26 Philogen S.p.A. Antikörper gegen tumorantigene
WO2019121869A1 (en) 2017-12-20 2019-06-27 INSERM (Institut National de la Santé et de la Recherche Médicale) Method of selection of an ire1-inhibitor therapy for patient suffering from cancer
SG11202005692WA (en) 2017-12-20 2020-07-29 Harbour Biomed Shanghai Co Ltd Antibodies binding ctla-4 and uses thereof
US11802154B2 (en) 2017-12-20 2023-10-31 Alexion Pharmaceuticals, Inc. Humanized anti-CD200 antibodies and uses thereof
WO2019121872A1 (en) 2017-12-20 2019-06-27 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods for the diagnosis and treatment of liver cancer
WO2019120527A1 (en) 2017-12-20 2019-06-27 Michael Heneka Novel means and methods for treating neurodegenerative diseases
PE20201149A1 (es) 2017-12-21 2020-10-26 Hoffmann La Roche Anticuerpos de union a hla-a2/wt1
EA202091557A1 (ru) 2017-12-22 2020-11-18 Тенеобио, Инк. Антитела, содержащие только тяжелые цепи, которые связываются с cd22
US20190211098A1 (en) 2017-12-22 2019-07-11 Genentech, Inc. Use of pilra binding agents for treatment of a disease
EP4219559A3 (de) 2017-12-22 2023-10-18 Jounce Therapeutics, Inc. Antikorper gegen lilrb2
CN109970857B (zh) 2017-12-27 2022-09-30 信达生物制药(苏州)有限公司 抗pd-l1抗体及其用途
WO2019129137A1 (zh) 2017-12-27 2019-07-04 信达生物制药(苏州)有限公司 抗lag-3抗体及其用途
WO2019129136A1 (zh) 2017-12-27 2019-07-04 信达生物制药(苏州)有限公司 抗pd-l1抗体及其用途
EP3732199A1 (de) 2017-12-27 2020-11-04 TeneoBio, Inc. Für cd3-delta-/epsilon-heterodimer spezifische antikörper
SG11202004158QA (en) 2017-12-28 2020-06-29 Nanjing Legend Biotech Co Ltd Single-domain antibodies and variants thereof against tigit
KR102845020B1 (ko) 2017-12-28 2025-08-12 난징 레전드 바이오테크 씨오., 엘티디. Pd-l1에 대한 항체 및 변이체
CN111886246B (zh) 2017-12-29 2024-12-17 艾莱克特有限责任公司 抗tmem106b抗体及其使用方法
CA3087331A1 (en) 2017-12-29 2019-07-04 City Of Hope Meditope-enabled t cells
WO2019129677A1 (en) 2017-12-29 2019-07-04 F. Hoffmann-La Roche Ag Anti-vegf antibodies and methods of use
TW201940518A (zh) 2017-12-29 2019-10-16 美商安進公司 針對ｍｕｃ１７和ｃｄ３之雙特異性抗體構建體
WO2019134741A1 (en) 2018-01-03 2019-07-11 Albert-Ludwigs-Universität Freiburg Single-channel multianalyte biosensor
WO2019134946A1 (en) 2018-01-04 2019-07-11 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and compositions for treating melanoma resistant
KR20240134250A (ko) 2018-01-04 2024-09-06 아이코닉 테라퓨틱스, 인코포레이티드 항-조직 인자 항체, 항체-약물 결합체, 및 관련 방법
US11466077B2 (en) 2018-01-05 2022-10-11 Ac Immune Sa Misfolded TDP-43 binding molecules
US11851478B2 (en) 2018-01-05 2023-12-26 Vanderbilt University Antibody-mediated neutralization of chikungunya virus
US12036273B2 (en) 2018-01-08 2024-07-16 H. Lee Moffitt Cancer Center And Research Institute, Inc. Compositions and methods for targeting CD99-expressing cancers
US12247060B2 (en) 2018-01-09 2025-03-11 Marengo Therapeutics, Inc. Calreticulin binding constructs and engineered T cells for the treatment of diseases
US11951129B2 (en) 2018-01-09 2024-04-09 H. Lee Moffitt Cancer Center And Research Institute, Inc. Compositions and methods for targeting CLEC12A-expressing cancers
JP7339262B2 (ja) 2018-01-12 2023-09-05 アムジェン インコーポレイテッド Ｐａｃ１抗体及びその使用
JP7358361B2 (ja) 2018-01-12 2023-10-10 ブリストル－マイヤーズ スクイブ カンパニー Ｔｉｍ３に対する抗体およびその使用
AU2019206724A1 (en) 2018-01-15 2020-07-16 Kite Pharma, Inc. Methods of administering chimeric antigen receptor immunotherapy in combination with 4-1BB agonist
US12174193B2 (en) 2018-01-15 2024-12-24 Epiaxis Therapeutics Pty Ltd Agents and methods for predicting response to therapy
CA3084518A1 (en) 2018-01-15 2019-07-18 Nanjing Legend Biotech Co., Ltd. Single-domain antibodies and variants thereof against pd-1
EP3740505A1 (de) 2018-01-16 2020-11-25 Lakepharma Inc. Bispezifischer antikörper, der cd3 und ein anderes ziel bindet
WO2019147822A2 (en) 2018-01-24 2019-08-01 Northwestern University Inhibiting tumor cell migration by inhibition of kinesin light chain 1, variant 1 (klc1c)
CN111868074A (zh) 2018-01-24 2020-10-30 昆士兰医学研究所理事会 Hpv免疫疗法
US12145984B2 (en) 2018-01-24 2024-11-19 Institut National De La Sante Et De La Recherche Medicale (Inserm) Methods for preventing ischemia reperfusion injury in an organ with antibody antagonists of IL-33
JP7542257B2 (ja) 2018-01-25 2024-08-30 エイシーエム バイオラブズ プライベート リミテッド 可溶化された封入抗原を含むポリマーソーム、ならびにその作製および使用方法
CN111655717A (zh) 2018-01-26 2020-09-11 豪夫迈·罗氏有限公司 IL-22 Fc融合蛋白及使用方法
EP3638698B1 (de) 2018-01-26 2021-03-03 Regeneron Pharmaceuticals, Inc. Anti-tmprss2-antikörper und antigenbindende fragmente
PL3743088T3 (pl) 2018-01-26 2023-03-20 F. Hoffmann-La Roche Ag Kompozycje i sposoby stosowania il-22 fc
WO2019147824A1 (en) 2018-01-26 2019-08-01 Progenity, Inc. Treatment of a disease of the gastrointestinal tract with a pde4 inhibitor
WO2019147579A1 (en) 2018-01-28 2019-08-01 Enable Biosciences Inc. Reagents and methods for blocking non-specific interactions with nucleic acids
TWI822728B (zh) 2018-01-31 2023-11-21 加藤元一 含有il-6抑制劑的哮喘治療劑
EP3746079A1 (de) 2018-01-31 2020-12-09 Bayer Aktiengesellschaft Antikörper-wirkstoff-konjugate (adcs) mit nampt-inhibitoren
EP3746476A1 (de) 2018-01-31 2020-12-09 Alector LLC Anti-ms4a4a-antikörper und verfahren zu ihrer verwendung
EP3746484A4 (de) 2018-01-31 2021-11-17 Alector LLC Anti-ms4a6a-antikörper und verfahren zur verwendung davon
MX2020008183A (es) 2018-02-01 2020-09-22 Pfizer Anticuerpos especificos para cd70 y sus usos.
MX2020008184A (es) 2018-02-01 2020-09-22 Pfizer Receptores de antigeno quimericos dirigidos a cd70.
AU2019214183B2 (en) 2018-02-01 2022-04-07 Innovent Biologics (Suzhou) Co., Ltd. Fully human anti-B cell maturation antigen (BCMA) single chain variable fragment, and application thereof
JP7539834B2 (ja) 2018-02-01 2024-08-26 メモリアル スローン ケタリング キャンサー センター ガレクチン－３に対する抗体及びその使用方法
WO2019148445A1 (en) 2018-02-02 2019-08-08 Adagene Inc. Precision/context-dependent activatable antibodies, and methods of making and using the same
WO2019148444A1 (en) 2018-02-02 2019-08-08 Adagene Inc. Anti-ctla4 antibodies and methods of making and using the same
WO2019150309A1 (en) 2018-02-02 2019-08-08 Hammack Scott Modulators of gpr68 and uses thereof for treating and preventing diseases
CN111699004A (zh) 2018-02-06 2020-09-22 豪夫迈·罗氏有限公司 眼科疾病的治疗
FR3077574B1 (fr) 2018-02-07 2022-04-01 Commissariat Energie Atomique Anticorps dirige contre le sous-type a des recepteurs aux endothelines et ses utilisations.
CR20200391A (es) 2018-02-08 2020-10-19 Genentech Inc Moléculas biespecíficas de unión al antígeno y métodos de uso
KR20220098056A (ko) 2018-02-09 2022-07-08 제넨테크, 인크. 비만 세포 매개 염증성 질환에 대한 치료 및 진단 방법
US12364736B2 (en) 2018-02-09 2025-07-22 Acceleron Pharma Inc. Methods for treating heterotopic ossification
TWI849895B (zh) 2018-02-09 2024-07-21 日商小野藥品工業股份有限公司 雙特異性抗體
JP7458318B2 (ja) 2018-02-12 2024-03-29 ハダシット メディカル リサーチ サービシーズ アンド ディベロップメント リミテッド 癌治療のためのｓｌａｍｆ６スプライスバリアントの調節
WO2019158512A1 (en) 2018-02-13 2019-08-22 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods for the prognosis and the treatment of glioblastoma
WO2019160866A2 (en) 2018-02-13 2019-08-22 Checkmate Pharmaceuticals, Inc. Compositions and methods for tumor immunotherapy
WO2019157772A1 (zh) 2018-02-13 2019-08-22 和元生物技术（上海）股份有限公司 抗trailr2抗体-毒素-偶联物及其在抗肿瘤治疗中的药物用途
SG11202007590TA (en) 2018-02-13 2020-09-29 Merck Sharp & Dohme Methods for treating cancer with anti-pd-1 antibodies
CA3091646A1 (en) 2018-02-14 2019-08-22 Abba Therapeutics Ag Anti-human pd-l2 antibodies
EP3752195A4 (de) 2018-02-14 2021-11-17 Viela Bio, Inc. Antikörper gegen felinen mcdonough-sarkom(fms)-ähnlichen tyrosinkinase-3-rezeptorliganden (flt3l) und verwendungen davon zur behandlung von autoimmun- und entzündungskrankheiten
CN111787949A (zh) 2018-02-15 2020-10-16 宏观基因有限公司 变体cd3-结合结构域及其在用于治疗疾病的组合疗法中的用途
CA3091311A1 (en) 2018-02-16 2019-08-22 Inserm (Institut National De La Sante Et De La Recherche Medicale) Use of antagonists of cxcr3b for treating vitiligo
MX2020008267A (es) 2018-02-20 2020-09-21 Seattle Genetics Inc Compuestos de auristatina f hidrofoba y conjugados de los mismos.
CA3091139A1 (en) 2018-02-21 2019-08-29 Genentech, Inc. Dosing for treatment with il-22 fc fusion proteins
DE102018107224A1 (de) 2018-02-21 2019-08-22 Immatics Biotechnologies Gmbh Peptide und Kombinationen von Peptiden nicht-kanonischen Ursprungs zur Verwendung in der Immuntherapie gegen verschiedene Krebsarten
EP3755712A1 (de) 2018-02-21 2020-12-30 Cell Design Labs, Inc. Chimäre transmembranrezeptoren und verwendungen davon
BR112020017053A2 (pt) 2018-02-21 2020-12-15 Celgene Corporation Anticorpos que se ligam ao bcma e usos dos mesmos
US20200399376A1 (en) 2018-02-26 2020-12-24 Genentech, Inc. Dosing for treatment with anti-tigit and anti-pd-l1 antagonist antibodies
EP3530282A1 (de) 2018-02-27 2019-08-28 Diaccurate Therapeutische verfahren
EP3759125A4 (de) 2018-02-28 2021-12-08 Dana-Farber Cancer Institute, Inc. Verfahren zur krebsbehandlung unter verwendung von kombinationen aus anti-btnl2 und immuncheckpoint-blockierungsreagenzien
MX387358B (es) 2018-02-28 2025-03-18 Pfizer Variantes de il-15 y usos de las mismas
US20210002373A1 (en) 2018-03-01 2021-01-07 Nextcure, Inc. KLRG1 Binding Compositions and Methods of Use Thereof
US20230065153A1 (en) 2018-03-01 2023-03-02 Hiroshima University Anti-integrin alpha-11 monoclonal antibody and use thereof
GB201803342D0 (en) 2018-03-01 2018-04-18 Medimmune Ltd Methods
NL2020520B1 (en) 2018-03-02 2019-09-12 Labo Bio Medical Invest B V Multispecific binding molecules for the prevention, treatment and diagnosis of neurodegenerative disorders
EP3758749A4 (de) 2018-03-02 2022-07-06 The University of Chicago Verfahren und zusammensetzung zur neutralisierung von influenza
CA3092588A1 (en) 2018-03-02 2019-09-06 Kodiak Sciences Inc. Il-6 antibodies and fusion constructs and conjugates thereof
JP7516250B2 (ja) 2018-03-05 2024-07-16 ヤンセン バイオテツク，インコーポレーテツド 抗ｉｌ－２３特異的抗体を用いたクローン病の治療方法
WO2019171258A1 (en) 2018-03-05 2019-09-12 Janssen Pharmaceutica Nv Assays to detect neurodegeneration
TW201946654A (zh) 2018-03-05 2019-12-16 比利時商健生藥品公司 抗ＰＨＦ－Ｔａｕ抗體及其用途
CN120005029A (zh) 2018-03-06 2025-05-16 英凯尔生物科技有限责任公司 丝氨酸蛋白酶抑制剂Kazal(SPIK)组合物和方法
IL277095B2 (en) 2018-03-07 2025-10-01 Pfizer Preparations containing anti-PD-1 antibody
WO2019170131A1 (zh) 2018-03-07 2019-09-12 复旦大学 靶向cd73的抗体及抗体-药物偶联物、其制备方法和用途
EP3737384B1 (de) 2018-03-08 2023-10-25 Purepharm Inc. Verfahren und zusammensetzungen zur vorbeugung und behandlung von störungen im zusammenhang mit alpha-synuclein
BR112020017701A2 (pt) 2018-03-12 2020-12-29 Zoetis Services Llc Anticorpos anti-ngf e métodos dos mesmos
CN112088169A (zh) 2018-03-12 2020-12-15 纪念斯隆凯特琳癌症中心 双特异性结合剂及其用途
KR102542988B1 (ko) 2018-03-13 2023-06-13 니치유 가부시키가이샤 주쇄 및 측쇄에 단분산 폴리에틸렌 글리콜을 가지는 헤테로이관능성 화합물
AU2019234836A1 (en) 2018-03-13 2020-09-17 The Regents Of The University Of California Inhibitors of integrin alpha 2 beta 1 and methods of use
CN110272490B (zh) 2018-03-14 2021-05-14 上海开拓者生物医药有限公司 靶向ctla-4抗体、其制备方法和用途
CN120399075A (zh) 2018-03-14 2025-08-01 诺维莫尼公司 抗-CD3ε抗体及其应用方法
WO2019177883A2 (en) 2018-03-14 2019-09-19 Boehringer Ingelheim International Gmbh Use of anti-il-36r antibodies for treatment of inflammatory bowel disease
US20200040103A1 (en) 2018-03-14 2020-02-06 Genentech, Inc. Anti-klk5 antibodies and methods of use
CA3087423A1 (en) 2018-03-14 2019-09-19 Beijing Xuanyi Pharmasciences Co., Ltd. Anti-claudin 18.2 antibodies
KR20200131846A (ko) 2018-03-14 2020-11-24 메모리얼 슬로안 케터링 캔서 센터 항-폴리시알산 항체 및 그 용도
EP3765516A2 (de) 2018-03-14 2021-01-20 Elstar Therapeutics, Inc. Multifunktionale moleküle und verwendungen davon
AU2019236105B2 (en) 2018-03-14 2025-07-31 Boehringer Ingelheim International Gmbh Use of anti-IL-36R antibodies for treatment of generalized pustular psoriasis
EP3765517A1 (de) 2018-03-14 2021-01-20 Elstar Therapeutics, Inc. An calreticulin bindende multifunktionsmoleküle und ihre verwendungen
AU2019234183B2 (en) 2018-03-15 2025-12-18 Biond Biologics Ltd. Methods and compositions for decreasing soluble immune receptor CD28
TWI827585B (zh) 2018-03-15 2024-01-01 日商中外製藥股份有限公司 對茲卡病毒具有交叉反應性的抗登革病毒抗體及其使用方法
US12325875B2 (en) 2018-03-16 2025-06-10 Bristol-Myers Squibb Company Metabolic enzyme activity and disulfide bond reduction during protein production
WO2019183266A1 (en) 2018-03-21 2019-09-26 ALX Oncology Inc. Antibodies against signal-regulatory protein alpha and methods of use
JP7351845B2 (ja) 2018-03-23 2023-09-27 ブリストル－マイヤーズ スクイブ カンパニー Ｍｉｃａおよび／またはｍｉｃｂに対する抗体ならびにそれらの使用
WO2019183437A1 (en) 2018-03-23 2019-09-26 North Carolina State University Methods and compositions for antibody to high affinity receptor for ige
EP4501355A3 (de) 2018-03-23 2025-04-30 Board Of Regents, The University Of Texas System Antikörper mit doppelter spezifität gegen pd-l1 und pd-l2 und verfahren zur verwendung davon
JP7390729B2 (ja) 2018-03-23 2023-12-04 ユニヴェルシテ リブル ドゥ ブリュッセル Ｗｎｔシグナル伝達アゴニスト分子
WO2019180272A1 (en) 2018-03-23 2019-09-26 Fundación Instituto De Investigación Sanitaria De Santiago De Compostela Anti-leptin affinity reagents for use in the treatment of obesity and other leptin-resistance associated diseases
US12281160B2 (en) 2018-03-23 2025-04-22 Csl Limited Method of treating asthma
EP3768723A4 (de) 2018-03-23 2021-12-29 Board of Regents, The University of Texas System Antikörper mit doppelter spezifität gegen menschlichen pd-l1 und pd-l2 und verwendungsverfahren dafür
WO2019190969A1 (en) 2018-03-26 2019-10-03 Sutro Biopharma, Inc. Anti-bcma receptor antibodies, compositions comprising anti bcma receptor antibodies and methods of making and using anti-bcma antibodies
DK3775909T3 (da) 2018-03-26 2023-07-24 Glycanostics S R O Midler og fremgangsmåder til glykoprofilering af et protein
WO2019190931A1 (en) 2018-03-26 2019-10-03 Regeneron Pharmaceuticals, Inc. Anti-pfrh5 antibodies and antigen-binding fragments thereof
AU2019244481A1 (en) 2018-03-28 2020-10-01 Axon Neuroscience Se Antibody-based methods of detecting and treating Alzheimer's disease
WO2019185683A1 (en) 2018-03-28 2019-10-03 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and pharmaceutical compositions for treating cancer
CN112313248A (zh) 2018-03-29 2021-02-02 百时美施贵宝公司 纯化单体单克隆抗体的方法
JP2021519073A (ja) 2018-03-29 2021-08-10 ジェネンテック， インコーポレイテッド 哺乳動物細胞におけるラクトジェニック活性の制御
WO2019185792A1 (en) 2018-03-29 2019-10-03 Philogen S.P.A Cancer treatment using immunoconjugates and immune check-point inhibitors
AU2019241350B2 (en) 2018-03-30 2025-10-02 Nanjing Legend Biotech Co., Ltd. Single-domain antibodies against LAG-3 and uses thereof
CN116854816A (zh) 2018-04-02 2023-10-10 阿拉玛布治疗学股份有限公司 连接蛋白43抗体及其用途
WO2019192432A1 (zh) 2018-04-02 2019-10-10 上海博威生物医药有限公司 结合淋巴细胞活化基因-3(lag-3)的抗体及其用途
CR20250022A (es) 2018-04-02 2025-02-25 Bristol Myers Squibb Co Anticuerpos anti-trem-1, ácidos nucleicos y vectores de los mismos (divisional 2020-0450)
CN110343178B (zh) 2018-04-03 2022-07-22 上海开拓者生物医药有限公司 抗人lag-3单克隆抗体及其应用
TW202011029A (zh) 2018-04-04 2020-03-16 美商建南德克公司 偵測及定量fgf21之方法
WO2019193375A1 (en) 2018-04-04 2019-10-10 INSERM (Institut National de la Santé et de la Recherche Médicale) Use of fzd7 inhibitors for the treatment of retinal neovascularization
MX2020010094A (es) 2018-04-06 2021-01-15 Dana Farber Cancer Inst Inc Kir3dl3 como receptor de hhla2, anticuerpos anti-hhla2 y usos de estos.
WO2019195561A2 (en) 2018-04-06 2019-10-10 BioLegend, Inc. Anti-tetraspanin 33 agents and compositions and methods for making and using the same
BR112020020479A2 (pt) 2018-04-09 2021-01-12 Checkmate Pharmaceuticals Empacotamento de oligonucleotídeos em partículas similares a vírus
US10654944B2 (en) 2018-04-10 2020-05-19 Y-Biologics Inc. Cell engaging binding molecules
EP3552620A1 (de) 2018-04-11 2019-10-16 Los Angeles Biomedical Research Institute at Harbor-UCLA Medical Center Verfahren zur behandlung von infektionen mit candida auris
JP2021521273A (ja) 2018-04-12 2021-08-26 メディアファーマ エス．アール．エル． Ｌｇａｌｓ３ｂｐ抗体−薬剤結合体及びがん治療のためのその使用
GB201806022D0 (en) 2018-04-12 2018-05-30 Medimmune Ltd Pyrrolobenzodiazepines and conjugates thereof
MX2020010808A (es) 2018-04-13 2021-03-02 Sangamo Therapeutics France Receptor de antigeno quimerico especifico para el receptor de interleucina-23.
US12012599B2 (en) 2018-04-13 2024-06-18 Cz Biohub Sf, Llc Compositions and methods for modulating left-right differentiation factor (LEFTY) and bone morphogenic factor (BMP)
CR20250325A (es) 2018-04-13 2025-08-29 Genentech Inc Formulaciones inmunoconjugadas anti-cd79b estables (divisional expediente 2020-0550)
EP3775908A1 (de) 2018-04-13 2021-02-17 INSERM (Institut National de la Santé et de la Recherche Médicale) Verfahren zur vorhersage des ergebnisses und der behandlung von patienten mit prostatakrebs oder brustkrebs
US20210147547A1 (en) 2018-04-13 2021-05-20 Novartis Ag Dosage Regimens For Anti-Pd-L1 Antibodies And Uses Thereof
AU2019254483B2 (en) 2018-04-16 2025-02-27 Merck Patent Gmbh Viscosity reduction of highly concentrated protein formulations
CN108623687A (zh) 2018-04-17 2018-10-09 中山康方生物医药有限公司 神经生长因子的单克隆抗体及其编码基因和应用
AR115052A1 (es) 2018-04-18 2020-11-25 Hoffmann La Roche Anticuerpos multiespecíficos y utilización de los mismos
AR114789A1 (es) 2018-04-18 2020-10-14 Hoffmann La Roche Anticuerpos anti-hla-g y uso de los mismos
CN112189018A (zh) 2018-04-20 2021-01-05 汉诺威医学院 结合疱疹病毒抗原的嵌合抗原受体和car-t细胞
CN108373505B (zh) 2018-04-20 2019-08-20 北京智仁美博生物科技有限公司 抗il-4r抗体及其用途
WO2019209952A2 (en) 2018-04-23 2019-10-31 Emory University Vip antagonists and uses in treating cancer
US11884725B2 (en) 2018-04-24 2024-01-30 Ampsource Biopharma Shanghai Inc. Antibody against TIM-3 and application thereof
IT201800004853A1 (it) 2018-04-24 2019-10-24 Metodi per trattare il cancro
WO2019207030A1 (en) 2018-04-26 2019-10-31 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods for predicting a response with an immune checkpoint inhibitor in a patient suffering from a lung cancer
WO2019207066A1 (en) 2018-04-26 2019-10-31 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and compositions for the treatment of sjögren's syndrome
WO2019207159A1 (en) 2018-04-27 2019-10-31 Fondazione Ebri Rita Levi-Montalcini Antibody directed against a tau-derived neurotoxic peptide and uses thereof
EP4556031A3 (de) 2018-04-27 2025-06-25 University of Iowa Research Foundation Zusammensetzungen zur chelatbildung von metallen bei niedrigen temperaturen
US20210047405A1 (en) 2018-04-27 2021-02-18 Novartis Ag Car t cell therapies with enhanced efficacy
US20210396739A1 (en) 2018-05-01 2021-12-23 Novartis Ag Biomarkers for evaluating car-t cells to predict clinical outcome
EP3788071A1 (de) 2018-05-02 2021-03-10 The United States Of America, As Represented By The Secretary, Department of Health and Human Services Antikörper und verfahren zur diagnose, prävention und behandlung von epstein-barr-virusinfektion
WO2019211369A1 (en) 2018-05-03 2019-11-07 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and pharmaceutical compositions for treating cancer
CA3096703A1 (en) 2018-05-03 2019-11-07 University Of Rochester Anti-influenza neuraminidase monoclonal antibodies and uses thereof
WO2019211370A1 (en) 2018-05-03 2019-11-07 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and pharmaceutical compositions for treating cancer
BR112020022145A2 (pt) 2018-05-04 2021-01-26 Merck Patent Gmbh inibição combinada de pd-1/pd-l1, tgfbeta e dna-pk para o tratamento de câncer
US12077583B2 (en) 2018-05-09 2024-09-03 Nectin Therapeutics Ltd. Antibodies specific to human NECTIN4
US10647755B2 (en) 2018-05-09 2020-05-12 The Hong Kong University Of Science And Technology Photoresponsive protein hydrogels and methods and uses thereof
KR20240056644A (ko) 2018-05-10 2024-04-30 주식회사 뉴라클사이언스 서열 유사성 19, 멤버 a5 항체를 갖는 항-패밀리 및 그의 사용 방법
MX2020012217A (es) 2018-05-14 2021-03-02 Harpoon Therapeutics Inc Porción de unión para activación condicional de moléculas de inmunoglobulina.
EP3793598A1 (de) 2018-05-14 2021-03-24 Jounce Therapeutics, Inc. Verfahren zur behandlung von krebs
MX2020012251A (es) 2018-05-14 2021-04-28 Werewolf Therapeutics Inc Polipeptidos de interleucina-2 activables y metodos de uso de los mismos.
US20210130430A1 (en) 2018-05-14 2021-05-06 Werewolf Therapeutics, Inc. Activatable cytokine polypeptides and methods of use thereof
WO2019222296A1 (en) 2018-05-14 2019-11-21 Werewolf Therapeutics, Inc. Activatable interleukin 12 polypeptides and methods of use thereof
JP2021523185A (ja) 2018-05-15 2021-09-02 イミュノミック セラピューティックス， インコーポレイテッドＩｍｍｕｎｏｍｉｃ Ｔｈｅｒａｐｅｕｔｉｃｓ， Ｉｎｃ． アレルゲンを含む改善されたｌａｍｐ構築物
CN110483639A (zh) 2018-05-15 2019-11-22 复旦大学 靶向axl的抗体及抗体-药物偶联物及其制备方法和用途
TW202003048A (zh) 2018-05-15 2020-01-16 美商伊繆諾金公司 用抗體-藥物偶聯物及flt3抑制劑之組合治療
CN112118859A (zh) 2018-05-16 2020-12-22 杰特有限公司 1型可溶性补体受体变体及其用途
TW202016131A (zh) 2018-05-16 2020-05-01 德商英麥提克生物技術股份有限公司 用於抗癌免疫治療的肽
CA3098103A1 (en) 2018-05-23 2019-11-28 Adc Therapeutics Sa Molecular adjuvant
WO2019225777A1 (ko) 2018-05-23 2019-11-28 에이비엘바이오 주식회사 항-ror1 항체 및 그 용도
AU2019274654B2 (en) 2018-05-23 2023-07-20 Pfizer Inc. Antibodies specific for CD3 and uses thereof
US11525010B2 (en) 2018-05-23 2022-12-13 Pfizer Inc. Antibodies specific for GUCY2c and uses thereof
WO2019225787A1 (ko) 2018-05-24 2019-11-28 에이비엘바이오 주식회사 항-b7-h3 항체 및 그 용도
US20210213063A1 (en) 2018-05-25 2021-07-15 Novartis Ag Combination therapy with chimeric antigen receptor (car) therapies
CR20200566A (es) 2018-05-25 2021-02-19 Alector Llc Anticuerpos anti-sirpa y metodos de utilización de los mismos
EP3575320A1 (de) 2018-05-29 2019-12-04 Heinrich-Pette-Institut Leibniz-Institut für Experimentelle Virologie Neue therapie zur behandlung von transplantat-wirt-reaktion
WO2019231935A1 (en) 2018-05-29 2019-12-05 Omeros Corporation Masp-2 inhibitors and methods of use
CN110551215A (zh) 2018-05-30 2019-12-10 中山康方生物医药有限公司 抗白细胞介素-17a抗体、其药物组合物及其用途
EP3816182A4 (de) 2018-05-30 2022-07-13 Chugai Seiyaku Kabushiki Kaisha Ligandbindungsmolekül mit einzeldomänen-antikörper
UY38247A (es) 2018-05-30 2019-12-31 Novartis Ag Anticuerpos frente a entpd2, terapias de combinación y métodos de uso de los anticuerpos y las terapias de combinación
SG11202010025YA (en) 2018-05-31 2020-11-27 Glyconex Inc Therapeutic antibodies binding to biantennary lewis b and lewis y antigens
WO2019232244A2 (en) 2018-05-31 2019-12-05 Novartis Ag Antibody molecules to cd73 and uses thereof
EP3802593B1 (de) 2018-05-31 2024-09-11 Alexion Pharmaceuticals, Inc. Dosierung und verabreichung von anti-c5 antikörpern zur behandlung von paroxysalen nocturalen hämoglobin-uria (pnh) in pädiatrischen patienten
GB201808927D0 (en) 2018-05-31 2018-07-18 Institute Of Cancer Res Royal Cancer Hospital Materials and methods for monitoring the development of resistance of cancers to treatment
PE20210320A1 (es) 2018-06-01 2021-02-16 Novartis Ag Moleculas de union contra bcma y usos de las mismas
JP2021525806A (ja) 2018-06-01 2021-09-27 タユー ファシャ バイオテック メディカル グループ カンパニー， リミテッド 疾患または状態を処置するための組成物およびそれらの使用
EP3803332A1 (de) 2018-06-01 2021-04-14 NanoView Biosciences, Inc. Zusammensetzungen, systeme und verfahren zur verbesserten markierungsfreien und fluoreszenzbasierten detektion von nanopartikeln
CN119405833A (zh) 2018-06-01 2025-02-11 卫材R&D管理有限公司 剪接调节抗体-药物缀合物及其使用方法
WO2019227490A1 (en) 2018-06-01 2019-12-05 Tayu Huaxia Biotech Medical Group Co., Ltd. Compositions and methods for imaging
EP3802603A1 (de) 2018-06-04 2021-04-14 Alexion Pharmaceuticals, Inc. Dosierung und verabreichung von anti-c5-antikörpern zur behandlung des atypischen hämolytisch-urämischen syndroms (ahus) bei kindern
US20210230300A1 (en) 2018-06-04 2021-07-29 Bayer Aktiengesellschaft Inhibitors of shp2
CN112867394B9 (zh) 2018-06-04 2024-12-06 马萨诸塞州渤健公司 具有降低的效应功能的抗vla-4抗体
EP3805400A4 (de) 2018-06-04 2022-06-29 Chugai Seiyaku Kabushiki Kaisha Antigen-bindendes molekül mit veränderter halbwertszeit im cytoplasma
MA52783A (fr) 2018-06-05 2021-04-14 Amgen Inc Modulation de la phagocytose cellulaire dépendant de l'anticorps
WO2019234099A1 (en) 2018-06-06 2019-12-12 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods for diagnosing, predicting the outcome and treating a patient suffering from heart failure with preserved ejection fraction
WO2019235581A1 (ja) 2018-06-06 2019-12-12 国立大学法人大阪大学 Ｒｅｇｎａｓｅ－１が関与する疾患の治療および／または予防方法
TWI920652B (zh) 2018-06-07 2026-04-01 美商思進公司 喜樹鹼結合物
JP7269963B2 (ja) 2018-06-08 2023-05-09 クリスタル バイオサイエンス インコーポレイテッド 同じ軽鎖ｉを有する多様な抗体を産生するためのトランスジェニック動物
WO2019234221A1 (en) 2018-06-08 2019-12-12 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods for stratification and treatment of a patient suffering from chronic lymphocytic leukemia
CN119841953A (zh) 2018-06-08 2025-04-18 艾利妥 抗siglec-7抗体及其使用方法
JP7428664B2 (ja) 2018-06-12 2024-02-06 ザ ユニバーシティ オブ ノース カロライナ アット チャペル ヒル 合成肝臓指向性アデノ随伴ウイルスカプシドおよびその使用
EP3807644A4 (de) 2018-06-12 2022-07-06 Angiex, Inc. Antikörper-oligonukleotid-konjugate
CA3102125A1 (en) 2018-06-13 2019-12-19 Crystal Bioscience Inc. Transgenic chicken that makes antibodies with long cdr-h3s stabilized by multiple disulfide bridges and diversified by gene conversion
JP7572861B2 (ja) 2018-06-13 2024-10-24 クリスタル バイオサイエンス インコーポレイテッド 遺伝子変換による自律型重鎖可変ドメインの改変による抗体の産生
GB201809746D0 (en) 2018-06-14 2018-08-01 Berlin Chemie Ag Pharmaceutical combinations
CA3103327A1 (en) 2018-06-18 2019-12-26 Bayer Aktiengesellschaft Binder/active agent conjugates directed against cxcr5, having enzymatically cleavable linkers and improved activity profile
TWI870353B (zh) 2018-06-18 2025-01-21 法商天賜製藥公司 用於治療癌症之組合物及方法
CN112469440B (zh) 2018-06-18 2024-09-06 优瑞科生物技术公司 靶向前列腺特异性膜抗原(psma)的构建体和其用途
WO2019245269A1 (ko) 2018-06-18 2019-12-26 연세대학교 산학협력단 Flt3 억제제를 유효성분으로 포함하는 만성 골수성 백혈병 약물 내성 억제용 조성물
CA3102036A1 (en) 2018-06-18 2019-12-26 Anwita Biosciences, Inc. Cytokine fusion proteins and uses thereof
CA3104295A1 (en) 2018-06-19 2019-12-26 Atarga, Llc Antibody molecules to complement component 5 and uses thereof
EP3810085A1 (de) 2018-06-20 2021-04-28 Progenity, Inc. Behandlung der erkrankung des gastrointestinaltraktes mit einem integrin-inhibitor
WO2019246271A1 (en) 2018-06-20 2019-12-26 Progenity, Inc. Treatment of a disease of the gastrointestinal tract with an il-12/il-23 inhibitor
US12171764B2 (en) 2018-06-20 2024-12-24 Biora Therapeutics, Inc. Treatment of a disease of the gastrointestinal tract with a JAK or other kinase inhibitor
US20230312700A1 (en) 2018-06-20 2023-10-05 Progenity, Inc. Treatment of a disease of the gastrointestinal tract with a tnf inhibitor
US20230041197A1 (en) 2018-06-20 2023-02-09 Progenity, Inc. Treatment of a disease of the gastrointestinal tract with an immunomodulator
US12227565B2 (en) 2018-06-20 2025-02-18 Biora Therapeutics, Inc. Method of formulating a pharmaceutical composition comprising administering an immune modulator to the small intestine
US12559570B2 (en) 2018-06-20 2026-02-24 Pharma Foods International Co., Ltd. Anti-PAD2 antibody
WO2019246445A1 (en) 2018-06-20 2019-12-26 The Research Foundation For The State University Of New York Triazamacrocycle-derived chelator compositions for coordination of imaging and therapy metal ions and methods of using same
TW202016144A (zh) 2018-06-21 2020-05-01 日商第一三共股份有限公司 包括cd3抗原結合片段之組成物及其用途
TW202017567A (zh) 2018-06-21 2020-05-16 美商優曼尼蒂治療股份有限公司 用於治療及預防神經病症之組成物及方法
WO2019243825A1 (en) 2018-06-21 2019-12-26 Curadev Pharma Limited Small molecule modulators of human sting, conjugates and therapeutic applications
US12139537B2 (en) 2018-06-22 2024-11-12 Junten Bio Co., Ltd. Antibody inducing immune tolerance, induced lymphocyte, and cell therapy agent therapeutic method using induced lymphocyte
TWI832868B (zh) 2018-06-22 2024-02-21 日商順天生化股份有限公司 用於誘發感染性免疫耐受之組合物
AU2019288683A1 (en) 2018-06-22 2021-01-21 Junten Bio Co., Ltd. Antibody capable of inducing immune tolerance produced using cell mixture having complexed state, and induced lymphocyte or cell therapeutic agent and cell therapy method each using induced lymphocyte
TWI890148B (zh) 2018-06-23 2025-07-11 美商建南德克公司 以pd-1軸結合拮抗劑、鉑劑及拓撲異構酶ii抑制劑治療肺癌之方法
MX2020013466A (es) 2018-06-26 2021-04-19 Immunogen Inc Inmunoconjugados dirigidos a adam9 y métodos para usarlos.
TW202504930A (zh) 2018-06-27 2025-02-01 台灣浩鼎生技股份有限公司 用於糖蛋白工程的糖苷合成酶變體及其使用方法
US20210355199A1 (en) 2018-06-28 2021-11-18 University Of Virginia Patent Foundation Compositions and methods for detecting and regulating fibronectin-integrin interaction and signaling
JP7538723B2 (ja) 2018-06-28 2024-08-22 アレクシオン ファーマシューティカルズ， インコーポレイテッド 抗ｃ５抗体の産生方法
US10925947B2 (en) 2018-06-29 2021-02-23 Immatics Biotechnologies Gmbh A*03 restricted peptides for use in immunotherapy against cancers and related methods
US20210139610A1 (en) 2018-06-29 2021-05-13 Research Institute At Nationwide Children's Hospital Compositions and methods for mediating eps
CA3104664A1 (en) 2018-06-29 2020-01-02 North Carolina State University In situ sprayed bioresponsive immunotherapeutic gel for post-surgical treatment
ES3061216T3 (en) 2018-06-29 2026-03-31 Hope City Cd6 targeted chimeric antigen receptors for treatment of certain autoimmune disorders
WO2020006347A1 (en) 2018-06-29 2020-01-02 Boehringer Ingelheim International Gmbh Anti-cd40 antibodies for use in treating autoimmune disease
MX2020013923A (es) 2018-06-29 2021-03-29 Apitbio Inc Anticuerpos anti molécula de adhesión celular l1 (l1cam) y usos de estos.
AU2019293589A1 (en) 2018-06-29 2021-01-21 Alector Llc Anti-SIRP-beta1 antibodies and methods of use thereof
CA3105454A1 (en) 2018-07-03 2020-01-09 Catalent Pharma Solutions, Llc Multifunctional protein molecules comprising decorin and use thereof
WO2020010250A2 (en) 2018-07-03 2020-01-09 Elstar Therapeutics, Inc. Anti-tcr antibody molecules and uses thereof
WO2020007898A1 (en) 2018-07-04 2020-01-09 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and compositions for treating brain injury or neurodegenerative disease
WO2020008083A1 (es) 2018-07-05 2020-01-09 Consejo Superior De Investigaciones Científicas Diana terapéutica en receptores de quimiocinas para la selección de compuestos útiles para el tratamiento de procesos patológicos que implican la señalización de quimiocinas
WO2020014306A1 (en) 2018-07-10 2020-01-16 Immunogen, Inc. Met antibodies and immunoconjugates and uses thereof
KR102891320B1 (ko) 2018-07-11 2025-11-28 스칼러 락, 인크. 고친화도, 이소형-선택적 TGFβ1 억제제 및 그의 용도
PT3677278T (pt) 2018-07-11 2022-02-03 Scholar Rock Inc Inibidores seletivos da isoforma tgfbeta1 e sua utilização
GB201811364D0 (en) 2018-07-11 2018-08-29 Adc Therapeutics Sa Combination therapy
EP3820896A1 (de) 2018-07-11 2021-05-19 Scholar Rock, Inc. Tgfbeta1-inhibitoren und verwendung davon
BR112021000394A2 (pt) 2018-07-12 2021-04-06 F-Star Beta Limited Moléculas de anticorpo que se ligam a pd-l1 e cd137
GB201811403D0 (en) 2018-07-12 2018-08-29 F Star Beta Ltd Antibody molecules
AU2019301206B2 (en) 2018-07-12 2025-10-30 Invox Pharma Limited Antibody molecules that bind CD137 and OX40
SMT202300110T1 (it) 2018-07-13 2023-05-12 Alector Llc Anticorpi anti-sortilina e relativi metodi di uso
WO2020012435A1 (en) 2018-07-13 2020-01-16 Lausanne University Hospital Hiv binding agents
CN110713537B (zh) 2018-07-13 2023-04-21 江苏怀瑜药业有限公司 一种sema4d抗体及其制备方法和应用
KR20210031898A (ko) 2018-07-13 2021-03-23 난징 레전드 바이오테크 씨오., 엘티디. 전염병을 치료하기 위한 공동수용체 시스템
KR102895164B1 (ko) 2018-07-16 2025-12-04 리제너론 파마슈티칼스 인코포레이티드 항-il36r 항체
US12297258B2 (en) 2018-07-17 2025-05-13 Humabs Biomed Sa Antibodies against Campylobacter species
EP3823611A1 (de) 2018-07-18 2021-05-26 Genentech, Inc. Verfahren zur behandlung von lungenkrebs mit einem pd-1-achsen-bindenden antagonisten, einem antimetabolit und einem platinmittel
WO2020016838A2 (en) 2018-07-18 2020-01-23 Janssen Biotech, Inc. Sustained response predictors after treatment with anti-il23 specific antibody
EP3823991A4 (de) 2018-07-19 2022-08-03 Tayu Huaxia Biotech Medical Group Co., Ltd. Anti-pd-1-antikörper, darreichungsformen und verwendungen davon
KR20250024129A (ko) 2018-07-20 2025-02-18 피에르 파브르 메디카먼트 Vista의 수용체
LT3823990T (lt) 2018-07-20 2026-04-10 TeneoTwo, Inc. Antikūnai iš sunkiosios grandinės, besirišantys prie cd19
JP7072715B2 (ja) 2018-07-20 2022-05-20 サーフィス オンコロジー インコーポレイテッド 抗ｃｄ１１２ｒ組成物及び方法
EP3826625A4 (de) 2018-07-23 2022-08-24 Magenta Therapeutics, Inc. Verwendung von anti-cd5-antikörpermedikamentenkonjugat (adc) in der allogenen zelltherapie
JP2021531306A (ja) 2018-07-25 2021-11-18 アドバンスド アクセラレーター アプリケーションズ エスエー 神経内分泌腫瘍の処置の方法
US20220267369A1 (en) 2018-07-25 2022-08-25 Merck Sharp & Dohme Corp. Methods of separating host cell lipases from a production protein in chromatographic processes
CN112512584A (zh) 2018-07-27 2021-03-16 国立大学法人大阪大学 用于抑制衰老、预防、改善或治疗衰老相关疾病或症状、或者延长寿命的组合物
SG11202100555PA (en) 2018-07-27 2021-02-25 Alector Llc Anti-siglec-5 antibodies and methods of use thereof
WO2020025532A1 (en) 2018-07-30 2020-02-06 Amgen Research (Munich) Gmbh Prolonged administration of a bispecific antibody construct binding to cd33 and cd3
CA3101835A1 (en) 2018-07-31 2020-02-06 Ascentage Pharma (Suzhou) Co., Ltd. Method for treating cancer by combination of iap inhibitor and modulator of immune checkpoint molecule
TW202019955A (zh) 2018-07-31 2020-06-01 德商英麥提克生物技術股份有限公司 B*07 限制肽和肽組合的抗癌免疫治療和相關方法
WO2020025108A1 (en) 2018-07-31 2020-02-06 Astrazeneca Ab Linkers and conjugates
US12435137B2 (en) 2018-08-03 2025-10-07 Chugai Seiyaku Kabushiki Kaisha Antigen-binding molecule containing two antigen-binding domains that are linked to each other
BR112021002032A2 (pt) 2018-08-03 2021-07-20 Amgen Research (Munich) Gmbh construtos de anticorpos para cldn18.2 e cd3
MX2021001398A (es) 2018-08-07 2021-08-16 In3Bio Ltd Métodos y composiciones para la inhibición de la vía egf/egfr en combinación con inhibidores de la cinasa del linfoma anaplásico.
IL280525B2 (en) 2018-08-08 2024-11-01 Genentech Inc Use of tryptophan derivatives and l-methionine for protein formulation
RU2764740C1 (ru) 2018-08-09 2022-01-20 Бейцзин Уиздомаб Байотекнолоджи Ко., Лтд Биспецифическое антитело против вируса бешенства и его применение
SG11202101415UA (en) 2018-08-10 2021-03-30 Sangamo Therapeutics France New car constructs comprising tnfr2 domains
MX2021001431A (es) 2018-08-10 2021-05-12 Chugai Pharmaceutical Co Ltd Molecula de union al antigeno anti grupo de diferenciacion 137 (cd137) y su uso.
AU2019321490B2 (en) 2018-08-13 2025-09-04 Inhibrx Biosciences, Inc. Ox40-binding polypeptides and uses thereof
CN110818793A (zh) 2018-08-14 2020-02-21 中山康方生物医药有限公司 抗IL-1β的抗体、其药物组合物及其用途
IL261156A (en) 2018-08-14 2020-02-27 Fass Deborah Chimeric quiescin sulfhydryl oxidase (qsox1) antibodies and uses of same
TW202021618A (zh) 2018-08-17 2020-06-16 美商２３與我有限公司 抗ｉｌ１ｒａｐ抗體及其使用方法
US12259395B2 (en) 2018-08-17 2025-03-25 Ab Studio Inc. Catabodies and methods of use thereof
JP2021534188A (ja) 2018-08-17 2021-12-09 メルサナ セラピューティクス インコーポレイテッド ＮａＰｉ２ｂに標的指向されたポリマー抗体−薬物コンジュゲートおよびその使用方法
EP3837277A4 (de) 2018-08-17 2022-05-11 Icahn School of Medicine at Mount Sinai Rekombinante viren der newcastle-krankheit und deren verwendungen zur prävention einer rsv-krankheit oder infektion mit dem menschlichen metapneumovirus
WO2020041361A1 (en) 2018-08-20 2020-02-27 The General Hospital Corporation Antagonistic anti-tumor necrosis factor receptor superfamily polypeptides
US11548938B2 (en) 2018-08-21 2023-01-10 Quidel Corporation DbpA antibodies and uses thereof
KR102917630B1 (ko) 2018-08-21 2026-01-27 앨버트 아인슈타인 컬리지 오브 메디신 인간 Tim-3에 대한 모노클로날 항체
US12173070B2 (en) 2018-08-21 2024-12-24 Abl Bio Inc. Anti-PD-L1/anti-LAG3 bispecific antibodies and uses thereof
EP3841123A2 (de) 2018-08-23 2021-06-30 Seagen Inc. Anti-tigit-antikörper
WO2020041758A1 (en) 2018-08-24 2020-02-27 City Of Hope Masked cytokine conjugates
EP3841201A1 (de) 2018-08-24 2021-06-30 Yeda Research and Development Co. Ltd Verfahren zur modulation der m2-makrophagenpolarisation und verwendung derselben in der therapie
PL3843757T3 (pl) 2018-08-27 2024-08-05 Affimed Gmbh Kriokonserwowane komórki nk wstępnie obciążone konstruktem przeciwciała
SG11202101811VA (en) 2018-08-30 2021-03-30 Tcr2 Therapeutics Inc Compositions and methods for tcr reprogramming using fusion proteins
CN109053895B (zh) 2018-08-30 2020-06-09 中山康方生物医药有限公司 抗pd-1-抗vegfa的双功能抗体、其药物组合物及其用途
AR119259A1 (es) 2018-08-31 2021-12-09 Alector Llc Anticuerpos anti-cd33 y métodos de uso de los mismos
US20210340279A1 (en) 2018-08-31 2021-11-04 Yale University Compositions and methods of using cell-penetrating antibodies in combination with immune checkpoint modulators
CA3107085A1 (en) 2018-08-31 2020-03-05 Adc Therapeutics Sa Combination of anti-cd19 antibody-pyrroloenzodiazepine conjugate and ve netoclax
GB201814281D0 (en) 2018-09-03 2018-10-17 Femtogenix Ltd Cytotoxic agents
US20210317479A1 (en) 2018-09-06 2021-10-14 The Broad Institute, Inc. Nucleic acid assemblies for use in targeted delivery
CN112823167B (zh) 2018-09-07 2025-07-15 辉瑞大药厂 抗-αvβ8抗体和组合物及其用途
EP3847196A4 (de) 2018-09-07 2023-01-04 ITabMed (HK) Limited Bispezifische antigenbindende proteine und verwendungen davon
WO2020048607A1 (en) 2018-09-07 2020-03-12 Université Libre de Bruxelles Srsf2 as rna epigenetic factor
WO2020052543A1 (en) 2018-09-10 2020-03-19 Nanjing Legend Biotech Co., Ltd. Single-domain antibodies against cd33 and constructs thereof
EP3849545A1 (de) 2018-09-10 2021-07-21 Institut National de la Santé et de la Recherche Médicale (INSERM) Verfahren zur behandlung von neurofibromatose
EP3850008A1 (de) 2018-09-10 2021-07-21 INSERM (Institut National de la Santé et de la Recherche Médicale) Verwendung eines inhibitors der ntsr1-aktivierung oder expression zur verhinderung von gewichtsverlust, muskelschwund und verringertem proteinblutspiegel bei probanden, die diese benötigen
WO2020053122A1 (en) 2018-09-10 2020-03-19 INSERM (Institut National de la Santé et de la Recherche Médicale) Combination of her2/neu antibody with heme for treating cancer
EP3850006A1 (de) 2018-09-11 2021-07-21 Amgen Inc. Verfahren zur modulation der antikörperabhängigen zellvermittelten zytotoxizität
WO2020053325A1 (en) 2018-09-12 2020-03-19 Acm Biolabs Pte Ltd Polymersomes comprising a covalently bound antigen as well as methods of making and uses thereof
WO2020053808A1 (en) 2018-09-12 2020-03-19 Georg Dewald Method of diagnosing vasoregulatory disorders
AU2019339469A1 (en) 2018-09-13 2021-03-11 Immune-Onc Therapeutics, Inc. Novel LILRB4 antibodies and uses thereof
US10899826B1 (en) 2018-09-13 2021-01-26 Teva Pharmaceuticals International Gmbh Pharmaceutical compositions for an anti-CGRP antagonist antibody
AU2019337547A1 (en) 2018-09-13 2021-03-18 Merck Sharp & Dohme Llc Combination of PD-1 antagonist and LAG3 antagonist for treating non-microsatellite instablity-high/proficient mismatch repair colorectal cancer
US12441782B2 (en) 2018-09-14 2025-10-14 The Rockefeller University Anti-HIV antibody 10-1074 variants
CN120267816A (zh) 2018-09-14 2025-07-08 田边三菱制药株式会社 含有人抗il-33单克隆抗体的医药用组合物
GB201815041D0 (en) 2018-09-14 2018-10-31 Scancell Ltd Epitopes
JP2022500454A (ja) 2018-09-17 2022-01-04 ストロ バイオファーマ インコーポレーテッド 抗葉酸受容体抗体コンジュゲートによる併用療法
US11945850B2 (en) 2018-09-17 2024-04-02 Immatics Biotechnologies Gmbh B*44 restricted peptides for use in immunotherapy against cancers and related methods
US20210371537A1 (en) 2018-09-18 2021-12-02 Merrimack Pharmaceuticals, Inc. Anti-tnfr2 antibodies and uses thereof
TW202024121A (zh) 2018-09-18 2020-07-01 德商英麥提克生物技術股份有限公司 A*01 限制肽和肽組合物在抗癌免疫治療中的用途和相關方法
JP2022501388A (ja) 2018-09-19 2022-01-06 ラホヤ インスティチュート フォー イミュノロジー 関節リウマチにおけるｐｔｐｒｓ及びプロテオグリカン
CA3111401A1 (en) 2018-09-19 2020-03-26 Genentech, Inc. Therapeutic and diagnostic methods for bladder cancer
WO2020058372A1 (en) 2018-09-19 2020-03-26 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and pharmaceutical composition for the treatment of cancers resistant to immune checkpoint therapy
SG11202102713TA (en) 2018-09-21 2021-04-29 Teneobio Inc Methods for purifying heterodimeric, multispecific antibodies
US12195544B2 (en) 2018-09-21 2025-01-14 Harpoon Therapeutics, Inc. EGFR binding proteins and methods of use
AU2019342133B8 (en) 2018-09-21 2025-08-07 Genentech, Inc. Diagnostic methods for triple-negative breast cancer
CN113166236A (zh) 2018-09-21 2021-07-23 北卡罗来纳大学查佩尔希尔分校 限制穿过黏液的合成粘合剂
EP3854875B1 (de) 2018-09-21 2026-01-14 Institute of Science Tokyo Menschlicher monoklonaler antikörper, der spezifisch an humanes hmgb1 bindet, und pharmazeutische zusammensetzung zur behandlung oder vorbeugung von morbus alzheimer, die den menschlichen monoklonalen antikörper enthält
EP3626265A1 (de) 2018-09-21 2020-03-25 INSERM (Institut National de la Santé et de la Recherche Médicale) Anti-human-cd45rc-antikörper und verwendungen davon
HUE063462T2 (hu) 2018-09-24 2024-01-28 Janssen Biotech Inc A colitis ulcerosa kezelésének biztonságos és hatékony eljárása anti-IL12/IL23 antitesttel
US12421524B2 (en) 2018-09-24 2025-09-23 Merck Sharp & Dohme Llc Expression vectors for eukaryotic expression systems
EP3856772A1 (de) 2018-09-25 2021-08-04 Institut National de la Santé et de la Recherche Médicale (INSERM) Verwendung von antagonisten von th17-zytokinen zur behandlung von bronchialer remodellierung bei patienten mit allergischem asthma
WO2020068557A1 (en) 2018-09-25 2020-04-02 BioLegend, Inc. Anti-tlr9 agents and compositions and methods for making and using the same
CN119306844A (zh) 2018-09-25 2025-01-14 哈普恩治疗公司 Dll3结合蛋白及使用方法
CA3114024A1 (en) 2018-09-26 2020-04-02 Merck Patent Gmbh Combination of a pd-1 antagonist, an atr inhibitor and a platinating agent for the treatment of cancer
CN113286812B (zh) 2018-09-27 2025-05-30 西里欧发展公司 掩蔽型细胞因子多肽
JP7465272B2 (ja) 2018-09-27 2024-04-10 マレンゴ・セラピューティクス，インコーポレーテッド Ｃｓｆ１ｒ／ｃｃｒ２多特異性抗体
SG11202102851XA (en) 2018-09-27 2021-04-29 Celgene Corp SIRPa BINDING PROTEINS AND METHODS OF USE THEREOF
BR112021005868A2 (pt) 2018-09-27 2021-10-19 Tizona Therapeutics Anticorpos anti-hla-g, composições compreendendo anticorpos anti-hla-g e métodos de uso de anticorpos anti-hla-g
CN112930187A (zh) 2018-09-27 2021-06-08 弗斯弗加姆股份有限公司 用于同种异体γ/δ-T细胞的扩增和使用的方法和组合物
BR112021005669A2 (pt) 2018-09-28 2021-06-22 Amgen Inc. anticorpos contra bcma solúvel
US20210380675A1 (en) 2018-09-28 2021-12-09 Kyowa Kirin Co., Ltd. Il-36 antibodies and uses thereof
WO2020069405A1 (en) 2018-09-28 2020-04-02 Novartis Ag Cd22 chimeric antigen receptor (car) therapies
WO2020069433A1 (en) 2018-09-28 2020-04-02 Imaginab, Inc. Cd8 imaging constructs and methods of use thereof
KR20210068079A (ko) 2018-09-28 2021-06-08 추가이 세이야쿠 가부시키가이샤 Cd3 및 cd137에 결합할 수 있지만 동시에는 결합하지 않는 항원 결합 분자
SG11202100935TA (en) 2018-09-28 2021-02-25 Massachusetts Inst Technology Collagen-localized immunomodulatory molecules and methods thereof
US20210347851A1 (en) 2018-09-28 2021-11-11 Novartis Ag Cd19 chimeric antigen receptor (car) and cd22 car combination therapies
WO2020070062A1 (en) 2018-10-01 2020-04-09 INSERM (Institut National de la Santé et de la Recherche Médicale) Use of tim-3 inhibitors for the treatment of exacerbations in patients suffering from severe asthma
EP4588483A3 (de) 2018-10-03 2025-09-24 University of Pittsburgh- Of the Commonwealth System of Higher Education Kovalente adaptersynnotch- und chimäre antigenrezeptoren (cars) für programmierbares antigen-targeting
JP2022504287A (ja) 2018-10-03 2022-01-13 スターテン・バイオテクノロジー・ベー・フェー ヒト及びカニクイザルａｐｏｃ３に特異的な抗体、並びにその使用の方法
JP7592585B2 (ja) 2018-10-04 2024-12-02 アンスティチュ ナショナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシュ メディカル 粘膜炎症性疾患の処置のための方法及び医薬組成物
IL281988B2 (en) 2018-10-05 2025-03-01 Bavarian Nordic As Combination therapy for treating cancer with an intravenous administration of a recombinant mva and an immune checkpoint antagonist or agonist
CN112771074A (zh) 2018-10-05 2021-05-07 国家儿童医院研究所 用于酶促破坏细菌生物膜的组合物和方法
JP2022512648A (ja) 2018-10-09 2022-02-07 アンスティチュ ナショナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシュ メディカル 心筋線維化の処置のためのαＶ－インテグリン（ＣＤ５１）阻害剤の使用
KR20210075132A (ko) 2018-10-09 2021-06-22 아이벡스 바이오사이언시스, 엘엘씨 필라민-a에 대한 항체 및 이의 치료적 용도
TW202028244A (zh) 2018-10-09 2020-08-01 美商建南德克公司 用於確定突觸形成之方法及系統
EP3863722A2 (de) 2018-10-10 2021-08-18 Tilos Theapeutics, Inc. Anti-lap-antikörper und verwendungen davon
KR20210074341A (ko) 2018-10-10 2021-06-21 베링거 인겔하임 인터내셔날 게엠베하 고밀도 생물 반응기 배양에서 막 기체 전달을 위한 방법
US12590169B2 (en) 2018-10-11 2026-03-31 Inhibrx Biosciences, Inc. 5T4 single domain antibodies and therapeutic compositions thereof
AU2019356573B2 (en) 2018-10-11 2025-12-18 Inhibrx Biosciences, Inc. PD-1 single domain antibodies and therapeutic compositions thereof
MX2021003976A (es) 2018-10-11 2021-05-27 Amgen Inc Procesamiento posterior de constructos de anticuerpos biespecificos.
JP7611820B2 (ja) 2018-10-11 2025-01-10 インヒブルクス バイオサイエンシズ インコーポレイテッド Ｄｌｌ３シングルドメイン抗体およびその治療用組成物
CN113166261A (zh) 2018-10-11 2021-07-23 印希比股份有限公司 B7h3单域抗体及其治疗性组合物
EP3863672A4 (de) 2018-10-11 2022-06-29 The Scripps Research Institute Antikörperverbindungen mit reaktivem arginin und verwandte antikörperarzneimittelkonjugate
CA3115660A1 (en) 2018-10-12 2020-04-16 Hassan JUMAA-WEINACHT Monoclonal antibody composition for treatment of philadelphia chromosome positive acute lymphoblastic leukemia
WO2020077286A1 (en) 2018-10-12 2020-04-16 Quidel Corporation Extraction reagent for use in an assay for detection of group a streptococcus
JP2022505041A (ja) 2018-10-15 2022-01-14 メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツング Ｄｎａアルキル化剤及びａｔｒ阻害剤を使用する併用療法
UY38407A (es) 2018-10-15 2020-05-29 Novartis Ag Anticuerpos estabilizadores de trem2
WO2020081493A1 (en) 2018-10-16 2020-04-23 Molecular Templates, Inc. Pd-l1 binding proteins
WO2020079692A1 (en) 2018-10-17 2020-04-23 Biolinerx Ltd. Treatment of metastatic pancreatic adenocarcinoma
EP3867405A4 (de) 2018-10-17 2022-07-20 The University of Queensland Epigenetischer biomarker und verwendungen dafür
EP3867943A1 (de) 2018-10-18 2021-08-25 DH Technologies Development Pte. Ltd. Funktionalisierung eines probennahmeelements zur verwendung mit einem massenspektrometriesystem
CN112955462B (zh) 2018-10-18 2024-05-07 国家医疗保健研究所 用于治疗实体瘤的βIG-H3拮抗剂和免疫检查点抑制剂的组合
MX2021004356A (es) 2018-10-18 2021-05-31 Merck Sharp & Dohme Llc Formulaciones de anticuerpos anti-rsv y metodos de uso de las mismas.
US20210353750A1 (en) 2018-10-18 2021-11-18 Jounce Therapeutics, Inc. Methods of Treating Cancer
EP3867646A1 (de) 2018-10-18 2021-08-25 F. Hoffmann-La Roche AG Diagnostische und therapeutische verfahren für sarkomatoiden nierenkrebs
US12365722B2 (en) 2018-10-19 2025-07-22 University Of Maryland, College Park Multispecific antibodies targeting multiple epitopes on the HIV-1 envelope
WO2020079239A1 (en) 2018-10-19 2020-04-23 Medimmune Limited Pyrrolobenzodiazepine conjugates
KR20210081350A (ko) 2018-10-19 2021-07-01 메드임뮨 리미티드 피롤로벤조디아제핀 컨쥬게이트
JP7401538B2 (ja) 2018-10-22 2023-12-19 シャンハイ、ケンパーソー、バイオテクノロジー、カンパニー、リミテッド 抗ｃｌｄｎ１８．２抗体およびその使用
MX2021004598A (es) 2018-10-23 2021-06-15 Scholar Rock Inc Inhibidores selectivos de rgmc y el uso de los mismos.
US20210380942A1 (en) 2018-10-24 2021-12-09 Jounce Therapeutics, Inc. Methods and compositions for the treatment of cancer and infectious diseases
AU2019365238A1 (en) 2018-10-24 2021-05-13 F. Hoffmann-La Roche Ag Conjugated chemical inducers of degradation and methods of use
US12129305B2 (en) 2018-10-25 2024-10-29 The Medical College Of Wisconsin, Inc. Targeting CLPTM1L for treatment and prevention of cancer
TWI824043B (zh) 2018-10-25 2023-12-01 西班牙商瑪製藥股份有限公司 藥物抗體共軛物
KR102692543B1 (ko) 2018-10-26 2024-08-07 재단법인 목암생명과학연구소 Ids를 포함하는 융합 단백질 및 이의 용도
WO2020087065A1 (en) 2018-10-26 2020-04-30 Teneobio, Inc. Heavy chain antibodies binding to cd38
EP3870299A1 (de) 2018-10-26 2021-09-01 Jounce Therapeutics, Inc. Verfahren zur behandlung von krebs
WO2020092455A2 (en) 2018-10-29 2020-05-07 The Broad Institute, Inc. Car t cell transcriptional atlas
CN119033684A (zh) 2018-10-29 2024-11-29 豪夫迈·罗氏有限公司 抗体制剂
US12240893B2 (en) 2018-10-30 2025-03-04 Alexion Pharmaceuticals, Inc. Subcutaneous dosage and administration of anti-C5 antibodies for treatment of paroxysmal nocturnal hemoglobinuria (PNH)
RU2724469C2 (ru) 2018-10-31 2020-06-23 Закрытое Акционерное Общество "Биокад" Моноклональное антитело, которое специфически связывается с cd20
WO2020089343A1 (en) 2018-10-31 2020-05-07 Juno Therapeutics Gmbh Methods for selection and stimulation of cells and apparatus for same
CN113614535B (zh) 2018-10-31 2024-08-16 亚利桑那大学评议会 用于辐射诱导的肺损伤的生物标志物和使用方法
MA54089A (fr) 2018-10-31 2022-02-09 Merck Sharp & Dohme Anticorps anti-pd-1 humain et procédés d'utilisation associés
US12264189B2 (en) 2018-10-31 2025-04-01 Mayo Foundation For Medical Education And Research Methods and materials for treating cancer
US12624086B2 (en) 2018-10-31 2026-05-12 Mayo Foundation For Medical Education And Research Materials and methods for treating cancer
US12257286B2 (en) 2018-10-31 2025-03-25 Mayo Foundation For Medical Education And Research Methods and materials for treating cancer
EP3873912B1 (de) 2018-10-31 2026-03-25 Intocell, Inc. Kondensierte heterocyclische benzodiazepinderivate und verwendungen davon
CN111116745B (zh) 2018-11-01 2022-10-14 上海新理念生物医药科技有限公司 抗CD79b抗体、其药物偶联物及其应用
MX2021004819A (es) 2018-11-02 2021-06-08 Annexon Inc Composiciones y metodos para tratar lesiones cerebrales.
EP4219550A1 (de) 2018-11-02 2023-08-02 Oklahoma Medical Research Foundation Monoklonale antikörper gegen etld1 und verwendungen davon
EP3877055A1 (de) 2018-11-05 2021-09-15 Ludwig Institute for Cancer Research Ltd Humanisierte und variante tgf-beta1-spezifische antikörper sowie verfahren und verwendungen davon
CA3118027A1 (en) 2018-11-05 2020-05-14 Ludwig Institute For Cancer Research Ltd. Humanized and variant tgf-.beta.3 specific antibodies and methods and uses thereof
CN113260626B (zh) 2018-11-05 2024-09-13 豪夫迈·罗氏有限公司 在原核宿主细胞中产生双链蛋白质的方法
US20220025058A1 (en) 2018-11-06 2022-01-27 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and pharmaceutical compositions for the treatment of acute myeloid leukemia by eradicating leukemic stem cells
EP3878869A4 (de) 2018-11-07 2023-04-19 Shanghai Hyamab Biotech Co., Ltd. Nkg2a-antikörper, herstellungsverfahren dafür und anwendung davon
JP7503056B6 (ja) 2018-11-07 2024-07-16 メルク・シャープ・アンド・ドーム・エルエルシー 抗ｌａｇ３抗体および抗ｐｄ－１抗体の共－製剤
EP3876989A4 (de) 2018-11-09 2022-12-07 University of Massachusetts Anti-cfae-antikörper und verfahren zur verwendung
GB201818477D0 (en) 2018-11-13 2018-12-26 Emstopa Ltd Tissue plasminogen activator antibodies and method of use thereof
EP3880711A4 (de) 2018-11-15 2022-12-28 The General Hospital Corporation Agonistische polypeptide der tumornekrosefaktorrezeptorsuperfamilie
CN113412279B (zh) 2018-11-15 2024-09-24 拜奥迪斯私人有限公司 人源化抗SIRPα抗体
MX2021005708A (es) 2018-11-16 2021-09-21 Bristol Myers Squibb Co Anticuerpos anti grupo 2a del receptor inhibidor de células asesinas naturales (anti-nkg2a) y usos de los mismos.
ES2994459T3 (en) 2018-11-16 2025-01-24 S Biomedic Nv Compositions for treating oxidative stress-associated skin diseases and skin ageing
EP3880837A1 (de) 2018-11-16 2021-09-22 F. Hoffmann-La Roche AG Streptavidin-beschichtete festphasen mit einem element eines bindungspaars
CN113330034A (zh) 2018-11-16 2021-08-31 阿尔伯特爱因斯坦医学院 针对B7-H3的IgV结构域的单克隆抗体及其用途
JP7627216B2 (ja) 2018-11-16 2025-02-05 メモリアル スローン ケタリング キャンサー センター ムチン－１６に対する抗体およびそれを使用する方法
AU2019383076B2 (en) 2018-11-19 2026-02-05 Enlivex Therapeutics R&D Ltd Early apoptotic cells for use treating sepsis
US12227548B2 (en) 2018-11-19 2025-02-18 Dana-Farber Cancer Institute, Inc. Use of IRE1α-XBP1 signaling pathway biomarkers for modulating immune responses
CN113348011B (zh) 2018-11-19 2023-04-18 比奥拉治疗股份有限公司 用生物治疗剂治疗疾病的方法和装置
JP7625518B2 (ja) 2018-11-20 2025-02-03 バヴァリアン・ノルディック・アクティーゼルスカブ ４－１ｂｂｌ（ｃｄ１３７ｌ）及び／またはｃｄ４０ｌをコードする組み換えｍｖａの腫瘍内及び／または静脈内投与によって、がんを治療する療法
CN111196851B (zh) 2018-11-20 2021-11-16 厦门万泰凯瑞生物技术有限公司 针对人抗缪勒管激素的特异性抗体及其应用
MA55149A (fr) 2018-11-20 2021-09-29 Janssen Biotech Inc Procédé sûr et efficace de traitement du psoriasis avec un anticorps spécifique anti-il-23
JP7463366B2 (ja) 2018-11-20 2024-04-08 タケダ ワクチン，インコーポレイテッド 新規の抗ジカウイルス抗体及びその使用
WO2020104479A1 (en) 2018-11-20 2020-05-28 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and compositions for treating cancers and resistant cancers with anti transferrin receptor 1 antibodies
EP3885365A1 (de) 2018-11-20 2021-09-29 Shanghai Pharmaexplorer Co., Ltd. Ox40-antikörper, herstellungsverfahren dafür und verwendung davon
EP3884276A2 (de) 2018-11-23 2021-09-29 Katholieke Universiteit Leuven Vorhersage einer behandlungsreaktion bei entzündlichen darmerkrankungen
CN116003597A (zh) 2018-11-27 2023-04-25 舒泰神（北京）生物制药股份有限公司 特异性识别粒细胞-巨噬细胞集落刺激因子受体α的抗体及其用途
CN111234018A (zh) 2018-11-29 2020-06-05 上海开拓者生物医药有限公司 全人抗gitr抗体及其制备方法
WO2020109251A1 (en) 2018-11-29 2020-06-04 Adc Therapeutics Sa Dosage regime
SG11202105152YA (en) 2018-11-30 2021-06-29 Abl Bio Inc Anti-pd-l1/anti-4-1bb bispecific antibodies and uses thereof
CN111253485A (zh) 2018-11-30 2020-06-09 上海开拓者生物医药有限公司 抗人tim-3单克隆抗体及其应用
US12139551B2 (en) 2018-12-03 2024-11-12 Bristol-Myers Squibb Company Anti-IDO antibody and uses thereof
CN113166257B (zh) 2018-12-03 2023-05-30 上海开拓者生物医药有限公司 Cd47抗体及其制备方法和应用
EA202191201A1 (ru) 2018-12-03 2022-01-26 Эдженсис, Инк. Фармацевтические композиции, включающие конъюгаты анти-191p4d12 антитело-лекарственное средство, и способы их применения
KR20210099614A (ko) 2018-12-04 2021-08-12 노파르티스 아게 Cd3에 대한 결합 분자 및 이의 용도
US11034710B2 (en) 2018-12-04 2021-06-15 Sumitomo Dainippon Pharma Oncology, Inc. CDK9 inhibitors and polymorphs thereof for use as agents for treatment of cancer
BR112021010908A2 (pt) 2018-12-06 2021-08-31 Genentech, Inc. Método para tratamento de linfoma difuso de grandes células b, kit e imunoconjugado
EP3891292A1 (de) 2018-12-06 2021-10-13 Pfizer Inc. Zellen mit reduzierter inhibitorproduktion und verfahren zur verwendung davon
US12428484B2 (en) 2018-12-06 2025-09-30 Alexion Pharmaceuticals, Inc. Anti-ALK2 antibodies and uses thereof
WO2020115261A1 (en) 2018-12-07 2020-06-11 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and compositions for treating melanoma
WO2020118293A2 (en) 2018-12-07 2020-06-11 Georgia Tech Research Corporation Antibodies that bind to natively folded myocilin
KR102396194B1 (ko) 2018-12-07 2022-05-10 서울대학교 산학협력단 항 c-Met 아고니스트 항체 및 이의 용도
TWI821474B (zh) 2018-12-07 2023-11-11 大陸商江蘇恆瑞醫藥股份有限公司 Ｃｄ３抗體及其藥物用途
KR102433184B1 (ko) 2018-12-07 2022-08-17 서울대학교 산학협력단 항 c-Met 아고니스트 항체 및 이의 용도
EP3894427A1 (de) 2018-12-10 2021-10-20 Genentech, Inc. Photovernetzende peptide zur stellenspezifischen konjugation an fc-haltige proteine
MX2021006930A (es) 2018-12-11 2021-11-17 Q32 Bio Inc Construcciones de proteínas de fusión para enfermedades asociadas al complemento.
CN113366016B (zh) 2018-12-12 2022-12-16 上海开拓者生物医药有限公司 抗人白细胞介素5(il-5)单克隆抗体及其应用
CN111303283A (zh) 2018-12-12 2020-06-19 上海君实生物医药科技股份有限公司 抗il-17a抗体及其应用
CN120189526A (zh) 2018-12-13 2025-06-24 卫材R&D管理有限公司 荷伯希二烯抗体-药物缀合物及使用方法
EP3894543A1 (de) 2018-12-14 2021-10-20 INSERM (Institut National de la Santé et de la Recherche Médicale) Isolierte humane mhc-abgeleitete peptide und verwendungen davon zur stimulierung und aktivierung der suppressiven funktion von cd8cd45rc + cd45rc low tregs
WO2020127374A2 (en) 2018-12-17 2020-06-25 Alligator Bioscience Ab Novel polypeptides
EP3898681A2 (de) 2018-12-17 2021-10-27 Alligator Bioscience AB Polypeptide
GB201820554D0 (en) 2018-12-17 2019-01-30 Univ Oxford Innovation Ltd BTLA antibodies
GB201820547D0 (en) 2018-12-17 2019-01-30 Oxford Univ Innovation Modified antibodies
US12703762B2 (en) 2018-12-18 2026-08-11 Novartis Ag Reversal binding agents for anti-factor XI/XIa antibodies and uses thereof
WO2020128864A1 (en) 2018-12-18 2020-06-25 Janssen Biotech, Inc. Safe and effective method of treating lupus with anti-il12/il23 antibody
TW202039535A (zh) 2018-12-18 2020-11-01 德商英麥提克生物技術股份有限公司 B*08限制肽和肽組合物抗癌免疫治療和相關方法
JP2022514867A (ja) 2018-12-18 2022-02-16 カタパルト セラピューティクス ビー．ヴイ． 移植片対宿主病（ＧｖＨＤ）の防止又は処置のための抗ＣＣＲ７ ＭＡＢの使用
GB201820725D0 (en) 2018-12-19 2019-01-30 Adc Therapeutics Sarl Pyrrolobenzodiazepine resistance
US20220347309A1 (en) 2018-12-19 2022-11-03 Adc Therapeutics Sa Pyrrolobenzodiazepine resistance
TW202039554A (zh) 2018-12-19 2020-11-01 瑞士商諾華公司 抗ＴＮＦ－α抗體
AR117327A1 (es) 2018-12-20 2021-07-28 23Andme Inc Anticuerpos anti-cd96 y métodos de uso de estos
WO2020128927A1 (en) 2018-12-20 2020-06-25 Kyowa Kirin Co., Ltd. Fn14 antibodies and uses thereof
US20210386763A1 (en) 2018-12-20 2021-12-16 Novartis Ag Pharmaceutical combinations
CN113227131B (zh) 2018-12-20 2025-03-04 豪夫迈·罗氏有限公司 经修饰的抗体Fc及其使用方法
GB201820983D0 (en) 2018-12-21 2019-02-06 Pirbright Inst Virus
WO2020127864A1 (en) 2018-12-21 2020-06-25 F. Hoffmann-La Roche Ag Method for improving inhibition of vegf-binding to vegf-r1 of an anti-vegf antibody
WO2020127873A1 (en) 2018-12-21 2020-06-25 F. Hoffmann-La Roche Ag Antibody that binds to vegf and il-1beta and methods of use
JP7737143B2 (ja) 2018-12-21 2025-09-10 エイム・イムノテック・インコーポレイテッド がん治療のための組成物および方法
MX2021007589A (es) 2018-12-21 2021-12-10 23Andme Inc Anticuerpos anti il-36 y procedimientos de uso de estos.
EP3897117A1 (de) 2018-12-21 2021-10-27 Compass Therapeutics LLC Transgene maus, die eine gemeinsame menschliche leichte kette exprimiert
JP7560459B2 (ja) 2018-12-21 2024-10-02 ジェネンテック， インコーポレイテッド アポトーシスに耐性のある細胞株を使用してポリペプチドを生成する方法
WO2020128893A1 (en) 2018-12-21 2020-06-25 Pfizer Inc. Combination treatments of cancer comprising a tlr agonist
WO2020127885A1 (en) 2018-12-21 2020-06-25 INSERM (Institut National de la Santé et de la Recherche Médicale) Compositions for treating cancers and resistant cancers
WO2020132810A1 (en) 2018-12-24 2020-07-02 Generon (Shanghai) Corporation Ltd. Multispecific antigen binding proteins capable of binding cd19 and cd3, and use thereof
BR112021012631A2 (pt) 2018-12-26 2021-12-14 Xilio Dev Inc Anticorpos anti-ctla4 e métodos de uso dos mesmos
CN113330033B (zh) 2018-12-26 2024-11-29 先天制药公司 白细胞免疫球蛋白样受体2中和性抗体
EP3902607A4 (de) 2018-12-27 2023-04-19 University Of Utah Research Foundation Beim nachweis und zur behandlung von multipler sklerose und anderer demyelinisierender erkrankungen nützliche zusammensetzungen und verfahren
KR20210119407A (ko) 2018-12-27 2021-10-05 베링거 인겔하임 인터내셔날 게엠베하 수장 족저 농포증 치료용 항-il-36r 항체
SG11202107007VA (en) 2018-12-27 2021-07-29 Akeso Biopharma Inc Antibody against human il-4ra and use thereof
KR20210109520A (ko) 2018-12-28 2021-09-06 쓰촨 케룬-바이오테크 바이오파마수티컬 컴퍼니 리미티드 항체 및 이의 용도
EP3902560A1 (de) 2018-12-28 2021-11-03 F. Hoffmann-La Roche AG Peptide-mhc-i-antikörper-fusionsprotein zur therapeutischen verwendung bei einem patienten mit verstärkter immunantwort
CN111378045B (zh) 2018-12-28 2022-08-02 长春金赛药业有限责任公司 二价双特异性抗体及其制备方法、编码基因、宿主细胞、组合物
US11447551B2 (en) 2018-12-28 2022-09-20 Sparx Bioscience Limited Binding molecules specific for claudin 18.2, compositions and methods thereof, for the treatment of cancer and other diseases
WO2020141145A1 (en) 2018-12-30 2020-07-09 F. Hoffmann-La Roche Ag Anti-rabbit cd19 antibodies and methods of use
MX2021004504A (es) 2019-01-02 2021-10-01 Neuracle Science Co Ltd Anti-familia con similitud de secuencia 19, anticuerpos del miembro a5 y método de uso de los mismos.
MX2021008121A (es) 2019-01-03 2021-12-10 Inst Nat Sante Rech Med Metodos y composiciones farmaceuticas para mejorar las respuestas inmunitarias dependientes de celulas t cd8+ en sujetos que sufren de cancer.
CN113924311A (zh) 2019-01-07 2022-01-11 印希比股份有限公司 包含修饰的il-2多肽的多肽及其用途
WO2020146795A1 (en) 2019-01-11 2020-07-16 Omeros Corporation Methods and compositions for treating cancer
CN111434688A (zh) 2019-01-11 2020-07-21 上海开拓者生物医药有限公司 Cd73抗体及其制备方法和应用
EP3908372A1 (de) 2019-01-13 2021-11-17 Yissum Research and Development Company of the Hebrew University of Jerusalem Ltd. Für menschliches nectin-2 spezifische antikörper
WO2020148206A1 (en) 2019-01-14 2020-07-23 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and kits for generating and selecting a variant of a binding protein with increased binding affinity and/or specificity
CN115120716A (zh) 2019-01-14 2022-09-30 健泰科生物技术公司 用pd-1轴结合拮抗剂和rna疫苗治疗癌症的方法
US20220153827A1 (en) 2019-01-15 2022-05-19 Janssen Biotech, Inc. Anti-TNF Antibody Compositions and Methods for the Treatment of Juvenile Idiopathic Arthritis
CN109762067B (zh) 2019-01-17 2020-02-28 北京天广实生物技术股份有限公司 结合人Claudin 18.2的抗体及其用途
US11680105B2 (en) 2019-01-17 2023-06-20 Regents Of The University Of Minnesota Antibody fragments for detecting cancer and methods of use
JP2022523640A (ja) 2019-01-18 2022-04-26 ウニベルシテ カソリーク デ ルーベン ウイルス組成物
AU2020210614A1 (en) 2019-01-21 2021-08-26 Sanofi Therapeutic RNA and anti-PD1 antibodies for advanced stage solid tumor cancers
SG11202107981VA (en) 2019-01-22 2021-08-30 Genentech Inc Immunoglobulin a antibodies and methods of production and use
CN118894938A (zh) 2019-01-22 2024-11-05 百时美施贵宝公司 抗IL-7Rα亚基的抗体及其用途
BR112021014236A2 (pt) 2019-01-22 2021-09-28 Innate Pharma Anticorpo, composição farmacêutica, kit e método para predizer ou avaliar a eficácia
CN113795511B (zh) 2019-01-23 2024-07-23 大有华夏生物医药集团有限公司 抗pd-l1双抗体及其用途
KR20210118878A (ko) 2019-01-23 2021-10-01 얀센 바이오테크 인코포레이티드 건선성 관절염의 치료 방법에 사용하기 위한 항-tnf 항체 조성물
MX2021008561A (es) 2019-01-23 2021-08-19 Genentech Inc Metodos de produccion de proteinas multimericas en celulas huesped eucariotas.
CN113614107A (zh) 2019-01-23 2021-11-05 Encefa公司 Cd31竞争剂及其用途
WO2020154032A1 (en) 2019-01-23 2020-07-30 Massachusetts Institute Of Technology Combination immunotherapy dosing regimen for immune checkpoint blockade
WO2020154510A1 (en) 2019-01-24 2020-07-30 University Of Georgia Research Foundation Treatment and detection of infection and disease associated with different fungal pathogens
US12642850B2 (en) 2019-01-24 2026-06-02 Massachusetts Institute Of Technology Nucleic acid nanostructure platform for programming immune stimulation
WO2020153467A1 (ja) 2019-01-24 2020-07-30 中外製薬株式会社 新規がん抗原及びそれらの抗原に対する抗体
WO2020154595A1 (en) 2019-01-24 2020-07-30 Massachusetts Institute Of Technology Nucleic acid nanostructure platform for antigen presentation and vaccine formulations formed therefrom
JP2020117502A (ja) 2019-01-28 2020-08-06 ファイザー・インク 変形性関節症の徴候および症状を処置する方法
US20220073600A1 (en) 2019-01-28 2022-03-10 Maple Biotech Llc Methods for treating disease using psmp antagonists
GB201901197D0 (en) 2019-01-29 2019-03-20 Femtogenix Ltd G-A Crosslinking cytotoxic agents
GB201901305D0 (en) 2019-01-30 2019-03-20 Immunocore Ltd Specific binding molecules
SG11202108099WA (en) 2019-01-30 2021-08-30 Scholar Rock Inc LTBP COMPLEX-SPECIFIC INHIBITORS OF TGFβ AND USES THEREOF
AU2019427766A1 (en) 2019-01-30 2021-09-16 Nomocan Pharmaceuticals Llc Antibodies to M(H)DM2/4 and their use in diagnosing and treating cancer
US12121566B2 (en) 2019-01-30 2024-10-22 Horizon Therapeutics Usa, Inc. Methods for treating gout
WO2020160325A1 (en) 2019-01-30 2020-08-06 Horizon Pharma Rheumatology Llc Reducing immunogenicity to pegloticase
CN113474370B (zh) 2019-02-01 2025-04-01 瑞泽恩制药公司 抗IL2受体γ抗原结合蛋白
WO2020160402A1 (en) 2019-02-01 2020-08-06 NanoView Biosciences, Inc. Systems and methods for vesicle cargo labeling and detection
AU2020219112A1 (en) 2019-02-04 2021-08-26 Alamab Therapeutics, Inc. Connexin 43 antibodies and use thereof
EP3693063A1 (de) 2019-02-06 2020-08-12 Diaccurate Verfahren und zusammensetzungen zur behandlung von krebs
CN113396230A (zh) 2019-02-08 2021-09-14 豪夫迈·罗氏有限公司 癌症的诊断和治疗方法
IL264768A (en) 2019-02-10 2020-08-31 Sagi Irit Anti-matrix metalloproteinase 7 (mmp-7) inhibitory antibody and uses thereof
US20220381790A1 (en) 2019-02-11 2022-12-01 University Of Virginia Patent Foundation Selection and blockade of fertilization competent male and female gametes
KR20220007584A (ko) 2019-02-11 2022-01-18 주무토르 바이오로직스 인코포레이티드 항-clec2d 항체 및 이의 사용 방법
EP3924739A1 (de) 2019-02-12 2021-12-22 Biogen MA Inc. Biomarker von progressiver multifokaler leukoenzephalopathie
US10871640B2 (en) 2019-02-15 2020-12-22 Perkinelmer Cellular Technologies Germany Gmbh Methods and systems for automated imaging of three-dimensional objects
CN119708241A (zh) 2019-02-15 2025-03-28 因特格尔莫来库乐有限公司 密封蛋白6抗体及其用途
JP2022520793A (ja) 2019-02-15 2022-04-01 ジャスト－エヴォテック バイオロジックス、インコーポレイテッド 自動バイオ製造システム、施設、及びプロセス
US11254736B2 (en) 2019-02-15 2022-02-22 Integral Molecular, Inc. Antibodies comprising a common light chain and uses thereof
JP7232925B2 (ja) 2019-02-15 2023-03-03 ウーシー バイオロジクス アイルランド リミテッド 改善された均一性を有する抗体薬物コンジュゲートの調製するプロセス
US12109273B2 (en) 2019-02-15 2024-10-08 Wuxi Xdc Singapore Private Limited Process for preparing antibody-drug conjugates with improved homogeneity
EP3927430A1 (de) 2019-02-18 2021-12-29 Pfizer Inc. Verfahren zur behandlung von chronischen schmerzen im unteren rücken
WO2020169472A2 (en) 2019-02-18 2020-08-27 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods of inducing phenotypic changes in macrophages
KR102398485B1 (ko) 2019-02-18 2022-05-16 에이티비 테라퓨틱스 식물 세포 또는 식물 전체에서 결합제-독소 융합 단백질의 생산 방법
CN113874394B (zh) 2019-02-20 2024-01-19 和铂抗体有限公司 抗体
JP7579795B2 (ja) 2019-02-21 2024-11-08 マレンゴ・セラピューティクス，インコーポレーテッド ＮＫｐ３０に結合する抗体分子およびその使用
SG11202109122SA (en) 2019-02-21 2021-09-29 Marengo Therapeutics Inc Anti-tcr antibody molecules and uses thereof
WO2020172598A1 (en) 2019-02-21 2020-08-27 Elstar Therapeutics, Inc. Multifunctional molecules that bind to t cells and uses thereof to treat autoimmune disorders
AU2020226893B2 (en) 2019-02-21 2025-02-27 Marengo Therapeutics, Inc. Multifunctional molecules that bind to T cell related cancer cells and uses thereof
SG11202109056TA (en) 2019-02-21 2021-09-29 Marengo Therapeutics Inc Multifunctional molecules that bind to calreticulin and uses thereof
MX2021010119A (es) 2019-02-21 2021-12-10 Trishula Therapeutics Inc Tratamiento combinado con anticuerpos anti-cd39 y anticuerpos anti-pd1 o anti-pd-l1.
CA3131036A1 (en) 2019-02-22 2020-08-27 Wuhan Yzy Biopharma Co., Ltd. Cd3 antigen-binding fragment and application thereof
EP3927371A1 (de) 2019-02-22 2021-12-29 Novartis AG Kombinationstherapien von chimären egfrviii-antigenrezeptoren und pd-1-inhibitoren
JP7621263B2 (ja) 2019-02-22 2025-01-24 武▲漢▼友芝友生物制▲薬▼股▲ふん▼有限公司 改変されたＦｃ断片、それを含む抗体、及びそれらの使用
EP3930687A4 (de) 2019-02-25 2023-06-07 The University of Chicago Verfahren und zusammensetzungen zur behandlung von entzündungs- und autoimmunzuständen mit ecm-affinitätspeptiden, die mit entzündungshemmenden mitteln verbunden sind
EP3931563A4 (de) 2019-02-26 2022-12-21 Dana-Farber Cancer Institute, Inc. Dynamische bh3-profilierung für die abbildung lebender zellen
WO2020176637A1 (en) 2019-02-26 2020-09-03 Pantheryx, Inc. Compositions for management of disorders of the gastrointestinal tract
CN119735688A (zh) 2019-02-26 2025-04-01 茵思博纳公司 高-亲和力抗-mertk抗体及其用途
CN113710706A (zh) 2019-02-27 2021-11-26 豪夫迈·罗氏有限公司 用于抗tigit抗体和抗cd20抗体或抗cd38抗体治疗的给药
SG11202108707WA (en) 2019-02-27 2021-09-29 Epiaxis Therapeutics Pty Ltd Methods and agents for assessing t-cell function and predicting response to therapy
MX2021010254A (es) 2019-02-27 2021-09-21 Angiex Inc Conjugados de anticuerpo-farmaco que comprenden anticuerpos anti-tm4sf1 y metodos de uso de los mismos.
CN113874083A (zh) 2019-03-01 2021-12-31 梅里麦克制药股份有限公司 抗-tnfr2抗体及其用途
WO2020178193A1 (en) 2019-03-01 2020-09-10 INSERM (Institut National de la Santé et de la Recherche Médicale) Method of treatment of sarcoidosis
MX2021010441A (es) 2019-03-01 2021-09-21 Allogene Therapeutics Inc Receptores antigenicos quimericos y agentes de union dirigidos a dll3.
US10570210B1 (en) 2019-03-04 2020-02-25 Beijing Mabworks Biotech Co.Ltd Antibodies binding CD40 and uses thereof
EP4592313A3 (de) 2019-03-05 2025-11-19 Takeda Pharmaceutical Company Limited Eingeschränkt bedingt aktivierte bindungsproteine
WO2020178313A1 (en) 2019-03-05 2020-09-10 INSERM (Institut National de la Santé et de la Recherche Médicale) New biomarkers and biotargets in renal cell carcinoma
WO2020181058A1 (en) 2019-03-05 2020-09-10 Massachusetts Institute Of Technology Dna launched rna replicon system (drep) and uses thereof
JP7664045B2 (ja) 2019-03-06 2025-04-17 リガケム バイオサイエンシズ， インク． ヒトｄｌｋ１に対する抗体を含む抗体薬物コンジュゲート及びその使用
BR112021017144A2 (pt) 2019-03-08 2021-11-09 Genentech Inc Ensaio para detectar uma proteína associada à membrana, métodos para quantificar a concentração de proteína circulante, para determinar se um paciente com linfoma de células b tem probabilidade de exibir uma resposta a uma terapia anti-cd20, para determinar a afinidade de um anticorpo anti-cd20, para determinar a ativação de células t e método de tratamento de um tumor
CN113784990B (zh) 2019-03-08 2025-10-21 丹尼斯科美国公司 融合多肽
EP3938396A1 (de) 2019-03-11 2022-01-19 Jounce Therapeutics, Inc. Anti-icos-antikörper zur behandlung von krebs
CA3133074A1 (en) 2019-03-11 2020-09-17 Memorial Sloan Kettering Cancer Center Cd22 antibodies and methods of using the same
CA3132199A1 (en) 2019-03-12 2020-09-17 President And Fellows Of Harvard College Methods and compositions for treating cancer
MA55316A (fr) 2019-03-13 2022-01-19 Merck Sharp & Dohme Polythérapies anticancéreuses comprenant des agents de blocage de ctla-4 et pd-1
EP3938784B1 (de) 2019-03-13 2026-04-29 Merck Patent GmbH Verfahren zur herstellung lipidierter proteinhaltiger strukturen
WO2020186247A1 (en) 2019-03-13 2020-09-17 University Of Virginia Patent Foundation Compositions and methods for promoting islet viability and enhancing insulin secretion
MA55283A (fr) 2019-03-14 2022-01-19 Janssen Biotech Inc Procédés de production de compositions d'anticorps anti-tnf
CN113840837A (zh) 2019-03-14 2021-12-24 詹森生物科技公司 用于产生抗tnf抗体组合物的方法
EP3938397A1 (de) 2019-03-14 2022-01-19 Biond Biologics Ltd. Mittel zur blockierung von kleinen freisetzungen
KR20210141990A (ko) 2019-03-14 2021-11-23 얀센 바이오테크 인코포레이티드 항-il12/il23 항체 조성물을 생성하기 위한 제조 방법
MA55296A (fr) 2019-03-14 2022-03-23 Hoffmann La Roche Traitement du cancer avec des anticorps bispécifiques de her2xcd3 en combinaison avec un mab anti-her2
WO2020183011A1 (en) 2019-03-14 2020-09-17 Institut Curie Htr1d inhibitors and uses thereof in the treatment of cancer
EP3938390A1 (de) 2019-03-14 2022-01-19 Janssen Biotech, Inc. Herstellungsverfahren zur herstellung von anti-tnf-antikörperzusammensetzungen
US11541086B2 (en) 2019-03-14 2023-01-03 Northwestern Univeristy Compositions and methods for treating Alzheimer's disease
CN113631560B (zh) 2019-03-15 2025-02-18 麦迪穆有限责任公司 氮杂环丁烷并苯并二氮杂䓬二聚体和用于治疗癌症的包含它们的缀合物
MX2021011328A (es) 2019-03-18 2021-12-10 Janssen Biotech Inc Método para tratar la psoriasis en sujetos pediátricos con anticuerpo anti-il12/il23.
IL286467B2 (en) 2019-03-18 2026-02-01 Janssen Pharmaceuticals Inc Methods for producing bioconjugates of polysaccharides E. coli o-antigen, preparations thereof and methods for using them
CR20210522A (es) 2019-03-18 2021-12-17 Janssen Pharmaceuticals Inc Bioconjugados de antígenos–polisacáridos de e. coli, métodos de producción y métodos de utilización de los mismos
JP7601758B2 (ja) 2019-03-19 2024-12-17 中外製薬株式会社 Ｍｔａ依存的に抗原に対する結合活性が変化する抗原結合ドメインを含む抗原結合分子及び当該抗原結合ドメイン取得用ライブラリ
CN113661176B (zh) 2019-03-19 2025-02-18 阿尔伯特爱因斯坦医学院 用于预防和治疗单纯疱疹病毒感染的单克隆抗体
JP2022525149A (ja) 2019-03-20 2022-05-11 スミトモ ダイニッポン ファーマ オンコロジー， インコーポレイテッド ベネトクラクスが失敗した急性骨髄性白血病（ａｍｌ）の処置
SG11202109932WA (en) 2019-03-20 2021-10-28 Imcheck Therapeutics Sas Antibodies having specificity for btn2 and uses thereof
CA3130701A1 (en) 2019-03-21 2020-09-24 Yajin Ni Methods for enhancing tcr.alpha..beta.+cell depletion efficiency
EP3941941A1 (de) 2019-03-22 2022-01-26 Regeneron Pharmaceuticals, Inc. Multispezifische egfr-x-cd28-antikörper
EP3942026A1 (de) 2019-03-22 2022-01-26 Université de Paris Neue inhibitoren der lrrk2/pp1-interaktion
AU2020247119A1 (en) 2019-03-25 2021-09-23 Max-Delbrück-Centrum Für Molekulare Medizin In Der Helmholtz-Gemeinschaft Enhancement of cytolytic T-cell activity by inhibiting EBAG9
EP3947446A1 (de) 2019-03-25 2022-02-09 INSERM (Institut National de la Santé et de la Recherche Médicale) Behandlung von tauopathie-erkrankungen durch abzielen auf neue tau-spezies
WO2020193718A1 (en) 2019-03-27 2020-10-01 INSERM (Institut National de la Santé et de la Recherche Médicale) Recombinant proteins with cd40 activating properties
JP2022525275A (ja) 2019-03-28 2022-05-12 エービー ストゥーディオ インコーポレイテッド ヘテロ多量体タンパク質及びその使用法
WO2020194317A1 (en) 2019-03-28 2020-10-01 Yeda Research And Development Co. Ltd. Method of treating lipid-related disorders
WO2020198731A2 (en) 2019-03-28 2020-10-01 Danisco Us Inc Engineered antibodies
PH12021552414A1 (en) 2019-03-29 2022-07-25 Atarga Llc Anti fgf23 antibody
KR20240104214A (ko) 2019-03-29 2024-07-04 메디뮨 리미티드 화합물 및 이의 접합체
KR102829207B1 (ko) 2019-03-29 2025-07-02 브리스톨-마이어스 스큅 컴퍼니 크로마토그래피 수지의 소수성을 측정하는 방법
WO2020201073A1 (en) 2019-03-29 2020-10-08 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods for the treatment of keloid, hypertrophic scars and/or hyperpigmentation disorders
WO2020205716A1 (en) 2019-04-01 2020-10-08 Genentech, Inc. Compositions and methods for stabilizing protein-containing formulations
WO2020201362A2 (en) 2019-04-02 2020-10-08 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods of predicting and preventing cancer in patients having premalignant lesions
GB201904717D0 (en) 2019-04-03 2019-05-15 Univ London Queen Mary Treatment and diagnosis of mental disorders
PL3946377T3 (pl) 2019-04-03 2026-04-20 Orega Biotech Terapie skojarzone oparte na inhibitorach pd1 i il-17b
JP7575401B2 (ja) 2019-04-03 2024-10-29 ジェンザイム・コーポレーション 断片化が低減した抗アルファベータｔｃｒ結合ポリペプチド
TWI862565B (zh) 2019-04-04 2024-11-21 日商小野藥品工業股份有限公司 雙特異性抗體
US20220249458A1 (en) 2019-04-04 2022-08-11 Bayer Aktiengesellschaft Agonists Of Adiponectin
CA3133654A1 (en) 2019-04-05 2020-10-08 Teneobio, Inc. Heavy chain antibodies binding to psma
CN113993534A (zh) 2019-04-09 2022-01-28 特殊外科医院 针对iRhom2的蛋白结合物
MX2021012171A (es) 2019-04-09 2021-12-10 Abcuro Inc Anticuerpos reductores del miembro 1 de la subfamilia g de receptores similares a la lectina de linfocitos citoliticos (klrg1).
CN114072505B (zh) 2019-04-11 2023-05-30 香港大学 核酸mazzocchio及其制造和使用方法
WO2020210805A1 (en) 2019-04-11 2020-10-15 The Johns Hopkins University Nanoparticles for drug delivery to brain
GB2597416A (en) 2019-04-12 2022-01-26 Geltor Inc Recombinant elastin and production thereof
CA3136602A1 (en) 2019-04-15 2020-10-22 Qwixel Therapeutics Llc Fusion protein composition(s) comprising targeted masked type i interferons (ifna and ifnb) and an antibody against tumor antigen, for use in the treatment of cancer
EP3957652A4 (de) 2019-04-16 2023-06-21 Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. Anti-fxi/fxia-antikörper und dessen verwendung
EP3956046A1 (de) 2019-04-17 2022-02-23 Bristol-Myers Squibb Company Verfahren zur regenerierung von chromatografieharzen
AU2020259884A1 (en) 2019-04-17 2021-10-07 Chugai Seiyaku Kabushiki Kaisha Therapeutic agent for urological cancer which is characterized by being administered with il-6 inhibitor and ccr2 inhibitor in combination
CA3133909A1 (en) 2019-04-18 2020-10-22 Elpida TSIKA Novel molecules for therapy and diagnosis
JP7813582B2 (ja) 2019-04-18 2026-02-13 ジェネンテック， インコーポレイテッド 抗体力価試験
EP3725370A1 (de) 2019-04-19 2020-10-21 ImmunoBrain Checkpoint, Inc. Modifizierte anti-pd-l1-antikörper und verfahren und verwendungen zur behandlung einer neurodegenerativen erkrankung
KR20220002967A (ko) 2019-04-19 2022-01-07 제넨테크, 인크. 항 mertk 항체 및 이의 사용 방법
JPWO2020213724A1 (de) 2019-04-19 2020-10-22
RU2734432C1 (ru) 2019-04-23 2020-10-16 Закрытое Акционерное Общество "Биокад" Моноклональное антитело, которое специфически связывается с GITR
WO2020216947A1 (en) 2019-04-24 2020-10-29 Heidelberg Pharma Research Gmbh Amatoxin antibody-drug conjugates and uses thereof
EP3959305A1 (de) 2019-04-26 2022-03-02 Allogene Therapeutics, Inc. Verfahren zur herstellung allogener car-t-zellen
US12629394B2 (en) 2019-04-29 2026-05-19 The Broad Institute, Inc. Atlas of Choroid Plexus cell types and therapeutic and diagnostic uses thereof
JP7711945B2 (ja) 2019-04-30 2025-07-23 センティ バイオサイエンシズ インコーポレイテッド キメラ受容体及びその使用方法
US20220289854A1 (en) 2019-04-30 2022-09-15 Dana-Farber Cancer Institute, Inc. Methods for treating cancer using combinations of anti-cx3cr1 and immune checkpoint blockade agents
US20220220565A1 (en) 2019-04-30 2022-07-14 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and compositions for treating melanoma
CA3138566A1 (en) 2019-04-30 2020-11-05 Larimar Therapeutics, Inc. Frataxin-sensitive markers for determining effectiveness of frataxin replacement therapy
US20220226496A1 (en) 2019-05-02 2022-07-21 Legochem Biosciences, Inc. Ligand-drug conjugate including linker having tris structure
MX2021013222A (es) 2019-05-03 2022-01-06 Genentech Inc Metodos para tratar el cancer con un anticuerpo anti-pd-l1.
CN113966344A (zh) 2019-05-03 2022-01-21 细胞基因公司 抗-bcma抗体结合物、包含其的组合物及其制备及使用方法
US20220362394A1 (en) 2019-05-03 2022-11-17 Sutro Biopharma, Inc. Anti-bcma antibody conjugates
AU2020268896B2 (en) 2019-05-03 2024-11-28 F. Hoffmann-La Roche Ag Methods of reducing the enzymatic hydrolysis activity rate in a composition obtained from a purification platform
KR20220004751A (ko) 2019-05-04 2022-01-11 인히브릭스, 인크. CLEC12a 결합 폴리펩타이드 및 이의 용도
CN114040926B (zh) 2019-05-04 2025-07-29 印希比生物科学有限公司 结合cd123的多肽及其用途
EP3966245A1 (de) 2019-05-04 2022-03-16 Inhibrx, Inc. Cd33-bindende polypeptide und verwendungen davon
GB201906578D0 (en) 2019-05-09 2019-06-26 Cancer Research Tech Ltd Detection of fusion protein
KR20220005568A (ko) 2019-05-09 2022-01-13 제넨테크, 인크. 항체의 제조 방법
MX2021013671A (es) 2019-05-09 2021-12-10 Boehringer Ingelheim Int Anticuerpos anti-sema3a y sus usos para tratar enfermedades oculares.
WO2020231954A1 (en) 2019-05-10 2020-11-19 The University Of North Carolina At Chapel Hill Office Of Technology Commercialization Methods, systems, and computer readable media for generating images of microvasculature using ultrasound
TWI925817B (zh) 2019-05-10 2026-05-21 日商武田藥品工業股份有限公司 抗體藥物結合物
BR112021022815A2 (pt) 2019-05-14 2021-12-28 Genentech Inc Métodos para tratar linfoma folicular, kits, imunoconjugados e polatuzumabe vedotina
WO2020232303A1 (en) 2019-05-14 2020-11-19 Harpoon Therapeutics, Inc. EpCAM BINDING PROTEINS AND METHODS OF USE
BR112021022666A2 (pt) 2019-05-14 2022-03-29 Werewolf Therapeutics Inc Frações de separação e seus métodos e uso
CA3137649A1 (en) 2019-05-15 2020-11-19 Chugai Seiyaku Kabushiki Kaisha An antigen-binding molecule, a pharmaceutical composition, and a method
AU2020275142A1 (en) 2019-05-15 2021-12-16 Neotx Therapeutics Ltd. Cancer treatment
JP2022532381A (ja) 2019-05-16 2022-07-14 プロサイセデクス インコーポレイティド Ｖｃａｍ－１及びカルプロテクチンのための分析検出方法
JP2022532385A (ja) 2019-05-16 2022-07-14 プロサイセデクス インコーポレイティド 血中のＶＣＡＭ－１及びα２－マクログロブリンの検出のためのアッセイ方法
AU2020279979A1 (en) 2019-05-20 2021-11-25 Les Laboratoires Servier Mcl-1 inhibitor antibody-drug conjugates and methods of use
CA3135592A1 (en) 2019-05-20 2020-11-26 Xiaochao Ma Therapeutic agents for erythropoietic protoporphyria (epp) and x-linked protoporphyria (xlp)
CN114630838A (zh) 2019-05-20 2022-06-14 法国国家健康和医学研究院 新的抗cd25抗体
US20220240808A1 (en) 2019-05-20 2022-08-04 Albert-Ludwigs-Universitat Freiburg Disposable wearable sensor for continuous monitoring of breath biochemistry
UY38701A (es) 2019-05-21 2020-12-31 Novartis Ag Moléculas de unión a cd19, conjugados, composiciones que las comprenden y usos de las mismas
US12037378B2 (en) 2019-05-21 2024-07-16 Novartis Ag Variant CD58 domains and uses thereof
EP3972690A4 (de) 2019-05-23 2023-07-05 Janssen Biotech, Inc. Verfahren zur behandlung einer entzündlichen darmerkrankung mit einer kombinationstherapie von antikörpern gegen il-23 und tnf-alpha
CN114008073B (zh) 2019-05-23 2025-08-12 Ac免疫有限公司 抗tdp-43结合分子及其用途
WO2020234632A1 (en) 2019-05-23 2020-11-26 Ichorlabs, D.O.O Method for removal of nucleic acids impurities from liquid composition comprising genetically engineered particles or proteins
US20200369759A1 (en) 2019-05-23 2020-11-26 Fibrogen, Inc. Methods of treatment of muscular dystrophies
JP7607289B2 (ja) 2019-05-23 2024-12-27 シァメン・ユニヴァーシティ 新規の抗ｂ型肝炎ウイルス抗体及びその使用
JP2022534227A (ja) 2019-05-23 2022-07-28 プロサイセデクス インコーポレイティド ヒト血清アルブミン、ビタミンｄ、ｃ反応性タンパク質、及び抗トランスグルタミナーゼ自己抗体の検出のためのアッセイ方法
WO2020240360A1 (en) 2019-05-24 2020-12-03 Pfizer Inc. Combination therapies using cdk inhibitors
US20220241412A1 (en) 2019-05-24 2022-08-04 Pfizer Inc. Combination therapies using cdk inhibitors
TWI883004B (zh) 2019-05-24 2025-05-11 法商賽諾菲公司 治療全身性硬化症之方法
WO2020243021A2 (en) 2019-05-24 2020-12-03 Foundation Medicine, Inc. Ntrk fusion molecules and uses thereof
WO2020237491A1 (en) 2019-05-28 2020-12-03 Shanghaitech University Composition and methods to treat ectodermal dysplasia 2, clouston type
ES3041245T3 (en) 2019-05-30 2025-11-11 Viti Inc Methods for detecting a mycobacterium tuberculosis infection
MA56026A (fr) 2019-06-03 2022-04-06 Janssen Biotech Inc Anticorps anti-tnf, compositions et méthodes pour le traitement de la spondylarthrite ankylosante active
JP2022536279A (ja) 2019-06-03 2022-08-15 ヤンセン バイオテツク，インコーポレーテツド 乾癬性関節炎を治療するための抗ｔｎｆ抗体組成物及び方法
CN114206355A (zh) 2019-06-03 2022-03-18 芝加哥大学 用靶向癌症的佐剂治疗癌症的方法和组合物
US20200385453A1 (en) 2019-06-04 2020-12-10 Janssen Biotech, Inc. Safe and Effective Method of Treating Psoriatic Arthritis with Anti-IL23 Specific Antibody
AR119264A1 (es) 2019-06-05 2021-12-09 Genentech Inc Método para reutilización de cromatografía
WO2020247054A1 (en) 2019-06-05 2020-12-10 Massachusetts Institute Of Technology Compounds, conjugates, and compositions of epipolythiodiketopiperazines and polythiodiketopiperazines and uses thereof
JP2022535125A (ja) 2019-06-06 2022-08-04 プロサイセデクス インコーポレイティド 血中ヘモグロビンＡ１Ｃ（ＨｂＡ１ｃ）の検出
GB201908128D0 (en) 2019-06-07 2019-07-24 Adc Therapeutics Sa Pyrrolobenzodiazepine-antibody conjugates
JP2022536140A (ja) 2019-06-10 2022-08-12 アーデーセー セラピューティクス ソシエテ アノニム 併用療法
EP3980423A1 (de) 2019-06-10 2022-04-13 Sutro Biopharma, Inc. 5h-pyrrolo[3,2-d]pyrimidin-2,4-diaminverbindungen und ihre antikörper-konjugate
SG11202113092WA (en) 2019-06-10 2021-12-30 Adc Therapeutics Sa Combination therapy comprising an anti-cd19 antibody drug conjugate and a pi3k inhibitor or a secondary agent
US11246906B2 (en) 2019-06-11 2022-02-15 Alkermes Pharma Ireland Limited Compositions and methods for subcutaneous administration of cancer immunotherapy
TWI877170B (zh) 2019-06-11 2025-03-21 美商阿列克特有限責任公司 抗揀選蛋白抗體之使用方法
US20220226269A1 (en) 2019-06-12 2022-07-21 President And Fellows Of Harvard College Methods and compositions for modulation of an interspecies gut bacterial pathway for levodopa metabolism
PH12021553101A1 (en) 2019-06-12 2023-10-02 Novartis Ag Natriuretic peptide receptor 1 antibodies and methods of use
US20220259547A1 (en) 2019-06-13 2022-08-18 Amgeng Inc. Automated biomass-based perfusion control in the manufacturing of biologics
CN114206927B (zh) 2019-06-14 2025-03-21 特尼奥生物股份有限公司 与cd22和cd3结合的多特异性重链抗体
CA3141926A1 (en) 2019-06-14 2020-12-17 Dana-Farber Cancer Institute, Inc. Antibodies against muc1 and methods of use thereof
EP3983410A1 (de) 2019-06-17 2022-04-20 Sutro Biopharma, Inc. 1-(4-(aminomethyl)benzyl)-2-butyl-2h-pyrazolo[3,4-c]quinolin-4-aminderivate und verwandte verbindungen als toll-like- rezeptor (tlr) 7/8-agonisten sowie antikörper-wirkstoff-konjugate davon zur verwendung in der krebstherapie und -diagnose
BR112021025421A2 (pt) 2019-06-17 2022-02-01 Visterra Inc Moléculas de anticorpo humanizado para cd138 e os usos dos mesmos
US12384832B2 (en) 2019-06-19 2025-08-12 Christopher Oelkrug Antibody-mediated neutralization of beta-lactamases
KR20220044490A (ko) 2019-06-21 2022-04-08 백시넥스 인코포레이티드 세마포린-4d 차단(sema4d) 및 dc1 요법을 사용한 조합 요법
IL267614A (en) 2019-06-24 2019-09-26 Lotem Michal Nucleic acids to modulate SLAMF6 isoforms
US11905532B2 (en) 2019-06-25 2024-02-20 Massachusetts Institute Of Technology Compositions and methods for molecular memory storage and retrieval
GB201909135D0 (en) 2019-06-25 2019-08-07 Institute Of Cancer Res Royal Cancer Hospital Means and methods for treating cancer
EP4245862B1 (de) 2019-06-25 2025-01-15 Actome GmbH Verfahren und kit zur messung von analyten in zweikomponentensystemen und deren verwendung
EP3990922A1 (de) 2019-06-25 2022-05-04 ProciseDx Inc. Nachweis von anti-tnf-alpha biologika und anti-wirkstoff-antikörpern
MX2021015823A (es) 2019-06-26 2022-02-03 Hoffmann La Roche Lineas celulares de mamifero con inactivacion del gen sirtuina-1 (sirt-1).
WO2020264200A1 (en) 2019-06-26 2020-12-30 Amunix Pharmceuticals, Inc. Cd3 antigen binding fragments and compositions comprising same
JP2022538974A (ja) 2019-06-26 2022-09-07 マサチューセッツ インスチテュート オブ テクノロジー 免疫調節融合タンパク質－金属水酸化物錯体およびその方法
TWI877179B (zh) 2019-06-27 2025-03-21 德商百靈佳殷格翰國際股份有限公司 抗-angpt2抗體
BR112021025806A2 (pt) 2019-06-28 2022-02-08 Hoffmann La Roche Métodos para produzir um anticorpo da subclasse igg1 humana cultivando uma célula cho e uso da remoção de sítios de splice de doador não pareados em uma parte de uma sequência de ácido nucleico de humano ou hamster
WO2020264384A1 (en) 2019-06-28 2020-12-30 Amgen Inc. Anti-cgrp receptor/anti-pac1 receptor bispecific antigen binding proteins
IL289219B2 (en) 2019-06-28 2025-06-01 Genentech Inc Composition and methods for stabilizing liquid protein formulations
GB201909393D0 (en) 2019-06-28 2019-08-14 Gen2 Neuroscience Ltd Tau epitope and binding molecules
DK3993876T3 (en) 2019-07-01 2024-12-02 Tonix Pharma Ltd Anti-cd154 antibodies and uses thereof
JP7604401B2 (ja) 2019-07-03 2024-12-23 オックスフォード バイオセラピューティックス リミテッド 抗体および使用方法
GB2585252A (en) 2019-07-05 2021-01-06 Gen2 Neuroscience Ltd Tau epitope and binding molecules
JP6881658B2 (ja) 2019-07-05 2021-06-02 小野薬品工業株式会社 Ｐｄ−１／ｃｄ３二重特異性タンパク質による血液がん治療
EP3998280A4 (de) 2019-07-08 2023-06-21 TERUMO Kabushiki Kaisha Hybridom und verfahren zu seiner herstellung sowie monoklonaler antikörper und verfahren zu seiner herstellung
CA3145385A1 (en) 2019-07-08 2021-01-14 Steven D. Goodman Antibody compositions for disrupting biofilms
JP7658946B2 (ja) 2019-07-08 2025-04-08 インケア バイオテック， エルエルシー カザール型抗セリンプロテアーゼ阻害因子（ｓｐｉｋ）抗体、免疫複合体、及び使用方法
EP3997121A4 (de) 2019-07-09 2024-03-27 Beijing SoloBio Genetechnology Company Ltd. Antikörper, die spezifisch pseudomonas pcrv erkennen, und deren verwendungen
JP7359864B2 (ja) 2019-07-10 2023-10-11 中外製薬株式会社 クローディン６結合分子およびその使用
WO2021005232A1 (en) 2019-07-11 2021-01-14 Umc Utrecht Holding B.V. Intranasal administration of neutralising antiviral antibodies
EP3998286A4 (de) 2019-07-11 2023-04-26 Wuhan Yzy Biopharma Co., Ltd. Vierwertiger symmetrischer bispezifischer antikörper
AR119382A1 (es) 2019-07-12 2021-12-15 Hoffmann La Roche Anticuerpos de pre-direccionamiento y métodos de uso
WO2021010326A1 (ja) 2019-07-12 2021-01-21 中外製薬株式会社 抗変異型ｆｇｆｒ３抗体およびその使用
AR119393A1 (es) 2019-07-15 2021-12-15 Hoffmann La Roche Anticuerpos que se unen a nkg2d
CA3146986A1 (en) 2019-07-15 2021-01-21 Shanghai Junshi Biosciences Co., Ltd. Anti-tigit antibodies and application thereof
US20220267416A1 (en) 2019-07-15 2022-08-25 Lausanne University Hospital Hiv binding agents
AU2020312686B2 (en) 2019-07-15 2026-07-30 Intervet International B.V. Caninized antibodies against canine CTLA-4
IL268111A (en) 2019-07-16 2021-01-31 Fainzilber Michael Methods of treating pain
WO2021009263A1 (en) 2019-07-16 2021-01-21 INSERM (Institut National de la Santé et de la Recherche Médicale) Antibodies having specificity for cd38 and uses thereof
US12668621B2 (en) 2019-07-16 2026-06-30 Ramot At Tel-Aviv University Ltd. Compositions and methods for the treatment of tuberculosis
EP4001312A4 (de) 2019-07-18 2023-08-16 JW Bioscience Spezifisch an wrs-protein bindende antikörper und verwendung davon
KR102478445B1 (ko) 2019-07-18 2022-12-20 주식회사 큐어바이오테라퓨틱스 Wrs 단백질에 특이적으로 결합하는 항체 및 이의 용도
JP2022541538A (ja) 2019-07-19 2022-09-26 ザ・チルドレンズ・ホスピタル・オブ・フィラデルフィア グリピカン２結合ドメインを含有するキメラ抗原受容体
WO2021013693A1 (en) 2019-07-23 2021-01-28 Bayer Pharma Aktiengesellschaft Antibody drug conjugates (adcs) with nampt inhibitors
EP4004018A1 (de) 2019-07-24 2022-06-01 GlaxoSmithKline Biologicals SA Modifizierte humane cytomegalovirus-proteine
BR112021005478A2 (pt) 2019-07-24 2021-06-15 H. Lundbeck A/S anticorpos anti-mglur5 e uso dos mesmos
KR20220044753A (ko) 2019-07-25 2022-04-11 큐라데브 파마 프라이버트 리미티드 아세틸 조효소 a 신테타제 단쇄 2(acss2)의 소분자 억제제
EP4004037A1 (de) 2019-07-26 2022-06-01 Vanderbilt University Humane monoklonale antikörper gegen enterovirus d68
EP4004041A1 (de) 2019-07-26 2022-06-01 Amgen Inc. Anti-il13-antigenbindende proteine
PH12022550165A1 (en) 2019-07-26 2023-05-08 Visterra Inc Interleukin-2 agents and uses thereof
CN112300279A (zh) 2019-07-26 2021-02-02 上海复宏汉霖生物技术股份有限公司 针对抗cd73抗体和变体的方法和组合物
EP4004548B1 (de) 2019-07-29 2026-01-14 Yeda Research and Development Co. Ltd Verfahren zur behandlung und diagnose von lungenkrebs
CN120842421A (zh) 2019-07-30 2025-10-28 魁尔斯弗生物治疗股份有限公司 双特异性抗LRRC15和CD3ε抗体
CA3149309A1 (en) 2019-07-30 2021-02-04 Ono Pharmaceutical Co., Ltd. Bispecific antibody
AU2020320910A1 (en) 2019-07-30 2022-03-10 Akeso Biopharma, Inc. Anti-human p40 protein domain antibody and use thereof
PH12022550239A1 (en) 2019-07-31 2022-12-19 Alector Llc Anti-ms4a4a antibodies and methods of use thereof
GB201910899D0 (en) 2019-07-31 2019-09-11 Scancell Ltd Binding members
US20220281967A1 (en) 2019-08-02 2022-09-08 Orega Biotech Novel il-17b antibodies
WO2021023644A1 (en) 2019-08-02 2021-02-11 INSERM (Institut National de la Santé et de la Recherche Médicale) Neutralizing granzyme b for providing cardioprotection in a subject who experienced a myocardial infarction
CA3146474A1 (en) 2019-08-02 2021-02-11 Denis BURGER Methods for treating or preventing cancers involving the administration of anti-ccr5 receptor agents
EP4008730A4 (de) 2019-08-02 2023-09-06 Akeso Pharmaceuticals, Inc. Anti-ctla4-anti-pd-bispezifischer antikörper und verwendungen davon
BR112022002028A2 (pt) 2019-08-02 2022-04-12 Cttq Akeso Shanghai Biomed Tech Co Ltd Anticorpo anti-pd-1 e uso farmacêutico do mesmo
TWI832183B (zh) 2019-08-06 2024-02-11 香港商新旭生技股份有限公司 結合至病理性tau種類之抗體及其用途
EP4031658A1 (de) 2019-08-07 2022-07-27 DB Biotech, AS Verbesserte meerrettichperoxidase-polypeptide
WO2021025140A1 (ja) 2019-08-08 2021-02-11 小野薬品工業株式会社 二重特異性タンパク質
MX2022001841A (es) 2019-08-12 2022-08-17 Biond Biologics Ltd Anticuerpos contra ilt2 y uso de los mismos.
CN114127121B (zh) 2019-08-12 2025-04-11 北京恩瑞尼生物科技股份有限公司 用于通过cd39表达细胞的adcc靶向促进和增强t细胞介导的免疫反应的方法和组合物
CN114502583A (zh) 2019-08-12 2022-05-13 杰特创新股份有限公司 补体c2结合蛋白及其用途
WO2021028752A1 (en) 2019-08-15 2021-02-18 Janssen Biotech, Inc. Anti-tfn antibodies for treating type i diabetes
WO2021034639A1 (en) 2019-08-16 2021-02-25 Regeneron Pharmaceuticals, Inc. High concentration anti-c5 formulations
WO2021035170A1 (en) 2019-08-21 2021-02-25 Precision Biosciences, Inc. Compositions and methods for tcr reprogramming using fusion proteins
US20240140988A1 (en) 2019-08-22 2024-05-02 Ariel Scientific Innovations Ltd. Scaled-up methods for purifying antibodies
GB201912059D0 (en) 2019-08-22 2019-10-09 Bergenbio As Combaination therapy of a patient subgroup
CN114585644A (zh) 2019-08-30 2022-06-03 艾吉纳斯公司 抗cd96抗体及其使用方法
EP4021581A4 (de) 2019-08-30 2023-08-30 Foundation Medicine, Inc. Kmt2a-maml2-fusionsmoleküle und verwendungen davon
GB201912657D0 (en) 2019-09-03 2019-10-16 Scancell Ltd Binding members
WO2021042166A1 (en) 2019-09-03 2021-03-11 Envision Sciences Pty Ltd Methods for confirming detection and evaluating the progression of a prostate cancer and related therapies
EP3789401A1 (de) 2019-09-03 2021-03-10 Gamamabs Pharma Amhrii-bindende antikörperarzneimittelkonjugate und deren verwendung bei der behandlung von krebserkrankungen
JP7808546B2 (ja) 2019-09-03 2026-01-29 中山康方生物医▲藥▼有限公司 抗ｃｄ４７モノクローナル抗体及びその使用
CN117683133A (zh) 2019-09-03 2024-03-12 百奥泰生物制药股份有限公司 一种抗tigit免疫抑制剂及应用
TW202519557A (zh) 2019-09-04 2025-05-16 美商建南德克公司 Cd8 結合劑及其用途
US12460009B2 (en) 2019-09-04 2025-11-04 Inserm (Institut National De La Sante Et De La Recherche Medicale) Monoclonal antibodies specific for IL20-Rb, encoding nucleic acids thereof and methods of use thereof to treat bacterial-induced exacerbation of chronic obstructive pulmonary disease
WO2021044009A1 (en) 2019-09-04 2021-03-11 Deutsches Zentrum Für Neurodegenerative Erkrankungen E.V. (Dzne) Herv inhibitors for use in treating tauopathies
JP2022548530A (ja) 2019-09-05 2022-11-21 ファルマ、マール、ソシエダード、アノニマ 薬物抗体コンジュゲート
CN114929743B (zh) 2019-09-05 2026-01-02 纪念斯隆凯特琳癌症中心 抗steap1抗体及其用途
GB201912882D0 (en) 2019-09-06 2019-10-23 Scancell Ltd Ssea-4 binding members
TW202535466A (zh) 2019-09-09 2025-09-16 德商百靈佳殷格翰國際股份有限公司 抗-il-23p19抗體調配物
US20220306741A1 (en) 2019-09-10 2022-09-29 Amgen Inc. Purification Method for Bispecific antigen-binding Polypeptides with Enhanced Protein L Capture Dynamic Binding Capacity
WO2021048359A1 (en) 2019-09-11 2021-03-18 Bausch Health Ireland Limited Methods of treating nonalcoholic fatty liver disease (nafld) using il-17ra antibody
WO2021048292A1 (en) 2019-09-11 2021-03-18 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and compositions for treating melanoma
KR20220080098A (ko) 2019-09-11 2022-06-14 아임케어 바이오테크, 엘엘씨. 항-세린 프로테아제 억제제 카잘(spik) 항체의 에피토프
WO2021048852A1 (en) 2019-09-11 2021-03-18 Yeda Research And Development Co. Ltd. Methods of treating breast cancer
ES3064633T3 (en) 2019-09-12 2026-04-28 Hoffmann La Roche Compositions and methods of treating lupus nephritis
EP3792632A1 (de) 2019-09-16 2021-03-17 Vito NV Immuntherapiemarker
US20220324957A1 (en) 2019-09-16 2022-10-13 Opsidio, LLC Anti-stem cell factor antibodies and methods of use thereof in renal disease
AU2020347827A1 (en) 2019-09-17 2022-05-05 Merck Patent Gmbh Camphorsulfonic acid and combinations thereof with cationic excipients as viscosity reducing agents in high concentrated protein formulations
JP2022548881A (ja) 2019-09-18 2022-11-22 ノバルティス アーゲー Ｅｎｔｐｄ２抗体、組合せ療法並びに抗体及び組合せ療法を使用する方法
WO2021055816A1 (en) 2019-09-18 2021-03-25 Molecular Templates, Inc. Pd-l1 binding molecules comprising shiga toxin a subunit scaffolds
TW202124446A (zh) 2019-09-18 2021-07-01 瑞士商諾華公司 與ｅｎｔｐｄ２抗體之組合療法
AU2020349509A1 (en) 2019-09-18 2022-03-31 Genentech, Inc. Anti-KLK7 antibodies, anti-KLK5 antibodies, multispecific anti-KLK5/KLK7 antibodies, and methods of use
AU2020348876A1 (en) 2019-09-19 2022-04-07 Seagen Inc. Selective drug release from internalized conjugates of biologically active compounds
MX2022003266A (es) 2019-09-20 2022-04-11 Genentech Inc Dosis para anticuerpos anti-triptasa.
WO2021054778A1 (ko) 2019-09-20 2021-03-25 경북대학교 산학협력단 Cox2 단백질의 아세틸화 검출용 항체 및 이의 용도
TWI859339B (zh) 2019-09-24 2024-10-21 德商百靈佳殷格翰國際股份有限公司 抗nrp1a抗體及其用於治療眼或眼部疾病之用途
CN114450324B (zh) 2019-09-26 2024-02-27 日油株式会社 具有肽连接子的异双官能单分散聚乙二醇
KR20220088428A (ko) 2019-09-26 2022-06-27 주식회사 에스티큐브앤컴퍼니 글리코실화된 ctla-4에 대해 특이적인 항체 및 이의 사용 방법
AU2020351734A1 (en) 2019-09-27 2022-04-14 Genentech, Inc. Dosing for treatment with anti-TIGIT and anti-PD-L1 antagonist antibodies
WO2021058729A1 (en) 2019-09-27 2021-04-01 INSERM (Institut National de la Santé et de la Recherche Médicale) Anti-müllerian inhibiting substance type i receptor antibodies and uses thereof
CN114746119A (zh) 2019-09-27 2022-07-12 詹森生物科技公司 抗-ceacam抗体及其用途
US12590171B2 (en) 2019-09-27 2026-03-31 Nanjing GenScript Biotech Co., Ltd. Anti-VHH domain antibodies and use thereof
US12441788B2 (en) 2019-09-27 2025-10-14 Inserm (Institut National De La Sante Et De La Recherche Medicale) Anti-müllerian inhibiting substance antibodies and uses thereof
WO2021058744A1 (en) 2019-09-27 2021-04-01 INSERM (Institut National de la Santé et de la Recherche Médicale) Use of müllerian inhibiting substance inhibitors for treating cancer
CA3155669A1 (en) 2019-09-27 2021-04-01 Pfizer Inc. Neisseria meningitidis compositions and methods thereof
CA3155930A1 (en) 2019-09-27 2021-04-01 Starkage Therapeutics Senescent cell-associated antigen-binding domains, antibodies and chimeric antigen receptors comprising the same, and uses thereof
CN114206931B (zh) 2019-09-30 2024-06-04 四川科伦博泰生物医药股份有限公司 抗pd-1抗体及其用途
WO2021063968A1 (en) 2019-09-30 2021-04-08 INSERM (Institut National de la Santé et de la Recherche Médicale) Method and composition for diagnosing chronic obstructive pulmonary disease
WO2021064009A1 (en) 2019-09-30 2021-04-08 Scirhom Gmbh Protein binders to irhom2 epitopes
AU2020358898B2 (en) 2019-10-01 2025-10-16 Epsilogen Ltd Hybrid antibody
EP3800201A1 (de) 2019-10-01 2021-04-07 INSERM (Institut National de la Santé et de la Recherche Médicale) Cd28h-stimulierung verbessert nk-zellen-abtötungsaktivitäten
EP4038222A4 (de) 2019-10-02 2023-10-18 Arizona Board of Regents on behalf of Arizona State University Verfahren und zusammensetzungen zur identifizierung von neoantigenen zur verwendung bei der behandlung und vorbeugung von krebs
EP4037714A1 (de) 2019-10-03 2022-08-10 INSERM (Institut National de la Santé et de la Recherche Médicale) Verfahren und zusammensetzungen zur modulation von makrophagen-polarisation
KR20220079606A (ko) 2019-10-04 2022-06-13 씨젠 인크. 캄프토테신 펩티드 접합체
KR20220079590A (ko) 2019-10-04 2022-06-13 티에이이 라이프 사이언시스 Fc 돌연변이 및 부위-특이적인 접합 성질을 포함하는 항체 조성물
US20220363776A1 (en) 2019-10-04 2022-11-17 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and pharmaceutical composition for the treatment of ovarian cancer, breast cancer or pancreatic cancer
EP4037712A4 (de) 2019-10-04 2023-11-01 Albert Einstein College of Medicine Kir3dl3 ist ein hemmender rezeptor für das immunsystem und verwendungen davon
WO2021067820A1 (en) 2019-10-04 2021-04-08 Seagen Inc. Formulation of antibody-drug conjugate
CN114466861A (zh) 2019-10-04 2022-05-10 默克专利股份有限公司 蛋白a亲和色谱中单克隆抗体的洗脱
WO2021064079A1 (en) 2019-10-04 2021-04-08 Merck Patent Gmbh Purification of proteins and viral inactivation
EP4041889A1 (de) 2019-10-08 2022-08-17 Luxembourg Institute Of Health (LIH) Dj-1-hemmer zur verwendung bei der behandlung von immunalterung
KR20220082007A (ko) 2019-10-08 2022-06-16 넥틴 테라퓨틱스 리미티드 폴리오바이러스 수용체(pvr)에 대한 항체 및 이의 용도
KR20220088438A (ko) 2019-10-09 2022-06-27 주식회사 에스티큐브앤컴퍼니 글리코실화된 lag3에 대해 특이적인 항체 및 이의 사용 방법
PE20221413A1 (es) 2019-10-09 2022-09-20 Ose Immunotherapeutics Anticuerpos humanizados anti-receptor tipo quimiocina 1 y sus aplicaciones terapeuticas
EP3804754A1 (de) 2019-10-09 2021-04-14 OSE Immunotherapeutics Cmklr1-agonisten mit resolvin-e1-ähnlicher fähigkeit und ihre therapeutischen anwendungen
CA3157509A1 (en) 2019-10-10 2021-04-15 Kodiak Sciences Inc. Methods of treating an eye disorder
EP3808766A1 (de) 2019-10-15 2021-04-21 Sangamo Therapeutics France Interleukin-23-rezeptor-spezifischer chimärer antigen-rezeptor
CR20220166A (es) 2019-10-18 2022-06-15 Genentech Inc Métodos para usar inmunoconjugados anti-cd79b para tratar linfoma difuso de linfocitos b grandes
GB201915163D0 (en) 2019-10-18 2019-12-04 Univ Southampton Cancer vaccine
KR20220083773A (ko) 2019-10-18 2022-06-20 이뮤노믹 쎄라퓨틱스, 인크. 암 항원을 포함하는 개선된 lamp 구축물
US20210147525A1 (en) 2019-10-18 2021-05-20 The Regents Of The University Of California Methods and compositions for treating pathogenic blood vessel disorders
CN114786679A (zh) 2019-10-21 2022-07-22 诺华股份有限公司 具有维奈托克和tim-3抑制剂的组合疗法
WO2021079195A1 (en) 2019-10-21 2021-04-29 Novartis Ag Tim-3 inhibitors and uses thereof
CN114846030A (zh) 2019-10-23 2022-08-02 佛罗里达大学研究基金会公司 催化抗体38c2的新型缀合化学
EP3812008A1 (de) 2019-10-23 2021-04-28 Gamamabs Pharma Amh-kompetitiver antagonistischer antikörper
WO2021080608A1 (en) 2019-10-25 2021-04-29 Medimmune, Llc Branched moiety for use in conjugates
MX2022004712A (es) 2019-10-25 2022-08-04 Regeneron Pharma Regimenes de dosificacion para tratar o prevenir enfermedades asociadas a c5.
CA3158174A1 (en) 2019-10-28 2021-05-06 Monash University Antibodies for binding plasmin
UA129038C2 (uk) 2019-10-28 2024-12-25 Медіммуне Лімітед Сухий порошкоподібний склад антитіла, що зв'язує тимічний стромальний лімфопоетин (tslp)
WO2021086909A1 (en) 2019-10-29 2021-05-06 Eisai R&D Managment Co., Ltd. Combination of a pd-1 antagonist, a vegfr/fgfr/ret tyrosine kinase inhibitor and a cbp/beta-catenin inhibitor for treating cancer
US20230044248A1 (en) 2019-11-01 2023-02-09 Ares Trading S.A. COMBINED INHIBITION OF PD-1, TGFBeta AND ATM TOGETHER WITH RADIOTHERAPY FOR THE TREATMENT OF CANCER
JP7777524B2 (ja) 2019-11-04 2025-11-28 コード バイオセラピューティクス インコーポレイテッド 脳特異的血管新生抑制因子１（ｂａｉ１）抗体及びその使用
WO2021090146A1 (en) 2019-11-04 2021-05-14 Astrazeneca Ab Combination therapy for treating cancer
CN114787188A (zh) 2019-11-05 2022-07-22 震动疗法股份有限公司 用抗pd-1抗体治疗癌症的方法
US12527839B2 (en) 2019-11-05 2026-01-20 Acceleron Pharma Inc. Treatments for systemic sclerosis
US20230340122A1 (en) 2019-11-05 2023-10-26 Glaxosmithkline Intellectual Property (No. 4) Ltd. Combined inhibition of pd-1, tgfb and tigit for the treatment of cancer
CN114728171A (zh) 2019-11-05 2022-07-08 默克专利有限公司 抗tigit抗体及其应用
IL292458A (en) 2019-11-06 2022-06-01 Genentech Inc Diagnostic and treatment methods for the treatment of hematological cancer
WO2021090062A1 (en) 2019-11-07 2021-05-14 Eisai R&D Management Co., Ltd. Anti-mesothelin eribulin antibody-drug conjugates and methods of use
KR20220099990A (ko) 2019-11-07 2022-07-14 인3바이오 리미티드 비티로신 표적화 키나아제 억제제와 병용하여 성장 인자 항체를 사용하기 위한 방법 및 조성물
US20220396839A1 (en) 2019-11-12 2022-12-15 Foundation Medicine, Inc. Methods of detecting a fusion gene encoding a neoantigen
EP4058466A1 (de) 2019-11-13 2022-09-21 Amunix Pharmaceuticals, Inc. Strichcodierte xten-polypeptide und zusammensetzungen davon sowie verfahren zu ihrer herstellung und verwendung
WO2021097344A1 (en) 2019-11-13 2021-05-20 Amgen Inc. Method for reduced aggregate formation in downstream processing of bispecific antigen-binding molecules
BR112022009110A2 (pt) 2019-11-14 2022-07-26 Werewolf Therapeutics Inc Polipeptídeos de citocina ativáveis e métodos de uso destes
CN115151566A (zh) 2019-11-15 2022-10-04 普利安特治疗公司 用于活化整合素的组合物和方法
CN114641270A (zh) 2019-11-15 2022-06-17 豪夫迈·罗氏有限公司 防止水性蛋白质溶液中可见颗粒的形成
EP3825330A1 (de) 2019-11-19 2021-05-26 International-Drug-Development-Biotech Anti-cd117-antikörper und verfahren zur verwendung davon
BR112022009798A2 (pt) 2019-11-20 2022-10-18 Bavarian Nordic As Vírus mva recombinante para administração intratumoral e/ou intravenosa para tratamento de câncer
US11774451B2 (en) 2019-11-21 2023-10-03 The Board Of Trustees Of The Leland Stanford Junior University Molecular vibrational spectroscopic markers for detection of cancer
KR20220131895A (ko) 2019-11-21 2022-09-29 인쎄름 (엥스띠뛰 나씨오날 드 라 쌍떼 에 드 라 흐쉐르슈 메디깔) 항-pd-1/il-15 면역사이토카인을 이용하여 pd-1을 표적으로 하는 신규한 면역요법
US20230037414A1 (en) 2019-11-22 2023-02-09 INSERM (Institut National de la Santé et de la Recherche Médicale Inhibitors of adrenomedullin for the treatment of acute myeloid leukemia by eradicating leukemic stem cells
MX2022006330A (es) 2019-11-25 2022-08-17 Akeso Biopharma Inc Anticuerpo biespecífico anti-pd-1 anti-vegfa, composición farmacéutica y uso del mismo.
CN110894238B (zh) 2019-11-25 2021-01-19 华道(上海)生物医药有限公司 Car-t细胞的检测用单克隆抗体、试剂盒及应用
GB201917254D0 (en) 2019-11-27 2020-01-08 Adc Therapeutics Sa Combination therapy
JP7699389B2 (ja) 2019-12-04 2025-06-27 オメロス コーポレーション Ｍａｓｐ－２阻害剤および使用方法
BR112022010895A2 (pt) 2019-12-04 2022-09-06 Omeros Corp Composto, composição farmacêutica, e, método para tratar uma doença ou distúrbio associado à serina protease-2 associada à lectina de ligação ao manan
AU2020395306B2 (en) 2019-12-04 2025-04-24 Omeros Corporation MASP-2 inhibitors and methods of use
AU2020398216A1 (en) 2019-12-04 2022-06-30 The Board Of Trustees Of The Leland Stanford Junior University Enhancing blood-brain barrier drug transport by targeting endogenous regulators
EP4069301A1 (de) 2019-12-04 2022-10-12 Bayer Aktiengesellschaft Inhibitoren von shp2
CN115003699A (zh) 2019-12-05 2022-09-02 艾利妥 抗trem2抗体的使用方法
WO2021113596A2 (en) 2019-12-05 2021-06-10 Sorrento Therapeutics, Inc. Compositions and methods comprising an anti-cd47 antibody in combination with a tumor targeting antibody
WO2021113776A1 (en) 2019-12-06 2021-06-10 Juno Therapeutics, Inc. Anti-idiotypic antibodies to bcma-targeted binding domains and related compositions and methods
US11897950B2 (en) 2019-12-06 2024-02-13 Augusta University Research Institute, Inc. Osteopontin monoclonal antibodies
MX2022006751A (es) 2019-12-06 2022-08-19 Regeneron Pharma Minitrampas de vegf y metodos de uso de las mismas.
WO2021113780A1 (en) 2019-12-06 2021-06-10 Juno Therapeutics, Inc. Anti-idiotypic antibodies to gprc5d-targeted binding domains and related compositions and methods
US12076400B2 (en) 2019-12-06 2024-09-03 Zymeworks Bc Inc. Methods of using a bispecific antigen-binding construct targeting HER2 in combination with CDK4/6 inhibitors for the treatment of breast cancer
WO2021111005A1 (en) 2019-12-06 2021-06-10 Thoas Fioretos Novel agents and uses thereof
JP2023504748A (ja) 2019-12-09 2023-02-06 ジェネンテック， インコーポレイテッド 抗ｐｄ－ｌ１抗体製剤
EP4073516A1 (de) 2019-12-09 2022-10-19 Celcuity Inc. Verfahren zur behandlung von krebspatienten mit gegen ras-knoten oder rtk gerichteten therapeutika
EP4072682A1 (de) 2019-12-09 2022-10-19 Institut National de la Santé et de la Recherche Médicale (INSERM) Antikörper mit spezifität gegen her4 und verwendungen davon
IL293729A (en) 2019-12-11 2022-08-01 Ichilov Tech Ltd A non-invasive test to identify and monitor systemic inflammation
CN115916818A (zh) 2019-12-11 2023-04-04 库利南肿瘤股份有限公司 抗cd19抗体和多特异性结合蛋白
WO2021119400A1 (en) 2019-12-12 2021-06-17 Alector Llc Methods of use of anti-cd33 antibodies
CR20220330A (es) 2019-12-13 2022-08-04 Genentech Inc Anticuerpos anti-ly6g6d y métodos de uso.
PE20221326A1 (es) 2019-12-13 2022-09-09 Alector Llc Anticuerpos anti-mertk y metodos de uso de los mismos
HRP20260121T1 (hr) 2019-12-17 2026-03-13 Chinook Therapeutics, Inc. Farmaceutski prihvatljiva sol atrasentana za uporabu u postupku za liječenje iga nefropatije
JP7369297B2 (ja) 2019-12-17 2023-10-25 ファイザー・インク Ｃｄ４７、ｐｄ－ｌ１に特異的な抗体、およびその使用
BR112022012010A2 (pt) 2019-12-18 2022-08-30 Hoffmann La Roche Anticorpos, ácido nucleico isolado, célula hospedeira, formulação farmacêutica, uso do anticorpo, método de produção de um anticorpo, método de tratamento de um indivíduo que tem câncer e método de tratamento de um indivíduo que tem uma doença inflamatória ou autoimune
BR112022011824A2 (pt) 2019-12-18 2022-08-30 Teneofour Inc Anticorpos de cadeia pesada que se ligam a cd38
AU2020408213A1 (en) 2019-12-19 2022-06-23 Ortho-Clinical Diagnostics, Inc. Monoclonal antibody fusions
PH12022551471A1 (en) 2019-12-20 2023-04-24 Momenta Pharmaceuticals Inc Antibodies against integrin alpha 11 beta 1
BR112022011797A2 (pt) 2019-12-20 2022-08-30 Intervet Int Bv Anticorpos contra receptor alfa de interleucina-4 canino
JP7807372B2 (ja) 2019-12-20 2026-01-27 ハドソン インスティチュート オブ メディカル リサーチ Ｃｘｃｌ１０結合タンパク質及びその使用
WO2021123092A1 (en) 2019-12-20 2021-06-24 Intervet International B.V. Bispecific caninized antibodies for treating atopic dermatitis
CA3164996A1 (en) 2019-12-20 2021-06-14 Novarock Biotherapeutics, Ltd. Anti-interleukin-23 p19 antibodies and methods of use thereof
IL293640A (en) 2019-12-20 2022-08-01 Amgen Inc CD40 antagonistic mesothelin-targeted multispecific antibody constructs for the treatment of solid tumors
US20230057071A1 (en) 2019-12-20 2023-02-23 Novartis Ag Combination of anti tim-3 antibody mbg453 and anti tgf-beta antibody nis793, with or without decitabine or the anti pd-1 antibody spartalizumab, for treating myelofibrosis and myelodysplastic syndrome
CN115515678A (zh) 2019-12-23 2022-12-23 基因泰克公司 载脂蛋白l1特异性抗体及其使用方法
CA3164797A1 (en) 2019-12-23 2021-07-01 Eisai R&D Management Co., Ltd. Method of producing eribulin based antibody-drug conjugate
MY202559A (en) 2019-12-27 2024-05-08 Chugai Pharmaceutical Co Ltd Anti-ctla-4 antibody and use thereof
CA3160927A1 (en) 2019-12-27 2021-07-01 Affimed Gmbh Method for the production of bispecific fcyriii x cd30 antibody construct
CN118440203A (zh) 2019-12-27 2024-08-06 凯奥目生物科学株式会社 抗cdcp1抗体
US20230076643A1 (en) 2019-12-30 2023-03-09 City Of Hope Methods of making and using regulatory t cells and effector t cells having chimeric antigen receptors targeted to cd6, cd19, and/or an il-13r for treatment of autoimmune disorders and cancers
TWI877278B (zh) 2019-12-30 2025-03-21 美商思進公司 以非海藻糖苷化抗－ｃｄ７０抗體治療癌症之方法
WO2021138474A2 (en) 2020-01-03 2021-07-08 Marengo Therapeutics, Inc. Anti-tcr antibody molecules and uses thereof
JP7456075B2 (ja) 2020-01-03 2024-03-27 ビオシオン インコーポレイテッド 抗体結合ｂｃｍａ及びその使用
EP4084821A4 (de) 2020-01-03 2024-04-24 Marengo Therapeutics, Inc. An cd33 bindende multifunktionsmoleküle und ihre verwendungen
CN115052663B (zh) 2020-01-08 2026-06-09 辛瑟斯治疗股份有限公司 Alk5抑制剂缀合物及其用途
IL294611B1 (en) 2020-01-08 2026-05-01 Regeneron Pharma Treatment of fibrodysplasia ossificans progressive
CN110818795B (zh) 2020-01-10 2020-04-24 上海复宏汉霖生物技术股份有限公司 抗tigit抗体和使用方法
CA3166328A1 (en) 2020-01-11 2021-07-15 Scholar Rock, Inc. Tgf-beta inhibitors and use thereof
CA3167427A1 (en) 2020-01-11 2021-07-15 Scholar Rock, Inc. Tgfb inhibitors and use thereof
WO2021146303A1 (en) 2020-01-13 2021-07-22 Jounce Therapeutics, Inc. Methods for the treatment of cancer
TWI869528B (zh) 2020-01-13 2025-01-11 美商威特拉公司 C5ar1抗體分子及其用途
EP4090335A1 (de) 2020-01-17 2022-11-23 Novartis AG Kombination aus einem tim-3-inhibitor und einem hypomethylierungsmittel zur verwendung bei der behandlung von myelodysplastischem syndrom oder chronischer myelomonozytischer leukämie
EP4090770A1 (de) 2020-01-17 2022-11-23 INSERM (Institut National de la Santé et de la Recherche Médicale) Verfahren und zusammensetzungen zur behandlung von melanom
US12662535B2 (en) 2020-01-17 2026-06-23 Immunelogic Therapeutics, Inc. Pro-antibody that reduces off-target toxicity
CN115427447B (zh) 2020-01-17 2025-02-18 百进生物科技公司 抗tlr7药剂和组合物以及制备和使用其的方法
CN113138276B (zh) 2020-01-19 2022-09-16 厦门万泰凯瑞生物技术有限公司 用于检测HBcAg的方法及抗体
US20230097908A1 (en) 2020-01-22 2023-03-30 Medimmune Limited Compounds and conjugates thereof
US20230093169A1 (en) 2020-01-22 2023-03-23 Amgen Research (Munch) Gmbh Combinations of antibody constructs and inhibitors of cytokine release syndrome and uses thereof
IL272194A (en) 2020-01-22 2021-07-29 Yeda Res & Dev Multispecific antibodies for use in treating diseases
KR20220145339A (ko) 2020-01-22 2022-10-28 라모트 앳 텔-아비브 유니버시티 리미티드 항-ide 항체 및 이의 용도
TW202140076A (zh) 2020-01-22 2021-11-01 英商梅迪繆思有限公司 化合物及其軛合物
WO2021150925A1 (en) 2020-01-24 2021-07-29 Dana-Farber Cancer Institute, Inc. Uses of biomarkers for improving immunotherapy
IL294800A (en) 2020-01-27 2022-09-01 Genentech Inc Methods of treating cancer with an antibody to an anti-ti antagonist
WO2021194481A1 (en) 2020-03-24 2021-09-30 Genentech, Inc. Dosing for treatment with anti-tigit and anti-pd-l1 antagonist antibodies
WO2022050954A1 (en) 2020-09-04 2022-03-10 Genentech, Inc. Dosing for treatment with anti-tigit and anti-pd-l1 antagonist antibodies
WO2021151974A1 (en) 2020-01-28 2021-08-05 Stichting Het Nederlands Kanker Instituut - Antoni Van Leeuwenhoek Ziekenhuis Interfering with mrna splicing to enhance response to checkpoint immunotherapies.
EP4097129A1 (de) 2020-01-29 2022-12-07 Inhibrx, Inc. Cd28 einzeldomänenantikörper sowie multivalente und multispezifische konstrukte davon
IL272390A (en) 2020-01-30 2021-08-31 Yeda Res & Dev Cancer treatment methods
IL272389A (en) 2020-01-30 2021-08-31 Yeda Res & Dev Kits containing antibodies to PD-L1 and their uses in therapy
EP4096647A1 (de) 2020-01-30 2022-12-07 Yeda Research and Development Co. Ltd Behandlung einer akuten lebererkrankung mit tlr-mik-inhibitoren
US12617858B2 (en) 2020-01-31 2026-05-05 The Cleveland Clinic Foundation Anti-Müllerian hormone receptor 2 antibodies and methods of use
BR102020002165A2 (pt) 2020-01-31 2021-11-30 Fundação Oswaldo Cruz Anticorpo, seu uso, composição farmacêutica o compreendendo, método de diagnóstico de infecções fúngicas, kit de diagnóstico de infecções fúngicas e método para tratamento de infecções fúngicas.
US12486331B2 (en) 2020-01-31 2025-12-02 Gensun Biopharma Inc. Bispecific T cell engagers
CN114845740B (zh) 2020-01-31 2026-06-02 先天制药公司 癌症的治疗
BR112022015077A2 (pt) 2020-01-31 2022-10-04 Genentech Inc Métodos para induzir células t cd8+ específicas de neoepítopos em um indivíduo com um tumor e para induzir o tráfico de células t cd8+, vacinas de rna, vacina de rna para uso e antagonistas de ligação
US20250263466A1 (en) 2020-02-03 2025-08-21 Vir Biotechnology, Inc. Antibodies against sars-cov-2 and methods of using the same
WO2021156329A1 (en) 2020-02-05 2021-08-12 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods of treatment of cancer disease by targeting an epigenetic factor
KR20220139926A (ko) 2020-02-05 2022-10-17 다이아뎀 바이오쎄라퓨틱스 인크 인공 시냅스
KR20220137698A (ko) 2020-02-05 2022-10-12 라리마 테라퓨틱스, 인코포레이티드 Tat 펩티드 결합 단백질 및 이의 용도
AU2021218927B2 (en) 2020-02-10 2024-12-19 Shanghai Escugen Biotechnology Co., Ltd. Claudin 18.2 antibody and use thereof
US20230312704A1 (en) 2020-02-10 2023-10-05 Shanghai Escugen Biotechnology Co., Ltd. Cldn18.2 antibody and use thereof
AU2021219671A1 (en) 2020-02-10 2022-07-14 Regeneron Pharmaceuticals, Inc. Anti-Tmprss2 Antibodies and Antigen-Binding Fragments
KR20220140568A (ko) 2020-02-11 2022-10-18 벤더르빌트 유니버시티 중증 급성 호흡기 증후군 코로나바이러스 2(SARS-CoV-2)에 대한 인간 단일클론 항체
IL295382B1 (en) 2020-02-12 2026-08-01 Chugai Seiyaku Kk Anti-CD137 antigen-binding molecule for use in cancer treatment
CN113248611B (zh) 2020-02-13 2026-02-06 上海泰槿生物技术有限公司 抗bcma抗体、其药物组合物及应用
EP4103605A1 (de) 2020-02-13 2022-12-21 Amgen Inc. Behandlung von atopischer dermatitis mit anti-tslp-antikörper
CR20220457A (es) 2020-02-13 2023-01-09 Amgen Inc Formulaciones de anticuerpos anti-tslp humanos y métodos de tratamiento de una enfermedad inflamatoria
TWI890283B (zh) 2020-02-14 2025-07-11 美商基利科學股份有限公司 結合ccr8之抗體及融合蛋白及其用途
WO2021167908A1 (en) 2020-02-17 2021-08-26 Board Of Regents, The University Of Texas System Methods for expansion of tumor infiltrating lymphocytes and use thereof
MX2022010120A (es) 2020-02-18 2022-09-05 Amgen Inc Formulaciones de anticuerpos anti-tslp humanos y metodos de uso de los mismos.
CN115484971A (zh) 2020-02-19 2022-12-16 艾琳治疗公司 靶向蛋白的分子
US20230090247A1 (en) 2020-02-19 2023-03-23 Aelin Therapeutics Molecules targeting ras protein
BR112022016550A2 (pt) 2020-02-21 2022-11-16 Harpoon Therapeutics Inc Proteínas de ligação a flt3 e métodos de uso
JP7745556B2 (ja) 2020-02-21 2025-09-29 マクロジェニクス，インコーポレーテッド Ｃｄ１３７結合分子及びその使用
EP4108683A4 (de) 2020-02-21 2024-04-03 Jiangsu Hengrui Pharmaceuticals Co., Ltd. Anti-il-2-antikörper, antigenbindendes fragment davon und medizinische verwendung davon
CN115768794A (zh) 2020-02-24 2023-03-07 艾利妥 抗trem2抗体的使用方法
US12029736B2 (en) 2020-02-25 2024-07-09 Mediboston Limited Camptothecin derivatives and conjugates thereof
KR102444740B1 (ko) 2020-02-25 2022-09-19 한국과학기술연구원 Ksp 억제제와 유사분열 억제제를 포함하는 암의 예방 또는 치료용 약학 조성물
HUE062777T2 (hu) 2020-02-26 2023-12-28 Vir Biotechnology Inc SARS-CoV-2 elleni antitestek
CN119708230A (zh) 2020-02-27 2025-03-28 正大天晴药业集团股份有限公司 结合il4r的抗体及其用途
WO2021173920A1 (en) 2020-02-27 2021-09-02 The Regents Of The University Of Michigan Methods for detecting food allergies
US20230045494A1 (en) 2020-02-28 2023-02-09 Orega Biotech Combination therapies based on ctla4 and il-17b inhibitors
KR20220145859A (ko) 2020-02-28 2022-10-31 상하이 헨리우스 바이오테크, 인크. 항cd137 작제물, 다중 특이적 항체 및 그 용도
IL295759A (en) 2020-02-28 2022-10-01 Tallac Therapeutics Inc Transglutaminase mediated coupling
JP7715722B2 (ja) 2020-02-28 2025-07-30 上海復宏漢霖生物技術股▲フン▼有限公司 抗ｃｄ１３７コンストラクト及びその使用
AU2021225962A1 (en) 2020-02-28 2022-10-20 Genzyme Corporation Modified binding polypeptides for optimized drug conjugation
BR112022017267A2 (pt) 2020-03-03 2022-12-13 Array Biopharma Inc Métodos para tratar o câncer usando (r)-n-(3-fluoro-4-((3-((1-hidroxipropan-2-il) amino)-1h-pirazolo[3,4-b]piridin-4-il)óxi)fenil)-3-(4-fluorofenil)-1-isopropil-2,4-dioxo-1,2,3,4-tetra-hidropirimidina-5-carboxamida
KR102978225B1 (ko) 2020-03-03 2026-06-15 액티브 바이오테크 에이비 조합 요법에 사용하기 위한 타스퀴니모드 또는 이의 약학적으로 허용가능한 염
EP4114979A4 (de) 2020-03-04 2025-08-27 Found Medicine Inc Bcor-neuanordnungen und verwendungen davon
WO2021175954A1 (en) 2020-03-04 2021-09-10 Imcheck Therapeutics Sas Antibodies having specificity for btnl8 and uses thereof
US20230184745A1 (en) 2020-03-05 2023-06-15 Umc Utrecht Holding B.V. Screening method for effective target - E3 ligase combinations
EP4114854A1 (de) 2020-03-05 2023-01-11 UMC Utrecht Holding B.V. Membran-ubiquitin-ligasen zum target-proteinabbau
JP7859981B2 (ja) 2020-03-06 2026-05-15 ジーオー セラピューティクス，インコーポレイテッド 抗グリコｃｄ４４抗体およびその使用
WO2021177980A1 (en) 2020-03-06 2021-09-10 Genentech, Inc. Combination therapy for cancer comprising pd-1 axis binding antagonist and il6 antagonist
TWI867422B (zh) 2020-03-06 2024-12-21 美商奥默羅斯公司 用於治療和/或預防流感病毒誘導的急性呼吸窘迫症候群、肺炎或者流感病毒感染的一些其它肺部表現的抑制masp-2的方法
EP4118105A2 (de) 2020-03-09 2023-01-18 Pfizer Inc. Cd80-fc-fusionsprotein und verwendungen davon
US11896619B2 (en) 2020-03-10 2024-02-13 Massachusetts Institute Of Technology Compositions and methods for immunotherapy of NPM1c-positive cancer
JP2023517611A (ja) 2020-03-10 2023-04-26 ティジアーナ ライフ サイエンシズ パブリック リミティド カンパニー Ｉｌ－６／ｉｌ－６ｒ抗体の組成物及びその使用方法
TW202200615A (zh) 2020-03-12 2022-01-01 美商安進公司 用於治療和預防患者的crs之方法
GB202003632D0 (en) 2020-03-12 2020-04-29 Harbour Antibodies Bv SARS-Cov-2 (SARS2, COVID-19) antibodies
EP4118114A1 (de) 2020-03-13 2023-01-18 Genentech, Inc. Anti-interleukin-33-antikörper und verwendungen davon
CA3169626A1 (en) 2020-03-19 2021-09-23 Genentech, Inc. Isoform-selective anti-tgf-beta antibodies and methods of use
CN115427454A (zh) 2020-03-19 2022-12-02 安进公司 针对粘蛋白17的抗体及其用途
US20230147657A1 (en) 2020-03-20 2023-05-11 INSERM (Institut National de la Santé et de la Recherche Médicale) Chimeric antigen receptor specific for human cd45rc and uses thereof
WO2021186024A1 (en) 2020-03-20 2021-09-23 Centre National De La Recherche Scientifique (Cnrs) New anti-vegfc antibodies and uses thereof
JP2023518814A (ja) 2020-03-23 2023-05-08 ジェネンテック， インコーポレイテッド Ｃｏｖｉｄ－１９肺炎における、ｉｌ－６アンタゴニストに対する応答を予測するためのバイオマーカー
EP4107186A1 (de) 2020-03-23 2022-12-28 Genentech, Inc. Tocilizumab- und remdesivir-kombinationstherapie für covid-19-pneumonie
WO2021194951A1 (en) 2020-03-23 2021-09-30 Centivax, Inc. Anti-sars-cov-2 antibodies derived from 2dd8
EP4107184A1 (de) 2020-03-23 2022-12-28 Genentech, Inc. Verfahren zur behandlung von pneumonie, einschliesslich covid-19-pneumonie, mit einem il6-antagonisten
GB202004189D0 (en) 2020-03-23 2020-05-06 Bergenbio As Combination therapy
CA3169967A1 (en) 2020-03-24 2021-09-30 Genentech, Inc. Tie2-binding agents and methods of use
CN113444172A (zh) 2020-03-25 2021-09-28 兴盟生物医药(苏州)有限公司 金黄色葡萄球菌α-毒素特异性抗体及其应用
WO2021195385A1 (en) 2020-03-26 2021-09-30 Vanderbilt University HUMAN MONOCLONAL ANTIBODIES TO SEVERE ACUTE RESPIRATORY SYNDROME CORONAVIRUS 2 (SARS-GoV-2)
WO2021195418A1 (en) 2020-03-26 2021-09-30 Vanderbilt University Human monoclonal antibodies to severe acute respiratory syndrome coronavirus 2 (sars-cov-2)
US12098365B2 (en) 2020-03-26 2024-09-24 Genentech, Inc. Modified mammalian cells
JPWO2021200131A1 (de) 2020-03-30 2021-10-07
US20230203191A1 (en) 2020-03-30 2023-06-29 Danisco Us Inc Engineered antibodies
US11045546B1 (en) 2020-03-30 2021-06-29 Cytodyn Inc. Methods of treating coronavirus infection
JP7674383B2 (ja) 2020-03-30 2025-05-09 エフ． ホフマン－ラ ロシュ アーゲー Ｖｅｇｆ及びｐｄｇｆ－ｂに結合する抗体及び使用方法
US12478603B2 (en) 2020-03-31 2025-11-25 The Regents Of The University Of Michigan Serum metabolites as biomarkers for carnitine treatment of sepsis
WO2021197340A1 (zh) 2020-03-31 2021-10-07 百奥泰生物制药股份有限公司 用于治疗冠状病毒的抗体、融合蛋白及其应用
WO2021202807A1 (en) 2020-03-31 2021-10-07 Seattle Children's Hospital D/B/A Seattle Children's Research Institute Proteomic screening for lysosomal storage diseases
GB202004677D0 (en) 2020-03-31 2020-05-13 Alligator Bioscience Ab Methods and compositions
JP7736688B2 (ja) 2020-03-31 2025-09-09 中外製薬株式会社 多重特異性抗原結合分子を製造するための方法
WO2021202590A1 (en) 2020-03-31 2021-10-07 Alector Llc Anti-mertk antibodies and methods of use thereof
WO2021202235A1 (en) 2020-04-01 2021-10-07 University Of Rochester Monoclonal antibodies against the hemagglutinin (ha) and neuraminidase (na) of influenza h3n2 viruses
US11815513B2 (en) 2020-04-01 2023-11-14 Institut Pasteur Severe acute respiratory syndrome (SARS)-associated coronavirus diagnostics
US12326451B2 (en) 2020-04-01 2025-06-10 Institut Pasteur Severe acute respiratory syndrome (SARS)—associated coronavirus diagnostics
WO2021203031A2 (en) 2020-04-02 2021-10-07 Seattle Children's Hospital D/B/A Seattle Children's Research Institute Antibodies that specifically bind peptides associated with the primary immunodeficiencies: wiskott-aldrich syndrome and x-linked agammaglobulinemia
CR20220552A (es) 2020-04-02 2023-01-17 Regeneron Pharma Anticuerpos contra glicoproteína de espícula anti-sars-cov-2 y fragmentos de unión al antígeno
US20240183826A9 (en) 2020-04-02 2024-06-06 Chugai Seiyaku Kabushiki Kaisha Analysis method for impurity molecules in composition containing multi-specific antigen-binding molecules
CN115698717A (zh) 2020-04-03 2023-02-03 基因泰克公司 癌症的治疗和诊断方法
KR20240085798A (ko) 2020-04-03 2024-06-17 비스테라, 인크. 항체 분자-약물 접합체 및 이의 용도
WO2021198511A1 (en) 2020-04-03 2021-10-07 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and compositions for treatment of sars-cov-2 infection
WO2021203053A1 (en) 2020-04-03 2021-10-07 Vir Biotechnology, Inc. Immunotherapy targeting a conserved region in sars coronaviruses
CA3172451A1 (en) 2020-04-03 2021-10-07 Robert Paul Methods of use of anti-trem2 antibodies
KR20220164787A (ko) 2020-04-06 2022-12-13 이슘 리서치 디벨롭먼트 컴퍼니 오브 더 히브루 유니버시티 오브 예루살렘 엘티디. 암 및 감염의 치료를 위한 NKp46에 대한 항체 및 이의 작제물
KR20210124867A (ko) 2020-04-06 2021-10-15 하. 룬드벡 아크티에셀스카브 항-cgrp 항체를 사용하는 편두통 관련 성가심 증상 (mbs) 의 치료
WO2021207348A1 (en) 2020-04-07 2021-10-14 Albert Einstein College Of Medicine Method of treating and preventing ocular disease with hsv-2 delta gd
CN114729014A (zh) 2020-04-08 2022-07-08 纳诺皮技术有限公司 单克隆抗体及其用途
WO2021205325A1 (en) 2020-04-08 2021-10-14 Pfizer Inc. Anti-gucy2c antibodies and uses thereof
EP4132954A1 (de) 2020-04-08 2023-02-15 Institut National de la Santé et de la Recherche Médicale (INSERM) Verwendung von cdon-inhibitoren zur behandlung von endothelialer dysfunktion
WO2021204713A1 (en) 2020-04-08 2021-10-14 Bergenbio Asa Axl inhibitors for antiviral therapy
EP4132971A1 (de) 2020-04-09 2023-02-15 Merck Sharp & Dohme LLC Affinitätsgereifte anti-lap-antikörper und verwendungen davon
AU2021251875A1 (en) 2020-04-10 2022-11-03 Seagen Inc. Charge variant linkers
WO2021207662A1 (en) 2020-04-10 2021-10-14 Genentech, Inc. Use of il-22fc for the treatment or prevention of pneumonia, acute respiratory distress syndrome, or cytokine release syndrome
US12559565B2 (en) 2020-04-13 2026-02-24 Biosion Inc. Antibodies binding CTLA4 and uses thereof
CA3175523A1 (en) 2020-04-13 2021-10-21 Antti Virtanen Methods, complexes and kits for detecting or determining an amount of a .beta.-coronavirus antibody in a sample
BR112022020706A2 (pt) 2020-04-14 2022-11-29 Vir Biotechnology Inc Anticorpos contra sars-cov-2 e métodos de uso dos mesmos
WO2021209458A1 (en) 2020-04-14 2021-10-21 Ares Trading S.A. Combination treatment of cancer
CA3180222A1 (en) 2020-04-15 2021-10-21 Voyager Therapeutics, Inc. Tau binding compounds
KR20230016178A (ko) 2020-04-15 2023-02-01 엘커메스 파마 아일랜드 리미티드 혈관신생 억제제와 조합된 면역자극제
EP4136109A1 (de) 2020-04-17 2023-02-22 Zoetis Services LLC Katzenantikörpervarianten
GB2594084A (en) 2020-04-17 2021-10-20 Bertrand Marie Rene Joseph Medical methods and medical uses
IL297287A (en) 2020-04-17 2022-12-01 Zoetis Services Llc Canine antibody variants
WO2021209824A1 (en) 2020-04-17 2021-10-21 Institut Pasteur Methods and products for serological analysis of sars-cov-2 infection
CN113527485B (zh) 2020-04-17 2024-11-15 湖南麦济生物技术股份有限公司 抗人白细胞介素-4受体α抗体及其制备方法和应用
JP2023521825A (ja) 2020-04-20 2023-05-25 ジョンス セラピューティクス， インコーポレイテッド ワクチン接種及び感染性疾患の治療のための組成物及び方法
CR20220581A (es) 2020-04-21 2023-01-09 Pharma Mar Sa Conjugados de anticuerpos de fármacos
GB202005779D0 (en) 2020-04-21 2020-06-03 Scancell Ltd Anti-tumour immune responses
WO2021213466A1 (zh) 2020-04-22 2021-10-28 中山康方生物医药有限公司 抗cd73的抗体及其用途
BR112022021426A2 (pt) 2020-04-22 2022-12-13 Akeso Biopharma Inc Anticorpo biespecífico anti-cd73/anti-pd-1, molécula de ácido nucleico isolada, vetor, célula hospedeira, método para preparar o anticorpo biespecífico anti-cd73/anti-pd-1, conjugado, kit, usos do anticorpo biespecífico anti-cd73/anti-pd-1, composição farmacêutica, método in vitro, linhagem celular de hibridoma e anticorpo monoclonal anti-cd73
WO2021216378A1 (en) 2020-04-23 2021-10-28 The Schepens Eye Research Institute, Inc. Methods and materials for treatment of fibrosis
EP4138925A1 (de) 2020-04-24 2023-03-01 Sanofi Antitumor-kombinationen mit anti-ceacam5-antikörperkonjugaten, trifluridin und tipiracil
CA3181000A1 (en) 2020-04-24 2021-10-28 Sanofi Antitumor combinations containing anti-ceacam5 antibody conjugates and folfiri
MX2022013173A (es) 2020-04-24 2022-11-30 Hoffmann La Roche Modulacion de enzimas y vias con compuestos de sulfhidrilo y sus derivados.
AU2021261420A1 (en) 2020-04-24 2022-12-01 Marengo Therapeutics, Inc. Multifunctional molecules that bind to T cell related cancer cells and uses thereof
BR112022020477A2 (pt) 2020-04-24 2022-11-29 Sanofi Sa Combinações antitumor contendo conjugados de anticorpo anti-ceacam5 e cetuximabe
MX2022013198A (es) 2020-04-24 2022-11-14 Genentech Inc Metodos de uso de inmunoconjugados anti-cd79b.
CN115427082A (zh) 2020-04-24 2022-12-02 赛诺菲 含有抗ceacam5抗体缀合物和folfox的抗肿瘤组合
GB202006072D0 (en) 2020-04-24 2020-06-10 Bergenbio Asa Method of selecting patients for treatment with cmbination therapy
JP2023523145A (ja) 2020-04-27 2023-06-02 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア リポ蛋白（ａ）に対するイソ型非依存性抗体
US11634477B2 (en) 2020-04-28 2023-04-25 The Rockefeller University Neutralizing anti-SARS-CoV-2 antibodies and methods of use thereof
EP4143345A1 (de) 2020-04-28 2023-03-08 Genentech, Inc. Verfahren und zusammensetzungen zur immuntherapie gegen nicht-kleinzelligen lungenkrebs
KR20250007022A (ko) 2020-04-29 2025-01-13 테네오원, 인코포레이티드 변형된 중쇄 불변 영역을 갖는 다중특이적 중쇄 항체
WO2021222616A1 (en) 2020-04-29 2021-11-04 Teneobio, Inc. Methods of treating multiple myeloma
CR20220598A (es) 2020-04-30 2023-01-17 Genentech Inc Anticuerpos específicos para kras y sus usos
JP2023524464A (ja) 2020-04-30 2023-06-12 サイロパ ビー．ブイ． 抗ｃｄ１０３抗体
WO2021222533A1 (en) 2020-04-30 2021-11-04 Procisedx Inc. Methods of detecting antibodies to sars-cov-2
WO2021220218A1 (en) 2020-05-01 2021-11-04 Novartis Ag Immunoglobulin variants
US20230242647A1 (en) 2020-05-01 2023-08-03 Novartis Ag Engineered immunoglobulins
CA3181786A1 (en) 2020-05-01 2021-11-04 The Regents Of The University Of California Inhibitors of alpha 2 beta 1 integrin and methods of use thereof
JP2023527962A (ja) 2020-05-03 2023-07-03 レヴィーナ （スジョウ） バイオファーマ カンパニー， リミテッド 抗ｔｒｏｐ２抗体を含む抗体薬物複合体（ａｄｃ）、かかるａｄｃを含む組成物、ならびにそれらを作製および使用する方法
MX2022013840A (es) 2020-05-04 2023-02-09 Inhibrx Inc Polipéptidos de unión a pd-1 canina y usos de los mismos.
CA3177268A1 (en) 2020-05-05 2021-11-11 The University Of North Carolina At Chapel Hill Modified adeno-associated virus 5 capsids and uses thereof
CA3181949A1 (en) 2020-05-05 2021-11-11 Janssen Biotech, Inc. Methods of treating crohn's disease with anti-il23 specific antibody
WO2021224401A1 (en) 2020-05-07 2021-11-11 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and compositions for determining a reference range of β-galactose exposure platelet
PH12022500020A1 (en) 2020-05-08 2024-05-06 Vir Biotechnology Inc Antibodies against sars-cov-2
MX2022013812A (es) 2020-05-08 2022-12-15 Regeneron Pharma Trampas y mini-trampas de vegf y metodos para el tratamiento de trastornos oculares y cancer.
CN115443171A (zh) 2020-05-08 2022-12-06 诺沃库勒有限责任公司 向多能干细胞施加交变电场的组合物和方法
CN113637073B (zh) 2020-05-11 2024-04-12 上海赛比曼生物科技有限公司 Bcma抗体及其制备和应用
EP3909601A1 (de) 2020-05-11 2021-11-17 LeukoCom GmbH Neuer antikörper, der spezifisch an menschliches ceacam1/3/5 bindet, und dessen verwendung
CN121914272A (zh) 2020-05-12 2026-04-24 正大天晴药业集团股份有限公司 St2抗原结合蛋白
EP4149512A4 (de) 2020-05-12 2024-06-05 Board of Regents, The University of Texas System Verfahren zur behandlung von glioblastom
CN115551888B (zh) 2020-05-12 2026-04-28 百欧恩泰(珠海)医药研发有限公司 抗cd73抗体及其用途
EP4149558A1 (de) 2020-05-12 2023-03-22 INSERM (Institut National de la Santé et de la Recherche Médicale) Neues verfahren zur behandlung von kutanen t-zell-lymphomen und tfh-abgeleiteten lymphomen
AU2021273014A1 (en) 2020-05-13 2022-11-17 AbbVie Deutschland GmbH & Co. KG Anti-hemojuvelin (HJV) antibodies for treating anemia of chronic disease
US20230183366A1 (en) 2020-05-13 2023-06-15 Inserm (Institut National De La Santé Et De La Recherch Médicale) Recombinant proteins with ox40 activating properties
ES3075793T3 (en) 2020-05-13 2026-08-07 Disc Medicine Inc Anti-hemojuvelin (hjv) antibodies for treating myelofibrosis
JP2023524854A (ja) 2020-05-13 2023-06-13 ファイザー・インク がんを処置するための方法、治療、および使用
CR20220580A (es) 2020-05-15 2023-04-11 Sichuan Kelun Biotech Biopharmaceutical Co Ltd Conjugado anticuerpo-fármaco, método de preparación del mismo y uso del mismo
US20230192867A1 (en) 2020-05-15 2023-06-22 Bristol-Myers Squibb Company Antibodies to garp
CN115605184A (zh) 2020-05-15 2023-01-13 豪夫迈·罗氏有限公司（Ch） 防止胃肠外蛋白质溶液中的可见颗粒形成
JP7869149B2 (ja) 2020-05-19 2026-06-02 アンスティテュ・クリー サイトカイン放出症候群の診断及び処置の方法
JP2023525898A (ja) 2020-05-19 2023-06-19 エフ． ホフマン－ラ ロシュ アーゲー 非経口タンパク質溶液における可視粒子の形成を防止するためのキレート剤の使用
WO2021236638A1 (en) 2020-05-19 2021-11-25 Amgen Inc. Mageb2 binding constructs
CA3183927A1 (en) 2020-05-21 2021-11-25 Janssen Biotech, Inc. Method of treating inflammatory bowel disease with a combination therapy of antibodies to il-23 and tnf alpha
ES2987329T3 (es) 2020-05-22 2024-11-14 Philogen Spa Terapia con el inmunoconjugado de TNF-a para el tratamiento de tumores cerebrales
MX2022014598A (es) 2020-05-26 2023-03-31 Regeneron Pharma Anticuerpos anti-glicoproteína espicular sars-cov-2 y fragmentos de unión al antígeno.
WO2021239666A1 (en) 2020-05-26 2021-12-02 Diaccurate Therapeutic methods
CA3184802A1 (en) 2020-05-26 2021-12-02 Inserm (Institut National De La Sante Et De La Recherche Medicale) Severe acute respiratory syndrome coronavirus 2 (sars-cov-2) polypeptides and uses thereof for vaccine purposes
CA3181776A1 (en) 2020-05-26 2021-12-02 Boehringer Ingelheim International Gmbh Anti-pd-1 antibodies
EP3915641A1 (de) 2020-05-27 2021-12-01 International-Drug-Development-Biotech Anti-cd5-antikörper und verfahren zu ihrer verwendung
CN116133684B (zh) 2020-05-27 2025-07-18 阿里亚利斯治疗公司 抗人nr1抗体衍生物
WO2021238886A1 (en) 2020-05-27 2021-12-02 Staidson (Beijing) Biopharmaceuticals Co., Ltd. Antibodies specifically recognizing nerve growth factor and uses thereof
FR3110838B1 (fr) 2020-05-28 2022-06-24 Commissariat Energie Atomique Complexe immunomodulateur et ses applications pour la thérapie
JP2023527972A (ja) 2020-05-29 2023-07-03 アムジエン・インコーポレーテツド Ｃｄ３３及びｃｄ３に結合する二重特異性コンストラクトの有害作用軽減投与
PE20230460A1 (es) 2020-05-29 2023-03-10 23Andme Inc Anticuerpos anti-cd200r1 y metodos de uso de estos
CN116529260A (zh) 2020-06-02 2023-08-01 当康生物技术有限责任公司 抗cd93构建体及其用途
CN113754766A (zh) 2020-06-02 2021-12-07 明慧医药（上海）有限公司 抗b7-h3抗体及其制备和应用
WO2021247769A1 (en) 2020-06-02 2021-12-09 Dynamicure Biotechnology Llc Anti-cd93 constructs and uses thereof
WO2021247925A1 (en) 2020-06-03 2021-12-09 Vir Biotechnology, Inc. Structure-guided immunotherapy against sars-cov-2
CN115803062B (zh) 2020-06-03 2025-09-09 博泰康医药公司 滋养层细胞表面抗原2(trop-2)抗体
CN115768475A (zh) 2020-06-04 2023-03-07 Csl创新私人有限公司 治疗或预防急性呼吸窘迫综合征的方法
US20230235326A1 (en) 2020-06-05 2023-07-27 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and pharmaceutical compositions for treating ocular diseases
EP4161966A1 (de) 2020-06-05 2023-04-12 Eisai R&D Management Co., Ltd. Anti-bcma-antikörper-wirkstoff-konjugate und verfahren zur verwendung
EP4161565A4 (de) 2020-06-05 2024-07-24 The Johns Hopkins University Humanisierte antikörper gegen kcnk9
WO2021250026A1 (en) 2020-06-08 2021-12-16 Acticor Biotech Use of anti-gpvi antibodies for the treatment of acute respiratory distress syndrome
US20230398116A1 (en) 2020-06-08 2023-12-14 Y's Ac Co., Ltd. Agent for reversing resistance to anticancer drugs
US20220119513A1 (en) 2020-06-08 2022-04-21 Zoetis Services Llc Anti-tgfb antibodies and therapeutic uses thereof
CA3184495A1 (en) 2020-06-08 2021-12-16 F. Hoffmann-La Roche Ag Anti-hbv antibodies and methods of use
GB202008651D0 (en) 2020-06-09 2020-07-22 Univ Newcastle Method of identifying complement modulators
WO2021249969A1 (en) 2020-06-10 2021-12-16 Merck Patent Gmbh Combination product for the treatment of cancer diseases
GB202008860D0 (en) 2020-06-11 2020-07-29 Univ Oxford Innovation Ltd BTLA antibodies
WO2021252708A1 (en) 2020-06-11 2021-12-16 President And Fellows Of Harvard College Stabilized trioxacarcin antibody drug conjugates and uses thereof
EP4163301B1 (de) 2020-06-11 2025-10-01 Iwate Medical University Humanisierter anti-gpc-1-antikörper
US20230332104A1 (en) 2020-06-11 2023-10-19 Novartis Ag Zbtb32 inhibitors and uses thereof
JP2023529206A (ja) 2020-06-12 2023-07-07 ジェネンテック， インコーポレイテッド がん免疫療法のための方法及び組成物
EP4165077A1 (de) 2020-06-12 2023-04-19 VIR Biotechnology, Inc. Antikörpertherapien für sars-cov-2-infektion
WO2021257497A1 (en) 2020-06-15 2021-12-23 Sarepta Therapeutis, Inc. Adeno-associated virus antibodies and fragments thereof
WO2021257503A1 (en) 2020-06-16 2021-12-23 Genentech, Inc. Methods and compositions for treating triple-negative breast cancer
WO2021255189A1 (en) 2020-06-17 2021-12-23 Tiziana Life Sciences, Plc Compositions and methods for augmenting chimeric antigen receptor (car) t cell therapies
WO2021257124A1 (en) 2020-06-18 2021-12-23 Genentech, Inc. Treatment with anti-tigit antibodies and pd-1 axis binding antagonists
WO2021260696A1 (en) 2020-06-22 2021-12-30 Ramot At Tel-Aviv University Ltd. Multi subunit protein modules, cells expressing same and uses thereof
WO2021262765A1 (en) 2020-06-22 2021-12-30 The Board Of Trustees Of The Leland Stanford Junior University Tsp-1 inhibitors for the treatment of aged, atrophied or dystrophied muscle
US20230235040A1 (en) 2020-06-22 2023-07-27 Almirall, S.A. Anti-il-36 antibodies and methods of use thereof
WO2021259963A1 (en) 2020-06-23 2021-12-30 Pandora Endocrine Innovation B.V. Immunization against wnt4 for treatment and prophylaxis of breast cancer
CN116194478A (zh) 2020-06-24 2023-05-30 阿雷克森制药公司 皮下（sc）施用抗c5抗体治疗补体相关病症
KR20230042273A (ko) 2020-06-24 2023-03-28 비스테라, 인크. April에 대한 항체 분자 및 그의 용도
EP4172192A1 (de) 2020-06-24 2023-05-03 Genentech, Inc. Apoptoseresistente zelllinien
PH12022553407A1 (en) 2020-06-25 2024-04-22 Amunix Pharmaceuticals Inc Her-2 targeted bispecific compositions and methods for making and using the same
CN116723856A (zh) 2020-06-25 2023-09-08 默沙东有限责任公司 靶向丝氨酸413处磷酸化的tau的高亲和力抗体
WO2021260139A1 (en) 2020-06-25 2021-12-30 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods of treatment and diagnostic of pathological conditions associated with intense stress
CA3183682A1 (en) 2020-06-26 2021-12-30 Minerva Biotechnologies Corporation Anti-nme antibody and method of treating cancer or cancer metastasis
EP4171632A2 (de) 2020-06-26 2023-05-03 Pfizer Inc. Verfahren zur behandlung von entzündlicher darmerkrankung mit tl1a-antikörpern
EP4172193A1 (de) 2020-06-29 2023-05-03 Zoetis Services LLC Katzenantikörpervarianten zur verbesserung der stabilität
JP2023532122A (ja) 2020-06-29 2023-07-26 ジェネンテック， インコーポレイテッド ペルツズマブにトラスツズマブを加えた固定用量配合剤
IL299027A (en) 2020-06-30 2023-02-01 Teneobio Inc Multispecific antibodies that bind BCMA
US20230250173A1 (en) 2020-07-01 2023-08-10 Pfizer Inc. Biomarkers for pd-1 axis binding antagonist therapy
EP4175979A2 (de) 2020-07-02 2023-05-10 Inhibrx, Inc. Polypeptide mit modifizierten il-2-polypeptiden und verwendungen davon
US20240409617A1 (en) 2020-07-03 2024-12-12 Dana-Farber Cancer Institute, Inc. Multispecific coronavirus antibodies
EP3933035A1 (de) 2020-07-03 2022-01-05 Aarhus Universitet Zusammensetzungen mit extrazellulären vesikeln und sting-stimulatorischen mitteln
CA3182945A1 (en) 2020-07-06 2022-01-13 Israel Vlodavsky Heparanase-neutralizing a54 monoclonal antibody
US20240279353A1 (en) 2020-07-06 2024-08-22 Kiromic BioPharma, Inc. Mesothelin isoform binding molecules and chimeric pd1 receptor molecules, cells containing the same and uses thereof
WO2022010797A2 (en) 2020-07-07 2022-01-13 Bionecure Therapeutics, Inc. Novel maytansinoids as adc payloads and their use for the treatment of cancer
EP4178529A1 (de) 2020-07-07 2023-05-17 F. Hoffmann-La Roche AG Alternative tenside als stabilisatoren für therapeutische proteinformulierungen
WO2022008597A1 (en) 2020-07-08 2022-01-13 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and pharmaceutical composition for the treatment of infectious diseases
EP4178530A1 (de) 2020-07-09 2023-05-17 F. Hoffmann-La Roche AG Konzentrierte proteinzusammensetzungen, ihre herstellung und verwendung
WO2022008976A1 (en) 2020-07-10 2022-01-13 Institut Pasteur Use of gdf11 to diagnose and treat anxiety and depression
WO2022008703A1 (en) 2020-07-10 2022-01-13 Universiteit Gent Dyes for use in a method of photoporation of the inner limiting membrane
WO2022008688A1 (en) 2020-07-10 2022-01-13 F. Hoffmann-La Roche Ag Antibodies which bind to cancer cells and target radionuclides to said cells
KR102916382B1 (ko) 2020-07-13 2026-01-21 상하이 준스 바이오사이언스 컴퍼니 리미티드 항-cldn-18.2 항체 및 그 용도
JP2023535302A (ja) 2020-07-13 2023-08-17 ジェネンテック， インコーポレイテッド ポリペプチドの免疫原性を予測するための細胞ベースの方法
AU2021308574A1 (en) 2020-07-13 2023-03-09 Janssen Biotech, Inc. Safe and effective method of treating psoriatic arthritis with anti-IL23 specific antibody
AU2021308283A1 (en) 2020-07-14 2023-02-02 F. Hoffmann-La Roche Ag Assays for fixed dose combinations
WO2022013328A1 (en) 2020-07-15 2022-01-20 Université Libre de Bruxelles Method for determining sensitivity to an antineoplastic agent
JP7846667B2 (ja) 2020-07-16 2026-04-15 レジェンド バイオテック アイルランド リミテッド Ｃｄ２０結合分子及びその使用
CA3186065A1 (en) 2020-07-16 2022-01-20 Xiaohu FAN Cd19 binding molecules and uses thereof
CA3176556A1 (en) 2020-07-16 2022-01-20 Novartis Ag Anti-betacellulin antibodies, fragments thereof, and multi-specific binding molecules
CA3185122A1 (en) 2020-07-17 2022-01-20 Cecilia Pui Chi Chiu Anti-notch2 antibodies and methods of use
MX2023000662A (es) 2020-07-17 2023-02-27 Pfizer Anticuerpos terapeuticos y sus usos.
WO2022013613A2 (en) 2020-07-17 2022-01-20 Onena Medicines S.L. Antibodies against lefty proteins
IL299860A (en) 2020-07-21 2023-03-01 Genentech Inc Antibody-conjugated chemical factors for the discharge of BRM and their methods
WO2022020456A2 (en) 2020-07-21 2022-01-27 Allogene Therapeutics, Inc. Chimeric antigen receptors with enhanced signaling and activities and uses thereof
US12655219B2 (en) 2020-07-21 2026-06-16 Shanghai Junshi Biosciences Co., Ltd. Anti-CTLA-4 antibody and use thereof
US20230293512A1 (en) 2020-07-23 2023-09-21 Erasmus University Medical Center Rotterdam S100 proteins as novel therapeutic targets in myeloproliferative neoplasms
TW202219067A (zh) 2020-07-24 2022-05-16 瑞士商赫孚孟拉羅股份公司 用於表現抗體多聚體融合之方法
GB2597532A (en) 2020-07-28 2022-02-02 Femtogenix Ltd Cytotoxic compounds
EP4189395A1 (de) 2020-07-28 2023-06-07 Institut National de la Santé et de la Recherche Médicale (INSERM) Verfahren und zusammensetzungen zur prävention und behandlung von krebs
WO2022026592A2 (en) 2020-07-28 2022-02-03 Celltas Bio, Inc. Antibody molecules to coronavirus and uses thereof
IL300121A (en) 2020-07-29 2023-03-01 Dynamicure Biotechnology Llc Anti-cd93 constructs and uses thereof
US20230227555A1 (en) 2020-07-30 2023-07-20 Tiziana Life Sciences Plc Cd-3 antibodies for the treatment of coronavirus
WO2022024065A1 (en) 2020-07-30 2022-02-03 Janssen Biotech, Inc. Method of treating psoriasis in pediatric subjects with anti-il12/il23 antibody
CN120040592A (zh) 2020-07-31 2025-05-27 百奥泰生物制药股份有限公司 Cd47抗体及其应用
GB202011993D0 (en) 2020-07-31 2020-09-16 Adc Therapeutics Sa ANTI-IL 13Ra2 antibodies
AR123085A1 (es) 2020-07-31 2022-10-26 Genentech Inc FORMULACIONES DE ANTICUERPO ANTI-INTEGRINA b7 Y DISPOSITIVOS
JP7904195B2 (ja) 2020-08-03 2026-08-12 ジェネンテック， インコーポレイテッド リンパ腫のための診断及び治療方法
TW202212354A (zh) 2020-08-03 2022-04-01 美商健生生物科技公司 用於病毒治療劑中之多向生物運輸的材料及方法
WO2022029494A1 (en) 2020-08-04 2022-02-10 Abbott Rapid Diagnostics International Unlimited Company Assays for detecting sars-cov-2
US20220043000A1 (en) 2020-08-04 2022-02-10 Abbott Laboratories Methods and kits for detecting sars-cov-2 protein in a sample
KR20230095918A (ko) 2020-08-05 2023-06-29 주노 쎄러퓨티크스 인코퍼레이티드 Ror1-표적 결합 도메인에 대한 항이디오타입 항체 및 관련 조성물 및 방법
US12247978B2 (en) 2020-08-05 2025-03-11 Arizona Board Of Regents On Behalf Of Northern Arizona University Compositions and methods for detection and treatment of coronavirus infection
GB202012161D0 (en) 2020-08-05 2020-09-16 Adc Therapeutics Sa Combination therapy
BR112023001942A2 (pt) 2020-08-06 2023-02-28 Bioverativ Usa Inc Citocinas inflamatórias e fadiga em indivíduo com doença mediada por complemento
JP2023534765A (ja) 2020-08-07 2023-08-10 フォーティス セラピューティクス，インク． 免疫複合体を標的とするｃｄ４６およびその使用方法
US12221463B2 (en) 2020-08-07 2025-02-11 The Board Of Regents Of The University Of Oklahoma Method of promoting wound healing by inhibiting CCR3
WO2022031948A1 (en) 2020-08-07 2022-02-10 Genentech, Inc. T cell-based methods for predicting polypeptide immunogenicity
TWI883241B (zh) 2020-08-07 2025-05-11 大陸商百奧泰生物製藥股份有限公司 抗pd-l1抗體及其應用
KR20230077722A (ko) 2020-08-10 2023-06-01 지브이20 테라퓨틱스 엘엘씨 Igsf8을 표적화하여 자가면역 질환 및 암을 치료하기 위한 조성물 및 방법
IL300505A (en) 2020-08-10 2023-04-01 Janssen Biotech Inc Materials and methods for the production of biologically engineered virus-specific lymphocytes
WO2022035998A1 (en) 2020-08-11 2022-02-17 City Of Hope Compositions and uses of sars-cov-2 targeted chimeric antigen receptor modified nk cells
EP4196612A1 (de) 2020-08-12 2023-06-21 Genentech, Inc. Diagnostische und therapeutische verfahren für krebs
JP2023537396A (ja) 2020-08-12 2023-08-31 ビオンド バイオロジクス リミテッド Ｉｌｔ２に対する抗体およびその使用
CN116615452A (zh) 2020-08-14 2023-08-18 Ac免疫有限公司 人源化抗tdp-43结合分子及其用途
KR20230048422A (ko) 2020-08-14 2023-04-11 에프. 호프만-라 로슈 아게 오크렐리주맙으로 다발성 경화증을 치료하는 방법
WO2022038152A1 (en) 2020-08-17 2022-02-24 Atb Therapeutics Recombinant immunotoxin comprising a ribotoxin or rnase
WO2022037531A1 (zh) 2020-08-17 2022-02-24 中山康方生物医药有限公司 抗cd73的抗体及其用途
IL300704A (en) 2020-08-18 2023-04-01 Omeros Corp Monoclonal antibodies, preparations and methods for detecting complement factor D
US12037409B2 (en) 2020-08-21 2024-07-16 Shanghai GenBase Biotechnology Co., Ltd. Antibody specifically bound to glycosylated CEACAM5
AU2021334950A1 (en) 2020-08-24 2023-03-02 Charité - Universitätsmedizin Berlin Chimeric antigen receptor (CAR)-expressing cells recognizing CEA
US20240009310A1 (en) 2020-08-24 2024-01-11 Charité - Universitätsmedizin Berlin A CHIMERIC ANTIGEN RECEPTOR CONSTRUCT ENCODING A CHECKPOINT INHIBITORY MOLECULE AND AN IMMUNE STIMULATORY CYTOKINE AND CAR-EXPRESSING CELLS RECOGNIZING CD44v6
CA3190573A1 (en) 2020-08-26 2022-03-03 Andreas Loew Methods of detecting trbc1 or trbc2
AU2021331075A1 (en) 2020-08-26 2023-04-06 Marengo Therapeutics, Inc. Multifunctional molecules that bind to calreticulin and uses thereof
WO2022043863A1 (en) 2020-08-26 2022-03-03 Citius Pharmaceuticals, Inc. Combination for use in methods of treating cancer
WO2022044010A1 (en) 2020-08-26 2022-03-03 Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd. Anti-t-cell immunoglobulin and itim domain (tigit) antibodies for the treatment of fungal infections
JP2023539645A (ja) 2020-08-26 2023-09-15 マレンゴ・セラピューティクス，インコーポレーテッド Ｎｋｐ３０に結合する抗体分子およびその使用
CN114106173A (zh) 2020-08-26 2022-03-01 上海泰槿生物技术有限公司 抗ox40抗体、其药物组合物及应用
EP4204448A2 (de) 2020-08-27 2023-07-05 cureab GmbH Anti-golph2-antikörper zur makrophagen- und dendritischen zelldifferenzierung
JP2023539201A (ja) 2020-08-28 2023-09-13 ジェネンテック， インコーポレイテッド 宿主細胞タンパク質のＣＲＩＳＰＲ／Ｃａｓ９マルチプレックスノックアウト
WO2022043558A1 (en) 2020-08-31 2022-03-03 Advanced Accelerator Applications International Sa Method of treating psma-expressing cancers
WO2022047359A1 (en) 2020-08-31 2022-03-03 Berg Llc Protein biomarkers for pancreatic cancer
WO2022047381A1 (en) 2020-08-31 2022-03-03 Genentech, Inc. Methods for producing antibodies
CN114106190B (zh) 2020-08-31 2025-04-08 普米斯生物技术(珠海)有限公司 一种抗vegf/pd-l1双特异性抗体及其用途
US20230321285A1 (en) 2020-08-31 2023-10-12 Advanced Accelerator Applications International Sa Method of treating psma-expressing cancers
WO2022049061A1 (en) 2020-09-01 2022-03-10 Merck Patent Gmbh Nkp30 binders
KR20230087451A (ko) 2020-09-02 2023-06-16 주식회사 파멥신 암 환자를 치료하기 위한 pd-1 길항제 및 vegfr-2에 대한 길항제의 조합 요법
US20230312744A1 (en) 2020-09-02 2023-10-05 The University Of Tokyo Modulatory Substance of Tumor Immune Microenvironment, and Preventive, Diagnostic and/or Therapeutic Utilization of the Same
CN116323663A (zh) 2020-09-04 2023-06-23 豪夫迈·罗氏有限公司 与vegf-a和ang2结合的抗体及其使用方法
EP4208197A1 (de) 2020-09-04 2023-07-12 Rutgers, The State University of New Jersey Sars-cov-2-impfstoffe und -antikörper
EP4208721A1 (de) 2020-09-04 2023-07-12 PamGene B.V. Verfahren zur vorhersage der reaktion eines patienten auf eine behandlung mit einem pd-1- oder pd-l1-immun-checkpoint-inhibitor
KR20230060509A (ko) 2020-09-04 2023-05-04 노바록 바이오테라퓨틱스 리미티드 넥틴-4 항체 및 이의 용도
US20250122282A2 (en) 2020-09-04 2025-04-17 Merck Patent Gmbh Anti-ceacam5 antibodies and conjugates and uses thereof
US20230340149A1 (en) 2020-09-07 2023-10-26 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods of treatment of inflammatory bowel diseases
KR102528412B1 (ko) 2020-09-08 2023-05-04 클립스비엔씨 주식회사 신규한 포도상구균 감염 질환의 예방 또는 치료용 조성물
CN116829592A (zh) 2020-09-11 2023-09-29 免疫医疗有限公司 治疗性b7-h4结合分子
CN116601173A (zh) 2020-09-11 2023-08-15 阿雷克森制药公司 抗铜蓝蛋白抗体及其用途
KR20230066095A (ko) 2020-09-12 2023-05-12 메디뮨 리미티드 항-b7h4 항체-약물 접합체 요법에 대한 점수산정 방법
KR20230069181A (ko) 2020-09-14 2023-05-18 화이자 인코포레이티드 암 치료를 위한 방법, 요법 및 용도
PE20231575A1 (es) 2020-09-14 2023-10-04 Ichnos Sciences SA Anticuerpos que se unen a il1rap y usos de estos
EP4214241A2 (de) 2020-09-15 2023-07-26 Bayer Aktiengesellschaft Neuartige anti-a2ap-antikörper und verwendungen davon
IL301306A (en) 2020-09-16 2023-05-01 Harvard College Methods of treating an individual that has failed an anti-pd-1/anti-pd-l1 therapy
WO2022060412A1 (en) 2020-09-17 2022-03-24 Genentech, Inc. Results of empacta: a randomized, double-blind, placebo-controlled, multicenter study to evaluate the efficacy and safety of tocilizumab in hospitalized patients with covid-19 pneumonia
PE20231385A1 (es) 2020-09-17 2023-09-12 Janssen Pharmaceuticals Inc Composiciones de vacunas multivalentes y usos de las mismas
EP3970752A1 (de) 2020-09-17 2022-03-23 Merck Patent GmbH Moleküle mit löslichkeitsmarkierung und zugehörige verfahren
CN114195894B (zh) 2020-09-17 2025-02-25 普米斯生物技术(珠海)有限公司 一种靶向4-1bb的抗体及其应用
CN114195900B (zh) 2020-09-17 2024-02-23 普米斯生物技术(珠海)有限公司 一种抗4-1bb/pd-l1双特异性抗体及其用途
MX2023002191A (es) 2020-09-18 2023-03-03 Chugai Pharmaceutical Co Ltd Anticuerpo anti antigenos de leucocitos humanos (hla) isoforma dq2.5 y su uso para el tratamiento de la enfermedad celiaca.
WO2022061061A1 (en) 2020-09-21 2022-03-24 Boehringer Ingelheim International Gmbh Use of anti-cd40 antibodies for treatment of inflammatory conditions
WO2022061214A1 (en) 2020-09-21 2022-03-24 Genentech, Inc. Purification of multispecific antibodies
WO2022058621A1 (en) 2020-09-21 2022-03-24 Theravectys High throughput methods and products for sars-cov-2 sero-neutralization assay
US11225508B1 (en) 2020-09-23 2022-01-18 The University Of North Carolina At Chapel Hill Mouse-adapted SARS-CoV-2 viruses and methods of use thereof
KR20230068415A (ko) 2020-09-24 2023-05-17 에프. 호프만-라 로슈 아게 유전자 녹아웃을 갖는 포유류 세포주
EP4217387A2 (de) 2020-09-24 2023-08-02 Fred Hutchinson Cancer Center Gegen sox2-antigene gerichtete immuntherapie
WO2022066973A1 (en) 2020-09-24 2022-03-31 Fred Hutchinson Cancer Research Center Immunotherapy targeting pbk or oip5 antigens
US20230365692A1 (en) 2020-09-24 2023-11-16 Merck Sharp & Dohme Llc Stable formulations of programmed death receptor 1 (pd-1) antibodies and hyaluronidase variants and fragments thereof and methods of use thereof
GB202015226D0 (en) 2020-09-25 2020-11-11 Adc Therapeutics S A Pyrrol obenzodiazepine-antibody conugates and uses thereof
CA3194936A1 (en) 2020-09-28 2022-03-31 Zoetis Services Llc Canine antibody variants
BR112023005684A2 (pt) 2020-09-28 2023-11-07 Humabs Biomed Sa Anticorpos contra sars-cov-2
PH12023550779A1 (en) 2020-09-28 2023-11-20 Angitia Biomedicines Ltd Anti-sclerostin constructs and uses thereof
WO2022064049A1 (en) 2020-09-28 2022-03-31 INSERM (Institut National de la Santé et de la Recherche Médicale) Method for diagnosing brucella infection
DE102020125457A1 (de) 2020-09-29 2022-03-31 Immatics Biotechnologies Gmbh Amidierte Peptide und ihre deamidierten Gegenstücke, die durch HLA-A*02-Moleküle präsentiert werden, zur Verwendung in der Immuntherapie gegen verschiedene Krebsarten
IL301414A (en) 2020-09-29 2023-05-01 Zoetis Services Llc Feline antibody variants
DE102020125465A1 (de) 2020-09-29 2022-03-31 Immatics Biotechnologies Gmbh Amidierte Peptide und ihre deamidierten Gegenstücke, die durch nicht-HLA-A*02-Moleküle präsentiert werden, zur Verwendung in der Immuntherapie gegen verschiedene Krebsarten
TW202229312A (zh) 2020-09-29 2022-08-01 德商英麥提克生物技術股份有限公司 由非ｈｌａ－ａ*０２顯露以用於不同類型癌症之免疫治療的醯胺化肽及其脫醯胺化對應物
TW202214294A (zh) 2020-09-30 2022-04-16 美商碩騰服務公司 具有ｈｙａＣ及ｎａｎＰ缺失之新穎多殺性巴斯德氏菌株及疫苗
EP4225950A4 (de) 2020-10-05 2025-02-26 4C Biomed Limited Marker für die reaktion auf pd-1/pd-l1-immuntherapie
TW202446417A (zh) 2020-10-05 2024-12-01 美商建南德克公司 用抗 fcrh5/抗 cd3 雙特異性抗體進行治療之給藥
WO2022073915A1 (en) 2020-10-05 2022-04-14 INSERM (Institut National de la Santé et de la Recherche Médicale) Gdf3 as biomarker and biotarget in post-ischemic cardiac remodeling
KR20230104157A (ko) 2020-10-07 2023-07-07 조에티스 서비시즈 엘엘씨 항-ngf 항체 및 그의 사용 방법
GB202015916D0 (en) 2020-10-07 2020-11-18 Adc Therapeutics Sa Combination therapy
EP4225792A1 (de) 2020-10-08 2023-08-16 Affimed GmbH Trispezifische bindemittel
EP4217378A4 (de) 2020-10-08 2025-02-26 The Trustees Of Dartmouth College Verfahren und mittel zur behandlung, prävention, diagnose und beurteilung einer therapie für fibrotische, autoimmune und entzündliche erkrankungen
US12006550B2 (en) 2020-10-12 2024-06-11 University Of South Carolina Targeting treatment for ADAM30 in pathological cells
EP3981789A1 (de) 2020-10-12 2022-04-13 Commissariat À L'Énergie Atomique Et Aux Énergies Alternatives Anti-lilrb-antikörper und verwendungen davon
MX2023004299A (es) 2020-10-13 2023-07-07 Univ Pennsylvania Direccionamiento de células t cd4+ in vivo para terapeuticos de arnm.
EP4228764A1 (de) 2020-10-14 2023-08-23 Five Prime Therapeutics, Inc. Anti-c-chemokinrezeptor-8-(ccr8)-antikörper und verfahren zur verwendung davon
CA3195512A1 (en) 2020-10-14 2022-04-21 Vahe Bedian Compositions and methods for treatment of thyroid eye disease
JP7905331B2 (ja) 2020-10-15 2026-08-14 インターベット インターナショナル ベー． フェー． イヌインターロイキン－３１受容体アルファに対するイヌ化抗体
US20230414700A1 (en) 2020-10-15 2023-12-28 INSERM (Institut National de la Santé et de la Recherche Médicale) Tg2 inhibitors for improving mucociliary clearance in respiratory diseases
US20230382978A1 (en) 2020-10-15 2023-11-30 The United States Of America, As Represented By The Secretary, Department Of Health & Human Services Antibody specific for sars-cov-2 receptor binding domain and therapeutic methods
WO2022082030A2 (en) 2020-10-15 2022-04-21 Gritstone Bio, Inc. Antigen-binding proteins and related methods of use
CN116670169A (zh) 2020-10-16 2023-08-29 魁尔斯弗生物治疗股份有限公司 与pd-l1结合的多特异性结合化合物
MX2023004395A (es) 2020-10-16 2023-05-22 Univ Georgia Glicoconjugados.
US20230372528A1 (en) 2020-10-16 2023-11-23 University Of Georgia Research Foundation, Inc. Glycoconjugates
WO2022079297A1 (en) 2020-10-16 2022-04-21 Ac Immune Sa Antibodies binding to alpha-synuclein for therapy and diagnosis
WO2022082217A1 (en) 2020-10-16 2022-04-21 Eureka Therapeutics, Inc. Compositions for preventing or treating viral and other microbial infections
WO2022084300A1 (en) 2020-10-20 2022-04-28 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods for diagnosis and monitoring form of coronavirus infection
WO2022086957A1 (en) 2020-10-20 2022-04-28 Genentech, Inc. Peg-conjugated anti-mertk antibodies and methods of use
AU2021363536A1 (en) 2020-10-20 2023-02-23 F. Hoffmann-La Roche Ag Combination therapy of PD-1 axis binding antagonists and LRRK2 inhitibors
CN113416249B (zh) 2020-10-21 2023-04-07 北京智仁美博生物科技有限公司 针对破伤风毒素的组合物
WO2022087274A1 (en) 2020-10-21 2022-04-28 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Antibodies that neutralize type-i interferon (ifn) activity
EP4232064A1 (de) 2020-10-21 2023-08-30 Institut National de la Santé et de la Recherche Médicale (INSERM) C-terminale sparc-fragmente zur behandlung von krebs
JP2023546743A (ja) 2020-10-23 2023-11-07 中山康方生物医▲藥▼有限公司 抗ｃｄ７３抗体及びその使用
US20220127344A1 (en) 2020-10-23 2022-04-28 Boehringer Ingelheim International Gmbh Anti-sema3a antibodies and their uses for treating a thrombotic disease of the retina
WO2022084531A1 (en) 2020-10-23 2022-04-28 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and compositions for treating glioma
MX2023004724A (es) 2020-10-23 2024-02-23 Hq Han Antagonistas bifuncionales de la activina y del factor alfa de necrosis tumoral y usos de los mismos.
KR20230098221A (ko) 2020-10-26 2023-07-03 아케소 바이오파마, 인크. 항-tigit 항체, 약학 조성물 및 이의 용도
JP2023546503A (ja) 2020-10-26 2023-11-02 ヤンセン ファーマシューティカ エヌ．ベー． 抗タウ抗体の安全な投与方法
AU2021367878A1 (en) 2020-10-26 2023-06-22 Janssen Pharmaceutica Nv Methods of reducing tau in human subjects
WO2022093981A1 (en) 2020-10-28 2022-05-05 Genentech, Inc. Combination therapy comprising ptpn22 inhibitors and pd-l1 binding antagonists
WO2022093641A1 (en) 2020-10-30 2022-05-05 BioLegend, Inc. Anti-nkg2a agents and compositions and methods for making and using the same
WO2022093640A1 (en) 2020-10-30 2022-05-05 BioLegend, Inc. Anti-nkg2c agents and compositions and methods for making and using the same
IL302333A (en) 2020-10-30 2023-06-01 Genentech Inc Purification platforms for obtaining pharmaceutical preparations with a reduced hydrolytic enzyme activity rate
WO2022090527A1 (en) 2020-11-02 2022-05-05 Ares Trading S.A. Combination treatment of cancer
WO2022090455A1 (en) 2020-11-02 2022-05-05 F. Hoffmann-La Roche Ag Sars-cov-2 nucleocapsid antibodies
US20230372319A1 (en) 2020-11-02 2023-11-23 Ares Trading S.A. Combination Treatment of Cancer
US11919945B2 (en) 2020-11-04 2024-03-05 The Rockefeller University Neutralizing anti-SARS-CoV-2 antibodies
JP7716473B2 (ja) 2020-11-04 2025-07-31 ジェネンテック， インコーポレイテッド 抗ｃｄ２０／抗ｃｄ３二重特異性抗体の皮下投薬
WO2022098638A2 (en) 2020-11-04 2022-05-12 Genentech, Inc. Dosing for treatment with anti-cd20/anti-cd3 bispecific antibodies
EP4240493A2 (de) 2020-11-04 2023-09-13 Genentech, Inc. Dosierung zur behandlung mit bispezifischen anti-cd20/anti-cd3-antikörpern und anti-cd79b-antikörper-wirkstoffkonjugaten
WO2022096547A1 (en) 2020-11-05 2022-05-12 INSERM (Institut National de la Santé et de la Recherche Médicale) Use of il-6 inhibitors for the treatment of acute chest syndrome in patients suffering from sickle cell disease
TW202225188A (zh) 2020-11-06 2022-07-01 德商安美基研究（慕尼黑）公司 與ｃｄ３結合的多肽構建體
WO2022097065A2 (en) 2020-11-06 2022-05-12 Novartis Ag ANTIBODY Fc VARIANTS
US20250215081A1 (en) 2020-11-06 2025-07-03 Novartis Ag Anti-cd19 agent and b cell targeting agent combination therapy for treating b cell malignancies
EP4240770A1 (de) 2020-11-06 2023-09-13 Amgen Research (Munich) GmbH Polypeptidkonstrukte mit selektiver bindung an cldn6 und cd3
JP2023548421A (ja) 2020-11-06 2023-11-16 インサーム（インスティテュ ナシオナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシェ メディカル） 多のう胞性卵巣症候群（ｐｃｏｓ）を診断および処置するための方法
CA3200317A1 (en) 2020-11-06 2022-05-12 Amgen Inc. Multitargeting bispecific antigen-binding molecules of increased selectivity
CN114437212B (zh) 2020-11-06 2023-03-14 上海麦济生物技术有限公司 抗人胸腺基质淋巴细胞生成素抗体及其制备方法和应用
AU2021373318A1 (en) 2020-11-06 2023-05-25 Amgen Inc. Antigen binding domain with reduced clipping rate
WO2022095970A1 (zh) 2020-11-06 2022-05-12 百奥泰生物制药股份有限公司 双特异抗体及其应用
AU2021373366A1 (en) 2020-11-06 2023-06-01 Novartis Ag Cd19 binding molecules and uses thereof
TW202233248A (zh) 2020-11-08 2022-09-01 美商西健公司 組合療法
JP7397996B2 (ja) 2020-11-09 2023-12-13 武田薬品工業株式会社 抗体薬物コンジュゲート
JP7849358B2 (ja) 2020-11-10 2026-04-21 サノフイ Ｃｅａｃａｍ５抗体－薬物コンジュゲート製剤
JP2023554587A (ja) 2020-11-12 2023-12-28 アンセルム（アンスティチュート・ナシオナル・ドゥ・ラ・サンテ・エ・ドゥ・ラ・ルシェルシュ・メディカル） Ｓａｒｓ－ｃｏｖ－２ スパイクタンパク質の受容体結合ドメインにコンジュゲートまたは融合している抗体およびワクチン目的でのそれらの使用
KR20230107617A (ko) 2020-11-13 2023-07-17 노파르티스 아게 키메라 항원 수용체(car)-발현 세포를 사용한 병용 요법
EP4244391A1 (de) 2020-11-16 2023-09-20 INSERM (Institut National de la Santé et de la Recherche Médicale) Verfahren und zusammensetzungen zur vorhersage und behandlung von uvealem melanom
CR20230253A (es) 2020-11-16 2023-07-26 Hoffmann La Roche Glucoformas de fab ricas en manosa
CA3202233A1 (en) 2020-11-18 2022-05-27 Kiromic BioPharma, Inc. Gamma-delta t cell manufacturing processes and chimeric pd1 receptor molecules
TW202233684A (zh) 2020-11-18 2022-09-01 美商泰尼歐生物公司 結合於葉酸受體α之重鏈抗體
GB202105804D0 (en) 2020-11-20 2021-06-09 Univ Cape Town Use of microvirin in the identification of mycobacterium tuberculosis mannose-capped lipoarabinomannan
MX2023005979A (es) 2020-11-20 2023-08-11 Scherer Technologies Llc R P Enlazadores de escisión doble de glicósido para conjugados de anticuerpo y fármaco.
KR20230110297A (ko) 2020-11-20 2023-07-21 조에티스 서비시즈 엘엘씨 소 항체 변이체
US20240002522A1 (en) 2020-11-20 2024-01-04 Inserm (Institut National De La Sante Et De La Recherche Medicale Anti-cd25 antibodies
US20240002521A1 (en) 2020-11-20 2024-01-04 INSERM (Institut National de la Santé et de la Recherche Médicale) Anti-cd25 antibodies
CA3199429A1 (en) 2020-11-23 2022-05-27 Davide Corti Anti-influenza antibodies and combinations thereof
WO2022106726A2 (en) 2020-11-23 2022-05-27 Norimun As IgY ANTIBODIES FOR THE PREVENTION AND TREATMENT OF CORONA VIRUS CAUSED DISEASES
KR20230135569A (ko) 2020-11-23 2023-09-25 비르 바이오테크놀로지, 인코포레이티드 인플루엔자 a 바이러스에 대한 항체
PH12023551390A1 (en) 2020-11-23 2023-12-04 Humabs Biomed Sa Broadly neutralizing antibodies against influenza neuraminidase
GB202018395D0 (en) 2020-11-23 2021-01-06 Scancell Ltd Immunotherapy
JP2023553808A (ja) 2020-11-24 2023-12-26 ノバルティス アーゲー Ｍｃｌ－１阻害剤抗体－薬物コンジュゲートおよび使用方法
CN116761635A (zh) 2020-11-24 2023-09-15 诺华股份有限公司 Bcl-xl抑制剂抗体药物缀合物及其使用方法
EP4251187A4 (de) 2020-11-25 2025-09-10 Xilio Dev Inc Tumorspezifische spaltbare linker
JP2023550785A (ja) 2020-11-25 2023-12-05 ヴィア・バイオテクノロジー・インコーポレイテッド 複数のベータコロナウイルスに結合する抗体
JP2024501121A (ja) 2020-11-25 2024-01-11 イナート・ファルマ・ソシエテ・アノニム 癌の処置
EP4251283A1 (de) 2020-11-27 2023-10-04 General Nanotherapeutics LLC Verfahren und zusammensetzung zur behandlung von immunvermittelten erkrankungen
EP4251282A1 (de) 2020-11-27 2023-10-04 Institut National de la Santé et de la Recherche Médicale (INSERM) Verfahren zur diagnose und überwachung von toxischer epidermaler nekrolyse
IL303317A (en) 2020-12-01 2023-07-01 Akouos Inc ANTI-NATURAL ANTIBODY STRUCTURES AND RELATED METHODS FOR THE TREATMENT OF SYMPTOMS ASSOCIATED WITH VESTIBULAR SWANNOMA
WO2022119841A1 (en) 2020-12-01 2022-06-09 Abbott Laboratories Use of one or more biomarkers to determine traumatic brain injury (tbi) in a subject having received a head computerized tomography scan that is negative for a tbi
WO2023102384A1 (en) 2021-11-30 2023-06-08 Abbott Laboratories Use of one or more biomarkers to determine traumatic brain injury (tbi) in a subject having received a head computerized tomography scan that is negative for a tbi
WO2022117040A1 (zh) 2020-12-02 2022-06-09 迈威(上海)生物科技股份有限公司 抗人b7-h3抗体及其应用
US20240024500A1 (en) 2020-12-02 2024-01-25 Westfaelische Wilhelms-Universitaet Muenster Electrostatic nanoparticles and use thereof
JP2023553399A (ja) 2020-12-02 2023-12-21 アレクトル エルエルシー 抗ソルチリン抗体の使用法
CN116723861A (zh) 2020-12-02 2023-09-08 上海复宏汉霖生物技术股份有限公司 抗GARP/TGFβ抗体及使用方法
EP4255451A4 (de) 2020-12-03 2025-01-01 The Board Of Regents Of The University Of Texas System Verfahren zur identifizierung von lilrb-blockierenden antikörpern
AU2021390550A1 (en) 2020-12-04 2023-06-22 Qiagen Sciences Llc Compositions and methods for diagnosing sars-cov-2 (covid-19) and for monitoring sars-cov-2-specific immunological memory
CA3203977A1 (en) 2020-12-04 2022-06-09 Visterra, Inc. Methods of using interleukin-2 agents
US20240067758A1 (en) 2020-12-07 2024-02-29 UCB Biopharma SRL Multi-specific antibodies and antibody combinations
EP4255435A4 (de) 2020-12-07 2025-01-08 Siemens Healthcare Diagnostics, Inc. Dibromopyridazindione enthaltende etiketten für immunoassays und verfahren zu ihrer herstellung und verwendung
BR112023008265A2 (pt) 2020-12-07 2024-02-06 UCB Biopharma SRL Anticorpos contra interleucina-22
TW202237639A (zh) 2020-12-09 2022-10-01 日商武田藥品工業股份有限公司 鳥苷酸環化酶ｃ（ｇｃｃ）抗原結合劑之組成物及其使用方法
TW202237638A (zh) 2020-12-09 2022-10-01 日商武田藥品工業股份有限公司 烏苷酸環化酶ｃ（ｇｃｃ）抗原結合劑之組成物及其使用方法
US20240025985A1 (en) 2020-12-09 2024-01-25 National University Corporation Tokyo Medical And Dental University Agent for Preventing or Treating Frontotemporal Lobar Degeneration
WO2022130023A1 (en) 2020-12-14 2022-06-23 University Health Network Immunoglobulin light chain antibodies and uses thereof
US20220184124A1 (en) 2020-12-14 2022-06-16 Allogene Therapeutics, Inc. Methods and reagents for characterizing car t cells for therapies
EP4259661A1 (de) 2020-12-14 2023-10-18 Novartis AG Reverse bindemittel für anti-natriuretische peptidrezeptor-1 (npr1)-antikörper und verwendungen davon
WO2022130206A1 (en) 2020-12-16 2022-06-23 Pfizer Inc. TGFβr1 INHIBITOR COMBINATION THERAPIES
KR20230157296A (ko) 2020-12-16 2023-11-16 보이저 테라퓨틱스, 인크. 타우 결합 화합물
EP4262858A1 (de) 2020-12-16 2023-10-25 Molecular Templates, Inc. Klinische verfahren zur verwendung eines pd-l1-bindenden moleküls mit einem shigatoxineffektor
WO2022129120A1 (en) 2020-12-17 2022-06-23 F. Hoffmann-La Roche Ag Anti-hla-g antibodies and use thereof
CN112500491B (zh) 2020-12-18 2022-04-08 深圳市迈加瑞生物技术有限公司 一种特异性中和辅助性T细胞TGF-β信号的双特异性抗体、其药物组合及其用途
MX2023007028A (es) 2020-12-18 2023-09-21 Kiniksa Pharmaceuticals Ltd Composiciones de proteínas y métodos para producir y usar las mismas.
US20240400708A1 (en) 2020-12-18 2024-12-05 Zoetis Services Llc Mutations in feline antibody constant regions
EP4740951A3 (de) 2020-12-22 2026-08-05 Foundation Medicine, Inc. Igh-umordnungen und deren verwendung
CN116670282A (zh) 2020-12-22 2023-08-29 豪夫迈·罗氏有限公司 靶向xbp1的寡核苷酸
US20240131138A1 (en) 2020-12-23 2024-04-25 Institut National De La Santé Et De La Recherche Médicale (Inserm) Chlamydia vaccine based on targeting momp vs4 antigen to antigen presenting cells
WO2022140797A1 (en) 2020-12-23 2022-06-30 Immunowake Inc. Immunocytokines and uses thereof
CA3197426A1 (en) * 2020-12-23 2022-06-30 Regeneron Pharmaceuticals, Inc. Methods for obtaining antibodies that bind transmembrane proteins and cells that produce the same
MX2023007611A (es) 2020-12-23 2023-07-12 Cantargia Ab Anticuerpo anti-il1rap.
US20240317871A1 (en) 2020-12-30 2024-09-26 Immunomic Therapeutics, Inc. Anti-HVEM Antibodies
EP4273167A4 (de) 2020-12-30 2025-03-26 Bio-Thera Solutions, Ltd. Anti-cldn18.2-antikörper sowie herstellungsverfahren dafür und verwendung davon
CN114685669A (zh) 2020-12-30 2022-07-01 和铂医药(苏州)有限公司 结合trop2的抗体及其用途
WO2022147147A1 (en) 2020-12-30 2022-07-07 Abbott Laboratories Methods for determining sars-cov-2 antigen and anti-sars-cov-2 antibody in a sample
US20250199010A1 (en) 2020-12-31 2025-06-19 Alamar Biosciences, Inc. Binder molecules with high affinity and/ or specificity and methods of making and use thereof
CN116829598A (zh) 2021-01-06 2023-09-29 豪夫迈·罗氏有限公司 采用pd1-lag3双特异性抗体和cd20 t细胞双特异性抗体的组合疗法
AU2022205313A1 (en) 2021-01-06 2023-07-20 Tonix Pharma Limited Methods of inducing immune tolerance with modified anti-cd154 antibodies
PE20240690A1 (es) 2021-01-12 2024-04-10 Hoffmann La Roche Anticuerpos split que se unen a celulas cancerosas y dirigen radionuclidos a dichas celulas
EP4277665A1 (de) 2021-01-13 2023-11-22 Memorial Sloan Kettering Cancer Center Anti-dll3-antikörper-wirkstoff-konjugat
CN114763381B (zh) 2021-01-13 2025-01-28 博生吉医药科技(苏州)有限公司 B7-h3嵌合抗原受体修饰的t细胞及其应用
CN117425501A (zh) 2021-01-13 2024-01-19 纪念斯隆凯特琳癌症中心 抗体-吡咯并苯二氮䓬衍生物缀合物
WO2022155503A1 (en) 2021-01-14 2022-07-21 Gritstone Bio, Inc. Multi-specific antibodies and methods of use
EP4277904A1 (de) 2021-01-15 2023-11-22 Seagen Inc. Immunmodulatorische antikörper-wirkstoff-konjugate
EP4277926A1 (de) 2021-01-15 2023-11-22 The Rockefeller University Neutralisierende anti-sars-cov-2-antikörper
TW202241925A (zh) 2021-01-15 2022-11-01 德商英麥提克生物技術股份有限公司 用於不同類型癌症免疫治療的ｈｌａ展示肽
CA3208974A1 (en) 2021-01-20 2022-07-28 Bioentre Llc Ctla4-binding proteins and methods of treating cancer
AR124681A1 (es) 2021-01-20 2023-04-26 Abbvie Inc Conjugados anticuerpo-fármaco anti-egfr
WO2022159590A1 (en) 2021-01-20 2022-07-28 Visterra, Inc. Interleukin-2 mutants and uses thereof
US20240101717A1 (en) 2021-01-22 2024-03-28 Bionecure Therapeutics, Inc. Anti-her-2/trop-2 constructs and uses thereof
JP2024512824A (ja) 2021-01-22 2024-03-19 ロイヤル カレッジ オブ サージャンズ イン アイルランド コロナウイルスの治療
WO2022159842A1 (en) 2021-01-25 2022-07-28 Vir Biotechnology, Inc. Antibody combination therapies for sars-cov-2 infection
WO2022162587A1 (en) 2021-01-27 2022-08-04 Centre Hospitalier Universitaire Vaudois (C.H.U.V.) Anti-sars-cov-2 antibodies and use thereof in the treatment of sars-cov-2 infection
MX2023008785A (es) 2021-01-28 2023-12-14 Zoetis Services Llc Mutaciones en regiones constantes de anticuerpos caninos.
US12653400B2 (en) 2021-01-29 2026-06-16 The Regents Of The University Of California Implantable imagers for in vivo imaging
EP4284510A1 (de) 2021-01-29 2023-12-06 Novartis AG Dosierungsschemata für anti-cd73- und anti-enpd2-antikörper und verwendungen davon
MX2023008986A (es) 2021-01-29 2023-08-15 Inst Nat Sante Rech Med Polipeptidos antigenicos de chlamydia trachomatis y usos de los mismos con fines de vacuna.
GB2603166A (en) 2021-01-29 2022-08-03 Thelper As Therapeutic and Diagnostic Agents and Uses Thereof
AU2022212007A1 (en) 2021-01-29 2023-09-07 Merck Sharp & Dohme Llc Compositions of programmed death receptor 1 (pd-1) antibodies and methods of obtaining the compositions thereof
IL303859A (en) 2021-02-03 2023-08-01 Allogene Therapeutics Inc Formulations and processes for CAR T CELL drug products
MX2023009113A (es) 2021-02-03 2023-08-10 Seagen Inc Conjugados y compuestos inmunoestimulantes.
EP4288458A1 (de) 2021-02-03 2023-12-13 Genentech, Inc. Degraderplattform für multispezifische bindungsproteine und verfahren zur verwendung
CN113501878B (zh) 2021-02-03 2022-12-02 北京智仁美博生物科技有限公司 针对人tslp的多种抗体及其用途
EP4288457A2 (de) 2021-02-05 2023-12-13 Boehringer Ingelheim International GmbH Anti-il1rap-antikörper
CN117136197A (zh) 2021-02-09 2023-11-28 胡默波斯生物医学公司 抗呼吸道合胞病毒、人偏肺病毒和小鼠肺炎病毒的抗体和其使用方法
CA3207791A1 (en) 2021-02-09 2022-08-18 Shanghai Junshi Biosciences Co., Ltd. Anti-cd112r antibody and use thereof
CN120093941A (zh) 2021-02-09 2025-06-06 苏州宜联生物医药有限公司 生物活性物偶联物及其制备方法和用途
US20240123058A1 (en) 2021-02-10 2024-04-18 Xiamen University Epitope peptide and antibody for preventing and treating eb virus infection and related diseases
KR20230159823A (ko) 2021-02-11 2023-11-22 넥틴 테라퓨틱스 리미티드 Cd112r에 대한 항체 및 이의 용도
WO2022172085A2 (en) 2021-02-15 2022-08-18 Takeda Pharmaceutical Company Limited Cell therapy compositions and methods for modulating tgf-b signaling
GB202102396D0 (en) 2021-02-19 2021-04-07 Adc Therapeutics Sa Molecular adjuvant
BR112023016713A2 (pt) 2021-02-19 2023-10-31 Seoul Nat Univ R&Db Foundation Anticorpo ou um fragmento de ligação ao antígeno do mesmo, molécula de ácido nucleico, métodos para produzir um anticorpo ou um fragmento de ligação ao antígeno do mesmo e para detectar agrupamento de diferenciação 47 ou determinar uma quantidade de agrupamento de diferenciação 47 em uma amostra, e, uso do anticorpo ou de um fragmento de ligação ao antígeno do mesmo
EP4047016A1 (de) 2021-02-19 2022-08-24 Université de Strasbourg Anti-tenascin-c(tnc)-antikörper (nanobodies) mit einer einzigen domäne und deren verwendung
CA3208641A1 (en) 2021-02-19 2022-08-25 Ashraf AMANULLAH Formulations of dr5 binding polypeptides
CN116917322A (zh) 2021-02-19 2023-10-20 沙裴隆有限公司 针对pd-l1及cd47的双特异性单域抗体及其用途
BR112023016706A2 (pt) 2021-02-19 2023-10-31 Seoul Nat Univ R&Db Foundation Anticorpo ou um fragmento de ligação ao antígeno do mesmo, molécula de ácido nucleico, métodos para produzir um anticorpo ou um fragmento de ligação ao antígeno do mesmo e para detectar agrupamento de diferenciação 47 ou determinar uma quantidade de agrupamento de diferenciação 47 em uma amostra, e, uso do anticorpo ou de um fragmento de ligação ao antígeno do mesmo
WO2022182415A1 (en) 2021-02-24 2022-09-01 Massachusetts Institute Of Technology Himastatin derivatives, and processes of preparation thereof, and uses thereof
US20240230671A9 (en) 2021-02-24 2024-07-11 Alladapt Immunotherapeutics, Inc. Compositions and methods for identification of cross-reactive allergenic proteins and treatment of allergies
US12521444B2 (en) 2021-02-25 2026-01-13 Fortvita Biologics Limited Anti-HER2 antibody-drug conjugates and uses thereof
WO2022183074A2 (en) 2021-02-25 2022-09-01 Teneobio, Inc. Anti-psma antibodies and car-t structures
MX2023009882A (es) 2021-02-26 2023-08-30 Teneobio Inc Anticuerpos anti-muc1-c y estructuras car-t.
JP2024507958A (ja) 2021-02-26 2024-02-21 ナンジン レジェンド バイオテック カンパニー，リミテッド 外因的に導入されたサイトカインを発現する操作された免疫エフェクター細胞
CA3211686A1 (en) 2021-02-26 2022-09-01 Bayer Aktiengesellschaft Inhibitors of il-11 or il-11ra for use in the treatment of abnormal uterine bleeding
WO2022187272A1 (en) 2021-03-01 2022-09-09 Xilio Development, Inc. Combination of masked ctla4 and pd1/pdl1 antibodies for treating cancer
TW202317612A (zh) 2021-03-01 2023-05-01 美商艾希利歐發展股份有限公司 用於治療癌症的ｃｔｌａ４及ｐｄ１／ｐｄｌ１抗體之組合
MX2023010055A (es) 2021-03-01 2023-11-17 Scirhom Gmbh Anticuerpos humanizados contra irhom2.
JP2024509165A (ja) 2021-03-02 2024-02-29 シージーアールピー ダイアグノスティクス ゲーエムベーハー 片頭痛の治療及び／又は発生の低減
KR20230165212A (ko) 2021-03-02 2023-12-05 다나-파버 캔서 인스티튜트 인크. 적혈구 장애의 치료 방법
WO2022184082A1 (en) 2021-03-03 2022-09-09 Sorrento Therapeutics, Inc. Antibody-drug conjugates comprising an anti-bcma antibody
BR112023014103A2 (pt) 2021-03-04 2023-10-10 Boehringer Ingelheim Int Métodos para o tratamento de gpp
EP4301782A1 (de) 2021-03-05 2024-01-10 Go Therapeutics, Inc. Anti-glyco-cd44-antikörper und deren verwendungen
CN117715933A (zh) 2021-03-05 2024-03-15 当康生物技术有限责任公司 抗vista的构建体及其用途
WO2022187626A1 (en) 2021-03-05 2022-09-09 Regeneron Pharmaceuticals, Inc. Anti-sars-cov-2-variant-spike glycoprotein antibodies and antigen-binding fragments
US20240150455A1 (en) 2021-03-05 2024-05-09 Shanghai GenBase Biotechnology Co., Ltd. Anti-cldn6 antibody and use thereof
WO2022188652A1 (zh) 2021-03-09 2022-09-15 四川科伦博泰生物医药股份有限公司 Ror1结合蛋白及其用途
EP4294927A2 (de) 2021-03-10 2023-12-27 Immunowake Inc. Immunmodulatorische moleküle und verwendungen davon
CN114933649B (zh) 2021-03-10 2023-04-21 北京智仁美博生物科技有限公司 抗水痘-带状疱疹病毒的抗体及其用途
CN117320749A (zh) 2021-03-12 2023-12-29 中外制药株式会社 用于治疗或预防重症肌无力的药物组合物
CA3212551A1 (en) 2021-03-12 2022-09-15 Trince bv Methods for delivering a cargo into a cell
BR112023018353A2 (pt) 2021-03-12 2024-02-06 Janssen Biotech Inc Método seguro e eficaz para tratamento da artrite psoriática com anticorpo específico anti-il23
AU2022233411A1 (en) 2021-03-12 2023-09-14 Akeso Biopharma, Inc. Pharmaceutical combination containing anti-pd-1-anti-vegfa bispecific antibody, and use thereof
EP4304732A1 (de) 2021-03-12 2024-01-17 Genentech, Inc. Anti-klk7-antikörper, anti-klk5-antikörper, multispezifische anti-klk5/klk7-antikörper und verfahren zur verwendung
EP4305062A1 (de) 2021-03-12 2024-01-17 Janssen Biotech, Inc. Verfahren zur behandlung von patienten mit psoriasisarthritis mit unzureichender reaktion auf eine tnf-therapie mit anti-il23-spezifischem antikörper
EP4454652A3 (de) 2021-03-15 2025-05-21 F. Hoffmann-La Roche AG Zusammensetzungen und verfahren zur behandlung von lupus nephritis
EP4308603A1 (de) 2021-03-17 2024-01-24 Receptos Llc Verfahren zur behandlung von atopischer dermatitis mit anti-il-13-antikörpern
GB202103706D0 (en) 2021-03-17 2021-04-28 Ucl Business Ltd CD160 binding domain
US20220306700A1 (en) 2021-03-17 2022-09-29 Molecular Templates, Inc. Pd-l1 binding proteins comprising shiga toxin a subunit scaffolds and cd8+ t cell antigens
US20240165094A1 (en) 2021-03-17 2024-05-23 Institut National de la Santé et de la Recherche Médicale Methods and compositions for treating melanoma
JP2024510435A (ja) 2021-03-18 2024-03-07 シージェン インコーポレイテッド 生体活性化合物の内部移行複合体からの選択的薬物放出
WO2022195051A1 (en) 2021-03-18 2022-09-22 Université De Genève Peptides and use thereof for diagnosing and treating antiphospholipid syndrome
EP4308935A1 (de) 2021-03-18 2024-01-24 Novartis AG Biomarker für krebs und verfahren zur verwendung davon
US20240174746A1 (en) 2021-03-18 2024-05-30 Alector Llc Anti-tmem106b antibodies and methods of use thereof
EP4308607A2 (de) 2021-03-18 2024-01-24 MedImmune Limited An ccr9 bindendes therapeutisches bindungsmolekül
IL305886A (en) 2021-03-18 2023-11-01 Seagen Inc Selective release of drugs from internalized conjugates of biologically active compounds
WO2022195504A1 (en) 2021-03-19 2022-09-22 Pfizer Inc. Method of treating osteoarthritis pain with an anti ngf antibody
WO2022197877A1 (en) 2021-03-19 2022-09-22 Genentech, Inc. Methods and compositions for time delayed bio-orthogonal release of cytotoxic agents
US12448444B2 (en) 2021-03-22 2025-10-21 Novimmune Sa Bispecific antibodies targeting CD47 and PD-L1 and methods of use thereof
JP2024512574A (ja) 2021-03-22 2024-03-19 ノビミューン エスアー Ｃｄ４７およびｐｄ－ｌ１を標的とする二重特異性抗体ならびにその使用方法
WO2022204071A1 (en) 2021-03-22 2022-09-29 Juno Therapeutics, Inc. Method to assess potency of viral vector particles
US20240168012A1 (en) 2021-03-22 2024-05-23 Juno Therapeutics, Inc. Methods of determining potency of a therapeutic cell composition
KR20240012352A (ko) 2021-03-23 2024-01-29 인쎄름 (엥스띠뛰 나씨오날 드 라 쌍떼 에 드 라 흐쉐르슈 메디깔) T 세포 림프종의 진단 및 치료 방법
EP4314063A1 (de) 2021-03-23 2024-02-07 Alector LLC Anti-tmem106b-antikörper zur behandlung und prävention von coronavirusinfektionen
WO2022204202A1 (en) 2021-03-23 2022-09-29 Vir Biotechnology, Inc. Antibodies that bind to multiple sarbecoviruses
GB202104037D0 (en) 2021-03-23 2021-05-05 Bergenbio Asa Combination therapy
US12365739B2 (en) 2021-03-24 2025-07-22 Wake Forest University Health Sciences Monoclonal antibodies to angiotensin-(1-12), compositions including the same, and methods of use thereof
WO2022204724A1 (en) 2021-03-25 2022-09-29 Dynamicure Biotechnology Llc Anti-igfbp7 constructs and uses thereof
WO2022201122A1 (en) 2021-03-26 2022-09-29 Janssen Biotech, Inc. Humanized antibodies against paired helical filament tau and uses thereof
CA3214310A1 (en) 2021-03-26 2022-09-29 Rupesh Nanjunda Anti-tau antibodies and uses thereof
WO2022204529A1 (en) 2021-03-26 2022-09-29 Abcuro, Inc. Anti-klrg1 antibodies
CA3212311A1 (en) 2021-03-26 2022-09-29 Abcuro, Inc. Anti-klrg1 antibodies
BR112023019689A2 (pt) 2021-03-26 2023-10-31 Arcellx Inc Terapias multifuncionais de célula imunológica
WO2022204581A2 (en) 2021-03-26 2022-09-29 Scholar Rock, Inc. Tgf-beta inhibitors and use thereof
US20240174744A1 (en) 2021-03-29 2024-05-30 Scirhom Gmbh Methods of treatment using protein binders to irhom2 epitopes
IL307233A (en) 2021-03-30 2023-11-01 Bayer Ag Anti-SEMA3A antibodies and uses thereof
AU2022249605A1 (en) 2021-03-31 2023-09-14 F. Hoffmann-La Roche Ag Purification of antibodies by mixed mode chromatography
TW202304508A (zh) 2021-03-31 2023-02-01 美商百歐維拉提夫美國公司 減少冷凝集素疾病患者之手術相關溶血
WO2022212836A1 (en) 2021-04-01 2022-10-06 Pyxis Oncology, Inc. Gpnmb antibodies and methods of use
TW202304994A (zh) 2021-04-02 2023-02-01 美商泰尼歐生物公司 促效性抗ｉｌ－２ｒ抗體及使用方法
US20250282887A1 (en) 2021-04-02 2025-09-11 Amgen Inc. Mageb2 binding constructs
JP2024514530A (ja) 2021-04-02 2024-04-02 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア 切断型ｃｄｃｐ１に対する抗体およびその使用
JPWO2022215679A1 (de) 2021-04-05 2022-10-13
CA3214821A1 (en) 2021-04-06 2022-10-13 Guisong WANG Protein markers for estrogen receptor (er)-positive-like and estrogen receptor (er)-negative-like breast cancer
US20240402177A1 (en) 2021-04-06 2024-12-05 Bpgbio, Inc. Protein markers for estrogen receptor (er)-positive luminal a (la)-like and luminal b1 (lb1)-like breast cancer
PE20260568A1 (es) 2021-04-06 2026-03-10 Teneobio Inc Anticuerpos anti-cd19 y estructuras car-t
WO2022216798A1 (en) 2021-04-06 2022-10-13 Berg Llc Protein markers for the prognosis of breast cancer progression
TW202304979A (zh) 2021-04-07 2023-02-01 瑞士商諾華公司 抗ＴＧＦβ抗體及其他治療劑用於治療增殖性疾病之用途
US12016860B2 (en) 2021-04-08 2024-06-25 Nurix Therapeutics, Inc. Combination therapies with Cbl-b inhibitor compounds
TW202305009A (zh) 2021-04-08 2023-02-01 美商默沙東有限責任公司 以皮下投予抗pd1抗體治療癌症之方法
CA3214757A1 (en) 2021-04-08 2022-10-13 Andreas Loew Multifuntional molecules binding to tcr and uses thereof
EP4320153A1 (de) 2021-04-09 2024-02-14 INSERM (Institut National de la Santé et de la Recherche Médicale) Verfahren zur behandlung von anaplastischem grosszelligem lymphom
JP2024513474A (ja) 2021-04-09 2024-03-25 エフ． ホフマン－ラ ロシュ アーゲー 異種ポリペプチドを発現する細胞クローンを選択するための方法
CN117202897A (zh) 2021-04-09 2023-12-08 基因泰克公司 使用raf抑制剂和pd-1轴抑制剂的组合疗法
JP2024514816A (ja) 2021-04-09 2024-04-03 シージェン インコーポレイテッド 抗ｔｉｇｉｔ抗体を用いるがんの治療方法
WO2022218957A1 (en) 2021-04-12 2022-10-20 Acm Biolabs Pte Ltd Polymersomes comprising a soluble encapsulated polynucleotide and an ionizable lipid as well as methods of making and uses thereof
GB202105187D0 (en) 2021-04-12 2021-05-26 Medimmune Ltd Pyrrolobenzodiazepine conjugates
WO2022218998A1 (en) 2021-04-13 2022-10-20 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods for treating hepatitis b and d virus infection
WO2022218384A1 (zh) 2021-04-14 2022-10-20 中山康方生物医药有限公司 抗cd47的单克隆抗体及其用途
WO2022221409A1 (en) 2021-04-14 2022-10-20 Villaris Therapeutics, Inc. Anti-cd122 antibodies and uses thereof
CN115215937B (zh) 2021-04-15 2023-05-26 上海麦济生物技术有限公司 抗人masp-2抗体及其制备方法和应用
AR125344A1 (es) 2021-04-15 2023-07-05 Chugai Pharmaceutical Co Ltd Anticuerpo anti-c1s
US20220332822A1 (en) 2021-04-16 2022-10-20 Tiziana Life Sciences Plc Subcutaneous administration of antibodies for the treatment of disease
CN117337303A (zh) 2021-04-16 2024-01-02 特尼奥生物股份有限公司 抗cd20抗体及car-t结构
JP2024514222A (ja) 2021-04-19 2024-03-28 ジェネンテック， インコーポレイテッド 改変された哺乳動物細胞
US20240368605A1 (en) 2021-04-19 2024-11-07 Institut National de la Santé et de la Recherche Médicale Use of splice switching oligonucleotides for exon skipping-mediated knockdown of pim2
CA3212610A1 (en) 2021-04-20 2022-10-27 Philip MOQUIST Modulation of antibody-dependent cellular cytotoxicity
US20240190951A1 (en) 2021-04-23 2024-06-13 Amgen Inc. Anti-tslp antibody compositions and uses thereof
EP4326903A1 (de) 2021-04-23 2024-02-28 Inserm (Institut National De La Sante Et De La Recherche Medicale) Verfahren und zusammensetzungen zur behandlung von krankheiten im zusammenhang mit zellalterungsansammlung
KR20230175245A (ko) 2021-04-23 2023-12-29 암젠 인크 변형된 항-tslp 항체
WO2022228364A1 (zh) 2021-04-25 2022-11-03 江苏恒瑞医药股份有限公司 抗masp2抗体、其抗原结合片段及医药用途
TW202302649A (zh) 2021-04-26 2023-01-16 大陸商江蘇恆瑞醫藥股份有限公司 抗ｎｅｃｔｉｎ－４抗體和抗ｎｅｃｔｉｎ－４抗體－藥物偶聯物及其醫藥用途
US12472248B2 (en) 2021-04-29 2025-11-18 The Government Of The United States, As Represented By The Secretary Of The Army Antibodies against fentanyl and fentanyl analogs
CN117396231A (zh) 2021-04-30 2024-01-12 新基公司 使用抗BCMA抗体药物缀合物（ADC）与γ分泌酶抑制剂（GSI）的组合的组合疗法
CA3213632A1 (en) 2021-04-30 2022-11-03 F. Hoffmann-La Roche Ag Dosing for combination treatment with anti-cd20/anti-cd3 bispecific antibody and anti-cd79b antibody drug conjugate
WO2022228706A1 (en) 2021-04-30 2022-11-03 F. Hoffmann-La Roche Ag Dosing for treatment with anti-cd20/anti-cd3 bispecific antibody
US20250281633A1 (en) 2021-05-03 2025-09-11 Merck Patent Gmbh Her2 targeting fc antigen binding fragment-drug conjugates
AR125732A1 (es) 2021-05-03 2023-08-09 UCB Biopharma SRL Anticuerpos anti-trem1
BR112023022878A2 (pt) 2021-05-04 2024-01-23 Regeneron Pharma Agonistas do receptor fgf21 multiespecíficos e seus usos
MX2023012929A (es) 2021-05-05 2023-11-13 Huyabio Int Llc Terapias de combinacion que comprenden inhibidores de shp2 e inhibidores de tirosina cinasa egfr.
WO2022235867A2 (en) 2021-05-06 2022-11-10 The Rockefeller University Neutralizing anti-sars- cov-2 antibodies and methods of use thereof
US20240262917A1 (en) 2021-05-06 2024-08-08 Dana-Farber Cancer Institute, Inc. Antibodies against alk and methods of use thereof
MX2023012931A (es) 2021-05-06 2023-11-13 Amgen Res Munich Gmbh Moleculas de union a antigeno dirigidas a cd20 y cd22 para su uso en enfermedades proliferativas.
US20240262893A1 (en) 2021-05-12 2024-08-08 Applied Biomedical Science Institute Binding polypeptides against sars cov-2 and uses thereof
EP4337266A1 (de) 2021-05-12 2024-03-20 Genentech, Inc. Verfahren zur verwendung von anti-cd79b-immunkonjugaten zur behandlung von diffusem grossem b-zell-lymphom
KR20240007171A (ko) 2021-05-14 2024-01-16 제넨테크, 인크. 모수네투주맙 및 폴라투주맙 베도틴을 이용한 cd20 양성 증식성 장애의 치료 방법
WO2022241082A1 (en) 2021-05-14 2022-11-17 Genentech, Inc. Agonists of trem2
WO2022246433A1 (en) 2021-05-18 2022-11-24 University Of Tennessee Research Foundation Antibody-peptide fusion proteins for treating amyloid disorders
AU2022279156A1 (en) 2021-05-18 2023-11-02 Abbott Laboratories Methods of evaluating brain injury in a pediatric subject
EP4340876A1 (de) 2021-05-19 2024-03-27 Sutro Biopharma, Inc. Kombinationstherapie mit anti-folat-rezeptorkonjugaten mit bevacizumab
BR112023024064A2 (pt) 2021-05-20 2024-01-30 Janssen Biotech Inc Método de tratamento de doença inflamatória intestinal com uma terapia de combinação de anticorpos para il-23 e tnf-alfa
US12252550B2 (en) 2021-05-20 2025-03-18 Dianthus Therapeutics Opco, Inc. Antibodies that bind to C1S and uses thereof
KR20240012502A (ko) 2021-05-21 2024-01-29 세바스티안 보이머 프로타민 기반 나노입자의 표적 화합물로서의 항체-프로타민 융합
CN117396599A (zh) 2021-05-21 2024-01-12 基因泰克公司 用于生产目的重组产物的经修饰的细胞
KR20240035758A (ko) 2021-05-24 2024-03-18 비르 바이오테크놀로지, 인코포레이티드 조작된 폴리펩타이드
US20240226319A1 (en) 2021-05-25 2024-07-11 Merck Patent Gmbh Egfr targeting fc antigen binding fragment-drug conjugates
CA3220629A1 (en) 2021-05-28 2022-12-01 Tobin J. CAMMETT Methods for detecting cm-tma biomarkers
GB202107706D0 (en) 2021-05-28 2021-07-14 Adc Therapeutics S A Combination therapy
WO2022248268A1 (en) 2021-05-28 2022-12-01 Adc Therapeutics Sa Combination therapy
GB202107713D0 (en) 2021-05-28 2021-07-14 Medimmune Ltd Combination therapy
IL308795A (en) 2021-05-28 2024-01-01 Seagen Inc Anthracycline antibody conjugates
GB202107709D0 (en) 2021-05-28 2021-07-14 Adc Therapeutics S A Combination therapy
CA3217029A1 (en) 2021-05-30 2022-12-08 Biolojic Design Ltd. Engineered dual binding antibodies and uses thereof
JP7855319B2 (ja) 2021-05-31 2026-05-08 ワイズ・エー・シー株式会社 抗ｃｄ２６抗体と免疫チェックポイント阻害剤との併用療法
EP4347663A4 (de) 2021-05-31 2025-05-14 Shijiazhuang Yiling Pharmaceutical Co., Ltd. Monoklonale antikörper gegen cldn18.2 und fc-manipulierte versionen davon
WO2022253756A1 (en) 2021-06-01 2022-12-08 INSERM (Institut National de la Santé et de la Recherche Médicale) Use of b cell depleting agents for the treatment of rheumatic heart disease
CN117715940A (zh) 2021-06-02 2024-03-15 伊诺特伦公司 抗trem-1抗体
EP4348260A2 (de) 2021-06-03 2024-04-10 Scholar Rock, Inc. Tgf-beta inhibitoren und deren therapeutische verwendung
WO2022256534A1 (en) 2021-06-03 2022-12-08 Synthorx, Inc. Head and neck cancer combination therapy comprising an il-2 conjugate and pembrolizumab
TW202307006A (zh) 2021-06-03 2023-02-16 美商表面腫瘤學公司 用抗ｃｄ３９抗體及派姆單抗治療癌症之方法
JP2024520261A (ja) 2021-06-04 2024-05-24 中外製薬株式会社 抗ｄｄｒ２抗体およびその使用
GB202108055D0 (en) 2021-06-04 2021-07-21 Univ Court Of The Univ Of Aberdeen Antibodies and methods for generating the same
AU2022284373A1 (en) 2021-06-04 2024-01-04 Boehringer Ingelheim International Gmbh Anti-sirp-alpha antibodies
EP4351640A1 (de) 2021-06-07 2024-04-17 Ares Trading S.A. Kombinationsbehandlung von krebs
WO2022261183A2 (en) 2021-06-08 2022-12-15 Dana-Farber Cancer Institute, Inc. Compositions and methods for treating and/or identifying an agent for treating intestinal cancers
IL308015A (en) 2021-06-09 2023-12-01 Hoffmann La Roche Combination of a particular braf inhibitor (paradox breaker) and a pd-1 axis binding antagonist for use in the treatment of cancer
CA3221924A1 (en) 2021-06-11 2022-12-15 Genentech, Inc. Method for treating chronic obstructive pulmonary disease with an st2 antagonist
CA3218481A1 (en) 2021-06-14 2022-12-22 argenx BV Anti-il-9 antibodies and methods of use thereof
WO2022266034A1 (en) 2021-06-14 2022-12-22 Abbott Laboratories Methods of diagnosing or aiding in diagnosis of brain injury caused by acoustic energy, electromagnetic energy, an over pressurization wave, and/or blast wind
CN117642426A (zh) 2021-06-16 2024-03-01 艾莱克特有限责任公司 双特异性抗MerTK和抗PDL1抗体及其使用方法
WO2022266221A1 (en) 2021-06-16 2022-12-22 Alector Llc Monovalent anti-mertk antibodies and methods of use thereof
WO2022265912A1 (en) 2021-06-16 2022-12-22 Gundersen Lutheran Medical Foundation, Inc. Antibodies targeting an amphiregulin-derived cell surface neo-epitope
WO2022263638A1 (en) 2021-06-17 2022-12-22 Centre Hospitalier Universitaire Vaudois (C.H.U.V.) Anti-sars-cov-2 antibodies and use thereof in the treatment of sars-cov-2 infection
WO2022266659A1 (en) 2021-06-17 2022-12-22 Genentech, Inc. Anti-ubiquitination antibodies and methods of use
EP4355785A1 (de) 2021-06-17 2024-04-24 Amberstone Biosciences, Inc. Anti-cd3-konstrukte und verwendungen davon
CA3222880A1 (en) 2021-06-18 2022-12-22 Jeffrey Stavenhagen Antibodies which bind human fibrin or fibrinogen ?c domain and methods of use
WO2022262828A1 (zh) 2021-06-18 2022-12-22 正大天晴药业集团股份有限公司 抗il-36r抗体及其用途
KR20240021943A (ko) 2021-06-18 2024-02-19 남미 테라퓨틱스, 인크. 암의 치료에 사용하기 위한 마스킹된 유형 I 인터페론 (IFNα 및 IFNβ)을 포함하는 융합 단백질 조성물(들) 및 그의 방법
JP2024522234A (ja) 2021-06-18 2024-06-11 アリゲーター・バイオサイエンス・アーベー 新規な併用療法及びその使用
DK4358995T3 (da) 2021-06-23 2026-02-02 Scholar Rock Inc Myostatin-vej-hæmmer i kombination med en glp-1-vej-aktivator til brug ved behandling af metaboliske forstyrrelser
WO2022271987A1 (en) 2021-06-23 2022-12-29 TeneoFour, Inc. Anti-cd38 antibodies and epitopes of same
US20230174651A1 (en) 2021-06-23 2023-06-08 Janssen Biotech, Inc. Materials and methods for hinge regions in functional exogenous receptors
EP4359439A1 (de) 2021-06-24 2024-05-01 Yeda Research and Development Co. Ltd Kombinationstherapie zur behandlung von krebs mit einem anti-egfr-antikörper und einem axl-inhibitor
IL308633B2 (en) 2021-06-25 2025-12-01 Chugai Pharmaceutical Co Ltd Use of anti-ctla-4 antibody
CN117616123B (zh) 2021-06-25 2024-11-08 中外制药株式会社 抗ctla-4抗体
US20250084482A1 (en) 2021-06-25 2025-03-13 Foundation Medicine, Inc. Methods of using somatic hla-i loh to predict response of immune checkpoint inhibitor-treated patients with lung cancer
US20240165229A1 (en) 2021-06-29 2024-05-23 Seagen Inc. Methods of treating cancer with a combination of a nonfucosylated anti-cd70 antibody and a cd47 antagonist
IL309345A (en) 2021-07-01 2024-02-01 Albert Einstein College Medicine Compositions and methods for inhibiting the expression of tmigd2
CN115558023A (zh) 2021-07-02 2023-01-03 安源医药科技（上海）有限公司 抗cd3抗体及其用途
KR20240028452A (ko) 2021-07-02 2024-03-05 제넨테크, 인크. 암을 치료하기 위한 방법 및 조성물
JP2024526259A (ja) 2021-07-02 2024-07-17 メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツング 抗ｐｒｏｔａｃ抗体および複合体
CN118103397A (zh) 2021-07-08 2024-05-28 舒泰神(加州)生物科技有限公司 特异性识别tnfr2的抗体及其用途
EP4512826A3 (de) 2021-07-09 2025-04-02 Luxembourg Institute Of Health (LIH) Dimere proteinkomplexe und verwendungen davon
US20230038355A1 (en) 2021-07-09 2023-02-09 Janssen Biotech, Inc. Manufacturing Methods for Producing Anti-IL12/IL23 Antibody Compositions
WO2023280297A1 (zh) 2021-07-09 2023-01-12 江苏先声药业有限公司 Cd19抗体及其应用
IL309996A (en) 2021-07-09 2024-03-01 Janssen Biotech Inc Production methods for the production of anti-TNF antibody compositions
IL309997A (en) 2021-07-09 2024-03-01 Janssen Biotech Inc Production methods for the production of anti-TNF antibody compositions
WO2023285362A1 (en) 2021-07-12 2023-01-19 INSERM (Institut National de la Santé et de la Recherche Médicale) Use of il-36 inhibitors for the treatment of netherton syndrome
EP4370545A1 (de) 2021-07-12 2024-05-22 Genentech, Inc. Strukturen zur reduzierung der antikörper-lipase-bindung
WO2023287663A1 (en) 2021-07-13 2023-01-19 Genentech, Inc. Multi-variate model for predicting cytokine release syndrome
PE20240638A1 (es) 2021-07-14 2024-03-27 Genentech Inc Anticuerpos anti-receptor de quimiocinas de motivo c-c 8 (ccr8) y metodos de uso
EP4370541A1 (de) 2021-07-14 2024-05-22 2seventy bio, Inc. Gentechnisch hergestellte t-zell-rezeptoren, die an bindungsdomänen aus antikörpern fusioniert sind
JP7833531B2 (ja) 2021-07-14 2026-03-19 舒泰神（北京）生物製薬股フン有限公司 Ｃｄ４０を特異的に認識する抗体およびその使用
EP4370210A1 (de) 2021-07-14 2024-05-22 Regeneron Pharmaceuticals, Inc. Anti-sars-cov-2-spike-glykoprotein-antikörper und antigenbindende fragmente
WO2023285620A2 (en) 2021-07-14 2023-01-19 Alchemab Therapeutics Ltd. Compositions and methods for targeting viral proteins
EP4370647A1 (de) 2021-07-15 2024-05-22 Just-Evotec Biologics, Inc. Bidirektionales perfusionssystem mit tangentialer strömungsfiltration (tff)
JPWO2023286854A1 (de) 2021-07-16 2023-01-19
TW202321283A (zh) 2021-07-20 2023-06-01 美商英伊布里克斯公司 Cd8結合多肽及其用途
TW202309102A (zh) 2021-07-20 2023-03-01 美商英伊布里克斯公司 靶向cd8之經修飾il-2多肽及其用途
JP2024528631A (ja) 2021-07-22 2024-07-30 エフ・ホフマン－ラ・ロシュ・アクチェンゲゼルシャフト ヘテロ二量体Ｆｃドメイン抗体
JP2024526880A (ja) 2021-07-22 2024-07-19 ジェネンテック， インコーポレイテッド 脳標的化組成物及びその使用方法
US20240352153A1 (en) 2021-07-23 2024-10-24 Akeso Biopharma, Inc Pharmaceutical composition and use
WO2023004197A1 (en) 2021-07-23 2023-01-26 Teneoten, Inc. Heavy chain antibodies binding to hepatitis b surface antigen
GB202110726D0 (en) 2021-07-26 2021-09-08 Cambridge Entpr Ltd Conjugating reagents and conjugates thereof
WO2023005805A1 (zh) 2021-07-26 2023-02-02 北京万泰生物药业股份有限公司 人鼻病毒的通用亲和表位多肽、抗体及其用途
AU2022320627A1 (en) 2021-07-26 2024-02-08 Abcuro, Inc. Killer cell lectin-like receptor subfamily g member 1 (klrg1) depleting antibodies
WO2023007374A1 (en) 2021-07-27 2023-02-02 Pfizer Inc. Method of treatment of cancer pain with tanezumab
WO2023010060A2 (en) 2021-07-27 2023-02-02 Novab, Inc. Engineered vlrb antibodies with immune effector functions
CN118076633A (zh) 2021-07-29 2024-05-24 法国国家健康与医学研究院 人源化抗-人βig-h3蛋白及其用途
JP2024529381A (ja) 2021-07-30 2024-08-06 アフィメド ゲーエムベーハー デュプレックスボディ
US20240343803A1 (en) 2021-07-30 2024-10-17 Shandong Simcere Biopharmaceutical Co., Ltd. Anti-Pvrig/Anti-Tigit Bispecific Antibodies And Applications Thereof
JP2024529484A (ja) 2021-07-30 2024-08-06 インサーム（インスティテュ ナシオナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシェ メディカル） キメラタンパク質および免疫治療の方法
JP2024528217A (ja) 2021-08-03 2024-07-26 エフ・ホフマン－ラ・ロシュ・アクチェンゲゼルシャフト 二重特異性抗体および使用方法
JP2024531915A (ja) 2021-08-05 2024-09-03 ジーオー セラピューティクス，インコーポレイテッド 抗グリコｍｕｃ抗体およびその使用
US11807685B2 (en) 2021-08-05 2023-11-07 The Uab Research Foundation Anti-CD47 antibody and uses thereof
EP4380691A1 (de) 2021-08-06 2024-06-12 Institut Régional du Cancer de Montpellier (ICM) Verfahren zur behandlung von krebs
KR20240043786A (ko) 2021-08-09 2024-04-03 바이오세우스 인크. 항-tigit 항체 및 이의 용도
MX2024001877A (es) 2021-08-10 2024-02-28 Kymab Ltd Tratamiento de dermatitis atopica.
JP2024531151A (ja) 2021-08-10 2024-08-29 ビリジアン セラピューティクス， インコーポレイテッド 甲状腺眼疾患の処置のための組成物、用量および方法
CN117897409A (zh) 2021-08-13 2024-04-16 基因泰克公司 抗类胰蛋白酶抗体的给药
WO2023020537A1 (zh) 2021-08-18 2023-02-23 普米斯生物技术(珠海)有限公司 一种双特异性抗体及其用途
WO2023021055A1 (en) 2021-08-19 2023-02-23 F. Hoffmann-La Roche Ag Multivalent anti-variant fc-region antibodies and methods of use
US20240368249A1 (en) 2021-08-20 2024-11-07 Intervet Inc. Fusion proteins for treating atopic dermatitis
WO2023021169A1 (en) 2021-08-20 2023-02-23 Intervet International B.V. Antibodies and igg fusion proteins with an extended half-life
KR20240046905A (ko) 2021-08-20 2024-04-11 아케소 바이오파마, 인크. 항-TIGIT 항체 및 TGF-βR을 포함하는 융합 단백질, 이의 약학 조성물, 및 용도
MX2024002187A (es) 2021-08-20 2024-03-12 Tallac Therapeutics Inc Anticuerpos y conjugados de nectina-4.
JP2024534265A (ja) 2021-08-23 2024-09-18 イミュニタス セラピューティクス，インコーポレーテッド 抗ｃｄ１６１抗体及びその使用
WO2023026205A1 (en) 2021-08-24 2023-03-02 Cgrp Diagnostics Gmbh Preventative treatment of migraine
CA3229503A1 (en) 2021-08-25 2023-03-02 Jiangsu Hengrui Pharmaceuticals Co., Ltd. Pharmaceutical composition containing fusion protein
US20250127915A1 (en) 2021-08-26 2025-04-24 Shanghai Junshi Biosciences Co., Ltd. Anti-cldn-18.2 antibody-drug conjugate and use thereof
AU2022335718A1 (en) 2021-08-26 2024-03-28 Glycanostics S.R.O Glycoprotein biomarkers for diagnosing cancer
ES2991847T3 (es) 2021-08-27 2024-12-05 Medimmune Ltd Tratamiento de enfermedad pulmonar obstructiva crónica con un anticuerpo anti-interleucina-33
CN117813325A (zh) 2021-08-27 2024-04-02 H.隆德贝克有限公司 使用抗cgrp抗体治疗丛集性头痛
WO2023028591A1 (en) 2021-08-27 2023-03-02 Genentech, Inc. Methods of treating tau pathologies
TW202325727A (zh) 2021-08-30 2023-07-01 美商建南德克公司 抗聚泛素多特異性抗體
CA3230038A1 (en) 2021-08-31 2023-03-09 Hongwei Zhang Methods and systems of diagnosing brain injury
US12467921B2 (en) 2021-08-31 2025-11-11 Versitech Limited Antibodies and assays for detection of Burkholderia mallei
CN118715440A (zh) 2021-08-31 2024-09-27 雅培实验室 诊断脑损伤的方法和系统
WO2023032955A1 (ja) 2021-08-31 2023-03-09 大正製薬株式会社 抗成長ホルモン抗体
JP2024533166A (ja) 2021-09-01 2024-09-12 ヴィア・バイオテクノロジー・インコーポレイテッド 小児被験体におけるＳＡＲＳ－ＣｏＶ－２感染の抗体療法
WO2023034871A1 (en) 2021-09-01 2023-03-09 Vir Biotechnology, Inc. High concentration antibody therapies for sars-cov-2 infection
KR20240051162A (ko) 2021-09-02 2024-04-19 도이체스크레브스포르슝스젠트룸스티프퉁데스외펜트리헨레크츠 부작용이 감소된 항-cecam6 항체
WO2023034569A1 (en) 2021-09-03 2023-03-09 Go Therapeutics, Inc. Anti-glyco-cmet antibodies and their uses
JP2024534910A (ja) 2021-09-03 2024-09-26 ジーオー セラピューティクス，インコーポレイテッド 抗グリコｌａｍｐ１抗体およびその使用
WO2023039442A1 (en) 2021-09-08 2023-03-16 Vir Biotechnology, Inc. Broadly neutralizing antibody combination therapies for sars-cov-2 infection
EP4148067A1 (de) 2021-09-08 2023-03-15 F. Hoffmann-La Roche AG Verfahren zur expression einer antikörper-multimer-fusion
WO2023036982A1 (en) 2021-09-10 2023-03-16 Harbour Antibodies Bv Anti-sars2-s antibodies
GB202112935D0 (en) 2021-09-10 2021-10-27 Harbour Antibodies Bv Sars-cov-2 (sars2, covid-19) heavy chain only antibodies
TW202317639A (zh) 2021-09-13 2023-05-01 大陸商江蘇先聲藥業有限公司 抗人cd3抗體及其應用
IL286430A (en) 2021-09-14 2023-04-01 Yeda Res & Dev Multispecific antibodies for use in the treatment of diseases
JP2024531711A (ja) 2021-09-14 2024-08-29 グリカノスティクス エス．アール．オー． 乳がんにおけるマンマグロビンａグリコフォームを測定するためのレクチンの使用法
PL4401842T3 (pl) 2021-09-16 2025-11-24 Aboleris Pharma Domeny wiążące przeciwko ludzkiemu CD45RC i ich zastosowania
US20240316061A1 (en) 2021-09-17 2024-09-26 Institut Curie Bet inhibitors for treating pab1 deficient cancer
JP2024533616A (ja) 2021-09-20 2024-09-12 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア 新規のＷｎｔアゴニスト抗体およびその治療的使用
JP2024535888A (ja) 2021-09-20 2024-10-02 アルナイラム ファーマシューティカルズ， インコーポレイテッド インヒビンサブユニットベータｅ（ｉｎｈｂｅ）モジュレーター組成物およびその使用方法
WO2023044483A2 (en) 2021-09-20 2023-03-23 Voyager Therapeutics, Inc. Compositions and methods for the treatment of her2 positive cancer
AU2022352157A1 (en) 2021-09-21 2024-05-02 National Agriculture And Food Research Organization Vaccine including nonencapsulated strain as antigen
CN115925929A (zh) 2021-09-22 2023-04-07 上海康岱生物医药技术股份有限公司 抗tnfr2单克隆抗体及其应用
CN115838424A (zh) 2021-09-22 2023-03-24 上海康岱生物医药技术股份有限公司 靶向tigit的单克隆抗体
CA3232382A1 (en) 2021-09-27 2023-03-30 Zoetis Services Llc Anti- tgf.beta.1,2,3 antibodies and therapeutic uses thereof
CN118541392A (zh) 2021-09-28 2024-08-23 准星生物医药有限公司 多种形式的分子复合物
EP4410835A4 (de) 2021-09-29 2025-09-24 Akeso Biopharma Inc Anti-lag3-antikörper, pharmazeutische zusammensetzung und verwendung
US20250084155A1 (en) 2021-09-29 2025-03-13 Board Of Regents, The University Of Texas System Anti-hsp70 antibodies and therapeutic uses thereof
GB202113904D0 (en) 2021-09-29 2021-11-10 Alligator Bioscience Ab Methods and compositions
JPWO2023053282A1 (de) 2021-09-29 2023-04-06
WO2023056268A1 (en) 2021-09-30 2023-04-06 Abbott Laboratories Methods and systems of diagnosing brain injury
US11879010B2 (en) 2021-09-30 2024-01-23 The Charlotte Mecklenburg Hospital Authority Methods and compositions for pretargeted immunotherapy
WO2023056069A1 (en) 2021-09-30 2023-04-06 Angiex, Inc. Degrader-antibody conjugates and methods of using same
WO2023056403A1 (en) 2021-09-30 2023-04-06 Genentech, Inc. Methods for treatment of hematologic cancers using anti-tigit antibodies, anti-cd38 antibodies, and pd-1 axis binding antagonists
WO2023052541A1 (en) 2021-09-30 2023-04-06 Imcheck Therapeutics Combination of an anti-btn3a activating antibody and an il-2 agonist for use in therapy
EP4410839A4 (de) 2021-09-30 2025-10-08 Bio Thera Solutions Ltd Anti-b7-h3-antikörper und anwendung davon
CA3231484A1 (en) 2021-10-01 2023-04-06 Qinwen Mao Pathologic tdp-43 as a biomarker for the diagnosis of tdp-43 proteinopathy
TW202327595A (zh) 2021-10-05 2023-07-16 美商輝瑞大藥廠 用於治療癌症之氮雜內醯胺化合物的組合
US20230190807A1 (en) 2021-10-06 2023-06-22 Immatics Biotechnologies Gmbh Tcr compounds, compositions, and methods of treating
EP4413998A4 (de) 2021-10-08 2026-02-25 Chugai Pharmaceutical Co Ltd Verfahren zur herstellung einer vorgefüllten spritzenformulierung
CA3234995A1 (en) 2021-10-14 2023-04-20 Latticon (Suzhou) Biopharmaceuticals Co., Ltd. Novel antibody-cytokine fusion protein, preparation method therefor and use thereof
WO2023064876A1 (en) 2021-10-14 2023-04-20 Teneobio, Inc. Mesothelin binding proteins and uses thereof
CA3234994A1 (en) 2021-10-14 2023-04-20 Tiziana Life Sciences Plc Methods of suppressing microglial activation
EP4166150A1 (de) 2021-10-15 2023-04-19 Exeliom Biosciences Assoziation eines faecalibacterium-prausnitzii-stammes mit anti-pd-1-, anti-pd-l1- oder anti-ctla-4-antikörpern zur behandlung von krebs
CA3234162A1 (en) 2021-10-15 2023-04-20 Michele Fiscella Antibodies and methods of using thereof
EP4419558A1 (de) 2021-10-19 2024-08-28 Alector LLC Anti-cd300lb-antikörper und verfahren zur verwendung davon
US20250042976A1 (en) 2021-10-26 2025-02-06 Roche Diagnostics Operations, Inc. Monoclonal antibodies specific for sars-cov-2 rbd
US20250129165A1 (en) 2021-10-27 2025-04-24 Imcheck Therapeutics Butyrophilin (btn) 3a activating antibodies for use in methods for treating infectious disorders
MX2024005177A (es) 2021-10-28 2024-08-27 In3Bio Ltd Métodos de uso de anticuerpos anti-fce para aumentar la actividad de los inhibidores de braf y kras.
EP4423271A2 (de) 2021-10-28 2024-09-04 Regeneron Pharmaceuticals, Inc. Crispr/cas-assoziierte verfahren und zusammensetzungen zum ausklopfen von c5
KR20240099352A (ko) 2021-10-29 2024-06-28 얀센 바이오테크 인코포레이티드 항-il23 특이적 항체로 크론병을 치료하는 방법
US20240425925A1 (en) 2021-10-29 2024-12-26 GenoDx Pty Ltd Biomarkers and uses therefor
WO2023079428A1 (en) 2021-11-03 2023-05-11 Pfizer Inc. Combination therapies using tlr7/8 agonist
CN117980327A (zh) 2021-11-03 2024-05-03 杭州多禧生物科技有限公司 抗体的特异性偶联
TW202334221A (zh) 2021-11-03 2023-09-01 德商安富美德有限公司 雙特異性cd16a結合劑
WO2023079493A1 (en) 2021-11-03 2023-05-11 Affimed Gmbh Bispecific cd16a binders
EP4427044A1 (de) 2021-11-03 2024-09-11 Institut National de la Santé et de la Recherche Médicale (INSERM) Verfahren und zusammensetzungen zur behandlung von dreifach negativem brustkrebs (tnbc)
WO2023079058A1 (en) 2021-11-05 2023-05-11 Yokogawa Insilico Biotechnology Gmbh Cell culture with reduced production of lactate
US20250019430A1 (en) 2021-11-05 2025-01-16 Seoul National University Hospital Resistin-specific antibody and use thereof
WO2023078386A1 (zh) 2021-11-05 2023-05-11 正大天晴药业集团股份有限公司 抗cldn18.2抗体及其用途
US20260001961A1 (en) 2021-11-05 2026-01-01 Alligator Bioscience Ab Novel polypeptides
AU2022382383A1 (en) 2021-11-05 2024-06-20 Eli Lilly And Company Antitumor combinations containing anti-ceacam5 antibody-drug conjugates and anti-vegfr-2 antibodies
JP2024540374A (ja) 2021-11-05 2024-10-31 アメリカン ダイアグノスティックス アンド セラピー， エルエルシー （エーディーエックスアールエックス） がん胎児性抗原に対するモノクローナル抗体、及びそれらの使用
IL312538A (en) 2021-11-05 2024-07-01 Abviro Llc Broadly reactive human monoclonal influenza antibodies and methods for their use
WO2023081898A1 (en) 2021-11-08 2023-05-11 Alector Llc Soluble cd33 as a biomarker for anti-cd33 efficacy
WO2023081925A1 (en) 2021-11-08 2023-05-11 Immatics Biotechnologies Gmbh Adoptive cell therapy combination treatment and compositions thereof
US20250009731A1 (en) 2021-11-08 2025-01-09 Nurix Therapeutics, Inc. Toll-like receptor therapy combinations with cbl-b inhibitor compounds
CA3237437A1 (en) 2021-11-09 2023-05-19 Robert Pierce Anti-vista antibodies and uses thereof
WO2023086807A1 (en) 2021-11-10 2023-05-19 Genentech, Inc. Anti-interleukin-33 antibodies and uses thereof
EP4180061A1 (de) 2021-11-10 2023-05-17 Nerviano Medical Sciences S.r.l. Linker-reagenzien für anthracyclinderivate, antikörper-arznemittelkonjugate und verfahren
TW202330613A (zh) 2021-11-12 2023-08-01 美商建南德克公司 使用整聯蛋白β７拮抗劑治療克隆氏病之方法
JP2024544555A (ja) 2021-11-15 2024-12-03 ヤンセン バイオテツク，インコーポレーテツド 抗ｉｌ２３特異的抗体によるクローン病を処置する方法
EP4433167A1 (de) 2021-11-16 2024-09-25 AC Immune SA Moleküle für therapie und diagnose
WO2023091887A1 (en) 2021-11-16 2023-05-25 Genentech, Inc. Methods and compositions for treating systemic lupus erythematosus (sle) with mosunetuzumab
JP2024540505A (ja) 2021-11-17 2024-10-31 アンスティチュート、ナシオナル、ドゥ、ラ、サンテ、エ、ドゥ、ラ、ルシェルシュ、メディカル ユニバーサルサルベコウイルスワクチン
KR20240142405A (ko) 2021-11-17 2024-09-30 씨에스피씨 메가리스 바이오파마슈티칼 씨오., 엘티디. 항체-약물 복합체 및 그의 용도
JP2024540484A (ja) 2021-11-17 2024-10-31 アルトゥルバイオ， インコーポレイテッド 抗ｐｓｇｌ－１抗体をｊａｋ阻害剤と組み合わせて使用してｔ細胞媒介性炎症性疾患またはがんを治療する方法
CN116135884A (zh) 2021-11-17 2023-05-19 普米斯生物技术(珠海)有限公司 抗tigit-抗pd-l1双特异性抗体、其药物组合物及用途
WO2023092004A1 (en) 2021-11-17 2023-05-25 Voyager Therapeutics, Inc. Compositions and methods for the treatment of tau-related disorders
EP4433170A1 (de) 2021-11-18 2024-09-25 Oxford BioTherapeutics Ltd Pharmazeutische kombinationen
WO2023088966A1 (en) 2021-11-19 2023-05-25 Adc Therapeutics Sa Anti-psma conjugates
TW202440647A (zh) 2021-11-19 2024-10-16 英商米羅比奧有限公司 經工程改造之pd-1抗體及其用途
WO2023089032A1 (en) 2021-11-19 2023-05-25 Institut Curie Methods for the treatment of hrd cancer and brca-associated cancer
WO2023088963A1 (en) 2021-11-19 2023-05-25 Adc Therapeutics Sa Anti-il-13ralpha2 conjugates
KR20240103043A (ko) 2021-11-23 2024-07-03 얀센 바이오테크 인코포레이티드 항-il23 특이적 항체로 궤양성 결장염을 치료하는 방법
WO2023097024A1 (en) 2021-11-24 2023-06-01 Dana-Farber Cancer Institute, Inc. Antibodies against ctla-4 and methods of use thereof
WO2023096904A2 (en) 2021-11-24 2023-06-01 President And Fellows Of Harvard College C-16 modified trioxacarcins, antibody drug conjugates, and uses thereof
US20230348614A1 (en) 2021-11-24 2023-11-02 Visterra, Inc. Engineered antibody molecules to cd138 and uses thereof
CN118159286A (zh) 2021-11-25 2024-06-07 正大天晴药业集团股份有限公司 抗Siglec-15抗体及其应用
CN118284809A (zh) 2021-11-25 2024-07-02 豪夫迈·罗氏有限公司 少量抗体副产物的定量
WO2023097119A2 (en) 2021-11-29 2023-06-01 Dana-Farber Cancer Institute, Inc. Methods and compositions to modulate riok2
JP2024544058A (ja) 2021-12-01 2024-11-27 ストロ バイオファーマ インコーポレーテッド 抗葉酸受容体コンジュゲートがん治療法
KR20240011866A (ko) 2021-12-01 2024-01-26 추가이 세이야쿠 가부시키가이샤 항체 함유 제제의 조제 방법
TW202333772A (zh) 2021-12-01 2023-09-01 美商威特拉公司 使用介白素-2藥劑之方法
WO2023102476A1 (en) 2021-12-02 2023-06-08 California Institute Of Technology Antibodies for coronaviruses and uses thereof
WO2023099763A1 (en) 2021-12-03 2023-06-08 Institut Curie Sirt6 inhibitors for use in treating resistant hrd cancer
US11939391B2 (en) 2021-12-06 2024-03-26 MedAbome, Inc. Anti-TfR1 antibody MAb11-22.1 conjugates for cancer treatment
EP4445911A4 (de) 2021-12-06 2025-10-22 Beijing Solobio Genetechnology Co Ltd Bispezifischer antikörper mit spezifischer bindung an klebsiella pneumoniae-o2- und o1-antigene sowie zusammensetzung
US20240409621A1 (en) 2021-12-06 2024-12-12 Xiamen University Antibody for recognizing rsv pre-f protein and use thereof
WO2023104904A2 (en) 2021-12-08 2023-06-15 Genclis The sars-cov-2 and variants use two independent cell receptors to replicate
CA3240483A1 (en) 2021-12-10 2023-06-15 Thomas Dudler Therapeutic antibodies that bind to the serine protease domain of masp-2 and uses thereof
GB202117928D0 (en) 2021-12-11 2022-01-26 Cancer Research Tech Ltd Immunotherapy for cancer
WO2023105528A1 (en) 2021-12-12 2023-06-15 Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd. Antibodies specific to ceacam1
WO2023110937A1 (en) 2021-12-14 2023-06-22 INSERM (Institut National de la Santé et de la Recherche Médicale) Depletion of nk cells for the treatment of adverse post-ischemic cardiac remodeling
TW202334405A (zh) 2021-12-15 2023-09-01 美商英特瑞斯生物療法公司 假型分型之病毒顆粒、包含其之組合物及其用途
AU2022409610A1 (en) 2021-12-16 2024-05-30 Intervet International B.V. Caninized antibodies to canine interleukin-31 receptor alpha 1
MX2024007088A (es) 2021-12-16 2024-08-22 Intervet Int Bv Anticuerpos caninizados contra el ngf humano.
EP4448564A1 (de) 2021-12-17 2024-10-23 F. Hoffmann-La Roche AG Neuer antikörper zum nachweis von amyloid beta 42 (a-beta42)
JP2025503439A (ja) 2021-12-17 2025-02-04 アボット・ラボラトリーズ 血液試料におけるｕｃｈ－ｌ１、ｇｆａｐ及び他のバイオマーカーを決定するためのシステム及び方法
WO2023114543A2 (en) 2021-12-17 2023-06-22 Dana-Farber Cancer Institute, Inc. Platform for antibody discovery
CN118488965A (zh) 2021-12-17 2024-08-13 上海复宏汉霖生物技术股份有限公司 抗ox40抗体、多特异性抗体及其使用方法
AU2022411573A1 (en) 2021-12-17 2024-06-27 Shanghai Henlius Biologics Co., Ltd. Anti-ox40 antibodies and methods of use
WO2023114544A1 (en) 2021-12-17 2023-06-22 Dana-Farber Cancer Institute, Inc. Antibodies and uses thereof
CA3223956A1 (en) 2021-12-20 2023-06-29 Vetoquinol Sa Anti-canine interleukine-31-receptor a (il-31ra) antibodies and the uses thereof
EP4452327A1 (de) 2021-12-20 2024-10-30 Synthorx, Inc. Kopf-hals-krebskombinationstherapie mit einem il-2-konjugat und pembrolizumab
CN118401674A (zh) 2021-12-21 2024-07-26 豪夫迈·罗氏有限公司 用于确定水解活性的方法
WO2023118165A1 (en) 2021-12-21 2023-06-29 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and compositions for treating melanoma
PE20250390A1 (es) 2021-12-22 2025-02-11 Boehringer Ingelheim Int Anticuerpos anti-c3 y fragmentos de union al antigeno de estos y sus usos para tratar enfermedades oftalmicas u oculares
WO2023118508A1 (en) 2021-12-23 2023-06-29 Bavarian Nordic A/S Recombinant mva viruses for intraperitoneal administration for treating cancer
CN116333135A (zh) 2021-12-24 2023-06-27 百奥泰生物制药股份有限公司 抗FRα抗体及其抗体药物偶联物和用途
KR20230098953A (ko) 2021-12-27 2023-07-04 경북대학교 산학협력단 Asm에 특이적으로 결합하는 항체 및 이의 용도
CN118302448A (zh) 2021-12-28 2024-07-05 江苏恒瑞医药股份有限公司 抗ror1抗体和抗ror1抗体药物偶联物及其医药用途
JP2025504363A (ja) 2022-01-05 2025-02-12 インヒブルクス バイオサイエンシズ インコーポレイテッド γδＴ細胞結合ポリペプチド及びその使用
TW202334193A (zh) 2022-01-05 2023-09-01 美商英伊布里克斯公司 靶向γδ T細胞之經修飾IL-2多肽及其用途
UY40097A (es) 2022-01-07 2023-07-14 Johnson & Johnson Entpr Innovation Inc Materiales y métodos de proteínas de unión a il-1b
WO2023141445A1 (en) 2022-01-19 2023-07-27 Genentech, Inc. Anti-notch2 antibodies and conjugates and methods of use
CA3248133A1 (en) 2022-01-24 2023-07-27 Novimmune Sa COMPOSITION AND METHODS FOR THE SELECTIVE ACTIVATION OF CYTOKINE SIGNALING PATHWAYS
AR128331A1 (es) 2022-01-26 2024-04-17 Genentech Inc Inductores químicos de degradación conjugados con anticuerpos y métodos de estos
AU2023213987A1 (en) 2022-01-26 2024-09-05 Idexx Laboratories, Inc. Methods and compositions for differentiating progressive chronic kidney disease from stable chronic kidney disease
AR128330A1 (es) 2022-01-26 2024-04-17 Genentech Inc Inductores químicos de degradación conjugados con anticuerpo y métodos de estos
EP4469159A1 (de) 2022-01-27 2024-12-04 The Rockefeller University Breit neutralisierende anti-sars-cov-2-antikörper gegen die n-terminale domäne des spike-proteins und verfahren zur verwendung davon
WO2023144235A1 (en) 2022-01-27 2023-08-03 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods for monitoring and treating warburg effect in patients with pi3k-related disorders
WO2023144973A1 (ja) 2022-01-27 2023-08-03 中外製薬株式会社 抗ｖｅｇｆ抗体及びパクリタキセルと組み合わせて使用する抗ｐｄ－ｌ１抗体を含む医薬組成物
WO2023143444A1 (zh) 2022-01-28 2023-08-03 上海君实生物医药科技股份有限公司 抗dkk1抗体、其药物组合物及用途
GB202201137D0 (en) 2022-01-28 2022-03-16 Thelper As Therapeutic and diagnostic agents and uses thereof
EP4470570A1 (de) 2022-01-28 2024-12-04 Duality Biologics (Suzhou) Co., Ltd. Her3-antikörper-wirkstoff-konjugat und verwendung davon
WO2023147470A2 (en) 2022-01-28 2023-08-03 Georgiamune Inc. Antibodies to programmed cell death protein 1 that are pd-1 agonists
US20250101067A1 (en) 2022-01-28 2025-03-27 Glaxosmithkline Biologicals Sa Modified human cytomegalovirus proteins
WO2023144303A1 (en) 2022-01-31 2023-08-03 INSERM (Institut National de la Santé et de la Recherche Médicale) Cd38 as a biomarker and biotarget in t-cell lymphomas
US20250230412A1 (en) 2022-02-01 2025-07-17 President And Fellows Of Harvard College Methods and compositions for treating cancer
IL314482A (en) 2022-02-02 2024-09-01 Regeneron Pharma Anti-tfr:gaa and anti-cd63:gaa insertions for treatment of pompe disease
EP4473096A1 (de) 2022-02-02 2024-12-11 Pfizer Inc. Cysteinprototrophie
JP2025507303A (ja) 2022-02-04 2025-03-18 アボット・ラボラトリーズ 試料におけるユビキチンカルボキシ末端ヒドロラーゼｌ１及び／又はグリア原線維性酸性タンパク質の存在を検出する又はその量を測定するためのラテラルフロー方法、アッセイ及びデバイス
TW202342548A (zh) 2022-02-07 2023-11-01 美商威特拉公司 抗獨特型(anti-idiotype)抗體分子及其用途
AU2023217319A1 (en) 2022-02-08 2024-08-22 Assistance Publique-Hôpitaux De Paris (Aphp) Neutralization of acyl-coa binding protein confers autophagy-dependent organ protection
WO2023154780A1 (en) 2022-02-09 2023-08-17 Martell Diagnostic Laboratories, Inc. Anti-her2/neu antibodies and methods of use
AU2023217968A1 (en) 2022-02-09 2024-09-26 Janssen Biotech, Inc. Methods and compositions comprising v beta 17 bispecific t cell engagers and bioengineered virus specific lymphocytes
CN114181310B (zh) 2022-02-14 2022-07-05 中山康方生物医药有限公司 抗tigit抗体、其药物组合物及用途
TW202348252A (zh) 2022-02-16 2023-12-16 英商梅迪繆思有限公司 用治療性結合分子治療癌症的組合療法
EP4480499A1 (de) 2022-02-16 2024-12-25 Medilink Therapeutics (Suzhou) Co., Ltd. Konjugat aus antikörper-eribulin oder einem derivat davon, zwischenprodukt davon, herstellungsverfahren dafür, pharmazeutische zusammensetzung davon und verwendung davon
EP4480966A4 (de) 2022-02-16 2026-01-28 Utc Therapeutics Shanghai Co Ltd Humanisierter anti-cd28-antikörper und bispezifischer antikörper davon mit anti-cd40-antikörper
AU2023221539A1 (en) 2022-02-16 2024-08-22 Ac Immune Sa Humanized anti-tdp-43 binding molecules and uses thereof
WO2023156634A1 (en) 2022-02-17 2023-08-24 Atb Therapeutics Recombinant immunotoxin comprising a ribosome inactivating protein
EP4230222A1 (de) 2022-02-17 2023-08-23 Oxsonics Limited Kombinationstherapie mit anti-axl-antikörper-pbd-konjugat und nanocups
WO2023156587A1 (en) 2022-02-18 2023-08-24 INSERM (Institut National de la Santé et de la Recherche Médicale) Use of tcr-deficient car-tregs in combination with anti-tcr complex monoclonal antibodies for inducing durable tolerance
WO2023155902A1 (en) 2022-02-18 2023-08-24 Chongqing Mingdao Haoyue Biotechnology Co., Ltd. Intranasal formulations and anti-sars-cov-2-spike protein antibodies
WO2023156683A1 (en) 2022-02-21 2023-08-24 Acticor Biotech Treatment of cardiovascular diseases using anti-human gpvi antibodies
MX2024010324A (es) 2022-02-23 2024-08-30 Alector Llc Metodos de uso de anticuerpos anti-trem2.
KR20240153590A (ko) 2022-02-24 2024-10-23 아케소 파마슈티컬스, 인코포레이티드 항-ctla4-항-pd-1 이중특이적 항체 및 치아우라닙을 포함하는 약제학적 조성물
US20250163169A1 (en) 2022-02-25 2025-05-22 Institut National de la Santé et de la Recherche Médicale Antibodies for preventing the cleavage of cd95l by metalloproteases
CA3243763A1 (en) 2022-02-28 2023-08-31 Nectin Therapeutics Ltd. Humanized antibodies directed against nectin-2 and their drug conjugates
IL315262A (en) 2022-03-03 2024-10-01 Pfizer Multiple specific antibodies related to IL-4, IL-13 and/or TSLP and their uses
EP4490192A1 (de) 2022-03-07 2025-01-15 Novimmune S.A. Cd28-bispezifische antikörper zur gezielten t-zell-aktivierung
EP4490187A4 (de) 2022-03-08 2026-02-25 Immunedge Inc Epo-rezeptor-agonisten und -antagonisten
EP4489862A1 (de) 2022-03-09 2025-01-15 Merck Patent GmbH Anti-ceacam5-antikörper und konjugate und verwendungen davon
KR20240159839A (ko) 2022-03-09 2024-11-06 아스트라제네카 아베 FRα에 대한 결합 분자
CN119213128A (zh) 2022-03-09 2024-12-27 株式会社丘阿德 与Eva1蛋白质结合的人源化抗体或其功能性片段、抗体药物缀合物和嵌合抗原受体
CN119604314A (zh) 2022-03-09 2025-03-11 默克专利有限公司 抗gd2抗体、免疫偶联物及其治疗用途
WO2023170207A1 (en) 2022-03-09 2023-09-14 Alderaan Biotechnology Anti-cd160 transmembrane isoform antibodies
EP4489782A4 (de) 2022-03-10 2026-03-25 Omeros Corp Masp-2- und masp-3-inhibitoren sowie zugehörige zusammensetzungen und verfahren zur behandlung von sichelzellanämie
JP2025509286A (ja) 2022-03-10 2025-04-11 ビバソル， インコーポレイテッド 抗体－薬物コンジュゲートおよびその使用
WO2023170434A1 (en) 2022-03-11 2023-09-14 Macomics Limited Compositions and methods for modulation of macrophage activity
EP4490517A1 (de) 2022-03-11 2025-01-15 Astrazeneca AB Bewertungsverfahren für eine anti-fr-alpha-antikörper-wirkstoff-konjugattherapie
WO2023174925A1 (en) 2022-03-14 2023-09-21 Novimmune Sa Bispecific gpc3xcd28 and gpc3xcd3 antibodies and their combination for targeted killing of gpc3 positive malignant cells
GB202203588D0 (en) 2022-03-15 2022-04-27 Argonaut Therapeutics Ltd Cancer diagnostic
KR20250004952A (ko) 2022-03-17 2025-01-08 씨젠 인크. 캄프토테신 접합체
US20250195681A1 (en) 2022-03-18 2025-06-19 Duality Biologics (Suzhou) Co., Ltd. Anti-gpc3 antibody drug conjugate and use thereof
AU2022446336A1 (en) 2022-03-18 2024-09-19 Beijing Mabworks Biotech Co., Ltd B7-h3-binding antibody and use thereof
EP4493593A1 (de) 2022-03-18 2025-01-22 Evolveimmune Therapeutics, Inc. Bispezifische antikörperfusionsmoleküle und verfahren zur verwendung davon
US20230414750A1 (en) 2022-03-23 2023-12-28 Hoffmann-La Roche Inc. Combination treatment of an anti-cd20/anti-cd3 bispecific antibody and chemotherapy
KR20240163119A (ko) 2022-03-25 2024-11-18 상하이 헨리우스 바이오테크, 인크. 항-msln 항체 및 사용 방법
JPWO2023182530A1 (de) 2022-03-25 2023-09-28
WO2023178645A1 (zh) 2022-03-25 2023-09-28 嘉和生物药业有限公司 靶向cd3的抗体及其应用
TW202402790A (zh) 2022-03-25 2024-01-16 英商梅迪繆思有限公司 減少呼吸系統感染之方法
WO2023192872A1 (en) 2022-03-28 2023-10-05 Massachusetts Institute Of Technology Rna scaffolded wireframe origami and methods thereof
JP2025510997A (ja) 2022-03-30 2025-04-15 ノバルティス アーゲー 抗ナトリウム利尿ペプチド受容体１（ｎｐｒ１）抗体を使用して障害を治療する方法
KR20230140746A (ko) 2022-03-30 2023-10-10 연세대학교 산학협력단 암전이의 검출용 신규 바이오마커
WO2023186015A1 (zh) 2022-03-30 2023-10-05 映恩生物制药（苏州）有限公司 B7h4抗体药物偶联物及其用途
JP2025512860A (ja) 2022-03-30 2025-04-22 ヤンセン バイオテツク，インコーポレーテツド Ｉｌ－２３に特異的な抗体によって軽度から中等度の乾癬を治療する方法
CA3247117A1 (en) 2022-03-31 2025-07-08 Juntendo Educational Foundation METHOD FOR EVALUATING THE QUALITY OF A T-LYMPHOCYTE INDUCTION FORMULATION INHIBITORS
EP4501354A4 (de) 2022-03-31 2026-03-25 Pharma Foods Int Co Ltd Zusammensetzung und verfahren zur hemmung von fibrose
EP4504148A1 (de) 2022-04-01 2025-02-12 Genentech, Inc. Hydroxypropylmethylcellulosederivate zur stabilisierung von polypeptiden
WO2023187176A1 (en) 2022-04-01 2023-10-05 Trince bv Method for delivering a cargo into cell
WO2023192976A1 (en) 2022-04-01 2023-10-05 Board Of Regents, The University Of Texas System Dual specificity antibodies to human pd-l1 and pd-l2 and methods of use therefor
WO2023191816A1 (en) 2022-04-01 2023-10-05 Genentech, Inc. Dosing for treatment with anti-fcrh5/anti-cd3 bispecific antibodies
GB202204813D0 (en) 2022-04-01 2022-05-18 Bradcode Ltd Human monoclonal antibodies and methods of use thereof
WO2023186078A1 (zh) 2022-04-02 2023-10-05 普米斯生物技术(珠海)有限公司 针对c-Met的抗体及其用途
CN116925233A (zh) 2022-04-02 2023-10-24 普米斯生物技术(珠海)有限公司 抗tigit-抗pvrig双特异性抗体、其药物组合物及用途
CN119013296A (zh) 2022-04-02 2024-11-22 普米斯生物技术(珠海)有限公司 针对c-Met的单克隆抗体以及双特异性抗体
CN116925222A (zh) 2022-04-02 2023-10-24 普米斯生物技术(珠海)有限公司 抗pvrig抗体、其药物组合物及用途
WO2023196866A1 (en) 2022-04-06 2023-10-12 Mirobio Limited Engineered cd200r antibodies and uses thereof
CA3247402A1 (en) 2022-04-06 2023-10-12 Larimar Therapeutics, Inc. FRATAXIN-SENSITIVE MARKERS FOR MONITORING FRATAXIN REPLACEMENT THERAPY
WO2023195532A1 (ja) 2022-04-07 2023-10-12 ブライトパス・バイオ株式会社 ヒトｔｉｍ－３およびヒトｃｄ３９に対する二重特異性抗体およびその用途
IL316153A (en) 2022-04-08 2024-12-01 Ac Immune Sa Anti-tdp-43 binding molecules
EP4257609A1 (de) 2022-04-08 2023-10-11 iOmx Therapeutics AG Kombinationstherapien basierend auf pd-1-inhibitoren und sik3-inhibitoren
WO2023193239A1 (en) 2022-04-08 2023-10-12 Peter Peizhi Luo Anti-cd28 antibodies and methods of use thereof
WO2023196943A1 (en) 2022-04-08 2023-10-12 Inhibrx, Inc. Dr5 agonist and plk1 inhibitor or cdk inhibitor combination therapy
CA3247515A1 (en) 2022-04-10 2023-10-19 Immunomic Therapeutics, Inc. Bicistronic lamp constructions comprising genes that enhance the immune response and methods of their use
WO2023198648A1 (en) 2022-04-11 2023-10-19 Institut National de la Santé et de la Recherche Médicale Methods for the diagnosis and treatment of t-cell malignancies
WO2023201256A1 (en) 2022-04-12 2023-10-19 Vir Biotechnology, Inc. High dose antibody therapies for sars-cov-2 infection
WO2023200814A1 (en) 2022-04-12 2023-10-19 Eisai R & D Management Co., Ltd. Eribulin-based antibody-drug conjugates and methods of use
AU2023254206A1 (en) 2022-04-13 2024-10-17 Genentech, Inc. Pharmaceutical compositions of mosunetuzumab and methods of use
TW202545564A (zh) 2022-04-13 2025-12-01 美商建南德克公司 治療性蛋白質之醫藥組成物及使用方法
WO2023198727A1 (en) 2022-04-13 2023-10-19 F. Hoffmann-La Roche Ag Pharmaceutical compositions of anti-cd20/anti-cd3 bispecific antibodies and methods of use
EP4508077A4 (de) 2022-04-14 2026-03-25 Invisishield Tech Ltd Zusammensetzungen zur prävention oder behandlung von influenza-infektionen
CA3256035A1 (en) 2022-04-14 2023-10-19 Invisishield Technologies Ltd. COMPOSITIONS FOR PREVENTING OR TREATMENT OF CORONAVIRUS INFECTIONS
WO2023198874A1 (en) 2022-04-15 2023-10-19 Institut National de la Santé et de la Recherche Médicale Methods for the diagnosis and treatment of t cell-lymphomas
EP4511388A1 (de) 2022-04-19 2025-02-26 F. Hoffmann-La Roche AG Verbesserte produktionszellen
AU2023256252A1 (en) 2022-04-20 2024-11-07 Abion Inc. Method for predicting prognosis of breast cancer patient using ctc expressing c-met
KR20250025354A (ko) 2022-04-25 2025-02-21 비온드 바이오로직스 엘티디 항-ilt3 항체 및 이의 용도
AU2023262513A1 (en) 2022-04-25 2024-12-05 Visterra, Inc. Antibody molecules to april and uses thereof
IL316174A (en) 2022-04-26 2024-12-01 Novartis Ag Multiple specific antibodies targeting IL-13 and IL-18
KR20250005335A (ko) 2022-04-26 2025-01-09 추가이 세이야쿠 가부시키가이샤 의약 제제 함유 필터 내장 시린지
US20230407252A1 (en) 2022-04-28 2023-12-21 Allogene Therapeutics, Inc. Methods for donor cell analysis
EP4514844A1 (de) 2022-04-29 2025-03-05 Broadwing Bio LLC Komplementfaktor-h-verwandte 4-spezifische antikörper und verwendungen davon
CN119487063A (zh) 2022-04-29 2025-02-18 博闻生物有限责任公司 双特异性抗体以及治疗眼部疾病的方法
AU2023259251A1 (en) 2022-04-29 2024-11-14 Broadwing Bio, Inc. Angiopoietin-related protein 7-specific antibodies and uses thereof
CA3248580A1 (en) 2022-04-29 2023-11-02 Purinomia Biotech, Inc. METHODS AND COMPOSITIONS FOR THE TREATMENT OF DISEASES AND DISORDERS CAUSED BY EOSINOPHIL ACTIVITY
CN117085122A (zh) 2022-04-29 2023-11-21 中山康方生物医药有限公司 抗人il-4ra的抗体及其用途
WO2023215725A1 (en) 2022-05-02 2023-11-09 Fred Hutchinson Cancer Center Compositions and methods for cellular immunotherapy
PE20242350A1 (es) 2022-05-03 2024-12-16 Genentech Inc Anticuerpos anti-ly6e, inmunoconjugados y usos de estos
WO2023215498A2 (en) 2022-05-05 2023-11-09 Modernatx, Inc. Compositions and methods for cd28 antagonism
JP2025517120A (ja) 2022-05-05 2025-06-03 インヒブルクス バイオサイエンシズ インコーポレイテッド アルブミン結合ポリペプチド及びその使用
EP4518905A1 (de) 2022-05-06 2025-03-12 Seagen Inc. Immunmodulatorische antikörper-wirkstoff-konjugate
EP4524158A4 (de) 2022-05-09 2025-12-17 Staidson Beijing Biopharmaceuticals Co Ltd Antikörper mit spezifischer gdf15-erkennung und verwendung davon
JP2025517657A (ja) 2022-05-10 2025-06-10 アンスティチュ ナショナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシュ メディカル シンシチン－１融合タンパク質及び標的細胞へのカーゴ送達のためのその使用
AR129268A1 (es) 2022-05-11 2024-08-07 Hoffmann La Roche Anticuerpo que se une a vegf-a e il6 y métodos de uso
JP2025517650A (ja) 2022-05-11 2025-06-10 ジェネンテック， インコーポレイテッド 抗ＦｃＲＨ５／抗ＣＤ３二重特異性抗体による処置のための投与
US20240059799A1 (en) 2022-05-11 2024-02-22 Pfizer Inc. Anti-tl1a antibodies and methods of use thereof
WO2023218320A1 (en) 2022-05-11 2023-11-16 Pfizer Inc. Anti-lymphotoxin beta receptor antibodies and methods of use thereof
AU2023268600A1 (en) 2022-05-12 2024-11-07 Amgen Research (Munich) Gmbh Multichain multitargeting bispecific antigen-binding molecules of increased selectivity
WO2023217227A1 (zh) 2022-05-12 2023-11-16 先声再明医药有限公司 喜树碱类衍生物及配体-药物偶联物
WO2023220695A2 (en) 2022-05-13 2023-11-16 Voyager Therapeutics, Inc. Compositions and methods for the treatment of her2 positive cancer
KR20250075537A (ko) 2022-05-18 2025-05-28 앵스띠뛰 파스퇴르 인간 시르코바이러스의 확인
EP4527415A1 (de) 2022-05-18 2025-03-26 Medilink Therapeutics (Suzhou) Co., Ltd. Antikörper-wirkstoff-konjugat mit bioaktiver proteinabbaumittelverbindung, verfahren zur herstellung davon und verwendung davon
IL317037A (en) 2022-05-18 2025-01-01 Systimmune Inc Ligand-drug conjugate and its uses
EP4526342A1 (de) 2022-05-18 2025-03-26 Janssen Biotech, Inc. Verfahren zur bewertung und behandlung von psoriasisarthritis mit il23-antikörper
IL317101A (en) 2022-05-20 2025-01-01 Novartis Ag Antibody-drug conjugates of anticancer compounds and methods of using them
EP4279090A1 (de) 2022-05-20 2023-11-22 ADC Therapeutics SA Zusammensetzung enthaltend ein auf pyrrolobenzodiazepin basierendes antikörper-wirkstoff-konjugat
CN119562832A (zh) 2022-05-20 2025-03-04 诺华股份有限公司 Met bcl-xl抑制剂抗体-药物缀合物及其使用方法
EP4525925A1 (de) 2022-05-20 2025-03-26 Novartis AG Epha2 bcl-xl-inhibitor-antikörper-wirkstoff-konjugate und verfahren zur verwendung davon
WO2023222886A1 (en) 2022-05-20 2023-11-23 Depth Charge Ltd Antibody-cytokine fusion proteins
WO2023230448A1 (en) 2022-05-23 2023-11-30 Vir Biotechnology, Inc. Combination immunotherapy for influenza
US20260184814A1 (en) 2022-05-23 2026-07-02 Humabs Biomed Sa Broadly neutralizing antibodies against influenza neuraminidase
EP4529455A1 (de) 2022-05-23 2025-04-02 Inhibrx Biosciences, Inc. Kombinationstherapie mit dr5-agonist und iap-antagonist
US20250197804A1 (en) 2022-05-24 2025-06-19 Trince bv T cells, compositions comprising t cells and use thereof
WO2023230554A1 (en) 2022-05-25 2023-11-30 Pfizer Inc. Combination of a braf inhibitor, an egfr inhibitor, and a pd-1 antagonist for the treatment of braf v600e-mutant, msi-h/dmmr colorectal cancer
GB202207691D0 (en) 2022-05-25 2022-07-06 Cambridge Entpr Ltd Quinone protected forms and conjugates
IL316894A (en) 2022-05-26 2025-01-01 Pfizer ANTI-TNFR2 ANTIBODIES AND METHODS OF USE THEREOF
WO2023233330A1 (en) 2022-05-31 2023-12-07 Pfizer Inc. Anti-bmp9 antibodies and methods of use thereof
WO2023235699A1 (en) 2022-05-31 2023-12-07 Jounce Therapeutics, Inc. Antibodies to lilrb4 and uses thereof
WO2023232080A1 (zh) 2022-06-01 2023-12-07 百奥泰生物制药股份有限公司 抗cldn18.2抗体及其抗体药物偶联物和用途
WO2023235415A1 (en) 2022-06-01 2023-12-07 Genentech, Inc. Method to identify a patient with an increased likelihood of chemotherapy-induced peripheral neuropathy
AU2023279443A1 (en) 2022-06-03 2025-01-23 Ube Corporation Antibody-multidrug conjugate
JP2025517572A (ja) 2022-06-03 2025-06-05 エフ． ホフマン－ラ ロシュ アーゲー 改良された産生細胞
CN117229396A (zh) 2022-06-06 2023-12-15 普米斯生物技术(珠海)有限公司 抗cd40抗体及其用途
JP2025523387A (ja) 2022-06-07 2025-07-23 ジェネンテック， インコーポレイテッド 抗ｐｄ－ｌ１アンタゴニストおよび抗ｔｉｇｉｔアンタゴニスト抗体を含む、肺がん治療の有効性を判定するための方法
JPWO2023238869A1 (de) 2022-06-07 2023-12-14
AU2023282410A1 (en) 2022-06-07 2024-12-05 Duality Biologics (Suzhou) Co., Ltd. Anti-b7h3 antibody-drug conjugate and use thereof
TW202412744A (zh) 2022-06-07 2024-04-01 瑞士商意梭凱普公司 包括應用在食道黏膜之藥劑的藥物遞送系統及其應用
WO2023239803A1 (en) 2022-06-08 2023-12-14 Angiex, Inc. Anti-tm4sf1 antibody-drug conjugates comprising cleavable linkers and methods of using same
WO2023240201A1 (en) 2022-06-08 2023-12-14 Larimar Therapeutics, Inc. Frataxin-sensitive markers for monitoring progression and treatment of leigh syndrome
WO2023237661A1 (en) 2022-06-09 2023-12-14 Institut National de la Santé et de la Recherche Médicale Use of endothelin receptor type b agonists for the treatment of aortic valve stenosis
WO2023240218A1 (en) 2022-06-09 2023-12-14 Allogene Therapeutics Inc. Methods for detecting genomic abnormalities in cells
WO2023237663A1 (en) 2022-06-09 2023-12-14 Institut National de la Santé et de la Recherche Médicale Use of the f359l missense irf4 variant for increasing the stability of regulatory t cells
US20260053913A1 (en) 2022-06-10 2026-02-26 Bioentre Llc Combinations of ctla4 binding proteins and methods of treating cancer
JP2025519559A (ja) 2022-06-11 2025-06-26 インヒブルクス バイオサイエンシズ インコーポレイテッド ＦｃＲｎ結合ポリペプチド及びその使用
EP4536358A1 (de) 2022-06-13 2025-04-16 Genentech Inc. Verfahren zur verzögerung oder prävention des auftretens von morbus alzheimer mit crenezumab
CN117229398A (zh) 2022-06-15 2023-12-15 中山康方生物医药有限公司 抗cldn18.2抗体、其药物组合物及用途
WO2023245078A1 (en) 2022-06-15 2023-12-21 Humabs Biomed Sa Anti-parvovirus antibodies and uses thereof
IL317666A (en) 2022-06-15 2025-02-01 Bioverativ Usa Inc Anti-complement formulation for C1S antibody
CN120035602A (zh) 2022-06-17 2025-05-23 辉瑞公司 Il-12变体、抗-pd1抗体、融合蛋白及其用途
IL316871A (en) 2022-06-17 2025-01-01 Genentech Inc Using kosmotropes to improve the throughput of the affinity chromatography purification step
EP4321537A4 (de) 2022-06-22 2025-04-23 Akeso Biopharma, Inc. Pharmazeutische zusammensetzung und verwendung davon
US20250243263A1 (en) 2022-06-22 2025-07-31 Voyager Therapeutics, Inc. Tau binding compounds
CA3259327A1 (en) 2022-06-22 2023-12-28 Genentech, Inc. METHODS OF TREATMENT OF FOLLICULAR LYMPHOMA NOT PREVIOUSLY TREATED WITH MOSUNETUZUMAB AND LENALIDOMIDE
EP4296279A1 (de) 2022-06-23 2023-12-27 Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung e.V. Anti-transthyretin(ttr)-bindende proteine und ihre verwendungen
MA71249A (fr) 2022-06-24 2025-04-30 Bioverativ Usa Inc. Méthodes de traitement de maladies médiées par complément
CN119698486A (zh) 2022-06-29 2025-03-25 阿克托姆有限责任公司 检测单细胞中的生物分子
WO2024006876A1 (en) 2022-06-29 2024-01-04 Abbott Laboratories Magnetic point-of-care systems and assays for determining gfap in biological samples
WO2024003310A1 (en) 2022-06-30 2024-01-04 Institut National de la Santé et de la Recherche Médicale Methods for the diagnosis and treatment of acute lymphoblastic leukemia
WO2024006472A1 (en) 2022-06-30 2024-01-04 Vir Biotechnology, Inc. Antibodies that bind to multiple sarbecoviruses
AU2023298151A1 (en) 2022-07-01 2025-01-02 Neurogene Inc. Neo-2/15 variants and uses thereof for preferentially stimulating t-regulatory cells
WO2024008274A1 (en) 2022-07-04 2024-01-11 Universiteit Antwerpen T regulatory cell modification
WO2024008799A1 (en) 2022-07-06 2024-01-11 Institut National de la Santé et de la Recherche Médicale Methods for the treatment of proliferative glomerulonephritis
WO2024010365A1 (ko) 2022-07-07 2024-01-11 주식회사 부스트이뮨 신규한 tctp 결합분자
CN119585308A (zh) 2022-07-13 2025-03-07 基因泰克公司 针对用抗fcrh5/抗cd3双特异性抗体进行的治疗的给药
WO2024013234A1 (en) 2022-07-13 2024-01-18 Institut National de la Santé et de la Recherche Médicale Methods for diagnosis, prognosis, stratification and treating of myocarditis
CN119486763A (zh) 2022-07-14 2025-02-18 苏州宜联生物医药有限公司 抗体药物偶联物及其制备方法和用途
JP2025523049A (ja) 2022-07-14 2025-07-17 バイオ－テラ ソリュ－ションズ，エルティーディー． 抗Ｎｅｃｔｉｎ－４抗体及びその使用
WO2024013727A1 (en) 2022-07-15 2024-01-18 Janssen Biotech, Inc. Material and methods for improved bioengineered pairing of antigen-binding variable regions
WO2024015953A1 (en) 2022-07-15 2024-01-18 Danisco Us Inc. Methods for producing monoclonal antibodies
EP4554682A1 (de) 2022-07-15 2025-05-21 Fibrogen, Inc. Modifizierter anti-galectin-9-antikörper und verwendungen davon
EP4558226A1 (de) 2022-07-19 2025-05-28 Staidson Biopharma Inc. Antikörper, die spezifisch b- und t-lymphozyten-dämpfungsglied (btla) erkennen, und verwendungen davon
EP4558523A1 (de) 2022-07-19 2025-05-28 Biolegend, Inc. Anti-cd157-antikörper, antigenbindende fragmente davon sowie zusammensetzungen und verfahren zur herstellung und verwendung davon
KR20250040020A (ko) 2022-07-19 2025-03-21 제넨테크, 인크. 항-fcrh5/항-cd3 이중특이성 항체로 치료하기 위한 투약법
EP4558529A1 (de) 2022-07-22 2025-05-28 Bristol-Myers Squibb Company An menschliches pad4 bindende antikörper und verwendungen davon
US20260029402A1 (en) 2022-07-22 2026-01-29 Institut National de la Santé et de la Recherche Médicale Garp as a biomarker and biotarget in t-cell malignancies
EP4309733A1 (de) 2022-07-22 2024-01-24 Institut National de la Santé et de la Recherche Médicale (INSERM) Neutralisierung von acyl-coa-bindungsproteinen zur behandlung von herzstörungen
CN119907674A (zh) 2022-07-22 2025-04-29 詹森生物科技公司 遗传指令向效应免疫细胞的增强转移
CN119654349A (zh) 2022-07-22 2025-03-18 基因泰克公司 抗steap1抗原结合分子及其用途
WO2024020429A1 (en) 2022-07-22 2024-01-25 Lyell Immunopharma, Inc. Immune cell therapy
WO2024026284A2 (en) 2022-07-25 2024-02-01 Interius Biotherapeutics, Inc. Mutated polypeptides, compositions comprising the same, and uses thereof
AU2023313117A1 (en) 2022-07-27 2025-02-13 Mediboston Limited Auristatin derivatives and conjugates thereof
EP4561613A1 (de) 2022-07-27 2025-06-04 Teneobio, Inc. Mesothelinbindende proteine und verwendungen davon
JP2025526405A (ja) 2022-07-27 2025-08-13 ヒューマブス・バイオメッド・ソシエテ・アノニム Ｒｓｖ及びｍｐｖパラミクソウイルスに対する広域中和抗体
GB202210957D0 (en) 2022-07-27 2022-09-07 Alligator Bioscience Ab Novel dosages
CN119546344A (zh) 2022-07-27 2025-02-28 明慧医药（杭州）有限公司 抗体药物偶联物及其应用
GB202210965D0 (en) 2022-07-27 2022-09-07 Alligator Bioscience Ab Novel dosages
WO2024023246A1 (en) 2022-07-28 2024-02-01 Philogen S.P.A. Antibody binding to pd1
WO2024024565A1 (ja) 2022-07-28 2024-02-01 国立大学法人 東京大学 ニューロトリミンの機能阻害剤
MA71622A (fr) 2022-07-29 2025-05-30 Alector Llc Domaines de liaison à l'antigène cd98hc et leurs utilisations
IL318627A (en) 2022-07-29 2025-03-01 Regeneron Pharma Anti-TFR charge fusions and methods of using them
WO2024023283A1 (en) 2022-07-29 2024-02-01 Institut National de la Santé et de la Recherche Médicale Lrrc33 as a biomarker and biotarget in cutaneous t-cell lymphomas
AU2023314795A1 (en) 2022-07-29 2025-03-06 Alector Llc Anti-gpnmb antibodies and methods of use thereof
CN120659627A (zh) 2022-07-29 2025-09-16 瑞泽恩制药公司 用于转铁蛋白受体（tfr）介导的脑和肌肉递送的组合物和方法
CN119497721A (zh) 2022-07-29 2025-02-21 艾莱克特有限责任公司 转铁蛋白受体抗原结合结构域及其用途
WO2024028794A1 (en) 2022-08-02 2024-02-08 Temple Therapeutics BV Methods for treating endometrial and ovarian hyperproliferative disorders
WO2024030982A2 (en) 2022-08-02 2024-02-08 Diadem Spa Device for detection and prognostic assessment of neurodegenerative disorders
US20240052047A1 (en) 2022-08-03 2024-02-15 Pfizer Inc. Anti- il27r antibodies and methods of use thereof
CA3263767A1 (en) 2022-08-03 2024-02-08 Voyager Therapeutics, Inc. COMPOSITIONS AND PROCESSES ALLOWING CROSSING THE BLOOD-BRAIN BARRIER
IL318450A (en) 2022-08-03 2025-03-01 Seagen Inc Immunostimulatory ANTI-PD-L1-Drug conjugates
US20260060969A1 (en) 2022-08-04 2026-03-05 Institut National de la Santé et de la Recherche Médicale Methods for the treatment of lymphoproliferative disorders
EP4565331A1 (de) 2022-08-05 2025-06-11 Janssen Biotech, Inc. Cd98-bindende konstrukte zur behandlung von hirntumoren
CN120077064A (zh) 2022-08-05 2025-05-30 詹森生物科技公司 用于治疗脑肿瘤的转铁蛋白受体结合蛋白
CN119998325A (zh) 2022-08-08 2025-05-13 Atb治疗公司 抗CD79b的人源化抗体
WO2024036139A2 (en) 2022-08-09 2024-02-15 Qlsf Biotherapeutics, Inc. Antibodies binding to clec12a
US20260083725A1 (en) 2022-08-10 2026-03-26 Institut National de la Santé et de la Recherche Médicale Sigmari ligand for the treatment of pancreatic cancer
WO2024033400A1 (en) 2022-08-10 2024-02-15 Institut National de la Santé et de la Recherche Médicale Sk2 inhibitor for the treatment of pancreatic cancer
US20260125454A1 (en) 2022-08-11 2026-05-07 Shanghai Junshi Biosciences Co., Ltd. Anti-cgrp antibody and use
EP4321522A1 (de) 2022-08-12 2024-02-14 Seagen Inc. Zytotoxische verbindungen und konjugate davon
WO2024039672A2 (en) 2022-08-15 2024-02-22 Dana-Farber Cancer Institute, Inc. Antibodies against msln and methods of use thereof
CA3263665A1 (en) 2022-08-15 2024-02-22 Dana-Farber Cancer Institute, Inc. Anti-CLDN4 antibodies and their methods of use
WO2024040090A1 (en) 2022-08-16 2024-02-22 Allogene Therapeutics Inc. In vitro method for inhibiting hhv-6 infection
CA3264784A1 (en) 2022-08-18 2024-02-22 Immunocore Limited MULTI-DOMAIN BONDING MOLECULES
WO2024038165A1 (en) 2022-08-18 2024-02-22 Immunocore Ltd T cell receptor fusion proteins specific for mage a4
US20260042848A1 (en) 2022-08-18 2026-02-12 BioLegend, Inc. Anti-axl antibodies, antigen-binding fragments thereof and methods for making and using the same
JP2025528212A (ja) 2022-08-18 2025-08-26 イムノコア リミテッド 複数ドメイン結合性分子
TW202423994A (zh) 2022-08-18 2024-06-16 英商英美偌科有限公司 多域結合分子
CA3265264A1 (en) 2022-08-19 2024-02-22 Fibrogen, Inc. CCR8 ANTIBODIES AND THEIR USES
KR20250094657A (ko) 2022-08-19 2025-06-25 메디뮨 리미티드 급성 호흡부전의 치료
CN121293357A (zh) 2022-08-22 2026-01-09 雅博得乐医疗公司 Dll3结合分子及其用途
WO2024043227A1 (ja) 2022-08-23 2024-02-29 小野薬品工業株式会社 二重特異性抗体
WO2024044687A1 (en) 2022-08-26 2024-02-29 Valo Health, Inc. Biomarker combinations for prognosis and management of diabetic retinopathy
TW202423972A (zh) 2022-08-26 2024-06-16 英商梅迪繆思有限公司 使用抗介白素－３３抗體的氣喘治療
KR20250057832A (ko) 2022-08-31 2025-04-29 장춘 진사이언스 파마슈티컬 씨오., 엘티디. 갑상선 자극 호르몬 수용체에 결합하는 항체 및 이의 용도
WO2024047110A1 (en) 2022-08-31 2024-03-07 Institut National de la Santé et de la Recherche Médicale Method to generate more efficient car-t cells
EP4581366A1 (de) 2022-09-01 2025-07-09 Genentech, Inc. Therapeutische und diagnostische verfahren für blasenkrebs
WO2024050524A1 (en) 2022-09-01 2024-03-07 University Of Georgia Research Foundation, Inc. Compositions and methods for directing apolipoprotein l1 to induce mammalian cell death
WO2024052318A1 (en) 2022-09-06 2024-03-14 Institut National de la Santé et de la Recherche Médicale Novel dual split car-t cells for the treatment of cd38-positive hematological malignancies
US20260078185A1 (en) 2022-09-07 2026-03-19 Dynamicure Biotechnology Llc Anti-vista constructs and uses thereof
CA3266599A1 (en) 2022-09-07 2024-11-07 Quantitative Biosciences, Inc. UNIQUE VARIABLE DOMAIN ANTIBODIES SPECIFIC TO FENTANYL AND USE IN A CONTINUOUS AGGLUTINATION TEST
CN116836286A (zh) 2022-09-07 2023-10-03 中国科学院合肥物质科学研究院 能够特异性结合ror1的抗体、其偶联药物及其制备方法和应用
EP4584291A1 (de) 2022-09-08 2025-07-16 Institut National de la Santé et de la Recherche Médicale Antikörper mit spezifität gegen ltbp2 und verwendungen davon
EP4585226A1 (de) 2022-09-09 2025-07-16 Institute Of Science Tokyo Therapeutikum für coronavirus-infektion
US20240117051A1 (en) 2022-09-09 2024-04-11 Akeso Biopharma, Inc. Therapeutic combination and use thereof
WO2024054678A2 (en) 2022-09-09 2024-03-14 Regents Of The University Of Minnesota Antibodies against fentanyl and analogs and methods of use thereof
CN119997982A (zh) 2022-09-09 2025-05-13 迈里克斯制药有限公司 包含nmt抑制剂的抗体药物偶联物及其用途
EP4584297A1 (de) 2022-09-11 2025-07-16 Yeda Research and Development Co. Ltd Anti-klk4-antikörper und verwendungen davon
WO2024056668A1 (en) 2022-09-12 2024-03-21 Institut National de la Santé et de la Recherche Médicale New anti-itgb8 antibodies and its uses thereof
WO2024059183A1 (en) 2022-09-14 2024-03-21 President And Fellows Of Harvard College Methods and compositions for modulation of piezo1 in the treatment of cancer
AU2023343470A1 (en) 2022-09-14 2025-02-06 Amgen Inc. Bispecific molecule stabilizing composition
AU2023342055A1 (en) 2022-09-15 2025-03-13 Abbott Laboratories Biomarkers and methods for differentiating between mild and supermild traumatic brain injury
JP2025535203A (ja) 2022-09-15 2025-10-23 ボイジャー セラピューティクス インコーポレイテッド タウ結合化合物
US20260103629A1 (en) 2022-09-20 2026-04-16 Yale University Compositions of wet adhesives derived from vibrio cholerae biofilm adhesins and methods thereof
KR20250068754A (ko) 2022-09-20 2025-05-16 바이오세우스 인크. 항-her2 항체 및 이의 용도
WO2024062019A1 (en) 2022-09-21 2024-03-28 Synabs Anti-ccr8 antibodies and uses thereof
US20260098083A1 (en) 2022-09-21 2026-04-09 Industry-Academic Cooperation Foundation, Yonsei University Novel Antibody For Prevention Or Treatment Of Fibrotic Disease
US12054552B2 (en) 2022-09-21 2024-08-06 Sanofi Biotechnology Humanized anti-IL-1R3 antibody and methods of use
EP4590699A1 (de) 2022-09-22 2025-07-30 Pfizer Inc. Verfahren zur behandlung mit ifn-beta-antikörpern
WO2024067344A1 (zh) 2022-09-27 2024-04-04 舒泰神（北京）生物制药股份有限公司 特异性识别light的抗体及其应用
KR20250075694A (ko) 2022-09-28 2025-05-28 리제너론 파마슈티칼스 인코포레이티드 세포 기반 요법을 강화하기 위한 항체 저항성 변형 수용체
US12233115B2 (en) 2022-09-30 2025-02-25 Extend Biosciences, Inc. Long-acting parathyroid hormone
WO2024068996A1 (en) 2022-09-30 2024-04-04 Centre Hospitalier Universitaire Vaudois (C.H.U.V.) Anti-sars-cov-2 antibodies and use thereof in the treatment of sars-cov-2 infection
CN117802214A (zh) 2022-09-30 2024-04-02 厦门英博迈生物科技有限公司 多发性硬化诊断的标志物及其应用
JP2025532758A (ja) 2022-10-04 2025-10-03 イムチェック セラピューティクス エスエーエス 癌の治療における使用のためのｂｔｎ３ａ活性化抗体、ｂｃｌ２阻害剤及び低メチル化剤の併用
WO2024074649A1 (en) 2022-10-05 2024-04-11 Alcea Therapeutics, Inc. Notch4 antibodies, compositions, and methods for treating airway inflammation
CN119948059A (zh) 2022-10-05 2025-05-06 法国国家健康医学研究院 靶向dc的抗尼帕病毒感染疫苗
EP4598958A1 (de) 2022-10-05 2025-08-13 Amgen Inc. Kombinationstherapien mit t-zell-umleitenden therapien und agonistischen anti-il-2r-antikörpern oder fragmenten davon
WO2024077239A1 (en) 2022-10-07 2024-04-11 Genentech, Inc. Methods of treating cancer with anti-c-c motif chemokine receptor 8 (ccr8) antibodies
WO2024074713A1 (en) 2022-10-07 2024-04-11 Institut National de la Santé et de la Recherche Médicale Method to generate improving car-t cells
WO2024079192A1 (en) 2022-10-12 2024-04-18 Institut National de la Santé et de la Recherche Médicale Cd81 as a biomarker and biotarget in t-cell malignancies
GB202215115D0 (en) 2022-10-13 2022-11-30 Univ Nottingham VEGF antibodies
EP4602069A1 (de) 2022-10-14 2025-08-20 Ebbil, Ltd. Sil-6r- und ctgf-bindende proteine und verfahren zur verwendung davon
US20260234258A1 (en) 2022-10-20 2026-08-13 Repertoire Immune Medicines, Inc. Cd8 t cell targeted il2
WO2024086796A1 (en) 2022-10-20 2024-04-25 Alector Llc Anti-ms4a4a antibodies with amyloid-beta therapies
CN120693395A (zh) 2022-10-20 2025-09-23 北京三诺佳邑生物技术有限责任公司 特异性结合TRAIL或FasL的抗体组合以及双特异性抗体
AU2023362569A1 (en) 2022-10-21 2025-04-24 Novimmune Sa Pd-l1xcd28 bispecific antibodies for immune checkpoint-dependent t cell activation
EP4605000A1 (de) 2022-10-21 2025-08-27 Institut National de la Santé et de la Recherche Médicale Verfahren und pharmazeutische zusammensetzungen zur behandlung von osteoarthritis
WO2024089417A1 (en) 2022-10-24 2024-05-02 Memorial Sloan-Kettering Cancer Center Tumour stratification for responsiveness to an immune checkpoint inhibitor
JP2025535474A (ja) 2022-10-24 2025-10-24 キャンサー・リサーチ・テクノロジー・リミテッド 酸化還元状態改変剤によるチェックポイント阻害剤に対する腫瘍の感応化
JP2026500084A (ja) 2022-10-25 2026-01-06 ジェネンテック， インコーポレイテッド 多発性骨髄腫の治療方法および診断方法
WO2024089551A1 (en) 2022-10-25 2024-05-02 Janssen Biotech, Inc. Msln and cd3 binding agents and methods of use thereof
KR20250079227A (ko) 2022-10-25 2025-06-04 머크 샤프 앤드 돔 엘엘씨 엑사테칸-유래 adc 링커-페이로드, 제약 조성물, 및 그의 용도
EP4609196A1 (de) 2022-10-26 2025-09-03 Eximmium Biotechnologies GmbH Verfahren zur bestimmung der extrazellulären vesikelrückgewinnung
AU2023366516A1 (en) 2022-10-28 2025-05-15 Aduro Biotech Holdings, Europe B.V. Treatment of iga nephropathy using an endothelin receptor antagonist and an april binding antibody
WO2024097639A1 (en) 2022-10-31 2024-05-10 Modernatx, Inc. Hsa-binding antibodies and binding proteins and uses thereof
US20260176337A1 (en) 2022-11-02 2026-06-25 Kira Pharmaceuticals (Us) Llc Anti-c5 antibody fused to factor h for use in the treatment of complement-mediated diseases
WO2024097441A1 (en) 2022-11-02 2024-05-10 Kira Pharmaceuticals (Us) Llc Anti-c5 antibody fused to factor h for use in the treatment of complement-mediated diseases
AU2023371614A1 (en) 2022-11-04 2025-05-15 Regeneron Pharmaceuticals, Inc. Calcium voltage-gated channel auxiliary subunit gamma 1 (cacng1) binding proteins and cacng1-mediated delivery to skeletal muscle
US20240165227A1 (en) 2022-11-04 2024-05-23 Gilead Sciences, Inc. Anticancer therapies using anti-ccr8 antibody, chemo and immunotherapy combinations
WO2024094003A1 (zh) 2022-11-04 2024-05-10 普米斯生物技术(珠海)有限公司 抗ccr8的抗体及其用途
IL320029A (en) 2022-11-08 2025-06-01 Genentech Inc Compositions and methods for treating childhood idiopathic nephrotic syndrome
WO2024100200A1 (en) 2022-11-09 2024-05-16 Cis Pharma Ag Anti-l1-cam antibodies and their uses for diagnostic and therapeutic applications
CA3272953A1 (en) 2022-11-10 2024-05-16 Famewave Ltd. ANTIBODIES AGAINST CARCINOEMBRYONIC ANTIGEN-BINDED CELL ADHESION MOLECULE 1 (CEACAM1) FOR THE PURPOSE OF INHIBITING NETOSIS-MEDIATED ACTIVITIES
CN120456916A (zh) 2022-11-14 2025-08-08 瑞泽恩制药公司 抗fgfr3抗体和抗原结合片段及其使用方法
AU2023379457A1 (en) 2022-11-14 2025-05-15 Regeneron Pharmaceuticals, Inc. Compositions and methods for fibroblast growth factor receptor 3-mediated delivery to astrocytes
WO2024105205A1 (en) 2022-11-17 2024-05-23 Bayer Aktiengesellschaft Antibody-drug conjugates (a2dcs) with enzymatically cleavable groups
JP2025541670A (ja) 2022-11-18 2025-12-23 ジェネンテック， インコーポレイテッド Ｉａ－ｌｃ－ｍｓ／ｍｓベースのアッセイのための質量タグを使用した信号増幅および多重化
EP4619764A1 (de) 2022-11-18 2025-09-24 Universiteit Antwerpen Igfbp2 als biomarker für thoraxaortenaneurysmen und dissektionen
CN120530137A (zh) 2022-11-21 2025-08-22 泰博尔治疗公司 人源化抗agr2抗体
TW202426490A (zh) 2022-11-21 2024-07-01 美商黛安瑟斯醫療運營公司 結合ｃ１ｓ之抗體及其用途
WO2024112818A1 (en) 2022-11-22 2024-05-30 Humabs Biomed Sa Engineered anti-sars-cov-2 antibodies and uses thereof
CN120239710A (zh) 2022-11-22 2025-07-01 上海宏成药业有限公司 抗ccr8抗体及其用途
AU2023383916A1 (en) 2022-11-22 2025-07-10 Janssen Biotech, Inc. Method of treating ulcerative colitis with anti-il23 specific antibody
JP2025538565A (ja) 2022-11-23 2025-11-28 エフ． ホフマン－ラ ロシュ アーゲー 組換えタンパク質発現を増加させるための方法
WO2024111657A1 (ja) 2022-11-25 2024-05-30 中外製薬株式会社 タンパク質の製造方法
CN120456922A (zh) 2022-11-25 2025-08-08 国立大学法人大阪大学 针对血液癌的抗体
TW202440623A (zh) 2022-11-28 2024-10-16 美商艾洛基因醫療公司 靶向密連蛋白１８﹒２之嵌合抗原受體及結合劑以及其用途
WO2024115935A1 (en) 2022-11-29 2024-06-06 Inserm Methods for the treatment of b-cell lymphoma using cd39 inhibitors
CN120282987A (zh) 2022-11-30 2025-07-08 因特格尔莫来库乐有限公司 包括双特异性型式的针对紧密连接蛋白6的抗体
US20260191905A1 (en) 2022-12-01 2026-07-09 Modernatx, Inc. Gpc3-specific antibodies, binding domains, and related proteins and uses thereof
WO2024118998A2 (en) 2022-12-01 2024-06-06 Vir Biotechnology, Inc. Engineered anti-sars-cov-2 antibodies and methods of using the same
EP4588936A4 (de) 2022-12-08 2026-08-12 Changchun Bcht Biotechnology Co Spezifisch an rsv bindende antikörper
WO2024121632A1 (en) 2022-12-09 2024-06-13 Crispr Therapeutics Ag Use of anti-cd117 antibody drug conjugate (adc)
EP4634397A1 (de) 2022-12-12 2025-10-22 Genentech Inc. Optimierung des sialinsäuregehalts von polypeptiden
WO2024129756A1 (en) 2022-12-13 2024-06-20 Seagen Inc. Site-specific engineered cysteine antibody drug conjugates
KR20250116773A (ko) 2022-12-14 2025-08-01 머크 샤프 앤드 돔 엘엘씨 아우리스타틴 링커-페이로드, 제약 조성물, 및 그의 용도
AU2023393382A1 (en) 2022-12-14 2025-06-19 Pheon Therapeutics Ltd Cytotoxic compounds
JP2026501282A (ja) 2022-12-20 2026-01-14 ジェネンテック， インコーポレイテッド Ｐｄ－１軸結合アンタゴニストおよびｒｎａワクチンを用いて膵臓がんを処置する方法
US20260217861A1 (en) 2022-12-22 2026-07-30 Jjulius-Maximilians-Universität-Würzburg Antibodies for use as coagulants
CN120677175A (zh) 2022-12-22 2025-09-19 供石公司 肌生成抑制蛋白活化的选择性和强效抑制剂
WO2024133723A1 (en) 2022-12-22 2024-06-27 Institut National de la Santé et de la Recherche Médicale Methods for decreasing therapeutic acquired resistance to chemotherapy and/or radiotherapy
KR20250137203A (ko) 2022-12-27 2025-09-17 예일 유니버시티 항체 약물 접합체
EP4644548A1 (de) 2022-12-27 2025-11-05 Chugai Seiyaku Kabushiki Kaisha Polypeptid mit kontrollierter assoziation
IL321713A (en) 2022-12-27 2025-08-01 Merck Patent Gmbh Anti-PROTAC VHH antibodies and complexes
EP4644422A1 (de) 2022-12-28 2025-11-05 BioRay Pharmaceutical Co., Ltd. Anti-nkg2a-antikörper und verwendung davon
US20260217863A1 (en) 2022-12-30 2026-07-30 Uif (University Industry Foundation), Yonsei University Antibody or peptide binding specifically to rnase a, immunoassay device and method for detecting rnase a, and method for collecting rnase a
IL321809A (en) 2023-01-06 2025-08-01 Immunocore Ltd Binding molecules against a piwil1 peptide-hla complex
JP2026503002A (ja) 2023-01-06 2026-01-27 アレクトル エルエルシー 抗ｉｌ１８結合タンパク質抗体及びその使用方法
KR20250133715A (ko) 2023-01-06 2025-09-08 이뮤노코어 리미티드 Prame 펩타이드-hla 복합체에 대한 결합 분자
WO2024150017A1 (en) 2023-01-13 2024-07-18 Akrivia Biomedics Limited Method of profiling diseases
CN121002062A (zh) 2023-01-13 2025-11-21 再生元制药公司 Fgfr3结合分子及其使用方法
WO2024154122A1 (en) 2023-01-18 2024-07-25 Gilboa Therapeutics LTD Immune cells expressing a complement receptor and uses thereof
CN120548194A (zh) 2023-01-18 2025-08-26 辉瑞公司 针对呼吸道疾病的疫苗
PE20252286A1 (es) 2023-01-18 2025-09-18 Genentech Inc Anticuerpos multiespecificos y usos de estos
EP4653018A1 (de) 2023-01-18 2025-11-26 Medilink Therapeutics (Suzhou) Co., Ltd. Antikörper-wirkstoff-konjugat sowie herstellungsverfahren dafür und verwendung davon
EP4655007A1 (de) 2023-01-23 2025-12-03 Yale University Antikörper-oligonukleotid-konjugate
US12534540B2 (en) 2023-01-23 2026-01-27 Clemson University Research Foundation CYP1A1-targeted monoclonal antibody with reactivity across vertebrate taxa
EP4654982A1 (de) 2023-01-27 2025-12-03 Regeneron Pharmaceuticals, Inc. Modifizierte rhabdovirus-glycoproteine und verwendungen davon
EP4660297A1 (de) 2023-01-30 2025-12-10 Juntendo Educational Foundation Verfahren zur selektiven induktion antigenspezifischer induktiver regulatorischer t-zellen
CN116574189A (zh) 2023-01-30 2023-08-11 北京智仁美博生物科技有限公司 针对人il-36r和/或人il-1r3的多种抗体及其用途
US20260217828A1 (en) 2023-01-31 2026-07-30 University Of Rochester Immune checkpoint blockade therapy for treating staphylococcus aureus infections
JP2026506361A (ja) 2023-02-02 2026-02-24 アンスティチュ ナショナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシュ メディカル 選択された結核菌防御抗原を樹状細胞に標的化させる抗結核ワクチン
TW202448501A (zh) 2023-02-02 2024-12-16 美商麥迪紐有限責任公司 用抗ｔｓｌｐ抗體治療慢性鼻竇炎
WO2024161038A1 (en) 2023-02-03 2024-08-08 Immusmol Sas Method of predicting success of a cancer therapy
TW202448960A (zh) 2023-02-07 2024-12-16 美商Ｇｏ治療公司 包括抗醣MUC4抗體及MIC蛋白α1-α2結構域之抗體融合蛋白及其用途
WO2024168061A2 (en) 2023-02-07 2024-08-15 Ayan Therapeutics Inc. Antibody molecules binding to sars-cov-2
CN120897928A (zh) 2023-02-13 2025-11-04 英特维特国际股份有限公司 针对犬il-4的犬抗体
WO2024169990A1 (zh) 2023-02-13 2024-08-22 浙江大学绍兴研究院 双特异性抗体及其应用
US20260234236A1 (en) 2023-02-13 2026-08-13 Intervet Inc. Canine antibodies to canine il-13
JP2026506602A (ja) 2023-02-13 2026-02-25 アンスティチュ ナショナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシュ メディカル 鉄過剰関連疾患の処置方法
WO2024170543A1 (en) 2023-02-14 2024-08-22 Institut National de la Santé et de la Recherche Médicale Anti-cd44 antibodies and uses thereof
US20260234253A1 (en) 2023-02-14 2026-08-13 Evolvelmmune Therapeutics, Inc. Combination of bispecific antibodies and chimeric antigen receptor t cells for treatment
TW202448517A (zh) 2023-02-16 2024-12-16 瑞典商阿斯特捷利康公司 用治療性結合分子治療癌症的組合療法
PE20260929A1 (es) 2023-02-17 2026-05-06 Apogee Therapeutics Inc Anticuerpos que se unen al receptor alfa de interleuquina 4 y metodos de uso
IL322840A (en) 2023-02-20 2025-10-01 Akeso Biopharma Co Ltd Fusion protein comprising a TGF-βRII extracellular region fragment, its pharmaceutical composition and use
AU2024226156A1 (en) 2023-02-21 2025-08-28 Teneobio, Inc. C-kit binding proteins, chimeric antigen receptors, and uses thereof
JP2026506893A (ja) 2023-02-23 2026-02-27 イムチェック セラピューティクス エスエーエス Ｂｔｎ３ａ活性化抗体と免役チェックポイント阻害剤の併用
WO2024175760A1 (en) 2023-02-24 2024-08-29 Institut National de la Santé et de la Recherche Médicale Methods for the treatment of endometriosis
IL322523A (en) 2023-02-28 2025-10-01 Eisai R&D Man Co Ltd Anti-PSMA antibodies, conjugates and methods of use
EP4673181A1 (de) 2023-03-01 2026-01-07 Sanofi Verwendung von anti-ceacam5-immunkonjugaten zur behandlung von neuroendokrinem krebs mit ceacam5 expression
JPWO2024181580A1 (de) 2023-03-02 2024-09-06
CN120882743A (zh) 2023-03-02 2025-10-31 瑞韦博治疗公司 包含单特异性和双特异性非阻断性抗细胞因子抗体的基于细胞因子的疗法和方法
EP4427763A1 (de) 2023-03-06 2024-09-11 Sanofi Antitumorkombinationen mit anti-ceacam5-antikörper-wirkstoff-konjugaten, anti-vegfr-2-antikörpern und anti-pd1/pd-l1-antikörpern
EP4678186A1 (de) 2023-03-07 2026-01-14 Akeso Pharma Co., Ltd. Pharmazeutische zusammensetzung mit bispezifischem anti-ctla4-anti-pd-1-antikörper und verwendung davon
CN120858176A (zh) 2023-03-07 2025-10-28 居里研究所 Brca相关癌症中的ung/udg抑制
WO2024184494A1 (en) 2023-03-08 2024-09-12 Ac Immune Sa Anti-tdp-43 binding molecules and uses thereof
AU2024232598A1 (en) 2023-03-08 2025-07-17 Amgen Inc. Controlled-ice nucleation lyophilization process for bispecific molecules
WO2024191807A1 (en) 2023-03-10 2024-09-19 Seagen Inc. Methods of treating cancer with anti-tigit antibodies
EP4676540A1 (de) 2023-03-10 2026-01-14 Novartis AG Panras-inhibitor-antikörper-wirkstoff-konjugate und verfahren zur verwendung davon
GB202303531D0 (en) 2023-03-10 2023-04-26 Fusion Antibodies Plc Antibodies and uses thereof
EP4676951A1 (de) 2023-03-10 2026-01-14 Genentech Inc. Fusionen mit proteasen und verwendungen davon
CN120835901A (zh) 2023-03-13 2025-10-24 豪夫迈·罗氏有限公司 采用pd1-lag3双特异性抗体和hla-g t细胞双特异性抗体的组合疗法
GB202303784D0 (en) 2023-03-15 2023-04-26 Institute Of Cancer Res Royal Cancer Hospital Cancer treatment
JP2026508657A (ja) 2023-03-16 2026-03-11 アイタブメッド カンパニー， リミテッド 多重特異性抗原結合タンパク質及びその使用
EP4680344A1 (de) 2023-03-16 2026-01-21 Inmagene Pte. Ltd. Auf ilt7 gerichtete antikörper und verwendungen davon
EP4431526A1 (de) 2023-03-16 2024-09-18 Emfret Analytics GmbH & Co. KG Anti-gpvi-antikörper und funktionelle fragmente davon
WO2024194686A2 (en) 2023-03-17 2024-09-26 Oxitope Pharma B.V. Anti-phosphocholine antibodies and methods of use thereof
WO2024194685A2 (en) 2023-03-17 2024-09-26 Oxitope Pharma B.V. Anti-phosphocholine antibodies and methods of use thereof
WO2024194673A1 (en) 2023-03-21 2024-09-26 Institut Curie Methods for the treatment of dedifferentiated liposarcoma
EP4683630A1 (de) 2023-03-21 2026-01-28 Institut Curie Vps4b-inhibitor zur verwendung in verfahren zur behandlung von hrd-krebs
WO2024194402A1 (en) 2023-03-21 2024-09-26 Institut Curie Farnesyl transferase inhibitor for use in methods for the treatment of hrd cancer
AU2024238898A1 (en) 2023-03-22 2025-10-16 Salubris Biotherapeutics, Inc. Anti-5t4 antigen binding domains, antibody-drug conjugates and methods of use thereof
WO2024197302A1 (en) 2023-03-23 2024-09-26 Yale University Compositions and methods for delivering antibody oligonucleotide conjugates for exon skipping
JP2026511090A (ja) 2023-03-23 2026-04-10 サノフイ 癌治療における患者選択のためのＣＥＡＣＡＭ５ ｍＲＮＡアッセイ
WO2024206126A1 (en) 2023-03-27 2024-10-03 Modernatx, Inc. Cd16-binding antibodies and uses thereof
WO2024199364A1 (zh) 2023-03-29 2024-10-03 中山康方生物医药有限公司 抗lag3抗体、药物组合物及用途
KR20250167591A (ko) 2023-03-31 2025-12-01 제넨테크, 인크. 항-알파 v 베타 8 인테그린 항체 및 사용 방법
EP4666070A2 (de) 2023-03-31 2025-12-24 The Regents of University of California Induziertes pluripotentes stammzellenmodell des fasrigen dysplasie/mccune-albright-syndroms und verfahren zur verwendung
JP2026517628A (ja) 2023-04-04 2026-06-02 アボット・ラボラトリーズ 対象が亜急性後天性脳損傷（ａｂｉ）を負った、負った可能性がある、又は負っていると推測されるかどうかを決定するためのバイオマーカーの使用
CN121985963A (zh) 2023-04-05 2026-05-05 维硕公司 抗体偶联药物及其用途
WO2024211234A1 (en) 2023-04-05 2024-10-10 Sorrento Therapeutics, Inc. Antibody-drug conjugates and uses thereof
WO2024211236A2 (en) 2023-04-05 2024-10-10 Sorrento Therapeutics, Inc. Antibody-drug conjugates and uses thereof
TW202446788A (zh) 2023-04-10 2024-12-01 美商維爾生物科技公司 結合多種薩貝冠狀病毒之抗體
CN118767127A (zh) 2023-04-10 2024-10-15 康方药业有限公司 抗ctla4-抗pd-1双特异性抗体的医药用途
EP4695282A1 (de) 2023-04-12 2026-02-18 Shanghai Kangabio Co., Limited Multifunktionale moleküle mit maskiertem interleukin 12 und verfahren zur verwendung
JP2026515781A (ja) 2023-04-13 2026-05-19 アリゲーター・バイオサイエンス・アーベー 併用療法
EP4695290A1 (de) 2023-04-13 2026-02-18 Institut Curie Verfahren zur behandlung von akuter lymphoblastischer t-zell-leukämie
EP4696331A1 (de) 2023-04-14 2026-02-18 Hainan Simcere Zaiming Pharmaceutical Co., Ltd. Anti-cdh6-antikörper-wirkstoff-konjugat und verwendung davon
WO2024214811A1 (ja) 2023-04-14 2024-10-17 中外製薬株式会社 タンパク質含有医薬製剤の安定化方法
EP4695258A1 (de) 2023-04-14 2026-02-18 Nira Biosciences, Inc. Benzoporphyrinanaloga, konjugate und verfahren zu deren verwendung
JP2026514048A (ja) 2023-04-14 2026-05-01 カイマブ・リミテッド 抗ｏｘ４０ｌ抗体を含有する医薬製剤
KR20260012304A (ko) 2023-04-17 2026-01-26 피크 바이오, 인크. 항체 및 항체-약물 접합체 및 사용 방법 및 합성 공정 및 중간체
JP2026521103A (ja) 2023-04-18 2026-06-26 キューエルエスエフ バイオセラピューティクス， インコーポレイテッド Ｌｙ６ｇ６ｄに結合する抗体
KR20250169631A (ko) 2023-04-18 2025-12-03 주노 쎄러퓨티크스 인코퍼레이티드 치료 세포 조성물의 효력을 평가하기 위한 세포독성 검정
WO2024218650A1 (en) 2023-04-19 2024-10-24 Pfizer Inc. Lilrb1 and lilrb2 antibodies and methods of use thereof
WO2024218706A1 (en) 2023-04-21 2024-10-24 Pfizer Inc. Improved cells and cell cultures
KR20250174033A (ko) 2023-04-23 2025-12-11 씨에스피씨 메가리스 바이오파마슈티칼 씨오., 엘티디. 항체 약물 접합체의 이용
CN121398855A (zh) 2023-04-24 2026-01-23 默沙东有限责任公司 Trop2结合剂及其缀合物
CN118852442A (zh) 2023-04-26 2024-10-29 上海麦科思生物医药有限公司 抗ptk7抗体及其用途
WO2024226829A2 (en) 2023-04-26 2024-10-31 Yale University Enpp3-binding molecules, compositions formed therefrom, and methods of use thereof for the treatment of cancer
TW202506731A (zh) 2023-04-27 2025-02-16 法商感應檢查療法公司 治療多重抗藥性細菌感染之方法
AU2024262099A1 (en) 2023-04-28 2025-12-11 Abbott Laboratories Diagnosis of late-stage hepatocellular carcinoma
EP4549462A1 (de) 2023-04-28 2025-05-07 Shenzhen Mindray Bio-Medical Electronics Co., Ltd. Prokollagen-i-n-terminaler propeptidspezifischer antikörper, kit und verwendung davon
GB202306345D0 (en) 2023-04-28 2023-06-14 Immunocore Ltd Binding molecules
CN121079317A (zh) 2023-04-28 2025-12-05 深圳深信生物科技有限公司 经修饰的递送载体及其应用
AU2024261955A1 (en) 2023-04-28 2025-10-30 Jiangsu Hengrui Pharmaceuticals Co., Ltd. Anti-tf antibody and anti-tf antibody-drug conjugate and medical use thereof
JP2026514143A (ja) 2023-04-28 2026-05-01 アポジー セラピューティクス， インコーポレイテッド Ｏｘ４０ｌに結合する抗体及びその使用方法
WO2024227154A1 (en) 2023-04-28 2024-10-31 Broadwing Bio Llc Complement component 3 (c3)-specific antibodies and uses thereof
WO2024226971A1 (en) 2023-04-28 2024-10-31 Abbott Point Of Care Inc. Improved assays, cartridges, and kits for detection of biomarkers, including brain injury biomarkers
TW202448936A (zh) 2023-05-03 2024-12-16 美商健生生物科技公司 以針對ＩＬ－２３及ＴＮＦ α的抗體的組合來治療潰瘍性結腸炎之方法
JP2026517843A (ja) 2023-05-03 2026-06-02 アイオーエックス セラピューティクス リミテッド Ｉｎｋｔ細胞調節剤リポソーム組成物及び使用方法
AU2024266663A1 (en) 2023-05-03 2025-12-18 Janssen Biotech, Inc. Method of treating crohn's disease with a combination of antibodies to il-23 and tnf alpha
AU2024265613A1 (en) 2023-05-04 2025-09-25 Novasenta, Inc. Anti-cd161 antibodies and methods of use thereof
WO2024233341A1 (en) 2023-05-05 2024-11-14 Genentech, Inc. Dosing for treatment with anti-fcrh5/anti-cd3 bispecific antibodies
JP2026517839A (ja) 2023-05-05 2026-06-02 大塚製薬株式会社 抗ｉｌ１ｒａｐ抗体
AU2024269754A1 (en) 2023-05-08 2025-10-23 F. Hoffmann-La Roche Ag Targeted interferon alpha fusion proteins and methods of use
AU2024268933A1 (en) 2023-05-10 2025-11-20 Chugai Seiyaku Kabushiki Kaisha Methods and compositions for treating cancer
KR20260010739A (ko) 2023-05-11 2026-01-21 유니버시티 하스피탈즈 클리블랜드 메디컬 센터 항불안 치료
KR20260011157A (ko) 2023-05-12 2026-01-22 제넨테크, 인크. 항체 점도를 낮추는 방법 및 조성물
WO2024236557A1 (en) 2023-05-12 2024-11-21 Gilboa Therapeutics LTD Compositions comprising an fc domain for the treatment of medical conditions
EP4710946A1 (de) 2023-05-12 2026-03-18 Medilink Therapeutics (Suzhou) Co., Ltd. Multiprojektil-antikörper-wirkstoff-konjugat sowie herstellungsverfahren dafür und verwendung davon
CN121219323A (zh) 2023-05-12 2025-12-26 智泽童康(广州)生物科技有限公司 抗cldn6抗体及其用途
KR20260011720A (ko) 2023-05-16 2026-01-23 씨에스피씨 메가리스 바이오파마슈티칼 씨오., 엘티디. 항체-약물 접합체를 포함하는 약제 조성물
JP2026517390A (ja) 2023-05-16 2026-05-29 エフ・ホフマン－ラ・ロシュ・アクチェンゲゼルシャフト Ｐｄ－１調節ｉｌ－２免疫サイトカインおよびその使用
AU2024273758A1 (en) 2023-05-17 2025-12-04 Genentech, Inc. Anti-tl1a antibody therapeutic methods
WO2024236156A1 (en) 2023-05-17 2024-11-21 Institut National de la Santé et de la Recherche Médicale Anti-cathepsin-d antibodies
KR20260013471A (ko) 2023-05-18 2026-01-28 클레이드 쎄라퓨틱스 인코포레이티드 세포 치료법에 대한 자연살해세포 세포독성 억제
WO2024238877A1 (en) 2023-05-18 2024-11-21 Medimmune, Llc Treatment of corticosteroid dependent asthma with anti-tslp antibody
CN119039450A (zh) 2023-05-22 2024-11-29 上海君实生物医药科技股份有限公司 抗pd-1-抗vegf的双特异性抗体、其药物组合物及其用途
WO2024240162A1 (en) 2023-05-23 2024-11-28 Shanghai Allygen Biologics Co., Ltd. Pd-l1 and trop-2 targeting conjugates comprising effector molecules and uses thereof
EP4716697A2 (de) 2023-05-23 2026-04-01 Lead Biologics International AB Antikörper und verwendungen davon
CN121152803A (zh) 2023-05-25 2025-12-16 百进公司 Ceacam6结合抗体和其抗原结合片段
AU2024277678A1 (en) 2023-05-25 2025-11-27 Dispatch Biotherapeutics, Inc. Synthetic cancer antigens as targets for treating cancers
WO2024245951A1 (en) 2023-05-26 2024-12-05 Institut National de la Santé et de la Recherche Médicale Combination of slc8a1 inhibitor and mitochondria-targeted antioxidant for treating melanoma
TW202448933A (zh) 2023-05-31 2024-12-16 美商建南德克公司 用抗轉化生長因子β３抗體治療ＴＧＦβ相關病症之方法
JP2026520908A (ja) 2023-06-05 2026-06-25 ピュア バイオロジクス スプウカ アクツィイナ 抗ｇａｒｐ抗体及び使用方法
CN121240857A (zh) 2023-06-05 2025-12-30 纯生物制剂股份有限公司 抗ror1抗体和使用方法
EP4719483A1 (de) 2023-06-05 2026-04-08 Sanofi Antitumorkombinationen mit anti-ceacam5-antikörper-wirkstoff-konjugaten, anti-pd1/pd-l1-antikörpern und anti-ctla4-antikörpern
WO2024254455A1 (en) 2023-06-08 2024-12-12 Genentech, Inc. Macrophage signatures for diagnostic and therapeutic methods for lymphoma
WO2024251927A2 (en) 2023-06-09 2024-12-12 Boehringer Ingelheim International Gmbh Methods for the treatment and prevention of gpp
EP4725969A1 (de) 2023-06-09 2026-04-15 Latticon (Suzhou) Biopharmaceuticals Co., Ltd. Komplementäres bispezifisches anti-her2-antikörper-wirkstoff-konjugat, herstellungsverfahren dafür und verwendung davon
EP4725501A1 (de) 2023-06-09 2026-04-15 Staidson (Beijing) Biopharmaceuticals Co., Ltd. Spezifisch an masp3 bindende antikörper und spezifisch an masp3 und masp2 bindender multispezifischer antikörper
CN119119267A (zh) 2023-06-12 2024-12-13 三生国健药业（上海）股份有限公司 抗bdca2抗体
AU2024304180A1 (en) 2023-06-13 2026-01-08 Adcentrx Therapeutics, Inc. Methods and compositions related to antibodies and antibody drug conjugates (adcs) that bind nectin-4 proteins
MX2025014635A (es) 2023-06-14 2026-02-03 Amgen Inc Moleculas captadoras de enmascaramiento de celulas t
WO2024256583A1 (en) 2023-06-14 2024-12-19 Immutrin Ltd Anti-fibril antibodies
WO2024256635A1 (en) 2023-06-15 2024-12-19 Institut National de la Santé et de la Recherche Médicale Dpm1 inhibitor for treating cancer
EP4729546A1 (de) 2023-06-16 2026-04-22 Jiangsu BioJeTay Biotechnology Co., Ltd. Antikörper zur spezifischen erkennung von faktor xiia und verwendung davon
TW202515607A (zh) 2023-06-20 2025-04-16 英商凱麥博有限公司 Ox40及ox40l調節劑治療化膿性汗腺炎之用途
CN121532650A (zh) 2023-06-20 2026-02-13 艾洛基治疗公司 工程化的细胞的检测方法
AU2024311429A1 (en) 2023-06-20 2026-02-05 Kymab Limited Dosing and treatment of immune-mediated diseases and biomarkers associated with immune-mediated diseases
JP2026522631A (ja) 2023-06-22 2026-07-08 ジェネンテック， インコーポレイテッド 抗体及びその使用
TW202504929A (zh) 2023-06-22 2025-02-01 美商建南德克公司 用於癌症治療之方法及組成物
WO2024261302A1 (en) 2023-06-22 2024-12-26 Institut National de la Santé et de la Recherche Médicale Nlrp3 inhibitors, pak1/2 inhibitors and/or caspase 1 inhibitors for use in the treatment of rac2 monogenic disorders
AU2024313073A1 (en) 2023-06-23 2026-02-12 H. Lundbeck A/S Combinational treatment
WO2024261239A1 (en) 2023-06-23 2024-12-26 Imcheck Therapeutics Bispecific antibodies targeting btn3a and the pd-1/pd-l1 inhibitory axis
CN121729432A (zh) 2023-06-23 2026-03-24 派克西斯肿瘤学公司 抗klrg1抗体及其用途
EP4735019A1 (de) 2023-06-30 2026-05-06 Institut National de la Santé et de la Recherche Médicale Verfahren zur behandlung von stoffwechselerkrankungen
KR20260042361A (ko) 2023-06-30 2026-03-31 머크 샤프 앤드 돔 엘엘씨 치료 조합물, 및 이의 용도 및 치료 방법
WO2025002264A1 (zh) 2023-06-30 2025-01-02 默沙东有限责任公司 包含偶联物的药物组合的治疗方法和用途
JP2026526141A (ja) 2023-07-04 2026-08-06 ティージェイ バイオファーマ （シャンハイ） カンパニー， リミテッド 抗ｒｏｒ１抗体およびその使用
EP4739706A1 (de) 2023-07-05 2026-05-13 CSL Innovation Pty Ltd Verfahren zur behandlung oder prävention einer komplikation von sichelzellanämie
WO2025010424A1 (en) 2023-07-06 2025-01-09 Vir Biotechnology, Inc. Antibodies against staphylococcus antigens and methods of using the same
CN122003247A (zh) 2023-07-07 2026-05-08 维里迪安治疗公司 治疗活动性和慢性甲状腺眼病的方法
JP2026524012A (ja) 2023-07-10 2026-07-16 リジェネロン・ファーマシューティカルズ・インコーポレイテッド 二重特異性ｐｄ－ｌ１×４－１ｂｂ抗体およびそれらの使用方法
JP2026524011A (ja) 2023-07-10 2026-07-16 リジェネロン・ファーマシューティカルズ・インコーポレイテッド 二重特異性ｐｄ－ｌ１×ｃｄ２８抗体およびそれらの使用方法
IL325726A (en) 2023-07-11 2026-03-01 Genentech Inc Compositions and methods for treating multiple sclerosis
EP4743488A1 (de) 2023-07-13 2026-05-20 VIR Biotechnology, Inc. Breit neutralisierende antikörper gegen rsv und mpv-paramyxoviren
WO2025012417A1 (en) 2023-07-13 2025-01-16 Institut National de la Santé et de la Recherche Médicale Anti-neurotensin long fragment and anti-neuromedin n long fragment antibodies and uses thereof
WO2025017153A1 (en) 2023-07-19 2025-01-23 F. Hoffmann-La Roche Ag Dsfv as an igg fragment format and methods of production and labelling thereof
WO2025024265A1 (en) 2023-07-21 2025-01-30 Bristol-Myers Squibb Company Methods of assessing citrullination and activity of pad4 modulators
CN119350497A (zh) 2023-07-24 2025-01-24 星尘生物科技(上海)有限公司 人源化抗cd19单链可变区片段及其用途
CN121548587A (zh) 2023-07-24 2026-02-17 豪夫迈·罗氏有限公司 多特异性抗体
CN121909049A (zh) 2023-07-25 2026-04-21 默克专利股份公司 艾杜糖苷酸酶可切割化合物
CN122541561A (zh) 2023-07-25 2026-08-11 深圳迈瑞生物医疗电子股份有限公司 抗甲状腺球蛋白抗体、试剂盒和用途
EP4497756A3 (de) 2023-07-25 2025-09-17 Shenzhen Mindray Bio-Medical Electronics Co., Ltd. Antikörper, kit, nachweisverfahren und probenanalysator zum nachweis von schilddrüsenstimulationshormon
AR133384A1 (es) 2023-07-28 2025-09-24 Regeneron Pharma Anti-tfr:esfingomielinasa ácida para el tratamiento de la deficiencia de esfingomielinasa ácida
IL326018A (en) 2023-07-28 2026-03-01 Regeneron Pharma Introduction of anti-TFR:GAA and anti-CD63:GAA for the treatment of Pompe disease
KR20260048598A (ko) 2023-07-31 2026-04-10 아스트라제네카 아베 Cd123 항체-약물 접합체 및 이의 사용 방법
WO2025026332A1 (zh) 2023-08-01 2025-02-06 先声药业有限公司 抗il4r抗体及其应用
US12269875B2 (en) 2023-08-03 2025-04-08 Jeff R. Peterson Gout flare prevention methods using IL-1BETA blockers
WO2025034542A1 (en) 2023-08-04 2025-02-13 Cornell University Gene signature panel predicting cancer response to immune checkpoint blockade and radiation therapy
EP4758173A1 (de) 2023-08-07 2026-06-17 Janssen Biotech, Inc. Enpp3- und cd3-bindende wirkstoffe und verfahren zur verwendung davon
WO2025032158A1 (en) 2023-08-08 2025-02-13 Institut National de la Santé et de la Recherche Médicale Method to treat tauopathies
WO2025034806A1 (en) 2023-08-08 2025-02-13 Wisconsin Alumni Research Foundation Single-domain antibodies and variants thereof against fibroblast activation protein
CR20260043A (es) 2023-08-09 2026-03-26 Hoffmann La Roche Anticuerpos anti-proteína a-beta, métodos y usos de estos
AU2024320793A1 (en) 2023-08-09 2026-03-12 F. Hoffmann-La Roche Ag Mono and multispecific anti-trem2 antibodies, methods and uses thereof
AU2024323186A1 (en) 2023-08-09 2026-01-15 F. Hoffmann-La Roche Ag Mono and multispecific anti-trem2 antibodies, methods and uses thereof
CN121605481A (zh) 2023-08-10 2026-03-03 中外制药株式会社 信息处理系统、信息处理方法、程序和用于制造分子化合物的方法
WO2025036848A1 (en) 2023-08-11 2025-02-20 Wuxi Biologics (Shanghai) Co., Ltd. Anti-muc16 antibodies and uses thereof
WO2025038750A2 (en) 2023-08-14 2025-02-20 President And Fellows Of Harvard College Methods and compositions for treating cancer
AU2024325977A1 (en) 2023-08-14 2026-01-29 F. Hoffmann-La Roche Ag Methods of treatment
US20250099605A1 (en) 2023-08-15 2025-03-27 Gilead Sciences, Inc. Treatment of non-small cell lung cancer using sacituzumab govitecan and an anti-pd-1 antibody or antigen binding fragment thereof
KR20260053355A (ko) 2023-08-16 2026-04-21 아케소 바이오파마 컴퍼니 리미티드 화합물 및 이를 포함하는 항체 약물 접합체
EP4509142A1 (de) 2023-08-16 2025-02-19 Ona Therapeutics S.L. Fgfr4 als target in der krebsbehandlung
EP4761816A2 (de) 2023-08-16 2026-06-24 University of Tennessee Research Foundation Verfahren zur hemmung des fibrillenwachstums
EP4761754A2 (de) 2023-08-18 2026-06-24 Immatics Biotechnologies GmbH Mhc-anzeigepeptide zur verwendung in der immuntherapie gegen krebs verschiedener art
EP4766723A1 (de) 2023-08-23 2026-07-01 Depth Charge Ltd Interleukin-2-variante proteine zur erleichterung kovalenter chemischer konjugation und verwendungen davon
CN121712529A (zh) 2023-08-23 2026-03-20 微粒疗法有限公司 抗cd203c抗体缀合物及其用途
CN122070304A (zh) 2023-08-24 2026-05-19 瑞泽乐特公司 用于抗胰岛素受体抗体的高浓度调配物和其用途
AR133647A1 (es) 2023-08-25 2025-10-22 Proteologix Us Inc Constructos de anticuerpos multiespecíficos anti-il-13 y usos de los mismos
KR20260042555A (ko) 2023-08-25 2026-03-31 키메드 바이오사이언시스 (청두) 컴퍼니 리미티드 알츠하이머병 치료제의 개발 및 용도
IL326774A (en) 2023-08-25 2026-04-01 Proteologix Us Inc Anti-tslp antibody constructs and uses thereof
EP4771049A1 (de) 2023-08-28 2026-07-08 Regeneron Pharmaceuticals, Inc. Gegen cxcr4 antikörper resistente modifizierte rezeptoren
WO2025049818A1 (en) 2023-08-29 2025-03-06 Enosi Therapeutics Corporation Tnfr1 antagonists lacking agonist activity and uses thereof
AU2024330914A1 (en) 2023-08-31 2026-01-15 Amgen Inc. Methods for analyzing antibody co-formulations
EP4770666A2 (de) 2023-09-01 2026-07-08 Children's Hospital Medical Center Identifizierung von zielmolekülen für die immuntherapie bei melanomen unter verwendung von aus spleissen stammenden neoantigenen
WO2025048860A1 (en) 2023-09-01 2025-03-06 Inhibrx Biosciences, Inc. Ox40 agonist therapy
WO2025048887A1 (en) 2023-09-01 2025-03-06 Inhibrx Biosciences, Inc. Ox40 agonist therapy
WO2025049905A1 (en) 2023-09-01 2025-03-06 Gennao Bio, Inc. Dnase co-expression in host cells
CN122003435A (zh) 2023-09-03 2026-05-08 科越医药(美国)有限责任公司 包含抗因子d部分的多特异性构建体
WO2025054320A1 (en) 2023-09-05 2025-03-13 Tizona Therapeutics Anti-ackr4 antibodies, compositions and uses thereof
WO2025054181A1 (en) 2023-09-05 2025-03-13 Seagen Inc. Targeted degrader molecules and ligand drug conjugates thereof
CN122122186A (zh) 2023-09-06 2026-05-29 维里迪安治疗公司 抗igf-1r抗体的药物组合物
WO2025051895A1 (en) 2023-09-06 2025-03-13 Novimmune Sa Combination therapy with a cea x cd28 bispecific antibody and blocking anti-pd-1 antibodies for enhanced in vivo anti-tumor activity
AU2023464289A1 (en) 2023-09-08 2026-03-12 The Regents Of The University Of Michigan MICRORNA-DERIVED RNAs AND POLYPEPTIDES AND USES THEREOF
US20250084125A1 (en) 2023-09-08 2025-03-13 Genentech, Inc. High viscosity ultrafiltration/diafiltration and single-pass tangential flow filtration processes
EP4774301A2 (de) 2023-09-08 2026-07-15 Mlab Biosciences, Inc. Bifunktionelle proteine und verwendungen davon
EP4777539A1 (de) 2023-09-11 2026-07-22 Evolveimmune Therapeutics, Inc. Bispezifische antikörperfusionsmoleküle zum targeting von b7-h4 und cd3 sowie verfahren zur verwendung davon
AU2024339935A1 (en) 2023-09-14 2026-04-09 Medizinische Universität Innsbruck Enhancement of car-t cell efficacy by inhibiting nr2f6
KR20260074706A (ko) 2023-09-14 2026-05-26 아케소 바이오파마 컴퍼니 리미티드 약물 조합 및 그 용도
WO2025166725A1 (en) 2024-02-08 2025-08-14 Duality Biologics (Suzhou) Co., Ltd. Antibody-drug conjugate
WO2025054996A1 (en) 2023-09-15 2025-03-20 Duality Biologics (Suzhou) Co., Ltd. Antibody-drug conjugate
WO2025056748A1 (en) 2023-09-15 2025-03-20 Duality Biologics (Suzhou) Co., Ltd. Antibody-drug conjugate
WO2025061032A1 (zh) 2023-09-18 2025-03-27 南京蓬勃生物科技有限公司 靶向人源ror1和cd3的双特异性抗体
CN121909048A (zh) 2023-09-19 2026-04-21 苏州宜联生物医药有限公司 抗b7h3抗体药物偶联物在制备治疗鼻咽癌和/或肺淋巴上皮瘤样癌的药物中的用途
WO2025064435A1 (en) 2023-09-19 2025-03-27 Imaginab, Inc. Antigen binding constructs directed to integrin αvβ6
CN122094980A (zh) 2023-09-20 2026-05-26 进化免疫治疗公司 靶向cd180和cd3的双特异性抗体融合分子及其使用方法
EP4780849A1 (de) 2023-09-20 2026-07-29 Evolveimmune Therapeutics, Inc. Multispezifische antikörper zur bindung von cd3 und cd2 und verfahren zur verwendung davon
EP4780848A1 (de) 2023-09-20 2026-07-29 Biond Biologics Ltd. Anti-ilt3-blockade-kombinationen
WO2025061149A1 (zh) 2023-09-21 2025-03-27 南京传奇生物科技有限公司 抗gcc抗体、嵌合抗原受体及其用途
WO2025068180A1 (en) 2023-09-25 2025-04-03 Institut National de la Santé et de la Recherche Médicale Methods of treatment of cancer by targetting cancer - associated fibroblasts
AR133909A1 (es) 2023-09-25 2025-11-12 Hoffmann La Roche ANTICUERPO QUE SE UNE A C3bBb
WO2025068157A1 (en) 2023-09-25 2025-04-03 Stromacare COMBINATION OF A βIG-H3 ANTAGONIST AND A PDFG-AA ANTAGONIST FOR THE TREATMENT OF CANCER
US12122842B1 (en) 2023-09-27 2024-10-22 R&D Systems, Inc. Human CD30-specific binding proteins and uses thereof
WO2025068393A1 (en) 2023-09-27 2025-04-03 Institut Curie Methods for the treatment of fibrotic related diseases
WO2025072313A1 (en) 2023-09-27 2025-04-03 BioLegend, Inc. Anti-gpc4 antibodies
US20250109187A1 (en) 2023-09-28 2025-04-03 Novavax, Inc. ANTI-SARS-CoV-2 SPIKE (S) ANTIBODIES AND THEIR USE IN TREATING COVID-19
IL327431A (en) 2023-09-28 2026-05-01 Nanjing Leads Biolabs Co Ltd BDCA2 monoclonal antibody, fusion protein consisting of the same antibody and TACI and method and use thereof
CN122295357A (zh) 2023-09-29 2026-06-26 崔克斯生物公司 TNF-α变体融合分子
EP4788839A1 (de) 2023-10-03 2026-08-12 Institut National de la Santé et de la Recherche Médicale Verfahren zur prognose und behandlung von patienten mit melanom
CN122121894A (zh) 2023-10-06 2026-05-29 勃林格殷格翰国际有限公司 抗SIRP-α抗体用于治疗癌症的用途
CN122094710A (zh) 2023-10-06 2026-05-26 勃林格殷格翰国际有限公司 使用抗SIRPα抗体治疗肝脏疾病或障碍
WO2025073890A1 (en) 2023-10-06 2025-04-10 Institut National de la Santé et de la Recherche Médicale Method to capture circulating tumor extracellular vesicles
EP4786499A1 (de) 2023-10-08 2026-08-05 Guangdong Fapon Biopharma Inc. Anti-pd1-il10-fusionsprotein und verwendung davon
IL327670A (en) 2023-10-11 2026-06-01 Antikor Biopharma Ltd Antibodies, conjugates, and uses thereof
WO2025078915A1 (en) 2023-10-12 2025-04-17 Siemens Healthcare Diagnostics Inc. Pregabalin haptens, immunogens, and protein conjugates and methods of production and use thereof
WO2025078632A1 (en) 2023-10-12 2025-04-17 Institut National de la Santé et de la Recherche Médicale Methods of prognosis and treatment of patients suffering from cancer
CN122003405A (zh) 2023-10-12 2026-05-08 美国西门子医学诊断股份有限公司 甲苯噻嗪半抗原、免疫原和蛋白质偶联物及其生产和使用方法
CN122349614A (zh) 2023-10-13 2026-07-07 卫材R&D管理有限公司 抗体-药物缀合物代谢物
EP4791439A1 (de) 2023-10-13 2026-08-19 Sutro Biopharma, Inc. Antikörper-wirkstoff-konjugate mit doppelter nutzlast
US12540197B2 (en) 2023-10-13 2026-02-03 Sutro Biopharma, Inc. Anti-tissue factor antibodies and antibody conjugates, compositions comprising anti-tissue factor antibodies or antibody conjugates, and methods of making and using anti-tissue factor antibodies and antibody conjugates
EP4791430A1 (de) 2023-10-13 2026-08-19 Gilead Sciences, Inc. Kombinationstherapien zur behandlung von krebs
TW202530697A (zh) 2023-10-13 2025-08-01 日商衛材R&D企管股份有限公司 用於基於艾日布林之抗體－藥物結合物之生物標記及使用方法
CN122422333A (zh) 2023-10-17 2026-07-17 百时美施贵宝公司 Gspt1降解化合物、抗cd33抗体和抗体-药物缀合物及其用途
IL327762A (en) 2023-10-17 2026-06-01 Biontech Zhuhai Pharmaceuticals R&D Co Ltd Bispecific antibody against ccr8 and ctla4
WO2025083061A1 (en) 2023-10-17 2025-04-24 Adc Therapeutics Sa Anti-napi2b conjugates
WO2025083064A1 (en) 2023-10-17 2025-04-24 Adc Therapeutics Sa Anti-asct2 conjugates
WO2025083067A1 (en) 2023-10-17 2025-04-24 Adc Therapeutics Sa Anti-claudin-6 conjugates
GB202315963D0 (en) 2023-10-18 2023-11-29 Cancer Research Tech Ltd Binding molecules
TW202517674A (zh) 2023-10-19 2025-05-01 德商拜耳廠股份有限公司 抗gpc3抗體及其放射性結合物
TW202535940A (zh) 2023-10-24 2025-09-16 美商思進公司 化學治療化合物及使用方法
KR20260105764A (ko) 2023-10-30 2026-07-07 알로젠 테라퓨틱스 인코포레이티드 조작된 세포
EP4548936A1 (de) 2023-10-30 2025-05-07 BioNTech SE Antikörper-wirkstoff-konjugate mit einem massgeschneiderten arzneimittel-zu-antikörper-verhältnis
KR20260102788A (ko) 2023-11-01 2026-07-01 이뮤노코어 리미티드 소형 멀티도메인 단백질의 정제 방법
GB202316777D0 (en) 2023-11-01 2023-12-13 Cambridge Entpr Ltd New therapeutic use
JPWO2025100417A1 (de) 2023-11-06 2025-05-15
WO2025101506A1 (en) 2023-11-07 2025-05-15 Qiagen Sciences, Llc Compositions and methods for detecting cell-mediated immunity to epstein-barr virus
WO2025101820A1 (en) 2023-11-08 2025-05-15 Fred Hutchinson Cancer Center Compositions and methods for cellular immunotherapy
WO2025101862A1 (en) 2023-11-08 2025-05-15 Axelyf ehf. Single domain antibody binders of myc
CN122161849A (zh) 2023-11-09 2026-06-05 豪夫迈·罗氏有限公司 具有条件性活性的多特异性抗体
AU2024376185A1 (en) 2023-11-10 2026-05-14 BioNTech SE Co-delivery system
EP4574839A1 (de) 2023-12-22 2025-06-25 BioNTech SE System zur gemeinsamen lieferung
IL328096A (en) 2023-11-10 2026-06-01 Pfizer Anti-migis-alpha antibodies and methods of use thereof
CN119454937A (zh) 2023-11-13 2025-02-18 苏州宜联生物医药有限公司 抗b7h3抗体-药物偶联物治疗癌症的方法
CN122249237A (zh) 2023-11-14 2026-06-19 先声再明医药股份有限公司 配体-药物偶联物、偶联连接子及其用途
EP4556492A1 (de) 2023-11-14 2025-05-21 Acticor Biotech Behandlung von herz-kreislauf-erkrankungen mit anti-humanen gpvi-antikörpern in subpopulationen von personen
WO2025106474A1 (en) 2023-11-14 2025-05-22 Genentech, Inc. Therapeutic and diagnostic methods for treating cancer with anti-fcrh5/anti-cd3 bispecific antibodies
AR134368A1 (es) 2023-11-17 2026-01-07 Wuxi Biologics Ireland Ltd Anticuerpos anti-muc16 y usos de los mismos
US20250163168A1 (en) 2023-11-17 2025-05-22 Pfizer Inc. Novel antibodies and antibody conjugates for the treatment of metabolic disorders
WO2025106634A1 (en) 2023-11-17 2025-05-22 Genentech, Inc. Mcl-1 inhibitor compounds and use in antibody drug conjugates
WO2025109043A2 (en) 2023-11-22 2025-05-30 Institut National de la Santé et de la Recherche Médicale Use of neutralizing anti-agr2 antibodies for preventing resistance to chemotherapy
AR134424A1 (es) 2023-11-22 2026-01-14 Novartis Ag Conjugados de anticuerpo anti-cd7-fármaco y métodos de uso de los mismos
UY40985A (es) 2023-11-22 2025-06-30 Servier Lab Conjugados de anticuerpo anti-cd74-fármaco y métodos de uso de los mismos
EP4563586A1 (de) 2023-11-28 2025-06-04 Université Paris Cité Neue inhibitoren der lrrk2/pp1-interaktion
IL328469A (en) 2023-11-28 2026-07-01 Novimmune Sa Method for treating disease using antibodies against CD47 and against mesothelin as a single agent and in combination with antibodies against PD-1
WO2025114411A1 (en) 2023-11-29 2025-06-05 Institut National de la Santé et de la Recherche Médicale New method to treat brain or neurologic disorders
AU2024392365A1 (en) 2023-11-30 2026-07-16 Genzyme Corporation Methods for treating cd20-related disorders
WO2025117848A1 (en) 2023-12-01 2025-06-05 Genentech, Inc. Low-viscosity variants of antibodies
WO2025122634A1 (en) 2023-12-05 2025-06-12 Voyager Therapeutics, Inc. Compositions and methods for the treatment of tau-related disorders
WO2025120015A1 (en) 2023-12-06 2025-06-12 Institut National de la Santé et de la Recherche Médicale Cd5 targeting antibodies with depleting and t or b-cell activation effects
US20250186604A1 (en) 2023-12-06 2025-06-12 Adc Therapeutics Sa Anti-psma antibody conjugates
CN122341639A (zh) 2023-12-07 2026-07-03 免疫医疗有限公司 治疗哮喘的方法
CN120118196A (zh) 2023-12-08 2025-06-10 百奥泰生物制药股份有限公司 融合蛋白及其应用
AR134580A1 (es) 2023-12-08 2026-01-28 Janssen Biotech Inc ANTICUERPOS DE CD33, ANTICUERPOS MULTIESPECÍFICOS DE CD33 / Vd2 Y USOS DE ESTOS
CN122349567A (zh) 2023-12-11 2026-07-07 济世易为生物有限公司 利用反式剪接和拆分型选择标记的蛋白质表达
AU2024401943A1 (en) 2023-12-12 2026-07-30 Janssen Biotech, Inc. Enpp3 × cd3 bispecific antibodies and use thereof
KR20250091367A (ko) 2023-12-13 2025-06-23 주식회사 노드큐어 개 pdl-1 항체 및 이의 용도
CN122459340A (zh) 2023-12-14 2026-07-24 豪夫迈·罗氏有限公司 与folr1结合的抗体及使用方法
CN122349615A (zh) 2023-12-14 2026-07-07 基因泰克公司 使用抗体进行结构确定的方法
EP4570262A1 (de) 2023-12-15 2025-06-18 Max-Delbrück-Centrum für Molekulare Medizin in der Helmholtz-Gemeinschaft Chimärer antigenrezeptor gegen den chemokinrezeptor ccr7
AU2024408268A1 (en) 2023-12-17 2026-07-09 Viridian Therapeutics, Inc. Compositions, doses, and methods for treatment of thyroid eye disease
WO2025132479A1 (en) 2023-12-18 2025-06-26 Institut National de la Santé et de la Recherche Médicale Flt3 inhibitor for modulating macrophages polarization
EP4574841A1 (de) 2023-12-19 2025-06-25 BioNTech SE Antibakterielle polypeptide
AU2024403128A1 (en) 2023-12-19 2026-06-25 Vectory Therapeutics B.V. Anti-tdp-43 antibodies and uses thereof
GB202319601D0 (en) 2023-12-20 2024-01-31 Ucl Business Ltd Polypeptide
WO2025137086A1 (en) 2023-12-20 2025-06-26 Genentech, Inc. Reducing alpha-gal
WO2025134327A1 (ja) 2023-12-21 2025-06-26 中外製薬株式会社 情報処理システム、情報処理方法、情報処理プログラム、および分子化合物の製造方法
AU2024402334A1 (en) 2023-12-22 2026-05-28 F. Hoffmann-La Roche Ag Activatable fusion proteins and methods of use
GB202319967D0 (en) 2023-12-22 2024-02-07 Epsilogen Ltd Heteromultimeric proteins
CN120271706A (zh) 2023-12-29 2025-07-08 上海安领科生物医药有限公司 抗egfr单抗、其双特异性抗体、药物组合物和用途
WO2025147544A1 (en) 2024-01-02 2025-07-10 Abcuro, Inc. Methods of treating inclusion body myositis (ibm)
IL330343A (en) 2024-01-05 2026-08-01 Medimmune Llc Treatment of chronic obstructive pulmonary disease using an anti-TSLP antibody
AU2025205814A1 (en) 2024-01-05 2026-07-09 Immunocore Limited Multi-domain molecules
WO2025151496A1 (en) 2024-01-09 2025-07-17 Viridian Therapeutics, Inc. Compositions and methods for treatment of thyroid eye disease
WO2025151502A1 (en) 2024-01-09 2025-07-17 Viridian Therapeutics, Inc. Modified antibodies
WO2025151492A1 (en) 2024-01-09 2025-07-17 Viridian Therapeutics, Inc. Compositions and methods for treatment of thyroid eye disease
WO2025151752A1 (en) 2024-01-10 2025-07-17 Xilio Development, Inc. Masked il-2 cytokines and methods of use thereof
WO2025149974A1 (en) 2024-01-11 2025-07-17 Takeda Pharmaceutical Company Limited Combination therapy with an anti-alpha4beta7 antibody
WO2025151806A1 (en) 2024-01-11 2025-07-17 Regeneron Pharmaceuticals, Inc. P75 neurotrophin receptor (p75ntr)-binding proteins and p75ntr-mediated delivery to the nervous system
WO2025149947A1 (en) 2024-01-12 2025-07-17 Seagen Inc. Antibody-drug conjugates
TW202539700A (zh) 2024-01-16 2025-10-16 美商建南德克公司 用ｐｄ－１軸結合拮抗劑及ｒｎａ疫苗治療泌尿上皮癌之方法
WO2025155602A1 (en) 2024-01-16 2025-07-24 Genentech, Inc. Method of treating hemophilia a
WO2025153608A1 (en) 2024-01-18 2025-07-24 Institut National de la Santé et de la Recherche Médicale Wip1 inhibitor for the treatment of glomerular disease
WO2025155798A2 (en) 2024-01-18 2025-07-24 Amgen Inc. Methods for analyzing co-formulated therapeutic proteins
WO2025155991A2 (en) 2024-01-19 2025-07-24 Bpgbio, Inc. Predictive biomarkers for response to coenzyme q10 treatment in pancreatic cancer
WO2025155971A1 (en) 2024-01-19 2025-07-24 Immunomic Therapeutics, Inc Anti-activin receptor 1c (alk-7) receptor antibodies
US20250242056A1 (en) 2024-01-26 2025-07-31 Regeneron Pharmaceuticals, Inc. Methods and compositions for using plasma cell depleting agents and/or b cell depleting agents to suppress host anti-aav antibody response and enable aav transduction and re-dosing
WO2025160331A1 (en) 2024-01-26 2025-07-31 Futuregen Biopharmaceutical (Beijing) Co., Ltd. Antibodies capable of specifically binding tl1a and use thereof
WO2025162964A1 (en) 2024-01-30 2025-08-07 Institut National de la Santé et de la Recherche Médicale Methods for the treatment of endometriosis
WO2025166045A1 (en) 2024-01-31 2025-08-07 Alector Llc β-GLUCOCEREBROSIDASE ENZYMES, FUSION PROTEINS AND COMPLEXES COMPRISING THE SAME, AND METHODS OF USE THEREOF
WO2025166042A1 (en) 2024-01-31 2025-08-07 Alector Llc Cd98hc antigen-binding domains and uses therefor
WO2025166040A1 (en) 2024-01-31 2025-08-07 Alector Llc Multi-specific binding proteins that bind to gpnmb and a blood brain barrier target and methods of use thereof
WO2025166077A1 (en) 2024-01-31 2025-08-07 Alector Llc Compositions comprising progranulin and uses thereof
WO2025168481A1 (en) 2024-02-05 2025-08-14 Nerviano Medical Sciences S.R.L. Imino-anthracycline derivatives and methods
WO2025167631A1 (zh) 2024-02-05 2025-08-14 北京三诺佳邑生物技术有限责任公司 特异性结合HBV pre-S1抗原、PD-L1抗原和CD3抗原的多特异性抗体及其应用
WO2025171006A1 (en) 2024-02-06 2025-08-14 Paragon Therapeutics, Inc. Il-23 binding protein compositions and methods of use
WO2025168716A1 (en) 2024-02-07 2025-08-14 Eyebiotech Limited Compositions, doses, and methods for treatment of ocular diseases
EP4740956A1 (de) 2024-02-08 2026-05-13 Shanghai Bao Pharmaceuticals Co., Ltd. Pharmazeutische kombination zur subkutanen verabreichung und deren verwendung
WO2025171378A1 (en) 2024-02-09 2025-08-14 Rezolute, Inc. Insulin receptor modulation for tumor associated hyperinsulinism
WO2025171411A1 (en) 2024-02-09 2025-08-14 Herophilus, Inc. Compositions and methods related to modulating macrophage migration inhibitory factor (mif)-cd74 signaling and related treatments for neuroinflammatory conditions
WO2025171388A1 (en) 2024-02-09 2025-08-14 Dispatch Biotherapeutics, Inc. Engineered cancer antigens with modified domains and related methods and uses
WO2025171383A2 (en) 2024-02-09 2025-08-14 Dispatch Biotherapeutics, Inc. Engineered cancer antigens and related methods and uses
WO2025174974A1 (en) 2024-02-14 2025-08-21 Bristol-Myers Squibb Company Anti-cd33 antibodies and uses thereof
TW202600175A (zh) 2024-02-15 2026-01-01 德商馬克專利公司 用於治療gd2陽性癌症之抗gd2抗體及免疫結合物
WO2025178959A1 (en) 2024-02-20 2025-08-28 University Of Georgia Research Foundation, Inc. Single-domain antibodies and variants thereof against tab1
WO2025177214A1 (en) 2024-02-20 2025-08-28 Takeda Pharmaceutical Company Limited Therapeutic methods
WO2025176777A1 (en) 2024-02-20 2025-08-28 Institut Curie Dut inhibition in homologous recombination deficiency cancer
WO2025176860A1 (en) 2024-02-23 2025-08-28 Charité - Universitätsmedizin Berlin Körperschaft des öffentlichen Rechts Dual chimeric antigen receptor construct targeting cea and epcam
US20250361320A1 (en) 2024-02-27 2025-11-27 Bristol-Myers Squibb Company Anti-ceacam5 antibodies and uses thereof
US12521446B2 (en) 2024-02-27 2026-01-13 Bristol-Myers Squibb Company Anti-CEACAM5 antibody drug conjugates
WO2025181553A2 (en) 2024-02-27 2025-09-04 Bon Vivant Compositions comprising truncated casein polypeptides
WO2025180665A1 (en) 2024-02-28 2025-09-04 Evotec International Gmbh Antibodies binding to cd2, and multifunctional molecules comprising such antibodies
WO2025193454A1 (en) 2024-03-01 2025-09-18 Prelude Therapeutics Incorporated Brm and brg1 targeting antibody-drug conjugates and methods of use thereof
AU2025227417A1 (en) 2024-03-01 2026-06-18 Boehringer Ingelheim International Gmbh Antibodies to connective tissue growth factor (ctgf) and uses thereof
GB202403391D0 (en) 2024-03-08 2024-04-24 Myricx Pharma Ltd Novel compounds and their use in therapy
WO2025191147A1 (en) 2024-03-14 2025-09-18 Synabs Anti-ccr8 antibodies and uses thereof
WO2025199118A1 (en) 2024-03-18 2025-09-25 Willow Neuroscience, Inc. Anti-trem1 antibody constructs, compositions comprising anti-trem1 antibody constructs and methods of using anti-trem1 antibody constructs
WO2025199030A1 (en) 2024-03-18 2025-09-25 Amgen Inc. Glp-1 receptor agonists and their medical use
WO2025199107A1 (en) 2024-03-19 2025-09-25 Alexion Pharmaceuticals, Inc. Risk evaluation and management strategy involving patient follow-ups relating to the use or discontinuation of a complement inhibitor
CA3249015A1 (en) 2024-03-20 2025-10-31 Janssen Biotech, Inc. Methods of treating crohn’s disease with anti-il23 specific antibody
WO2025198912A1 (en) 2024-03-21 2025-09-25 Hoffmann-La Roche Inc. Methods of treating myasthenia gravis
US20250295801A1 (en) 2024-03-21 2025-09-25 Seagen Inc. Cd25 antibodies, antibody drug conjugates, and uses thereof
WO2025199464A1 (en) 2024-03-22 2025-09-25 Eisai R&D Management Co., Ltd. Anti-trop2 antibody-drug conjugates and methods of use
GB202404476D0 (en) 2024-03-28 2024-05-15 King S College London Cancer
CN121079107A (zh) 2024-04-03 2025-12-05 复旦大学 一种连接子、抗体药物偶联物及其制备方法
WO2025210195A1 (en) 2024-04-03 2025-10-09 Institut Pasteur Apsab combines a nuclease/helicase protein and an argonaute-like protein to cleave dna
WO2025210123A1 (en) 2024-04-03 2025-10-09 Institut National de la Santé et de la Recherche Médicale Methods and pharmaceutical composition for treating cancers
TW202540173A (zh) 2024-04-04 2025-10-16 英商梅迪繆思有限公司 治療及選擇對象之方法
WO2025210264A1 (en) 2024-04-04 2025-10-09 Merck Patent Gmbh Antibody-drug-conjugates binding napi2b
WO2025210275A1 (en) 2024-04-05 2025-10-09 Blue Bees Therapeutics Immunomodulatory complex comprising heparan sulfate binding peptide and uses thereof for therapy
WO2025213047A1 (en) 2024-04-05 2025-10-09 Tizona Therapeutics, Inc. Anti-il-18bp antibodies, compositions comprising anti-il-18bp antibodies and methods of using anti-il-18bp antibodies
WO2025217069A1 (en) 2024-04-08 2025-10-16 Beth Israel Deaconess Medical Center, Inc. Compositions and methods for treating cardiotoxicity
TW202602940A (zh) 2024-04-09 2026-01-16 美商安進公司 激動性抗ｉｌ－２ｒｂｇ重鏈抗體
WO2025215060A1 (en) 2024-04-11 2025-10-16 F. Hoffmann-La Roche Ag Antibodies that specifically bind modified oligonucleotides
WO2025215647A1 (en) 2024-04-11 2025-10-16 Biond Biologics Ltd. Combination cancer treatment with staggered dosing
WO2025215252A1 (en) 2024-04-12 2025-10-16 Ensocell Ltd Therapeutic agents and methods for targeting myeloid cell subtypes
IL323020A (en) 2024-04-13 2026-03-01 Immuneoncia Therapeutics Inc Neoadjuvant immunotherapy with pd-l1 inhibitor in treating cancer
EP4635983A1 (de) 2024-04-15 2025-10-22 Ymmunobio AG Neuartiger antikörper mit spezifischer bindung an nptxr und verwendung davon
WO2025221247A1 (en) 2024-04-17 2025-10-23 Amgen Inc. Treatment of eosinophilic esophagitis with anti-tslp antibody
WO2025219956A1 (en) 2024-04-18 2025-10-23 Comed Therapeutics Ltd. Compositions and methods for rna delivery to cells
WO2025224050A1 (en) 2024-04-22 2025-10-30 Institut National de la Santé et de la Recherche Médicale Methods of treatment of patients suffering from hypomelanosis of ito
WO2025224166A1 (en) 2024-04-23 2025-10-30 F. Hoffmann-La Roche Ag Anti-drug antibody assays
TW202604943A (zh) 2024-04-24 2026-02-01 美商建南德克公司 治療狼瘡性腎炎之組成物及方法
GB202405758D0 (en) 2024-04-24 2024-06-05 King S College London Compounds
WO2025224297A1 (en) 2024-04-26 2025-10-30 Institut National de la Santé et de la Recherche Médicale Antibodies having specificity to tgfbi and uses thereof
EP4643858A1 (de) 2024-04-29 2025-11-05 Institut National de la Santé et de la Recherche Médicale Verfahren und pharmazeutische zusammensetzung zur behandlung von gebärmuttererkrankungen
WO2025228998A1 (en) 2024-04-30 2025-11-06 Institut National de la Santé et de la Recherche Médicale Use of hdac4 inhibitors for the treatment of melanoma
WO2025231185A1 (en) 2024-05-01 2025-11-06 Legend Biotech Ireland Limited Viral glycoprotein variants and uses thereof
WO2025231454A1 (en) 2024-05-02 2025-11-06 Kira Pharmaceuticals (Us) Llc Anti-c5 antibody fused to factor h for use in the treatment of complement-mediated diseases
TW202544034A (zh) 2024-05-06 2025-11-16 美商榮都醫療公司 結合至ｃｄ２８及ｎｅｃｔｉｎ－４之雙特異性抗體
TW202611068A (zh) 2024-05-08 2026-03-16 英商凱麥博有限公司 頭頸部異位性皮膚炎的治療
WO2025233224A1 (en) 2024-05-09 2025-11-13 F. Hoffmann-La Roche Ag Use of atr inhibitors in combination with anti-pd(l)1 therapy
US20260022170A1 (en) 2024-05-10 2026-01-22 Adaptam Therapeutics S.L Anti-siglec-9 antibodies and uses thereof
WO2025232879A1 (en) 2024-05-10 2025-11-13 Cytocares (Shanghai) Inc. Anti-lilrb2 monospecific and bispecific antibody constructs and uses thereof
WO2025233675A1 (en) 2024-05-10 2025-11-13 Institut Pasteur Use of talosaminidase to regulate populations of archaeal methanogens in industrial, agricultural and medical settings
EP4650368A1 (de) 2024-05-13 2025-11-19 Epok Therapeutics Inc. Tetravalente erythropoietinrezeptoragonisten
WO2025240335A1 (en) 2024-05-13 2025-11-20 Regeneron Pharmaceuticals, Inc. Fgfr3 binding molecules and methods of use thereof
WO2025238187A1 (en) 2024-05-15 2025-11-20 Cis Biopharma Ag Immunoconjugates targeting l1-cam
WO2025238052A1 (en) 2024-05-15 2025-11-20 Institut National de la Santé et de la Recherche Médicale Depletion of plasmacytoid dendritic cells for the treatment of respiratory viral infections
TW202613165A (zh) 2024-05-17 2026-04-01 比利時商Ｕｃｂ生物製藥公司 具有il-11和il-17結合特異性的多特異性抗體
WO2025238135A2 (en) 2024-05-17 2025-11-20 UCB Biopharma SRL Antibody with binding specificity for il-11
WO2025242680A1 (en) 2024-05-20 2025-11-27 Thabor Therapeutics Humanized anti-agr2 antibody
WO2025242685A1 (en) 2024-05-20 2025-11-27 Thabor Therapeutics Optimized anti-agr2 antibody
WO2025242726A1 (en) 2024-05-21 2025-11-27 Onconick Ltd. Antibody binding to FGFR1 and conjugates comprising the same
WO2025242732A1 (en) 2024-05-21 2025-11-27 Institut National de la Santé et de la Recherche Médicale Pan antibodies against sars-cov-2 spike protein and uses thereof for therapeutical purposes
WO2025242845A1 (en) 2024-05-22 2025-11-27 Merck Patent Gmbh Colorectal cancer treatment
WO2025242909A1 (en) 2024-05-24 2025-11-27 Paul Scherrer Institut CD30-targeting antibody-radioligand conjugates and their therapeutic use
WO2025247829A1 (en) 2024-05-27 2025-12-04 Institut National de la Santé et de la Recherche Médicale Methods and pharmaceutical composition for treating prostate cancer
TW202547557A (zh) 2024-05-30 2025-12-16 德商拜恩技術股份公司 抗體藥物結合物之新用途
TW202613130A (zh) 2024-05-30 2026-04-01 日商安斯泰來製藥股份有限公司 Ｓｔｉｎｇ促效劑免疫刺激性抗體藥物結合物
WO2025250825A1 (en) 2024-05-30 2025-12-04 Sutro Biopharma, Inc. Anti-trop2 antibodies, compositions comprising anti-trop2 antibodies and methods of making and using anti-trop2 antibodies
WO2025248134A1 (en) 2024-05-31 2025-12-04 Tonix Pharma Limited Treatment methods comprising administration of modified cd154 antibodies
TW202606758A (zh) 2024-05-31 2026-02-16 美商維泰克斯製藥公司 抗cd74抗體組合物及方法
WO2025248505A1 (en) 2024-05-31 2025-12-04 Wayne State University Methods for treating endometrial and ovarian hyperproliferative disorders
WO2025248097A2 (en) 2024-05-31 2025-12-04 Gamamabs Pharma Humanized anti-human her3 antibodies and uses thereof
WO2025248102A1 (en) 2024-05-31 2025-12-04 Institut National de la Santé et de la Recherche Médicale Tbk1 inhibitor for use in the treatment of vitiligo
WO2025253171A1 (en) 2024-06-04 2025-12-11 Institut Pasteur Characterization of viruses associated with the zoonotic fish-borne oncogenic liver flukes and applications thereof
TW202607016A (zh) 2024-06-06 2026-02-16 美商必治妥美雅史谷比公司 抗fap抗體及其用途
US20250376536A1 (en) 2024-06-06 2025-12-11 Bristol-Myers Squibb Company Multispecific anti-cd40 / anti-fap antibodies and uses thereof
TW202613174A (zh) 2024-06-10 2026-04-01 德商馬克專利公司 Muc-1條件性cd40促效劑
WO2025257151A1 (en) 2024-06-10 2025-12-18 Institut National de la Santé et de la Recherche Médicale Methods and pharmaceutical composition for treating ciliopathies
WO2025257588A1 (en) 2024-06-10 2025-12-18 Affimed Gmbh Cd16a/tumor antigen polyspecific binder for use in the treatment of immune checkpoint inhibitor resistance
EP4663659A1 (de) 2024-06-10 2025-12-17 Merck Patent GmbH Muc-1-bedingte cd40-agonisten
WO2025257181A1 (en) 2024-06-11 2025-12-18 Institut National de la Santé et de la Recherche Médicale Antibodies targeting trans-active response dna-binding protein-43 (tdp-43)
GB202408360D0 (en) 2024-06-11 2024-07-24 Cancer Research Tech Ltd Tumour sensitisation
WO2025257715A1 (en) 2024-06-12 2025-12-18 Seagen Inc. Anti-ceacam5 antibodies, antibody-drug conjugates and methods of uses thereof
WO2025257365A1 (en) 2024-06-14 2025-12-18 Institut National de la Santé et de la Recherche Médicale Adenosine a2a antagonists for the treatment of endometriosis
WO2025259871A1 (en) 2024-06-14 2025-12-18 Gilead Sciences, Inc. Anti-ccr8 antibodies and uses thereof
WO2025262604A1 (en) 2024-06-17 2025-12-26 Janssen Biotech, Inc. Methods of treating crohn's disease with anti-il23 specific antibody
WO2025262564A1 (en) 2024-06-17 2025-12-26 Pfizer Inc. Use of anti-cxcr5 antibodies
WO2025264533A1 (en) 2024-06-17 2025-12-26 Adcentrx Therapeutics Inc. Methods and compositions related to antibody drug conjugates (adcs) that bind steap-1 proteins
WO2025264572A1 (en) 2024-06-17 2025-12-26 Alector Llc Transferrin receptor antigen-binding domains and uses therefor
WO2025264860A2 (en) 2024-06-18 2025-12-26 Yale University Methods of treating post-covid airway disease
EP4667490A1 (de) 2024-06-20 2025-12-24 Université de Lorraine Anti-prokollagen-antikörper und verwendungen davon
TW202617771A (zh) 2024-06-21 2026-05-01 美商艾普吉醫療股份有限公司 結合ｉｌ－１３之抗體及結合ｏｘ４０ｌ之抗體
WO2025264972A1 (en) 2024-06-21 2025-12-26 Apogee Therapeutics, Inc. Antibodies that bind il-4r alpha and antibodies that bind
WO2025262247A1 (en) 2024-06-21 2025-12-26 H. Lundbeck A/S Treatment of headache disorders and/or psychiatric symptoms using anti-cgrp antibodies, and compositions and methods related thereto
WO2026006162A2 (en) 2024-06-24 2026-01-02 Genentech, Inc. B vitamin modulation
WO2026006456A1 (en) 2024-06-25 2026-01-02 Genentech, Inc. Methods of treating cancer using subcutaneous dosing of mosunetuzumab as a monotherapy or in combination with lenalidomide
WO2026006472A2 (en) 2024-06-25 2026-01-02 Kiniksa Pharmaceuticals, Gmbh Compositions of il-1r1 antibodies and methods of producing and using the same
CA3258952A1 (en) 2024-06-27 2026-03-01 Janssen Biotech, Inc. Methods of treating ulcerative colitis with anti-il23 specific antibody
WO2026003242A1 (en) 2024-06-28 2026-01-02 Institut National de la Santé et de la Recherche Médicale Dendritic cells-targeting vaccine against hbv infection
EP4674430A1 (de) 2024-07-01 2026-01-07 Universität zu Köln Editierte zytotoxische zellen mit chimären antigenrezeptoren zum targeting von cd30 zur behandlung von infektionen
WO2026011013A1 (en) 2024-07-02 2026-01-08 Epibiologics, Inc. Binding agents and uses thereof
WO2026009227A1 (en) 2024-07-04 2026-01-08 Yeda Research And Development Co. Ltd. Compositions for downregulating zeb2 in macrophages and uses thereof
WO2026012976A1 (en) 2024-07-08 2026-01-15 Institut National de la Santé et de la Recherche Médicale Use of inhibitor of gasdermind for treatment of rac2 monogenic disorders
WO2026013052A1 (en) 2024-07-09 2026-01-15 Institut National de la Santé et de la Recherche Médicale Methods of treating familial adenomatous polyposis
WO2026013071A1 (en) 2024-07-09 2026-01-15 Institut National de la Santé et de la Recherche Médicale Setdb1 inhibitor for use in the treatment of uveal melanoma
WO2026013153A1 (en) 2024-07-10 2026-01-15 Institut National de la Santé et de la Recherche Médicale Methods of prognosis and treatment of patients suffering from myc-high tumors
WO2026013218A1 (en) 2024-07-10 2026-01-15 Ac Immune Sa Anti-tdp-43 vectors, binding molecules and uses thereof
WO2026019976A1 (en) 2024-07-17 2026-01-22 The Broad Institute, Inc. Universal covalent crosslinker for antibody-oligo conjugates
WO2026018181A1 (en) 2024-07-17 2026-01-22 Pfizer Inc. Immunogenic compositions and uses thereof
US20260078179A1 (en) 2024-07-18 2026-03-19 Novarock Biotherapeutics, Ltd. Cdh17 antibodies and uses thereof
WO2026020051A1 (en) 2024-07-19 2026-01-22 Nurix Therapeutics, Inc. Bifunctional compounds for degrading aurora kinase via ubiquitin proteosome pathway
WO2026022667A1 (en) 2024-07-22 2026-01-29 Universita' Degli Studi Di Parma Antibodies and therapeutic uses thereof
EP4684803A1 (de) 2024-07-25 2026-01-28 CeMM - Forschungszentrum für Molekulare Medizin GmbH Antikörperkonjugierte chemische induktoren des abbaus von rbm39 und therapeutische verwendungen davon
WO2026024987A1 (en) 2024-07-26 2026-01-29 Telix Targeting Technologies, Inc. Antibodies and methods of making and using same
WO2026030017A1 (en) 2024-07-30 2026-02-05 Siemens Healthcare Diagnostics Inc. Nitazene analogs and conjugates and methods of production and use thereof
DE212025000115U1 (de) 2024-07-30 2026-06-18 Sairopa B.V. Anti-SIRP Alpha-Antikörperformulierungen und ihre Verwendung
WO2026030464A1 (en) 2024-07-30 2026-02-05 Genentech, Inc. Dosage regimen for reducing cytokine release syndrome (crs) with anti-fcrh5/anti-cd3 bispecific antibodies in multiple myeloma therapy
WO2026033259A1 (en) 2024-08-05 2026-02-12 Lys Therapeutics Antibodies for treating neurological and neurovascular disorders
WO2026036047A1 (en) 2024-08-08 2026-02-12 Altus Enterprises, Inc. Antibody molecules to fixa and fx and uses thereof
WO2026037841A1 (en) 2024-08-12 2026-02-19 ONA Therapeutics S.L. Anti-fgfr4 molecules and uses thereof
WO2026038097A1 (en) 2024-08-12 2026-02-19 Janssen Biotech, Inc. Method of treating psoriatic arthritis with a combination therapy of antibodies to il-23 and tnf alpha
WO2026039638A1 (en) 2024-08-14 2026-02-19 Mayo Foundation For Medical Education And Research Tshr-targeted radiopharmaceuticals for diagnosis and therapy of thyroid cancer
WO2026037918A1 (en) 2024-08-14 2026-02-19 Epsilogen Ltd Heteromultimeric proteins
WO2026043823A2 (en) 2024-08-19 2026-02-26 Sutro Biopharma, Inc. Antibodies comprising site-specific non-natural amino acid residues, methods of preparation and uses thereof
WO2026044153A1 (en) 2024-08-21 2026-02-26 Bpgbio, Inc. Use of biomarkers in the diagnosis of pancreatic cancer
US20260139068A1 (en) 2024-08-21 2026-05-21 Eisai R&D Management Co., Ltd. Anti-cd73 antibodies, conjugates, and methods of use
WO2026044149A2 (en) 2024-08-21 2026-02-26 Eisai R&D Management Co., Ltd. Synthesis of drug-linker combinations for antibody-drug conjugates
WO2026044177A1 (en) 2024-08-23 2026-02-26 Janssen Biotech, Inc. Methods of treatment with gprc5d antibodies with enhanced effector function
WO2026044176A1 (en) 2024-08-23 2026-02-26 University Of Massachusetts Anti-etec adhesin protein antibodies and methods of use
WO2026050255A2 (en) 2024-08-27 2026-03-05 Regeneron Pharmaceuticals, Inc. Anti-slc3a2-apis antigen-binding proteins and methods of use thereof
TW202615094A (zh) 2024-08-28 2026-04-16 美商建南德克公司 使用莫蘇妥珠單抗與帕羅托珠單抗維多汀組合之皮下給藥治療癌症之方法
WO2026050572A2 (en) 2024-08-29 2026-03-05 Marengo Therapeutics, Inc. Multifunctional molecules binding to tcr and uses thereof
WO2026055183A1 (en) 2024-09-03 2026-03-12 Vir Biotechnology, Inc Antiviral compositions and methods of using the same
WO2026055211A2 (en) 2024-09-04 2026-03-12 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Photoactivatable dye compounds for conjugate formation and methods of making and using the same
WO2026055461A1 (en) 2024-09-05 2026-03-12 Aperture Therapeutics, Inc. Antibody oligonucleotide conjugates comprising an antisense polynucleotide agent conjugated to a cd33 antibody and methods of use thereof
WO2026055521A1 (en) 2024-09-06 2026-03-12 University Of Tennessee Research Foundation Antibody-peptide fusion proteins for treating amyloid disorders
WO2026052977A1 (en) 2024-09-09 2026-03-12 Finn Therapeutics Ltd. Antibodies binding receptor activity-modifying protein (ramp)-3 and uses thereof
WO2026059931A2 (en) 2024-09-11 2026-03-19 Telix Targeting Technologies, Inc. Dll3 antigen binding constructs
US20260167709A1 (en) 2024-09-11 2026-06-18 Novartis Ag Antibodies targeting il-31
WO2026057679A1 (en) 2024-09-11 2026-03-19 Institut National de la Santé et de la Recherche Médicale Inhibitor of rab30 for use in a method of treatment of metabolic dysfunction-associated steatotic liver disease (masld)
WO2026057740A1 (en) 2024-09-12 2026-03-19 Astrazeneca Ab Treatment of cancer with therapeutic binding molecules
WO2026058045A1 (en) 2024-09-12 2026-03-19 Takeda Pharmaceutical Company Limited Alpha4beta7 inhibitor and il-23 inhibitor combination therapy
WO2026062579A1 (en) 2024-09-19 2026-03-26 Comed Therapeutics Ltd. Compositions and methods for protein delivery to cells
WO2026069312A1 (en) 2024-09-24 2026-04-02 Yeda Research And Development Co. Ltd. Immune cells expressing an inducible therapeutic agent and uses thereof
WO2026073816A1 (en) 2024-09-25 2026-04-09 Centre Hospitalier Universitaire Vaudois Potency-tuned cd70 ligands, targeted chimeric antigen receptors (cars) and methods for cancer
WO2026072685A1 (en) 2024-09-25 2026-04-02 Genentech, Inc. Compositions and methods of treating lupus nephritis
WO2026072990A1 (en) 2024-09-27 2026-04-02 Abcuro, Inc. Methods of treating t-cell large granular lymphocytic leukemia
WO2026068859A1 (en) 2024-09-30 2026-04-02 Université Libre de Bruxelles Wnt signaling agonist molecules in the treatment of a bone-related disease or disorder
WO2026069251A1 (en) 2024-09-30 2026-04-02 Sarepta Therapeutics, Inc. Adeno-associated virus capsid antibodies and fragments thereof
WO2026069244A1 (en) 2024-09-30 2026-04-02 Sarepta Therapeutics, Inc. Sarcoglycan antibodies and fragments thereof
WO2026073840A1 (en) 2024-10-01 2026-04-09 F. Hoffmann-La Roche Ag Antibodies that bind to cd3 and uses therefor
WO2026075999A2 (en) 2024-10-01 2026-04-09 Sarepta Therapeutics, Inc. Dystrophin and micro-dystrophin antibodies and fragments thereof
WO2026074471A1 (en) 2024-10-02 2026-04-09 Janssen Pharmaceutica Nv Combination therapies with hafnium oxide nanoparticles and pd-l1 antibodies for use in the treatment of non small cell lung cancer
WO2026078067A1 (en) 2024-10-08 2026-04-16 Novimmune Sa Fcrh5 monospecific antibodies and derived fcrh5xcd28 bispecific antibodies and use thereof
WO2026080697A1 (en) 2024-10-09 2026-04-16 Sutro Biopharma, Inc. Antibody conjugates with high payload to antibody ratios, compositions comprising the same, and methods of their use
WO2026080688A1 (en) 2024-10-09 2026-04-16 Sutro Biopharma, Inc. Dual mechanism of action payload antibody drug conjugates
WO2026080829A1 (en) 2024-10-10 2026-04-16 Apogee Therapeutics, Inc. Methods of administering antibodies that bind interleukin 13
WO2026078029A1 (en) 2024-10-10 2026-04-16 F. Hoffmann-La Roche Ag Splitted interleukin-2 prodrugs and uses thereof
WO2026085419A2 (en) 2024-10-18 2026-04-23 Apogee Therapeutics, Inc. Antibodies that bind il-13 in combination with hyaluronidase or a variant thereof
WO2026085414A1 (en) 2024-10-18 2026-04-23 Apogee Therapeutics, Inc. Antibodies that bind tslp and antibodies that bind interleukin 4 receptor alpha in combination with hyaluronidase or a variant thereof
WO2026085436A1 (en) 2024-10-18 2026-04-23 Health Research, Inc. Borrelia burgdorferi cspz-binding proteins and methods of use thereof
WO2026082966A1 (en) 2024-10-18 2026-04-23 Novimmune Sa Methods of treating disease using anti-cd47 x anti-mesothelin antibodies in combination with chemotherapy
WO2026085417A2 (en) 2024-10-18 2026-04-23 Apogee Therapeutics, Inc. Antibodies that bind interleukin 4 receptor alpha in combination with hyaluronidase or a variant thereof
EP4729543A1 (de) 2024-10-18 2026-04-22 Harfang Therapeutics Anti-il-4-rezeptor-antikörper zur veterinärmedizinischen verwendung
WO2026085415A1 (en) 2024-10-18 2026-04-23 Apogee Therapeutics, Inc. Antibodies that bind il-13 and antibodies that bind tslp in combination with hyaluronidase or a variant thereof
WO2026086785A1 (en) 2024-10-21 2026-04-30 Shenzhen Wondercel Biotechnology Limited Eukaryotic cells expressing exogenous inosine monophosphate dehydrogenase comprising chimeric antigen receptor binding to gucy2c
WO2026087510A2 (en) 2024-10-21 2026-04-30 Merck Patent Gmbh Pharmaceutical compositions containing stabilized antibody-drug conjugates
WO2026086936A1 (en) 2024-10-24 2026-04-30 Itabmed Co., Ltd. Uses of multispecific antigen binding proteins capable of binding cd19 and cd3
WO2026088163A1 (en) 2024-10-25 2026-04-30 Takeda Pharmaceutical Company Limited Compositions of engineered cytokine expressing cells and methods of use thereof
WO2026093738A1 (en) 2024-10-28 2026-05-07 Institute Of Cancer Research: Royal Cancer Hospital Cancer treatment
WO2026096515A1 (en) 2024-10-28 2026-05-07 Legend Biotech Ireland Limited Viral glycoprotein variants and uses thereof
WO2026093923A1 (en) 2024-10-29 2026-05-07 Csl Behring Ag Method for detection of a plasma protein
US20260146100A1 (en) 2024-10-30 2026-05-28 Regeneron Pharmaceuticals, Inc. Multispecific antigen-binding molecules that bind cd22 and 4-1bb and methods of use thereof
WO2026096637A1 (en) 2024-10-30 2026-05-07 Tiziana Life Sciences Plc Glp-1 agonists and foralumab combination therapies
WO2026096576A1 (en) 2024-10-30 2026-05-07 Regeneron Pharmaceuticals, Inc. Multispecific antigen-binding molecules that bind psma and 4-1bb and methods of use thereof
WO2026096695A1 (en) 2024-10-31 2026-05-07 Bristol-Myers Squibb Company Anti-fucosyl-gm1 antibody drug conjugates
WO2026099206A1 (en) 2024-11-05 2026-05-15 Celgene Corporation Therapy for the treatment of non-hodgkin lymphoma
WO2026102093A1 (en) 2024-11-07 2026-05-15 Voyager Therapeutics, Inc. Compositions and methods for the treatment of tau-related disorders
WO2026102349A1 (en) 2024-11-08 2026-05-15 Genentech, Inc. Anti-interleukin-23 receptor vhh antibodies and uses thereof
WO2026104330A1 (en) 2024-11-12 2026-05-21 F. Hoffmann-La Roche Ag Pd-1-regulated il-2 immunoconjugates and uses thereof
WO2026107136A1 (en) 2024-11-14 2026-05-21 Bristol-Myers Squibb Company Anti-ceacam5 antibody drug conjugates for the treatment of cancer
US20260144884A1 (en) 2024-11-22 2026-05-28 Bristol-Myers Squibb Company Anti-lrrc15 antibody drug conjugates
US20260144885A1 (en) 2024-11-22 2026-05-28 Bristol-Myers Squibb Company Anti-lrrc15 antibodies and uses thereof
GB202417285D0 (en) 2024-11-25 2025-01-08 Univ Oxford Innovation Ltd Expanded t cell population
WO2026112563A1 (en) 2024-11-25 2026-05-28 Abbott Laboratories Systems and methods for tbi adjudication
WO2026117686A1 (en) 2024-11-27 2026-06-04 Nammi Therapeutics, Inc. FUSION PROTEIN COMPOSITION(S) COMPRISING MASKED TYPE I INTERFERONS (IFNα AND IFNβ) FOR USE IN THE TREATMENT OF CANCER AND METHODS THEREOF
WO2026115454A2 (en) 2024-11-27 2026-06-04 Astrazeneca Ab Claudin 18.2 antibodies, antigen binding fragments and antibody drug conjugates thereof and methods of use in cancer therapy
WO2026117540A1 (en) 2024-11-27 2026-06-04 Vir Biotechnology, Inc. Anti-hiv-1 antibodies and uses thereof
WO2026117756A2 (en) 2024-11-27 2026-06-04 Dispatch Biotherapeutics, Inc. Systems and methods for expression of synthetic cancer antigens and cytokine receptors
WO2026117415A1 (en) 2024-11-27 2026-06-04 Genentech, Inc. Afucosylation modification
CN122103334A (zh) 2024-11-29 2026-05-29 深圳迈瑞生物医疗电子股份有限公司 抗雌二醇免疫复合物的抗体和试剂盒
WO2026122407A1 (en) 2024-12-04 2026-06-11 Merck Sharp & Dohme Llc Amyloid beta binder, and uses thereof
WO2026128475A1 (en) 2024-12-09 2026-06-18 Century Therapeutics, Inc. Genetically engineered induced pluripotent stem cells and effector cells derived therefrom
WO2026125320A1 (en) 2024-12-10 2026-06-18 Intervet International B.V. Caninized il31rα antibodies with an extended half life
WO2026125322A1 (en) 2024-12-10 2026-06-18 Intervet International B.V. CANINIZED IL31Rα ANTIBODIES WITH AN EXTENDED HALF LIFE
WO2026125321A1 (en) 2024-12-10 2026-06-18 Intervet International B.V. Caninized il31rα antibodies with an extended half life
WO2026128221A1 (en) 2024-12-12 2026-06-18 University Of Rochester Antt-tgfbp3 antibodies to treat cancer and sarcopenia
US20260167719A1 (en) 2024-12-17 2026-06-18 Merck Sharp & Dohme Llc Nectin-4 antibodies
WO2026136288A2 (en) 2024-12-18 2026-06-25 Generate Biomedicines, Inc. Antibodies or antigen-binding fragments thereof capable of binding to free drug and uses thereof
GB202418667D0 (en) 2024-12-19 2025-02-05 Immutrin Ltd Anti-fibril antibodies with engineered Fc regions
WO2026136223A1 (en) 2024-12-19 2026-06-25 Zoetis Services Llc Compositions and methods for improving feline antibody functions
WO2026136785A1 (en) 2024-12-19 2026-06-25 Amgen Inc. T cell engager masking molecules with reduced isomerization tendencies
WO2026136402A1 (en) 2024-12-19 2026-06-25 Zoetis Services Llc Compositions and methods for improving canine antibody functions
WO2026132786A1 (en) 2024-12-20 2026-06-25 Centessa Pharmaceuticals (Uk) Limited Anti-cd3 binding agents and uses thereof
WO2026133192A1 (en) 2024-12-20 2026-06-25 Pfizer Inc. Combination therapies using cdk4 inhibitors with pd-1 axis binding antagonists
WO2026147633A1 (en) 2025-01-02 2026-07-09 The Board Of Regents Of The University Of Oklahoma Hemicyanine compounds having optoacoustic properties and methods of use
WO2026148288A1 (en) 2025-01-06 2026-07-09 M2 Therapeutics, Inc. Antibodies and antigen-binding fragments thereof to growth hormone receptor and methods of use
WO2026151706A2 (en) 2025-01-07 2026-07-16 Genentech, Inc. Anti-trop2 bispecific antibodies
WO2026156021A1 (en) 2025-01-16 2026-07-23 Merck Sharp & Dohme Llc Bispecific antibody constructs that bind alpp/alppl2 and cd3
WO2026161391A2 (en) 2025-01-21 2026-07-30 Bristol-Myers Squibb Company Cd19 binding molecules including cd3- and cd19- bispecific t cell engagers and related methods and uses
WO2026159667A1 (en) 2025-01-24 2026-07-30 Hovione Farmaciência Sa Synthetic sugars as enablers for viscosity reduction of highly concentrated biological molecules
WO2026165269A1 (en) 2025-01-29 2026-08-06 Sutro Biopharma, Inc. Anti-b7-h3 antibodies, compositions comprising anti-b7-h3 antibodies and methods of making and using anti- b7-h3 antibodies
WO2026165196A1 (en) 2025-01-29 2026-08-06 Astellas Pharma Inc. Anti-b7-h3 dual payload immunomodulatory antibody drug conjugates
GB202501483D0 (en) 2025-01-31 2025-03-19 Univ Oxford Innovation Ltd Cancer treatment
GB202501482D0 (en) 2025-01-31 2025-03-19 Univ Oxford Innovation Ltd Antiviral treatment
GB202501484D0 (en) 2025-01-31 2025-03-19 Univ Oxford Innovation Ltd Antimicrobial
GB202501534D0 (en) 2025-02-03 2025-03-19 Cambridge Entpr Ltd Targeted phagocytic degradation

Family Cites Families (90)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4179337A (en) 1973-07-20 1979-12-18 Davis Frank F Non-immunogenic polypeptides
US4237224A (en) 1974-11-04 1980-12-02 Board Of Trustees Of The Leland Stanford Jr. University Process for producing biologically functional molecular chimeras
GB1594097A (en) 1976-12-16 1981-07-30 Int Inst Of Differentiation Production of specific immune nucleic acids cell dialysates and antibodies
US4440859A (en) 1977-05-27 1984-04-03 The Regents Of The University Of California Method for producing recombinant bacterial plasmids containing the coding sequences of higher organisms
US5583013A (en) 1977-11-08 1996-12-10 Genentech, Inc. Method and means for microbial polypeptide expression
US4366246A (en) 1977-11-08 1982-12-28 Genentech, Inc. Method for microbial polypeptide expression
US4704362A (en) * 1977-11-08 1987-11-03 Genentech, Inc. Recombinant cloning vehicle microbial polypeptide expression
US5420020A (en) 1977-11-08 1995-05-30 Genentech, Inc. Method and means for microbial polypeptide expression
US4565785A (en) 1978-06-08 1986-01-21 The President And Fellows Of Harvard College Recombinant DNA molecule
US4342832A (en) 1979-07-05 1982-08-03 Genentech, Inc. Method of constructing a replicable cloning vehicle having quasi-synthetic genes
US4431740A (en) 1979-09-12 1984-02-14 The Regents Of The University Of California DNA Transfer vector and transformed microorganism containing human proinsulin and pre-proinsulin genes
US4418149A (en) 1980-01-10 1983-11-29 President And Fellows Of Harvard College Fused hybrid gene
GB2068969B (en) 1980-02-05 1983-07-27 Upjohn Co Gene expression
US4634665A (en) 1980-02-25 1987-01-06 The Trustees Of Columbia University In The City Of New York Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US4399216A (en) 1980-02-25 1983-08-16 The Trustees Of Columbia University Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US5179017A (en) 1980-02-25 1993-01-12 The Trustees Of Columbia University In The City Of New York Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US6455275B1 (en) 1980-02-25 2002-09-24 The Trustees Of Columbia University In The City Of New York DNA construct for producing proteinaceous materials in eucaryotic cells
US4348376A (en) 1980-03-03 1982-09-07 Goldenberg Milton David Tumor localization and therapy with labeled anti-CEA antibody
DK170476B1 (da) 1980-04-03 1995-09-11 Biogen Inc Rekombinant DNA-molekyle, uni-cellulær vært transformeret med mindst ét rekombinant DNA-molekyle, fremgangsmåde til transformering af en uni-cellulær vært, samt fremgangsmåder til fremstilling af et polpeptid, der udviser den immunologiske eller biologiske aktivitet af human beta-interferon
US4370417A (en) 1980-04-03 1983-01-25 Abbott Laboratories Recombinant deoxyribonucleic acid which codes for plasminogen activator
ZA811895B (en) 1980-04-07 1982-04-28 Univ California Expression of hormone genomic clones
US4338397A (en) 1980-04-11 1982-07-06 President And Fellows Of Harvard College Mature protein synthesis
US4510244A (en) 1980-04-17 1985-04-09 The Board Of Trustees Of The Leland Stanford Jr. University Cell labeling with antigen-coupled microspheres
IE63126B1 (en) 1980-06-06 1995-03-22 Biogen Inc Improved vectors and methods for making such vectors and for expressing cloned genes
WO1982001461A1 (en) 1980-07-18 1982-05-13 Leland Stanford Junior Univ Human hybridomas,precursors and products
US4668629A (en) 1980-07-18 1987-05-26 The Board Of Trustees Of Leland Stanford Jr. University Human hybridomas, precursors and products
US4403036A (en) 1980-12-02 1983-09-06 University Of Iowa Research Foundation Genetic reagents for generating plasmids containing multiple copies of DNA segments
US4419446A (en) 1980-12-31 1983-12-06 The United States Of America As Represented By The Department Of Health And Human Services Recombinant DNA process utilizing a papilloma virus DNA as a vector
NZ199391A (en) 1981-01-02 1985-12-13 Genentech Inc Chimeric polypeptides comprising a proinsulin sequence,and preparation by recombinant dna technique;production of human insulin
NO820248L (no) * 1981-01-28 1982-07-29 Coats Patons Plc Fremgangsmaate ved fremstilling av monoklone antistoffer og celler istand til aa produsere slike antistoffer
NZ199722A (en) 1981-02-25 1985-12-13 Genentech Inc Dna transfer vector for expression of exogenous polypeptide in yeast;transformed yeast strain
US5137721A (en) 1981-03-09 1992-08-11 Cetus Corporation Employing strains of E. coli expressing non-indigenous adhesins and toxoids of E. coli
US4495280A (en) 1981-05-20 1985-01-22 The Board Of Trustees Of The Leland Stanford Jr. University Cloned high signal strength promoters
US4474893A (en) * 1981-07-01 1984-10-02 The University of Texas System Cancer Center Recombinant monoclonal antibodies
US4792447A (en) 1981-07-23 1988-12-20 Board Of Regents, The University Of Texas System Anti-immunoglobulin toxin conjugates useful in the treatment of B cell tumors
ZW18282A1 (en) * 1981-08-31 1983-03-23 Genentech Inc Preparation of polypeptides in vertebrate cell culture
NZ201918A (en) 1981-09-18 1987-04-30 Genentech Inc N-terminal methionyl analogues of bovine growth hormone
US4444878A (en) * 1981-12-21 1984-04-24 Boston Biomedical Research Institute, Inc. Bispecific antibody determinants
EP0088994B1 (de) 1982-03-15 1991-06-19 Schering Corporation Hybride DNS, damit hergestellte Bindungszusammensetzung und Verfahren dafür
US5149636A (en) 1982-03-15 1992-09-22 Trustees Of Columbia University In The City Of New York Method for introducing cloned, amplifiable genes into eucaryotic cells and for producing proteinaceous products
US4766075A (en) 1982-07-14 1988-08-23 Genentech, Inc. Human tissue plasminogen activator
IL68561A (en) 1982-05-05 1991-01-31 Genentech Inc Preparation of polypeptide with human tissue plasminogen activator function,processes for making it,and dna and transformed cell intermediates thereof
US4500637A (en) 1982-07-19 1985-02-19 The United States Of America As Represented By The Department Of Health And Human Services Prevention of graft versus host disease following bone marrow transplantation
JPS5944399A (ja) 1982-09-07 1984-03-12 Takeda Chem Ind Ltd 新規ｄｎａ
US4511502A (en) 1982-12-22 1985-04-16 Genentech, Inc. Purification and activity assurance of precipitated heterologous proteins
US4599197A (en) 1982-12-22 1986-07-08 Genentech, Inc. Purification and activity assurance of precipitated heterologous proteins
US4512922A (en) * 1982-12-22 1985-04-23 Genentech, Inc. Purification and activity assurance of precipitated heterologous proteins
US4965196A (en) 1983-01-19 1990-10-23 Genentech, Inc. Polycistronic expression vector construction
US4713339A (en) 1983-01-19 1987-12-15 Genentech, Inc. Polycistronic expression vector construction
GB8308235D0 (en) 1983-03-25 1983-05-05 Celltech Ltd Polypeptides
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4518584A (en) * 1983-04-15 1985-05-21 Cetus Corporation Human recombinant interleukin-2 muteins
JPS6050089A (ja) * 1983-08-27 1985-03-19 浅山　金吾 ２輪車用ブレ−キ装置
US6054561A (en) 1984-02-08 2000-04-25 Chiron Corporation Antigen-binding sites of antibody molecules specific for cancer antigens
JPS6147500A (ja) 1984-08-15 1986-03-07 Res Dev Corp Of Japan キメラモノクロ−ナル抗体及びその製造法
US5807715A (en) 1984-08-27 1998-09-15 The Board Of Trustees Of The Leland Stanford Junior University Methods and transformed mammalian lymphocyte cells for producing functional antigen-binding protein including chimeric immunoglobulin
EP0173494A3 (de) * 1984-08-27 1987-11-25 The Board Of Trustees Of The Leland Stanford Junior University Chimäre Rezeptoren durch Verbindung und Expression von DNS
GB8422238D0 (en) 1984-09-03 1984-10-10 Neuberger M S Chimeric proteins
EP0196864A3 (de) 1985-03-25 1988-03-23 Cetus Corporation Behandlung und Sekretion von rekombinanten Proteinen mittels alkalischer Phosphatase, dazu verwendbare DNA-Sequenzen und mittels dieser Sequenzen transformierte Zellen
US5618920A (en) 1985-11-01 1997-04-08 Xoma Corporation Modular assembly of antibody genes, antibodies prepared thereby and use
US5576195A (en) 1985-11-01 1996-11-19 Xoma Corporation Vectors with pectate lyase signal sequence
DE3689123T2 (de) * 1985-11-01 1994-03-03 Xoma Corp Modulare einheit von antikörpergenen, daraus hergestellte antikörper und verwendung.
JPS62201581A (ja) 1986-02-28 1987-09-05 Rikagaku Kenkyusho 新規プラスミド、微生物細胞及びヒト免疫グロブリンＧ　Ｆｃ領域蛋白質の製造方法
EP0234592A1 (de) 1986-02-28 1987-09-02 Teijin Limited Plasmid, das ein DNA-Fragment enthält, welches für die Fc-Region von menschlichem Immunoglobulin G Protein codiert, und Verwendung desselben zur Herstellung des genannten Proteins
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
US6548640B1 (en) 1986-03-27 2003-04-15 Btg International Limited Altered antibodies
NO873164L (no) 1986-07-30 1988-02-01 Teijin Ltd Muse-humane kimaere antistoffer.
IL85035A0 (en) 1987-01-08 1988-06-30 Int Genetic Eng Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same
CA1341235C (en) 1987-07-24 2001-05-22 Randy R. Robinson Modular assembly of antibody genes, antibodies prepared thereby and use
US5336603A (en) 1987-10-02 1994-08-09 Genentech, Inc. CD4 adheson variants
DE3744595A1 (de) 1987-12-31 1989-07-13 Andreas Dr Plueckthun Verfahren zur gentechnischen herstellung von antikoerpern
US5965405A (en) 1988-04-16 1999-10-12 Celltech Limited Method for producing Fv fragments in eukaryotic cells
KR0161525B1 (ko) 1988-10-19 1998-12-01 리챠드 지. 워터맨 암치료를 위한 신규의 고친화성 변형된 항체군
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US5098833A (en) 1989-02-23 1992-03-24 Genentech, Inc. DNA sequence encoding a functional domain of a lymphocyte homing receptor
US5225538A (en) 1989-02-23 1993-07-06 Genentech, Inc. Lymphocyte homing receptor/immunoglobulin fusion proteins
US5116964A (en) 1989-02-23 1992-05-26 Genentech, Inc. Hybrid immunoglobulins
US5081235A (en) 1989-07-26 1992-01-14 City Of Hope Chimeric anti-cea antibody
GB9014932D0 (en) 1990-07-05 1990-08-22 Celltech Ltd Recombinant dna product and method
GB9022543D0 (en) 1990-10-17 1990-11-28 Wellcome Found Antibody production
CA2108580A1 (en) 1991-05-31 1992-12-01 Arthur J. Ammann Treatment of hiv-associated immune thrombocytopenic purpura
WO1994004679A1 (en) 1991-06-14 1994-03-03 Genentech, Inc. Method for making humanized antibodies
GB9115364D0 (en) 1991-07-16 1991-08-28 Wellcome Found Antibody
EP0604580A1 (de) 1991-09-19 1994-07-06 Genentech, Inc. Expression in E.Coli von Antikörperfragmenten mit mindestens einem cystein in freier -SH Form. Anwendung in der Herstellung bifunktioneller Antikörper.
US5686072A (en) 1992-06-17 1997-11-11 Board Of Regents, The University Of Texas Epitope-specific monoclonal antibodies and immunotoxins and uses thereof
WO1994009363A1 (en) 1992-10-14 1994-04-28 Board Of Regents, The University Of Texas System Cancer diagnosis and therapy
US5736137A (en) 1992-11-13 1998-04-07 Idec Pharmaceuticals Corporation Therapeutic application of chimeric and radiolabeled antibodies to human B lymphocyte restricted differentiation antigen for treatment of B cell lymphoma
AU691811B2 (en) * 1993-06-16 1998-05-28 Celltech Therapeutics Limited Antibodies
US5561053A (en) 1994-08-05 1996-10-01 Genentech, Inc. Method for selecting high-expressing host cells
US6979556B2 (en) 2000-12-14 2005-12-27 Genentech, Inc. Separate-cistron contructs for secretion of aglycosylated antibodies from prokaryotes

Also Published As

Publication number Publication date
AU2642984A (en) 1984-10-11
JPH07194384A (ja) 1995-08-01
ES531372A0 (es) 1985-12-01
EP0125023B2 (de) 2002-03-13
ES8602119A1 (es) 1985-12-01
JP2001346591A (ja) 2001-12-18
DE3484664D1 (de) 1991-07-11
JP2001346592A (ja) 2001-12-18
KR840008264A (ko) 1984-12-14
CA1218613A (en) 1987-03-03
HK129394A (en) 1994-11-25
EP0125023B1 (de) 1991-06-05
NZ207746A (en) 1991-04-26
JPH07222597A (ja) 1995-08-22
ATE64151T1 (de) 1991-06-15
IL71455A0 (en) 1984-07-31
US4816567A (en) 1989-03-28
CY1793A (en) 1995-02-17
DK126292A (da) 1992-10-15
US7923221B1 (en) 2011-04-12
ZA842583B (en) 1984-11-28
NZ222542A (en) 1991-04-26
DK170895B1 (da) 1996-03-04
IE57198B1 (en) 1992-06-03
KR840008693A (ko) 1984-12-17
AU639910B2 (en) 1993-08-12
AU5201390A (en) 1990-08-30
NZ222543A (en) 1991-04-26
AU598441B2 (en) 1990-06-28
DK174048B1 (da) 2002-05-06
JPS60155132A (ja) 1985-08-15
IE840840L (en) 1984-10-08
JP3559795B2 (ja) 2004-09-02
DK179684A (da) 1984-11-16
DK126292D0 (da) 1992-10-15
EP0125023A1 (de) 1984-11-14
US6331415B1 (en) 2001-12-18
JP3162055B2 (ja) 2001-04-25
DK179684D0 (da) 1984-04-05

Similar Documents

Publication Publication Date Title
AU598441B2 (en) Recombinant immunoglobin preparations
EP0006694B1 (de) Verfahren zur Herstellung eines ausgewählten Proteins
EP0012494B1 (de) DNS-Transfer-Vektor, durch diesen Vektor modifizierter Mikroorganismus und Synthesis eines eukariotischen Proteins durch den modifizierten Mikroorganismus
KR960011919B1 (ko) IgA 단백질 분해효소를 이용한 재조합 단백질의 효소적 절단방법
US6027720A (en) G-CSF conjugate
JP3242106B2 (ja) 組換えｄｎａ由来コレラトキシンサブユニット類似体
JP2882775B2 (ja) ヒトーグリア由来神経突起因子
AU634314B2 (en) Chimeric mouse-human a10 antibody with specificity to a human tumor cell antigen
EP0531404B1 (de) Ubiquitinspezifische protease
JPH03505397A (ja) インスリン様成長因子結合タンパク質の製造
US5681720A (en) DNA encoding human granulocyte colony stimulating factor plasmids and host cells comprising same, and methods of expressing the encoded polypeptide
AU616873B2 (en) Horse gamma-interferon
HK1008048B (en) Excretion of heterologous proteins from e. coli
IL99507A (en) Preparation of antigen-specific immunoglobulins known in a transformed host cell, vectors and transformed cells using it
CA2283497A1 (en) Vectors and methods for expression of mutant proteins
WO1992012173A1 (en) A method for constructing antigens
KR840000949B1 (ko) 유전자 재조합 단백질의 제조방법
KR890002397A (ko) 하이브리드 인터페론 및 그의 제조방법
KR910700341A (ko) 합성 인터루킨-6

Legal Events

Date Code Title Description
KB Patent renewed
KB Patent renewed
PEL Intention of commissioner to extend period of protection
EXTG Extension of patent term granted
EXTG Extension of patent term granted
EXTN Extension order renewed
EXP Patent expired